Clustering O 0 3.2841031497810036e-05
of O 0 1.3568377710271307e-07
missense O 0 0.0001389634417137131
mutations O 0 2.260469045722857e-05
in O 0 3.951909377519769e-07
the O 0 0.0001532943861093372
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999918937683105
telangiectasia I-Disease 1 0.9999992847442627
gene O 0 4.800970418727957e-05
in O 0 1.122258552754829e-07
a O 0 6.733034183525888e-07
sporadic B-Disease 0 0.09880361706018448
T I-Disease 1 0.9913842678070068
- I-Disease 0 0.09971939772367477
cell I-Disease 0 0.06451168656349182
leukaemia I-Disease 1 0.8624264001846313
. O 0 6.918993449289701e-07

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999964237213135
telangiectasia I-Disease 1 0.9999997615814209
( O 0 0.002371696289628744
A B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999978542327881
T I-Disease 1 1.0
) O 0 6.612295067043306e-08
is O 0 3.9001054830123394e-08
a O 0 8.732593670401911e-08
recessive B-Disease 0 0.0002765272802207619
multi I-Disease 1 0.6184086203575134
- I-Disease 1 0.9995019435882568
system I-Disease 0 0.461702823638916
disorder I-Disease 1 0.8143165707588196
caused O 0 7.839573186174675e-07
by O 0 3.634741396751906e-09
mutations O 0 1.2466394139210024e-07
in O 0 6.5423160222621846e-09
the O 0 7.793979683867747e-09
ATM O 0 5.642033102049027e-06
gene O 0 7.009224844978235e-08
at O 0 1.2417933703545714e-07
11q22 O 0 1.750806632117019e-06
- O 0 4.9523896450409666e-05
q23 O 0 7.944043318275362e-06
( O 0 1.8099818532846257e-08
ref O 0 2.493905594747048e-05
. O 0 7.983116390164469e-09
3 O 0 2.2443032321461942e-08
) O 0 1.7669107066353718e-08
. O 0 6.876145164369518e-08

The O 0 5.182059226171987e-07
risk O 0 9.720408343127929e-06
of O 0 7.933378043389894e-08
cancer B-Disease 0 0.00015820373664610088
, O 0 4.0300374593016386e-08
especially O 0 2.6362267036006415e-08
lymphoid B-Disease 0 2.3708425942459144e-05
neoplasias I-Disease 0 0.0004311119264457375
, O 0 3.918986024586957e-08
is O 0 3.388237601598121e-08
substantially O 0 1.2271299283383996e-06
elevated O 0 4.8367041017627344e-05
in O 0 1.0303016324542114e-06
A B-Disease 1 0.9999934434890747
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 4.0477443690178916e-05
and O 0 7.785393449921685e-07
has O 0 2.0994848455302417e-06
long O 0 2.7818575745186536e-06
been O 0 1.5057820519359666e-06
associated O 0 1.0301296242687386e-06
with O 0 3.0334679195220815e-06
chromosomal O 1 0.9999992847442627
instability O 1 0.9999433755874634
. O 0 3.25717956002336e-05

By O 0 2.9264319323374366e-07
analysing O 0 2.536828105803579e-05
tumour B-Disease 1 0.9999960660934448
DNA O 0 3.353443753439933e-05
from O 0 2.4664933206963724e-08
patients O 0 5.678398551367536e-08
with O 0 2.8421871522965603e-09
sporadic B-Disease 0 0.0025749097112566233
T I-Disease 1 0.945068895816803
- I-Disease 0 0.004383683204650879
cell I-Disease 0 0.023127174004912376
prolymphocytic I-Disease 0 0.1428578943014145
leukaemia I-Disease 1 0.949615478515625
( O 0 2.6565490429675265e-07
T B-Disease 0 0.02761474810540676
- I-Disease 0 2.025719550147187e-05
PLL I-Disease 0 2.7871532438439317e-05
) O 0 3.2459046561683635e-09
, O 0 1.7680020780730388e-09
a O 0 1.4378396251402137e-08
rare O 0 5.855052904735203e-07
clonal B-Disease 0 0.00012647277617361397
malignancy I-Disease 0 0.009671764448285103
with O 0 1.812423988667433e-08
similarities O 0 1.606350537031176e-07
to O 0 1.1151781720286635e-08
a O 0 4.718813215731643e-07
mature B-Disease 0 2.615043740661349e-05
T I-Disease 0 0.4888657033443451
- I-Disease 0 0.0005535272648558021
cell I-Disease 0 0.0052737887017428875
leukaemia I-Disease 0 0.027038075029850006
seen O 0 2.3564434741274454e-05
in O 0 5.08460175296932e-07
A B-Disease 1 0.9999837875366211
- I-Disease 1 0.9999938011169434
T I-Disease 1 0.9999998807907104
, O 0 7.734215046184545e-08
we O 0 1.1505931318822604e-08
demonstrate O 0 3.9022167719338086e-09
a O 0 1.4817388427346145e-09
high O 0 7.922472455845764e-09
frequency O 0 4.142425780173653e-08
of O 0 2.145248423346402e-09
ATM O 0 2.2087784600444138e-05
mutations O 0 2.8397403184499126e-07
in O 0 8.369030268795541e-08
T B-Disease 0 0.1408289074897766
- I-Disease 0 0.00035881955409422517
PLL I-Disease 0 0.0008939965628087521
. O 0 1.0562483794274158e-06

In O 0 2.598437447431934e-07
marked O 0 6.993906822572171e-07
contrast O 0 1.6496541377364338e-07
to O 0 3.4446796526310663e-09
the O 0 3.66209640390025e-09
ATM O 0 3.72962313122116e-05
mutation O 0 2.5878307496896014e-07
pattern O 0 3.822418875643052e-05
in O 0 1.4566647905667196e-06
A B-Disease 1 0.9999909400939941
- I-Disease 1 0.9999970197677612
T I-Disease 1 1.0
, O 0 2.974830692892283e-07
the O 0 1.6131651570105987e-09
most O 0 1.0124142635348221e-09
frequent O 0 1.2182948871952703e-08
nucleotide O 0 2.160054890509855e-08
changes O 0 3.5175813373200526e-09
in O 0 1.7851276012947892e-09
this O 0 2.137105958865959e-08
leukaemia B-Disease 0 0.0006089298985898495
were O 0 3.002373603067099e-07
missense O 0 6.28359048278071e-05
mutations O 0 4.26791893914924e-06
. O 0 4.4957286604585533e-07

These O 0 1.7522620510135312e-07
clustered O 0 2.3456188500858843e-05
in O 0 9.159411007431117e-09
the O 0 1.6050198947681338e-09
region O 0 1.5658738306001396e-08
corresponding O 0 1.8234636023350959e-09
to O 0 6.739825364476815e-10
the O 0 3.899952860653144e-10
kinase O 0 4.933544346386043e-07
domain O 0 6.267372754109601e-08
, O 0 5.691830562426503e-09
which O 0 1.0888361323679874e-08
is O 0 7.971202364842611e-09
highly O 0 4.606502290727121e-09
conserved O 0 8.713605836874194e-09
in O 0 3.752982813409744e-09
ATM O 0 4.691541471402161e-05
- O 0 1.2492792848206591e-05
related O 0 2.047857350362392e-07
proteins O 0 7.157070491814466e-09
in O 0 7.726986162026606e-09
mouse O 0 1.4308014215203002e-05
, O 0 6.4607830196905525e-09
yeast O 0 6.376392889251292e-07
and O 0 1.1885605033512547e-07
Drosophila O 0 1.746300995364436e-06
. O 0 3.1283798307413235e-07

The O 0 1.8481608776710345e-07
resulting O 0 3.732504012532445e-07
amino O 0 1.242004259438545e-07
- O 0 2.7673625027091475e-06
acid O 0 1.6000445413055786e-08
substitutions O 0 8.949827545734479e-09
are O 0 6.066736002452444e-10
predicted O 0 2.4295417233588523e-08
to O 0 7.752358199830667e-10
interfere O 0 6.94415405178006e-08
with O 0 1.2838830443229199e-08
ATP O 0 2.096915341098793e-05
binding O 0 6.9420880208781455e-06
or O 0 6.583891263289843e-07
substrate O 0 8.878842345438898e-05
recognition O 0 5.380877041716303e-07
. O 0 3.7176619116507936e-07

Two O 0 2.071329134878397e-07
of O 0 6.920747530614335e-09
seventeen O 0 2.695834382393514e-07
mutated O 0 6.698871857224731e-06
T B-Disease 0 0.016212452203035355
- I-Disease 0 1.388090822729282e-05
PLL I-Disease 0 2.3051265088724904e-05
samples O 0 3.6855027474302915e-07
had O 0 6.344929204260552e-08
a O 0 2.5661613278771256e-08
previously O 0 2.235853571619373e-06
reported O 0 0.0004930425784550607
A B-Disease 1 0.9997867941856384
- I-Disease 1 0.9998859167098999
T I-Disease 1 0.9999947547912598
allele O 0 4.181767872069031e-05
. O 0 4.5571292162094323e-07

In O 0 3.257924277022539e-07
contrast O 0 6.136393722044886e-07
, O 0 1.6520669277042543e-08
no O 0 9.69513980209058e-09
mutations O 0 4.127669228637387e-08
were O 0 5.779901357527706e-08
detected O 0 1.0766866580524947e-06
in O 0 8.125161654604085e-10
the O 0 7.747066321783791e-10
p53 O 0 6.922014517130037e-09
gene O 0 3.327155084775768e-08
, O 0 3.707391948992722e-09
suggesting O 0 5.330842967055105e-08
that O 0 5.009322290305818e-09
this O 0 4.307835510530822e-08
tumour B-Disease 1 0.9999971389770508
suppressor O 0 6.598220352316275e-05
is O 0 2.7640129474093555e-07
not O 0 1.4852964191902629e-08
frequently O 0 1.2102168156502557e-08
altered O 0 8.164690257217444e-08
in O 0 1.0685464069126738e-08
this O 0 1.3626835482227762e-07
leukaemia B-Disease 0 0.11182045191526413
. O 0 3.6242695955479576e-07

Occasional O 0 5.5105356295825914e-05
missense O 0 0.00022816901037003845
mutations O 0 4.210403403703822e-06
in O 0 2.3068123411462693e-08
ATM O 0 5.4819960496388376e-05
were O 0 4.296085762689472e-07
also O 0 4.718165058648083e-08
found O 0 1.0143267559215019e-07
in O 0 1.0505808489824631e-07
tumour B-Disease 1 0.999997615814209
DNA O 0 2.325546483916696e-05
from O 0 3.5228268302489596e-08
patients O 0 6.29700522836174e-08
with O 0 1.032438046166817e-08
B B-Disease 0 0.002761015435680747
- I-Disease 0 0.00037509205867536366
cell I-Disease 0 0.0010304899187758565
non I-Disease 0 7.98076725914143e-05
- I-Disease 1 0.9934158325195312
Hodgkins I-Disease 1 0.9999932050704956
lymphomas I-Disease 1 0.9789746999740601
( O 0 8.899497316861016e-08
B B-Disease 0 0.0001279878051718697
- I-Disease 0 1.884775520011317e-05
NHL I-Disease 0 4.7888558896147515e-08
) O 0 1.873704524868458e-09
and O 0 3.588300323542626e-09
a O 0 1.3879946436645696e-07
B B-Disease 0 0.0005148842465132475
- I-Disease 0 2.39909077208722e-05
NHL I-Disease 0 1.56852763666393e-06
cell O 0 1.6768019122537225e-05
line O 0 7.717237895121798e-05
. O 0 6.825354716966103e-07

The O 0 1.3987767033540877e-07
evidence O 0 8.683794305852643e-08
of O 0 1.1395827614890663e-09
a O 0 1.058238741080686e-08
significant O 0 1.4977054263454193e-08
proportion O 0 5.043820294758916e-08
of O 0 5.438584249617406e-09
loss O 0 9.26070788409561e-06
- O 0 6.309241143753752e-05
of O 0 8.375067039878559e-08
- O 0 0.009043385274708271
function O 0 7.993447752596694e-07
mutations O 0 3.132496431135223e-07
and O 0 6.842169852916413e-08
a O 0 4.767757388890459e-08
complete O 0 3.2438023822578543e-07
absence O 0 1.0350568402373028e-07
of O 0 6.689123699388233e-10
the O 0 2.5054389674039612e-09
normal O 0 1.9205808499123123e-08
copy O 0 9.758071684018432e-08
of O 0 1.5426260269180148e-09
ATM O 0 9.463038622925524e-06
in O 0 4.162135969210112e-09
the O 0 1.2253321690636199e-09
majority O 0 1.294471108082007e-08
of O 0 9.11997943831011e-09
mutated O 0 8.728015382075682e-05
tumours B-Disease 1 0.9999960660934448
establishes O 0 8.350389748557063e-07
somatic O 0 2.078317891118786e-07
inactivation O 0 8.577389053243678e-06
of O 0 4.190925384506272e-09
this O 0 7.660773349016381e-09
gene O 0 1.1900248608753827e-07
in O 0 2.4493616024301446e-09
the O 0 1.5200427583295095e-09
pathogenesis O 0 1.7399709406618058e-07
of O 0 2.0198227534962143e-09
sporadic B-Disease 0 0.006514443084597588
T I-Disease 1 0.9165900945663452
- I-Disease 0 0.00013306527398526669
PLL I-Disease 0 4.0888338844524696e-05
and O 0 1.4332615982937114e-08
suggests O 0 1.2145455308143482e-08
that O 0 1.4958660976560623e-09
ATM O 0 3.512164312269306e-06
acts O 0 1.3584769931185292e-07
as O 0 2.877172811110995e-08
a O 0 1.7097081581596285e-06
tumour B-Disease 1 0.9999939203262329
suppressor O 0 0.0015603081556037068
. O 0 2.3589925604028394e-06

As O 0 2.694680176773545e-07
constitutional O 0 5.735873642720435e-08
DNA O 0 1.0827536698343465e-06
was O 0 6.312258733487397e-07
not O 0 3.6521703439262865e-09
available O 0 3.365487000195344e-09
, O 0 3.493364042483904e-09
a O 0 4.4209667038330736e-08
putative O 0 1.4596167602576315e-05
hereditary O 0 0.019879203289747238
predisposition O 0 0.0007719748537056148
to O 0 4.286519470042549e-06
T B-Disease 1 0.971993625164032
- I-Disease 0 0.0001261712604900822
PLL I-Disease 0 7.811170507920906e-05
will O 0 2.8640323890272157e-08
require O 0 3.5040144119591332e-09
further O 0 3.1214368867438225e-09
investigation O 0 9.976682235901535e-08
. O 0 1.7347131731071386e-08
. O 0 1.3979791901874705e-07

Myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999979734420776
protein O 0 0.0001672832149779424
kinase O 0 0.000212814673432149
is O 0 2.6784420015246724e-07
involved O 0 1.449896380734117e-08
in O 0 1.1698648716418347e-09
the O 0 1.7372012162120143e-10
modulation O 0 4.007820741946944e-09
of O 0 3.3034391888620007e-10
the O 0 5.2087516522192345e-09
Ca2 O 0 2.478579062881181e-06
+ O 0 1.3724557902605738e-05
homeostasis O 0 0.0014815855538472533
in O 0 6.502087899207254e-07
skeletal O 0 0.4066658616065979
muscle O 0 0.00032959700911305845
cells O 0 4.433093636180274e-06
. O 0 4.6729729774597217e-07

Myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.0006416221149265766
DM B-Disease 1 0.9999998807907104
) O 0 1.0421451861475362e-06
, O 0 3.3452270287170904e-08
the O 0 5.442579720238427e-09
most O 0 1.0191846655516201e-07
prevalent O 0 0.0036309650167822838
muscular B-Disease 1 0.983385443687439
disorder I-Disease 0 0.33071205019950867
in O 0 1.4050685592792433e-07
adults O 0 2.5809372345975135e-06
, O 0 4.6328946012863526e-08
is O 0 1.9381198512746778e-07
caused O 0 3.7703844668612874e-07
by O 0 4.754650451133102e-09
( O 0 6.670894059368493e-09
CTG O 0 7.59206932343659e-06
) O 0 6.7386975999284005e-09
n O 0 6.126124844740843e-06
- O 0 1.8928744793811347e-06
repeat O 0 6.69662298946605e-08
expansion O 0 1.5775231787529265e-08
in O 0 6.308503719409941e-10
a O 0 2.6704769506835646e-09
gene O 0 1.0141541828545542e-08
encoding O 0 1.0457902988036949e-08
a O 0 8.150702512921271e-08
protein O 0 2.4459745873173233e-06
kinase O 0 7.699867273913696e-05
( O 0 4.6959715405137104e-07
DM B-Disease 1 0.9999992847442627
protein O 0 3.619762537709903e-06
kinase O 0 2.2437900042859837e-05
; O 0 3.6578331474856896e-08
DMPK O 0 3.441251828917302e-05
) O 0 3.1714511017355562e-09
and O 0 2.029322265784117e-09
involves O 0 3.289720940102825e-09
changes O 0 3.94225541100468e-09
in O 0 7.586889338995206e-09
cytoarchitecture O 0 2.0386383766890503e-05
and O 0 2.0301794734223222e-07
ion O 0 0.00021338503574952483
homeostasis O 0 0.004082101862877607
. O 0 2.7256382963969372e-06

To O 0 1.2679315375407896e-07
obtain O 0 9.598343808647769e-08
clues O 0 1.374186098246355e-07
to O 0 5.6493894007303425e-09
the O 0 1.968838203580958e-09
normal O 0 4.771441908246743e-08
biological O 0 1.025835132395514e-07
role O 0 2.207325433545293e-09
of O 0 3.7326924884339974e-10
DMPK O 0 7.991885468072724e-06
in O 0 2.962269762818437e-09
cellular O 0 4.604221430781763e-06
ion O 0 2.9909369914093986e-05
homeostasis O 0 0.0015026273904368281
, O 0 5.547927273141795e-08
we O 0 4.7518064150153805e-08
have O 0 1.300980101426319e-09
compared O 0 8.701847242775784e-09
the O 0 1.8471481011417268e-09
resting O 0 2.5870608624245506e-06
[ O 0 1.0992488697070257e-08
Ca2 O 0 2.8368162929837126e-08
+ O 0 1.4799890379890712e-07
] O 0 1.6294885085699207e-07
i O 0 3.856764578813454e-07
, O 0 8.693099573520158e-10
the O 0 9.190728039731866e-11
amplitude O 0 2.301894141965022e-08
and O 0 5.344349851554853e-09
shape O 0 9.867336103752677e-08
of O 0 6.734145463482832e-10
depolarization O 0 7.087708695507899e-07
- O 0 6.487450446002185e-05
induced O 0 8.192408859031275e-05
Ca2 O 0 8.026264026739227e-07
+ O 0 1.4579184153262759e-06
transients O 0 2.590885924291797e-05
, O 0 2.1074713529856126e-08
and O 0 2.3738850885024476e-09
the O 0 2.3330984366687346e-10
content O 0 5.4380033809309225e-09
of O 0 3.8421851811243357e-10
ATP O 0 4.2210672290821094e-07
- O 0 3.6687513329525245e-06
driven O 0 2.866748900487437e-06
ion O 0 3.608092583817779e-06
pumps O 0 8.879173947207164e-07
in O 0 6.850327860519201e-09
cultured O 0 4.487836849875748e-05
skeletal O 0 0.0022230790928006172
muscle O 0 1.3981821211928036e-06
cells O 0 4.284465759951672e-08
of O 0 1.0960973240159433e-09
wild O 0 7.205217116279528e-07
- O 0 4.3778898543678224e-05
type O 0 0.00047887800610624254
and O 0 1.5960081611865462e-07
DMPK O 0 0.00014438758080359548
[ O 0 2.840255035607697e-07
- O 0 5.134458115207963e-05
/ O 0 0.00015157721645664424
- O 0 0.0002942299470305443
] O 0 3.386049456821638e-06
knockout O 0 8.012268517632037e-05
mice O 0 5.6264801969518885e-05
. O 0 5.709861170544173e-07

In O 0 7.846394964872161e-07
vitro O 0 3.4159871574956924e-05
- O 0 2.8704678697977215e-05
differentiated O 0 4.735863967653131e-06
DMPK O 0 0.0001506804401287809
[ O 0 7.952638725328143e-07
- O 0 3.098627712461166e-05
/ O 0 4.945234832121059e-05
- O 0 4.7035468014655635e-05
] O 0 1.6288173299017217e-07
myotubes O 0 4.0932286538009066e-07
exhibit O 0 1.596487635424637e-07
a O 0 2.322285652667233e-08
higher O 0 1.2349813971468393e-07
resting O 0 2.9905368137406185e-06
[ O 0 2.296828682801788e-08
Ca2 O 0 4.2260698052132284e-08
+ O 0 2.2548418598944409e-07
] O 0 1.5791103180617938e-07
i O 0 6.770289218138714e-08
than O 0 2.292551481986038e-09
do O 0 6.752567394130438e-09
wild O 0 1.6063436802937758e-08
- O 0 1.1242761502217036e-05
type O 0 2.348322595935315e-05
myotubes O 0 5.418962246039882e-06
because O 0 4.7898125465906105e-09
of O 0 2.861015591104632e-10
an O 0 4.3520418380182946e-09
altered O 0 3.469845353265555e-07
open O 0 2.173279156636454e-08
probability O 0 1.3211961302772579e-08
of O 0 3.2808478156454157e-09
voltage O 0 0.00010051952267531306
- O 0 7.976505003171042e-06
dependent O 0 1.5662644727854058e-06
l O 0 1.5972940673236735e-05
- O 0 1.0308323226126959e-06
type O 0 2.628169568197336e-06
Ca2 O 0 2.063306823174571e-07
+ O 0 3.1755843110659043e-07
and O 0 4.434757983062809e-08
Na O 0 2.5140529942291323e-06
+ O 0 6.838645845164137e-07
channels O 0 8.279023973045696e-07
. O 0 2.7875276487066003e-07

The O 0 5.812592007714557e-07
mutant O 0 3.6213853036315413e-06
myotubes O 0 4.395148152980255e-06
exhibit O 0 2.82567668818956e-07
smaller O 0 4.1745725098962794e-08
and O 0 2.9976683357801903e-09
slower O 0 2.615013556805934e-07
Ca2 O 0 6.601596282962419e-07
+ O 0 8.204824553104118e-07
responses O 0 2.5469926612231575e-08
upon O 0 2.7430921978321976e-09
triggering O 0 5.1339895890123444e-08
by O 0 2.953851829801124e-09
acetylcholine O 0 1.4437089248531265e-06
or O 0 1.1363084695403813e-07
high O 0 3.7135549746381e-07
external O 0 9.701919907456613e-07
K O 0 1.3913007023802493e-05
+ O 0 1.0622670743032359e-06
. O 0 1.0451126541966005e-07

In O 0 2.851490989996819e-07
addition O 0 3.0565605158017206e-08
, O 0 6.341949632115984e-09
we O 0 2.080594585507356e-09
observed O 0 2.6495334815024307e-09
that O 0 1.4508270973490056e-10
these O 0 4.1968506447886966e-10
Ca2 O 0 1.7457385581565177e-07
+ O 0 6.331642339318932e-07
transients O 0 1.0714733434724621e-05
partially O 0 8.745409445509722e-07
result O 0 5.326855401222019e-09
from O 0 2.5980770312905577e-10
an O 0 1.902266538733599e-10
influx O 0 8.619709945811849e-10
of O 0 1.232649815552378e-10
extracellular O 0 1.3487919225951828e-08
Ca2 O 0 3.828531802696489e-08
+ O 0 8.357976355455321e-08
through O 0 1.541872851618109e-09
the O 0 1.7027763643540084e-09
l O 0 5.810712991660694e-06
- O 0 3.908546204911545e-06
type O 0 1.8211538190371357e-05
Ca2 O 0 1.1343502137606265e-06
+ O 0 2.2139522570796544e-06
channel O 0 8.965445886133239e-06
. O 0 5.679112859979796e-07

Neither O 0 1.2293379541006288e-06
the O 0 1.2354378853274284e-08
content O 0 5.7746120774027077e-08
nor O 0 1.6754256648709998e-08
the O 0 2.0449331117333713e-10
activity O 0 1.3648602248395036e-08
of O 0 2.8512969763028195e-10
Na O 0 6.461802399826411e-07
+ O 0 2.57103664580427e-07
/ O 0 3.357894513555948e-07
K O 0 4.279206109458755e-07
+ O 0 1.0924249949084697e-07
ATPase O 0 3.434913651290117e-06
and O 0 2.4639165374651384e-08
sarcoplasmic O 0 2.0909187696815934e-06
reticulum O 0 3.88532589568058e-06
Ca2 O 0 2.2878275558468886e-06
+ O 0 2.456077254464617e-06
- O 0 2.276251734656398e-06
ATPase O 0 3.272700632805936e-05
are O 0 1.2629035595068672e-08
affected O 0 3.9378981853133155e-08
by O 0 1.8720479388889544e-08
DMPK O 0 0.00024228388792835176
absence O 0 1.0587453971311334e-06
. O 0 4.853556561101868e-07

In O 0 1.3543761667733634e-07
conclusion O 0 3.8947234770603245e-08
, O 0 4.022862487573775e-09
our O 0 7.155537828928971e-10
data O 0 6.138685559875512e-09
suggest O 0 8.164359854845316e-09
that O 0 2.073448079897844e-09
DMPK O 0 1.13075338958879e-05
is O 0 1.1308205927207382e-08
involved O 0 8.065811130109068e-09
in O 0 1.821860884376747e-09
modulating O 0 1.4840340156752063e-07
the O 0 9.922096477765763e-10
initial O 0 9.760375618839134e-09
events O 0 4.028375411024854e-09
of O 0 1.0060293709202028e-09
excitation O 0 8.203111292459653e-07
- O 0 0.0001842354831751436
contraction O 0 3.481110979919322e-05
coupling O 0 2.816329651977867e-05
in O 0 7.191364659320243e-08
skeletal O 0 0.0014835040783509612
muscle O 0 9.49759214563528e-06
. O 0 4.0052857031014355e-08
. O 0 1.7354948056436115e-07

Constitutional O 0 7.787935464875773e-05
RB1 O 0 0.013350029475986958
- O 0 0.0003975189756602049
gene O 0 8.686080946063157e-06
mutations O 0 7.007779913692502e-06
in O 0 1.4446686691371724e-07
patients O 0 5.378065566219448e-07
with O 0 7.346486796677709e-08
isolated O 0 0.0003968276141677052
unilateral B-Disease 0 0.0029312868136912584
retinoblastoma I-Disease 0 0.1251750886440277
. O 0 2.396173385932343e-06

In O 0 4.580142842769419e-07
most O 0 8.451449673430034e-08
patients O 0 1.4162804973238963e-07
with O 0 1.425798856757865e-08
isolated O 0 8.979460108093917e-05
unilateral B-Disease 0 0.0015471361111849546
retinoblastoma I-Disease 0 0.021433893591165543
, O 0 1.0948426165668934e-07
tumor B-Disease 0 1.2981662621314172e-05
development O 0 2.190282799574561e-08
is O 0 8.067380541376679e-09
initiated O 0 8.6515692387934e-09
by O 0 4.69281502546437e-10
somatic O 0 3.650082902595386e-08
inactivation O 0 3.809091367656947e-06
of O 0 2.969555934484447e-09
both O 0 4.4299794943469806e-09
alleles O 0 7.572880100781276e-09
of O 0 2.411668420521096e-09
the O 0 1.0570369113338529e-07
RB1 O 0 0.0009149418328888714
gene O 0 1.7883237433125032e-06
. O 0 5.175816113478504e-07

However O 0 6.657136850662937e-07
, O 0 1.8311391514203024e-08
some O 0 4.027205791068411e-10
of O 0 3.22740750791084e-10
these O 0 1.9656948069268765e-08
patients O 0 2.1892557811042934e-07
can O 0 2.9812028401465795e-08
transmit O 0 0.0002496718370821327
retinoblastoma B-Disease 0 0.1644611805677414
predisposition O 0 0.006616953294724226
to O 0 3.8081000752754335e-07
their O 0 1.7567865029377572e-07
offspring O 0 4.221850758767687e-06
. O 0 3.714312981628609e-07

To O 0 2.0055438199051423e-07
determine O 0 3.678724880273876e-08
the O 0 1.6747857545240663e-09
frequency O 0 4.7001202574392664e-07
and O 0 1.639438806932958e-08
nature O 0 2.8826001141624147e-08
of O 0 1.3086404182516276e-09
constitutional O 0 1.1378722319932422e-07
RB1 O 0 0.0011311075650155544
- O 0 2.0517745724646375e-05
gene O 0 1.2582338513311697e-06
mutations O 0 7.959065442264546e-07
in O 0 6.01568572733413e-08
patients O 0 2.401425263087731e-07
with O 0 2.2654115028331034e-08
isolated O 0 0.001133144716732204
unilateral B-Disease 0 0.0013032323913648725
retinoblastoma I-Disease 0 0.002806594129651785
, O 0 7.486784880939013e-08
we O 0 6.960235943154203e-09
analyzed O 0 2.1196983723825724e-08
DNA O 0 1.1891228979266089e-07
from O 0 5.889132292935528e-09
peripheral O 0 3.548081804183312e-05
blood O 0 1.1584609183046268e-06
and O 0 3.7003857755735226e-08
from O 0 4.826028643378777e-08
tumor B-Disease 0 0.0009057990391738713
tissue O 0 0.0001464966480853036
. O 0 5.063503749624942e-07

The O 0 1.0335969591324101e-07
analysis O 0 8.325629607952578e-08
of O 0 6.72782221045054e-08
tumors B-Disease 1 0.9999943971633911
from O 0 3.307767570959186e-08
54 O 0 1.7684624253888614e-07
( O 0 1.8067661811116409e-09
71 O 0 7.75424382482015e-08
% O 0 8.687381369831826e-10
) O 0 1.9697762865256152e-10
of O 0 6.130573826368391e-10
76 O 0 2.2985385328411212e-07
informative O 0 8.422124665230513e-05
patients O 0 2.5062008717213757e-06
showed O 0 1.5651340845579398e-06
loss O 0 2.1436301267385716e-07
of O 0 6.264406771094855e-09
constitutional O 0 5.431019189927611e-07
heterozygosity O 0 0.00225148000754416
( O 0 3.1293902793549933e-06
LOH O 1 0.999383807182312
) O 0 1.0218143842166683e-07
at O 0 4.830098987440579e-07
intragenic O 0 5.444755151984282e-05
loci O 0 4.137797077419236e-06
. O 0 1.0125346534550772e-06

Three O 0 1.2150778161412745e-07
of O 0 2.218769878936655e-08
13 O 0 1.7935570895133424e-07
uninformative O 0 0.009151531383395195
patients O 0 3.307121369289234e-05
had O 0 3.785386581967032e-07
constitutional O 0 4.4356042394610995e-07
deletions O 0 2.6690411687013693e-05
. O 0 2.661879761944874e-06

For O 0 1.7657306727869582e-07
39 O 0 5.247635499472381e-07
randomly O 0 2.94035231718226e-07
selected O 0 5.282864776745555e-07
tumors B-Disease 1 0.9999897480010986
, O 0 3.285221055193688e-07
SSCP O 0 0.0003417390980757773
, O 0 2.4452599944879694e-08
hetero O 0 4.074404841958312e-06
- O 0 3.6045023534825305e-06
duplex O 0 0.00012080723536200821
analysis O 0 7.027094994782601e-08
, O 0 2.5986830465285493e-09
sequencing O 0 1.2558510675830803e-08
, O 0 7.257032308416456e-09
and O 0 3.0691422736595086e-09
Southern O 0 5.033438554846725e-09
blot O 0 2.3486306872655405e-06
analysis O 0 1.2600979815147184e-08
were O 0 8.440990129088277e-09
used O 0 1.0533733885154106e-08
to O 0 8.898966896708771e-09
identify O 0 8.340933845829568e-07
mutations O 0 2.257099595226464e-06
. O 0 3.341146452839894e-07

Mutations O 0 4.814757267013192e-05
were O 0 7.974473419380956e-07
detected O 0 3.1035156098369043e-06
in O 0 7.955755165767187e-09
21 O 0 1.165139984493635e-08
( O 0 7.005288571448887e-10
91 O 0 1.0903658420602369e-08
% O 0 1.0729694910338594e-09
) O 0 3.3722322156926055e-10
of O 0 5.233299127382907e-09
23 O 0 4.1544288251316175e-05
tumors B-Disease 1 0.9999970197677612
with O 0 1.7347236280329525e-05
LOH O 1 0.9998570680618286
. O 0 5.721838078898145e-06

In O 0 3.782009230235417e-07
6 O 0 1.8537072321578307e-07
( O 0 3.0824478525204313e-09
38 O 0 9.059782257736515e-09
% O 0 6.350201475768813e-10
) O 0 5.271394432071475e-10
of O 0 2.7643323186055113e-09
16 O 0 3.1339564884547144e-05
tumors B-Disease 1 0.9999997615814209
without O 0 9.1123465608689e-06
LOH O 1 0.9999191761016846
, O 0 9.638759479457804e-08
one O 0 1.3826645606229704e-08
mutation O 0 5.054577911778324e-08
was O 0 3.919151367881568e-07
detected O 0 7.273217306646984e-06
, O 0 1.0447834597471228e-08
and O 0 5.964487126419726e-09
in O 0 4.034188538781791e-09
9 O 0 7.368421250930624e-08
( O 0 1.0047099818777383e-09
56 O 0 5.4557478534889015e-09
% O 0 3.199623344052327e-10
) O 0 5.176679085394653e-10
of O 0 3.886906796424228e-09
the O 0 5.359079295885749e-06
tumors B-Disease 1 0.9999998807907104
without O 0 3.149308395222761e-05
LOH O 1 0.9998348951339722
, O 0 3.61968908180188e-08
both O 0 2.468694804136362e-09
mutations O 0 1.3137434962118277e-07
were O 0 3.1488323770645366e-07
found O 0 5.287254793984175e-07
. O 0 2.091727679953692e-07

Thus O 0 2.254812670798856e-06
, O 0 2.80285732401353e-08
a O 0 4.593061486701799e-09
total O 0 3.0838356313012127e-09
of O 0 1.0970218067285487e-09
45 O 0 2.7035550687060095e-08
mutations O 0 8.710086518703974e-08
were O 0 1.4814547455443972e-07
identified O 0 4.692838047049008e-06
in O 0 4.7421545446013624e-07
tumors B-Disease 1 0.9999973773956299
of O 0 3.531767944764397e-08
36 O 0 6.918743565620389e-06
patients O 0 1.6043097730289446e-06
. O 0 3.859391313199012e-07

Thirty O 0 4.183486908004852e-06
- O 0 1.4598798770748544e-05
nine O 0 3.051376040730247e-08
of O 0 8.729604261681345e-10
the O 0 1.7492983728217837e-09
mutations O 0 1.2617506683909596e-07
- O 0 2.990445636896766e-06
including O 0 1.2759100442849558e-08
34 O 0 3.1737158678879496e-08
small O 0 7.864346684982593e-08
mutations O 0 1.0151067186825458e-07
, O 0 7.8152666560527e-09
2 O 0 7.921127753718338e-09
large O 0 4.21922372595418e-08
structural O 0 3.1749259505886585e-06
alterations O 0 6.440352080971934e-06
, O 0 5.069156117087914e-08
and O 0 1.8164385551244777e-08
hypermethylation O 0 0.00027673618751578033
in O 0 3.008438511642453e-07
3 O 0 1.824262108129915e-05
tumors O 1 0.9999995231628418
- O 0 0.0028319936245679855
were O 0 6.099954589444678e-06
not O 0 3.6018104054846845e-08
detected O 0 5.045624789090652e-07
in O 0 4.211388737740407e-10
the O 0 1.1719528680842473e-09
corresponding O 0 9.943511969368046e-08
peripheral O 0 7.466501847375184e-05
blood O 0 5.332253294909606e-06
DNA O 0 7.86489272286417e-06
. O 0 1.2692855761997635e-06

In O 0 3.4647598567971727e-07
6 O 0 1.5640119954696274e-07
( O 0 2.427451573083772e-09
17 O 0 6.033505695057784e-09
% O 0 4.439509870834968e-10
) O 0 9.113935300897325e-11
of O 0 1.1959677692630066e-10
the O 0 2.0519159704690537e-09
36 O 0 1.6084935339222284e-07
patients O 0 3.4627703371370444e-08
, O 0 3.5565617118038517e-09
a O 0 7.253022005215826e-08
mutation O 0 2.473527729307534e-07
was O 0 5.791190233139787e-06
detected O 0 8.301641173602547e-06
in O 0 4.11146494627701e-09
constitutional O 0 7.599214590925385e-09
DNA O 0 5.32618798843032e-07
, O 0 7.28515736625468e-09
and O 0 4.1528500638321475e-09
1 O 0 2.2308583869090626e-09
of O 0 1.2812396976702445e-10
these O 0 6.0685683145322855e-09
mutations O 0 1.2633967116926215e-07
is O 0 2.2908741570404345e-08
known O 0 1.0519824655830234e-07
to O 0 8.66048477377035e-09
be O 0 3.226659828214906e-08
associated O 0 7.867977558362327e-08
with O 0 5.553432558258464e-08
reduced O 0 3.393093265913194e-06
expressivity O 0 0.0007999772788025439
. O 0 8.026662499105441e-07

The O 0 2.500160860563483e-07
presence O 0 1.2782233227426332e-07
of O 0 1.8242671817603195e-09
a O 0 2.2947837408082705e-08
constitutional O 0 9.916159449119277e-09
mutation O 0 1.8957834413413366e-07
was O 0 5.6711523939156905e-06
not O 0 5.12620097481431e-08
associated O 0 7.882743346954157e-08
with O 0 8.237014625933625e-09
an O 0 3.6563940764011704e-09
early O 0 1.0983376341755502e-07
age O 0 1.1330210725191137e-07
at O 0 2.9698870207539585e-07
treatment O 0 1.1054429478463135e-06
. O 0 1.6032100802476634e-07

In O 0 5.469727284435066e-07
1 O 0 5.069490498499363e-07
patient O 0 5.299868007568875e-06
, O 0 7.49443884728862e-09
somatic O 0 7.339133958339517e-07
mosaicism O 0 0.0008663312764838338
was O 0 2.4476932594552636e-05
demonstrated O 0 2.3874591192907246e-07
by O 0 8.443064025698277e-10
molecular O 0 1.0356211888051803e-08
analysis O 0 4.141720744144095e-09
of O 0 1.9694768038647226e-09
DNA O 0 3.516681772453012e-06
and O 0 7.07064202742913e-08
RNA O 0 3.347359154304286e-07
from O 0 3.368262824210433e-08
peripheral O 0 0.00012215466995257884
blood O 0 2.1557167201535776e-05
. O 0 7.629759579685924e-07

In O 0 6.117800808169704e-07
2 O 0 6.954538207537553e-07
patients O 0 1.9904943826531962e-07
without O 0 5.241500122821208e-09
a O 0 2.5230011857502177e-08
detectable O 0 2.1651263523381203e-05
mutation O 0 2.0173256132238748e-07
in O 0 2.70364797216871e-08
peripheral O 0 0.01106630265712738
blood O 0 4.159709351370111e-05
, O 0 2.525692543997593e-08
mosaicism O 0 3.1673855119151995e-05
was O 0 3.765170049518929e-06
suggested O 0 5.161422791388759e-07
because O 0 1.1887981266056613e-08
1 O 0 3.0586349009098512e-09
of O 0 8.151799235633916e-10
the O 0 4.3932942617175286e-08
patients O 0 6.863251655886415e-07
showed O 0 4.291608274797909e-05
multifocal O 1 0.9998626708984375
tumors B-Disease 1 0.9999998807907104
and O 0 2.2227063709578943e-06
the O 0 1.0191649302271344e-08
other O 0 2.005672294913552e-09
later O 0 4.2177674686172395e-08
developed O 0 8.197769716389303e-07
bilateral B-Disease 0 1.1614318282227032e-05
retinoblastoma I-Disease 0 0.0020630802027881145
. O 0 1.6169617538253078e-06

In O 0 1.912393372549559e-07
conclusion O 0 4.127889496885473e-08
, O 0 8.651602101394928e-09
our O 0 2.197030557482549e-09
results O 0 3.262688341720832e-09
emphasize O 0 1.2130754178940606e-08
that O 0 3.612128374186341e-09
the O 0 6.903631000199084e-10
manifestation O 0 3.293926909009315e-07
and O 0 1.4227563127633402e-08
transmissibility O 0 1.603766719426858e-07
of O 0 9.90368009823328e-10
retinoblastoma B-Disease 0 4.39736186308437e-06
depend O 0 6.024722409847527e-08
on O 0 1.7490548032128572e-07
the O 0 4.106825546301707e-09
nature O 0 2.3077548405581183e-07
of O 0 1.314867881241355e-09
the O 0 3.60602925297826e-09
first O 0 3.669110881787674e-08
mutation O 0 4.787933605143735e-08
, O 0 1.4722592034388526e-09
its O 0 5.033167216339507e-10
time O 0 5.4801945204019376e-09
in O 0 1.6496888299855073e-09
development O 0 5.528438151713999e-08
, O 0 8.957308672563613e-09
and O 0 2.7262134771888213e-09
the O 0 6.161521293179817e-10
number O 0 4.323283508966824e-09
and O 0 3.442945484266602e-09
types O 0 2.5643460688229425e-08
of O 0 5.752400222824861e-10
cells O 0 1.5365305472414548e-08
that O 0 2.275652333239009e-09
are O 0 1.939949090257187e-09
affected O 0 9.357681740596036e-09
. O 0 2.832013956677315e-09
. O 0 9.962116820361189e-08

Hereditary B-Disease 1 0.9999828338623047
deficiency I-Disease 1 0.9998733997344971
of I-Disease 0 4.6655540586471034e-07
the I-Disease 0 1.1635881236315981e-07
fifth I-Disease 0 4.243834609951591e-06
component I-Disease 0 4.892453034699429e-06
of I-Disease 0 7.2757426750058585e-09
complement I-Disease 0 3.514803665893851e-07
in O 0 3.7612903014405674e-08
man O 0 1.9156592315994203e-05
. O 0 2.791374242860911e-07

I O 0 0.00033976431586779654
. O 0 7.749032192805316e-06

Clinical O 0 0.00021494593238458037
, O 0 4.043589285629423e-07
immunochemical O 0 0.00021684198873117566
, O 0 1.5823968624317786e-07
and O 0 1.2092019119336328e-07
family O 0 6.491307544820302e-07
studies O 0 8.646278359947246e-08
. O 0 2.434905184145464e-07

The O 0 5.221228320806404e-07
first O 0 9.271361989249272e-08
recognized O 0 9.854039717538399e-08
human O 0 1.711915871283054e-07
kindred O 0 0.00011045696010114625
with O 0 2.3182303266366944e-05
hereditary B-Disease 1 0.9999860525131226
deficiency I-Disease 1 0.9921495914459229
of I-Disease 0 2.833322909623348e-08
the I-Disease 0 4.229779193565264e-08
fifth I-Disease 0 2.4021221634029644e-06
component I-Disease 0 1.226367021445185e-05
of I-Disease 0 1.0065076772036718e-08
complement I-Disease 0 9.955797395377886e-07
( O 0 5.0754543678976916e-08
C5 O 0 4.9771500925999135e-05
) O 0 2.2032297763985298e-08
is O 0 7.882758268351608e-08
described O 0 3.3219098440895323e-06
. O 0 8.35144874145044e-07

The O 0 3.332973790293181e-07
proband O 0 5.9286339819664136e-05
, O 0 4.0427554637290086e-08
a O 0 2.0546938372945078e-08
20 O 0 2.1143845785331905e-08
- O 0 4.615040325006703e-06
year O 0 6.50414690994694e-08
- O 0 8.031575998757035e-05
old O 0 6.119193130871281e-05
black O 0 7.252569503179984e-06
female O 0 3.03393403555674e-06
with O 0 5.0563932745717466e-05
systemic B-Disease 1 0.9999998807907104
lupus I-Disease 1 0.9999867677688599
erythematosus I-Disease 1 0.9999940395355225
since O 0 9.717832654132508e-06
age O 0 3.3265700949414168e-06
11 O 0 1.9705191789398668e-07
, O 0 9.575742154765976e-08
lacked O 0 6.1961973187862895e-06
serum O 0 0.00014668521180283278
hemolytic O 0 0.010022877715528011
complement O 0 1.7270710372940812e-07
activity O 0 1.4246863884181948e-06
, O 0 1.0124321825344396e-08
even O 0 8.668979312176361e-09
during O 0 1.0451844190129123e-07
remission O 0 2.279125510540325e-06
. O 0 2.5246001200684987e-07

C5 O 0 0.022005833685398102
was O 0 0.0001539926161058247
undetectable O 0 0.0005691872211173177
in O 0 8.975782606057692e-08
her O 0 2.7716203021554975e-07
serum O 0 6.609357114939485e-07
by O 0 3.649259783244929e-09
both O 0 1.49313024166986e-08
immunodiffusion O 0 9.262988169211894e-05
and O 0 3.160751248287852e-06
hemolytic O 1 0.9018723964691162
assays O 0 0.00010402368206996471
. O 0 1.6028507161536254e-06

Other O 0 1.1950368161706137e-07
complement O 0 1.9228539827054192e-07
components O 0 3.874674234793929e-07
were O 0 2.5384327528854556e-08
normal O 0 2.1488817836257113e-08
during O 0 2.468780735398468e-08
remission O 0 2.443838411636534e-07
of O 0 9.29644894398507e-09
lupus O 0 0.0031536088790744543
, O 0 4.1190496347098815e-08
but O 0 1.4773520717881183e-07
C1 O 0 0.00084501231322065
, O 0 8.100936099708633e-08
C4 O 0 5.189027433516458e-05
, O 0 1.484679614804918e-07
C2 O 0 3.478890721453354e-05
, O 0 1.2131240012536182e-08
and O 0 4.0515789834216775e-08
C3 O 0 0.007632023189216852
levels O 0 8.565174312025192e-07
fell O 0 2.8978209229535423e-05
during O 0 3.265828638632229e-07
exacerbations O 0 0.000727530918084085
. O 0 7.375634254458419e-07

A O 0 9.244471584679559e-06
younger O 0 1.0417745670565637e-06
half O 0 2.576448991931102e-07
- O 0 0.0007163548143580556
sister O 0 0.0009865862084552646
, O 0 2.6777419748214015e-07
who O 0 3.538450528139947e-07
had O 0 1.2838728480346617e-06
no O 0 2.0838460841332562e-06
underlying O 0 0.028938759118318558
disease O 0 0.0002632606483530253
, O 0 4.570848588514309e-08
was O 0 3.976087100454606e-05
also O 0 4.739003713893908e-07
found O 0 5.8593208507318195e-08
to O 0 2.722515191067032e-08
lack O 0 6.406571628758684e-07
immunochemically O 0 0.000400794466258958
detectable O 0 0.00013829997624270618
C5 O 0 0.0003813504590652883
. O 0 7.71699546930904e-07

By O 0 1.7727120393828955e-06
hemolytic O 1 0.9759442806243896
assay O 0 0.00022421190806198865
, O 0 1.873466430879489e-07
she O 0 2.9298712789227466e-08
exhibited O 0 1.3258086539735814e-07
1 O 0 1.9022756703179766e-08
- O 0 7.820301107130945e-06
2 O 0 2.6511928652439565e-08
% O 0 4.2826717172594897e-10
of O 0 1.696761481317921e-10
the O 0 3.4175078322817853e-09
normal O 0 6.183472578413785e-07
serum O 0 1.0893273838519235e-06
C5 O 0 2.8921001558046555e-06
level O 0 6.405361574479684e-08
and O 0 2.6803665953423206e-09
normal O 0 3.387641500651739e-09
concentrations O 0 1.1735596494588663e-08
of O 0 3.227739742150959e-10
other O 0 8.749140301134162e-10
complement O 0 8.741792356659062e-08
components O 0 3.3766104934329633e-06
. O 0 2.869462889520946e-07

C5 O 0 0.0009800181724131107
levels O 0 2.0051852516189683e-06
of O 0 6.931659690678771e-09
other O 0 4.8069912494952405e-09
family O 0 7.817192937409345e-08
members O 0 1.3988289415678423e-09
were O 0 5.662337798639783e-08
either O 0 5.465548902350292e-09
normal O 0 2.1743655764794312e-08
or O 0 5.9868723312206384e-09
approximately O 0 7.3323875859898635e-09
half O 0 3.2926603665828225e-08
- O 0 9.063431207323447e-06
normal O 0 5.147575166120077e-07
, O 0 1.0275874373633087e-08
consistent O 0 3.9073356106200663e-07
with O 0 1.2308002794725326e-07
autosomal O 0 0.0013962812954559922
codominant O 0 0.0010700239799916744
inheritance O 0 1.289296051254496e-06
of O 0 8.321339173278375e-09
the O 0 3.8263706869656744e-08
gene O 0 1.621347473701462e-05
determining O 0 0.030960820615291595
C5 B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999983310699463
. O 0 1.4763853869226296e-05

Normal O 0 0.0003535948053468019
hemolytic O 1 0.9977940320968628
titers O 0 0.0013301534345373511
were O 0 8.669824751450506e-07
restored O 0 8.285327339763171e-07
to O 0 1.593873477645502e-08
both O 0 6.450441958349984e-08
homozygous O 0 0.0062189665623009205
C5 B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999980926513672
deficient I-Disease 1 0.9999997615814209
( O 0 5.178964329388691e-06
C5D B-Disease 1 0.9999994039535522
) O 0 1.660562674032917e-07
sera O 0 2.8828457288909703e-05
by O 0 2.8848810007531256e-09
addition O 0 2.229578077717065e-09
of O 0 1.939860272415217e-09
highly O 0 7.83761493039492e-07
purified O 0 3.2485036172147375e-06
human O 0 6.132918883849925e-07
C5 O 0 0.00027153207338415086
. O 0 8.843992418405833e-07

In O 0 4.4217935624146776e-07
specific O 0 2.1259181437471852e-07
C5 O 0 3.883821773342788e-05
titrations O 0 0.00017997136455960572
, O 0 5.275343184507619e-08
however O 0 8.008875340692612e-09
, O 0 1.767364810056904e-09
it O 0 3.812483662102295e-09
was O 0 1.9826748030027375e-06
noted O 0 4.4756568229331606e-08
that O 0 8.149995678330413e-10
when O 0 8.527269446112484e-10
limited O 0 1.3163909962088383e-09
amounts O 0 1.301111662854737e-09
of O 0 4.666386166363168e-10
C5 O 0 5.879022864974104e-06
were O 0 7.511672350801746e-08
assayed O 0 6.455778134295542e-07
in O 0 2.020913436595606e-09
the O 0 1.1661309695654154e-09
presence O 0 8.484378533069048e-09
of O 0 5.763712285222766e-10
low O 0 1.1380798241589218e-06
dilutions O 0 7.620080850756494e-07
of O 0 6.509182970404481e-09
either O 0 3.644118805823382e-06
C5D B-Disease 1 0.9999991655349731
serum O 0 7.017887401161715e-05
, O 0 4.7626378396614655e-09
curving O 0 3.544496109952888e-07
rather O 0 7.22840853839557e-09
than O 0 1.578780661759538e-09
linear O 0 6.858253698283079e-08
dose O 0 6.38990087509228e-08
- O 0 1.3416535011856467e-06
response O 0 1.2277447503095118e-08
plots O 0 3.121236318293086e-07
were O 0 5.511455825057965e-08
consistently O 0 1.0307640252449346e-07
obtained O 0 2.247802166621682e-09
, O 0 5.530109148388362e-10
suggesting O 0 6.91868828894826e-09
some O 0 9.377403298316267e-10
inhibitory O 0 9.605503947796024e-08
effect O 0 8.925233174750247e-08
. O 0 9.307186132900824e-08

Further O 0 2.0023637148369744e-07
studies O 0 2.4596248593411474e-08
suggested O 0 5.7981203838153306e-08
that O 0 4.7886250520434714e-09
low O 0 3.9856545299699064e-06
dilutions O 0 3.214671596651897e-05
of O 0 1.7107765870605363e-07
C5D B-Disease 1 0.9999995231628418
serum O 0 0.00045858992962166667
contain O 0 1.6009488490453805e-07
a O 0 5.4513613179096865e-08
factor O 0 8.820713048862672e-08
( O 0 1.121125747793883e-09
or O 0 9.523282606949124e-09
factors O 0 2.94622193308669e-09
) O 0 4.733609615392709e-10
interfering O 0 4.348359894379428e-08
at O 0 6.99570819051587e-08
some O 0 8.548912688866039e-10
step O 0 5.857097562511626e-08
in O 0 6.215656433994354e-09
the O 0 2.8375414018455558e-08
hemolytic O 0 0.12002776563167572
assay O 0 9.78289108388708e-07
of O 0 8.88848372682105e-09
C5 O 0 6.895422120578587e-05
, O 0 8.741038115545052e-09
rather O 0 4.984503920724137e-09
than O 0 4.071090131674282e-09
a O 0 4.6057053282311244e-08
true O 0 1.6073664710347657e-06
C5 O 0 0.00019505641830619425
inhibitor O 0 4.357627403805964e-06
or O 0 2.1561984908657905e-07
inactivator O 0 1.5671845176257193e-05
. O 0 5.039997859057621e-07

Of O 0 4.460964078134566e-07
clinical O 0 3.893698249157751e-06
interest O 0 1.124690129472583e-06
are O 0 1.1944784716888535e-07
( O 0 5.259646940203311e-09
a O 0 6.019346443508766e-08
) O 0 3.201114484596701e-09
the O 0 8.281402785748071e-10
documentation O 0 4.6188748115127964e-07
of O 0 3.334900497975468e-07
membranous O 1 0.9994263648986816
glomerulonephritis B-Disease 1 1.0
, O 0 0.013683774508535862
vasculitis B-Disease 1 0.9999998807907104
, O 0 0.0019388896180316806
and O 0 0.2280697077512741
arthritis B-Disease 1 1.0
in O 0 1.986858023883542e-06
an O 0 1.5337934655690333e-06
individual O 0 1.8056891804008046e-07
lacking O 0 6.888983534736326e-06
C5 O 0 0.0006372890202328563
( O 0 1.1327569993113684e-08
and O 0 1.4672810522142754e-08
its O 0 1.6929317947500522e-09
biologic O 0 6.238391847546154e-07
functions O 0 4.468046377326118e-09
) O 0 1.2763425871753498e-09
, O 0 4.676082188126429e-09
and O 0 1.854583508986707e-08
( O 0 1.1172454961183576e-08
b O 0 1.0672674761735834e-05
) O 0 1.4566368111701422e-09
a O 0 1.6483559406310633e-08
remarkable O 0 6.651634976151399e-07
propensity O 0 0.0004141942772548646
to O 0 1.498192341387039e-05
bacterial B-Disease 1 0.9999995231628418
infections I-Disease 1 0.9999995231628418
in O 0 1.319808831112823e-07
the O 0 4.1603758660357926e-08
proband O 0 7.640285912202671e-05
, O 0 1.3015120536863378e-08
even O 0 8.151705421788336e-10
during O 0 9.216888363638986e-10
periods O 0 4.992743996012905e-09
of O 0 8.017460584319736e-10
low O 0 2.879940439015627e-06
- O 0 1.9771800907619763e-06
dose O 0 9.211518658958084e-08
or O 0 6.101972260807997e-09
alternate O 0 8.682516039471011e-09
- O 0 1.5626300182702835e-06
day O 0 5.289887781145808e-07
corticosteroid O 0 7.74899817770347e-05
therapy O 0 3.0608712222601753e-06
. O 0 1.267566460683156e-07

Other O 0 1.1306690339552006e-07
observations O 0 2.7946481395701994e-07
indicate O 0 4.0033847881204565e-07
that O 0 3.353491706548084e-09
the O 0 1.2120184855746174e-08
C5D B-Disease 1 0.9999905824661255
state O 0 1.3955091304751477e-08
is O 0 3.0761651004240775e-08
compatible O 0 3.677077131669648e-07
with O 0 7.59194129784646e-09
normal O 0 1.7187014123010158e-07
coagulation O 0 2.362590521443053e-06
function O 0 4.5702989837081986e-07
and O 0 3.519045677080612e-08
the O 0 1.6155916604532194e-09
capacity O 0 6.000982466503046e-08
to O 0 9.201540862591173e-09
mount O 0 0.000193577550817281
a O 0 3.108503733528778e-06
neutrophilic O 1 0.5732126832008362
leukocytosis O 0 0.028103245422244072
during O 0 1.3396895155892707e-05
pyogenic B-Disease 1 0.5132685899734497
infection I-Disease 0 0.00034884928027167916
. O 0 4.602350500704233e-08
. O 0 3.081218551415077e-07

Susceptibility O 0 0.30595406889915466
to O 0 0.0003694619226735085
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.001965237781405449
twins O 0 0.001384015311487019
: O 0 2.8446837774254163e-08
the O 0 1.70094238693963e-09
role O 0 3.334065246107798e-09
of O 0 2.1800691807349892e-10
genes O 0 1.985371334001229e-08
, O 0 1.6515093292923666e-08
HLA O 0 5.0763464969350025e-05
, O 0 4.6410580267775003e-08
and O 0 3.642349710730741e-08
the O 0 1.5301287348279402e-08
environment O 0 5.020467597205425e-06
. O 0 3.84952159038221e-07

OBJECTIVE O 0 4.090226411790354e-06
To O 0 3.4771321821835954e-08
determine O 0 3.054660524526298e-08
the O 0 1.1198690863523098e-09
relative O 0 3.2977331443362345e-07
effects O 0 1.0335556055451889e-07
of O 0 2.4480912852453685e-09
genetic O 0 5.099348072690191e-06
and O 0 1.0371872605219323e-07
environmental O 0 4.804133979519065e-08
factors O 0 2.196734172343895e-08
in O 0 2.418731703812682e-08
susceptibility O 0 0.0037936086300760508
to O 0 0.00508601451292634
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0022366002667695284
AS B-Disease 1 0.9997164607048035
) O 0 3.4434404483363323e-07
. O 0 3.1617352647117514e-07

METHODS O 0 6.494766421383247e-05
Twins O 0 0.0001349146623397246
with O 0 5.931340183451539e-07
AS B-Disease 1 0.8702712655067444
were O 0 1.7870266333375184e-07
identified O 0 1.2963197093540657e-07
from O 0 7.171386817717007e-10
the O 0 2.6610298409224242e-09
Royal O 0 4.6674236386934354e-07
National O 0 8.631365489009113e-08
Hospital O 0 2.1568705051322468e-05
for O 0 3.043795686608064e-06
Rheumatic B-Disease 1 0.9999405145645142
Diseases I-Disease 0 0.008647781796753407
database O 0 4.795967925019795e-06
. O 0 1.051151684805518e-06

Clinical O 0 6.831451173638925e-05
and O 0 1.9769603909480793e-07
radiographic O 0 2.834017141140066e-05
examinations O 0 7.940217869872868e-07
were O 0 1.6929929813613853e-07
performed O 0 2.525158606658806e-07
to O 0 4.287357580068374e-09
establish O 0 2.77992171504593e-07
diagnoses O 0 0.0018735030898824334
, O 0 6.236678586901689e-07
and O 0 1.5446248653461225e-05
disease O 0 0.0005317250033840537
severity O 0 1.6821821191115305e-05
was O 0 1.1002810424542986e-05
assessed O 0 1.4593734931622748e-06
using O 0 4.736513758984984e-08
a O 0 6.846791222869797e-08
combination O 0 4.361600502988949e-08
of O 0 2.0698720515355262e-09
validated O 0 2.2950960101297824e-06
scoring O 0 5.30206477833417e-07
systems O 0 3.554649083525874e-05
. O 0 8.004325877664087e-07

HLA O 0 0.0018394337967038155
typing O 0 1.813258495531045e-05
for O 0 2.1727099408508366e-07
HLA O 0 7.29555613361299e-05
- O 0 1.4122078937361948e-05
B27 O 0 1.7682563111520722e-06
, O 0 1.10721556367821e-08
HLA O 0 2.215464292021352e-06
- O 0 1.5674614814997767e-06
B60 O 0 3.8917983147257473e-07
, O 0 2.5838853279225305e-09
and O 0 7.322170869628053e-09
HLA O 0 4.394373536342755e-05
- O 0 0.0002539957931730896
DR1 O 1 0.7485331296920776
was O 0 1.2390398296702188e-05
performed O 0 2.420947566861287e-07
by O 0 2.9503945953024413e-09
polymerase O 0 6.917337941558799e-06
chain O 0 4.8116220568772405e-05
reaction O 0 5.325303931158487e-08
with O 0 7.868630191865122e-10
sequence O 0 1.0709540809727969e-08
- O 0 3.1561077662445314e-07
specific O 0 4.598882163975304e-09
primers O 0 2.0794170723092975e-06
, O 0 6.154829979010401e-09
and O 0 4.957132038185819e-09
zygosity O 0 3.3919413908733986e-06
was O 0 1.7883357372738828e-07
assessed O 0 1.8745514296369947e-07
using O 0 1.347907812032645e-07
microsatellite O 0 0.00010593748447718099
markers O 0 0.00022634565539192408
. O 0 1.5307160765587469e-06

Genetic O 0 0.00010057464533019811
and O 0 9.262416966748788e-08
environmental O 0 3.0654344840286285e-08
variance O 0 3.3628705153887495e-08
components O 0 3.0958003662817646e-06
were O 0 1.4143813586997567e-07
assessed O 0 2.2726317183696665e-06
with O 0 1.251355818965294e-08
the O 0 4.109795170847974e-09
program O 0 3.046932661732171e-08
Mx O 0 2.6158643322560238e-06
, O 0 3.8796688084374864e-10
using O 0 7.747111285816288e-10
data O 0 7.590725381589891e-09
from O 0 6.877188263310074e-10
this O 0 1.8289985082020621e-09
and O 0 6.413610975641859e-09
previous O 0 6.295838073100413e-09
studies O 0 2.1075425848948726e-09
of O 0 3.2098392832580203e-09
twins O 0 1.6678137399139814e-05
with O 0 3.5389098229643423e-07
AS B-Disease 1 0.9983117580413818
. O 0 2.212063236584072e-06

RESULTS O 0 7.104158157744678e-06
Six O 0 5.3330801108586456e-08
of O 0 4.117342911058586e-09
8 O 0 1.6252266732408316e-07
monozygotic O 0 7.935650501167402e-05
( O 0 2.817238282659673e-07
MZ O 1 0.9951400756835938
) O 0 3.0436689257840044e-07
twin O 0 0.007721010595560074
pairs O 0 3.1524007226835238e-06
were O 0 1.6341400623787194e-05
disease O 0 1.395121853420278e-05
concordant O 0 7.572588401671965e-06
, O 0 4.310770052029511e-08
compared O 0 5.343343332242512e-07
with O 0 5.556883841961735e-09
4 O 0 1.120709391955188e-08
of O 0 9.317036031575299e-10
15 O 0 1.76266272688963e-08
B27 O 0 1.674335180723574e-06
- O 0 1.4674325939267874e-05
positive O 0 4.423615678206261e-07
dizygotic O 0 6.879503416712396e-06
( O 0 1.3398842035883263e-08
DZ O 0 0.014501085504889488
) O 0 2.8134035545690494e-08
twin O 0 7.976013148436323e-05
pairs O 0 7.243814792445846e-08
( O 0 1.0992231569417754e-09
27 O 0 1.1789485832025548e-08
% O 0 7.44181660738974e-10
) O 0 8.204615320472897e-10
and O 0 3.424398098417214e-09
4 O 0 4.8967079280259895e-09
of O 0 4.298501554700351e-09
32 O 0 3.9634010136069264e-06
DZ O 1 0.9975411891937256
twin O 0 0.00660735322162509
pairs O 0 2.29473187118856e-07
overall O 0 5.275886678646202e-07
( O 0 5.182658302516074e-09
12 O 0 5.233648181501849e-09
. O 0 9.846158333104427e-10
5 O 0 6.979924638272905e-09
% O 0 5.345695441860698e-09
) O 0 1.2772785495940298e-08
. O 0 1.0751112000662033e-07

Nonsignificant O 0 0.0007285477477125823
increases O 0 6.391574061126448e-06
in O 0 2.6159858279584114e-08
similarity O 0 1.0238198200340776e-07
with O 0 5.457756913074263e-09
regard O 0 3.1092454833014926e-08
to O 0 1.1953441791945352e-08
age O 0 2.5664118652457546e-07
at O 0 1.9417033399804495e-05
disease O 0 1.6428779417765327e-05
onset O 0 5.83076916882419e-06
and O 0 1.530400766114326e-07
all O 0 1.123407589176395e-09
of O 0 2.8981450572729273e-09
the O 0 3.569227828847943e-07
disease O 0 3.902869138983078e-05
severity O 0 1.61896605277434e-06
scores O 0 2.9065617468404525e-07
assessed O 0 1.0768694664875511e-06
were O 0 7.406831628031796e-07
noted O 0 4.438828682395979e-07
in O 0 1.9438842002728052e-07
disease O 0 0.00012784654973074794
- O 0 0.04795670881867409
concordant O 1 0.6788848638534546
MZ O 1 0.9998095631599426
twins O 0 9.610333654563874e-05
compared O 0 1.067849552782718e-06
with O 0 1.8675689261726802e-07
concordant O 0 0.030402982607483864
DZ O 1 0.9984768033027649
twins O 0 0.0002752179862000048
. O 0 1.5705991245340556e-06

HLA O 0 0.004701383411884308
- O 0 0.0001282309094676748
B27 O 0 5.802306986879557e-06
and O 0 4.843698064860291e-08
B60 O 0 2.7567682536755456e-07
were O 0 3.3248586106537914e-08
associated O 0 3.022593020318709e-08
with O 0 2.6004745024010845e-08
the O 0 3.2895161439228104e-07
disease O 0 4.55659392173402e-05
in O 0 1.6876388286846122e-08
probands O 0 0.00023331442207563668
, O 0 4.146892251810641e-08
and O 0 1.0226797186874137e-08
the O 0 1.5440390077614552e-09
rate O 0 2.023535216721939e-06
of O 0 1.8150046798837138e-08
disease O 0 1.6992122482406558e-06
concordance O 0 1.1451916179794353e-06
was O 0 8.84056953509571e-06
significantly O 0 8.469925774079456e-07
increased O 0 1.3761336958850734e-07
among O 0 6.792990348003514e-08
DZ O 1 0.979749321937561
twin O 0 0.028523677960038185
pairs O 0 6.121068736320012e-07
in O 0 1.4845316975709011e-08
which O 0 1.9016286501027935e-07
the O 0 7.339260577055029e-08
co O 0 0.0003454750985838473
- O 0 0.017188819125294685
twin O 0 0.0031444004271179438
was O 0 2.7464288905321155e-06
positive O 0 5.581612949612236e-09
for O 0 1.1244065678539528e-09
both O 0 5.490677690289658e-09
B27 O 0 1.6849166968313511e-06
and O 0 2.3360225043234095e-07
DR1 O 0 0.029484756290912628
. O 0 4.908343385068292e-07

Additive O 0 2.3047310605761595e-05
genetic O 0 6.299434971879236e-06
effects O 0 9.81243715614255e-07
were O 0 4.118452423540475e-08
estimated O 0 4.761874894398943e-09
to O 0 3.2107927427915683e-10
contribute O 0 1.6889388776419878e-09
97 O 0 1.4795564773351089e-08
% O 0 4.206154868846568e-10
of O 0 1.9322818345379744e-10
the O 0 2.490535333521393e-09
population O 0 1.45014809049826e-08
variance O 0 3.9905464177536487e-07
. O 0 4.124608494748827e-07

CONCLUSION O 0 3.798411853495054e-06
Susceptibility O 0 0.00015805265866219997
to O 0 4.941346674058877e-07
AS B-Disease 1 0.9145374894142151
is O 0 2.7526114720899386e-08
largely O 0 1.3267618115264668e-08
genetically O 0 7.087114539672257e-08
determined O 0 2.7245000637776684e-06
, O 0 3.742348297919307e-08
and O 0 1.013568251551078e-08
the O 0 1.4725513031166315e-09
environmental O 0 2.056176242604124e-07
trigger O 0 9.155403972727072e-07
for O 0 5.344737097345842e-09
the O 0 1.9885705171418522e-07
disease O 0 8.045412687351927e-05
is O 0 1.4452695040745311e-07
probably O 0 1.0862298722713604e-06
ubiquitous O 0 4.727389296022011e-06
. O 0 2.3836440732338815e-07

HLA O 0 0.025298675522208214
- O 0 0.0002910885086748749
B27 O 0 5.4004926823836286e-06
accounts O 0 1.972820768969541e-07
for O 0 5.2828110774783e-09
a O 0 5.06344548512061e-08
minority O 0 6.451365663906472e-08
of O 0 3.6302363892737333e-10
the O 0 2.578007807230165e-09
overall O 0 1.3060922583463253e-06
genetic O 0 2.8213404220878147e-05
susceptibility O 0 0.0002135979593731463
to O 0 5.978595254418906e-06
AS B-Disease 1 0.9982531666755676
. O 0 3.999281034339219e-06

Cell O 0 0.00012512710236478597
cycle O 0 1.5432793588843197e-05
- O 0 2.5244549760827795e-05
dependent O 0 1.145936607827025e-06
colocalization O 0 1.1558230653463397e-05
of O 0 1.755127776448262e-08
BARD1 O 0 0.001569612417370081
and O 0 8.868014589324957e-08
BRCA1 O 0 1.3650941355081159e-06
proteins O 0 5.2427804320132054e-09
in O 0 2.8513200689417317e-09
discrete O 0 1.7259824289794778e-06
nuclear O 0 0.00022211689793039113
domains O 0 2.4460027816530783e-06
. O 0 4.237151927100058e-07

Germ O 0 0.08239436894655228
- O 0 0.004241960123181343
line O 0 2.9831318897777237e-05
mutations O 0 3.169735691699316e-07
of O 0 1.2994821885214947e-09
the O 0 1.735576837802455e-08
BRCA1 O 0 1.5339968740590848e-05
gene O 0 7.376203257081215e-07
predispose O 0 9.535260119264422e-07
women O 0 9.634565145688612e-09
to O 0 6.499568439011227e-09
early O 0 1.6148243275893037e-06
- O 1 0.9724785685539246
onset O 1 0.9994091987609863
breast B-Disease 1 0.9999933242797852
and I-Disease 1 0.9998310804367065
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999969005584717
by O 0 1.4697914707539894e-07
compromising O 0 1.582919867360033e-05
the O 0 2.8240755511887983e-08
genes O 0 5.039839265918999e-07
presumptive O 0 5.864297054358758e-05
function O 0 5.900727160224051e-07
as O 0 2.7458678886205234e-08
a O 0 4.951469918523799e-07
tumor B-Disease 0 0.00014612999802920967
suppressor O 0 4.777057620231062e-05
. O 0 7.410082503156445e-07

Although O 0 3.03265863976776e-07
the O 0 3.6055340935092772e-09
biochemical O 0 2.2156133638873143e-07
properties O 0 1.4150238030197215e-06
of O 0 5.137160474788516e-09
BRCA1 O 0 2.9808670660713688e-06
polypeptides O 0 1.0290235508136902e-07
are O 0 1.6630247401394627e-08
not O 0 3.9455517963915554e-08
understood O 0 1.570370073977756e-07
, O 0 3.4147058514122364e-09
their O 0 6.49162279486859e-10
expression O 0 2.1853587384157436e-08
pattern O 0 1.6580702322244179e-06
and O 0 3.876269971669899e-08
subcellular O 0 1.0629790267557837e-05
localization O 0 1.0009443940361962e-06
suggest O 0 4.977437839670529e-08
a O 0 1.7297637100455177e-08
role O 0 1.1669570199046575e-08
in O 0 1.0772722269791757e-08
cell O 0 1.6459547623526305e-05
- O 0 4.874590376857668e-05
cycle O 0 6.6537809289002325e-06
regulation O 0 5.526550239665085e-07
. O 0 3.494822635730088e-07

When O 0 1.534587909191032e-06
resting O 0 6.609159026993439e-05
cells O 0 2.1573052322310105e-07
are O 0 2.432155588039109e-09
induced O 0 8.791200230007234e-07
to O 0 7.903078191873192e-09
proliferate O 0 2.210588945672498e-06
, O 0 1.0634505498430258e-09
the O 0 3.8000599889009834e-10
steady O 0 2.5659123821242247e-06
- O 0 1.5059687257235055e-06
state O 0 1.520448766889615e-09
levels O 0 1.5419200360966556e-09
of O 0 1.880714056712307e-10
BRCA1 O 0 6.207235969668545e-08
increase O 0 2.3087436407109863e-09
in O 0 8.684631347399829e-10
late O 0 6.827021792332744e-08
G1 O 0 2.8014897907269187e-05
and O 0 1.3103345075649031e-08
reach O 0 2.8211196934080363e-08
a O 0 8.948001450903575e-09
maximum O 0 6.50414690994694e-08
during O 0 1.4983432095050375e-07
S O 0 6.91544046276249e-05
phase O 0 1.558222152198141e-06
. O 0 2.9289839176271926e-07

Moreover O 0 3.7879824503761483e-06
, O 0 2.432462764545562e-08
in O 0 4.290825916797303e-09
S O 0 8.989624802779872e-06
phase O 0 4.95709684855683e-07
cells O 0 2.6707795086622355e-07
, O 0 5.970200778193657e-09
BRCA1 O 0 1.4182511165472533e-07
polypeptides O 0 3.720697350217961e-08
are O 0 1.1439190927831078e-08
hyperphosphorylated O 0 2.6911079658020753e-06
and O 0 1.1176120473521678e-08
accumulate O 0 4.2257880750184995e-07
into O 0 3.0254061478274252e-09
discrete O 0 2.9103895826665394e-07
subnuclear O 0 9.763297566678375e-05
foci O 0 7.449687836924568e-05
termed O 0 9.710965969134122e-05
" O 0 7.524644843215356e-06
BRCA1 O 0 4.3528991227503866e-05
nuclear O 0 4.632553827832453e-05
dots O 0 3.4238375519635156e-05
. O 0 8.072599371189426e-07

" O 0 2.6802055799635127e-05
BRCA1 O 0 0.0005103031871840358
associates O 0 0.00010781120363390073
in O 0 1.2195550347371409e-08
vivo O 0 0.00010853292769752443
with O 0 6.803921337450447e-08
a O 0 1.4674709518658346e-06
structurally O 0 0.050497524440288544
related O 0 3.5803652281174436e-05
protein O 0 1.3745253454544581e-05
termed O 0 0.00018192807328887284
BARD1 O 0 0.0017857268685474992
. O 0 2.5813505999394692e-06

Here O 0 1.6045729580582702e-06
we O 0 3.655768310295571e-08
show O 0 2.5557033822565245e-08
that O 0 1.1875805894234759e-09
the O 0 4.0222158936842334e-10
steady O 0 1.2736144299196894e-06
- O 0 1.1003438658008236e-06
state O 0 1.856635511998661e-09
levels O 0 1.5532309882715367e-09
of O 0 2.4804933107525073e-10
BARD1 O 0 1.1238635124755092e-05
, O 0 2.217309225116537e-09
unlike O 0 1.8401361545627992e-09
those O 0 2.52630194541581e-10
of O 0 8.95518548205132e-10
BRCA1 O 0 5.1874458222300746e-06
, O 0 1.00772172828556e-08
remain O 0 6.725128542939274e-08
relatively O 0 2.2116800835192407e-08
constant O 0 1.0521971915977701e-07
during O 0 6.75171989428236e-08
cell O 0 6.009474873280851e-06
cycle O 0 8.022973815968726e-06
progression O 0 3.095390638918616e-05
. O 0 6.264427270252781e-07

However O 0 2.828209971994511e-06
, O 0 7.7031657497173e-08
immunostaining O 0 4.563366928778123e-06
revealed O 0 2.3889762701401196e-07
that O 0 2.2184861947494028e-08
BARD1 O 0 8.994233940029517e-05
resides O 0 9.793412800718215e-07
within O 0 3.387048863601194e-08
BRCA1 O 0 1.7150976418633945e-05
nuclear O 0 2.0177993064862676e-05
dots O 0 4.111242560611572e-06
during O 0 1.9678938656397804e-07
S O 0 2.0469489754759707e-05
phase O 0 1.3506279117336817e-07
of O 0 9.569179892920943e-10
the O 0 1.894366885579757e-09
cell O 0 2.590880285424646e-06
cycle O 0 1.3714410442844382e-06
, O 0 1.0429516805743333e-08
but O 0 2.726421310939031e-09
not O 0 2.0184749427443194e-09
during O 0 4.487219484872185e-09
the O 0 5.794336122022514e-09
G1 O 0 7.864878170948941e-06
phase O 0 7.231072345348366e-07
. O 0 2.597481056909601e-07

Nevertheless O 0 1.0246271813230123e-05
, O 0 1.3384033081820235e-07
BARD1 O 0 6.289866632869234e-06
polypeptides O 0 3.638815542217344e-07
are O 0 7.9940418729052e-09
found O 0 6.711222244604187e-09
exclusively O 0 4.91892127030269e-09
in O 0 2.2804449439917107e-09
the O 0 8.960550634817821e-10
nuclear O 0 4.346602224813978e-07
fractions O 0 2.5987425544826692e-09
of O 0 3.090145916928577e-10
both O 0 1.2755833056488086e-09
G1 O 0 2.693832357181236e-06
- O 0 5.015050646761665e-06
and O 0 2.0654174193168728e-07
S O 0 8.887796138878912e-05
- O 0 1.749584725985187e-06
phase O 0 2.579787860668148e-06
cells O 0 6.477924898717902e-07
. O 0 7.797923018415531e-08

Therefore O 0 1.5895310525593231e-06
, O 0 1.4450759699968785e-08
progression O 0 6.241361347747443e-07
to O 0 1.532386306735134e-08
S O 0 5.4285177611745894e-05
phase O 0 1.3014222304263967e-06
is O 0 2.886357641784798e-08
accompanied O 0 6.479815084503571e-08
by O 0 1.086901790792183e-09
the O 0 9.442860937625142e-10
aggregation O 0 4.578387091669356e-08
of O 0 3.1657461097012174e-09
nuclear O 0 2.5312750949524343e-05
BARD1 O 0 6.347600901790429e-06
polypeptides O 0 1.4879127263611736e-07
into O 0 3.2478567391081015e-08
BRCA1 O 0 1.3707761354453396e-05
nuclear O 0 1.5120218449737877e-05
dots O 0 3.1047267839312553e-05
. O 0 1.3825823543811566e-06

This O 0 9.680859847094325e-08
cell O 0 4.315526894060895e-06
cycle O 0 2.05218111659633e-06
- O 0 6.8010804170626216e-06
dependent O 0 3.936029031592625e-07
colocalization O 0 5.041491476731608e-06
of O 0 3.852644425705876e-09
BARD1 O 0 0.0008725491934455931
and O 0 3.5984223245577596e-07
BRCA1 O 0 2.9005855139985215e-06
indicates O 0 1.0300171027211036e-07
a O 0 1.0052568555352082e-08
role O 0 1.7172128607967352e-08
for O 0 4.719881818715521e-09
BARD1 O 0 6.172236317070201e-05
in O 0 3.817237015368846e-08
BRCA1 O 0 0.0001300014409935102
- O 0 0.0007631379994563758
mediated O 0 0.04610462859272957
tumor B-Disease 0 0.08090756088495255
suppression O 0 3.4570926800370216e-05
. O 0 1.0456684549353668e-06

Ethnic O 0 9.844428859651089e-06
differences O 0 2.5677827579784207e-06
in O 0 1.2085052070176516e-08
the O 0 1.7148627406982087e-08
HFE O 0 8.399635407840833e-05
codon O 0 1.5335053831222467e-06
282 O 0 1.6023188891267637e-06
( O 0 8.580514787581706e-08
Cys O 0 0.001988285221159458
/ O 0 4.469279519980773e-05
Tyr O 0 5.4560750868404284e-05
) O 0 6.893164083976444e-08
polymorphism O 0 2.2323411030811258e-05
. O 0 1.1771305707952706e-06

Recent O 0 2.496220758985146e-06
studies O 0 8.367658210772788e-08
have O 0 1.792047044091305e-08
shown O 0 3.811606177350768e-07
that O 0 5.9070422139484435e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.000378478376660496
HH B-Disease 1 0.999995231628418
) O 0 5.767049628957466e-07
is O 0 1.1432666724431328e-06
likely O 0 3.4863404607676785e-07
to O 0 8.055494937764252e-09
be O 0 6.052179202242769e-08
caused O 0 1.2012550598683447e-07
by O 0 5.936532598838085e-09
homozygosity O 0 4.738976258522598e-06
for O 0 3.6301548433925745e-09
a O 0 6.755635695299134e-08
Cys282Tyr O 0 1.8269955035066232e-05
mutation O 0 3.687956251496871e-08
in O 0 1.3231145068459682e-09
the O 0 2.4098660844629194e-09
HFE O 0 1.5036502190923784e-05
gene O 0 9.02751295939197e-08
located O 0 1.2920421568196616e-06
4 O 0 4.3947235894847836e-07
. O 0 4.7367038291667996e-07

5 O 0 4.940040980727645e-06
Mb O 0 1.8090062440023758e-05
telomeric O 0 7.491199357900769e-05
to O 0 2.438214323774446e-07
HLA O 0 0.0005796504556201398
- O 0 5.467747905640863e-05
A O 0 1.6720023268135265e-06
. O 0 3.8633831422885123e-07

Population O 0 1.7145103470284084e-07
studies O 0 7.164500104295257e-09
of O 0 4.0487554975321416e-10
this O 0 7.617640407353576e-10
polymorphism O 0 1.5954998389133834e-06
are O 0 9.170791237522735e-09
facilitated O 0 2.34476061677924e-07
by O 0 5.97368643440177e-09
the O 0 1.7354666592694912e-09
fact O 0 6.59445831274752e-09
that O 0 2.858039138686763e-09
the O 0 4.988384372239807e-09
Cys282Tyr O 0 2.9082413675496355e-05
mutation O 0 1.5254610730153217e-07
creates O 0 6.361093340956359e-08
a O 0 8.144409235910643e-08
Rsal O 0 1.7041738828993402e-05
restriction O 0 1.4974690429880866e-06
site O 0 3.680356894619763e-05
. O 0 6.831762107140094e-07

We O 0 8.826180533105799e-07
have O 0 9.693476243910482e-09
studied O 0 4.0074539242596074e-09
the O 0 8.126618822323906e-10
codon O 0 1.5179814738530695e-07
282 O 0 2.0057579774857004e-07
( O 0 1.002245308967531e-08
Cys O 0 0.00017769835540093482
/ O 0 1.1062782505177893e-05
Tyr O 0 7.024406841082964e-06
) O 0 3.982400187396706e-09
polymorphism O 0 4.0889602814786485e-07
in O 0 2.8000506357983568e-09
different O 0 2.8003657170927454e-09
ethnic O 0 6.14083148775535e-08
groups O 0 8.500111192688564e-08
. O 0 2.3399019255521125e-07

In O 0 3.118142331004492e-07
agreement O 0 2.6239345629619493e-07
with O 0 7.93788501596282e-09
previous O 0 1.6085266452137148e-08
observations O 0 1.2801520199445804e-07
the O 0 7.275229307879272e-09
Tyr O 0 1.5938512660795823e-06
allele O 0 4.960057253811101e-08
appeared O 0 5.818393589152038e-08
to O 0 6.87808388022404e-09
be O 0 8.549002927793481e-08
rare O 0 4.999807856620464e-07
or O 0 6.729548545081343e-07
absent O 0 2.1515050718790008e-07
in O 0 8.14707767915479e-09
Asiatic O 0 7.15499766101857e-07
( O 0 2.3453603503753584e-09
Indian O 0 9.082725682674209e-09
, O 0 1.382262970750503e-09
Chinese O 0 5.121895685356037e-10
) O 0 3.8215546283026924e-09
populations O 0 5.921867796132574e-08
. O 0 6.776490835136428e-08

The O 0 1.7476058644660952e-07
highest O 0 2.112035133450263e-07
allele O 0 5.711822836929059e-08
frequency O 0 1.3341825422230613e-07
( O 0 5.718487905426173e-10
7 O 0 3.752481880781033e-09
. O 0 5.46807987777953e-10
5 O 0 2.690154099482811e-09
% O 0 9.345121343429241e-10
) O 0 1.2688229356072611e-09
was O 0 3.1264221433957573e-06
found O 0 3.046404515316681e-07
in O 0 4.045964629995069e-08
Swedes O 0 1.5055959920573514e-05
. O 0 4.465246092877351e-07

Saamis O 0 0.0003218437486793846
( O 0 7.796153767003489e-08
2 O 0 2.864644166322705e-08
% O 0 2.4548758581488528e-09
) O 0 2.008133437314541e-09
and O 0 2.0256649690963968e-08
Mordvinians O 0 2.9904028906457825e-06
( O 0 6.395149965143787e-10
1 O 0 1.4729276687219794e-09
. O 0 4.3738590527198085e-10
8 O 0 2.5914466128540425e-09
% O 0 2.362694762059192e-10
) O 0 1.8523617362209421e-10
had O 0 4.170400469405422e-09
significantly O 0 6.010487219043625e-09
lower O 0 7.283851299888511e-09
frequencies O 0 8.266320072891631e-09
of O 0 2.0469907990872116e-09
the O 0 3.400123560481916e-08
Tyr O 0 0.00011571811774047092
allele O 0 4.900816747976933e-06
. O 0 6.020667342454544e-07

Comparisons O 0 4.754290330311051e-06
with O 0 2.0472455730669026e-08
allele O 0 1.783835870128314e-07
frequencies O 0 5.412302783724954e-08
based O 0 2.2590944226408283e-08
on O 0 1.0002289485555593e-07
prevalence O 0 3.187092443113215e-05
estimates O 0 2.380011920877223e-07
of O 0 2.01017709144935e-08
HH B-Disease 1 0.9998455047607422
showed O 0 3.113286948064342e-05
some O 0 1.0550806450737582e-08
disagreements O 0 2.8659808322117897e-06
with O 0 1.211782763022029e-08
the O 0 2.421924882867188e-09
RFLP O 0 6.654459866695106e-06
data O 0 1.8868354345613625e-07
, O 0 5.083173437725463e-09
particularly O 0 2.2964211865428297e-08
in O 0 7.282379144157858e-09
Finns O 0 8.947934475145303e-06
. O 0 3.479926249383425e-07

The O 0 5.139525569575198e-07
newly O 0 7.099710046531982e-07
described O 0 1.2210398381284904e-05
HFE O 0 0.002019353909417987
marker O 0 0.00032793081481941044
provides O 0 4.9486796882547424e-08
a O 0 5.5700208889675196e-09
new O 0 3.36018257662829e-09
approach O 0 1.0607997324996177e-07
to O 0 1.7731014434474446e-09
the O 0 2.395543485800289e-10
screening O 0 7.21422210858691e-09
of O 0 1.109402902876866e-09
HH B-Disease 1 0.9975780844688416
as O 0 1.3864902825844183e-07
well O 0 2.314635416666988e-08
as O 0 1.817193062692013e-09
studies O 0 1.441770730581382e-10
of O 0 6.037482319642962e-11
the O 0 1.1641310138088556e-09
relationship O 0 1.1076637207452222e-07
between O 0 1.0731726618473658e-08
the O 0 4.0530242273462136e-08
HFE O 0 0.002364348154515028
Tyr O 0 2.4658011170686223e-05
allele O 0 7.663698511350958e-07
and O 0 1.4470927567344916e-07
different O 0 1.955406361275891e-07
disorders O 0 0.24949099123477936
including O 0 1.6257168681477197e-05
cancer B-Disease 0 0.10065407305955887

Autosomal B-Disease 1 0.9995810389518738
dominant I-Disease 1 0.9952840209007263
neurohypophyseal I-Disease 1 0.9999061822891235
diabetes I-Disease 1 0.9999961853027344
insipidus I-Disease 1 0.9998419284820557
associated O 0 3.394984742044471e-05
with O 0 9.323656513515743e-08
a O 0 2.6918090156868857e-07
missense O 0 2.7906373361474834e-05
mutation O 0 2.409415174042806e-07
encoding O 0 1.8202264584488148e-07
Gly23 O 0 0.00010540131916059181
- O 0 0.0031359668355435133
- O 0 0.008483721874654293
> O 0 1.0682226275093853e-05
Val O 0 0.0004461062781047076
in O 0 2.5567598527231894e-07
neurophysin O 0 0.0008088828762993217
II O 0 0.0028693927451968193
. O 0 1.6756929426264833e-06

Autosomal B-Disease 1 0.9989506006240845
dominant I-Disease 1 0.9936552047729492
neurohypophyseal I-Disease 1 0.9999091625213623
diabetes I-Disease 1 0.9999966621398926
insipidus I-Disease 1 0.9999639987945557
( O 0 5.281553058011923e-06
ADNDI B-Disease 0 0.02519369125366211
) O 0 1.2937582027916505e-07
is O 0 1.5984818446668214e-06
an O 0 0.0008564970339648426
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
caused O 0 0.0004118264769203961
by O 0 5.308535833137284e-07
progressive O 0 0.0038798812311142683
degeneration O 0 0.2285171002149582
of O 0 3.3290401546537396e-08
the O 0 2.416868660759519e-08
magnocellular O 0 1.2883797353424598e-05
neurons O 0 2.2323115445033181e-07
of O 0 2.1906074731958824e-09
the O 0 5.655858448250228e-09
hypothalamus O 0 4.25253489311217e-07
leading O 0 1.358453545208249e-07
to O 0 5.402051073133407e-08
decreased O 0 1.4238758012652397e-05
ability O 0 2.5487810972890657e-08
to O 0 2.134017407229294e-09
produce O 0 9.367489894884784e-08
the O 0 2.6384299189885496e-08
hormone O 0 8.198817340598907e-07
arginine O 0 5.199602810534998e-07
vasopressin O 0 5.227575456956401e-07
( O 0 1.9328476597024746e-08
AVP O 0 6.266898253670661e-06
) O 0 3.4727246855936755e-08
. O 0 1.111719143409573e-07

Affected O 0 1.0357730388932396e-05
individuals O 0 9.18851341680238e-08
are O 0 4.382546325842895e-09
not O 0 9.379447440949207e-09
symptomatic O 0 1.0290593309036922e-05
at O 0 4.658272700908128e-06
birth O 0 2.9706111490668263e-06
, O 0 2.032778745331143e-08
but O 0 1.8541344459777065e-08
usually O 0 5.094454422760464e-07
develop O 0 1.7824932001531124e-05
diabetes B-Disease 0 0.2803938090801239
insipidus I-Disease 0 0.13464127480983734
at O 0 7.423701390507631e-06
1 O 0 5.720778517570579e-07
- O 0 0.0023792709689587355
6 O 0 1.3089478443362168e-06
yr O 0 0.0001541412784717977
of O 0 1.74457781554338e-08
age O 0 6.809542014707404e-07
. O 0 4.738971881579346e-07

The O 0 2.480586260844575e-07
genetic O 0 1.1859874575748108e-06
locus O 0 5.59678539957531e-07
of O 0 1.969620555541951e-08
the O 0 2.463353325765638e-07
disease O 0 0.0003080201568081975
is O 0 2.0330702454884886e-07
the O 0 2.5546313509039464e-08
AVP O 0 0.0006197576876729727
- O 0 0.0011952741770073771
neurophysin O 0 0.0007494520978070796
II O 0 0.002316470490768552
( O 0 1.937864269052625e-08
NPII O 0 6.151573415991152e-06
) O 0 2.3885915467758423e-09
gene O 0 1.9573741738554418e-08
, O 0 8.342952106943358e-09
and O 0 5.0619004099417e-08
mutations O 0 2.063365798221639e-07
that O 0 2.3347300981413355e-08
cause O 0 1.9361100100923068e-07
ADNDI B-Disease 0 9.701877570478246e-05
have O 0 5.892225019010766e-08
been O 0 1.0586793308675624e-07
found O 0 1.2209099509163934e-07
in O 0 1.9939661033419043e-09
both O 0 2.426118417275802e-09
the O 0 1.1858760640137689e-09
signal O 0 4.180369330697431e-07
peptide O 0 3.0047206944772142e-09
of O 0 1.6836633476291496e-10
the O 0 1.3959342570757372e-09
prepro O 0 5.425405106507242e-06
- O 0 1.3192543519835453e-05
AVP O 0 0.00012434186646714807
- O 0 9.677602065494284e-06
NPII O 0 8.432323738816194e-06
precursor O 0 1.7594372536677838e-07
and O 0 2.2843291702656643e-08
within O 0 2.0692572988423308e-08
NPII O 0 7.871753768995404e-05
itself O 0 1.327219592894835e-06
. O 0 3.070262550863845e-07

An O 0 3.8436999716395803e-07
affected O 0 3.620287316152826e-06
girl O 0 0.0010603655828163028
who O 0 1.560299551783828e-07
presented O 0 2.333256610143053e-08
at O 0 1.6521323686902178e-07
9 O 0 2.55815173488827e-08
months O 0 3.346048327301787e-09
of O 0 8.29607382790698e-10
age O 0 6.259309088818554e-07
and O 0 1.8355052588958642e-07
her O 0 2.6500913463678444e-07
similarly O 0 1.2538115470306366e-06
affected O 0 2.0286563540139468e-07
younger O 0 5.635347406496294e-07
brother O 0 4.4468383748608176e-06
and O 0 2.2621023276769847e-07
father O 0 2.003478357437416e-06
were O 0 4.632373133972578e-07
all O 0 3.734431430757468e-09
found O 0 9.025016822761245e-08
to O 0 8.680776986125238e-09
have O 0 3.054077879482975e-08
a O 0 2.9625368824781617e-08
novel O 0 3.2510928349438473e-07
missense O 0 1.3250330084702e-05
mutation O 0 1.1042170200425971e-07
( O 0 1.3966080514293822e-09
G1758 O 0 7.798709589224018e-07
- O 0 5.877902003703639e-05
- O 0 0.0003442773304414004
> O 0 2.319352461199742e-06
T O 0 4.191089828964323e-05
) O 0 5.569741889921431e-10
encoding O 0 1.2866868681626897e-09
the O 0 4.491216010205079e-10
amino O 0 3.6890661636590494e-09
acid O 0 2.1696582308550205e-09
substitution O 0 4.058661851047418e-09
Gly23 O 0 9.317485023530026e-07
- O 0 1.1645637641777284e-05
- O 0 4.908596019959077e-05
> O 0 2.494697810107027e-06
Val O 0 7.405407086480409e-05
within O 0 3.2292646778842027e-07
NPII O 0 0.00034063225029967725
. O 0 9.309846973337699e-07

The O 0 4.120012988551025e-07
mutation O 0 2.141971890523564e-06
was O 0 1.8255127542943228e-06
confirmed O 0 1.2343078026333387e-07
by O 0 8.799770689904562e-09
restriction O 0 4.0195286032940203e-07
endonuclease O 0 6.640797801082954e-05
analysis O 0 1.6088110896816943e-06
. O 0 6.810711852267559e-07

A O 0 1.2520966265583411e-05
T1 O 0 0.012395680882036686
- O 0 6.8875515353283845e-06
weighted O 0 2.7878866148967063e-07
magnetic O 0 2.602385507088911e-07
resonance O 0 1.533693989586027e-07
imaging O 0 2.314548510184977e-06
of O 0 3.424306616039985e-09
the O 0 1.9552459207261563e-07
fathers O 0 3.737054066732526e-05
pituitary O 0 0.0001673089136602357
gland O 0 0.00018606903904583305
demonstrates O 0 2.697698619158473e-06
an O 0 3.912160764230066e-07
attenuated O 0 0.06090307980775833
posterior O 0 0.011112022213637829
pituitary O 0 0.004346061032265425
bright O 0 0.0001554270857013762
spot O 0 9.244059765478596e-05
. O 0 1.4587361647500074e-06

This O 0 1.614391749171773e-07
mutation O 0 1.6332844552380266e-06
may O 0 9.423311553291569e-08
be O 0 1.7820590558770277e-09
valuable O 0 3.700002748630027e-09
for O 0 6.813239972203178e-10
developing O 0 6.181394063276002e-09
models O 0 2.4118219243973726e-07
of O 0 7.393505363495478e-09
dominantly B-Disease 0 0.3219245970249176
inherited I-Disease 1 0.635378360748291
neurodegeneration I-Disease 1 0.9999998807907104
, O 0 2.9265761440910865e-06
as O 0 1.4227860667404002e-08
the O 0 6.382818162897763e-10
early O 0 2.593524861538299e-08
age O 0 2.4689077449124852e-08
of O 0 1.513614344972325e-09
onset O 0 1.0404756721982267e-05
of O 0 6.024767884582616e-08
symptoms O 0 4.809318852494471e-06
suggests O 0 8.014670527245471e-08
that O 0 5.958619819779187e-09
this O 0 4.772585882051317e-09
mutation O 0 2.9118777433723153e-07
may O 0 1.6140069192260853e-07
be O 0 1.4252224289634796e-08
particularly O 0 1.0894095403557458e-08
deleterious O 0 8.436825993385355e-08
to O 0 6.834119492538093e-09
the O 0 2.0427910030207386e-08
magnocellular O 0 3.346198354847729e-05
neuron O 0 1.4890278180246241e-05
. O 0 3.732546360879496e-08
. O 0 1.794831803181296e-07

Frequent O 0 5.999132918077521e-05
inactivation O 0 4.667123357648961e-05
of O 0 1.7548642006204318e-07
PTEN O 0 0.003479576203972101
/ O 0 0.0003415818209759891
MMAC1 O 0 0.00434966990724206
in O 0 1.563918203828507e-06
primary O 1 0.8990198969841003
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999920129776001
. O 0 1.1115066627098713e-05

Sporadic B-Disease 1 0.999445378780365
prostate I-Disease 1 0.9999959468841553
carcinoma I-Disease 1 1.0
is O 0 0.00018089159857481718
the O 0 7.474257301964826e-08
most O 0 1.411324035416328e-07
common O 0 1.087858709070133e-05
male B-Disease 0 8.073149365372956e-05
cancer I-Disease 0 5.333402441465296e-06
in O 0 9.724216099016303e-09
the O 0 7.91937537769627e-09
Western O 0 4.0071660123430775e-07
world O 0 2.0516046106422436e-07
, O 0 2.064955673120039e-08
yet O 0 2.0351995644318777e-08
many O 0 7.324761630567167e-11
of O 0 1.0176274406470398e-10
the O 0 9.53354506449955e-10
major O 0 3.6328234642724055e-08
genetic O 0 4.012955656662598e-08
events O 0 6.318418233064449e-09
involved O 0 8.56261266335423e-08
in O 0 1.545395100777114e-08
the O 0 7.447372940561081e-09
progression O 0 2.7054975362261757e-06
of O 0 2.664519049844216e-09
this O 0 3.496765188515383e-08
often O 0 2.548848897276912e-05
fatal O 0 0.48825427889823914
cancer B-Disease 0 2.960702659038361e-05
remain O 0 1.6742411901304877e-07
to O 0 1.6070607955498417e-08
be O 0 1.7665441021108563e-07
elucidated O 0 1.952864113263786e-05
. O 0 4.221824099204241e-07

Numerous O 0 4.1389375837752596e-06
cytogenetic O 0 0.0012336740037426353
and O 0 1.1060482165703434e-06
allelotype O 0 2.2993348466116004e-05
studies O 0 2.8146970976195007e-08
have O 0 3.148645433270758e-08
reported O 0 9.232676916326454e-07
frequent O 0 9.139814096670307e-07
loss O 0 1.2034306564601138e-06
of O 0 8.269189777365682e-09
heterozygosity O 0 3.7765305023640394e-05
on O 0 3.7696827348554507e-06
chromosomal O 0 0.4746229350566864
arm O 0 0.011085012927651405
10q O 0 1.0680108061933424e-05
in O 0 3.115612798865186e-07
sporadic B-Disease 1 0.9991449117660522
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999911785125732
. O 0 1.2323381270107348e-05

Deletion O 0 1.641949165787082e-05
mapping O 0 1.5818468455108814e-05
studies O 0 1.4045406260265736e-07
have O 0 2.1186474796763832e-08
unambiguously O 0 1.4579779417545069e-05
identified O 0 1.524421236354101e-06
a O 0 1.0915398007682597e-07
region O 0 1.9576249599140283e-07
of O 0 4.983534473979034e-09
chromosome O 0 1.8498483768780716e-05
10q23 O 0 3.459151002971339e-06
to O 0 2.529901621528552e-08
be O 0 2.6651608919792125e-08
the O 0 2.760843997862139e-09
minimal O 0 4.711905603471678e-07
area O 0 7.775969379508751e-07
of O 0 1.0680980544464092e-08
loss O 0 4.169217208982445e-05
. O 0 1.1688392760333954e-06

A O 0 5.714922508559539e-07
new O 0 6.770186189442029e-08
tumor B-Disease 0 1.095913103199564e-05
suppressor O 0 6.69529572405736e-06
gene O 0 5.729236249862879e-07
, O 0 3.745354604234308e-08
PTEN O 0 7.44629287510179e-05
/ O 0 2.847755422408227e-05
MMAC1 O 0 0.003343431046232581
, O 0 3.671757724532654e-07
was O 0 4.570422333927127e-06
isolated O 0 5.923389835515991e-05
recently O 0 1.9050189621339086e-06
at O 0 3.5383527574595064e-07
this O 0 1.6609097430730912e-09
region O 0 2.8755490433240993e-08
of O 0 8.110823679352563e-10
chromosome O 0 4.827989869227167e-06
10q23 O 0 2.7781404696725076e-06
and O 0 8.133309137292599e-08
found O 0 4.759879601579087e-08
to O 0 2.649230168572103e-09
be O 0 9.454597105218454e-09
inactivated O 0 1.9295424635856762e-07
by O 0 1.1452502279851728e-09
mutation O 0 9.479049367655534e-08
in O 0 7.115314559769104e-08
three O 0 0.0002166518388548866
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999948740005493
cell O 0 0.008107186295092106
lines O 0 0.00027801425312645733
. O 0 1.6336630324076395e-06

We O 0 3.027260390808806e-06
screened O 0 1.577001421537716e-05
80 O 0 2.965551357192453e-05
prostate B-Disease 1 0.9847455620765686
tumors I-Disease 1 0.9999973773956299
by O 0 4.614559756532799e-08
microsatellite O 0 1.14428094093455e-05
analysis O 0 6.013655138303875e-07
and O 0 2.717600295909506e-07
found O 0 2.9340665719246317e-07
chromosome O 0 7.857035598135553e-06
10q23 O 0 1.7713684883347014e-06
to O 0 1.293597318152706e-08
be O 0 1.1188320492294679e-08
deleted O 0 4.146195919929596e-08
in O 0 9.918052157331658e-09
23 O 0 2.2762532125852886e-07
cases O 0 1.242243570231949e-07
. O 0 3.049916017516807e-07

We O 0 8.912523412618611e-07
then O 0 1.136321081673941e-08
proceeded O 0 8.770967063753687e-09
with O 0 3.282717986330397e-10
sequence O 0 1.3105888596598447e-09
analysis O 0 9.369787168367338e-10
of O 0 1.701973562084902e-10
the O 0 3.45841222326726e-09
entire O 0 4.55319337788751e-07
PTEN O 0 0.0003060437156818807
/ O 0 5.5420707212761045e-05
MMAC1 O 0 0.0002097470423905179
coding O 0 9.75316834228579e-06
region O 0 5.47639547221479e-06
and O 0 6.064636863811756e-07
tested O 0 5.742123221352813e-07
for O 0 3.2794591486862146e-09
homozygous O 0 2.5622128418945067e-07
deletion O 0 1.8654577615961898e-07
with O 0 2.204112270476344e-08
new O 0 3.670608705874656e-08
intragenic O 0 5.306009916239418e-05
markers O 0 4.016054663225077e-05
in O 0 7.048287731237224e-09
these O 0 2.718735903073366e-09
23 O 0 4.124450470044394e-08
cases O 0 6.77767708623378e-09
with O 0 6.389569762177416e-09
10q23 O 0 5.236854121903889e-06
loss O 0 4.814729663848993e-07
of O 0 3.760479572179065e-08
heterozygosity O 0 0.0005934294895268977
. O 0 8.743491548557358e-07

The O 0 1.4757890198779933e-07
identification O 0 1.1188154047658827e-07
of O 0 3.040730778280931e-09
the O 0 6.763446247504135e-09
second O 0 1.5789839835633757e-07
mutational O 0 3.340574403409846e-05
event O 0 1.6402102573920274e-06
in O 0 1.8387266820241166e-08
10 O 0 8.164624532014386e-09
( O 0 1.4092085276473654e-09
43 O 0 3.3890650286139135e-08
% O 0 1.6079315656725157e-08
) O 0 2.3831189821521548e-07
tumors B-Disease 1 0.9999961853027344
establishes O 0 2.2549895220436156e-05
PTEN O 0 0.0007266374304890633
/ O 0 5.737895116908476e-05
MMAC1 O 0 0.0005749491392634809
as O 0 5.410341685774256e-08
a O 0 2.5538128056723508e-08
main O 0 2.0167216518984787e-07
inactivation O 0 8.266012628155295e-06
target O 0 5.280517711980792e-07
of O 0 5.642045497467052e-09
10q O 0 2.3248530851560645e-06
loss O 0 7.048854513413971e-07
in O 0 1.2923746339765785e-07
sporadic B-Disease 1 0.9996634721755981
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999967813491821
. O 0 3.76399640344971e-07
. O 0 8.445969115200569e-07

Risk O 0 8.856594649842009e-05
reversals O 0 5.769091330876108e-06
in O 0 1.6830741245144054e-08
predictive O 0 1.4808659898335463e-06
testing O 0 6.264663625188405e-06
for O 0 1.3202511581766885e-05
Huntington B-Disease 1 0.9999991655349731
disease I-Disease 1 0.9999866485595703
. O 0 6.793560714868363e-06

The O 0 6.052733425576662e-08
first O 0 9.267432155013466e-09
predictive O 0 5.36095342340559e-07
testing O 0 5.012860583519796e-06
for O 0 6.9442990024981555e-06
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.999993085861206
( O 0 2.0997717342652322e-08
HD B-Disease 0 0.046179238706827164
) O 0 2.0900621677810705e-08
was O 0 1.2046432402712526e-06
based O 0 1.6755054232930888e-08
on O 0 2.4916388952078705e-08
analysis O 0 1.2016235118039731e-08
of O 0 1.0053272658794299e-09
linked O 0 4.5186579882283695e-06
polymorphic O 0 5.149283879291033e-07
DNA O 0 1.6047289363996242e-06
markers O 0 1.0957845006487332e-05
to O 0 7.74676056636281e-09
estimate O 0 2.79658365798241e-07
the O 0 1.5917520634900484e-09
likelihood O 0 2.7639224242648197e-08
of O 0 8.813439977828352e-10
inheriting O 0 5.653283210449445e-07
the O 0 1.49808823124431e-08
mutation O 0 1.424013760242815e-07
for O 0 6.565883126086192e-08
HD B-Disease 0 0.004200262948870659
. O 0 1.1134957276226487e-06

Limits O 0 2.3957186385814566e-06
to O 0 1.903749335951943e-08
accuracy O 0 1.4113859947428864e-07
included O 0 4.925305496783494e-09
recombination O 0 1.0196493605008072e-07
between O 0 5.861120300210132e-08
the O 0 6.760118687054728e-09
DNA O 0 5.032782610214781e-06
markers O 0 0.0002817097119987011
and O 0 1.1886739770261556e-07
the O 0 1.4823247518336302e-08
mutation O 0 4.212357112010068e-07
, O 0 1.2487379130732279e-08
pedigree O 0 2.819648670993047e-06
structure O 0 3.766578174690949e-06
, O 0 3.948653670704516e-08
and O 0 8.799116102409243e-09
whether O 0 4.637410011554266e-09
DNA O 0 5.631415689322239e-08
samples O 0 1.6252849732723007e-08
were O 0 7.775538435339513e-09
available O 0 2.22295803986583e-09
from O 0 2.9892865960334802e-09
family O 0 1.2925447379075194e-07
members O 0 7.47418216207052e-09
. O 0 9.359434471889472e-08

With O 0 1.9432020792464755e-07
direct O 0 1.7087938886106713e-07
tests O 0 1.2564336770992668e-07
for O 0 1.13280396174531e-09
the O 0 2.5385331614558027e-09
HD B-Disease 0 0.0003999532200396061
mutation O 0 1.0452462362309234e-07
, O 0 1.3172499757629907e-09
we O 0 2.9338405038714654e-09
have O 0 5.105937894711587e-10
assessed O 0 8.42951930479785e-09
the O 0 2.329985648863442e-10
accuracy O 0 2.554675688770658e-07
of O 0 8.043454235995284e-10
results O 0 2.893694528438573e-08
obtained O 0 1.3594587677800973e-08
by O 0 4.276682563641998e-09
linkage O 0 6.339690798995434e-07
approaches O 0 5.034362615674581e-08
when O 0 2.5034325723538586e-09
requested O 0 3.2687428319633227e-09
to O 0 8.458913569597826e-09
do O 0 3.058893227603221e-08
so O 0 9.167516190622393e-10
by O 0 2.2083938844286166e-10
the O 0 1.93597182729377e-09
test O 0 1.8672128021535173e-07
individuals O 0 1.236229962842117e-08
. O 0 6.401086949381352e-08

For O 0 2.268953664952278e-07
six O 0 3.351933131057194e-08
such O 0 5.669316127665525e-09
individuals O 0 4.9919250955099415e-09
, O 0 4.453820423577781e-09
there O 0 2.546555499804981e-08
was O 0 3.095275360465166e-07
significant O 0 5.0869971346401144e-08
disparity O 0 2.2715819625318545e-07
between O 0 1.4779432788714075e-08
the O 0 1.2990120978884079e-08
tests O 0 7.079872261783748e-07
. O 0 1.293733475904446e-07

Three O 0 5.141819769960421e-07
went O 0 1.7664261520167202e-07
from O 0 3.605987952681744e-09
a O 0 5.946587577909668e-08
decreased O 0 5.049795800005086e-05
risk O 0 3.0048428811824124e-07
to O 0 3.931666991974225e-09
an O 0 6.539746078004782e-09
increased O 0 4.281075689505087e-07
risk O 0 1.1520093039507628e-06
, O 0 3.019163141715353e-09
while O 0 5.77177905469739e-09
in O 0 2.2175798974899408e-09
another O 0 1.1777169461879566e-08
three O 0 4.435305456240712e-09
the O 0 2.15761737365483e-08
risk O 0 9.338212407783431e-07
was O 0 6.665899036306655e-06
decreased O 0 2.47536208917154e-05
. O 0 5.03247179040045e-07

Knowledge O 0 6.365984859257878e-07
of O 0 1.1574297964500602e-08
the O 0 5.8524820545358125e-09
potential O 0 1.6473251207571593e-08
reasons O 0 1.6950900683099235e-09
for O 0 2.3065416243639447e-10
these O 0 1.2957246386946508e-10
changes O 0 5.879275399855999e-10
in O 0 2.6242052975078423e-09
results O 0 4.9345040054049605e-08
and O 0 2.1893512780479796e-08
impact O 0 1.8350899466668125e-08
of O 0 2.3456009357047947e-10
these O 0 6.136285701785482e-09
risk O 0 5.014199899733285e-08
reversals O 0 1.3328116210686858e-07
on O 0 7.268657213899132e-07
both O 0 8.244610683050269e-08
patients O 0 1.59848340786084e-07
and O 0 1.6568478145018162e-08
the O 0 2.270800436576792e-09
counseling O 0 3.88798397921164e-08
team O 0 2.448128588738996e-09
can O 0 1.079649480928424e-09
assist O 0 7.777535837583116e-10
in O 0 1.6101588951045187e-09
the O 0 4.238561723823864e-10
development O 0 9.41418143440842e-09
of O 0 4.662275565614493e-10
strategies O 0 2.9045214233747174e-08
for O 0 1.7822018305579945e-09
the O 0 1.0702673192142242e-09
prevention O 0 1.5783004414515744e-07
and O 0 5.0652424476993474e-08
, O 0 3.933857684046416e-09
where O 0 4.159279143323147e-09
necessary O 0 5.7243623174940694e-09
, O 0 1.1070503402876852e-09
management O 0 1.8212112928850388e-09
of O 0 1.1275974598490279e-10
a O 0 6.364491156318763e-08
risk O 0 1.1909728669934339e-07
reversal O 0 2.535901799660678e-08
in O 0 4.668629927095935e-10
any O 0 1.1114849041149455e-09
predictive O 0 1.4638183643000957e-07
testing O 0 7.229473197867264e-08
program O 0 9.916689691635838e-09
. O 0 2.6511610684565312e-09
. O 0 4.486169302708731e-08

A O 0 7.296365765796509e-06
novel O 0 1.4497243228106527e-06
common O 0 7.183755315054441e-07
missense O 0 6.079837112338282e-05
mutation O 0 8.028897582335048e-07
G301C O 0 1.9769559003179893e-06
in O 0 1.0894469326672152e-08
the O 0 7.027400439341136e-09
N O 0 0.0006485350895673037
- O 0 9.963553748093545e-05
acetylgalactosamine O 0 0.0002518726687412709
- O 0 5.2293340559117496e-05
6 O 0 6.68767427214334e-07
- O 0 8.463748963549733e-05
sulfate O 0 2.8022324841003865e-05
sulfatase O 0 8.210419764509425e-06
gene O 0 1.0533155858638565e-07
in O 0 4.611656123643115e-08
mucopolysaccharidosis B-Disease 0 0.0005326622631400824
IVA I-Disease 0 0.07897122204303741
. O 0 2.4875182589312317e-06

Mucopolysaccharidosis B-Disease 1 0.9146140813827515
IVA I-Disease 1 0.9990541338920593
( O 0 0.000500027381349355
MPS B-Disease 1 0.9999825954437256
IVA I-Disease 1 0.9999994039535522
) O 0 2.2114916191640077e-06
is O 0 1.5369269021903165e-06
an O 0 1.183586755360011e-05
autosomal B-Disease 1 0.9999892711639404
recessive I-Disease 1 0.9999920129776001
lysosomal I-Disease 1 0.9999994039535522
storage I-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9999927282333374
caused O 0 0.00011061718396376818
by O 0 1.4091909861235763e-07
a O 0 0.00023281486937776208
genetic B-Disease 1 0.9999980926513672
defect I-Disease 1 0.9999948740005493
in O 0 7.048296879474947e-07
N O 0 0.06700394302606583
- O 0 0.00021615334844682366
acetylgalactosamine O 0 0.00038611184572800994
- O 0 0.0012635381426662207
6 O 0 1.8839706399376155e-06
- O 0 0.012180080637335777
sulfate O 0 0.03271050006151199
sulfatase O 0 0.0004186014994047582
( O 0 2.4870901782492183e-08
GALNS O 0 1.007536229735706e-05
) O 0 3.8336395391525e-08
. O 0 8.220553837645639e-08

In O 0 2.477758584973344e-07
previous O 0 7.79453301902322e-08
studies O 0 1.7228062532126387e-08
, O 0 1.1241476194356892e-08
we O 0 7.2974231102307385e-09
have O 0 4.604605141622642e-09
found O 0 2.025575973618743e-08
two O 0 1.1859235815592228e-09
common O 0 1.4674239601220052e-08
mutations O 0 1.1086355833356265e-08
in O 0 1.4644007118036484e-09
Caucasians O 0 9.146339152721339e-08
and O 0 3.4315789321226475e-08
Japanese O 0 2.2899048701674474e-07
, O 0 1.2811335103890542e-08
respectively O 0 1.0881888101721415e-07
. O 0 1.6718749407118594e-07

To O 0 2.4389674990743515e-07
characterize O 0 5.704991053789854e-06
the O 0 8.346836999351126e-09
mutational O 0 6.27461304247845e-06
spectrum O 0 2.881651880670688e-06
in O 0 8.694745368131862e-09
various O 0 2.378208519004943e-09
ethnic O 0 2.324071424197882e-08
groups O 0 6.3923852877678655e-09
, O 0 4.573296408239003e-09
mutations O 0 2.2645906483376166e-08
in O 0 1.4651773128093737e-09
the O 0 8.484152047572024e-09
GALNS O 0 2.7989954105578363e-05
gene O 0 8.263486250825736e-08
in O 0 1.67861138322678e-08
Colombian O 0 5.148991840542294e-05
MPS B-Disease 1 0.9999784231185913
IVA I-Disease 1 0.9999997615814209
patients O 0 2.046074587269686e-05
were O 0 1.2356568959148717e-06
investigated O 0 7.890918641351163e-05
, O 0 1.4958760630179313e-07
and O 0 3.1742910522325474e-08
genetic O 0 7.53802424924288e-08
backgrounds O 0 1.2093813950286858e-08
were O 0 4.728732960757043e-08
extensively O 0 1.2168324303729605e-07
analyzed O 0 1.1765543916908427e-07
to O 0 5.713813866492501e-09
identify O 0 8.938333451169456e-08
racial O 0 6.508179950515114e-08
origin O 0 3.2272751582240744e-08
, O 0 9.932779931887126e-09
based O 0 1.865133647527273e-08
on O 0 1.9218163060941151e-07
mitochondrial O 0 1.7765911252354272e-05
DNA O 0 1.2234770110808313e-05
( O 0 8.51342818464218e-09
mtDNA O 0 1.1316431169916541e-07
) O 0 1.67995040101232e-08
lineages O 0 4.926529300064431e-07
. O 0 2.6999023816642875e-07

Three O 0 7.844853371352656e-07
novel O 0 5.924036372562114e-07
missense O 0 6.904976180521771e-05
mutations O 0 1.8296248526894487e-05
never O 0 1.17497052087856e-06
identified O 0 9.88790588962729e-07
previously O 0 2.3735087495424523e-07
in O 0 5.544793513223567e-09
other O 0 2.698906431675141e-09
populations O 0 7.295603410284457e-08
and O 0 4.6010431020704345e-08
found O 0 1.0553849705274843e-07
in O 0 9.5955030587902e-09
16 O 0 4.979353818157506e-09
out O 0 5.001474345789347e-09
of O 0 1.3506344931357717e-09
19 O 0 1.397147570969537e-07
Colombian O 0 5.687650627805851e-06
MPS B-Disease 1 0.9992790818214417
IVA I-Disease 1 0.9999864101409912
unrelated O 0 2.254045830341056e-05
alleles O 0 2.3915794145068503e-07
account O 0 5.061321317612055e-08
for O 0 1.735603305519362e-08
84 O 0 3.463069106146577e-06
. O 0 4.1968633013311774e-07

2 O 0 7.461607083314448e-07
% O 0 2.262690834697878e-08
of O 0 1.7680897856919842e-09
the O 0 1.2738060606309887e-09
alleles O 0 1.839519470081541e-08
in O 0 1.361518453535382e-09
this O 0 4.7357708865547465e-09
study O 0 9.847106241522852e-08
. O 0 2.3647041302865546e-07

The O 0 2.8120066986048187e-07
G301C O 0 7.67825167713454e-06
and O 0 9.026341984963437e-08
S162F O 0 1.1163932640556595e-06
mutations O 0 2.8984402433707146e-07
account O 0 4.8613937764230286e-08
for O 0 2.442062552177049e-08
68 O 0 1.530568624730222e-06
. O 0 6.365960416587768e-07

4 O 0 1.412198002981313e-06
% O 0 1.2657085335376905e-07
and O 0 3.860657216137042e-08
10 O 0 7.403711066444885e-08
. O 0 2.465451984789979e-07

5 O 0 8.710716201676405e-07
% O 0 2.874397431185116e-08
of O 0 2.0513564180646426e-09
mutations O 0 7.137468855944462e-07
, O 0 4.7883169429496775e-08
respectively O 0 1.3536815401948843e-07
, O 0 1.1692853796319014e-08
whereas O 0 2.6844251266311403e-08
the O 0 2.491723050113137e-09
remaining O 0 8.603851142652275e-08
F69V O 0 0.0001899206981761381
is O 0 4.095391048508645e-08
limited O 0 1.1426739554565302e-08
to O 0 6.119805551207946e-09
a O 0 1.174171302409377e-07
single O 0 3.477024620224256e-06
allele O 0 1.5247296687448397e-05
. O 0 6.933552185728331e-07

The O 0 4.4714846580973244e-07
skewed O 0 7.480840849893866e-06
prevalence O 0 2.4852635760908015e-05
of O 0 1.1402854660502726e-08
G301C O 0 3.1393860808748286e-06
in O 0 2.479663230303686e-08
only O 0 1.4736759368361163e-08
Colombian O 0 3.5453751934255706e-07
patients O 0 3.841955020789101e-08
and O 0 1.2594437714952278e-09
haplotype O 0 1.2181652664366993e-07
analysis O 0 5.3229656238329426e-09
by O 0 2.280201361060108e-09
restriction O 0 1.573866370563337e-07
fragment O 0 3.93214122595964e-06
length O 0 6.007469437463442e-06
polymorphisms O 0 3.978719541919418e-05
in O 0 1.097710988773315e-08
the O 0 6.476662317567161e-09
GALNS O 0 1.8116270439350046e-05
gene O 0 4.391945651605056e-08
suggest O 0 2.7672140134882284e-08
that O 0 4.723196056488632e-09
G301C O 0 3.040376270746492e-07
originated O 0 5.686278115035748e-08
from O 0 2.5035373774073832e-09
a O 0 3.0982935328438543e-08
common O 0 2.65192682036286e-07
ancestor O 0 3.3891412840603152e-06
. O 0 5.785057055618381e-07

Investigation O 0 1.781039145498653e-06
of O 0 1.9963149355817222e-08
the O 0 1.1538500821473008e-08
genetic O 0 1.454750531593163e-06
background O 0 3.2986136488943885e-07
by O 0 6.109716732538573e-09
means O 0 1.971702801029096e-08
of O 0 1.3829065670378782e-09
mtDNA O 0 3.4320436270718346e-08
lineages O 0 2.8377199257079155e-08
indicate O 0 1.0746744294465316e-07
that O 0 8.880807200739582e-09
all O 0 3.3859490766730005e-09
our O 0 6.990399725737007e-08
patients O 0 1.919811687400852e-08
are O 0 9.711754733743305e-10
probably O 0 1.2270260363322905e-08
of O 0 5.01078178949399e-10
native O 0 5.876882269717498e-08
American O 0 3.5743408943744726e-07
descent O 0 0.001131159719079733

Low O 0 9.713774488773197e-06
frequency O 0 7.090419558153371e-07
of O 0 1.812423988667433e-08
BRCA1 O 0 8.900725333660375e-06
germline O 0 3.272789399488829e-06
mutations O 0 5.076296929473756e-07
in O 0 3.1332369587744324e-08
45 O 0 3.958339220844209e-06
German O 1 0.9962553977966309
breast B-Disease 1 0.9999973773956299
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
families O 0 3.497309080557898e-05
. O 0 2.8113627195125446e-06

In O 0 1.1122662613161083e-07
this O 0 1.0865286448336064e-09
study O 0 1.2096736945466091e-09
we O 0 2.329613391083285e-09
investigated O 0 1.4652262336767308e-07
45 O 0 2.4085582595034793e-07
German O 1 0.8878516554832458
breast B-Disease 1 0.9999878406524658
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 9.334383435088967e-07
for O 0 1.69249663173332e-08
germline O 0 1.3525086615118198e-05
mutations O 0 8.680190717313963e-07
in O 0 1.1939724764431503e-08
the O 0 5.8073286623994136e-08
BRCA1 O 0 4.260539571987465e-05
gene O 0 3.238549425077508e-06
. O 0 1.120258389164519e-06

We O 0 2.542261654525646e-06
identified O 0 8.391182291234145e-07
four O 0 1.3540114807142345e-08
germline O 0 3.088902303716168e-06
mutations O 0 1.2308489658607868e-06
in O 0 7.304696225673979e-08
three O 0 4.337527570896782e-06
breast B-Disease 1 0.9968269467353821
cancer I-Disease 0 0.0008316145394928753
families O 0 1.1250597964362896e-07
and O 0 2.1579224096512917e-07
in O 0 3.92671580584647e-07
one O 0 0.0004731818044092506
breast B-Disease 1 0.9999921321868896
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 7.094710599631071e-05
. O 0 1.1226926943663784e-08
among O 0 2.679855448661783e-09
these O 0 1.7439014676767783e-09
were O 0 2.578826183707861e-07
one O 0 4.754117810534808e-08
frameshift O 0 3.6979050491936505e-05
mutation O 0 4.477292065985239e-07
, O 0 1.6277233783057454e-08
one O 0 3.7428410593065564e-08
nonsense O 0 9.453434904571623e-05
mutation O 0 4.491315053201106e-07
, O 0 1.0056499633037674e-08
one O 0 4.6794101926650455e-09
novel O 0 1.084314504851136e-07
splice O 0 0.0002515093656256795
site O 0 0.00021448629559017718
mutation O 0 1.1997957471976406e-06
, O 0 1.8746563412719297e-08
and O 0 5.0103949433832895e-08
one O 0 1.375316287521855e-07
missense O 0 0.00019523433002177626
mutation O 0 1.3571159797720611e-05
. O 0 9.75164994088118e-07

The O 0 5.709436550205282e-07
missense O 0 8.434502524323761e-05
mutation O 0 1.212054121424444e-05
was O 0 8.653214536025189e-06
also O 0 9.899591191242507e-08
found O 0 4.7442714645740125e-08
in O 0 1.278853289932158e-08
2 O 0 2.3211282496049535e-07
. O 0 3.579416443244554e-07

8 O 0 2.183389597121277e-06
% O 0 3.423590300144497e-08
of O 0 2.4816966259777473e-09
the O 0 1.7277316244346252e-09
general O 0 4.777768403130267e-09
population O 0 3.380180357837048e-09
, O 0 1.1545099320997565e-09
suggesting O 0 4.904646289105585e-08
that O 0 8.656322769695635e-09
it O 0 4.4769631557528555e-08
is O 0 3.1154019097812125e-07
not O 0 1.2829719935325556e-06
disease O 0 5.199739007366588e-06
associated O 0 7.48274374018365e-07
. O 0 7.605552809764049e-07

The O 0 2.2037409053154988e-07
average O 0 7.729832987024565e-07
age O 0 7.348729980094504e-08
of O 0 2.8020448183951885e-08
disease O 0 0.00021749005827587098
onset O 0 2.5088242182391696e-05
in O 0 1.0484109935759989e-07
those O 0 7.623883391261188e-08
families O 0 8.514275862125942e-08
harbouring O 0 0.0006812146166339517
causative O 0 0.0004825941286981106
mutations O 0 3.864949121634709e-06
was O 0 5.682857135980157e-06
between O 0 1.655600527783463e-07
32 O 0 3.3759880579964374e-07
. O 0 4.447006460850389e-07

3 O 0 2.9189168344601057e-06
and O 0 4.893382197224128e-07
37 O 0 1.607916829016176e-06
. O 0 3.36536714939939e-07

4 O 0 2.03836384571332e-06
years O 0 2.4812251808725705e-07
, O 0 1.5578841328078852e-08
whereas O 0 2.6470898362163098e-08
the O 0 4.8684345443916754e-09
family O 0 6.430112762245699e-07
harbouring O 0 4.187227023066953e-05
the O 0 9.218827479173797e-09
missense O 0 1.7065223801182583e-05
mutation O 0 3.343785692777601e-07
had O 0 4.66056491177369e-07
an O 0 2.509346064272222e-09
average O 0 1.0211456356046256e-06
age O 0 3.552129612671706e-08
of O 0 9.444247606182898e-10
onset O 0 5.9295916798873805e-06
of O 0 4.2159900459637356e-08
51 O 0 7.1803565333539154e-06
. O 0 1.2738499890474486e-06

2 O 0 1.2304286428843625e-05
years O 0 1.8888280237661093e-06
. O 0 1.0754870345408563e-06

These O 0 1.3962112177523522e-07
findings O 0 5.240343625700916e-08
show O 0 1.6890629694898962e-07
that O 0 1.1847643754947512e-08
BRCA1 O 0 5.675757165590767e-06
is O 0 1.337811141866041e-07
implicated O 0 2.2940455437492346e-06
in O 0 1.0653919524372668e-08
a O 0 2.441377944251144e-08
small O 0 4.6774761841561485e-08
fraction O 0 2.983603621942166e-07
of O 0 7.0710389081796166e-06
breast B-Disease 1 0.999994158744812
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
families O 0 8.196519161174365e-07
suggesting O 0 6.747470706613967e-07
the O 0 2.683824718019423e-09
involvement O 0 6.166417421127335e-08
of O 0 3.0608759971073596e-09
another O 0 3.608391523357568e-07
susceptibility O 0 9.47670268942602e-05
gene O 0 2.9746536256425316e-06
( O 0 3.465605402652727e-07
s O 0 0.001398687600158155
) O 0 4.9344098442816176e-06

Paternal O 0 0.04251788184046745
transmission O 0 0.2879659831523895
of O 0 0.0019497416215017438
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.0005338085466064513

We O 0 7.455916488652292e-07
report O 0 3.7149252563040136e-08
a O 0 1.653558179270931e-08
rare O 0 2.0513678578026884e-07
case O 0 8.003412688140088e-08
of O 0 1.631514550126667e-07
paternally O 1 0.9989224672317505
transmitted O 1 0.9999915361404419
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5112197399139404
DM B-Disease 1 0.9999998807907104
) O 0 2.7941205189563334e-05
. O 0 4.594773145072395e-06

The O 0 2.1871690591979132e-07
proband O 0 5.61294837098103e-05
is O 0 4.990347335365186e-08
a O 0 1.1449384551553976e-08
23 O 0 1.33544215685788e-08
year O 0 8.503998394360224e-09
old O 0 0.002386521315202117
, O 0 3.2720796298235655e-05
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 0.9999991655349731
male O 0 0.01800484023988247
who O 0 0.0008625617483630776
suffers O 1 0.9987099170684814
severe O 0 0.40429413318634033
muscular B-Disease 1 0.9959973096847534
weakness I-Disease 1 0.9156064987182617
. O 0 8.267936209449545e-06

He O 0 7.120430382201448e-06
presented O 0 1.3919171806264785e-06
with O 0 7.0728938226238824e-06
respiratory O 0 0.4207172095775604
and O 0 7.033913220766408e-07
feeding O 0 3.647885023383424e-05
difficulties O 0 3.4376764688204275e-06
at O 0 4.328849172452465e-06
birth O 0 1.587188853591215e-05
. O 0 6.290835017352947e-07

His O 0 4.7088783503568266e-06
two O 0 7.297565502994985e-07
sibs O 1 0.768460214138031
suffer O 0 0.000695185677614063
from O 0 2.9555761216215615e-07
childhood O 0 0.0011442198883742094
onset O 1 0.9800655245780945
DM B-Disease 1 0.9999994039535522
. O 0 0.0001392885751556605

Their O 0 6.939658305782359e-07
late O 0 1.2481376643336262e-06
father O 0 2.648575218699989e-06
had O 0 3.968889572547596e-08
the O 0 5.444434902912576e-10
adult O 0 2.3942806848253895e-08
type O 0 5.980055448162602e-06
of O 0 1.1195625404525344e-07
DM B-Disease 1 1.0
, O 0 6.168747290757892e-07
with O 0 2.8704638665999482e-08
onset O 0 1.6727437468944117e-05
around O 0 7.758192168694222e-07
30 O 0 4.634229355815478e-08
years O 0 3.973115880739897e-08
. O 0 1.558859850092631e-07

Only O 0 2.643072321006912e-07
six O 0 1.356418088960254e-08
other O 0 1.5193238889210647e-09
cases O 0 3.8045295802646706e-09
of O 0 1.5185388502203523e-09
paternal O 0 0.00022151542361825705
transmission O 0 0.02399696409702301
of O 0 7.299969001905993e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0005875847418792546
been O 0 1.1094711226178333e-05
reported O 0 1.3751076039625332e-05
recently O 0 7.5803632171300706e-06
. O 0 6.25082066108007e-07

We O 0 8.03637419721781e-07
review O 0 5.2855757104453005e-08
the O 0 3.6167608907788917e-09
sex O 0 2.1641216108037042e-07
related O 0 1.5037026912523288e-07
effects O 0 3.9537113138976565e-07
on O 0 3.325880300053541e-07
transmission O 0 0.015390349552035332
of O 0 2.1094409021316096e-05
congenital B-Disease 1 0.9999994039535522
DM I-Disease 1 0.9999997615814209
. O 0 0.00023482799588236958

Decreased O 0 0.000966629886534065
fertility O 0 9.511051757726818e-06
of O 0 3.862776321028605e-09
males O 0 3.6144456316833384e-08
with O 0 9.416246449234222e-09
adult O 0 5.6335384215344675e-06
onset O 0 0.3313591480255127
DM B-Disease 1 1.0
and O 0 7.651307896594517e-06
contraction O 0 2.4616660084575415e-05
of O 0 5.9351172865262924e-09
the O 0 5.169212613509444e-09
repeat O 0 7.346142751885054e-07
upon O 0 8.474739132680043e-09
male O 0 1.3665044207300525e-07
transmission O 0 1.0491685316083021e-06
contribute O 0 8.465433687376844e-09
to O 0 3.789256020070297e-09
the O 0 6.033034072316923e-09
almost O 0 3.2883924916404794e-08
absent O 0 4.211682025356822e-08
occurrence O 0 2.4204697979257617e-07
of O 0 1.0846264331121347e-08
paternal O 0 9.065842459676787e-05
transmission O 0 0.0016286666505038738
of O 0 3.691383244586177e-05
congenital B-Disease 1 0.9999995231628418
DM I-Disease 1 0.9999998807907104
. O 0 0.0003393228107597679

Also O 0 3.272230742368265e-06
the O 0 8.771702475485199e-09
fathers O 0 2.7198993279853312e-08
of O 0 9.17024456370541e-10
the O 0 8.685944408171054e-09
reported O 0 2.0257948563084938e-05
congenitally O 0 0.0032253621611744165
affected O 0 3.020771600859007e-06
children O 0 1.1517661135940216e-07
showed O 0 7.331775009333796e-07
, O 0 2.370030394160949e-09
on O 0 4.0876184215221656e-08
average O 0 8.732108653930482e-07
, O 0 6.927324047723005e-09
shorter O 0 6.880736691528e-07
CTG O 0 1.7307629605056718e-05
repeat O 0 4.820246886083623e-07
lengths O 0 1.3137953828845639e-05
and O 0 1.2857385911502206e-07
hence O 0 3.602937681534968e-07
less O 0 4.2985774939552357e-07
severe O 0 7.799767627147958e-05
clinical O 0 0.0001788784866221249
symptoms O 0 3.461091182543896e-05
than O 0 4.184250101957332e-08
the O 0 6.576198074981221e-08
mothers O 0 2.2074955552398023e-07
of O 0 3.961914352146323e-09
children O 0 1.1056200719394838e-06
with O 0 8.793428423814476e-05
congenital B-Disease 1 0.9999994039535522
DM I-Disease 1 0.9999998807907104
. O 0 0.00019380729645490646

We O 0 1.5536606952082366e-06
conclude O 0 8.292322490888182e-07
that O 0 5.214151954646695e-08
paternal O 0 2.37300519074779e-05
transmission O 0 0.0006541861221194267
of O 0 2.1913079763180576e-05
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
is O 0 0.02081269957125187
rare O 0 3.600017589633353e-05
and O 0 9.301950854023744e-08
preferentially O 0 6.329746611299925e-07
occurs O 0 1.647388003789274e-08
with O 0 2.1586041842880377e-09
onset O 0 9.76084265857935e-07
of O 0 5.255979118601317e-08
DM B-Disease 1 0.9999998807907104
past O 0 1.4335412743093912e-05
30 O 0 3.093451539371017e-08
years O 0 4.6024797306642995e-09
in O 0 2.7907574029484294e-09
the O 0 2.9030025050502672e-09
father O 0 5.639137725665933e-07
. O 0 1.6715697270797136e-08
. O 0 1.1429555257791435e-07

The O 0 1.1471526022432954e-06
RB1 O 0 0.0011039075907319784
gene O 0 3.3357828215230256e-06
mutation O 0 1.2093972827642574e-06
in O 0 1.1411470879352237e-08
a O 0 4.813048803953279e-07
child O 0 7.800324965501204e-05
with O 0 2.180877527280245e-05
ectopic B-Disease 1 0.9999854564666748
intracranial I-Disease 1 0.9999915361404419
retinoblastoma I-Disease 1 0.9976547956466675
. O 0 9.520632738713175e-05

The O 0 7.583665819765883e-07
RB1 O 0 0.0005707564414478838
gene O 0 7.78717003413476e-06
mutation O 0 4.321947926655412e-06
was O 0 1.6329277059412561e-06
investigated O 0 2.9943209938210202e-06
in O 0 5.16922504800732e-08
a O 0 2.9765294584649382e-06
child O 0 0.000487538636662066
with O 0 1.0087438568007201e-05
ectopic B-Disease 1 0.9999904632568359
intracranial I-Disease 1 0.9999902248382568
retinoblastoma I-Disease 0 0.043876662850379944
using O 0 5.273441843200999e-07
DNA O 0 1.4528607152897166e-06
obtained O 0 1.798906268390965e-08
from O 0 5.731069840919645e-09
both O 0 2.5249542456862173e-09
the O 0 2.6314428414053737e-09
pineal B-Disease 0 2.1121704776305705e-05
and I-Disease 0 7.20489367722621e-07
retinal I-Disease 0 0.003417334286496043
tumours I-Disease 1 0.9999954700469971
of O 0 2.1126348670463813e-08
the O 0 4.2070095673807373e-07
patient O 0 8.226996578741819e-05
. O 0 9.91107413028658e-07

A O 0 8.432371942035388e-06
nonsense O 0 6.768119055777788e-05
mutation O 0 1.4277588888944592e-06
in O 0 1.5220397386883633e-08
exon O 0 1.398776930727763e-06
17 O 0 1.1790209697437604e-07
( O 0 1.6876251507369489e-09
codon O 0 3.6820104298840306e-08
556 O 0 4.614524584667379e-08
) O 0 4.001021181032627e-10
of O 0 1.6640575029036597e-10
the O 0 2.3135529048090575e-09
RB1 O 0 1.631668783375062e-05
gene O 0 3.741120835343281e-08
was O 0 2.101311793012428e-06
found O 0 1.5786586970989447e-07
to O 0 5.726152885188185e-09
be O 0 1.5141580433919444e-08
present O 0 1.2684993500045039e-08
homozygously O 0 9.106299330596812e-06
in O 0 6.590736845168976e-09
both O 0 3.4139440163727386e-09
the O 0 4.078986926003836e-09
retinal B-Disease 0 3.049054384973715e-06
and I-Disease 0 1.7249952577458316e-07
the I-Disease 0 3.575929383714538e-07
pineal I-Disease 1 0.8008161187171936
tumours I-Disease 1 0.9999874830245972
. O 0 7.081924195517786e-06

The O 0 1.0299228137000682e-07
same O 0 4.236222039821769e-08
mutation O 0 8.927395356295165e-08
was O 0 2.654203967722424e-07
present O 0 3.985107355219952e-08
heterozygously O 0 7.284461025847122e-05
in O 0 1.4595159747443631e-08
the O 0 2.73498423908336e-09
DNA O 0 5.030873921896273e-07
from O 0 1.531035742630138e-09
the O 0 7.992222994523956e-10
constitutional O 0 5.767696098502029e-09
cells O 0 4.800797537285462e-09
of O 0 4.033247624768421e-10
the O 0 1.4308333184942512e-08
patient O 0 4.86630142404465e-06
, O 0 5.862749841156756e-09
proving O 0 1.380471644552017e-06
it O 0 7.032120663552632e-09
to O 0 5.4412199190778665e-09
be O 0 5.464516839026601e-09
of O 0 1.980831498826774e-09
germline O 0 1.8819021079252707e-06
origin O 0 1.6959081960976619e-07
. O 0 3.938533552627632e-07

The O 0 6.474552805002531e-08
initial O 0 2.4714574919926235e-07
mutation O 0 3.1843518399909954e-07
was O 0 8.175861694326159e-07
shown O 0 3.8088153075932496e-08
to O 0 6.807995056590244e-09
have O 0 7.838196758314098e-09
occurred O 0 3.119617275615383e-08
in O 0 8.50399417551273e-10
the O 0 6.248320971735666e-09
paternally O 0 1.1074520443798974e-05
derived O 0 2.6086572688654996e-06
RB1 O 0 0.0002987207262776792
allele O 0 1.4343945622385945e-05
. O 0 1.5704943052696763e-06

The O 0 2.3468120957659266e-07
mutation O 0 1.3040387329965597e-06
is O 0 9.055329286411506e-08
in O 0 2.1095334368226304e-09
an O 0 2.3014274930233114e-09
area O 0 9.285462283514789e-07
of O 0 6.99608870835533e-10
the O 0 2.236499208052578e-09
gene O 0 3.0898544167712316e-08
that O 0 2.20641638293273e-09
encodes O 0 7.444759919650323e-09
the O 0 1.7725942935697958e-09
protein O 0 4.438439304976782e-08
- O 0 1.209256538459158e-06
binding O 0 4.127036277168372e-07
region O 0 1.5661106544939685e-07
known O 0 9.000554967997232e-08
as O 0 1.5654885388016737e-08
the O 0 3.3234366370038515e-09
pocket O 0 0.002098781056702137
region O 0 1.4245098327592132e-06
and O 0 1.9290656894099811e-07
has O 0 1.7885268732698023e-07
been O 0 5.1264159139918775e-08
detected O 0 1.5606298120474094e-07
in O 0 7.027826098848777e-10
other O 0 6.003243457897156e-10
cases O 0 4.3259396065309375e-09
of O 0 3.823209748787804e-09
retinoblastoma B-Disease 0 0.0002217508153989911
. O 0 1.0222627366829329e-07
. O 0 3.2418355999652704e-07

Low O 0 0.00018588601960800588
levels O 0 3.04348901636331e-07
of O 0 4.442282097727457e-09
beta O 0 1.9624543767804425e-08
hexosaminidase O 0 1.3908741038903827e-06
A O 0 4.7755570165008976e-08
in O 0 2.8408542185331953e-09
healthy O 0 3.793727785250667e-07
individuals O 0 1.1155674606300181e-08
with O 0 3.3205179761353065e-07
apparent O 1 0.6504957675933838
deficiency O 0 0.0591057613492012
of O 0 7.509760591162262e-10
this O 0 1.9473942458603233e-08
enzyme O 0 2.1407793155958643e-06
. O 0 3.837828330688353e-07

Appreciable O 0 0.00018178588652517647
beta O 0 9.957165275409352e-06
hexosaminidase O 0 0.00012917883577756584
A O 0 2.6022269139502896e-06
( O 0 9.604383066630362e-09
hex O 0 1.0199601092608646e-06
A O 0 1.3602914350485662e-08
) O 0 3.617545707434999e-10
activity O 0 6.007017105957857e-08
has O 0 5.060295293901618e-09
been O 0 4.402536113445876e-09
detected O 0 2.1929000126874598e-07
in O 0 1.6023128379671903e-09
cultured O 0 2.105919338646345e-05
skin O 0 0.0003441339358687401
fibroblasts O 0 8.319520929944701e-06
and O 0 4.3017123971367255e-05
melanoma B-Disease 1 0.9482324719429016
tissue O 0 0.000998736941255629
from O 0 3.2566592977900655e-08
healthy O 0 1.112717654905282e-06
individuals O 0 3.345352883599162e-09
previously O 0 4.366878272321628e-07
reported O 0 2.7096602934761904e-05
as O 0 2.078560555673903e-06
having O 0 0.0006257807253859937
deficiency B-Disease 0 0.042596153914928436
of I-Disease 0 3.3508253949321443e-09
hex I-Disease 0 8.271548722404987e-06
A I-Disease 0 1.46842822346116e-07
activity O 0 4.161607023434044e-07
indistinguishable O 0 1.5909453310314348e-08
from O 0 5.55285484260537e-10
that O 0 5.385215051667558e-10
of O 0 1.384072856325247e-09
patients O 0 3.4539121429588704e-07
with O 0 2.5165878469124436e-05
Tay B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
Sachs I-Disease 1 0.9999998807907104
disease I-Disease 1 0.8823331594467163
( O 0 5.331305601430358e-07
TSD B-Disease 0 0.001136349281296134
) O 0 1.1066353522437566e-07
. O 0 1.669961164907363e-07

Identification O 0 5.310532742441865e-06
and O 0 1.7207941027663765e-07
quantitation O 0 5.946518740529427e-06
of O 0 1.810375316324553e-08
hex O 0 5.231199611444026e-05
A O 0 7.366101613115461e-07
, O 0 7.929743972567849e-09
amounting O 0 2.8877067848043225e-08
to O 0 6.002422114903538e-09
3 O 0 1.2878051336429053e-07
. O 0 3.282001728166506e-07

5 O 0 2.531227664803737e-06
% O 0 2.8220893000252545e-07
- O 0 4.835726213059388e-05
6 O 0 7.196255751296121e-07
. O 0 2.6167350597461336e-07

9 O 0 1.1007741704815999e-06
% O 0 1.4727373987000192e-08
of O 0 1.0389048510361931e-09
total O 0 7.503293097954611e-09
beta O 0 1.0717999820997193e-08
hexosaminidase O 0 2.075071279250551e-06
activity O 0 1.1089167628597352e-06
, O 0 7.890666786636302e-09
has O 0 6.027156551624557e-09
been O 0 6.901554439053825e-09
obtained O 0 7.507959587371715e-09
by O 0 1.9279911001035543e-08
cellulose O 0 0.006063395645469427
acetate O 0 0.0004630798357538879
gel O 0 0.0005343397497199476
electrophoresis O 0 2.563541056588292e-05
, O 0 6.370515137632538e-08
DEAE O 0 1.8700102373259142e-05
- O 0 2.8596248284884496e-06
cellulose O 0 1.8591206753626466e-05
ion O 0 7.1115809987531975e-06
- O 0 5.387786131905159e-06
exchange O 0 3.3956462175410707e-07
chromatography O 0 6.414667950593866e-06
, O 0 7.0824088815868436e-09
radial O 0 1.2517207323980983e-06
immunodiffusion O 0 1.4339445442601573e-05
, O 0 2.723044900676541e-08
and O 0 8.821840680184323e-08
radioimmunoassay O 0 0.00015421566786244512
. O 0 6.636168450313562e-07

Previous O 0 7.161372195696458e-06
family O 0 1.68719509474613e-06
studies O 0 5.891739096597348e-09
suggested O 0 6.643266914352353e-08
that O 0 2.0497803454588848e-09
these O 0 1.5271043318776378e-09
individuals O 0 3.7247855910749195e-09
may O 0 6.820435771714983e-08
be O 0 2.4633527218043128e-08
compound O 0 2.387655740676564e-06
heterozygotes O 0 3.160619712616608e-07
for O 0 2.914675611975781e-09
the O 0 5.0771751247680186e-09
common O 0 8.267805640116421e-08
mutant O 0 4.1219661284230824e-07
TSD B-Disease 0 2.2260866899159737e-05
gene O 0 3.07402160615311e-07
and O 0 1.0988907916953394e-07
a O 0 4.6943503662078e-07
rare O 0 2.4307901185238734e-06
( O 0 2.0017369095626236e-08
allelic O 0 1.636657088965876e-06
) O 0 1.9202476053692408e-08
mutant O 0 7.928149443614529e-07
gene O 0 8.672570288581483e-07
. O 0 4.609308632552711e-07

Thus O 0 2.9433754207275342e-06
, O 0 2.0658735166989572e-08
the O 0 6.505480598661961e-10
postulated O 0 2.1885023215872934e-07
rate O 0 5.625875587611517e-07
mutant O 0 9.892588082038856e-08
gene O 0 4.422712507334836e-08
appears O 0 9.276296708549125e-08
to O 0 1.2998416787368683e-09
code O 0 2.827151179829457e-09
for O 0 1.2661660608870307e-09
the O 0 9.103168774338144e-10
expression O 0 8.207281076977324e-09
of O 0 8.754515445907884e-10
low O 0 2.5576455300324596e-06
amounts O 0 1.5420942744981403e-08
of O 0 1.012578909609374e-08
hex O 0 2.3806027456885204e-05
A O 0 5.406756145021063e-07
. O 0 3.6983050222261227e-07

Heterozygotes O 0 7.130821904866025e-05
for O 0 1.4299716610821633e-07
the O 0 2.437655410858497e-08
rare O 0 3.95113289641813e-07
mutant O 0 2.938506440841593e-06
may O 0 1.0219747537121293e-06
be O 0 3.165427742146676e-08
indistinguishable O 0 5.388909585235524e-08
from O 0 2.4731341419226283e-09
heterozygotes O 0 2.42418678908507e-07
for O 0 2.694338974151833e-09
the O 0 1.3131266740629144e-08
common O 0 5.482141318680078e-07
TSD B-Disease 0 0.00039251407724805176
mutant O 0 8.556996363040525e-06
. O 0 9.348414664600568e-07

However O 0 5.384429186960915e-07
, O 0 6.457863133135788e-09
direct O 0 9.808879930517378e-09
visualization O 0 1.33348453346116e-06
and O 0 3.784245450333401e-08
quantitation O 0 1.2561150469991844e-05
of O 0 1.2603959653745278e-08
hex O 0 2.2096528482506983e-05
A O 0 1.5321165847126395e-07
by O 0 1.754183243107832e-09
the O 0 8.345303892376421e-10
methods O 0 1.3980859137063817e-07
described O 0 6.1412683862727135e-06
may O 0 1.1022557799833521e-07
prevent O 0 8.901313464093619e-08
false O 0 1.973705110458468e-07
- O 0 1.2875161701231264e-05
positive O 0 2.255357998137697e-07
prenatal O 0 8.753237489145249e-05
diagnosis O 0 1.6495645468239672e-05
of O 0 8.473333146241657e-09
TSD B-Disease 0 0.0030677523463964462
in O 0 4.0089244635055366e-07
fetuses O 0 6.497316462628078e-06
having O 0 3.1608969663921016e-08
the O 0 4.177517887171689e-09
incomplete O 0 5.169943506189156e-06
hex B-Disease 0 0.04275817424058914
A I-Disease 0 0.003239411860704422
deficiency I-Disease 0 0.00551169877871871
of O 0 1.6442541772576647e-09
the O 0 1.3542801546861938e-08
type O 0 0.0005650327075272799
described O 0 3.493039548629895e-05
in O 0 1.641594593593254e-08
the O 0 9.378516629965361e-09
four O 0 4.792035568357278e-08
healthy O 0 4.332004209572915e-06
individuals O 0 5.313636393111665e-07

The O 0 4.280324787941936e-07
tumor B-Disease 0 2.7334001060808077e-05
suppressor O 0 1.0194214155490045e-05
gene O 0 4.0586710383649915e-06
Smad4 O 0 0.00010804522753460333
/ O 0 7.646073208888993e-05
Dpc4 O 0 4.772982356371358e-05
is O 0 5.5009955701734725e-08
required O 0 3.651014157668442e-09
for O 0 1.019246020916853e-09
gastrulation O 0 1.209887795994291e-05
and O 0 2.0552137414142635e-07
later O 0 4.0357218011877194e-08
for O 0 7.009141711478151e-09
anterior O 0 3.1735288530398975e-07
development O 0 1.2503943658259686e-08
of O 0 2.1199522137749227e-09
the O 0 1.1478751282822941e-08
mouse O 0 1.0337333151255734e-05
embryo O 0 1.3554137694882229e-05
. O 0 7.484084676434577e-07

Mutations O 0 6.583168578799814e-05
in O 0 1.1195241711448034e-07
the O 0 5.225471966241457e-08
SMAD4 O 0 0.0005202938336879015
/ O 0 0.00029049243312329054
DPC4 O 0 0.0015423402655869722
tumor B-Disease 0 0.00012483941100072116
suppressor O 0 7.881637429818511e-06
gene O 0 6.01530700805597e-07
, O 0 6.473895641789795e-09
a O 0 7.6406934113038e-09
key O 0 1.3775768081814022e-07
signal O 0 3.5937480902248353e-07
transducer O 0 3.0805151709500933e-06
in O 0 5.7798104080575285e-09
most O 0 1.2127977733200623e-08
TGFbeta O 0 1.3387008948484436e-05
- O 0 3.850641587632708e-05
related O 0 3.2725617984397104e-06
pathways O 0 1.1523615484065886e-07
, O 0 3.1029521174730235e-09
are O 0 2.3118180980663539e-10
involved O 0 2.9049298522210165e-09
in O 0 8.52385495520025e-10
50 O 0 5.383657075697101e-09
% O 0 2.28574870142495e-09
of O 0 7.288718961717677e-08
pancreatic B-Disease 1 0.9995318651199341
cancers I-Disease 0 0.1589968502521515
. O 0 1.1201001370864105e-06

Homozygous O 0 0.00037440352025441825
Smad4 O 0 0.0013410652754828334
mutant O 0 0.00015983829507604241
mice O 0 0.0010977769270539284
die O 0 4.092887320439331e-05
before O 0 1.5219235649510665e-08
day O 0 1.4469119946625142e-07
7 O 0 1.763480526051353e-07
. O 0 1.2041684271935083e-07

5 O 0 2.6772620458359597e-06
of O 0 2.1356966328767157e-07
embryogenesis O 0 0.00010366641072323546
. O 0 5.513997166417539e-06

Mutant O 0 8.97263907972956e-06
embryos O 0 1.5004037550170324e-06
have O 0 2.317807457075105e-08
reduced O 0 3.44189672318862e-08
size O 0 1.9247340787842404e-06
, O 0 3.1095897412569684e-08
fail O 0 1.9575352894207754e-07
to O 0 5.688357784805476e-09
gastrulate O 0 4.70441700599622e-05
or O 0 3.994201733803493e-07
express O 0 4.692363120284426e-08
a O 0 2.2025281154469667e-08
mesodermal O 0 1.4921239198883995e-05
marker O 0 0.0037299743853509426
, O 0 6.429205257063586e-08
and O 0 2.4447702529073467e-08
show O 0 6.864037231935072e-07
abnormal O 0 1.0847963494597934e-05
visceral O 0 1.7135620282715536e-06
endoderm O 0 2.0703901100205258e-05
development O 0 6.476788030340686e-07
. O 0 4.139156715154968e-07

Growth B-Disease 1 0.9999741315841675
retardation I-Disease 1 0.9999958276748657
of O 0 1.1764264229441324e-07
the O 0 1.6695821614121087e-07
Smad4 O 0 0.009065813384950161
- O 0 0.04384217783808708
deficient O 0 0.0002193912077927962
embryos O 0 1.6270101355075894e-07
results O 0 1.2887752198764701e-08
from O 0 1.754350553717643e-09
reduced O 0 4.5281293381549403e-08
cell O 0 1.926265667862026e-06
proliferation O 0 2.215118001913652e-06
rather O 0 7.496412379737194e-09
than O 0 7.304205240643569e-09
increased O 0 6.452128076261943e-08
apoptosis O 0 1.319878492722637e-06
. O 0 5.574731289925694e-07

Aggregation O 0 1.1973442269663792e-05
of O 0 1.2166397311830224e-07
mutant O 0 6.089585440349765e-06
Smad4 O 0 0.0004385021748021245
ES O 0 1.769826667441521e-05
cells O 0 2.249879997862081e-07
with O 0 1.2148003492029602e-08
wild O 0 1.0933948715319275e-06
- O 0 0.0006139202159829438
type O 0 0.00045239884639158845
tetraploid O 0 0.00010976576595567167
morulae O 0 0.0002296476741321385
rescues O 0 2.809280158544425e-05
the O 0 1.7360510184971645e-07
gastrulation B-Disease 0 0.002072147559374571
defect I-Disease 0 0.0007205261499620974
. O 0 1.638503022149962e-06

These O 0 2.2667389032449137e-07
results O 0 6.432173194070856e-08
indicate O 0 1.9349654678535444e-07
that O 0 3.1715359227746376e-09
Smad4 O 0 5.541789960261667e-06
is O 0 1.892547807358369e-08
initially O 0 2.6833346211674325e-08
required O 0 7.95581212020835e-10
for O 0 2.9906879750463133e-10
the O 0 2.301180634933786e-10
differentiation O 0 5.449614803865188e-08
of O 0 4.3635178803569374e-10
the O 0 1.4557258731784373e-09
visceral O 0 2.3092694334536645e-07
endoderm O 0 3.2300144994223956e-06
and O 0 4.951181509227354e-08
that O 0 2.567912993356458e-09
the O 0 1.6741341646309138e-09
gastrulation B-Disease 0 2.878713894460816e-05
defect I-Disease 0 1.878648799902294e-05
in O 0 3.225046230070916e-09
the O 0 4.9108033195466305e-09
epiblast O 0 4.423240534379147e-05
is O 0 9.075439066918989e-08
secondary O 0 7.125241552330408e-08
and O 0 2.4362238448816242e-08
non O 0 6.829560561527614e-07
- O 0 0.0007779470179229975
cell O 0 0.00013986982230562717
autonomous O 0 1.4849842955300119e-06
. O 0 6.755506092304131e-07

Rescued O 0 0.00011230239761061966
embryos O 0 1.4371576071425807e-05
show O 0 7.002011989243329e-05
severe O 0 0.00016146170673891902
anterior O 0 3.226234548492357e-05
truncations O 0 0.00017109174223151058
, O 0 6.095763751545746e-07
indicating O 0 6.692665465379832e-06
a O 0 6.169900501618031e-08
second O 0 1.0826529717178346e-07
important O 0 4.4332526982771014e-08
role O 0 3.251507862955805e-08
for O 0 1.689964435058755e-08
Smad4 O 0 5.1630839152494445e-05
in O 0 3.820186833536354e-08
anterior O 0 7.67645087762503e-06
patterning O 0 4.376382639748044e-05
during O 0 1.4594597814721055e-06
embryogenesis O 0 7.074712630128488e-05
. O 0 1.6488063465658342e-06

Prevalence O 0 0.001760053331963718
of O 0 5.525096824499087e-08
p16 O 0 1.0169862434850074e-05
and O 0 2.547192536894727e-07
CDK4 O 0 8.173492824425921e-05
germline O 0 9.44623116083676e-06
mutations O 0 1.0776461749628652e-06
in O 0 2.888235606235412e-08
48 O 0 8.3162367445766e-06
melanoma B-Disease 1 0.9950987696647644
- O 1 0.9771319031715393
prone O 1 0.9263179898262024
families O 0 5.566093363995606e-07
in O 0 1.537947440510834e-07
France O 0 2.14125157071976e-05
. O 0 1.2931725450471276e-06

The O 0 1.12825898668234e-06
French O 0 0.00015353690832853317
Familial B-Disease 1 0.8933410048484802
Melanoma I-Disease 1 0.9576054215431213
Study O 0 4.3644052993840887e-07
Group O 0 2.4914975256251637e-06
. O 0 5.247535455055186e-07

Germline O 0 0.00034555114689283073
mutations O 0 4.175942012807354e-05
in O 0 4.748037341073541e-08
the O 0 3.94225541100468e-09
p16 O 0 6.332367092909408e-07
and O 0 6.934518381740418e-08
CDK4 O 0 2.9268576327012852e-05
genes O 0 4.9042721883552076e-08
have O 0 6.123214824071965e-09
been O 0 3.808822413020607e-08
reported O 0 2.0810965395412495e-07
in O 0 4.179077639498985e-10
a O 0 4.687834120886691e-09
subset O 0 1.997966876388091e-07
of O 0 3.323432196111753e-08
melanoma B-Disease 0 0.1258600801229477
pedigrees O 0 4.762597382068634e-05
, O 0 1.992807909800831e-07
but O 0 3.463272335579859e-08
their O 0 2.946165755801644e-09
prevalence O 0 2.1069839931442402e-05
is O 0 4.8002412711412035e-08
not O 0 1.1610470806999729e-08
well O 0 1.3667881049173047e-08
known O 0 1.99307791604042e-07
. O 0 1.8718377248205798e-07

We O 0 4.2717121573332406e-07
searched O 0 9.70032033364987e-07
for O 0 3.86296816756726e-09
such O 0 3.253814107040398e-09
germline O 0 1.7831125660450198e-06
mutations O 0 1.9770547510233882e-07
in O 0 7.656741907169362e-09
48 O 0 1.979838771148934e-06
French O 0 0.0024227844551205635
melanoma B-Disease 1 0.9999308586120605
- O 1 0.9987890124320984
prone O 1 0.9842932820320129
families O 0 1.8068227802814363e-07
selected O 0 1.0185567056453237e-08
according O 0 9.690333868661583e-09
to O 0 8.291902275914254e-09
two O 0 5.0175268384577976e-09
major O 0 2.8559816200868227e-07
criteria O 0 1.7537031737901998e-07
families O 0 2.0601799377573116e-08
with O 0 7.405190682874263e-09
at O 0 7.582963803542953e-07
least O 0 1.3944821297684484e-08
three O 0 1.1538627830987025e-09
affected O 0 9.907576981049715e-09
members O 0 9.043080173576357e-11
( O 0 5.164824123937706e-10
n O 0 3.7776976569148246e-06
= O 0 3.632733864833426e-07
20 O 0 3.173738605255494e-09
) O 0 3.957410787958082e-10
or O 0 9.549347090853644e-09
families O 0 2.687041256166367e-09
with O 0 4.370992456870226e-09
two O 0 4.651716789538796e-09
affected O 0 5.316140061495389e-08
members O 0 8.825264963263635e-10
, O 0 2.646982633081052e-09
one O 0 1.4485080912507442e-09
of O 0 9.109816373475965e-11
them O 0 6.682326358919966e-10
affected O 0 7.145040559208837e-09
before O 0 5.273083636403442e-10
the O 0 2.4190061065354485e-10
age O 0 3.5039076085041643e-09
of O 0 1.2011228123220974e-10
50 O 0 6.951492714790675e-09
( O 0 7.537642732202698e-10
n O 0 3.760239678740618e-06
= O 0 9.484616612098762e-07
28 O 0 1.4094216460591724e-08
) O 0 6.190263857064338e-10
, O 0 9.276960311055404e-10
and O 0 3.1852851467562004e-09
one O 0 1.146039041444169e-09
additional O 0 3.978551266214936e-09
minor O 0 6.590939847228583e-07
criterion O 0 7.832034498278517e-06
. O 0 3.493956057809555e-07

Sixteen O 0 3.7130664622964105e-06
different O 0 7.83386511216122e-08
p16 O 0 2.8840549930464476e-06
germline O 0 6.414080871763872e-06
mutations O 0 2.114607923431322e-06
were O 0 4.0976109971779806e-07
found O 0 4.789678200722847e-07
in O 0 8.368947312931141e-09
21 O 0 8.542335905303844e-08
families O 0 9.302053349813377e-09
, O 0 2.8008304564508535e-09
while O 0 1.1581319903086751e-08
one O 0 1.1888843687302142e-08
germline O 0 5.137692937751126e-07
mutation O 0 5.919981660440499e-08
, O 0 8.50176018474258e-09
Arg24His O 0 6.873548500152538e-06
, O 0 1.9318267874268713e-08
was O 0 5.272637508824118e-07
detected O 0 1.2599292631421122e-06
in O 0 4.673121889453569e-09
the O 0 1.280864747599253e-08
CDK4 O 0 0.00012671167496591806
gene O 0 8.679371603648178e-07
. O 0 2.550775661802618e-07

The O 0 5.57206369933283e-08
frequency O 0 2.497291973213578e-07
of O 0 3.3881970562532615e-09
p16 O 0 8.180556960724061e-07
gene O 0 1.3701819057132525e-07
mutation O 0 1.546290491205582e-07
in O 0 6.7849463825098155e-09
our O 0 1.0206842482318734e-08
sample O 0 5.374426237381158e-08
( O 0 2.1453301357610144e-09
44 O 0 2.378752972376219e-09
% O 0 3.818587668291684e-10
) O 0 8.284452013285204e-10
is O 0 2.7249152267927457e-08
among O 0 2.0781873999453637e-09
the O 0 2.111095076529068e-09
highest O 0 5.230338047113037e-07
rates O 0 1.3297864143169136e-06
yet O 0 4.654443941376485e-08
reported O 0 4.580439849632967e-07
and O 0 2.6209702852497685e-08
the O 0 2.6987210244300286e-09
CDK4 O 0 0.00011329226981615648
mutation O 0 1.2299297225126793e-07
is O 0 1.1654800680105382e-08
the O 0 7.718615746554747e-10
second O 0 8.877847079702406e-08
mutation O 0 2.3280404093384277e-07
detected O 0 7.198115667961247e-07
in O 0 6.701088572924618e-10
this O 0 3.465001618963015e-09
gene O 0 1.1332739546787707e-07
worldwide O 0 1.2339559418705903e-07
. O 0 5.889752969778783e-07

In O 0 3.861269135541079e-07
summary O 0 1.040781626215903e-06
, O 0 3.9674365126529665e-08
our O 0 6.173335176384853e-09
results O 0 8.64635651964818e-09
show O 0 2.455931564782077e-07
frequent O 0 2.41306452153367e-07
involvement O 0 7.178674366059568e-08
of O 0 8.107637339271889e-10
the O 0 2.9442726035000533e-09
p16 O 0 1.8733861395503482e-07
gene O 0 1.1845491343365211e-07
in O 0 4.694842914432229e-08
familial B-Disease 0 0.12428416311740875
melanoma I-Disease 1 0.988492488861084
and O 0 1.9745382360270014e-06
confirm O 0 8.602834896009881e-06
the O 0 5.680508508021376e-09
role O 0 6.497870241872761e-09
of O 0 1.2695104967264115e-09
the O 0 9.47886480417992e-09
CDK4 O 0 3.602408105507493e-05
gene O 0 1.9507368165250227e-07
as O 0 3.531054204586326e-08
a O 0 1.7868030681711389e-06
melanoma B-Disease 1 0.7232344746589661
- O 0 0.0003845169267151505
predisposing O 0 8.168289059540257e-05
gene O 0 1.4194934010447469e-06
. O 0 8.554760455581345e-08
. O 0 4.309635528443323e-07

Progression O 0 7.846467633498833e-05
of O 0 9.083265695153386e-08
somatic O 0 2.113200207531918e-05
CTG O 0 0.0015106148784980178
repeat O 0 9.77101535681868e-06
length O 0 4.321201686252607e-06
heterogeneity O 0 1.7015920093399473e-05
in O 0 3.35594414480056e-08
the O 0 1.4034690742903422e-08
blood O 0 5.2539821808750276e-06
cells O 0 2.05972219191608e-06
of O 0 1.120946581067983e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999997615814209
patients O 0 0.002441778779029846
. O 0 3.0853841508360347e-06

The O 0 2.342599287885605e-07
genetic O 0 1.1132589179396746e-06
basis O 0 4.90950412768143e-07
of O 0 1.5126189282455016e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0012928217183798552
DM B-Disease 1 1.0
) O 0 1.4886736607877538e-06
is O 0 4.177822532369646e-08
the O 0 6.628111393069958e-10
expansion O 0 8.713676180605034e-08
of O 0 1.546974881527774e-09
an O 0 4.294095035106693e-08
unstable O 0 0.013253242708742619
CTG O 0 8.12887737993151e-05
repeat O 0 7.137672923818172e-07
in O 0 2.933202347676911e-09
the O 0 8.063807399594225e-10
34 O 0 8.901615444756317e-09
UTR O 0 1.7480024894211965e-07
of O 0 2.3029731455181945e-09
the O 0 1.2736711596517125e-07
DM B-Disease 1 0.9999994039535522
protein O 0 2.7803139346360695e-06
kinase O 0 5.611457709164824e-06
gene O 0 1.5313818835238635e-07
on O 0 2.431619350318215e-07
chromosome O 0 8.886135765351355e-05
19 O 0 2.7336170660419157e-06
. O 0 7.626572937624587e-07

One O 0 5.618122713713092e-07
of O 0 8.687385921746227e-09
the O 0 3.1571714131928275e-09
principal O 0 5.1827701241791146e-08
features O 0 7.307371419074116e-08
of O 0 3.2377427405805292e-09
the O 0 9.267848213312391e-07
DM B-Disease 1 1.0
mutation O 0 4.799033922608942e-05
is O 0 6.59217846532556e-07
an O 0 2.2076338979104548e-08
extraordinarily O 0 0.00016039951879065484
high O 0 4.148920197621919e-06
level O 0 4.835058220464816e-08
of O 0 5.674440917147194e-10
somatic O 0 3.173664993028069e-07
mosaicism O 0 0.00017850380390882492
, O 0 1.8443818916580312e-08
due O 0 4.9958138959027565e-08
to O 0 1.4013719074057462e-08
an O 0 1.6423962634348754e-08
extremely O 0 8.190601874957792e-06
high O 0 3.123448948372243e-07
degree O 0 4.858870195079135e-09
of O 0 1.0886653800668e-09
somatic O 0 1.4839578170722234e-06
instability O 0 4.147844265389722e-06
both O 0 7.115067202079217e-09
within O 0 1.4643008583448136e-08
and O 0 3.136579351803448e-08
between O 0 1.776094471495071e-08
different O 0 4.8641577876651354e-08
tissues O 0 4.653858923120424e-06
. O 0 2.81535278645606e-07

This O 0 3.0587071364607255e-07
instability O 0 2.231814278275124e-06
appears O 0 3.568543718301953e-07
to O 0 3.0359845748506586e-09
be O 0 1.5065145797521495e-09
biased O 0 4.296077449339464e-08
towards O 0 2.3958006689639433e-09
further O 0 7.363974430241171e-10
expansion O 0 1.7316651224064117e-08
and O 0 3.276120486006562e-09
continuous O 0 9.351083463116083e-08
throughout O 0 1.1353938234037741e-08
the O 0 7.936594159652088e-10
life O 0 1.2297720175524773e-08
of O 0 1.1738813254780212e-09
an O 0 1.1893833473664017e-08
individual O 0 1.1011684897255236e-09
, O 0 4.06638767103118e-09
features O 0 4.2971348079845484e-07
that O 0 1.0691032770182574e-07
could O 0 6.462702231146977e-07
be O 0 1.6027331639634212e-07
associated O 0 2.1051258158877317e-07
with O 0 1.922127346176694e-08
the O 0 1.9059365641282966e-08
progressive O 0 1.3606555739897885e-06
nature O 0 8.074909487731929e-07
of O 0 8.296773934546309e-09
the O 0 1.0997667914125486e-06
disease O 0 0.00017881080566439778
. O 0 1.7062860990790796e-07

Although O 0 7.992350106178492e-07
increasing O 0 1.230066857260681e-07
measured O 0 1.0099462315338315e-06
allele O 0 3.050742236609949e-07
size O 0 1.779353283382079e-06
between O 0 3.389479559245956e-07
patients O 0 2.1580706288659712e-07
clearly O 0 7.626428555340681e-08
correlates O 0 1.8036205062799127e-07
with O 0 9.651596855064781e-09
an O 0 8.759163172555873e-09
increased O 0 9.468602684137295e-07
severity O 0 6.847901386208832e-05
of O 0 3.787957609802106e-07
symptoms O 0 0.0002824247640091926
and O 0 1.560357532071066e-07
an O 0 1.5395345442925645e-08
earlier O 0 5.404529019870097e-07
age O 0 3.271226844958619e-08
of O 0 5.696487170858688e-10
onset O 0 9.168552423943765e-06
, O 0 3.779987434171517e-09
this O 0 5.102199218676162e-10
correlation O 0 2.427613026156905e-07
is O 0 2.8357883152807517e-08
not O 0 2.131958831697034e-09
precise O 0 4.0611192275719077e-07
and O 0 4.100956374486486e-08
measured O 0 5.775267709395848e-06
allele O 0 2.4601558834547177e-07
length O 0 1.9617677935457323e-06
cannot O 0 2.0973316168237943e-06
be O 0 1.4344293752799331e-08
used O 0 6.386550666093171e-08
as O 0 7.750219133129121e-09
an O 0 1.0732437161209418e-09
accurate O 0 2.7683283860824304e-06
predictor O 0 1.443845121684717e-05
of O 0 3.631373646229008e-09
age O 0 1.0163446972910606e-07
of O 0 2.7056495710553463e-08
onset O 0 0.0003540727775543928
. O 0 1.923884383359109e-06

In O 0 8.738408752151372e-08
order O 0 1.295034124382255e-08
to O 0 1.1181658932102323e-09
further O 0 2.7313140638085542e-09
characterize O 0 3.1964921731741924e-07
the O 0 4.4978962776554e-09
dynamics O 0 2.6978375444741687e-06
of O 0 1.9466372691567813e-07
DM B-Disease 1 0.9999997615814209
CTG O 0 0.05874035134911537
repeat O 0 2.641331320774043e-06
somatic O 0 1.3874297337679309e-06
instability O 0 4.419821834744653e-06
, O 0 2.023309342291668e-08
we O 0 1.529714310777308e-08
have O 0 1.2432853635502283e-09
studied O 0 1.5468303304899678e-09
repeat O 0 1.7239701222138137e-08
length O 0 4.565281130908261e-08
changes O 0 4.729424851745989e-09
over O 0 8.973929155331462e-09
time O 0 1.2553170058993146e-08
in O 0 3.1770834851840846e-08
111 O 0 0.009619571268558502
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
patients O 0 4.205418736091815e-05
with O 0 3.19435216056263e-08
varying O 0 4.309688961257052e-07
clinical O 0 7.281066700670635e-06
severity O 0 0.0004495090979617089
and O 0 3.8609744024142856e-07
CTG O 0 0.00017955739167518914
repeat O 0 1.1809255511252559e-06
size O 0 1.2801059483535937e-06
over O 0 3.796463232674796e-08
time O 0 5.111767453769289e-09
intervals O 0 4.096281358556553e-08
of O 0 5.834156491246745e-10
1 O 0 2.345563032690734e-08
- O 0 6.767101240257034e-06
7 O 0 7.668305812558174e-08
years O 0 3.170539386587734e-08
. O 0 1.1835226132461685e-07

We O 0 7.354902209044667e-06
have O 0 4.537812969829247e-08
found O 0 6.780741745870955e-09
a O 0 3.086542577079854e-09
direct O 0 1.78501267100728e-08
progression O 0 4.408762379171094e-06
of O 0 1.5647744211477743e-09
the O 0 1.7527316265031345e-09
size O 0 9.289112199439842e-07
heterogeneity O 0 2.945432129308756e-07
over O 0 3.575389939669549e-08
time O 0 1.9763641390113662e-08
related O 0 8.239626225758911e-08
to O 0 6.884646630567204e-09
initial O 0 5.00571424311147e-08
CTG O 0 6.4525061134190764e-06
repeat O 0 1.2316245090460143e-07
size O 0 9.344198588223662e-07
and O 0 6.564342669435064e-08
the O 0 1.401029070535742e-09
time O 0 6.347782743887365e-09
interval O 0 1.8971995530137065e-07
and O 0 1.0933459471118567e-08
always O 0 1.033791718896282e-08
biased O 0 1.719336673033922e-08
towards O 0 5.805265601566134e-09
further O 0 9.099441200532965e-09
expansion O 0 3.1285526347346604e-07
. O 0 1.9262604666892003e-07

Attempts O 0 2.5986037144321017e-06
to O 0 5.281151871372458e-08
mathematically O 0 4.6628676386717416e-07
model O 0 1.3474337947627646e-06
the O 0 8.76003181105034e-09
dynamics O 0 1.607022204552777e-05
have O 0 1.9619591284936178e-07
proved O 0 1.6549944348298595e-06
only O 0 6.254831319552068e-09
partially O 0 5.862752345819899e-07
successful O 0 6.364952298554272e-08
suggesting O 0 4.4222656470083166e-07
that O 0 1.0959536389520963e-08
individual O 0 1.2794552084471889e-09
specific O 0 4.769364903012274e-09
genetic O 0 3.02999609402832e-07
and O 0 3.566441080238292e-07
/ O 0 0.00014892536273691803
or O 0 1.4353290680446662e-06
environmental O 0 1.8133962953470473e-07
factors O 0 2.8448789990420664e-08
also O 0 1.2096379009562952e-07
play O 0 3.8087353715354766e-08
a O 0 3.5866872138967665e-08
role O 0 2.3133820192811072e-08
in O 0 7.421125935991313e-09
somatic O 0 6.271271217883623e-07
mosaicism O 0 8.113357762340456e-05
. O 0 4.623528582214931e-08
. O 0 3.3763583928703156e-07

Aspartylglucosaminuria B-Disease 1 0.9915899634361267
among O 0 3.871870376315201e-06
Palestinian O 0 1.8613845895742998e-05
Arabs O 0 6.045440841262462e-06
. O 0 6.957649816285993e-07

Aspartylglucosaminuria B-Disease 1 0.9999831914901733
( O 0 0.000527311465702951
AGU B-Disease 1 0.999984622001648
) O 0 4.311452812544303e-07
is O 0 1.8086535646943958e-07
a O 0 8.461173592877458e-07
rare O 0 0.00022284577426034957
disorder B-Disease 0 0.07118847966194153
of I-Disease 0 7.894885811765562e-08
glycoprotein I-Disease 1 0.6191605925559998
metabolism I-Disease 0 0.007117660716176033
caused O 0 1.0191055480390787e-05
by O 0 6.391655915649608e-08
the O 0 8.539420377928764e-06
deficiency B-Disease 0 0.05140051618218422
of I-Disease 0 2.857112768595016e-09
the I-Disease 0 6.29571985655275e-08
lysosomal I-Disease 0 0.35717564821243286
enzyme I-Disease 0 8.763227015151642e-06
aspartylglucosaminidase I-Disease 0 5.600340955425054e-05
( O 0 4.8212079661880125e-08
AGA O 0 8.447647815046366e-06
) O 0 5.9334791302489975e-08
. O 0 1.225999568532643e-07

AGU B-Disease 1 0.9999760389328003
is O 0 0.00024065135221462697
inherited O 0 0.02436293289065361
as O 0 5.766043500443629e-07
an O 0 2.663814768766315e-07
autosomal O 1 0.9798492789268494
recessive O 1 0.9971381425857544
trait O 0 0.06074223294854164
and O 0 8.443363185506314e-06
occurs O 0 2.5423099714316777e-07
with O 0 6.987597611640695e-09
a O 0 3.219583888380839e-08
high O 0 3.4784497415785154e-07
frequency O 0 1.2929974673170364e-06
in O 0 3.745833154766842e-08
Finland O 0 3.14363433062681e-06
because O 0 1.1176206626828389e-08
of O 0 5.758438170744284e-10
a O 0 1.6129544633258774e-07
founder O 0 1.5542697155979113e-06
effect O 0 2.891245571845502e-07
. O 0 2.36332667213901e-07

While O 0 2.0152808701823233e-06
very O 0 3.352554074353975e-07
few O 0 9.295246883311847e-08
patients O 0 3.177532335030264e-07
with O 0 8.312966315315862e-08
AGU B-Disease 1 0.999991774559021
have O 0 5.168091661289509e-07
been O 0 2.4194611114580766e-07
reported O 0 4.2228631969010166e-07
from O 0 1.1160905533103005e-09
non O 0 4.0802814282869804e-07
- O 0 3.61965321644675e-05
Finnish O 0 1.2361740118649323e-05
origin O 0 5.286977255991587e-08
, O 0 8.241936910735603e-08
we O 0 1.7723571090755286e-06
diagnosed O 0 0.00010818523151101544
the O 0 2.0378681853117087e-08
disorder O 0 0.0005446964059956372
in O 0 8.437224252588749e-09
8 O 0 7.101971846168453e-07
patients O 0 1.7412567387964373e-08
originating O 0 5.666915825486285e-09
from O 0 2.98888758187843e-09
3 O 0 1.9444918564204272e-08
unrelated O 0 5.15347949203715e-07
families O 0 4.282758325757641e-08
, O 0 1.3171546076051754e-09
all O 0 3.565532313842823e-10
Palestinian O 0 4.526894770151557e-07
Arabs O 0 4.218097515718e-08
from O 0 2.0697417113524352e-09
the O 0 1.8195167594825534e-09
region O 0 2.6820041298947217e-08
of O 0 6.861757384513112e-09
Jerusalem O 0 9.921307355398312e-05
. O 0 5.215694045546115e-07

The O 0 9.70505766417773e-07
clinical O 0 5.2007337217219174e-05
diagnosis O 0 0.006771837826818228
of O 0 4.02913747166167e-06
AGU B-Disease 1 0.9999997615814209
is O 0 8.772607543505728e-05
often O 0 7.975020821504586e-07
difficult O 0 3.7031647934782086e-06
, O 0 1.066976196284486e-08
in O 0 5.262373869996395e-10
particular O 0 2.8581592648180276e-09
early O 0 1.0302270148088155e-08
in O 0 5.197755559294137e-09
the O 0 1.3935879117354943e-09
course O 0 6.121571232142742e-07
of O 0 2.854672276342285e-09
the O 0 1.0952854267998191e-07
disease O 0 2.8036813091603108e-05
, O 0 8.630407499765624e-09
and O 0 1.777314473372371e-08
most O 0 2.621834083171848e-09
of O 0 8.440986798419203e-10
the O 0 5.529693325456719e-08
patients O 0 1.5210405024390639e-07
are O 0 7.017813175025367e-08
diagnosed O 0 3.138455213047564e-05
after O 0 8.329691603137235e-09
the O 0 1.9179404731062277e-09
age O 0 8.122934325172082e-09
of O 0 8.36749058930053e-10
5 O 0 3.412298710259165e-08
years O 0 2.7785745260189287e-08
. O 0 1.4734207809397049e-07

However O 0 9.59737121775106e-07
, O 0 1.7190151524459907e-08
since O 0 4.047182144972794e-09
these O 0 1.9783621407754026e-09
patients O 0 2.9765194753395008e-09
excrete O 0 4.682463305982765e-09
early O 0 1.6394379187545383e-09
large O 0 7.941686419599137e-09
amounts O 0 3.769324852243017e-09
of O 0 1.0526297611335167e-09
aspartylglucosamine O 0 2.9516753784264438e-05
in O 0 1.634661472849075e-08
urine O 0 1.595070784787822e-06
, O 0 5.139110914598177e-09
biochemical O 0 3.298902484516475e-08
screening O 0 9.937445355490127e-08
is O 0 6.52086669106211e-08
easy O 0 4.597240206294373e-07
by O 0 2.0848224480118915e-08
urine O 0 6.318215355349821e-07
chromatography O 0 1.7454003682360053e-05
. O 0 3.3999292270436854e-08
. O 0 1.3191771586207324e-07

Detection O 0 1.122352114180103e-05
of O 0 7.158875092727612e-08
heterozygous O 0 6.274070756262518e-07
carriers O 0 2.820138718107046e-07
of O 0 1.144800965136028e-08
the O 0 5.6449836847605184e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 0.9999998807907104
( O 0 1.0783328434627037e-06
ATM O 0 8.449894812656567e-05
) O 0 4.623931904035317e-09
gene O 0 1.5379438167428816e-08
by O 0 5.88311488414206e-09
G2 O 0 2.7617714295047335e-05
phase O 0 1.6796255977169494e-06
chromosomal O 0 0.0008898451342247427
radiosensitivity O 0 0.00011846129200421274
of O 0 2.677118970950687e-07
peripheral O 0 0.03423558175563812
blood O 0 0.0002973437949549407
lymphocytes O 0 0.00037703017005696893
. O 0 9.378982213092968e-07

In O 0 0.0026862998493015766
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.0004505702236201614
A B-Disease 1 0.9999951124191284
- I-Disease 1 0.9999985694885254
T I-Disease 1 1.0
) O 0 4.319197728364088e-07
patients O 0 1.8889492992002488e-07
, O 0 6.250919781791708e-09
mutations O 0 2.4463842507316258e-08
in O 0 2.1433179675511838e-09
a O 0 4.1422438812332985e-08
single O 0 1.7901376736517705e-07
gene O 0 1.024773297331194e-07
, O 0 1.1335718141936013e-08
ATM O 0 1.422811510565225e-05
, O 0 4.032349565363802e-09
result O 0 4.0229259923307836e-08
in O 0 4.1037114328901225e-07
an O 0 0.05406449735164642
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.176315294695087e-05
embraces O 0 2.0028644939884543e-05
a O 0 9.318764568888582e-07
variety O 0 2.5898725652950816e-07
of O 0 1.4709042872596001e-08
clinical O 0 2.051676347036846e-06
features O 0 1.128600888478104e-05
and O 0 1.1584521644181223e-06
manifests O 0 1.5622425735273282e-06
extreme O 0 5.265675099508371e-06
radiosensitivity O 0 0.00012379727559164166
and O 0 1.9432094688909274e-07
a O 0 5.424083937555224e-08
strong O 0 8.981741217439776e-08
pre O 0 4.0455528505844995e-05
- O 0 0.00011059597454732284
disposition O 0 0.00013186444994062185
to O 0 4.5853698793507647e-07
malignancy B-Disease 0 0.007431449834257364
. O 0 1.1567420870051137e-06

Heterozygotes O 0 7.761333108646795e-05
for O 0 1.3078904714802775e-07
the O 0 1.150902573243684e-08
ATM O 0 9.169391887553502e-06
gene O 0 1.3602738135887193e-07
have O 0 1.914246539058695e-08
no O 0 5.022604199211855e-08
clinical O 0 6.912096495170772e-08
expression O 0 7.21631678857193e-08
of O 0 1.1171308500479427e-07
A B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999959468841553
T I-Disease 1 1.0
but O 0 1.3105018297210336e-05
may O 0 5.813672942167614e-06
be O 0 3.804174411925487e-05
cancer B-Disease 0 0.0005613155663013458
prone O 0 0.0004294257378205657
with O 0 7.708085725255387e-09
a O 0 1.2617050515473238e-07
moderate O 0 2.8725491574732587e-05
increase O 0 2.724354075667179e-08
in O 0 1.6879148079240736e-09
in O 0 9.797344269202313e-09
vitro O 0 4.451210770639591e-05
radiosensitivity O 0 0.00027673167642205954
. O 0 9.109323286793369e-07

We O 0 3.591634822441847e-06
performed O 0 1.4889121757732937e-06
a O 0 1.2155042838912777e-07
blind O 0 1.2239171383043868e-06
chromosomal O 0 5.786028123111464e-05
analysis O 0 1.6494418275669886e-07
on O 0 2.0935657119025564e-07
G2 O 0 7.898807962192222e-05
- O 0 2.45263413489738e-06
phase O 0 1.252678544005903e-06
lymphocytes O 0 1.5641329582649632e-06
from O 0 6.33080310397105e-10
7 O 0 2.113162977934735e-08
unrelated O 0 4.0860277294996195e-06
A B-Disease 1 0.9999511241912842
- I-Disease 1 0.9999973773956299
T I-Disease 1 1.0
patients O 0 8.471011824440211e-06
, O 0 1.1135224298186586e-08
13 O 0 1.1531966492839274e-08
obligate O 0 1.0910855507972883e-06
A B-Disease 1 0.9999947547912598
- I-Disease 1 0.9999991655349731
T I-Disease 1 0.9999998807907104
heterozygotes O 0 4.500534851104021e-05
( O 0 1.4671300618829264e-08
parents O 0 4.243223106215055e-09
of O 0 3.488022370934374e-10
the O 0 1.572359487056474e-08
patients O 0 6.536431129688935e-08
) O 0 1.9198693745892115e-09
, O 0 3.967585815445318e-09
and O 0 4.731987246486824e-09
14 O 0 2.558799394591915e-09
normal O 0 9.936285572109682e-09
controls O 0 1.6418960058217635e-07
following O 0 2.874637194949514e-09
X O 0 9.365467121824622e-05
- O 0 3.2019702302932274e-06
irradiation O 0 7.519627729379863e-07
with O 0 5.637495359422928e-09
1 O 0 1.6754416520825544e-08
Gy O 0 5.376966328185517e-06
in O 0 1.7361421189576731e-09
order O 0 1.6391502599688579e-09
to O 0 5.108830580802248e-10
evaluate O 0 1.0368683689421232e-08
this O 0 5.131575719907744e-10
cytogenetic O 0 1.3714985698243254e-06
method O 0 6.329674562266518e-08
as O 0 4.788670793232086e-09
a O 0 4.9362900433891355e-09
tool O 0 6.700647503521395e-08
for O 0 4.919078477882977e-10
detection O 0 5.85443906686578e-08
of O 0 7.857836159530507e-09
ATM O 0 0.00012804150173906237
carriers O 0 8.194159022423264e-07
. O 0 1.8386886324606166e-07

Both O 0 2.1960588128422387e-05
A B-Disease 1 0.9954041242599487
- I-Disease 1 0.9997748732566833
T I-Disease 1 0.9999945163726807
homozygotes O 0 8.764597441768274e-05
and O 0 7.893530096225732e-08
heterozygotes O 0 2.2341907879308565e-06
showed O 0 2.247971195856735e-07
significantly O 0 7.895577880390192e-08
increased O 0 9.259993660748478e-09
levels O 0 4.683276433326e-09
of O 0 1.2154973694222804e-09
radiation O 0 3.8807706005172804e-05
- O 0 0.00021389916946645826
induced O 0 0.002112092450261116
chromatid O 0 0.06423453241586685
damage O 0 0.00029741806793026626
relative O 0 9.881986215987126e-07
to O 0 4.5149755045770235e-09
that O 0 2.5437290052110484e-09
of O 0 1.9930761485653647e-09
normal O 0 4.4432078993850155e-07
controls O 0 1.6491523638251238e-05
. O 0 8.928550983000605e-07

These O 0 3.382375268756732e-07
results O 0 8.780762073001824e-08
show O 0 1.069898871719488e-07
that O 0 2.3943660387715227e-09
the O 0 2.8644897565044403e-09
G2 O 0 6.742461118847132e-05
- O 0 4.421297035150928e-06
phase O 0 1.6761117649366497e-06
chromosomal O 0 0.0004959432990290225
radiosensitivity O 0 2.939904879895039e-05
assay O 0 3.3074759357987205e-06
can O 0 2.8657591855107967e-08
be O 0 2.943885357709064e-09
used O 0 8.127862827222998e-09
for O 0 4.713716639237475e-10
the O 0 6.575038291600777e-10
detection O 0 1.0454196797127224e-07
of O 0 2.6955637721925996e-08
A B-Disease 1 0.9999486207962036
- I-Disease 1 0.9999428987503052
T I-Disease 1 0.999993085861206
heterozygotes O 0 0.00013436248991638422
. O 0 8.517246214978513e-07

In O 0 8.020747372938786e-07
combination O 0 2.1671630747732706e-06
with O 0 2.273661969809382e-08
molecular O 0 7.882936188252643e-07
genetic O 0 1.1968998023803579e-06
analyses O 0 1.5201355836325092e-06
, O 0 1.8699852333270428e-08
this O 0 4.551480525805118e-09
test O 0 1.4644217571913032e-06
may O 0 6.118943929322995e-08
be O 0 1.3215910588115776e-09
of O 0 8.46905878759685e-11
value O 0 2.4636346296347256e-08
in O 0 8.378733817870909e-10
studies O 0 3.3625466300257756e-10
of O 0 5.39171096658464e-10
familial B-Disease 0 2.349731767026242e-05
and I-Disease 0 6.380925015037064e-07
sporadic I-Disease 0 0.014348632656037807
cancers I-Disease 0 9.941915050148964e-05
aimed O 0 3.0402331958612194e-06
at O 0 9.195112511406478e-07
determination O 0 9.330381800509713e-08
of O 0 4.935873376687994e-10
the O 0 2.2470389993145545e-09
potential O 0 1.0481466361511593e-08
involvement O 0 4.0573016946154894e-08
of O 0 1.039503483291071e-09
ATM O 0 0.00025661001564003527
mutations O 0 6.879949410176778e-07
in O 0 7.691361503248118e-08
tumor B-Disease 0 0.029080629348754883
risk O 0 4.349158189143054e-06
or O 0 3.871792131349139e-08
development O 0 4.2901898922309556e-08
. O 0 2.7423402215731585e-08
. O 0 3.2266356697618903e-07

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999861717224121
telangiectasia I-Disease 1 0.9999974966049194
: O 0 6.039610411789909e-07
identification O 0 3.978314566666086e-07
and O 0 1.555861928181912e-08
detection O 0 2.1743392153439345e-07
of O 0 2.1668211669378934e-09
founder O 0 5.681015409209067e-06
- O 0 0.00021503877360373735
effect O 0 2.7709276650966785e-07
mutations O 0 1.2359922152427316e-07
in O 0 2.8025244347418266e-09
the O 0 5.56282220287585e-09
ATM O 0 1.92311290447833e-05
gene O 0 4.945075460227599e-08
in O 0 1.3320740066546932e-08
ethnic O 0 2.1940317651569785e-07
populations O 0 7.637548833372421e-07
. O 0 2.518746669011307e-07

To O 0 7.596565865242155e-08
facilitate O 0 1.1489970574984909e-07
the O 0 2.4851636304390468e-09
evaluation O 0 8.72466454637788e-09
of O 0 1.269636396017404e-09
ATM O 0 1.261916713701794e-05
heterozygotes O 0 5.785018970527744e-07
for O 0 5.806982006362205e-09
susceptibility O 0 8.714158866496291e-06
to O 0 1.1079765016575038e-07
other O 0 1.9793110084265209e-07
diseases O 0 0.0002360437356401235
, O 0 2.8443743360639928e-08
such O 0 2.437456316783937e-07
as O 0 7.268085755640641e-05
breast B-Disease 1 0.6535806059837341
cancer I-Disease 0 0.00025786622427403927
, O 0 3.479215493484844e-08
we O 0 4.977324152832807e-08
have O 0 2.8368796201050372e-09
attempted O 0 1.5480773640774714e-07
to O 0 8.331089595969843e-09
define O 0 2.1639566227804607e-07
the O 0 6.176149813796883e-09
most O 0 6.5683982697350984e-09
common O 0 1.23220447179051e-08
mutations O 0 1.6327046381547916e-08
and O 0 3.5028384637314502e-09
their O 0 1.5787505747155706e-09
frequencies O 0 2.75036063612788e-06
in O 0 2.4538096113246866e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 1.0
( O 0 0.0005036090733483434
A B-Disease 1 0.9999978542327881
- I-Disease 1 0.9999954700469971
T I-Disease 1 0.9999997615814209
) O 0 4.967991529269966e-08
homozygotes O 0 4.3860606524503964e-07
from O 0 2.2539197175319714e-09
10 O 0 6.630453519562707e-09
ethnic O 0 3.49777948827068e-08
populations O 0 3.9764066173120227e-07
. O 0 1.8594384698644717e-07

Both O 0 4.5456397401721915e-07
genomic O 0 2.8137392291682772e-06
mutations O 0 8.224542398238555e-06
and O 0 5.1874977202714945e-08
their O 0 2.1539896533084857e-09
effects O 0 7.055270856426432e-08
on O 0 2.3247762825917562e-08
cDNA O 0 2.598323476377118e-07
were O 0 1.9789712268902804e-07
characterized O 0 2.602891981950961e-06
. O 0 3.8128132473502774e-07

Protein O 0 5.228201189311221e-06
- O 0 5.421319656306878e-06
truncation O 0 5.611082997347694e-06
testing O 0 3.599839999424148e-07
of O 0 1.25834875852604e-09
the O 0 1.439575902928425e-09
entire O 0 1.9911812643158555e-08
ATM O 0 2.6694681309891166e-07
cDNA O 0 4.377803008992487e-08
detected O 0 3.4000694881797244e-07
92 O 0 1.4548966476013447e-08
( O 0 1.3628045358871077e-09
66 O 0 2.9571115334192655e-08
% O 0 1.9750594493217477e-09
) O 0 1.294657936412591e-09
truncating O 0 3.2431807994726114e-07
mutations O 0 1.757426701942677e-07
in O 0 1.1123209908703302e-08
140 O 0 9.925265231913727e-08
mutant O 0 1.5412642824230716e-06
alleles O 0 1.3991385685585556e-06
screened O 0 7.334736437769607e-06
. O 0 1.175819079435314e-06

The O 0 1.818009280896149e-07
haplotyping O 0 2.7305211915518157e-05
of O 0 4.09829787884064e-08
patients O 0 4.5887469468652853e-07
with O 0 1.0157784835485018e-08
identical O 0 2.1041165382484905e-05
mutations O 0 3.191239329680684e-06
indicates O 0 2.5909596388373757e-06
that O 0 7.455263784095223e-08
almost O 0 1.119314507747049e-08
all O 0 1.995578285951538e-10
of O 0 1.6493166554720773e-10
these O 0 1.3091697725897689e-09
represent O 0 8.792070183005762e-09
common O 0 1.0263929794973592e-07
ancestry O 0 1.0946093880193075e-06
and O 0 1.509389306875164e-07
that O 0 3.139482274150396e-08
very O 0 6.993786882958375e-08
few O 0 1.699620177930683e-08
spontaneously O 0 1.1408102551513366e-07
recurring O 0 9.063067523129575e-07
ATM O 0 0.00011537886166479439
mutations O 0 3.951881808461621e-06
exist O 0 7.918885103208595e-07
. O 0 4.5809554194420343e-07

Assays O 0 4.5229167881188914e-05
requiring O 0 4.7676755343672994e-07
minimal O 0 4.1411072970731766e-07
amounts O 0 3.254237768146595e-08
of O 0 4.2999259708409454e-10
genomic O 0 3.701133977074278e-08
DNA O 0 8.997548661682231e-07
were O 0 4.513048779131168e-08
designed O 0 1.0029643817688338e-06
to O 0 4.417550325541697e-09
allow O 0 1.1931505561335598e-08
rapid O 0 1.9935797013204137e-07
screening O 0 1.6816902359551023e-07
for O 0 6.012963904566959e-09
common O 0 4.561929856095048e-08
ethnic O 0 9.708430326327289e-08
mutations O 0 2.544585413488676e-06
. O 0 7.624478257639566e-07

These O 0 6.96118078735708e-08
rapid O 0 5.355577741283923e-07
assays O 0 1.4102142813499086e-06
detected O 0 7.998008300091897e-07
mutations O 0 5.329785324192926e-08
in O 0 2.630920814539195e-09
76 O 0 1.590356077940669e-07
% O 0 3.585673313821758e-09
of O 0 3.748840349260263e-09
Costa O 0 2.6154327770200325e-06
Rican O 0 4.126908606849611e-06
patients O 0 1.7817377795381617e-07
( O 0 9.47036671306023e-10
3 O 0 2.270913235236094e-09
) O 0 3.699210660013108e-10
, O 0 1.610134248153372e-09
50 O 0 2.289933576093972e-09
% O 0 2.1130681926440076e-10
of O 0 7.350152153584588e-10
Norwegian O 1 0.5500355958938599
patients O 0 6.945080599507492e-07
( O 0 1.1463298088543183e-09
1 O 0 9.10256581221347e-09
) O 0 8.39111280459548e-10
, O 0 1.9151951136109346e-09
25 O 0 2.0573907022480853e-09
% O 0 2.384575314984261e-10
of O 0 1.6961606563725695e-09
Polish O 0 0.018412834033370018
patients O 0 3.599348872285191e-07
( O 0 9.199290773587165e-10
4 O 0 1.0176128384387084e-08
) O 0 2.2995014781201917e-09
, O 0 3.3677984845326137e-09
and O 0 1.7780807937128884e-08
14 O 0 5.566027638792548e-09
% O 0 3.8952469028075143e-10
of O 0 1.7436287969019304e-09
Italian O 0 0.0028871993999928236
patients O 0 5.990552836010465e-07
( O 0 2.1364527924561116e-09
1 O 0 8.9011908954717e-09
) O 0 3.53875173608742e-09
, O 0 5.932446534018254e-09
as O 0 6.022008669503975e-09
well O 0 2.3242575863946513e-08
as O 0 9.653125410125085e-09
in O 0 4.710366763305274e-09
patients O 0 4.0714471793990015e-09
of O 0 5.395929258966703e-10
Amish O 0 6.846503674751148e-05
/ O 0 4.206931043881923e-05
Mennonite O 0 2.4781396859907545e-05
and O 0 1.4081002746024751e-06
Irish O 0 3.4679967484407825e-06
English O 0 1.8305109961147537e-07
backgrounds O 0 4.871376972914732e-07
. O 0 3.320027417430538e-07

Additional O 0 2.990086898080335e-07
mutations O 0 5.813257075715228e-07
were O 0 2.0702243475057003e-08
observed O 0 3.104303303302913e-08
in O 0 1.8614437768960101e-09
Japanese O 0 4.7416296666824564e-08
, O 0 6.40098363202668e-10
Utah O 0 1.2908927260468772e-09
Mormon O 0 2.5852557872241277e-09
, O 0 1.2669947313526109e-09
and O 0 2.978723045998777e-09
African O 0 6.3137193251350254e-09
American O 0 6.532119556368343e-08
patients O 0 4.0315370597454603e-07
. O 0 1.877684212558961e-07

These O 0 1.0070898781577853e-07
assays O 0 6.75141052397521e-07
should O 0 6.219843307064821e-09
facilitate O 0 1.227355994615209e-08
screening O 0 1.0238432679443576e-07
for O 0 2.5262087888222595e-07
A B-Disease 1 0.9998977184295654
- I-Disease 1 0.9999185800552368
T I-Disease 1 0.9999979734420776
heterozygotes O 0 2.1444006051751785e-05
in O 0 1.5652588558623393e-08
the O 0 3.5058997926995517e-09
populations O 0 3.539577164701768e-08
studied O 0 5.083844456521547e-08
. O 0 1.3116448371874867e-08
. O 0 1.8096612564022507e-07

The O 0 3.022114242412499e-06
von B-Disease 1 0.9162400364875793
Hippel I-Disease 1 0.9965813755989075
- I-Disease 1 0.9014592170715332
Lindau I-Disease 1 0.9905619025230408
tumor I-Disease 0 0.015858186408877373
suppressor O 0 7.100422953953966e-05
gene O 0 1.2272048479644582e-06
is O 0 3.9822428021807355e-08
required O 0 5.023981231033758e-09
for O 0 3.984147678437466e-09
cell O 0 5.707755462935893e-06
cycle O 0 7.878321639509522e-07
exit O 0 5.622109711111989e-07
upon O 0 4.043603851755506e-08
serum O 0 6.05270406595082e-06
withdrawal O 0 8.014738341444172e-06
. O 0 6.872762128296017e-07

The O 0 2.2119631637451675e-07
inactivation O 0 1.1431552593421657e-05
of O 0 4.391032604189604e-08
the O 0 1.0435132935526781e-07
von B-Disease 1 0.9976046085357666
Hippel I-Disease 1 0.9998681545257568
- I-Disease 1 0.9998319149017334
Lindau I-Disease 1 0.9997766613960266
( I-Disease 0 1.1846851748487097e-06
VHL I-Disease 0 0.00031353571102954447
) I-Disease 0 7.400760893006009e-08
tumor I-Disease 0 1.8653508959687315e-05
suppressor O 0 6.831347036495572e-06
gene O 0 7.057221864670282e-07
predisposes O 0 1.0406552974018268e-05
affected O 0 1.8009615132541512e-06
individuals O 0 1.493734202995256e-08
to O 0 1.3112595453890208e-08
the O 0 1.2592359155405575e-07
human O 0 0.009901662357151508
VHL B-Disease 1 0.999992847442627
cancer I-Disease 1 0.9999865293502808
syndrome I-Disease 1 0.9999436140060425
and O 0 2.4099756501527736e-07
is O 0 2.723830050399556e-07
associated O 0 7.550771670139511e-07
with O 0 1.6459924836453865e-06
sporadic B-Disease 1 0.9998989105224609
renal I-Disease 1 0.9999996423721313
cell I-Disease 1 0.9999940395355225
carcinomas I-Disease 1 1.0
( O 0 1.8183738575316966e-05
RCC B-Disease 0 0.28426340222358704
) O 0 2.8044544819749717e-07
and O 0 5.184471092434251e-07
brain B-Disease 0 9.275221964344382e-05
hemangioblastomas I-Disease 0 0.00072537234518677
. O 0 1.495378342042386e-06

VHL O 0 0.0030648938845843077
- O 0 4.732896923087537e-05
negative O 0 2.4754065179877216e-06
786 O 0 9.412042345502414e-06
- O 0 0.0002707549720071256
0 O 0 9.224456789524993e-07
RCC B-Disease 0 6.256242340896279e-05
cells O 0 1.24538459544965e-07
are O 0 6.0602634022188795e-09
tumorigenic O 0 3.240310252294876e-05
in O 0 5.475798303677948e-08
nude O 0 0.2535807490348816
mice O 0 0.00035000487696379423
which O 0 1.345876057712303e-06
is O 0 2.521659610010829e-07
suppressed O 0 3.42284565135742e-08
by O 0 1.6574981387407206e-09
the O 0 1.3175615043437006e-09
reintroduction O 0 2.9989968197696726e-07
of O 0 9.608930895410595e-08
VHL B-Disease 0 0.00033888747566379607
. O 0 1.2595220368893933e-06

Remarkably O 0 0.001234221737831831
, O 0 8.940311602145812e-08
this O 0 2.4790092201243397e-09
occurs O 0 3.562685702007684e-09
without O 0 2.1554845408555678e-10
affecting O 0 1.9269605910920973e-09
the O 0 5.162775762457272e-10
growth O 0 7.459707944690308e-07
rate O 0 3.983944679930573e-06
and O 0 2.5527512548251252e-08
cell O 0 7.312432330763841e-07
cycle O 0 4.4224046291674313e-07
profile O 0 1.2100578317131294e-07
of O 0 1.6934679214486437e-09
these O 0 2.9093658593382088e-09
cells O 0 1.5740639014438784e-08
in O 0 2.912563745738339e-09
culture O 0 2.542324466503487e-07
. O 0 1.567045870842776e-07

The O 0 1.3793489017643878e-07
786 O 0 3.5869657040166203e-06
- O 0 6.084599590394646e-05
0 O 0 2.4290559963446867e-07
cell O 0 1.7910591850522906e-05
line O 0 0.00010084835230372846
, O 0 3.0916464055508186e-08
like O 0 3.7609819258932475e-08
many O 0 7.481570918344005e-09
cancer B-Disease 0 2.799267576847342e-06
cells O 0 7.375297172984574e-08
, O 0 1.3249359831490892e-08
fails O 0 7.855381767285508e-08
to O 0 1.0074580059082905e-09
exit O 0 3.703118522935256e-07
the O 0 6.570804345074066e-09
cell O 0 3.808692099482869e-06
cycle O 0 1.6328966694345581e-06
upon O 0 2.939454191164259e-08
serum O 0 5.220628281676909e-06
withdrawal O 0 3.7422241803142242e-06
. O 0 4.560433239930717e-07

Here O 0 2.2481219730252633e-06
, O 0 1.0872030387076848e-08
it O 0 2.3456110387343188e-09
is O 0 1.862793252982442e-09
shown O 0 1.300935470460729e-09
that O 0 2.813856647687629e-10
reintroduction O 0 5.448842710364943e-09
of O 0 6.193570101231671e-10
the O 0 1.750446565473851e-09
wild O 0 4.023682436127274e-07
- O 0 0.0006874065147712827
type O 0 0.0008248931262642145
VHL B-Disease 0 5.5844334383436944e-06
gene O 0 4.8904848171105186e-08
restores O 0 1.9613062818280014e-07
the O 0 2.8504827387365594e-09
ability O 0 2.2136424249197262e-08
of O 0 3.011157767573991e-09
VHL O 0 2.7734557079384103e-05
- O 0 9.547179070068523e-05
negative O 0 3.962755363318138e-05
RCC B-Disease 1 0.7423678040504456
cancer I-Disease 0 4.613491546479054e-05
cells O 0 3.5133314923996295e-08
to O 0 2.3007868943381027e-09
exit O 0 2.646192172051087e-07
the O 0 4.961114186130544e-09
cell O 0 3.3673172765702475e-06
cycle O 0 8.056755973484542e-07
and O 0 9.592684868664492e-09
enter O 0 2.881236760288175e-08
G0 O 0 2.119005876011215e-05
/ O 0 1.1980417866652715e-06
quiescence O 0 4.616884780261898e-06
in O 0 6.575032074351839e-08
low O 0 0.0001733955868985504
serum O 0 7.368522346951067e-05
. O 0 3.446291998443485e-07

Both O 0 2.508912757548387e-06
VHL O 0 0.0002953125222120434
- O 0 6.17493933532387e-05
positive O 0 1.9139204709972546e-07
and O 0 5.2612950440789064e-08
VHL O 0 1.5023973901406862e-05
- O 0 2.9591708425869e-06
negative O 0 3.5800684372588876e-07
RCC B-Disease 0 1.9487937606754713e-05
cells O 0 3.902709977410268e-08
exit O 0 6.6572958701272e-08
the O 0 4.328927438734809e-09
cell O 0 2.6479440293769585e-06
cycle O 0 7.587831873934192e-07
by O 0 4.327971936390895e-08
contact O 0 5.679325568053173e-06
inhibition O 0 3.822490270977141e-06
. O 0 1.2975854133401299e-06

The O 0 4.075369588463218e-07
cyclin O 0 0.00023393254377879202
- O 0 1.1767123396566603e-05
dependent O 0 7.759050504319021e-07
kinase O 0 4.081980932824081e-06
inhibitor O 0 1.1155184438393917e-06
, O 0 7.619926023494372e-09
p27 O 0 1.5766124761285027e-07
, O 0 6.666897034435237e-10
accumulates O 0 6.676545538653045e-09
upon O 0 6.305592714639374e-10
serum O 0 2.2473322758287395e-07
withdrawal O 0 1.5861089650570648e-06
, O 0 6.101553484683109e-09
only O 0 1.4445102891613715e-09
in O 0 1.9098400638739577e-09
the O 0 7.713994443214744e-10
presence O 0 6.918361350471969e-08
of O 0 3.767642642316105e-09
VHL B-Disease 0 2.7071908334619366e-05
, O 0 1.4023104455418434e-08
as O 0 4.424507427103208e-09
a O 0 6.957807219265533e-09
result O 0 3.0446076770829222e-09
of O 0 1.621988238165173e-10
the O 0 1.3617106331409445e-09
stabilization O 0 1.2025778062252357e-07
of O 0 3.9293113207605757e-10
the O 0 4.622962013201004e-09
protein O 0 2.956221578642726e-07
. O 0 1.252638668347572e-07

We O 0 3.8980235217422887e-07
propose O 0 8.804123297068145e-08
that O 0 3.421199101794059e-09
the O 0 1.1322315307538133e-09
loss O 0 5.858326446173123e-08
of O 0 4.480779747240149e-09
wild O 0 3.0112856620689854e-05
- O 0 0.17451521754264832
type O 0 0.10506874322891235
VHL B-Disease 0 1.648454235692043e-05
gene O 0 1.0369122804831932e-07
results O 0 5.9511492622732476e-08
in O 0 3.216335420219707e-09
a O 0 1.6152043258443882e-08
specific O 0 1.1584062775682469e-07
cellular O 0 0.012000598013401031
defect O 0 0.004019193351268768
in O 0 5.783937595538191e-08
serum O 0 1.901174255181104e-05
- O 0 1.227881421073107e-05
dependent O 0 1.0087602504427196e-06
growth O 0 4.0517073784940294e-07
control O 0 4.1231177760892024e-07
, O 0 6.966066390390324e-09
which O 0 3.422506367201095e-08
may O 0 7.669022750178556e-08
initiate O 0 9.502815601081238e-07
tumor B-Disease 0 4.6378943807212636e-05
formation O 0 1.5889219184828107e-06
. O 0 3.5136542919644853e-07

This O 0 1.8670561985345557e-07
is O 0 9.86251933454696e-08
corrected O 0 6.556234666277305e-07
by O 0 1.958478490493576e-09
the O 0 9.301588388410664e-10
reintroduction O 0 8.488299840792024e-08
of O 0 3.5521550145745096e-09
wild O 0 1.0054121958091855e-05
- O 0 0.035883937031030655
type O 0 0.44379135966300964
VHL B-Disease 0 0.00090599968098104
, O 0 1.3352543248856819e-07
implicating O 0 6.309049058472738e-05
VHL B-Disease 0 5.6366727221757174e-05
as O 0 5.797003055363348e-08
the O 0 1.3969624346188425e-09
first O 0 1.6256787915835957e-08
tumor B-Disease 0 2.813645323840319e-06
suppressor O 0 6.895674573570432e-07
involved O 0 1.0357895519064186e-07
in O 0 4.257004082575122e-09
the O 0 1.3572714063769808e-09
regulation O 0 6.376566830113006e-09
of O 0 7.620169495403672e-10
cell O 0 4.410794190334855e-06
cycle O 0 9.913590020005358e-07
exit O 0 1.6083723721749266e-06
, O 0 2.440302537820571e-08
which O 0 6.051302392506841e-08
is O 0 5.597223662334727e-08
consistent O 0 4.0548999891143467e-07
with O 0 1.0892827972952546e-08
its O 0 1.7042458111404812e-08
gatekeeper O 0 1.0323718015570194e-05
function O 0 2.3420714256872088e-08
in O 0 1.176896691212903e-09
the O 0 1.6996104079680663e-08
kidney O 0 3.333134009153582e-05
. O 0 8.190969680299531e-09
. O 0 9.268019596220256e-08

Piebaldism B-Disease 1 0.9999929666519165
with O 0 0.15977932512760162
deafness B-Disease 1 0.9999998807907104
: O 0 2.3295264384159964e-07
molecular O 0 1.3823423614667263e-06
evidence O 0 1.2087892287127033e-07
for O 0 2.6796266539008684e-08
an O 0 2.8844488042523153e-07
expanded O 0 0.03664466366171837
syndrome O 1 0.9998685121536255
. O 0 1.5624585785189993e-06

In O 0 2.8840938171015296e-07
a O 0 1.2283918238154e-07
South O 0 8.741876200701881e-08
African O 0 2.1450244247489536e-08
girl O 0 6.210365427250508e-06
of O 0 2.7342121899920357e-09
Xhosa O 0 0.00011366341641405597
stock O 0 8.708600034879055e-06
with O 0 7.292417336657309e-08
severe O 0 2.9959155654069036e-05
piebaldism B-Disease 0 0.00276594958268106
and O 0 1.1207061106688343e-05
profound O 0 0.040489040315151215
congenital O 1 1.0
sensorineural B-Disease 1 0.9999996423721313
deafness I-Disease 1 1.0
we O 0 0.016939517110586166
identified O 0 8.072309719864279e-05
a O 0 2.0192254623907502e-07
novel O 0 1.4719769581006403e-07
missense O 0 2.8890181056340225e-06
substitution O 0 1.4512458790250093e-07
at O 0 1.0741596270236187e-06
a O 0 2.2665783916409055e-08
highly O 0 5.090539900720614e-08
conserved O 0 5.577848583016021e-08
residue O 0 9.374278420182236e-07
in O 0 1.5780762252504132e-09
the O 0 6.611167169268128e-10
intracellular O 0 7.396809564852447e-08
kinase O 0 3.286299090632383e-07
domain O 0 2.3270121829455093e-08
of O 0 8.425272146617147e-10
the O 0 1.698554008555675e-08
KIT O 0 8.439845259999856e-05
proto O 0 0.0001976373459910974
- O 0 0.0002736431488301605
oncogene O 0 2.0645147742470726e-05
, O 0 3.0285658425555084e-08
R796G O 0 4.072900992468931e-06
. O 0 2.765378894764581e-07

Though O 0 1.197751657855406e-06
auditory B-Disease 0 4.924992936139461e-06
anomalies I-Disease 0 0.0006083277985453606
have O 0 1.2599036836036248e-07
been O 0 3.807348036843905e-08
observed O 0 3.920138169632992e-07
in O 0 9.914097987007153e-09
mice O 0 2.596388867459609e-06
with O 0 4.745339055034492e-08
dominant O 0 7.403923518722877e-05
white O 0 2.3814611267880537e-05
spotting O 0 0.01023336872458458
( O 0 3.9584347177878954e-07
W O 1 0.6797581315040588
) O 0 1.2787386260981748e-08
due O 0 5.000275393740594e-08
to O 0 1.1086528672876739e-07
KIT O 0 0.16052699089050293
mutations O 0 0.00013026464148424566
, O 0 3.582564750104211e-05
deafness B-Disease 1 1.0
is O 0 1.5109782907529734e-05
not O 0 2.3550829553187214e-07
typical O 0 5.518731541087618e-06
in O 0 6.704789257128141e-08
human O 0 3.105903090272477e-07
piebaldism B-Disease 0 0.00010802267934195697
. O 0 6.676541488559451e-07

Thus O 0 4.153916506766109e-06
, O 0 3.449112284670264e-08
the O 0 2.5005977288827808e-09
occurrence O 0 9.947133321475121e-07
of O 0 4.031314233543526e-07
sensorineural B-Disease 1 0.9999980926513672
deafness I-Disease 1 1.0
in O 0 6.304928319877945e-06
this O 0 9.532769240649941e-07
patient O 0 3.9556794945383444e-05
extends O 0 1.2805151072825538e-06
considerably O 0 1.1748848294246272e-07
the O 0 2.389981546002673e-09
phenotypic O 0 2.719267229167599e-07
range O 0 1.6816546803966048e-06
of O 0 3.7247713802202043e-09
piebaldism B-Disease 0 2.2955224267207086e-05
due O 0 1.2470509602735547e-07
to O 0 3.086414679387417e-08
KIT O 0 0.0001747373171383515
gene O 0 2.405170391739375e-07
mutation O 0 4.3902620205926723e-08
in O 0 3.475181253875803e-09
humans O 0 1.3720825364771372e-08
and O 0 9.918358045979403e-08
tightens O 0 4.182852717349306e-05
the O 0 1.944258087860362e-08
clinical O 0 8.171442118509731e-07
similarity O 0 1.9132762929530145e-07
between O 0 9.042040005624585e-08
piebaldism B-Disease 0 0.0015943115577101707
and O 0 2.2448347181125428e-07
the O 0 1.4049199581478433e-09
various O 0 1.5463937907966852e-09
forms O 0 2.8946007546437613e-07
of O 0 4.630912371794693e-06
Waardenburg B-Disease 1 0.9999951124191284
syndrome I-Disease 1 0.9998708963394165
. O 0 1.5911494699594186e-07
. O 0 7.257449965436535e-07

Cycloheximide O 0 7.662467396585271e-05
facilitates O 0 3.0416947538469685e-06
the O 0 2.031197610108393e-08
identification O 0 6.048117029422428e-08
of O 0 3.987333130339721e-09
aberrant O 0 6.267988646868616e-05
transcripts O 0 1.6791831512819044e-05
resulting O 0 1.7616866898606531e-06
from O 0 1.626835732793097e-08
a O 0 5.530326063762914e-08
novel O 0 1.384670866855231e-07
splice O 0 0.002112070331349969
- O 0 0.005052405875176191
site O 0 8.441938553005457e-05
mutation O 0 6.404701480278163e-08
in O 0 6.104626582015271e-09
COL17A1 O 0 7.787207141518593e-05
in O 0 1.4753042343329525e-08
a O 0 6.016511520101631e-07
patient O 0 1.2304978554311674e-05
with O 0 4.445717252110626e-07
generalized O 0 0.014517974108457565
atrophic B-Disease 1 0.9998726844787598
benign I-Disease 1 0.9985723495483398
epidermolysis I-Disease 1 0.9965085387229919
bullosa I-Disease 1 0.983065128326416
. O 0 4.2737847252283245e-05

Patients O 0 0.00047933877795003355
with O 0 9.251891128769785e-07
generalized O 0 0.002234681509435177
atrophic B-Disease 1 0.9999048709869385
benign I-Disease 1 0.9994838237762451
epidermolysis I-Disease 1 0.9992949962615967
bullosa I-Disease 1 0.9494444727897644
often O 0 1.188425267173443e-05
show O 0 9.437479093321599e-06
decreased O 0 1.3731470971833915e-05
expression O 0 2.4621783722977852e-08
of O 0 3.2042908326701536e-09
type O 0 0.0010259149130433798
XVII O 0 0.007339233532547951
collagen O 0 0.0031357731204479933
, O 0 8.39073592828754e-08
a O 0 1.767246828876523e-07
transmembrane O 0 9.008769666252192e-06
hemidesmosomal O 0 9.751290235726628e-06
protein O 0 1.831791109907499e-07
encoded O 0 8.42198559780627e-08
by O 0 4.8785040007715e-08
COL17A1 O 0 0.00027137392316944897
. O 0 5.782127914244484e-07

This O 0 3.2046568776422646e-07
report O 0 7.6886628619377e-08
documents O 0 6.380803085903608e-08
a O 0 5.099266431329852e-08
novel O 0 3.229695835216262e-07
splice O 0 0.002718621864914894
- O 0 0.00026976087247021496
site O 0 5.929505277890712e-05
mutation O 0 2.1536892802487273e-07
in O 0 1.1370842045721474e-08
COL17A1 O 0 5.4086744057713076e-05
in O 0 2.0375221509993935e-08
a O 0 1.1249652942524335e-07
patient O 0 4.433871708897641e-06
with O 0 6.094100513109879e-08
generalized O 0 0.005483790300786495
atrophic B-Disease 1 0.9999626874923706
benign I-Disease 1 0.9987196922302246
epidermolysis I-Disease 1 0.9642389416694641
bullosa I-Disease 1 0.77899169921875
, O 0 4.271747002349002e-06
and O 0 3.686584904016854e-08
applies O 0 1.5546486764606016e-08
a O 0 1.9753532143340635e-09
new O 0 1.0188436760927289e-09
methodology O 0 1.5268925679379208e-08
to O 0 1.0983638443207155e-09
define O 0 2.713883588967292e-07
and O 0 2.3448158970040822e-08
characterize O 0 5.271176632959396e-06
the O 0 6.808592800666702e-09
resulting O 0 1.7317071865363687e-07
mRNA O 0 2.737721160883666e-07
splice O 0 2.2573216483579017e-05
variants O 0 2.342429979762528e-06
. O 0 1.0954040590149816e-06

Mutational O 0 0.00020076779765076935
analysis O 0 1.2323899909461034e-06
of O 0 5.619816434432323e-08
COL17A1 O 0 0.0003791124909184873
identified O 0 1.9600774976424873e-06
a O 0 1.6064302599261282e-07
maternally O 0 0.0001595938520040363
inherited O 0 0.0030205831862986088
G O 0 0.023030763491988182
- O 0 0.0007166577270254493
to O 0 6.296308470155054e-07
- O 0 0.005674977786839008
T O 0 0.0022925331722944975
transversion O 0 3.758518687391188e-06
at O 0 6.106899519409126e-08
the O 0 2.0858914595578426e-09
- O 0 7.12784913048381e-06
1 O 0 6.63607124806731e-09
position O 0 1.584425568523784e-08
of O 0 1.7015200359793425e-09
exon O 0 6.649693773397303e-07
32 O 0 2.1250750137369323e-07
. O 0 1.6979521433313494e-07

This O 0 2.452589171753061e-07
acceptor O 0 7.123868499547825e-07
splice O 0 4.065470056957565e-05
- O 0 9.498416329734027e-05
site O 0 1.580141542945057e-05
mutation O 0 7.106904575948647e-08
led O 0 1.85437851740744e-08
to O 0 1.581831110541998e-09
the O 0 6.771419536200085e-10
formation O 0 5.9006261210470257e-08
of O 0 1.4139525106315887e-09
aberrant O 0 2.191399971707142e-06
transcripts O 0 2.944022412521008e-07
present O 0 1.205331159326306e-07
at O 0 5.436688752524788e-07
extremely O 0 6.405583917512558e-06
low O 0 2.8952272259630263e-05
levels O 0 2.9918382438154367e-07
. O 0 6.184958323274259e-08

Based O 0 3.6074870877200738e-06
on O 0 1.3938165466242936e-07
our O 0 8.95636809161715e-09
recent O 0 4.319524737894653e-09
finding O 0 3.352366162445719e-09
that O 0 1.86682691527551e-09
cycloheximide O 0 2.022686203417834e-06
stabilized O 0 1.787763903848827e-05
mutant O 0 2.3274411375950876e-07
COL17A1 O 0 3.578533096515457e-06
transcripts O 0 1.3128642706305982e-07
in O 0 3.199008613563592e-09
keratinocytes O 0 1.3235312508186325e-06
homozygous O 0 3.0698819841745717e-07
for O 0 1.1802828048246283e-08
a O 0 6.237178240553476e-07
frameshift O 0 0.00196828693151474
mutation O 0 1.214635744872794e-06
, O 0 5.890154586296603e-09
the O 0 5.033867767068045e-10
effects O 0 7.320470984950589e-08
of O 0 1.8020821501707474e-09
the O 0 5.280091475157178e-09
splice O 0 0.00028868901426903903
- O 0 0.0002752685977611691
site O 0 1.1624822036537807e-05
mutation O 0 1.8125556167092327e-08
on O 0 4.243822182559143e-09
splicing O 0 1.858960985146041e-08
of O 0 2.3521877778875933e-09
COL17A1 O 0 7.0672699621354695e-06
transcripts O 0 1.8998974837813876e-07
were O 0 3.083307831275306e-08
determined O 0 2.5445455520411997e-08
using O 0 1.0771386449448528e-08
reverse O 0 3.236360498704016e-06
transcriptase O 0 7.391079179797089e-06
polymerase O 0 2.462437805661466e-06
chain O 0 2.1233033749012975e-06
reaction O 0 5.313856465960498e-09
of O 0 1.9168350240406085e-10
total O 0 6.404760277689547e-09
RNA O 0 2.025255341209231e-08
from O 0 1.0091735225259413e-09
keratinocytes O 0 2.8739759727614e-07
incubated O 0 2.8389794692884607e-07
for O 0 4.080893400981722e-09
2 O 0 1.1493411733454195e-07
. O 0 2.1334858502086718e-07

5 O 0 4.041571628476959e-06
h O 0 8.202515891753137e-05
in O 0 2.808755006356023e-08
the O 0 5.492374999249705e-09
presence O 0 5.286543469651406e-08
or O 0 2.509801966255054e-08
absence O 0 1.346771405508207e-08
of O 0 1.580169550763344e-09
10 O 0 1.3504909190942271e-08
microg O 0 4.7106932470342144e-06
cycloheximide O 0 5.933121883572312e-06
per O 0 1.0451540219946764e-06
ml O 0 0.00015458078996744007
. O 0 6.287572205110337e-07

Using O 0 4.176038430614426e-07
this O 0 1.7096830617902015e-08
approach O 0 1.4715081420035858e-07
, O 0 7.010452218736418e-09
an O 0 7.225734233173853e-09
abnormally O 0 5.0448099500499666e-05
spliced O 0 5.796775803901255e-05
transcript O 0 0.0005550512578338385
was O 0 0.0011412259191274643
identified O 0 2.3922507352835964e-06
that O 0 1.997692899990966e-09
contains O 0 7.2999850608823635e-09
an O 0 7.67237995358272e-10
extra O 0 4.155013222373327e-09
264 O 0 2.2489611950504695e-08
bases O 0 1.629351054077688e-08
upstream O 0 1.8024026715579566e-08
from O 0 9.533909217651626e-10
exon O 0 6.826982712482277e-08
32 O 0 1.4219858179842504e-08
, O 0 1.6070416108959762e-09
resulting O 0 1.570336394252081e-08
in O 0 5.866150232236578e-09
a O 0 2.8932041118423513e-07
premature O 0 8.880149835022166e-06
termination O 0 3.317909431643784e-07
codon O 0 2.4863132352948014e-07
27 O 0 1.0481590351218983e-07
bp O 0 4.7168512651296624e-07
downstream O 0 1.7626366854983644e-07
from O 0 4.443002410425834e-09
the O 0 8.613042723482067e-09
cryptic O 0 4.584452653944027e-06
splice O 0 0.0001266924518859014
site O 0 5.6618908274685964e-05
. O 0 1.0345037253500777e-06

Three O 0 2.991284873132827e-07
other O 0 9.655224175730837e-09
splice O 0 7.840703801775817e-06
variants O 0 2.1217913399596e-06
, O 0 4.0550656166260524e-08
including O 0 1.943890914901658e-08
one O 0 8.255873318319118e-09
derived O 0 5.917766277008241e-09
from O 0 1.0851225473729187e-09
the O 0 4.511736262369226e-10
skipping O 0 1.608250599360872e-08
of O 0 6.207218072873388e-10
exon O 0 7.466206852768664e-08
32 O 0 4.7947235515266584e-08
, O 0 7.49156647827931e-09
were O 0 9.11593076580175e-08
also O 0 1.790427859305055e-07
identified O 0 1.1510769581946079e-06
. O 0 1.1446878289689266e-07

These O 0 1.728844125636897e-07
results O 0 7.66698917686881e-08
indicate O 0 6.987600187358112e-08
the O 0 1.7787989969875184e-09
usefulness O 0 3.216465671584956e-08
of O 0 1.1572348634913965e-09
cycloheximide O 0 1.9287806935608387e-05
treatment O 0 3.394765144548728e-07
in O 0 1.5107647355350196e-09
evaluating O 0 1.5967213329304286e-08
the O 0 1.1573849656443258e-09
abnormal O 0 3.582933914003661e-07
processing O 0 6.325100088133695e-08
of O 0 6.092386595213384e-10
mRNA O 0 9.964298719467024e-09
due O 0 9.612025841931882e-09
to O 0 1.8373795818149574e-09
splice O 0 8.860344678396359e-05
- O 0 0.00017943931743502617
site O 0 3.765496876440011e-05
mutations O 0 8.550417760488926e-07
, O 0 7.623636122389144e-08
because O 0 3.974616546997822e-08
( O 0 3.5822143029662357e-09
i O 0 3.906139909304329e-07
) O 0 7.2050604371654e-10
aberrant O 0 1.0868115651874177e-07
splicing O 0 5.391304824797771e-08
often O 0 1.354750356341583e-08
generates O 0 8.72128769202618e-09
a O 0 3.022281447329078e-08
premature O 0 3.776901621677098e-06
termination O 0 3.683963711864635e-07
codon O 0 5.045071134190948e-07
, O 0 2.0741213191399765e-08
( O 0 2.328786941063754e-09
ii O 0 2.6132388484256808e-06
) O 0 2.1963644236677737e-09
transcripts O 0 1.411596031175577e-07
with O 0 2.2180715930630868e-08
premature O 0 1.2292217434151098e-05
termination O 0 7.97532550222968e-07
codons O 0 1.626693659773082e-07
can O 0 7.206383045854636e-09
occur O 0 4.241087037115676e-09
at O 0 1.2047381403590407e-07
low O 0 2.740423587965779e-05
or O 0 6.891111752338475e-07
undetectable O 0 1.8056141925626434e-05
levels O 0 3.8140491653848585e-08
due O 0 4.80645967471105e-09
to O 0 3.106836787836187e-09
nonsense O 0 1.8944760086014867e-05
- O 0 1.9552569483494153e-06
mediated O 0 1.0616645340633113e-06
mRNA O 0 1.1763026108724262e-08
decay O 0 1.899150987583198e-07
, O 0 5.5881534954949075e-09
and O 0 6.860985113377183e-09
( O 0 1.538917215881952e-09
iii O 0 7.556347441095568e-07
) O 0 1.6100544231179015e-09
the O 0 9.832759051420226e-10
levels O 0 5.614970710610123e-09
of O 0 1.0312265624756733e-10
these O 0 6.615897829576056e-10
transcripts O 0 7.444990046678868e-08
can O 0 1.5911153283809654e-08
be O 0 3.3350002759391373e-09
increased O 0 7.973301130448363e-09
by O 0 1.9417194963011752e-08
cycloheximide O 0 6.394428783096373e-05
. O 0 3.3862355053315696e-07

A O 0 1.1594996067287866e-05
deletion O 0 1.4828056009719148e-05
mutation O 0 3.941936938645085e-06
in O 0 4.80426223248287e-08
COL17A1 O 0 0.00030384346609935164
in O 0 2.349516670108187e-08
five O 0 1.9558402897246197e-08
Austrian O 0 3.0166664146236144e-05
families O 0 7.894478670777971e-08
with O 0 9.44582296824592e-08
generalized O 0 0.02863483317196369
atrophic B-Disease 1 0.9999706745147705
benign I-Disease 1 0.9991289973258972
epidermolysis I-Disease 1 0.9936058521270752
bullosa I-Disease 0 0.472434937953949
represents O 0 2.66110805569042e-06
propagation O 0 1.2219728660056717e-06
of O 0 3.622796995728095e-08
an O 0 1.6331334506958228e-07
ancestral O 0 6.838059925939888e-05
allele O 0 1.865987724158913e-05
. O 0 8.933201911531796e-07

Patients O 0 0.00031103394576348364
with O 0 5.421999276222778e-07
generalized O 0 0.0057160151191055775
atrophic B-Disease 1 0.999964714050293
benign I-Disease 1 0.9997594952583313
epidermolysis I-Disease 1 0.9995405673980713
bullosa I-Disease 1 0.9985963702201843
, O 0 3.876376467815135e-06
a O 0 7.435552618062502e-08
usually O 0 4.434056322111246e-08
nonlethal O 0 7.604000984429149e-07
form O 0 6.121896944932814e-08
of O 0 1.4192468711371475e-07
junctional B-Disease 1 0.8144456148147583
epidermolysis I-Disease 1 0.917773425579071
bullosa I-Disease 0 0.452639639377594
, O 0 8.731825005270366e-07
have O 0 4.5261174363986356e-08
generalized O 0 5.733418220188469e-06
blistering B-Disease 0 0.10709291696548462
, O 0 2.085852247546427e-05
nail B-Disease 1 0.9999904632568359
dystrophy I-Disease 1 0.9998571872711182
, O 0 2.192365855080425e-06
patchy B-Disease 1 0.9951529502868652
alopecia I-Disease 1 0.9999867677688599
, O 0 3.256428499298636e-06
and O 0 4.365069980849512e-05
dental B-Disease 1 0.8406239151954651
abnormalities I-Disease 1 0.9969674944877625
. O 0 6.074446446291404e-06

Skin B-Disease 1 0.8624474406242371
fragility I-Disease 0 0.008021398447453976
in O 0 1.6557901005853637e-07
most O 0 2.4740225867958543e-08
cases O 0 7.457123807341759e-09
is O 0 1.2193968501605923e-08
due O 0 3.0636694958730004e-08
to O 0 4.288788435502511e-09
mutations O 0 1.7417357867088867e-07
in O 0 1.4439428541734856e-09
the O 0 1.5236769623783175e-09
gene O 0 4.2147519252466736e-08
encoding O 0 7.571988192012213e-08
type O 0 0.0014050912577658892
XVII O 0 0.03301968052983284
collagen O 0 0.015973199158906937
( O 0 3.9564380927004095e-07
COL17A1 O 0 0.00017446496349293739
) O 0 1.4354945676586794e-07
. O 0 3.2371889346904936e-07

Recently O 0 6.741528341080993e-05
, O 0 5.813313208591353e-08
we O 0 9.83402070886541e-09
reported O 0 5.313484408020486e-08
five O 0 8.011197927260127e-09
Austrian O 0 1.5373449059552513e-05
families O 0 1.7795099438444595e-07
with O 0 8.535836570899846e-08
generalized O 0 0.002830460201948881
atrophic B-Disease 1 0.9999401569366455
benign I-Disease 1 0.9959367513656616
epidermolysis I-Disease 1 0.9946681261062622
bullosa I-Disease 1 0.9505615830421448
who O 0 5.8814953263208736e-06
share O 0 2.620021462007571e-07
the O 0 1.2760659195976132e-08
same O 0 1.1249824893866389e-07
COL17A1 O 0 0.0009249816066585481
mutation O 0 4.327742772147758e-06
. O 0 3.383840123660775e-07

Affected O 0 2.735517409746535e-05
individuals O 0 8.91293367999424e-08
in O 0 1.1561720469899228e-08
three O 0 4.5778785207062356e-09
families O 0 8.461963574291076e-09
are O 0 3.1074887107962468e-09
homozygous O 0 3.2642834213447713e-08
for O 0 5.377037926024286e-09
4003delTC O 0 8.603171409049537e-06
, O 0 6.211105407771811e-09
whereas O 0 3.9948336194584044e-08
those O 0 2.709759083785457e-09
in O 0 2.6619741966271704e-09
two O 0 4.555805510619848e-09
others O 0 3.24412994245904e-08
are O 0 8.675199225649521e-09
compound O 0 4.709525001089787e-06
heterozygotes O 0 7.170762273744913e-06
. O 0 2.2960935552873707e-07

To O 0 1.551728274762354e-07
determine O 0 1.381876728601128e-07
if O 0 4.869622927117234e-09
the O 0 3.9170466870075415e-10
occurrence O 0 1.2959266371126432e-07
of O 0 9.600367167905688e-10
4003delTC O 0 3.882799774146406e-06
in O 0 3.850844532138353e-09
these O 0 2.3699580076197435e-09
unrelated O 0 2.720958320878708e-07
families O 0 1.1155568913068237e-08
signifies O 0 6.453482370716301e-08
propagation O 0 7.696395698530978e-08
of O 0 1.8654813249696645e-09
an O 0 2.71137867713378e-08
ancestral O 0 8.858901310304645e-06
allele O 0 6.747374641236092e-07
or O 0 8.976261511861594e-08
a O 0 8.863415246196382e-08
mutational O 0 3.469590956228785e-05
hot O 0 0.00013354296970646828
spot O 0 1.9718645489774644e-05
, O 0 1.702647445256389e-08
haplotypes O 0 1.436532670595625e-07
were O 0 8.557795183605776e-08
determined O 0 2.4073824533843435e-07
for O 0 8.485398161894864e-09
polymorphisms O 0 2.3599519408890046e-05
both O 0 1.3962067058059802e-08
within O 0 2.056858328103317e-08
and O 0 4.5246673607834964e-07
flanking O 0 0.0032765325158834457
COL17A1 O 0 0.009635821916162968
. O 0 1.9485908069327706e-06

Five O 0 2.0883421711914707e-06
intragenic O 0 9.335854701930657e-05
polymorphisms O 0 7.792510587023571e-05
were O 0 5.684645429937518e-07
chosen O 0 3.177259344511185e-08
based O 0 1.8805724977255522e-08
on O 0 1.41188678526305e-07
their O 0 6.919720618725478e-08
informativeness O 0 0.0001204813233925961
. O 0 1.5760021199184848e-07

One O 0 3.7170661926211324e-07
of O 0 3.812534288272218e-09
these O 0 3.0958287045024235e-09
, O 0 2.1397970062508875e-09
not O 0 1.6032268845833642e-09
previously O 0 4.8211159509037316e-08
reported O 0 2.3328532279265346e-06
, O 0 4.6980229484461233e-08
was O 0 2.1981147710903315e-06
2988 O 0 1.1715197842931957e-06
A O 0 2.3724473408037738e-07
or O 0 1.6188967322250392e-07
C O 0 1.616108238522429e-05
that O 0 1.938147864422035e-09
introduces O 0 5.238062428247758e-09
a O 0 2.193739190303745e-09
new O 0 2.131706589025839e-09
restriction O 0 5.3550870404706075e-08
site O 0 5.283081350171415e-07
for O 0 4.3246362047000275e-09
Eco0109 O 0 1.0866349384741625e-06
I O 0 2.7880616926267976e-06
. O 0 7.878113450487945e-08

All O 0 7.357214570902215e-08
the O 0 7.725335926522803e-09
4003delTC O 0 1.2853822681790916e-06
alleles O 0 1.4487828536857705e-07
showed O 0 6.310231128736632e-07
the O 0 1.859286280492256e-09
same O 0 8.007347673810727e-09
haplotype O 0 7.196770752671e-07
for O 0 3.837778095316935e-09
these O 0 3.8909795385677626e-09
five O 0 2.5303648953922675e-08
polymorphic O 0 9.058194336830638e-06
markers O 0 3.449248833931051e-05
. O 0 6.462325927714119e-07

Fourteen O 0 7.794050361553673e-06
microsatellite O 0 0.0001863513170974329
polymorphisms O 0 7.735502003924921e-05
were O 0 3.1573753744851274e-07
selected O 0 1.0821487705925392e-08
based O 0 2.496243567406964e-08
on O 0 7.665249057708934e-08
their O 0 1.1298245894408865e-08
high O 0 1.0923370155069279e-06
heterozygosity O 0 7.591793746541953e-06
and O 0 4.5558252281807654e-08
their O 0 1.468887678157671e-09
location O 0 1.5486681093079824e-07
within O 0 2.2470445060207567e-08
10q23 O 0 1.1406964404159226e-06
- O 0 2.0123858121223748e-05
q25 O 0 8.378799975616857e-06
near O 0 3.5387554817134514e-05
COL17A1 O 0 0.0002508801990188658
. O 0 3.928611249648384e-07

Three O 0 2.4669179765623994e-06
families O 0 7.982995953170757e-07
shared O 0 5.112745498081495e-07
microsatellite O 0 0.0001695089740678668
polymorphisms O 0 9.137445158557966e-05
covering O 0 4.1460065403953195e-05
at O 0 3.617726406446309e-06
most O 0 1.1586821280218373e-08
19 O 0 5.612939446564269e-08
cM O 0 3.991919129475718e-06
, O 0 1.4141366300179925e-08
whereas O 0 4.45888836964059e-08
the O 0 4.681704357523131e-09
others O 0 2.2849480529885113e-08
shared O 0 7.438769156209446e-09
smaller O 0 1.572621073364644e-07
regions O 0 7.371415478019117e-08
consistent O 0 1.5186981272563571e-06
with O 0 1.238042699469588e-07
cross O 0 5.213460462982766e-05
- O 0 0.0014960491098463535
over O 0 5.105202944832854e-07
events O 0 5.7277947718148425e-08
during O 0 2.6012335396785602e-08
passage O 0 3.260703929086617e-09
of O 0 2.44292641671251e-10
this O 0 1.7848245104090665e-09
mutation O 0 1.0245305048783848e-08
through O 0 8.380012239683765e-10
several O 0 3.875868959113404e-09
generations O 0 8.859865374688525e-08
. O 0 1.3696435985366406e-07

These O 0 3.0426735975197516e-07
results O 0 1.6965293525572633e-07
indicate O 0 3.6073936371394666e-07
that O 0 6.910840788521e-09
4003delTC O 0 4.356330919108586e-06
occurs O 0 2.4586915614577265e-08
on O 0 3.826582073429563e-08
a O 0 5.2202619116314963e-08
single O 0 5.609802542494435e-07
ancestral O 0 9.070063242688775e-06
allele O 0 1.102196506508335e-06
. O 0 4.283607779598242e-08
. O 0 3.22521458429037e-07

The O 0 1.2506923212640686e-06
haptoglobin O 0 0.00018587255908641964
- O 0 5.410335506894626e-05
gene O 0 7.277535019056813e-07
deletion O 0 1.0186711278947769e-06
responsible O 0 8.742640034142823e-07
for O 0 1.0694499508190347e-07
anhaptoglobinemia B-Disease 0 0.0009333983762189746
. O 0 2.180513774874271e-06

We O 0 1.144700036093127e-05
have O 0 4.27364348354331e-08
found O 0 1.1844615954714754e-08
an O 0 1.0626880486697132e-09
allelic O 0 6.751436103513697e-07
deletion O 0 2.669980005975958e-07
of O 0 7.373718524661399e-09
the O 0 5.22119805168586e-08
haptoglobin O 0 7.760208245599642e-05
( O 0 1.0247748427616443e-08
Hp O 0 7.368139876007263e-08
) O 0 2.3381336866634683e-09
gene O 0 1.4765936029448312e-08
from O 0 3.6031968519978363e-09
an O 0 8.308936649825682e-09
individual O 0 1.7321308831697024e-08
with O 0 1.1558087464891287e-07
anhaptoglobinemia B-Disease 0 0.01367313414812088
. O 0 2.5312106117780786e-06

The O 0 4.024545603442675e-07
Hp O 0 2.124709226336563e-06
gene O 0 4.5016881244919205e-07
cluster O 0 2.910766170316492e-06
consists O 0 2.732143755679317e-08
of O 0 2.5150432847453885e-09
coding O 0 5.327485268935561e-06
regions O 0 7.464455364925016e-08
of O 0 3.5249958507677093e-09
the O 0 6.460894041993015e-09
alpha O 0 3.085519750811727e-08
chain O 0 9.372809472552035e-06
and O 0 3.948230187234003e-09
beta O 0 2.9954849711799625e-09
chain O 0 1.2053644127263397e-07
of O 0 2.0569816683302378e-10
the O 0 1.319568565527618e-09
haptoglobin O 0 3.188173195667332e-06
gene O 0 3.0876275758373595e-08
( O 0 5.798567181969361e-10
Hp O 0 3.733443776354761e-08
) O 0 2.4890773886454554e-09
and O 0 1.2256366588303536e-08
of O 0 6.599110702332212e-10
the O 0 5.1460258276847526e-09
alpha O 0 2.425476530731885e-08
chain O 0 7.4232907536497805e-06
and O 0 5.363762767274238e-09
beta O 0 3.502270695676657e-09
chain O 0 1.1274979527797768e-07
of O 0 2.2275110922453933e-10
the O 0 1.2060935583591004e-09
haptoglobin O 0 7.26543839846272e-06
- O 0 1.3609290363092441e-05
related O 0 1.9511253412929364e-06
gene O 0 8.669857720633445e-07
( O 0 1.2047859598851574e-08
Hpr O 0 5.453021458379226e-06
) O 0 1.2318143838285778e-08
, O 0 7.112407551801425e-09
in O 0 3.4920715208386355e-09
tandem O 0 9.583985956851393e-06
from O 0 4.434713485323982e-09
the O 0 6.855373158032307e-09
5 O 0 8.800027018196488e-08
side O 0 4.42917234977358e-06
. O 0 4.806471451956895e-07

Southern O 0 3.3367184641974745e-06
blot O 0 0.00011961430573137477
and O 0 4.648889984082416e-08
PCR O 0 1.064029220287921e-06
analyses O 0 1.3742425153395743e-07
have O 0 1.0183584642220467e-08
indicated O 0 1.2501611479365238e-07
that O 0 1.0342013911923686e-09
the O 0 4.0311096127787494e-10
individual O 0 4.1659461991194746e-10
with O 0 7.248206923549105e-09
anhaptoglobinemia B-Disease 0 6.103998748585582e-05
was O 0 7.4693921305879485e-06
homozygous O 0 1.488376852876172e-07
for O 0 1.2278963401612941e-09
the O 0 9.169492387606226e-10
gene O 0 1.8352299235857572e-08
deletion O 0 1.6181125772618543e-07
and O 0 3.394509633380949e-07
that O 0 4.1091365865497664e-09
the O 0 1.197696386512348e-09
gene O 0 1.91065350207964e-08
deletion O 0 3.189737185493868e-08
was O 0 2.611736363178352e-06
included O 0 7.893891762478233e-08
at O 0 5.955219535280776e-07
least O 0 6.070211888697941e-09
from O 0 6.238993210949673e-10
the O 0 1.8021095726794556e-09
promoter O 0 1.3096584552840795e-05
region O 0 6.34037959912348e-08
of O 0 1.0708514075474795e-09
Hp O 0 1.2945395155838924e-07
to O 0 3.950806348740343e-09
Hpr O 0 4.1258084593209787e-07
alpha O 0 7.270942514736589e-09
but O 0 1.986393050046331e-09
not O 0 9.242838161505063e-10
to O 0 5.912069056535074e-09
Hpr O 0 9.971552572096698e-06
beta O 0 7.258031331502934e-08
( O 0 9.303597892085236e-09
Hpdel O 0 3.0003066058270633e-06
) O 0 2.9377501320482224e-08
. O 0 8.940653373201712e-08

In O 0 1.5880131343237736e-07
addition O 0 7.026237369700539e-08
, O 0 1.5823570009843024e-08
we O 0 8.94117757610502e-09
found O 0 1.6542017533538456e-08
seven O 0 1.0129145300297182e-09
individuals O 0 6.444250688630859e-10
with O 0 3.1962641422467186e-09
hypohaptoglobinemia B-Disease 0 6.408614717656747e-05
in O 0 5.417766502091581e-08
three O 0 5.018352311481067e-08
families O 0 9.215296614684121e-08
, O 0 1.661981485767683e-08
and O 0 2.710628876911869e-08
the O 0 1.419638184785299e-09
genotypes O 0 8.578273025250382e-08
of O 0 1.1795867616015698e-09
six O 0 6.692074450143082e-09
of O 0 1.1568508373471786e-09
the O 0 6.236010374749412e-09
seven O 0 1.518942305267501e-08
individuals O 0 2.5005693071733504e-09
were O 0 5.660782775862572e-08
found O 0 2.487517392069094e-08
to O 0 4.74121142346462e-09
be O 0 1.6572339234244282e-07
Hp2 O 0 4.835606159758754e-05
/ O 0 2.4325978301931173e-05
Hpdel O 0 4.767755308421329e-05
. O 0 4.638610846541269e-07

The O 0 9.31009537907812e-07
phenotypes O 0 1.9000086467713118e-05
and O 0 1.4830790462383447e-07
genotypes O 0 2.5184249352605548e-06
in O 0 1.582441377934174e-08
one O 0 7.606349328170836e-09
of O 0 5.876898412360276e-10
these O 0 3.2147406958671354e-09
three O 0 4.707142231552552e-09
families O 0 2.2827524759350126e-08
showed O 0 9.061884043148893e-07
the O 0 8.43005043549283e-09
father O 0 8.456962632408249e-07
to O 0 1.110485214894652e-08
be O 0 1.1222050488868263e-07
hypohaptoglobinemic B-Disease 0 3.052033207495697e-06
( O 0 1.443689501279266e-09
Hp2 O 0 2.717017082431994e-07
) O 0 1.0293739194366935e-09
and O 0 2.682299715672798e-09
Hp2 O 0 2.1105663563503185e-06
/ O 0 1.2755057241520262e-06
Hpdel O 0 2.0626175682991743e-05
, O 0 1.3790062425300675e-08
the O 0 2.8829614251435487e-09
mother O 0 3.8294379578474036e-07
to O 0 1.5798530261790233e-09
be O 0 1.7081250192063635e-08
Hp2 O 0 2.7473984118842054e-06
- O 0 5.51550056115957e-06
1 O 0 2.2823172685093596e-08
and O 0 2.4769876816321812e-08
Hp1 O 0 2.559148242653464e-06
/ O 0 1.1539698334672721e-06
Hp2 O 0 8.451749636151362e-06
, O 0 1.0211222978284695e-08
one O 0 1.5497392258367881e-09
of O 0 2.4819271637888107e-10
the O 0 5.182233753231458e-09
two O 0 1.4606995613064555e-08
children O 0 3.9171329291320944e-08
to O 0 5.7313758183852315e-09
be O 0 1.0772438230333137e-07
hypohaptoglobinemic B-Disease 0 2.5764932161109755e-06
( O 0 1.5581625989469217e-09
Hp2 O 0 8.795611279310833e-07
) O 0 1.2930292392354659e-09
and O 0 5.426202598357577e-09
Hp2 O 0 3.4907461667899042e-06
/ O 0 3.221855649826466e-06
Hpdel O 0 1.6732508811401203e-05
, O 0 3.9035288779132316e-08
and O 0 1.3031514534134203e-08
the O 0 1.062217980241087e-09
other O 0 1.5283398990817432e-09
child O 0 1.6508739975051867e-07
to O 0 1.156612583486094e-09
be O 0 2.2224588391850375e-08
Hp1 O 0 2.2253109364100965e-06
and O 0 1.3911029661528573e-08
Hp1 O 0 4.1523799154674634e-06
/ O 0 1.0272747203998733e-05
Hpdel O 0 1.9458611859590746e-05
, O 0 8.387596395209584e-09
showing O 0 3.6495336530606437e-07
an O 0 2.1288706353317366e-09
anomalous O 0 1.2830067134927958e-05
inheritance O 0 1.9113408598059323e-06
of O 0 5.567655136928806e-08
Hp O 0 1.040621555148391e-05
phenotypes O 0 1.4399673091247678e-05
in O 0 1.1935014754271833e-07
the O 0 5.099188982171654e-08
child O 0 7.066326816129731e-06
with O 0 1.7515368710974144e-07
Hp1 O 0 0.0003474804398138076
. O 0 1.2825903468183242e-06

The O 0 2.1161076801945455e-07
Hp2 O 0 4.032818469568156e-05
/ O 0 4.17874580307398e-05
Hpdel O 0 3.5479057260090485e-05
individuals O 0 4.999932201599222e-08
had O 0 2.7371521582608693e-07
an O 0 1.0296631991479899e-08
extremely O 0 1.13770438474603e-05
low O 0 9.819956176215783e-06
level O 0 7.401367696502348e-08
of O 0 1.969935103929288e-09
Hp O 0 8.68056559966135e-08
( O 0 1.04950237389545e-09
mean O 0 4.348160942413415e-08
+ O 0 1.7931979812146892e-07
/ O 0 7.334865586017258e-07
- O 0 9.911670531437267e-06
SD O 0 0.0001490418508183211
= O 0 3.6372819067764794e-07
0 O 0 7.474810104213248e-09
. O 0 1.314835240684431e-09
049 O 0 3.5638129247672623e-07
+ O 0 6.695486121088834e-08
/ O 0 2.24069381715708e-07
- O 0 4.0724751215748256e-07
0 O 0 4.187809210520754e-09
. O 0 3.7045908007904416e-10
043 O 0 8.050414379567883e-08
mg O 0 1.442900696702054e-07
/ O 0 3.0724243060831213e-07
ml O 0 1.2774997912856634e-06
; O 0 1.982297881397699e-09
n O 0 2.378070348640904e-06
= O 0 2.6585587420413503e-07
6 O 0 3.773208856472365e-09
) O 0 3.78305109460797e-10
, O 0 5.647964318455934e-10
compared O 0 3.8657120171592396e-08
with O 0 1.9491324110276764e-09
the O 0 2.895509387812467e-09
level O 0 1.1773951058557941e-07
( O 0 3.5955674548837635e-10
1 O 0 1.0088732071977802e-09
. O 0 3.862097031070988e-10
64 O 0 4.0133594225721936e-09
+ O 0 3.2220473400457195e-08
/ O 0 4.499494821175176e-07
- O 0 9.536952347843908e-07
1 O 0 6.153256570939902e-09
. O 0 7.180721572908055e-10
07 O 0 1.4532048453475e-08
mg O 0 5.210454219195526e-07
/ O 0 1.439850734641368e-06
ml O 0 1.8922481785921264e-06
) O 0 5.395033864097343e-10
obtained O 0 1.7332569823835797e-09
from O 0 1.1936940325085743e-09
52 O 0 3.522410096934436e-08
healthy O 0 6.410738961903917e-08
volunteers O 0 8.067657653043625e-09
having O 0 1.0356349555706856e-08
phenotype O 0 3.791839446876111e-07
Hp2 O 0 5.876506293134298e-06
, O 0 4.504481232459057e-09
whereas O 0 2.066807702760798e-08
the O 0 1.9844013099401536e-09
serum O 0 8.141261673699773e-07
Hp O 0 7.527349055180821e-08
level O 0 1.8026158343786847e-08
of O 0 3.294799433284368e-10
an O 0 3.4315312813504306e-09
individual O 0 9.21766218908715e-10
with O 0 1.025249929398342e-08
Hp1 O 0 2.1913121599936858e-05
/ O 0 9.902411875373218e-06
Hpdel O 0 1.7014783225022256e-05
was O 0 7.597241165058222e-06
0 O 0 1.038738901115721e-06
. O 0 3.866597637625091e-07

50 O 0 5.610874723060988e-06
mg O 0 1.1229560186620802e-05
/ O 0 1.8306665879208595e-05
ml O 0 8.342901855939999e-05
, O 0 5.0544525009854624e-08
which O 0 7.464680429336568e-09
was O 0 1.2469557475469628e-07
approximately O 0 4.0978815896153264e-09
half O 0 3.748204413511758e-09
the O 0 5.028925609273927e-10
level O 0 6.342868896780374e-09
of O 0 3.238469770128205e-10
Hp O 0 7.164667437109529e-08
in O 0 7.749362040954111e-09
control O 0 2.5411902697669575e-06
sera O 0 0.0002078125107800588
from O 0 4.444239642964476e-09
the O 0 5.177609896378499e-09
Hp1 O 0 9.818926628213376e-06
phenotype O 0 2.1434297536870872e-07
( O 0 4.6207906945205934e-10
1 O 0 2.587090763839228e-09
. O 0 6.366962512771579e-10
26 O 0 4.3207446509541114e-09
+ O 0 4.956482513307492e-08
/ O 0 2.8059125156687514e-07
- O 0 4.511822737640614e-07
0 O 0 4.1331658096055435e-09
. O 0 4.369414552396478e-10
33 O 0 9.040519444170059e-09
mg O 0 1.2893634959709743e-07
/ O 0 4.401917408358713e-07
ml O 0 4.124909082747763e-06
; O 0 9.904818298878126e-09
n O 0 7.673837899346836e-06
= O 0 4.927450163449976e-07
9 O 0 2.1826426888083006e-08
) O 0 4.288573385302641e-10
, O 0 6.250117645656417e-10
showing O 0 5.777851441735038e-08
a O 0 1.8033484039392533e-08
gene O 0 2.6437729161443713e-07
- O 0 1.1471677680674475e-05
dosage O 0 1.0245441444567405e-05
effect O 0 4.6233787998062326e-07
. O 0 1.5611017545325012e-07

The O 0 3.6926377333657e-07
other O 0 3.208616661254382e-08
allele O 0 3.764707230402564e-07
( O 0 6.132050422991142e-09
Hp2 O 0 2.253007096442161e-06
) O 0 1.823741824225067e-09
of O 0 3.670549142409385e-10
individuals O 0 1.964149731747966e-09
with O 0 8.212040825128497e-09
Hp2 O 0 7.08679945091717e-05
/ O 0 1.4971710697864182e-05
Hpdel O 0 1.7597320038476028e-05
was O 0 2.712030618567951e-05
found O 0 5.56712905108725e-07
to O 0 2.3631615775343562e-08
have O 0 5.6351225907746993e-08
, O 0 2.5212776311178686e-09
in O 0 4.585181401228766e-10
all O 0 9.008618850891992e-10
exons O 0 9.445318482903531e-08
, O 0 7.562804604788198e-09
no O 0 1.892237122547158e-08
mutation O 0 1.6823745951910496e-08
, O 0 1.1548887401957586e-09
by O 0 5.475301878554717e-10
DNA O 0 9.647606447060753e-08
sequencing O 0 3.7588239365504705e-07
. O 0 2.4620896965643624e-07

On O 0 1.1028567996618222e-06
the O 0 2.8361981652125223e-09
basis O 0 1.0343301326543042e-08
of O 0 4.0218861574459197e-10
the O 0 1.0176124387584196e-09
present O 0 1.0356449031689863e-08
study O 0 1.0386656867922284e-08
, O 0 3.2597899934927455e-09
the O 0 3.5480227089657035e-10
mechanism O 0 1.3498470785577865e-08
of O 0 6.272043440169739e-10
anhaptoglobinemia B-Disease 0 5.064867946202867e-05
and O 0 6.437181099272493e-08
the O 0 1.7194767831796298e-09
mechanism O 0 1.535508076244696e-08
of O 0 4.855263968650547e-10
anomalous O 0 4.584802354656858e-06
inheritance O 0 3.7369278516052873e-07
of O 0 1.708333563499309e-08
Hp O 0 3.231937398595619e-06
phenotypes O 0 2.5778720100788632e-06
were O 0 1.1339674301780178e-06
well O 0 2.8014525810249324e-07
explained O 0 1.625522600079421e-06
. O 0 2.590524559309415e-07

However O 0 5.319802198755497e-07
, O 0 2.062058968022029e-08
the O 0 9.653727817138247e-10
mechanism O 0 4.3997513188287485e-08
of O 0 2.1170235342538035e-08
hypohaptoglobinemia B-Disease 0 0.0013787522912025452
remains O 0 7.59066388127394e-05
unknown O 0 2.2765167159377597e-05

ATM O 0 0.0026308507658541203
mutations O 0 4.3208136048633605e-05
and O 0 8.276545599983365e-07
phenotypes O 0 0.00034700139076448977
in O 0 0.00029174171504564583
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
telangiectasia I-Disease 1 0.9999998807907104
families O 0 0.0001707335322862491
in O 0 1.3917005503572e-07
the O 0 4.836358513671257e-08
British O 0 6.807504632888595e-06
Isles O 0 6.73340109642595e-05
: O 0 5.6718900687258156e-09
expression O 0 5.147243076208952e-09
of O 0 6.889871451143392e-10
mutant O 0 2.9781432431263966e-07
ATM O 0 2.1353074771468528e-05
and O 0 1.7912643812678652e-08
the O 0 8.425629083319564e-09
risk O 0 6.415185680452851e-07
of O 0 1.9885477797743079e-07
leukemia B-Disease 1 0.9993706345558167
, O 0 0.0011758068576455116
lymphoma B-Disease 1 1.0
, O 0 1.2503018297138624e-05
and O 0 0.0003586399834603071
breast B-Disease 1 0.9994702935218811
cancer I-Disease 0 0.009709935635328293
. O 0 1.517335817879939e-06

We O 0 5.249216883385088e-07
report O 0 2.289406531019722e-08
the O 0 6.527330898009609e-10
spectrum O 0 2.9853111982447444e-08
of O 0 1.6067872588010346e-09
59 O 0 2.5344351683997957e-07
ATM O 0 2.7765361664933152e-05
mutations O 0 9.395956226398994e-07
observed O 0 1.3859320461051539e-05
in O 0 5.863782644155435e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 0 0.013817835599184036
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
) O 0 5.351533900466166e-07
patients O 0 1.4875169540573552e-07
in O 0 2.9350939456662672e-09
the O 0 6.8310175294072906e-09
British O 0 6.994759587541921e-06
Isles O 0 8.836702181724831e-05
. O 0 6.830850907135755e-07

Of O 0 2.885287813114701e-07
51 O 0 1.6486412732774625e-06
ATM O 0 0.00018835387891158462
mutations O 0 3.5053378724114737e-06
identified O 0 3.80360643248423e-06
in O 0 5.071293784908448e-08
families O 0 2.3917566593922857e-08
native O 0 2.4606103821156466e-08
to O 0 1.126837378961909e-08
the O 0 8.278785657012122e-09
British O 0 1.5448666772499564e-06
Isles O 0 4.0957802411867306e-05
, O 0 5.527984825448584e-08
11 O 0 2.0156136315563344e-08
were O 0 1.194574252849634e-07
founder O 0 5.535074478757451e-07
mutations O 0 9.849885884705145e-08
, O 0 2.286430245135307e-08
and O 0 2.9568296255888527e-08
2 O 0 1.3688673305978227e-08
of O 0 5.456765039824063e-10
these O 0 2.6375026607183827e-09
11 O 0 1.253802217604516e-08
conferred O 0 6.857400425275273e-09
a O 0 3.7375691874785844e-08
milder O 0 3.954291605623439e-05
clinical O 0 5.70180327486014e-06
phenotype O 0 5.046739715908188e-06
with O 0 2.342219040940563e-08
respect O 0 2.971347967672955e-08
to O 0 8.920722649463642e-08
both O 0 2.0263662463548826e-06
cerebellar B-Disease 1 0.6569762229919434
degeneration I-Disease 1 0.7915574908256531
and O 0 4.492113021115074e-06
cellular O 0 0.00022685987642034888
features O 0 0.00010899602784775198
. O 0 7.422214821417583e-06

We O 0 1.4235332628231845e-06
report O 0 6.273257469047167e-08
, O 0 5.671133340712231e-09
in O 0 2.3846222774182024e-09
two O 0 2.3490059675168595e-08
A B-Disease 1 0.999962329864502
- I-Disease 1 0.9999959468841553
T I-Disease 1 1.0
families O 0 6.534312433359446e-07
, O 0 1.3130215137380219e-08
an O 0 7.010986902145078e-09
ATM O 0 0.00045599977602250874
mutation O 0 3.9658405626141757e-07
( O 0 3.4801828086017395e-09
7271T O 0 7.70701490182546e-07
- O 0 0.00010907639807555825
- O 0 0.0040096743032336235
> O 0 1.0974504220939707e-06
G O 0 1.3870534530724399e-05
) O 0 2.598861570390909e-09
that O 0 9.268227962877518e-09
may O 0 4.006462361871854e-08
be O 0 6.084191372934811e-09
associated O 0 4.006217935170753e-08
with O 0 6.177316436151159e-09
an O 0 1.5919866314106912e-08
increased O 0 1.613118797649804e-06
risk O 0 3.6250758057576604e-06
of O 0 2.107878032120425e-07
breast B-Disease 1 0.98390132188797
cancer I-Disease 0 6.106811633799225e-05
in O 0 9.81941905564554e-09
both O 0 3.908669299335088e-08
homozygotes O 0 5.986057658446953e-06
and O 0 1.7845606237187894e-07
heterozygotes O 0 1.9055912616749993e-06
( O 0 7.91466359117976e-09
relative O 0 1.602878228368354e-06
risk O 0 1.235704729651843e-07
12 O 0 2.0542068046580653e-09
. O 0 9.867967554200163e-10
7 O 0 1.890383138913876e-08
; O 0 1.304683472369561e-08
P O 0 0.01900404877960682
= O 0 1.73530077063333e-06
. O 0 2.39927611112023e-09
0025 O 0 1.7028527565798868e-07
) O 0 8.547575425232878e-10
, O 0 3.791719438428487e-10
although O 0 1.7955015252368867e-09
there O 0 9.494517172470296e-09
is O 0 1.0381348225507736e-08
a O 0 2.568751789056023e-08
less O 0 1.1042986898246454e-06
severe O 0 0.0007744687027297914
A B-Disease 1 0.9999905824661255
- I-Disease 1 0.9999938011169434
T I-Disease 1 0.9999998807907104
phenotype O 0 9.230404430127237e-06
in O 0 8.84998119232705e-09
terms O 0 8.395470985078646e-09
of O 0 3.6683514559321395e-10
the O 0 2.232041662608708e-09
degree O 0 3.947403470760946e-08
of O 0 2.051381642331762e-07
cerebellar B-Disease 1 0.9926927089691162
degeneration I-Disease 1 0.987958550453186
. O 0 4.729432021122193e-06

This O 0 2.2687889611461287e-07
mutation O 0 7.749422366032377e-07
( O 0 9.111250420801298e-09
7271T O 0 4.737286474210123e-07
- O 0 9.084344492293894e-05
- O 0 0.0017208583885803819
> O 0 3.765522023968515e-06
G O 0 2.62322118942393e-05
) O 0 1.6920859158275903e-09
also O 0 9.742515683086594e-10
allows O 0 7.1623379449548e-10
expression O 0 1.933447846269587e-09
of O 0 3.814220050912809e-10
full O 0 1.1628670648633488e-07
- O 0 1.41322625495377e-05
length O 0 2.2615229227085365e-06
ATM O 0 6.985706477280473e-06
protein O 0 1.5447112033939447e-08
at O 0 1.754455070113181e-08
a O 0 4.87946882898882e-09
level O 0 2.032049906119937e-08
comparable O 0 9.221485441912591e-08
with O 0 1.8361534515065614e-09
that O 0 4.996878466556609e-09
in O 0 3.347384236462858e-08
unaffected O 0 2.7069560019299388e-05
individuals O 0 4.744163106806809e-08
. O 0 1.5787009033374488e-07

In O 0 1.2277217820155784e-07
addition O 0 4.670673448003981e-08
, O 0 7.792552381147289e-09
we O 0 5.804081215643464e-09
have O 0 6.158396570477009e-10
studied O 0 8.593678657575765e-09
18 O 0 2.5928281388587493e-07
A B-Disease 1 0.9999047517776489
- I-Disease 1 0.999990701675415
T I-Disease 1 1.0
patients O 0 1.9801882444880903e-06
, O 0 4.132645781140809e-09
in O 0 1.7939885132989275e-09
15 O 0 1.9837360198948772e-08
families O 0 7.148448499805227e-09
, O 0 7.008206015512997e-09
who O 0 1.7829769660693273e-07
developed O 0 0.00015613174764439464
leukemia B-Disease 1 0.9728268384933472
, O 0 6.909190415171906e-05
lymphoma B-Disease 1 1.0
, O 0 5.766439699073089e-07
preleukemic O 0 0.024087144061923027
T O 0 0.4879348874092102
- O 0 0.00026366309612058103
cell O 0 0.00017301077605225146
proliferation O 0 0.0008087518508546054
, O 0 2.5602000164326455e-07
or O 0 0.029792919754981995
Hodgkin B-Disease 1 0.9999998807907104
lymphoma I-Disease 1 1.0
, O 0 1.0993327350661275e-06
mostly O 0 4.7109711687198796e-08
in O 0 2.5306110984502084e-08
childhood O 0 1.8296073903911747e-05
. O 0 3.5657302532854374e-07

A O 0 1.3514384590962436e-05
wide O 0 1.7565798771101981e-06
variety O 0 9.203229467402707e-08
of O 0 5.11434183891879e-09
ATM O 0 0.00016888479876797646
mutation O 0 8.526365036232164e-07
types O 0 1.0778074965855922e-06
, O 0 9.967168423941075e-09
including O 0 1.7719326450560402e-08
missense O 0 2.5078457838390023e-05
mutations O 0 2.549599003032199e-06
and O 0 4.3474150857036875e-07
in O 0 1.6942399838626443e-07
- O 0 0.0017710328102111816
frame O 0 0.016325542703270912
deletions O 0 2.880907459257287e-06
, O 0 5.915478240581251e-08
were O 0 1.066742569832968e-07
seen O 0 1.472801386626088e-06
in O 0 2.4554986932656675e-09
these O 0 3.121914815551463e-08
patients O 0 2.187411070053713e-07
. O 0 7.195205853349762e-08

We O 0 1.398727590640192e-06
also O 0 3.407290805057528e-08
show O 0 2.10645456633074e-08
that O 0 3.2582653242130277e-10
25 O 0 9.13850162209684e-10
% O 0 1.4538743819958455e-10
of O 0 4.5435330497944904e-10
all O 0 2.56306094570391e-07
A B-Disease 1 0.9999891519546509
- I-Disease 1 0.9999970197677612
T I-Disease 1 1.0
patients O 0 4.184660156170139e-06
carried O 0 1.0076583976115217e-06
in O 0 7.574688964950838e-08
- O 0 0.00030241988133639097
frame O 0 0.006819987203925848
deletions O 0 1.1794772944995202e-05
or O 0 2.0156903701717965e-06
missense O 0 1.3376341485127341e-05
mutations O 0 8.827897204355395e-07
, O 0 1.3892839767493115e-08
many O 0 3.957939254117804e-10
of O 0 7.05658365074413e-10
which O 0 2.301526080827898e-07
were O 0 2.224928948635352e-06
also O 0 2.392464466538513e-07
associated O 0 2.465934016981919e-07
with O 0 5.304378269954668e-09
expression O 0 2.526984133055521e-08
of O 0 2.7679991632112433e-09
mutant O 0 1.6910693148020073e-06
ATM O 0 2.473302447469905e-05
protein O 0 1.1701218909365707e-06
. O 0 2.142473363164754e-07

The O 0 7.037382374619483e-07
DMPK O 0 9.185302042169496e-05
gene O 0 1.167526875178737e-06
of O 0 2.0930225730353413e-07
severely O 0 0.15932127833366394
affected O 0 0.22725865244865417
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.05144400894641876
is O 0 8.948019285526243e-07
hypermethylated O 0 0.00014329170517157763
proximal O 0 0.0007808112422935665
to O 0 1.0907634617751683e-07
the O 0 1.686641226683605e-08
largely O 0 1.029510414696233e-07
expanded O 0 7.780598707540776e-07
CTG O 0 0.00019896939920727164
repeat O 0 9.869038876786362e-06
. O 0 6.30634417575493e-07

Using O 0 1.8088277329297853e-06
methylation O 0 1.0100597137352452e-05
- O 0 5.306789171299897e-05
sensitive O 0 3.4987864637514576e-05
restriction O 0 3.313188869924488e-07
enzymes O 0 9.026496883279833e-08
, O 0 5.326266094840548e-09
we O 0 2.999206660803111e-09
characterized O 0 2.003971744102273e-08
the O 0 2.9054272876472e-10
methylation O 0 4.0009570057009114e-07
pattern O 0 5.3148391998547595e-06
on O 0 3.4067392107317573e-07
the O 0 9.466542216785001e-09
5 O 0 2.8347500347081223e-08
side O 0 1.9676272700053232e-07
of O 0 9.217258067906187e-10
the O 0 1.1255957943490102e-08
CTG O 0 7.455587910953909e-05
repeat O 0 2.410008050901524e-07
in O 0 1.1345727690681429e-09
the O 0 1.0666520999791373e-09
DMPK O 0 3.201664867447107e-06
gene O 0 5.8033395866630144e-09
of O 0 8.019387931490485e-10
normal O 0 8.015206276468234e-08
individuals O 0 2.5287036908849814e-09
and O 0 6.322564694016819e-09
of O 0 1.529267912303567e-08
patients O 0 9.468051871408534e-07
affected O 0 1.8376630350758205e-06
with O 0 0.00047843155334703624
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 8.237220754381269e-07
showing O 0 1.1712517107298481e-06
expansions O 0 6.824378147030075e-07
of O 0 7.265258616939718e-09
the O 0 4.0033608428302614e-08
repetitive O 0 3.48787652910687e-05
sequence O 0 1.2205508710394497e-06
. O 0 1.0154751635127468e-06

The O 0 1.2039491537052527e-07
gene O 0 6.47754177407478e-07
segment O 0 2.65481889982766e-06
analyzed O 0 2.9295873105184e-07
corresponds O 0 2.294744945174898e-07
to O 0 7.514636024552601e-09
the O 0 2.7520010714709997e-09
genomic O 0 1.7560024900831195e-07
SacI O 0 1.867917671916075e-05
- O 0 1.3443236639432143e-05
HindIII O 0 1.4587640180252492e-06
fragment O 0 3.199291711553087e-07
carrying O 0 1.395259374703528e-07
exons O 0 2.0491330587901757e-07
11 O 0 3.709459051037811e-08
- O 0 3.7492040974029806e-06
15 O 0 1.3887361660636088e-07
. O 0 1.2927615955504734e-07

There O 0 1.0470015467944904e-06
is O 0 2.7068573160704545e-08
constitutive O 0 1.3138537724444177e-07
methylation O 0 6.048025511518063e-07
in O 0 2.569418278142166e-08
intron O 0 8.761355275055394e-05
12 O 0 4.243484141852605e-08
at O 0 1.5854080714916563e-08
restriction O 0 1.9752562252506323e-08
sites O 0 1.819500461408552e-08
of O 0 1.2259914194956423e-09
SacII O 0 4.99390762342955e-06
and O 0 2.499421292156967e-08
HhaI O 0 1.8374597630099743e-06
, O 0 2.367260831803719e-09
localized O 0 1.2600455079336825e-07
1 O 0 5.3441664427111846e-09
, O 0 2.509982888199147e-09
159 O 0 9.800824329886382e-08
- O 0 2.021713044086937e-05
1 O 0 1.8622223763031798e-08
, O 0 1.4153069827216314e-09
232 O 0 1.4533046766018742e-08
bp O 0 2.1734746269430616e-07
upstream O 0 2.159507062060584e-08
of O 0 6.453944045858862e-10
the O 0 3.163579176401754e-09
CTG O 0 2.0465917259571142e-05
repeat O 0 3.8567975479963934e-07
, O 0 2.5519855118005808e-09
whereas O 0 3.835290307563355e-09
most O 0 1.583400743854213e-09
, O 0 3.2485061307596652e-09
if O 0 3.2368412394845336e-09
not O 0 2.2337878213818385e-09
all O 0 1.3997569769941265e-10
, O 0 2.814463384570587e-10
of O 0 4.590105726065552e-11
the O 0 3.019996752673393e-10
other O 0 1.6375995004480615e-10
sites O 0 7.231083731795707e-09
of O 0 2.6311103296094984e-10
SacII O 0 1.2687845583059243e-06
, O 0 6.498923621478525e-09
HhaI O 0 8.765800316723471e-07
, O 0 6.299921917474194e-09
and O 0 1.190804255202238e-08
HpaII O 0 2.4954258606157964e-06
in O 0 2.035959623114536e-09
this O 0 1.0463663269177914e-09
region O 0 2.5108937151685495e-08
are O 0 1.7213767078416709e-09
unmethylated O 0 2.186394340242259e-06
, O 0 5.236144851039626e-09
in O 0 7.761191134214585e-10
normal O 0 4.0414914082020914e-08
individuals O 0 4.030942690746997e-09
and O 0 1.6488866938502156e-09
most O 0 4.5776840651434725e-10
of O 0 5.658056800861289e-10
the O 0 4.8514365857954544e-08
patients O 0 2.1910479119924275e-07
. O 0 1.0403037720152497e-07

In O 0 2.5166335149151564e-07
a O 0 4.806278752766957e-08
number O 0 5.581101802931698e-09
of O 0 1.2133547500070563e-09
young O 0 1.5592196689340199e-07
and O 0 7.675344448898613e-08
severely O 0 0.0018531068926677108
affected O 0 2.8678371108981082e-06
patients O 0 1.6193538954212272e-07
, O 0 1.5820431187307804e-08
however O 0 6.706359467756329e-09
, O 0 8.024069741985329e-10
complete O 0 1.7447797651115593e-09
methylation O 0 3.796347414208867e-08
of O 0 3.8142053404577325e-10
these O 0 3.6140423986807946e-10
restriction O 0 1.6185659035272693e-08
sites O 0 2.989288532262435e-07
was O 0 2.3290474473469658e-06
found O 0 9.321594518496568e-08
in O 0 2.3676087756996367e-09
the O 0 7.914829680544244e-09
mutated O 0 1.3834501260134857e-06
allele O 0 1.7106686982515384e-06
. O 0 3.340318244227092e-07

In O 0 2.0278883994251373e-07
most O 0 1.1340432592987781e-08
of O 0 9.751643936795062e-10
these O 0 1.1898779739283327e-08
patients O 0 3.207295051765868e-08
, O 0 1.2439945740183589e-09
the O 0 7.23036297500812e-10
onset O 0 7.208172405626101e-07
of O 0 3.7006591124821853e-09
the O 0 2.596242666186299e-06
disease O 0 0.13795025646686554
was O 0 0.29439160227775574
congenital O 1 0.9999942779541016
. O 0 1.3593309631687589e-05

Preliminary O 0 4.472585715120658e-06
in O 0 1.4909794288087141e-07
vivo O 0 1.688765587459784e-05
footprinting O 0 6.853074592072517e-05
data O 0 6.84150336383027e-07
gave O 0 2.9230559306370196e-08
evidence O 0 3.632913703199847e-08
for O 0 3.5729204039824936e-09
protein O 0 1.9938306650146842e-07
- O 0 2.182361095037777e-05
DNA O 0 2.800992888296605e-06
contact O 0 5.917723910897621e-07
in O 0 1.7569992127874912e-09
normal O 0 2.2421554390916754e-08
genes O 0 2.7916104983205514e-08
at O 0 1.473010513564077e-07
an O 0 6.054047485548608e-09
Sp1 O 0 6.894227908560424e-07
consensus O 0 3.0987055144038322e-09
binding O 0 4.245621809673139e-08
site O 0 1.3730166301684221e-06
upstream O 0 1.23374988447722e-07
of O 0 8.957662944730771e-10
the O 0 7.2502528425388846e-09
CTG O 0 3.477460995782167e-05
repeat O 0 6.210503897818853e-07
and O 0 9.946089285506332e-09
for O 0 4.74578709663831e-10
a O 0 4.041443180113902e-09
significant O 0 6.178565215009257e-09
reduction O 0 1.4535762815626185e-08
of O 0 2.879948224343565e-10
this O 0 6.297120047626947e-10
interaction O 0 2.684316102730122e-09
in O 0 7.576517191409948e-10
cells O 0 6.2941207801259225e-09
with O 0 2.456398195960219e-09
a O 0 1.0009389228571308e-07
hypermethylated O 0 3.345904769957997e-05
DMPK O 0 2.198774745920673e-05
gene O 0 1.3503266416137194e-07
. O 0 1.8964286141454068e-08
. O 0 1.8302789328572544e-07

The O 0 3.9730134631099645e-06
hemochromatosis B-Disease 1 0.9999810457229614
gene O 0 1.419147247361252e-05
product O 0 4.939117843605345e-06
complexes O 0 7.967594683577772e-06
with O 0 1.905867463847244e-08
the O 0 5.5384301589356255e-09
transferrin O 0 2.643669631652301e-06
receptor O 0 1.1841819969049538e-07
and O 0 1.2416697892092543e-08
lowers O 0 4.4073695448787475e-07
its O 0 1.0009074680183971e-09
affinity O 0 4.210314319408326e-09
for O 0 3.3718719483211146e-10
ligand O 0 1.5095015726274141e-07
binding O 0 4.527593944203545e-07
. O 0 1.5800775088337105e-07

We O 0 1.1985903256572783e-06
recently O 0 5.614844553747389e-07
reported O 0 5.842882089268642e-08
the O 0 3.224177314020693e-10
positional O 0 1.1403860611380878e-07
cloning O 0 2.351817300905168e-07
of O 0 1.7116399408934058e-09
a O 0 5.572169925471826e-08
candidate O 0 5.521303592104232e-07
gene O 0 3.5966936593467835e-06
for O 0 8.306979725603014e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.8439546823501587
HFE O 1 0.9886941313743591
. O 0 1.1507944691402372e-05

The O 0 1.0455812571308343e-07
gene O 0 5.027405904911575e-07
product O 0 1.723275204312813e-06
, O 0 2.913398944315304e-08
a O 0 3.846867713264146e-08
member O 0 3.832921091628805e-09
of O 0 9.771529141389124e-10
the O 0 1.0994543053755024e-08
major O 0 5.095756705486565e-07
histocompatibility O 0 2.190058512496762e-05
complex O 0 7.521401585108833e-06
class O 0 3.444340279656899e-07
I O 0 2.6001431251643226e-05
- O 0 6.808699254179373e-06
like O 0 2.103351732785086e-07
family O 0 4.150034271788172e-07
, O 0 1.5511892215158696e-08
was O 0 2.733864903348149e-06
found O 0 1.55319696659717e-07
to O 0 1.523962644967014e-08
have O 0 2.288441436348876e-08
a O 0 2.684440403299959e-08
mutation O 0 2.0947354073541646e-08
, O 0 2.157904299693314e-09
Cys O 0 7.955134606163483e-06
- O 0 3.5558625768317143e-06
282 O 0 7.774619916744996e-07
- O 0 4.126607746002264e-05
- O 0 6.588354881387204e-05
> O 0 3.8024933246560977e-07
Tyr O 0 2.575075995991938e-06
( O 0 1.4983675411528452e-09
C282Y O 0 2.02520524794636e-08
) O 0 2.951631439263025e-10
, O 0 1.223089962643087e-10
in O 0 2.0689591706535282e-10
85 O 0 6.930337193011837e-09
% O 0 1.2354042233653217e-09
of O 0 8.072829515981539e-09
patient O 0 2.270706136187073e-05
chromosomes O 0 9.869698260445148e-06
. O 0 1.7167908481496852e-06

This O 0 6.986280709497805e-08
mutation O 0 2.0227777497439092e-07
eliminates O 0 4.771714543494454e-07
the O 0 9.999463479459791e-09
ability O 0 4.147303300783278e-08
of O 0 1.5751051574142139e-09
HFE O 0 7.306194311240688e-05
to O 0 1.809536520624988e-08
associate O 0 4.009306309171734e-08
with O 0 2.5847148421576094e-08
beta2 O 0 0.003788033267483115
- O 0 0.004297751002013683
microglobulin O 0 0.0002691033005248755
( O 0 1.06820809975261e-08
beta2m O 0 5.542572125705192e-06
) O 0 3.1855404980518642e-09
and O 0 8.71506866673144e-09
prevents O 0 8.754474123406908e-08
cell O 0 1.938384048116859e-05
- O 0 0.00015369366155937314
surface O 0 0.0023671910166740417
expression O 0 1.7970290855373605e-06
. O 0 5.169131895854662e-07

A O 0 7.801144420227502e-06
second O 0 7.11508221229451e-07
mutation O 0 2.2964904928812757e-06
that O 0 4.1489016666673706e-08
has O 0 1.385323287195206e-07
no O 0 2.8943349050791767e-08
effect O 0 2.108376051523919e-08
on O 0 1.6854714601777232e-07
beta2m O 0 4.469748091651127e-05
association O 0 3.9036478938214714e-08
, O 0 4.5011319116383675e-09
H63D O 0 1.1796404578490183e-05
, O 0 2.1082151135942695e-08
was O 0 1.1516071936057415e-06
found O 0 1.1234386221303794e-07
in O 0 2.0553942992052043e-09
eight O 0 2.0079073959067273e-09
out O 0 3.0635802783507415e-09
of O 0 1.124457971179993e-09
nine O 0 1.8623950381879695e-07
patients O 0 4.673676912148039e-08
heterozygous O 0 4.984503920724137e-09
for O 0 1.5221781612950736e-09
the O 0 2.1581936238135313e-08
C282Y O 0 5.332090495357988e-06
mutant O 0 3.2703401302569546e-06
. O 0 5.026025178267446e-07

In O 0 1.4245516410937853e-07
this O 0 7.528838885662026e-09
report O 0 2.4991685165787203e-08
, O 0 1.479016908945141e-09
we O 0 8.889292635316792e-10
demonstrate O 0 3.258434855268888e-09
in O 0 5.124348168017434e-10
cultured O 0 1.854079755503335e-06
293 O 0 2.1872608613193734e-07
cells O 0 1.286506403630483e-07
overexpressing O 0 4.5559313548437785e-06
wild O 0 8.379834639526962e-07
- O 0 7.003847713349387e-05
type O 0 0.0004871161945629865
or O 0 1.9161284114943555e-07
mutant O 0 1.4285502629718394e-06
HFE O 0 4.181077747489326e-05
proteins O 0 2.2838673174874202e-08
that O 0 6.510462391418059e-09
both O 0 1.0594499721960915e-09
the O 0 1.4015395510824646e-09
wild O 0 1.0925735978162265e-06
- O 0 6.391819624695927e-05
type O 0 0.005243921186774969
and O 0 2.3989744022401283e-06
H63D O 0 0.0037957951426506042
HFE O 0 0.00014328950783237815
proteins O 0 2.638656404485573e-08
form O 0 2.2211281702766428e-08
stable O 0 1.5029104361019563e-05
complexes O 0 2.9824936973454896e-06
with O 0 6.298336074905819e-09
the O 0 3.811824100807826e-08
transferrin O 0 6.7486624175217e-05
receptor O 0 1.859526719272253e-06
( O 0 4.5332971154721236e-08
TfR O 0 4.782710311701521e-05
) O 0 2.246388852711334e-08
. O 0 8.051765831851299e-08

The O 0 6.782593686693872e-07
C282Y O 0 1.584530036780052e-05
mutation O 0 1.9352326035004808e-06
nearly O 0 9.366738851213086e-08
completely O 0 2.0910455589273624e-07
prevents O 0 1.3439954216210026e-07
the O 0 2.7661148926938495e-09
association O 0 6.9683250281116216e-09
of O 0 6.729780066550006e-10
the O 0 9.16129838657298e-09
mutant O 0 4.725243798020529e-06
HFE O 0 0.00011201790766790509
protein O 0 1.7554884834680706e-07
with O 0 1.855199194267243e-08
the O 0 1.819101953515201e-07
TfR O 0 0.0289054736495018
. O 0 1.2284003787499387e-06

Studies O 0 9.859751344265533e-07
on O 0 2.68950202553242e-07
cell O 0 1.149112267739838e-05
- O 0 7.52307751099579e-05
associated O 0 5.906216529183439e-07
transferrin O 0 1.0290642649124493e-06
at O 0 5.3378226283484764e-08
37 O 0 8.34285707185245e-09
degrees O 0 2.8520940276166584e-08
C O 0 4.887854629487265e-06
suggest O 0 2.8643711402764893e-08
that O 0 1.5584064039231293e-09
the O 0 1.5656460572444075e-09
overexpressed O 0 8.313001671922393e-06
wild O 0 1.595165144863131e-06
- O 0 0.00015017653640825301
type O 0 0.0007051742868497968
HFE O 0 0.0005342534859664738
protein O 0 1.856084708151684e-07
decreases O 0 2.4707739498808223e-07
the O 0 1.164399687780815e-09
affinity O 0 7.622324993405982e-09
of O 0 1.2584544517579843e-09
the O 0 3.840811757527263e-08
TfR O 0 0.0002491659834049642
for O 0 1.0666713023965713e-07
transferrin O 0 6.673370080534369e-05
. O 0 3.993744712715852e-07

The O 0 2.837523425114341e-07
overexpressed O 0 8.39576096041128e-05
H63D O 0 9.809435141505674e-05
protein O 0 7.999411195669381e-07
does O 0 4.861440316972221e-08
not O 0 3.0894873326303696e-09
have O 0 5.149126125481018e-10
this O 0 5.846641226714411e-11
effect O 0 3.1362967778392203e-09
, O 0 8.813860197243173e-10
providing O 0 6.30368091059097e-10
the O 0 2.537844379091325e-10
first O 0 1.4776436740859822e-09
direct O 0 6.076026792811717e-09
evidence O 0 8.92302054467109e-08
for O 0 6.892292958582402e-09
a O 0 9.973295789222902e-08
functional O 0 4.84805070755101e-07
consequence O 0 3.971327799945357e-08
of O 0 1.4766969869128843e-09
the O 0 3.4902619461263384e-08
H63D O 0 0.0008491816115565598
mutation O 0 3.946096967410995e-06
. O 0 5.986132691759849e-07

Addition O 0 1.1977413123531733e-06
of O 0 2.488779671239172e-08
soluble O 0 4.824859843211016e-06
wild O 0 1.485944721935084e-06
- O 0 0.0001582803815836087
type O 0 0.0021974139381200075
HFE O 0 0.011540642939507961
/ O 0 0.00011429510050220415
beta2m O 0 0.0001383085473207757
heterodimers O 0 1.0890285011555534e-05
to O 0 1.9662836692191377e-08
cultured O 0 3.7065212836751016e-06
cells O 0 4.382439726668963e-07
also O 0 1.1916681330603751e-07
decreased O 0 1.9484327822283376e-06
the O 0 2.024790779486807e-09
apparent O 0 2.705975248318282e-07
affinity O 0 1.2852772179883232e-08
of O 0 1.1030708568782188e-09
the O 0 1.115665337891869e-08
TfR O 0 3.837484837276861e-05
for O 0 1.2361491830148452e-09
its O 0 5.438477446162437e-10
ligand O 0 8.329373635262982e-09
under O 0 4.834409761400593e-09
steady O 0 7.690151505812537e-06
- O 0 1.1397155503800604e-05
state O 0 5.426864735369463e-09
conditions O 0 2.4592743557150243e-06
, O 0 2.729522607936019e-09
both O 0 3.3666794352349427e-10
in O 0 1.3276370003367788e-09
293 O 0 3.091369293883872e-08
cells O 0 8.41088976244464e-09
and O 0 6.522705042755206e-09
in O 0 2.047229763491032e-08
HeLa O 0 0.0001559148367960006
cells O 0 3.171516596012225e-07
. O 0 1.520296564194723e-07

Furthermore O 0 1.7014824607031187e-06
, O 0 1.6901385180290163e-08
at O 0 5.5529847386992515e-09
4 O 0 1.807365812567241e-09
degrees O 0 3.291730976684448e-08
C O 0 7.572777394670993e-05
, O 0 6.282342646102279e-09
the O 0 2.5176831730533422e-09
added O 0 1.8667230961000314e-07
soluble O 0 2.7404638558437e-07
complex O 0 1.1964360169258725e-07
of O 0 7.052671779916864e-09
HFE O 0 0.0006429945933632553
/ O 0 1.2842431715398561e-05
beta2m O 0 8.02389968157513e-06
inhibited O 0 3.9656740113969136e-07
binding O 0 1.176186330553719e-07
of O 0 5.409038994486082e-09
transferrin O 0 3.3158771657326724e-06
to O 0 3.661546443822772e-08
HeLa O 0 9.03653126442805e-05
cell O 0 2.39877263084054e-05
TfR O 0 3.416641993680969e-05
in O 0 8.738870960200984e-09
a O 0 5.3578656178387973e-08
concentration O 0 1.972618883883115e-05
- O 0 2.6212204829789698e-05
dependent O 0 1.4376142871697084e-06
manner O 0 4.8782712838146836e-06
. O 0 2.482309184870246e-07

Scatchard O 0 0.00012883402814622968
plots O 0 1.0099835890287068e-05
of O 0 9.56283408015679e-09
these O 0 3.5088296712615374e-09
data O 0 2.555752232069608e-08
indicate O 0 2.8852843669824324e-08
that O 0 1.5990796464748769e-09
the O 0 1.8170231985692453e-09
added O 0 1.0131878980246256e-07
heterodimer O 0 7.530543371103704e-07
substantially O 0 2.733369512952777e-07
reduced O 0 2.319098690861665e-08
the O 0 1.0517426929368412e-09
affinity O 0 2.351202255113094e-08
of O 0 1.0161930852348178e-08
TfR O 0 0.00011492965859360993
for O 0 5.1570530956723815e-08
transferrin O 0 3.1225070415530354e-05
. O 0 2.0991295457406522e-07

These O 0 4.443928389719076e-07
results O 0 9.965670244582725e-08
establish O 0 4.67303493678628e-08
a O 0 2.421261058316304e-08
molecular O 0 3.083854153373977e-06
link O 0 9.099135786527768e-05
between O 0 2.0229542769811815e-06
HFE O 0 0.05392059311270714
and O 0 1.312012273047003e-06
a O 0 1.7765017901183455e-07
key O 0 4.393193933083239e-07
protein O 0 6.098644700358591e-09
involved O 0 1.7386648565320684e-08
in O 0 1.238542868264858e-08
iron O 0 0.00038883244269527495
transport O 0 7.0614223659504205e-06
, O 0 7.228105669554452e-09
the O 0 1.2667192850202014e-09
TfR O 0 1.7366421161568724e-05
, O 0 5.776283451552899e-09
and O 0 2.1799797522703557e-08
raise O 0 2.5141716264442948e-08
the O 0 3.834059458807104e-10
possibility O 0 1.0756870949535369e-08
that O 0 1.366362467614124e-09
alterations O 0 1.571319785398373e-07
in O 0 2.5979098872142004e-09
this O 0 7.565311710422407e-10
regulatory O 0 3.2296153307243e-08
mechanism O 0 1.6698051297225902e-07
may O 0 8.89600073605834e-08
play O 0 6.603180668918185e-09
a O 0 1.0632036584468096e-08
role O 0 2.5828816418993483e-08
in O 0 3.277358162634414e-09
the O 0 2.0155212610006856e-08
pathogenesis O 0 0.00011451197497081012
of O 0 3.747091977857053e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.5554156309226528e-05
. O 0 1.793444084796647e-06

Genomic O 0 1.0264041520713363e-05
organization O 0 3.7245959561005293e-07
of O 0 1.1331222182775491e-08
the O 0 1.4974883555396445e-08
UBE3A O 0 0.0003764154971577227
/ O 0 2.5882754925987683e-05
E6 O 0 0.00015360764518845826
- O 0 0.00356141384691
AP O 0 1.2301905371714383e-05
gene O 0 2.0465161298943713e-07
and O 0 4.2760323282209356e-08
related O 0 1.1326833373459522e-06
pseudogenes O 0 6.161040073493496e-05
. O 0 2.3543941551906755e-06

The O 0 1.12800501028687e-06
UBE3A O 0 0.00013332995877135545
gene O 0 1.1904419352504192e-06
encodes O 0 2.928146045633184e-07
the O 0 1.985916675550925e-08
E6 O 0 0.00015949908993206918
- O 0 0.0013771755620837212
AP O 0 9.248218702850863e-06
ubiquitin O 0 2.332772965019103e-06
- O 0 4.615678335539997e-06
protein O 0 5.361024335570619e-08
ligase O 0 2.49130209795112e-07
and O 0 2.2619140338520083e-08
has O 0 2.6858794299755573e-08
recently O 0 3.044969076881898e-08
been O 0 7.628288223315849e-09
shown O 0 3.4109828295214584e-09
to O 0 1.7049018863346532e-09
be O 0 9.305872339382404e-08
mutated O 0 1.4879475202178583e-05
in O 0 0.11486992239952087
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00035041087539866567
who O 0 3.694934491704771e-07
lack O 0 8.549410068781071e-08
15q11 O 0 1.68354126799386e-05
- O 0 9.889248030958697e-05
q13 O 0 1.2044091818097513e-05
deletions O 0 6.218277121661231e-06
or O 0 2.8872498205601005e-06
chromosome O 0 9.938397852238268e-05
15 O 0 2.049517206614837e-06
paternal O 0 0.0021470512729138136
uniparental B-Disease 0 0.4462336301803589
disomy I-Disease 0 0.02014773339033127
. O 0 8.071806405496318e-06

Previous O 0 3.232452399970498e-06
UBE3A O 0 8.536521636415273e-05
cDNA O 0 2.1877958715776913e-06
analysis O 0 7.634024541403051e-07
has O 0 4.5774616097560283e-08
shown O 0 5.8350160259124095e-09
a O 0 9.895490649114436e-09
coding O 0 5.542257781598892e-07
region O 0 3.2799363225421985e-08
of O 0 1.0190516208652411e-09
approximately O 0 8.645601923262802e-08
2 O 0 2.6938297992273874e-07
. O 0 5.269053531264944e-07

6 O 0 5.70630754737067e-06
kb O 0 0.00014243701298255473
and O 0 3.2159695706468483e-07
a O 0 1.1609456151973063e-07
3 O 0 5.802866098747472e-07
- O 0 0.012568935751914978
untranslated O 0 0.0039889272302389145
region O 0 5.571315341512673e-06
( O 0 8.164593445769697e-09
UTR O 0 6.528333074129478e-07
) O 0 5.882270226464925e-10
of O 0 2.0731384664518515e-10
< O 0 4.293096083074488e-07
50 O 0 5.5064304227414596e-09
bp O 0 3.249177211728238e-07
, O 0 8.762033321119134e-10
whereas O 0 4.340022563553703e-09
Northern O 0 2.924967601458661e-09
analysis O 0 8.9604865749493e-09
has O 0 3.972752082859188e-08
indicated O 0 1.9879820456480957e-08
mRNA O 0 1.4723743335665063e-09
sizes O 0 7.915660127366664e-09
of O 0 6.45914044472562e-10
5 O 0 4.405898579307177e-08
- O 0 1.6557836715946905e-05
8 O 0 3.4649249869289633e-07
kb O 0 6.4044252212625e-05
. O 0 4.6419964405686187e-07

We O 0 3.3414789868402295e-06
have O 0 1.0826545882025584e-08
analyzed O 0 1.8344110230827937e-08
additional O 0 5.173698136573535e-10
cDNA O 0 3.5715050472617804e-08
clones O 0 9.73605779108766e-07
and O 0 6.56534204779291e-09
provide O 0 1.747607614177582e-09
evidence O 0 4.442519241365517e-09
for O 0 8.76395511717476e-10
an O 0 1.5209070669541802e-09
additional O 0 1.788792403090156e-08
0 O 0 3.329587059397454e-07
. O 0 2.528177844851598e-07

5 O 0 1.6623134797555394e-06
kb O 0 1.0443297469464596e-05
of O 0 1.0333048194866024e-08
5 O 0 1.2524068893071671e-07
- O 0 7.236970850499347e-05
UTR O 0 1.911192521220073e-05
and O 0 1.8743273599852728e-08
> O 0 1.0737667821558716e-07
2 O 0 8.85335804667875e-09
kb O 0 9.190001151182514e-07
of O 0 6.208570546561987e-09
3 O 0 8.048078257161251e-07
- O 0 0.0030894980300217867
UTR O 0 0.0006649632705375552
. O 0 9.101437967728998e-07

We O 0 8.21178218757268e-06
have O 0 2.356059702890434e-08
established O 0 3.585112429149717e-09
the O 0 1.6849932560347725e-10
genomic O 0 1.00325516783073e-08
organization O 0 3.2408071781730996e-09
of O 0 9.12489861448762e-10
UBE3A O 0 4.435625305632129e-05
and O 0 7.732205098420764e-09
the O 0 8.587120459147002e-10
sequence O 0 9.951591550816374e-09
of O 0 5.20763920874856e-09
intron O 0 0.0005246901419013739
- O 0 0.0002497792011126876
exon O 0 2.6217605409328826e-05
borders O 0 8.630642696516588e-06
. O 0 9.609497055862448e-07

We O 0 4.353585609351285e-06
have O 0 6.304853172878211e-08
also O 0 7.69960717406093e-09
mapped O 0 5.251487891655415e-06
two O 0 5.01435071242895e-09
highly O 0 7.602928775440887e-08
homologous O 0 7.028555870647324e-08
processed O 0 1.7188160938985675e-07
pseudogenes O 0 4.3418211248535954e-07
, O 0 2.1039291198121646e-08
UBE3AP1 O 0 1.793527371773962e-05
and O 0 1.7451077383157099e-07
UBE3AP2 O 0 5.448370211524889e-05
, O 0 5.127586799602568e-09
to O 0 1.0498888425303221e-09
chromosomes O 0 3.5303802548014573e-08
2 O 0 2.0485968477146344e-08
and O 0 7.91074299399952e-08
21 O 0 2.583068869910221e-08
, O 0 3.1819940016220016e-09
respectively O 0 6.359443460723924e-08
, O 0 1.2102675306380206e-08
and O 0 1.7306678756767724e-08
determined O 0 1.673289915515852e-07
their O 0 1.0772511771506288e-09
genomic O 0 6.771271188199535e-08
organization O 0 9.967115488507261e-08
. O 0 8.419078767474275e-08

These O 0 1.8937976165034343e-07
results O 0 9.144263657390184e-08
will O 0 1.7962902276735804e-08
form O 0 6.098319182967771e-09
the O 0 3.979080120952716e-10
basis O 0 3.3126166698593806e-08
for O 0 9.782550325354578e-10
studies O 0 1.2849799002623286e-09
of O 0 1.0270069239481927e-09
mutation O 0 1.7734582513639907e-07
and O 0 1.1862025139919297e-08
imprinting O 0 4.016097591375001e-06
of O 0 1.987410342962903e-07
UBE3A O 0 0.010470040142536163
. O 0 1.9277688352303812e-06

Mutation O 0 3.077196015510708e-05
spectrum O 0 9.80174900178099e-06
and O 0 3.165168607210944e-07
genotype O 0 7.655959780095145e-05
- O 0 0.00016062067879829556
phenotype O 0 1.0927789844572544e-05
analyses O 0 1.9367612367204856e-06
in O 0 2.798317666474759e-07
Cowden B-Disease 1 0.9918944239616394
disease I-Disease 0 0.0005600479198619723
and O 0 1.198583504447015e-06
Bannayan B-Disease 1 0.9882929921150208
- I-Disease 1 0.9999947547912598
Zonana I-Disease 1 0.9999970197677612
syndrome I-Disease 1 0.9999958276748657
, O 0 6.095542630646378e-07
two O 0 3.1567569749313407e-06
hamartoma B-Disease 1 0.9991481304168701
syndromes I-Disease 1 0.8581013083457947
with O 0 2.7287958346278174e-06
germline O 0 0.013768836855888367
PTEN O 0 0.05341334268450737
mutation O 0 5.88542316108942e-05
. O 0 2.4742123514442937e-06

The O 0 3.0924038583179936e-06
tumour B-Disease 1 0.9999120235443115
suppressor O 0 0.000786305929068476
gene O 0 9.122309165832121e-06
PTEN O 0 0.00029209323110990226
, O 0 4.92959379982949e-08
which O 0 5.496335830912358e-09
maps O 0 1.5717229189249338e-06
to O 0 1.0424528795738297e-07
10q23 O 0 4.537609129329212e-05
. O 0 8.23092307200568e-07

3 O 0 3.710921419042279e-06
and O 0 9.498540975982905e-08
encodes O 0 5.43539329100895e-08
a O 0 2.136922461204449e-08
403 O 0 5.6438565820826625e-08
amino O 0 1.5506092410078054e-08
acid O 0 2.029431556138661e-08
dual O 0 5.751320131253124e-08
specificity O 0 3.9279444763451465e-07
phosphatase O 0 0.0338035486638546
( O 0 9.971123482444e-09
protein O 0 3.2198972377273094e-08
tyrosine O 0 1.3101991953590186e-06
phosphatase O 0 0.0018600632902234793
; O 0 5.8140638969916836e-09
PTPase O 0 1.710864466986095e-06
) O 0 2.172254598420409e-09
, O 0 2.7933666491009035e-09
was O 0 4.84728332139639e-07
shown O 0 4.423041488621493e-08
recently O 0 2.0437738612599787e-07
to O 0 4.899837868777013e-09
play O 0 2.289912970354635e-08
a O 0 3.2309891651038924e-08
broad O 0 1.245381554326741e-06
role O 0 8.269856266451825e-08
in O 0 2.568570600658404e-08
human O 0 9.567222605255665e-07
malignancy B-Disease 0 0.0011753701837733388
. O 0 8.035975724851596e-07

Somatic O 0 0.0004363495681900531
PTEN O 0 0.0007815042044967413
deletions O 0 1.5668198102503084e-05
and O 0 4.2003708244919835e-07
mutations O 0 5.920941816839331e-07
were O 0 2.930693021596653e-08
observed O 0 1.1391773568902863e-07
in O 0 1.6485007137134744e-08
sporadic B-Disease 0 0.09743119776248932
breast I-Disease 1 0.6958699226379395
, I-Disease 0 2.4034375201154035e-06
brain I-Disease 0 0.000882984371855855
, I-Disease 0 1.1929158745260793e-06
prostate I-Disease 1 0.7676961421966553
and I-Disease 0 0.05062403529882431
kidney I-Disease 1 0.9990549683570862
cancer I-Disease 0 0.005455633159726858
cell O 0 0.0005740202614106238
lines O 0 5.876932482351549e-05
and O 0 3.4898235412583745e-07
in O 0 9.386229571362037e-09
several O 0 4.936367759000859e-08
primary O 0 3.0255976525950246e-05
tumours B-Disease 1 0.999974250793457
such O 0 4.188933928617189e-07
as O 0 2.0753239368787035e-05
endometrial B-Disease 1 0.999631404876709
carcinomas I-Disease 1 1.0
, O 1 0.8736073970794678
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9986385703086853
thyroid B-Disease 1 0.9999991655349731
tumours I-Disease 1 0.9999992847442627
. O 0 3.380059570190497e-05

In O 0 8.9886484033741e-08
addition O 0 2.6391145269144545e-08
, O 0 1.2687462636051805e-08
PTEN O 0 1.4993843251431827e-05
was O 0 2.1009550437156577e-06
identified O 0 1.6037666910051485e-06
as O 0 5.444209527638577e-09
the O 0 4.432126221587396e-09
susceptibility O 0 2.530766550989938e-06
gene O 0 1.1465768778862184e-07
for O 0 9.245049881201339e-08
two O 0 2.480968032614328e-05
hamartoma B-Disease 1 0.9999502897262573
syndromes I-Disease 1 0.9999712705612183
Cowden B-Disease 1 0.9999796152114868
disease I-Disease 1 0.8137279152870178
( O 0 7.460228346189979e-08
CD B-Disease 0 0.00019384833285585046
; O 0 6.662745590801933e-07
MIM O 0 0.0002236542059108615
158350 O 0 2.0000707081635483e-06
) O 0 3.8708303229384455e-09
and O 0 1.7953654563029886e-08
Bannayan B-Disease 0 0.00030815822537988424
- I-Disease 0 0.21957236528396606
Zonana I-Disease 0 0.029521264135837555
( I-Disease 0 4.1922067595123735e-08
BZS I-Disease 0 3.980560904892627e-06
) I-Disease 0 5.651501933101599e-09
or I-Disease 0 4.284008170429843e-08
Ruvalcaba I-Disease 0 2.484848846506793e-05
- I-Disease 0 0.00010980721708619967
Riley I-Disease 0 6.889020733069628e-05
- I-Disease 1 0.9986659288406372
Smith I-Disease 1 0.9865889549255371
syndrome I-Disease 1 0.9998038411140442
( O 0 3.3133815691144264e-07
MIM O 0 0.0008098534890450537
153480 O 0 3.0049461201997474e-05
) O 0 8.758382108453588e-08
. O 0 1.1463800575484129e-07

Constitutive O 0 2.8416681743692607e-05
DNA O 0 1.0278137779096141e-05
from O 0 6.040012578978349e-08
37 O 0 7.545229863126224e-08
CD B-Disease 0 4.221238668833394e-06
families O 0 1.0732200905749778e-07
and O 0 1.9185343091976392e-08
seven O 0 1.436932262066648e-08
BZS B-Disease 0 2.3467824576073326e-05
families O 0 2.694618039811303e-08
was O 0 1.1746920591804155e-07
screened O 0 4.3346514644326817e-07
for O 0 4.16093932642525e-08
germline O 0 0.0002639885642565787
PTEN O 0 0.0014108313480392098
mutations O 0 1.3687645150639582e-05
. O 0 1.2795775319318636e-06

PTEN O 0 0.002154945395886898
mutations O 0 2.3555805455544032e-05
were O 0 1.5027409290269134e-06
identified O 0 5.725893288399675e-07
in O 0 5.363241406541874e-09
30 O 0 6.631731608308655e-09
of O 0 7.681634217604483e-10
37 O 0 4.56889601707644e-08
( O 0 1.635873991823189e-09
81 O 0 3.828436589969897e-08
% O 0 8.201642698324463e-10
) O 0 7.666528523131433e-10
CD B-Disease 0 4.506297955231275e-06
families O 0 3.5205697912488176e-08
, O 0 2.296538514912072e-09
including O 0 2.8870112966927763e-09
missense O 0 2.2280959456111304e-05
and O 0 4.700443128058396e-07
nonsense O 0 5.808285277453251e-05
point O 0 1.1924722684852895e-06
mutations O 0 4.712480858870549e-07
, O 0 1.9979671250780484e-09
deletions O 0 8.805265139244511e-08
, O 0 9.265788136758601e-09
insertions O 0 1.0713972642406588e-06
, O 0 1.8994112949144437e-08
a O 0 4.6340346671058796e-08
deletion O 0 2.431035682093352e-06
/ O 0 9.690494152891915e-06
insertion O 0 1.195252707475447e-06
and O 0 3.5950642995885573e-07
splice O 0 0.0004903617082163692
site O 0 0.0006670570001006126
mutations O 0 2.540920104365796e-05
. O 0 1.1185438779648393e-06

These O 0 1.665139421902495e-07
mutations O 0 5.685252517650952e-07
were O 0 6.723191603441592e-08
scattered O 0 9.358307124784915e-07
over O 0 1.1201221639112191e-07
the O 0 5.822231585739246e-09
entire O 0 9.175274584549697e-08
length O 0 6.56208896998578e-07
of O 0 1.7854553391316585e-08
PTEN O 0 0.0002997094707097858
, O 0 7.391083300944956e-08
with O 0 1.1547395040167885e-08
the O 0 4.776165241082708e-09
exception O 0 1.5546131493238136e-08
of O 0 9.556302416058315e-10
the O 0 6.748666070421905e-09
first O 0 9.879087059516678e-08
, O 0 6.401111107834367e-08
fourth O 0 5.722601486013446e-07
and O 0 1.3535421317101282e-07
last O 0 3.2198053645515756e-07
exons O 0 2.854189460776979e-06
. O 0 3.3940887078642845e-07

A O 0 4.524642918113386e-06
hot O 0 2.132352710759733e-05
spot O 0 4.46505600848468e-06
for O 0 1.6084683807093825e-08
PTEN O 0 7.191120675997809e-05
mutation O 0 2.019028926270039e-07
in O 0 6.881180958373534e-09
CD B-Disease 0 1.1060736142098904e-05
was O 0 3.3903099392773584e-05
identified O 0 3.613708656757808e-07
in O 0 3.237965007230059e-09
exon O 0 1.4400481518350716e-07
5 O 0 4.861838931446982e-08
that O 0 4.60256766032785e-09
contains O 0 2.0064080175075105e-08
the O 0 3.4774556567640502e-09
PTPase O 0 7.5711445788329e-06
core O 0 1.6454965816592448e-06
motif O 0 2.823688305397809e-07
, O 0 1.5555376986498004e-09
with O 0 5.641547784485113e-10
13 O 0 4.1597372768542584e-10
of O 0 1.2448128638986589e-10
30 O 0 1.3433234080650891e-08
( O 0 3.0268301753899607e-10
43 O 0 9.966179881359949e-09
% O 0 1.5909628059418424e-09
) O 0 1.0446693510246519e-09
CD B-Disease 0 1.2940164424435352e-06
mutations O 0 5.007581762583868e-07
identified O 0 3.243839614697208e-07
in O 0 3.0203726186783797e-09
this O 0 1.3312968505374556e-08
exon O 0 7.126422133296728e-06
. O 0 8.519731977685296e-07

Seven O 0 3.2479070455337933e-07
of O 0 6.313442213468079e-09
30 O 0 3.9451304445492497e-08
( O 0 2.85040657743707e-09
23 O 0 1.3559318112754681e-08
% O 0 1.3265031295617291e-09
) O 0 1.2615882782895937e-09
were O 0 2.2206199545848904e-08
within O 0 1.616689004890759e-09
the O 0 1.3254307651422437e-09
core O 0 7.245731922012055e-06
motif O 0 1.8040384475170868e-06
, O 0 7.448367256301935e-09
the O 0 2.223025985514937e-09
majority O 0 6.877192149090661e-09
( O 0 3.513716817504786e-10
five O 0 7.186859996011208e-10
of O 0 3.145353144606844e-10
seven O 0 2.0094708119700044e-09
) O 0 1.8250492783700167e-10
of O 0 1.0348086276756874e-10
which O 0 3.82338676274685e-08
were O 0 4.61272520624334e-07
missense O 0 8.563478331780061e-06
mutations O 0 1.3224446604453988e-07
, O 0 5.360152766087367e-09
possibly O 0 1.3037622181855113e-07
pointing O 0 3.968302735302132e-06
to O 0 7.897472897866464e-09
the O 0 1.8795460743348258e-09
functional O 0 9.633318853730088e-08
significance O 0 1.1601792415660839e-08
of O 0 1.2876492094804348e-09
this O 0 1.4884897758804527e-08
region O 0 7.627853619851521e-07
. O 0 1.5817570897525002e-07

Germline O 0 0.0016031938139349222
PTEN O 0 0.002235976979136467
mutations O 0 2.244029747089371e-05
were O 0 1.6338032082785503e-06
identified O 0 1.9987551240774337e-06
in O 0 7.002674440315104e-09
four O 0 6.500771032591501e-09
of O 0 1.3764225315071599e-09
seven O 0 1.5518638818434738e-08
( O 0 6.664522711474774e-09
57 O 0 3.7167120581216295e-07
% O 0 1.2775854152380361e-08
) O 0 7.094915321914641e-09
BZS B-Disease 0 8.167450687324163e-06
families O 0 2.0101465381117123e-08
studied O 0 2.7201335228710377e-07
. O 0 2.722482008721272e-07

Interestingly O 0 3.7244630220811814e-05
, O 0 1.3929911801824346e-07
none O 0 1.1280287814940948e-08
of O 0 3.084116295681838e-10
these O 0 1.536248461775358e-09
mutations O 0 1.1914851683059169e-07
was O 0 7.308779004233656e-07
observed O 0 9.008306278701639e-07
in O 0 1.635366331242949e-08
the O 0 3.8047634376425776e-08
PTPase O 0 4.5372718886937946e-05
core O 0 4.929705937684048e-06
motif O 0 8.8645210780669e-06
. O 0 3.081197803567193e-07

It O 0 9.455264944335795e-07
is O 0 2.2014430101080507e-07
also O 0 1.0960811813731652e-08
worthy O 0 2.135142196380002e-08
of O 0 1.0595226918042044e-09
note O 0 5.62174591323128e-07
that O 0 1.7110011185650364e-08
a O 0 9.930568012350705e-08
single O 0 1.744183919072384e-06
nonsense O 0 5.057748421677388e-05
point O 0 4.877238666267658e-07
mutation O 0 3.347678045884095e-08
, O 0 2.328218728919751e-09
R233X O 0 1.3197207238135888e-07
, O 0 8.956829944395395e-09
was O 0 3.4794817338479334e-07
observed O 0 1.6133022029407584e-07
in O 0 5.097708033474646e-09
the O 0 1.979468144952534e-09
germline O 0 4.4445559410632995e-07
DNA O 0 4.551231143068435e-07
from O 0 2.1563986152273174e-09
two O 0 2.3042738828138454e-09
unrelated O 0 1.644089593355602e-07
CD B-Disease 0 2.436702561681159e-05
families O 0 1.5750406134884543e-07
and O 0 1.2714818353742885e-07
one O 0 2.383905410852094e-07
BZS B-Disease 0 0.00013771136582363397
family O 0 1.3708082633456797e-06
. O 0 3.4814962646123604e-07

Genotype O 0 0.001564531004987657
- O 0 0.0003361811104696244
phenotype O 0 4.198698661639355e-06
studies O 0 2.2654589315607154e-08
were O 0 4.6583160440150095e-08
not O 0 5.6534856796019994e-09
performed O 0 6.158636267628026e-08
on O 0 4.083737437099444e-08
this O 0 2.158398348939272e-09
small O 0 8.34771540780821e-08
group O 0 3.4301393725399976e-08
of O 0 1.317846187731675e-08
BZS B-Disease 0 0.0001485328102717176
families O 0 2.5879666054606787e-07
. O 0 1.7021935150296486e-07

However O 0 1.5810556988071767e-06
, O 0 7.283021119519617e-08
genotype O 0 8.604361028119456e-06
- O 0 3.961130641982891e-05
phenotype O 0 5.761008878835128e-07
analysis O 0 2.3315259056744253e-08
inthe O 0 1.515775352345372e-06
group O 0 1.1358729068433604e-07
of O 0 1.747744171609611e-09
CD B-Disease 0 7.686969911446795e-05
families O 0 3.5265418318886077e-07
revealed O 0 7.087397762006731e-07
two O 0 7.003342350486719e-09
possible O 0 1.4983375251631514e-07
associations O 0 5.370631939172199e-09
worthy O 0 2.2682044686916925e-08
of O 0 7.8547746085178e-10
follow O 0 4.889216498327187e-08
- O 0 1.8643726434675045e-05
up O 0 1.0010305828700439e-07
in O 0 3.1743017103735838e-09
independent O 0 3.054823594084155e-08
analyses O 0 1.6065604313553195e-06
. O 0 2.6720124424173264e-07

The O 0 2.7178049322174047e-07
first O 0 9.584257298911325e-08
was O 0 3.7495474316529e-06
an O 0 2.2999630644449098e-08
association O 0 6.501405636072377e-08
noted O 0 3.2741425570748106e-07
in O 0 3.9624281633621194e-09
the O 0 2.5566477823701916e-09
group O 0 3.0494852865103894e-08
of O 0 4.555473498424334e-10
CD B-Disease 0 8.353753219125792e-05
families O 0 3.222533280222706e-07
with O 0 9.838347068580333e-06
breast B-Disease 1 0.9998016953468323
disease I-Disease 0 0.08250647783279419
. O 0 1.5514575579800294e-06

A O 0 2.3177206003310857e-06
correlation O 0 3.0934390906622866e-06
was O 0 9.65527988228132e-07
observed O 0 1.5908808848053013e-07
between O 0 7.684128888740815e-09
the O 0 3.9474916668780224e-09
presence O 0 1.4605247145027533e-07
/ O 0 2.0813001810893184e-06
absence O 0 1.789956272091331e-08
of O 0 8.107544080537821e-10
a O 0 1.2242462616995908e-06
PTEN O 0 0.0004876976599916816
mutation O 0 2.492091084604908e-07
and O 0 2.0663112110241855e-08
the O 0 2.1002752870202812e-09
type O 0 2.5874882339849137e-05
of O 0 1.1746170258675193e-07
breast O 0 0.019273415207862854
involvement O 0 1.4148309674055781e-05
( O 0 1.1851197001533365e-07
unaffected O 0 3.0928829801268876e-05
versus O 0 5.7304474466945976e-05
benign O 0 0.032930079847574234
versus O 0 0.0009177247993648052
malignant O 1 0.9188792109489441
) O 0 4.2874907535406237e-07
. O 0 4.3873657773474406e-07

Specifically O 0 4.08628466175287e-06
and O 0 6.415974951323733e-08
more O 0 3.805110004861945e-09
directly O 0 3.191343722619422e-08
, O 0 1.735719301620975e-08
an O 0 7.988630201793967e-09
association O 0 8.512749616329529e-08
was O 0 7.425677267747233e-06
also O 0 6.679758257632784e-08
observed O 0 3.6083537224840256e-07
between O 0 5.323077090224615e-09
the O 0 1.2369675284062964e-09
presence O 0 1.5508252459994765e-08
of O 0 5.232447808367624e-10
a O 0 2.7158202442478796e-07
PTEN O 0 0.007466386537998915
mutation O 0 1.142061228165403e-05
and O 0 0.00022203325352165848
malignant B-Disease 1 0.9999951124191284
breast I-Disease 1 0.9999207258224487
disease I-Disease 0 0.15781691670417786
. O 0 2.522958766348893e-06

Secondly O 0 0.0005850183661095798
, O 0 3.576325013909809e-07
there O 0 4.2259571841896104e-08
appeared O 0 2.671961567557446e-07
to O 0 9.51894207901205e-09
be O 0 9.435649417355307e-08
an O 0 1.4469430986707721e-08
interdependent O 0 2.5085466404561885e-05
association O 0 3.015550120721855e-08
between O 0 2.0383151166925018e-08
mutations O 0 5.544520149669552e-07
upstream O 0 1.7685310922388453e-06
and O 0 8.793349337565814e-08
within O 0 2.903722373659434e-09
the O 0 3.897560496568531e-09
PTPase O 0 1.3935128663433716e-05
core O 0 1.051072194968583e-05
motif O 0 1.3702280057259486e-06
, O 0 5.491285204328733e-09
the O 0 5.526935575872471e-10
core O 0 2.3760346721246606e-06
motif O 0 2.3047306285661762e-07
containing O 0 2.155593570307701e-08
the O 0 1.140032734880947e-09
majority O 0 1.2451102371358047e-09
of O 0 8.873352608240737e-10
missense O 0 6.569254765054211e-06
mutations O 0 3.2621309742353333e-07
, O 0 2.7943860558821143e-08
and O 0 5.376046274818691e-08
the O 0 2.7105448996422865e-09
involvement O 0 1.1126270038630537e-07
of O 0 1.1577735437029446e-09
all O 0 1.039196728669367e-08
major O 0 3.7042173062218353e-07
organ O 0 0.00013009012036491185
systems O 0 3.0388502636924386e-05
( O 0 4.644925333252559e-09
central O 0 4.0252899680126575e-08
nervous O 0 1.7815250430430751e-06
system O 0 2.212229901488172e-06
, O 0 8.586626449869073e-07
thyroid O 1 0.7555819153785706
, O 0 7.421199370583054e-07
breast O 0 0.10624007880687714
, O 0 6.0890511122124735e-06
skin O 1 0.9963802695274353
and O 1 0.6257455945014954
gastrointestinal O 1 0.9999583959579468
tract O 1 0.9998421669006348
) O 0 3.318360313642188e-06
. O 0 1.8323954691368272e-06

However O 0 1.042895860337012e-06
, O 0 9.216611474016645e-09
these O 0 1.8963181025455356e-10
observations O 0 1.361862000948122e-08
would O 0 9.597149741580324e-09
need O 0 2.5432245198686587e-09
to O 0 1.1091532137186277e-09
be O 0 1.897843304732305e-08
confirmed O 0 9.355647812014922e-09
by O 0 1.7100174054540673e-10
studying O 0 7.105813715213571e-10
a O 0 6.215585379720778e-09
larger O 0 4.475406711890173e-09
number O 0 1.7636941906928882e-09
of O 0 1.2321450526542321e-09
CD B-Disease 0 4.659359183278866e-05
families O 0 2.662908116235485e-07
. O 0 2.954138835775666e-07

Molecular O 0 0.2714378833770752
defects O 1 0.9996289014816284
leading O 0 2.677389829841559e-06
to O 0 3.04410399110111e-08
human O 0 1.5387425378321495e-07
complement B-Disease 0 4.7300945880124345e-05
component I-Disease 1 0.9953216910362244
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
in O 0 1.3799422049487475e-07
an O 0 1.8447266825205588e-08
African O 0 4.155680954909258e-08
- O 0 3.667722558020614e-05
American O 0 1.3210907923166815e-07
family O 0 6.582744845218258e-06
. O 0 6.439772164412716e-07

Complement B-Disease 0 0.0020551192574203014
component I-Disease 1 0.9979440569877625
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999997615814209
( O 0 5.098099791212007e-07
C6D B-Disease 0 0.0014636918203905225
) O 0 1.3716382341044664e-07
was O 0 0.000629037560429424
diagnosed O 0 0.00015312607865780592
in O 0 7.806357338324688e-09
a O 0 1.8677150137591525e-07
16 O 0 3.695364014788538e-08
- O 0 8.54495920066256e-06
year O 0 2.0405389022926101e-07
- O 0 6.998486787779257e-05
old O 0 2.0272540496080182e-05
African O 0 1.7380216377205215e-08
- O 0 3.1785916689841542e-06
American O 0 6.866682866757401e-08
male O 0 1.3674656429429888e-06
with O 0 1.8965438357554376e-05
meningococcal B-Disease 1 0.9999994039535522
meningitis I-Disease 1 0.9999940395355225
. O 0 8.245903700299095e-06

The O 0 7.790822564857081e-07
patients O 0 2.8312324502621777e-06
father O 0 1.945438043549075e-06
and O 0 6.859221457489184e-08
two O 0 2.7788395584593673e-08
brothers O 0 2.683491948118899e-05
also O 0 3.5232977779742214e-07
had O 0 1.477119667470106e-06
C6D B-Disease 0 7.580247620353475e-05
, O 0 8.275723217820996e-09
but O 0 1.3587588831853736e-08
gave O 0 7.953707026331358e-09
no O 0 2.2107562003270687e-08
history O 0 1.3339530369194108e-08
of O 0 3.1086469221008883e-07
meningitis B-Disease 1 0.9999960660934448
or O 0 8.904809192245011e-07
other O 0 5.1107562626384606e-08
neisserial B-Disease 0 0.037258148193359375
infection I-Disease 0 0.00021925401233602315
. O 0 5.277184982332983e-07

By O 0 1.0158911578628249e-07
using O 0 4.7537554337395704e-08
exon O 0 1.012086727314454e-06
- O 0 9.119613423536066e-06
specific O 0 6.102253991002726e-08
polymerase O 0 2.7111516828881577e-05
chain O 0 7.600391109008342e-05
reaction O 0 1.268645206664587e-07
( O 0 1.069243027451705e-09
PCR O 0 1.714193160751165e-07
) O 0 1.95005456227193e-09
/ O 0 1.3561870559897216e-07
single O 0 9.892248442611162e-08
- O 0 8.299923138110898e-06
strand O 0 5.42342422704678e-06
conformation O 0 1.8301305715340277e-07
polymorphism O 0 2.880962597373582e-07
as O 0 2.6270299269270936e-09
a O 0 2.187033665279614e-09
screening O 0 1.66121445488443e-08
step O 0 2.9449763516709027e-08
and O 0 8.265244044736164e-10
nucleotide O 0 3.116832125726887e-09
sequencing O 0 2.126289588844088e-09
of O 0 6.20773932258345e-10
target O 0 1.6230241328685224e-07
exons O 0 4.280781595866756e-08
, O 0 2.6029391975157523e-09
we O 0 3.3550400235782263e-09
determined O 0 2.4977104828849406e-08
that O 0 4.745769333069916e-10
the O 0 1.121433723660914e-09
proband O 0 5.516100372915389e-06
was O 0 9.32550392462872e-07
a O 0 5.2435829900332465e-08
compound O 0 8.236450526055705e-07
heterozygote O 0 3.591993333884602e-07
for O 0 4.439605127970481e-09
two O 0 2.5343062759475288e-08
C6 O 0 0.0011614757822826505
gene O 0 3.739484100151458e-06
mutations O 0 6.7018249865213875e-06
. O 0 1.3027286058786558e-06

The O 0 1.7372136085214152e-07
first O 0 2.6548766740575047e-08
, O 0 5.540416569971285e-09
1195delC O 0 2.1751667134140007e-07
located O 0 5.445385227176303e-07
in O 0 2.3213544420030985e-09
exon O 0 1.9998770994789083e-07
7 O 0 5.629900670101051e-07
, O 0 2.144709476681328e-08
is O 0 3.784100854886674e-08
a O 0 4.856482149762087e-08
novel O 0 1.2946048855155823e-07
mutation O 0 9.106250331569754e-08
, O 0 8.933966455515474e-09
while O 0 8.273575602402161e-09
the O 0 1.3079217708877877e-09
second O 0 1.241418061681543e-07
, O 0 4.6901234007634685e-09
1936delG O 0 5.6518711488706685e-08
in O 0 1.0336098643648484e-09
exon O 0 7.301798632397549e-08
12 O 0 4.26928465913079e-08
, O 0 2.1264042970869923e-08
has O 0 1.659334287751335e-07
been O 0 6.273018016145215e-08
described O 0 2.33066643318125e-07
before O 0 1.2436037977181513e-08
to O 0 1.5337137782012178e-08
cause O 0 2.924757893651986e-07
C6D B-Disease 0 3.984119030064903e-05
in O 0 7.401773416404467e-09
an O 0 6.9982011297042845e-09
unrelated O 0 2.1810453176840383e-07
African O 0 3.900878908780214e-08
- O 0 1.1972665561188478e-05
American O 0 5.267560609922839e-08
individual O 0 3.4942452487030096e-08
. O 0 1.7290798837166221e-07

Both O 0 8.310650514431472e-07
mutations O 0 2.9287789402587805e-06
result O 0 1.018924251638964e-07
in O 0 2.9046544725019885e-08
premature O 0 1.1541686944838148e-05
termination O 0 1.1891679605469108e-05
codons O 0 3.662105882540345e-06
and O 0 4.1076975776377367e-07
C6 O 0 0.005528166424483061
null O 0 0.0002520874550100416
alleles O 0 3.812151362581062e-06
. O 0 1.7574076309756492e-06

Allele O 0 1.939469439093955e-05
- O 0 8.385522960452363e-06
specific O 0 6.380584238740994e-08
PCR O 0 4.618355887942016e-06
indicated O 0 6.239641265892715e-07
that O 0 1.5302126232796809e-09
the O 0 7.80577269487992e-10
probands O 0 2.2439482563640922e-05
two O 0 1.3010483712605492e-07
brothers O 0 6.1619452026207e-05
also O 0 4.466029679406347e-07
inherited O 0 4.011007149529178e-06
the O 0 5.825119497870901e-09
1195delC O 0 4.889775482297409e-06
mutation O 0 1.1501021646154186e-07
from O 0 4.234749884091116e-09
their O 0 7.867764217905915e-09
heterozygous O 0 1.1519279041749542e-06
mother O 0 1.2919453183712903e-05
and O 0 2.766865847547706e-08
the O 0 4.723060609279628e-09
1936delG O 0 1.2539298950287048e-06
mutation O 0 3.648913704523693e-08
from O 0 3.4107745516820387e-09
their O 0 3.265776760130734e-09
homozygous O 0 7.248789870573091e-07
father O 0 9.779496394912712e-07
. O 0 1.7789693274039564e-08
. O 0 3.028745254596288e-07

PAX6 O 0 0.023957351222634315
mutations O 0 0.0004606212314683944
reviewed O 0 5.588918429566547e-05
. O 0 4.312129021855071e-06

Mutations O 0 5.152125595486723e-05
in O 0 1.598231875732381e-07
PAX6 O 0 0.00017083172861021012
are O 0 7.30988105601682e-08
responsible O 0 2.3390008152546216e-07
for O 0 1.9769672121583426e-08
human O 0 8.931565957936982e-07
aniridia B-Disease 1 0.9999985694885254
and O 0 1.8065054518956458e-06
have O 0 1.1881321881901385e-07
also O 0 4.927732177861799e-08
been O 0 1.0550227358407938e-07
found O 0 9.0702990007685e-08
in O 0 2.985265368238288e-08
patients O 0 9.589157912159862e-08
with O 0 2.7794737889053067e-07
Peters B-Disease 1 0.9999988079071045
anomaly I-Disease 1 0.9999996423721313
, O 0 0.00014672591350972652
with O 0 0.19367064535617828
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.999987006187439
, O 0 1.377441094518872e-05
with O 0 1.5911002265056595e-05
autosomal B-Disease 1 0.9468241333961487
dominant I-Disease 0 0.1814699023962021
keratitis I-Disease 1 0.981106162071228
, O 0 3.266406793045462e-06
and O 0 1.1304647387078148e-06
with O 0 1.250237528438447e-05
isolated B-Disease 1 0.9995610117912292
foveal I-Disease 1 0.9999990463256836
hypoplasia I-Disease 1 0.9999991655349731
. O 0 4.916550824418664e-05

No O 0 4.668964720622171e-06
locus O 0 2.4479907096974785e-06
other O 0 1.67172284903927e-08
than O 0 1.1324156723446777e-08
chromosome O 0 3.896476755471667e-06
11p13 O 0 1.2149624126323033e-05
has O 0 2.627199648941314e-07
been O 0 9.058455674448851e-08
implicated O 0 2.573136498540407e-06
in O 0 2.3328433940150717e-07
aniridia B-Disease 1 0.9999997615814209
, O 0 9.545468628857634e-07
and O 0 1.1261868593237523e-07
PAX6 O 0 9.330292232334614e-05
is O 0 3.5753430438489886e-07
clearly O 0 2.2501073715375242e-07
the O 0 8.87580675623667e-10
major O 0 4.654461704944879e-08
, O 0 1.7925392725715028e-08
if O 0 7.283601277663365e-09
not O 0 3.611783760959497e-09
only O 0 5.563095539784513e-10
, O 0 1.1164332791580023e-09
gene O 0 3.5293165723260245e-08
responsible O 0 6.823102580710838e-07
. O 0 3.570592923551885e-07

Twenty O 0 2.0030447558383457e-06
- O 0 1.4863052456348669e-05
eight O 0 4.607734638284455e-08
percent O 0 1.1588582538024639e-07
of O 0 4.196124336885987e-09
identified O 0 1.5628207847839803e-06
PAX6 O 0 4.892427386948839e-05
mutations O 0 5.174828743292892e-07
are O 0 7.339694718666578e-08
C O 0 0.002329694340005517
- O 0 0.0032282655593007803
T O 0 0.00016523079830221832
changes O 0 7.0231664928144255e-09
at O 0 2.9342110963170853e-08
CpG O 0 1.9424585389060667e-06
dinucleotides O 0 3.2965240279736463e-06
, O 0 3.324717612329664e-09
20 O 0 7.498424658969327e-10
% O 0 1.7193807488879997e-10
are O 0 3.34819810765552e-10
splicing O 0 4.4243911645480694e-08
errors O 0 2.178040631406475e-06
, O 0 1.3663839837363412e-08
and O 0 1.1902411500841481e-08
more O 0 6.951860753723338e-10
than O 0 3.4808067539415788e-09
30 O 0 2.1107124936747823e-09
% O 0 8.085677127844804e-10
are O 0 1.6564678517738685e-09
deletion O 0 6.019702425419382e-08
or O 0 4.4837996426849713e-08
insertion O 0 3.503943446503399e-07
events O 0 2.0987211257761373e-07
. O 0 3.2480062372997054e-07

There O 0 1.1316815289319493e-06
is O 0 3.903409862004992e-08
a O 0 1.649381253798765e-08
noticeably O 0 3.270851721026702e-06
elevated O 0 1.4458485566137824e-05
level O 0 1.3392791231581214e-07
of O 0 9.37003696854788e-10
mutation O 0 1.1200153693380344e-07
in O 0 5.328745888988351e-09
the O 0 3.864066400183219e-09
paired O 0 6.370211735884368e-08
domain O 0 1.8395615697386347e-08
compared O 0 2.7935686830460327e-07
with O 0 6.245103989499512e-09
the O 0 2.1549595441427982e-09
rest O 0 1.135892002679384e-08
of O 0 8.022049691192024e-10
the O 0 6.5573324548040546e-09
gene O 0 1.655107979559034e-07
. O 0 1.9300337328331807e-07

Increased O 0 2.5680226372060133e-06
mutation O 0 8.162695621649618e-07
in O 0 1.688018613776876e-08
the O 0 2.9788480571113496e-09
homeodomain O 0 2.3722830064798472e-06
is O 0 6.04375784973854e-08
accounted O 0 5.633713726638234e-07
for O 0 1.6574254191326077e-09
by O 0 3.802744785730283e-09
the O 0 1.3015715616404577e-08
hypermutable O 0 0.00021427863975986838
CpG O 0 0.00020093901548534632
dinucleotide O 0 4.4307776079222094e-06
in O 0 7.714719529872127e-09
codon O 0 7.421220971082221e-07
240 O 0 3.23378856137424e-07
. O 0 2.887310870391957e-07

Very O 0 2.3448394586012e-06
nearly O 0 6.247512374102371e-08
all O 0 3.0088900260238916e-09
mutations O 0 1.560704276926117e-07
appear O 0 7.084681641345014e-08
to O 0 3.6286891713643854e-08
cause O 0 4.42093869423843e-06
loss O 0 1.1539489150891313e-06
of O 0 3.900133105361192e-09
function O 0 8.800143547205153e-08
of O 0 7.079514752206251e-10
the O 0 1.3341661109222969e-09
mutant O 0 1.491232666239739e-07
allele O 0 4.702236466869181e-08
, O 0 2.6154107768405765e-09
and O 0 1.2566506724098758e-09
more O 0 3.231299949835176e-10
than O 0 1.3991703351479146e-09
80 O 0 1.8331195450471682e-09
% O 0 3.3715374936349463e-10
of O 0 5.435408234610861e-10
exonic O 0 8.456708201265428e-06
substitutions O 0 1.5977853706772294e-07
result O 0 4.164440881027076e-08
in O 0 1.8484213271108274e-08
nonsense O 0 2.2616850401391275e-05
codons O 0 2.7695643893821398e-06
. O 0 2.687566222903115e-07

In O 0 4.421991377512313e-07
a O 0 1.7640458338519238e-07
gene O 0 2.6462120672476885e-07
with O 0 8.863225708921618e-09
such O 0 2.421741562841362e-08
extraordinarily O 0 5.3691972425440326e-05
high O 0 1.4917844737283303e-06
sequence O 0 1.389954551456185e-08
conservation O 0 3.4816698413209224e-09
throughout O 0 2.9916635835292027e-10
evolution O 0 2.482879901677393e-09
, O 0 6.009409858620529e-09
there O 0 1.2077032707225044e-08
are O 0 2.27232241911679e-08
presumed O 0 4.8920096560323145e-06
undiscovered O 0 1.1499179890961386e-05
missense O 0 1.3773083992418833e-05
mutations O 0 5.487822249961027e-07
, O 0 1.1967653534838973e-08
these O 0 1.7362812299026587e-09
are O 0 3.5305403045526873e-09
hypothesized O 0 5.095571964375267e-08
to O 0 8.953619179408179e-09
exist O 0 5.476268327697653e-08
in O 0 6.351234649315529e-09
as O 0 1.3064543225027592e-07
- O 0 0.0003512436815071851
yet O 0 1.16636510938406e-06
unidentified O 0 1.751407808114891e-06
phenotypes O 0 1.2077163091817056e-07
. O 0 4.8672554875395235e-09
. O 0 9.750108631578769e-08

Genetic O 0 0.00012153261195635423
heterogeneity O 0 2.6676187189877965e-05
and O 0 6.245165877771797e-07
penetrance O 0 1.043339307216229e-05
analysis O 0 6.65657182707946e-08
of O 0 3.807418824663955e-09
the O 0 6.791060513933189e-08
BRCA1 O 0 0.00016358570428565145
and O 0 1.1833550388473668e-06
BRCA2 O 0 1.7290141840931028e-05
genes O 0 5.554798576667963e-07
in O 0 6.036050308466656e-06
breast B-Disease 1 0.9996789693832397
cancer I-Disease 0 0.05758603289723396
families O 0 7.742198704363545e-07
. O 0 7.042189054118353e-07

The O 0 0.00018941682355944067
Breast B-Disease 1 0.9999991655349731
Cancer I-Disease 1 0.9999692440032959
Linkage O 0 0.0065610650926828384
Consortium O 0 3.6434732464840636e-05
. O 0 7.556131436103897e-07

The O 0 8.155740971460546e-08
contribution O 0 7.286911340997904e-08
of O 0 1.304559038572961e-08
BRCA1 O 0 5.361895455280319e-05
and O 0 2.245546511403518e-06
BRCA2 O 0 0.012457283213734627
to O 0 0.004937880206853151
inherited B-Disease 1 1.0
breast I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999995231628418
was O 0 0.002749623265117407
assessed O 0 1.6291995052597485e-05
by O 0 2.127450926536767e-08
linkage O 0 0.0002935902448371053
and O 0 2.3462436615773186e-07
mutation O 0 1.405314620228637e-08
analysis O 0 9.336716288999014e-09
in O 0 2.539133792112125e-09
237 O 0 1.1502424968057312e-07
families O 0 3.4297340079092464e-08
, O 0 3.036818574386757e-09
each O 0 5.033224947936787e-10
with O 0 1.1219392526129468e-08
at O 0 9.624914127925877e-07
least O 0 6.088300530393553e-09
four O 0 2.397720466618125e-09
cases O 0 1.1991736492689142e-08
of O 0 1.712353423499735e-07
breast B-Disease 1 0.987291157245636
cancer I-Disease 0 5.5877349950606003e-05
, O 0 3.74798947433419e-09
collected O 0 6.280773234834669e-09
by O 0 5.1914962995169844e-08
the O 0 0.00015952250396367162
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999791383743286
Linkage O 0 0.0006569079705514014
Consortium O 0 8.142363185470458e-06
. O 0 5.054052394370956e-07

Families O 0 4.578187144943513e-06
were O 0 1.7304937216522376e-07
included O 0 1.0596445498833873e-08
without O 0 2.6068744940488386e-09
regard O 0 7.988934846991924e-09
to O 0 7.439872606873621e-10
the O 0 9.949346901905187e-10
occurrence O 0 2.544177732488606e-06
of O 0 3.6334267861093394e-07
ovarian B-Disease 1 0.8900830149650574
or I-Disease 0 1.9998267362097977e-06
other I-Disease 0 1.5177498369212117e-07
cancers I-Disease 0 0.007210330571979284
. O 0 7.299061621779401e-07

Overall O 0 0.0001822251215344295
, O 0 3.3006177545757964e-05
disease O 0 0.0010901358909904957
was O 0 1.1696526598825585e-05
linked O 0 0.002915109507739544
to O 0 2.1436710540001513e-07
BRCA1 O 0 2.147753184544854e-05
in O 0 1.406277227999908e-08
an O 0 5.632325716931064e-09
estimated O 0 1.4688302485410532e-07
52 O 0 7.170668681055758e-08
% O 0 8.279160135238328e-10
of O 0 8.54874948608142e-10
families O 0 7.073474961316606e-08
, O 0 7.4084116619133056e-09
to O 0 1.8690830216883114e-08
BRCA2 O 0 4.825549808629148e-07
in O 0 3.1558347046711788e-09
32 O 0 1.5655276186521405e-08
% O 0 1.1823978462999207e-09
of O 0 1.230221813308674e-09
families O 0 1.6208647934945475e-07
, O 0 3.831344130844627e-08
and O 0 1.7375210603631785e-08
to O 0 1.0093433644442484e-08
neither O 0 2.591581704791679e-08
gene O 0 3.153067140715393e-09
in O 0 8.554654207237888e-10
16 O 0 4.2586525417220855e-09
% O 0 8.04191935266374e-10
( O 0 4.143314580318247e-10
95 O 0 1.8930242262626962e-08
% O 0 4.627108030064164e-09
confidence O 0 2.0449708415526402e-07
interval O 0 8.427061857219087e-07
[ O 0 3.4244595781274256e-07
CI O 0 4.6654418838443235e-05
] O 0 3.021088446075737e-08
6 O 0 4.469844938626011e-09
% O 0 1.7246302164153349e-09
- O 0 1.9204295313102193e-05
28 O 0 2.418605333787127e-07
% O 0 1.9187089694838733e-09
) O 0 1.3871755966121668e-09
, O 0 1.990678955010594e-09
suggesting O 0 5.794427693217585e-08
other O 0 1.0764711788624481e-08
predisposition O 0 5.6420725741190836e-05
genes O 0 1.0212000915998942e-06
. O 0 8.414991157223994e-07

The O 0 2.438014234940056e-07
majority O 0 6.293463172823976e-08
( O 0 5.3758584250829244e-09
81 O 0 4.6640860063007494e-08
% O 0 1.565496843269898e-09
) O 0 3.5117672658735444e-10
of O 0 1.1885594730642879e-09
the O 0 8.305616574943997e-06
breast B-Disease 1 0.9999964237213135
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
families O 0 1.8772939824884816e-07
were O 0 7.755825208732858e-07
due O 0 2.9674237111976254e-07
to O 0 9.017617230711039e-08
BRCA1 O 0 2.4104978365357965e-05
, O 0 3.30756577682223e-08
with O 0 1.8961175740628278e-08
most O 0 4.2829459090398814e-08
others O 0 3.574203688572197e-08
( O 0 1.2247947100973988e-09
14 O 0 5.1133275391634925e-09
% O 0 2.6552449128303124e-09
) O 0 1.8306423044123221e-09
due O 0 4.71858783157586e-08
to O 0 2.1939102623491635e-07
BRCA2 O 0 3.059250593651086e-05
. O 0 3.7800654695274716e-07

Conversely O 0 4.2256844608346e-05
, O 0 8.829331221704706e-08
the O 0 2.685729638685075e-09
majority O 0 8.829108111285677e-09
of O 0 1.2831308238148154e-09
families O 0 4.205196191264804e-08
with O 0 7.896918674532571e-08
male B-Disease 0 1.5538191291852854e-05
and I-Disease 0 5.9161189710721374e-05
female I-Disease 0 0.028062546625733376
breast I-Disease 1 0.9617339372634888
cancer I-Disease 0 5.211839743424207e-05
were O 0 2.0915940979193692e-07
due O 0 2.654021784564975e-07
to O 0 2.3565004880765628e-07
BRCA2 O 0 1.1381362128304318e-05
( O 0 7.238949883969781e-09
76 O 0 4.337318557645631e-07
% O 0 2.184883562961204e-08
) O 0 4.1587178145618964e-08
. O 0 2.654533091117628e-07

The O 0 3.688885499286698e-07
largest O 0 6.125296749814879e-07
proportion O 0 1.1139605504695282e-07
( O 0 2.0009265355724892e-09
67 O 0 9.678792878275999e-08
% O 0 1.3467501558395156e-09
) O 0 4.3513673220196836e-10
of O 0 6.486796100269032e-10
families O 0 1.0317352305833083e-08
due O 0 2.240124885588557e-08
to O 0 7.958957937148625e-09
other O 0 2.7561666282593933e-09
genes O 0 3.446304575049908e-08
was O 0 4.129203261982184e-06
found O 0 4.092627818863548e-07
in O 0 1.918256131716589e-08
families O 0 3.2696174656621224e-08
with O 0 1.0235773117983626e-08
four O 0 1.900687074396501e-08
or O 0 6.861525037038518e-08
five O 0 2.3825035277980078e-09
cases O 0 9.6611376676492e-09
of O 0 2.4969292411469723e-08
female O 0 0.0017926916480064392
breast B-Disease 1 0.985413134098053
cancer I-Disease 0 0.00017308455426245928
only O 0 9.480333318379053e-08
. O 0 8.271400702142273e-07

These O 0 9.117912469491785e-08
estimates O 0 1.416410100318899e-07
were O 0 1.6460028007259098e-08
not O 0 1.1488952011973197e-09
substantially O 0 2.846876512307972e-08
affected O 0 1.5066646597006184e-08
either O 0 1.9998736000559347e-09
by O 0 1.2030676455054845e-09
changing O 0 2.338830640269407e-08
the O 0 2.499648932285936e-09
assumed O 0 4.6148767296472215e-07
penetrance O 0 2.2734595859219553e-06
model O 0 7.54889356358035e-07
for O 0 3.73043249624061e-08
BRCA1 O 0 8.363320375792682e-06
or O 0 9.104827114470027e-08
by O 0 3.420938199383272e-09
including O 0 2.9514993116208643e-08
or O 0 2.491102861768013e-07
excluding O 0 1.684034214122221e-05
BRCA1 O 0 4.44694233010523e-05
mutation O 0 3.677301378957054e-07
data O 0 8.354642773156229e-07
. O 0 8.625998475508823e-07

Among O 0 1.8819989691110095e-06
those O 0 7.093984777384321e-08
families O 0 1.478785662811788e-07
with O 0 9.82389678938489e-07
disease O 0 0.00018305702542420477
due O 0 5.701389227397158e-07
to O 0 4.791432388628891e-07
BRCA1 O 0 6.20868377154693e-05
that O 0 1.2931167248098063e-07
were O 0 2.4024407139222603e-06
tested O 0 9.605739705875749e-07
by O 0 1.7307330013593969e-09
one O 0 1.5640642114789216e-09
of O 0 1.3817300081875317e-10
the O 0 7.96250676504684e-10
standard O 0 3.922418656543414e-08
screening O 0 3.801323256169553e-09
methods O 0 1.038986585655266e-08
, O 0 1.0908354219907324e-09
mutations O 0 7.884137787073087e-09
were O 0 2.7185091511228165e-08
detected O 0 1.1375221902198973e-06
in O 0 2.5028976669005942e-09
the O 0 8.513602045567836e-10
coding O 0 7.68250600913234e-08
sequence O 0 1.325001708352147e-08
or O 0 9.438597459165976e-09
splice O 0 8.575211154493445e-07
sites O 0 2.983304909776052e-07
in O 0 2.2141395383812323e-09
an O 0 1.1586263060081592e-09
estimated O 0 1.4392752234471118e-07
63 O 0 2.885768601856853e-08
% O 0 5.142609116326469e-10
( O 0 3.722908648029488e-10
95 O 0 1.2699616469546982e-08
% O 0 6.7977445894484845e-09
CI O 0 4.862862260779366e-05
51 O 0 1.9213727853184537e-07
% O 0 2.1390960114331392e-08
- O 0 3.6636989534599707e-05
77 O 0 6.306194109129137e-07
% O 0 1.964712836866056e-08
) O 0 5.5562722423019295e-08
. O 0 1.3171079160656518e-07

The O 0 1.4397406289390347e-07
estimated O 0 4.704236857833166e-07
sensitivity O 0 3.836152245639823e-06
was O 0 6.0050920183130074e-06
identical O 0 5.225980430623167e-07
for O 0 1.4548070526032575e-09
direct O 0 4.699230338189864e-09
sequencing O 0 1.7466053492398714e-08
and O 0 8.097812198570864e-09
other O 0 7.059962614519577e-10
techniques O 0 2.933780933744856e-07
. O 0 2.7790099466074025e-07

The O 0 3.800441561452317e-07
penetrance O 0 7.049021951388568e-05
of O 0 5.4890893608217084e-08
BRCA2 O 0 6.807714089518413e-05
was O 0 2.4585003757238155e-06
estimated O 0 7.252593547946162e-08
by O 0 2.2416923872725647e-09
maximizing O 0 2.29650524374847e-07
the O 0 2.7933310775551945e-08
LOD O 0 0.016841787844896317
score O 0 3.8210509956115857e-07
in O 0 3.1822931845226776e-08
BRCA2 O 0 1.6880732800927944e-05
- O 0 2.323083572264295e-05
mutation O 0 7.660636924811115e-07
families O 0 4.274384934888076e-08
, O 0 7.2903976189309105e-09
over O 0 3.15628199132334e-08
all O 0 5.928012303257901e-09
possible O 0 7.429980541928671e-07
penetrance O 0 3.7852667446713895e-05
functions O 0 7.786395599396201e-07
. O 0 5.330263093128451e-07

The O 0 7.041168714749801e-08
estimated O 0 1.1808303668203735e-07
cumulative O 0 4.929664214614604e-07
risk O 0 3.4538206818979234e-06
of O 0 8.217230629270489e-08
breast B-Disease 1 0.9608221054077148
cancer I-Disease 0 0.0008066892041824758
reached O 0 1.5461962448171107e-06
28 O 0 1.9391386274492106e-07
% O 0 1.924837400579804e-09
( O 0 8.545439911245012e-10
95 O 0 3.7601640912043877e-08
% O 0 1.0000836603296648e-08
CI O 0 0.00018641816859599203
9 O 0 9.031749215182572e-08
% O 0 2.342213312189756e-09
- O 0 8.79497474670643e-06
44 O 0 2.271884724791562e-08
% O 0 9.567281411548834e-10
) O 0 3.0430849506934976e-10
by O 0 1.5666020702909123e-09
age O 0 1.6584159823196387e-08
50 O 0 2.4755977268142715e-09
years O 0 1.5420964505352686e-09
and O 0 2.305931223745006e-09
84 O 0 6.4522853726600715e-09
% O 0 3.121197189592806e-10
( O 0 2.0944176948312077e-10
95 O 0 4.195435998610719e-09
% O 0 3.0318529908868186e-09
CI O 0 1.656255881243851e-05
43 O 0 2.2849654612855375e-08
% O 0 2.9099318510361627e-09
- O 0 2.6200964384770487e-06
95 O 0 1.3897827955133835e-07
% O 0 2.428799161791062e-09
) O 0 9.491560870600324e-10
by O 0 3.248400659572326e-09
age O 0 7.312836913797582e-08
70 O 0 6.369543115170018e-08
years O 0 6.016833253852383e-08
. O 0 2.0377113685299264e-07

The O 0 3.642631554612308e-06
corresponding O 0 0.4793376624584198
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
risks O 0 8.179497672244906e-05
were O 0 9.824309472605819e-07
0 O 0 1.3408323411567835e-06
. O 0 4.464735070541792e-07

4 O 0 1.0170753057536785e-06
% O 0 2.5981295337373922e-08
( O 0 2.0434836045524207e-09
95 O 0 1.2979718633232551e-08
% O 0 5.73529090885927e-09
CI O 0 0.00029497823561541736
0 O 0 5.988587759020447e-08
% O 0 7.98983457173108e-09
- O 0 6.3196894188877195e-06
1 O 0 2.6973536293439793e-08
% O 0 5.936382496685155e-10
) O 0 1.1826860324415378e-10
by O 0 5.038507389087954e-10
age O 0 1.0914478210111156e-08
50 O 0 3.968932738018793e-09
years O 0 2.5655628732579316e-09
and O 0 4.2649523912530185e-09
27 O 0 9.05967922903983e-09
% O 0 3.3097205531795737e-10
( O 0 2.104496715782389e-10
95 O 0 5.765210975283708e-09
% O 0 4.537957565275974e-09
CI O 0 2.1049234419479035e-05
0 O 0 1.6345616415947006e-08
% O 0 3.4227851664070386e-09
- O 0 7.532751624239609e-06
47 O 0 3.356728939252207e-07
% O 0 1.6682022430103416e-09
) O 0 4.659200247836282e-10
by O 0 3.383302082937689e-09
age O 0 7.176921457130447e-08
70 O 0 4.485587368208144e-08
years O 0 4.269056574912611e-08
. O 0 1.8909841514869186e-07

The O 0 4.4774114371648466e-07
lifetime O 0 1.0419325917609967e-06
risk O 0 9.348466846859083e-06
of O 0 3.2602989108454494e-07
breast B-Disease 1 0.9995802044868469
cancer I-Disease 0 0.01938287541270256
appears O 0 1.2321502254053485e-06
similar O 0 5.194012331344311e-08
to O 0 1.4363513045623222e-08
the O 0 5.2328225308428955e-08
risk O 0 3.2444197586301016e-06
in O 0 2.0614690399156643e-08
BRCA1 O 0 6.417299573513446e-06
carriers O 0 1.9114233396066993e-07
, O 0 1.495319246203053e-08
but O 0 3.200566567329588e-08
there O 0 2.6968701050122945e-08
was O 0 1.8540997359650646e-07
some O 0 6.236554050964571e-10
suggestion O 0 3.0288198615835427e-08
of O 0 4.021203370285775e-10
a O 0 3.7676013420195886e-08
lower O 0 2.930078153440263e-06
risk O 0 2.5396539626854064e-07
in O 0 4.944808562612479e-09
BRCA2 O 0 1.1568369018277735e-06
carriers O 0 4.2786268750205636e-08
< O 0 8.544141678612505e-07
50 O 0 1.0782712500656544e-08
years O 0 2.8655553485634755e-09
of O 0 3.862481889882474e-09
age O 0 3.2626408597025147e-07
. O 0 3.7921216744507547e-07

Eye B-Disease 0 0.038626667112112045
movement I-Disease 0 0.0002614868280943483
abnormalities I-Disease 1 0.5035823583602905
correlate O 0 2.7417829187470488e-05
with O 0 1.3470210546984163e-07
genotype O 0 0.0013115142937749624
in O 0 5.380967650125967e-06
autosomal O 1 0.9994723200798035
dominant O 1 0.9919257760047913
cerebellar B-Disease 1 0.9998445510864258
ataxia I-Disease 1 0.9999936819076538
type I-Disease 1 0.99982750415802
I I-Disease 0 0.13680224120616913
. O 0 2.9088514565955848e-06

We O 0 3.400618197701988e-06
compared O 0 1.5363920056188363e-06
horizontal O 0 0.000266103888861835
eye O 0 0.0063972012139856815
movements O 0 0.00019224949937779456
( O 0 9.292924829651383e-08
visually O 0 3.679280098367599e-06
guided O 0 1.9728706774913007e-06
saccades O 0 0.000547101313713938
, O 0 3.3885996231219906e-08
antisaccades O 0 5.211788447923027e-06
, O 0 1.2587671349706397e-08
and O 0 1.0094703739582656e-08
smooth O 0 7.086910045472905e-06
pursuit O 0 5.0878497859230265e-06
) O 0 6.456113865738189e-09
in O 0 1.031044249977242e-09
control O 0 1.2345056177309743e-07
subjects O 0 2.7242455757914286e-07
( O 0 6.818377862316538e-09
n O 0 4.5681106712436303e-05
= O 0 2.1654855117958505e-06
14 O 0 6.745667135987787e-09
) O 0 3.2382492243243632e-09
and O 0 2.48296714744356e-07
patients O 0 3.4174245655549385e-08
with O 0 2.893830952643839e-09
three O 0 3.839843110142738e-09
forms O 0 1.0859123023010397e-07
of O 0 2.1066681199499726e-07
autosomal O 1 0.842471182346344
dominant O 0 0.012830378487706184
cerebellar B-Disease 0 0.017401721328496933
ataxias I-Disease 0 0.021603679284453392
type I-Disease 0 0.47072577476501465
I I-Disease 0 0.0015281722880899906
spinocerebellar B-Disease 1 0.9364356994628906
ataxias I-Disease 0 0.00046253102482296526
1 I-Disease 0 4.1065109712690173e-07
and I-Disease 0 7.421737535651118e-08
2 I-Disease 0 2.2418046086158938e-08
( O 0 2.397620102456699e-09
SCA1 B-Disease 0 8.983582119981293e-06
, O 0 6.01272365230443e-09
n O 0 2.706522082007723e-06
= O 0 2.0368972286632925e-07
11 O 0 1.8804855450582636e-09
; O 0 5.244498169076905e-10
SCA2 B-Disease 0 4.837714641325874e-06
, O 0 3.890192612487908e-09
n O 0 4.054512373841135e-06
= O 0 4.85445411868568e-07
10 O 0 2.1363792956918815e-09
) O 0 7.669805346388614e-10
and O 0 2.7357053511423146e-08
SCA3 B-Disease 1 0.9999960660934448
/ O 0 0.00017660565208643675
Machado B-Disease 0 2.1355863282224163e-05
- I-Disease 0 0.1555328071117401
Joseph I-Disease 0 0.20909588038921356
disease I-Disease 0 0.010985522530972958
( O 0 9.137132650494095e-08
MJD B-Disease 1 0.9999969005584717
) O 0 2.2190873139038558e-08
( O 0 7.335772433947341e-09
n O 0 3.0891565984347835e-05
= O 0 3.3249334592255764e-06
16 O 0 2.0568190706171663e-08
) O 0 8.3398656869349e-09
. O 0 3.778929524855812e-08

In O 0 7.966431212480529e-07
SCA1 B-Disease 0 0.00012406567111611366
, O 0 2.7733911167615588e-08
saccade O 0 7.787888307575486e-07
amplitude O 0 2.1159019070182694e-07
was O 0 1.4750234811344853e-07
significantly O 0 6.769049321064813e-08
increased O 0 2.8895083659108423e-08
, O 0 3.037044393749966e-09
resulting O 0 1.6186923801342346e-08
in O 0 1.9822534724767138e-08
hypermetria B-Disease 0 5.579482240136713e-05
. O 0 2.476265592576965e-07

The O 0 3.359223796906008e-07
smooth O 0 3.887898401444545e-06
pursuit O 0 5.8146265473624226e-06
gain O 0 4.069015176355606e-06
was O 0 8.817953130346723e-06
decreased O 0 2.0677383872680366e-05
. O 0 5.394708750827704e-07

In O 0 1.1409183571231551e-06
SCA2 B-Disease 0 0.00011117648682557046
, O 0 3.6386555990475244e-08
saccade O 0 2.2586953036807245e-06
velocity O 0 1.463484977648477e-06
was O 0 7.562763926216576e-07
markedly O 0 6.896365448483266e-06
decreased O 0 1.1164666830154601e-05
. O 0 2.5173440576509165e-07

The O 0 1.4642148471466498e-07
percentage O 0 4.88584646518575e-07
of O 0 6.53892318069893e-09
errors O 0 4.070277555001667e-07
in O 0 7.333925911012784e-09
antisaccades O 0 2.5530162020004354e-05
was O 0 2.5804695269471267e-06
greatly O 0 7.081007424858399e-08
increased O 0 1.168533980688835e-08
and O 0 6.723753109838526e-09
was O 0 3.977741869221063e-07
significantly O 0 5.709110340035295e-08
correlated O 0 8.095375392258575e-08
with O 0 1.054101073094671e-08
age O 0 5.308197046360874e-07
at O 0 1.843246354837902e-05
disease O 0 0.0003196496982127428
onset O 0 8.201741729862988e-05
. O 0 1.1459542292868719e-06

In O 0 1.5636733508017642e-07
addition O 0 2.794721787324761e-08
, O 0 3.4333316190071628e-09
a O 0 3.413143101482774e-09
correlation O 0 1.1459220417009419e-07
between O 0 1.161144602690456e-08
smooth O 0 9.469828000874259e-06
pursuit O 0 7.502417247451376e-06
gain O 0 6.449350166803924e-06
and O 0 3.8870201279905814e-08
the O 0 1.5000689579380833e-09
number O 0 2.402747556473628e-09
of O 0 6.235201244209065e-09
trinucleotide O 0 1.9541812434908934e-05
repeats O 0 2.465488023517537e-06
was O 0 7.909391570137814e-06
found O 0 9.777929790288908e-07
. O 0 4.907818720312207e-07

In O 0 9.65666458796477e-06
SCA3 B-Disease 1 0.999920129776001
, O 0 1.6943754417297896e-06
gaze B-Disease 0 5.474812860484235e-05
- I-Disease 0 0.0001063238742062822
evoked I-Disease 0 4.2337233026046306e-05
nystagmus I-Disease 0 0.004494155757129192
was O 0 8.294589861179702e-06
often O 0 4.488651583756109e-08
present O 0 2.6250276619066426e-08
as O 0 2.6511118633720798e-08
was O 0 5.411176857705868e-07
saccade O 0 3.667824103104067e-06
hypometria O 0 1.0720682439568918e-05
and O 0 9.762424646453383e-09
smooth O 0 3.124970135104377e-06
pursuit O 0 1.5488925555473543e-06
gain O 0 1.6664625945850275e-06
was O 0 9.215134923579171e-06
markedly O 0 2.353182753722649e-05
decreased O 0 5.462317403726047e-06
. O 0 2.1233346103599615e-07

Three O 0 4.2602272287695087e-07
major O 0 2.2107042241259478e-07
criteria O 0 6.968540589014083e-08
, O 0 2.8565787513201712e-09
saccade O 0 4.193286429199361e-07
amplitude O 0 9.169745851522748e-08
, O 0 1.206104993656254e-09
saccade O 0 8.141768148561823e-08
velocity O 0 3.350617134856293e-07
, O 0 3.169576601180779e-09
and O 0 2.909376961568455e-09
presence O 0 7.161016668533193e-09
of O 0 2.2094568397079684e-09
gaze B-Disease 0 3.572448986233212e-05
- I-Disease 0 0.00012414826778694987
evoked I-Disease 0 2.4175053113140166e-05
nystagmus I-Disease 0 0.00023641830193810165
, O 0 6.484746073454062e-09
permitted O 0 1.8575219584704428e-08
the O 0 6.135474905910598e-10
correct O 0 1.1889029138956175e-07
assignment O 0 1.956023076843394e-08
of O 0 3.8706512994757247e-10
90 O 0 5.628373767052608e-09
% O 0 3.412672644476089e-10
of O 0 2.992285585978749e-10
the O 0 6.510287864358588e-09
SCA1 B-Disease 0 0.00019918788166251034
, O 0 5.740893982419948e-09
90 O 0 1.6132021274373187e-09
% O 0 1.800177923394486e-10
of O 0 9.580204685111227e-11
the O 0 2.8020326059419176e-09
SCA2 B-Disease 0 0.00036457719397731125
, O 0 1.2046549535682516e-08
and O 0 6.8936869546121216e-09
93 O 0 8.680164143015645e-09
% O 0 2.845060576017744e-10
of O 0 6.478017566813321e-10
the O 0 9.094620878613568e-08
patients O 0 3.5822370136884274e-07
with O 0 1.0645839410017288e-07
SCA3 B-Disease 1 0.9999996423721313
to O 0 2.666880050128384e-07
their O 0 4.11984890646977e-09
genetically O 0 2.5981154294640874e-07
confirmed O 0 1.1631570941972313e-06
patient O 0 7.96890162746422e-06
group O 0 3.629562002060993e-07
and O 0 1.0979501752217402e-07
, O 0 9.967358494122891e-09
therefore O 0 2.3155759976134505e-08
, O 0 2.401524090700491e-09
may O 0 1.127574922321628e-08
help O 0 3.5050171653949747e-09
orient O 0 3.2491068850504234e-05
diagnoses O 0 1.8254419046570547e-05
of O 0 1.2069295785011036e-08
SCA1 B-Disease 0 0.0019429723033681512
, O 0 3.0847960630353555e-08
SCA2 B-Disease 0 2.9364558940869756e-05
, O 0 1.2462324505690958e-08
and O 0 1.1962386281538784e-07
SCA3 B-Disease 1 0.999995231628418
at O 0 1.352707499790995e-06
early O 0 9.703968117946715e-08
clinical O 0 2.3102342083802796e-07
stages O 0 1.2865162091202365e-07
of O 0 2.8505262594791247e-09
the O 0 2.7231544663663954e-07
diseases O 0 0.0009074446279555559
. O 0 1.9723085387113315e-08
. O 0 1.8343381213981047e-07

Genetic O 0 1.2976785910723265e-05
basis O 0 4.008228415841586e-07
and O 0 7.04525291439495e-08
molecular O 0 4.1092985156865325e-06
mechanism O 0 3.650965300039388e-05
for O 0 0.00012151187547715381
idiopathic B-Disease 1 0.9999998807907104
ventricular I-Disease 1 0.999991774559021
fibrillation I-Disease 1 0.9999978542327881
. O 0 0.0002616225101519376

Ventricular B-Disease 1 0.9984380602836609
fibrillation I-Disease 1 0.9973586201667786
causes O 0 1.9717912437045015e-05
more O 0 2.9301061132969153e-08
than O 0 5.4118354242405076e-09
300 O 0 1.525055992601665e-08
, O 0 1.2896056444944293e-09
000 O 0 5.4319078124365205e-09
sudden O 0 6.65211743466898e-08
deaths O 0 2.2096818952377362e-07
each O 0 1.493904444593852e-09
year O 0 1.8318727867949747e-08
in O 0 4.238984274707036e-09
the O 0 1.2062920440314429e-08
USA O 0 1.4637056438004947e-06
alone O 0 7.844479341656552e-07
. O 0 1.9663329453578626e-07

In O 0 2.1726540921918058e-07
approximately O 0 7.237088794909141e-08
5 O 0 3.366426071238493e-08
- O 0 3.6113563055550912e-06
12 O 0 5.380105250196721e-09
% O 0 1.9802562367665644e-10
of O 0 9.263235317691354e-11
these O 0 2.193283332729834e-09
cases O 0 2.2033052715642043e-08
, O 0 9.929483901771619e-09
there O 0 2.389166908756124e-08
are O 0 1.3693478351228805e-08
no O 0 1.7936136487151089e-07
demonstrable O 0 0.0014132896903902292
cardiac O 0 0.0005095321102999151
or O 0 7.479347345906717e-07
non O 0 2.7455142117105424e-05
- O 1 0.7955555319786072
cardiac O 0 0.10975547879934311
causes O 0 9.718282854009885e-07
to O 0 1.7708648769598767e-08
account O 0 7.333677132237426e-08
for O 0 3.5981146950803122e-09
the O 0 1.8619054076296493e-09
episode O 0 4.4385197384144703e-07
, O 0 2.7955428194559317e-08
which O 0 1.7176976285782075e-08
is O 0 4.195070246737487e-08
therefore O 0 5.5527653586295855e-08
classified O 0 1.1017363249266054e-05
as O 0 0.00016274959489237517
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999974966049194
fibrillation I-Disease 1 0.9999998807907104
( O 0 0.0008451785543002188
IVF B-Disease 1 0.9999960660934448
) O 0 3.717771960509708e-06
. O 0 1.670746314630378e-06

A O 0 4.17233877669787e-06
distinct O 0 2.095123647904984e-07
group O 0 3.110527302396804e-07
of O 0 3.405809678724836e-08
IVF B-Disease 1 0.9999996423721313
patients O 0 0.0002269684919156134
has O 0 3.9737682300255983e-07
been O 0 3.17778102498778e-07
found O 0 1.1019572809800593e-07
to O 0 2.536064913627456e-09
present O 0 3.82069700322063e-08
with O 0 3.380904090022341e-08
a O 0 2.800608172037755e-07
characteristic O 0 1.0544103133725002e-05
electrocardiographic O 0 0.00012369945761747658
pattern O 0 6.918158760527149e-05
. O 0 1.8760925968308584e-06

Because O 0 5.154128075446351e-07
of O 0 5.8242530798224834e-09
the O 0 1.4829404371141663e-09
small O 0 3.127385639345448e-08
size O 0 2.328342532109673e-07
of O 0 9.814209445124789e-10
most O 0 3.0850355603462276e-09
pedigrees O 0 1.561128556204494e-06
and O 0 4.1611457390899886e-08
the O 0 6.36308072898828e-09
high O 0 4.182314114586916e-06
incidence O 0 4.803745832759887e-05
of O 0 1.5089684168856365e-08
sudden B-Disease 0 4.172037370153703e-05
death I-Disease 0 3.1295335247705225e-06
, O 0 3.2986761766551354e-08
however O 0 1.1066328298170447e-08
, O 0 8.611362178889692e-10
molecular O 0 1.149178530113204e-08
genetic O 0 2.64956501183633e-08
studies O 0 2.38234898475298e-09
of O 0 1.7694738119189424e-08
IVF B-Disease 1 0.9999935626983643
have O 0 7.541546551692591e-07
not O 0 4.86425086876352e-08
yet O 0 2.381605312962165e-08
been O 0 2.3679712413127163e-08
done O 0 9.946945311867239e-08
. O 0 9.177146864658425e-08

Because O 0 4.6920245949877426e-05
IVF B-Disease 1 0.9999819993972778
causes O 0 0.003935593646019697
cardiac O 0 0.12910160422325134
rhythm O 0 0.032042354345321655
disturbance O 0 0.00414982670918107
, O 0 3.527876302200639e-08
we O 0 6.059454271678533e-09
investigated O 0 1.38356867296352e-07
whether O 0 3.065621712039501e-08
malfunction O 0 2.129078893631231e-05
of O 0 2.3341946153720983e-09
ion O 0 1.892908403533511e-05
channels O 0 6.032522378518479e-06
could O 0 6.071249572414672e-06
cause O 0 8.573248351240181e-07
the O 0 5.222363341772507e-08
disorder O 0 0.00011846264533232898
by O 0 1.6811291247975646e-09
studying O 0 1.0132821692820926e-08
mutations O 0 8.009810414932872e-08
in O 0 4.009258258719228e-09
the O 0 4.1378218185172955e-08
cardiac O 0 4.849746619584039e-05
sodium O 0 3.611989768614876e-06
channel O 0 2.2524167434312403e-05
gene O 0 5.403042450780049e-06
SCN5A O 0 0.0002389646542724222
. O 0 8.92294167442742e-07

We O 0 2.636916633491637e-06
have O 0 2.7114355205526408e-08
now O 0 9.683607693489193e-09
identified O 0 4.5069931786656525e-08
a O 0 1.3700740986166693e-08
missense O 0 2.2628761144005693e-05
mutation O 0 6.423860554605199e-07
, O 0 1.9240641080386922e-08
a O 0 6.572110322622393e-08
splice O 0 0.0008852934697642922
- O 0 0.0012240525102242827
donor O 0 8.700528724148171e-07
mutation O 0 1.4909909396010335e-07
, O 0 1.1043828962442603e-08
and O 0 3.4946715743444656e-08
a O 0 2.2312899261578423e-07
frameshift O 0 0.00013018243771512061
mutation O 0 1.9760199165830272e-07
in O 0 1.0841610276202118e-08
the O 0 5.1838546788474105e-09
coding O 0 8.478064046357758e-07
region O 0 1.2911378632907144e-07
of O 0 3.1714149084649534e-09
SCN5A O 0 8.68009083205834e-05
in O 0 3.0615723289884045e-08
three O 0 2.3775845647833194e-07
IVF B-Disease 1 0.9999712705612183
families O 0 2.605345571282669e-06
. O 0 7.27409371847898e-07

We O 0 2.9304814574970806e-07
show O 0 5.859645213490694e-08
that O 0 9.167586134672945e-10
sodium O 0 1.3341286297929855e-08
channels O 0 1.6029769511760605e-08
with O 0 1.4062013775628657e-09
the O 0 2.7211950470729107e-09
missense O 0 8.958677426562645e-06
mutation O 0 2.367732463426364e-07
recover O 0 1.7768203974810604e-07
from O 0 2.0394497202147477e-09
inactivation O 0 9.008305823954288e-06
more O 0 2.789043884732223e-09
rapidly O 0 1.7350902936641432e-08
than O 0 1.388297810045458e-09
normal O 0 1.803678628675698e-08
and O 0 5.2343271939037095e-09
that O 0 2.870790716258398e-09
the O 0 5.849368545085554e-09
frameshift O 0 7.800407183822244e-05
mutation O 0 1.5896266347681376e-07
causes O 0 1.062775911719882e-08
the O 0 8.875333246116668e-10
sodium O 0 6.09446075827691e-08
channel O 0 1.1610292176555959e-06
to O 0 4.8668582053323917e-08
be O 0 1.581078379331302e-07
non O 0 7.527620482505881e-07
- O 0 6.0652149841189384e-05
functional O 0 5.65863001611433e-06
. O 0 2.676853512184607e-07

Our O 0 1.002212911771494e-06
results O 0 8.308005305934785e-08
indicate O 0 5.972457728375957e-08
that O 0 3.849977670000726e-09
mutations O 0 8.393713812893111e-08
in O 0 3.080038224467785e-09
cardiac O 0 5.674149633705383e-06
ion O 0 3.6552042729454115e-05
- O 0 0.00032283883774653077
channel O 0 1.0768000720418058e-05
genes O 0 1.9001795692474843e-08
contribute O 0 6.020079101887177e-09
to O 0 1.5020015231570483e-09
the O 0 2.2637169916350786e-09
risk O 0 4.7395321445264926e-08
of O 0 1.8095285270192107e-09
developing O 0 1.0980271554217325e-06
IVF B-Disease 1 0.9998540878295898
. O 0 1.1605183658502938e-07
. O 0 2.490917552222527e-07

Molecular O 0 2.109629895130638e-05
heterogeneity O 0 1.4346408534038346e-05
in O 0 2.8977660804230254e-07
mucopolysaccharidosis B-Disease 0 0.0017901490209624171
IVA I-Disease 1 0.5188413262367249
in O 0 2.0066610773028515e-07
Australia O 0 1.1319356474359665e-07
and O 0 5.390482726852497e-08
Northern O 0 3.602786478040798e-07
Ireland O 0 6.645332746302302e-07
: O 0 3.805632253772728e-09
nine O 0 1.044948749751029e-08
novel O 0 3.519824431919005e-08
mutations O 0 6.56344170124612e-08
including O 0 5.745221187680727e-09
T312S O 0 8.154656825354323e-06
, O 0 3.756759170414625e-08
a O 0 4.3702279128865484e-08
common O 0 8.203824819474903e-08
allele O 0 1.758432546239419e-07
that O 0 2.3127554982238507e-08
confers O 0 3.694307224577642e-07
a O 0 1.0822745935001876e-06
mild O 0 0.006807141005992889
phenotype O 0 0.0003876930568367243
. O 0 1.5647565305698663e-06

Mucopolysaccharidosis B-Disease 1 0.9342361092567444
IVA I-Disease 1 0.9991284012794495
( O 0 0.00042190717067569494
MPS B-Disease 1 0.999974250793457
IVA I-Disease 1 0.9999992847442627
) O 0 5.777724709332688e-06
is O 0 2.224810032203095e-06
an O 0 5.332293767423835e-06
autosomal B-Disease 1 0.9999738931655884
recessive I-Disease 1 0.9999915361404419
lysosomal I-Disease 1 0.9999992847442627
storage I-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9999920129776001
caused O 0 0.0014835852198302746
by O 0 3.441057288000593e-07
a O 0 0.0002974574745167047
genetic B-Disease 1 0.9999986886978149
defect I-Disease 1 0.9999972581863403
in O 0 4.5293518269318156e-07
N O 0 0.03094511665403843
- O 0 0.00028449107776395977
acetylgalactosamine O 0 0.003923274576663971
- O 0 0.0007769823423586786
6 O 0 5.4109991651785094e-06
- O 0 0.031348198652267456
sulfate O 0 0.01937147043645382
sulfatase O 0 0.0002634151023812592
( O 0 3.381923008305421e-08
GALNS O 0 1.358646659355145e-05
) O 0 6.097344140698624e-08
. O 0 2.0866052352630504e-07

Previous O 0 9.016892477120564e-07
studies O 0 6.622595094540884e-08
of O 0 1.79443091496978e-08
patients O 0 9.574756631991477e-08
from O 0 3.038678419997609e-09
a O 0 1.2367505064503348e-07
British O 0 1.052787592925597e-05
- O 0 0.0037920319009572268
Irish O 0 4.093270490557188e-06
population O 0 1.2180231045988421e-08
showed O 0 3.172554272623529e-07
that O 0 2.0147901125255885e-09
the O 0 3.050786734348776e-09
I113F O 0 7.579081398034759e-07
mutation O 0 3.8023113546614695e-08
is O 0 2.472465787661804e-08
the O 0 2.265660992151197e-09
most O 0 2.949263722129558e-09
common O 0 2.692665646009118e-08
single O 0 3.034686812952714e-07
mutation O 0 9.92831132862193e-07
among O 0 1.296922164328862e-06
MPS B-Disease 1 0.9999980926513672
IVA I-Disease 1 1.0
patients O 0 0.0008372087613679469
and O 0 3.980041469731077e-07
produces O 0 6.335318630590336e-06
a O 0 4.415549938130425e-06
severe O 0 0.0011973708169534802
clinical O 0 5.821682862006128e-05
phenotype O 0 0.0001941453811014071
. O 0 1.3514052170648938e-06

We O 0 6.304107387222757e-07
studied O 0 1.613865379113122e-07
mutations O 0 1.2149283179496706e-07
in O 0 3.5056657576859607e-09
the O 0 3.9683198949092e-09
GALNS O 0 2.232030419691e-05
gene O 0 6.025434373668759e-08
from O 0 4.471618630930152e-09
23 O 0 1.6625902432565454e-08
additional O 0 5.00214525800402e-07
MPS B-Disease 1 0.9999957084655762
IVA I-Disease 1 1.0
patients O 0 0.00044500536751002073
( O 0 3.549757154885924e-09
15 O 0 7.019336223379469e-09
from O 0 1.032368524001015e-09
Australia O 0 1.356562950860507e-08
, O 0 2.19671636436658e-09
8 O 0 2.0139601097923787e-09
from O 0 6.119404982740662e-10
Northern O 0 9.858833038833836e-08
Ireland O 0 2.0753014950969373e-07
) O 0 2.1858912457872748e-09
, O 0 3.248518343212936e-09
with O 0 1.4993796204620935e-09
various O 0 6.0484959263362725e-09
clinical O 0 3.2581308460066793e-06
phenotypes O 0 3.354150612722151e-05
( O 0 1.56354232672129e-07
severe O 0 7.65193544793874e-06
, O 0 2.419211497795004e-08
16 O 0 1.0074680645288936e-08
cases O 0 8.435534937234479e-09
; O 0 2.1228290236763314e-09
intermediate O 0 1.2613392641469545e-07
, O 0 4.343549964147542e-09
4 O 0 1.4058320729759544e-08
cases O 0 2.759529316165299e-08
; O 0 3.680086280155592e-08
mild O 0 0.00040251208702102304
, O 0 1.6581542183757847e-07
3 O 0 1.9704476983406494e-07
cases O 0 8.537497819816053e-08
) O 0 5.143359871340181e-08
. O 0 2.72249508270761e-07

We O 0 5.228550435276702e-06
found O 0 2.5759231903066393e-07
two O 0 4.333272407563982e-09
common O 0 2.1870850019922727e-08
mutations O 0 1.0047875775853754e-07
that O 0 2.256923714583081e-08
together O 0 3.452890595667668e-08
accounted O 0 8.624189149486483e-07
for O 0 4.753707205651381e-09
32 O 0 6.897145965467644e-09
% O 0 2.0948572043710811e-10
of O 0 1.1663417454066405e-10
the O 0 4.843602852133699e-09
44 O 0 1.8762658982041103e-08
unrelated O 0 5.417177462163636e-08
alleles O 0 1.3937374809813718e-08
in O 0 6.7534946524006045e-09
these O 0 3.703527795551054e-08
patients O 0 7.934601171655231e-07
. O 0 1.4891577393427724e-07

One O 0 1.2736387589029619e-06
is O 0 5.434646865865034e-08
the O 0 2.827976519625963e-09
T312S O 0 2.088963583446457e-06
mutation O 0 3.5071863635494083e-07
, O 0 2.6809352959844546e-08
a O 0 7.113685995818742e-08
novel O 0 6.331865733955055e-07
mutation O 0 4.2263116029062076e-07
found O 0 8.55126884857782e-08
exclusively O 0 3.2113351977614e-08
in O 0 3.3525214604424036e-08
milder O 0 0.00020479298837017268
patients O 0 5.0918788474518806e-06
. O 0 4.1196710753865773e-07

The O 0 2.3913719360280083e-07
other O 0 1.653113557154029e-08
is O 0 1.8602023033054138e-08
the O 0 1.3231877815655935e-09
previously O 0 1.3815737531786e-07
described O 0 1.2874763797299238e-06
I113F O 0 1.3558369573729578e-06
that O 0 2.3092072254371487e-08
produces O 0 6.702570658490004e-07
a O 0 1.9364103991392767e-06
severe O 0 0.0001493850431870669
phenotype O 0 6.325772119453177e-05
. O 0 5.583340225712163e-07

The O 0 1.2514040292899153e-07
I113F O 0 2.490281303835218e-06
and O 0 2.950857691530473e-08
T312S O 0 3.4705601592577295e-07
mutations O 0 8.764114056702965e-08
accounted O 0 4.4624152906180825e-07
for O 0 7.356846687400775e-09
8 O 0 4.401111297624993e-08
( O 0 1.4516086110916149e-09
18 O 0 8.895114866902532e-09
% O 0 8.033272935747959e-10
) O 0 9.143034662706384e-10
and O 0 4.7107285183756176e-08
6 O 0 7.470764984418565e-08
( O 0 8.996530742599873e-10
14 O 0 2.1142745332269897e-09
% O 0 2.178614372239096e-10
) O 0 1.3005800603149709e-10
of O 0 1.89751936385818e-10
44 O 0 2.0805639877607973e-08
unrelated O 0 1.6038386263517168e-07
alleles O 0 5.401834712870368e-08
, O 0 2.819624356220629e-08
respectively O 0 5.309381094775745e-07
. O 0 8.763493042351911e-07

The O 0 4.0432962578051956e-07
relatively O 0 2.962859753097291e-07
high O 0 1.7279722897001193e-07
residual O 0 1.7965562619792763e-06
GALNS O 0 2.7089909053756855e-05
activity O 0 1.9770595827139914e-06
seen O 0 1.981539696771506e-07
when O 0 2.2671653443495643e-09
the O 0 5.219111809395827e-10
T312S O 0 5.201199826387892e-08
mutant O 0 2.4646780616421893e-08
cDNA O 0 5.101348321545629e-08
is O 0 1.6067909669459368e-08
overexpressed O 0 4.894553740086849e-07
in O 0 3.089711153592134e-09
mutant O 0 2.0890583130039886e-07
cells O 0 8.504392212671519e-08
provides O 0 7.681975056073043e-09
an O 0 1.2189543818763582e-09
explanation O 0 9.295208158732748e-09
for O 0 2.063096582460844e-09
the O 0 5.4977437713432664e-08
mild O 0 0.002337176352739334
phenotype O 0 5.1536684622988105e-05
in O 0 5.7062521818807e-07
patients O 0 4.252137557614333e-07
with O 0 2.6586861601174405e-09
this O 0 2.4767137674075457e-08
mutation O 0 3.289567757747136e-06
. O 0 4.244634226324706e-07

The O 0 4.346726356629915e-08
distribution O 0 1.1040864222877644e-07
and O 0 4.3647605529884e-09
relative O 0 1.3735069082088103e-08
frequencies O 0 6.078414660493081e-09
of O 0 4.706520728703367e-10
the O 0 2.3950834648900354e-09
I113F O 0 9.239986979991954e-07
and O 0 2.3660570391825786e-08
T312S O 0 3.839801649974106e-07
mutations O 0 2.4413591148686464e-08
in O 0 1.828569295980742e-09
Australia O 0 1.606226374128994e-09
corresponded O 0 9.42427824668357e-09
to O 0 1.9244776883198256e-09
those O 0 6.558030229975031e-10
observed O 0 6.042421318852575e-08
in O 0 3.1246296661180395e-09
Northern O 0 1.3517258423689782e-07
Ireland O 0 3.448228369506978e-07
and O 0 5.660761459580499e-08
are O 0 4.104601103449568e-09
unique O 0 3.219330357850936e-09
to O 0 1.91443927377577e-09
these O 0 9.7682684163658e-10
two O 0 1.7446467603932092e-09
populations O 0 2.3877818833284437e-08
, O 0 1.2872268806418674e-09
suggesting O 0 2.6825668797414437e-08
that O 0 2.8765294590726853e-09
both O 0 4.939753606159059e-10
mutations O 0 3.926196701087292e-09
were O 0 3.9128913442709745e-08
probably O 0 4.867016301091098e-08
introduced O 0 2.9831692671677956e-09
to O 0 8.032541742863941e-09
Australia O 0 1.4083816779475455e-08
by O 0 4.59877691483257e-09
Irish O 0 1.2019128803331114e-07
migrants O 0 5.121262969254303e-09
during O 0 6.886905268288501e-09
the O 0 1.5136432107709652e-09
19th O 0 3.7036556932434905e-07
century O 0 5.364264325180557e-06
. O 0 8.540524731870391e-07

Haplotype O 0 5.9459765907377005e-05
analysis O 0 4.239771271841164e-07
using O 0 1.6698911053936172e-07
6 O 0 9.381489718407465e-08
RFLPs O 0 1.1454296782176243e-06
provides O 0 5.190206486815896e-09
additional O 0 1.3765905082507857e-09
data O 0 6.912227945576888e-08
that O 0 3.2785585357686386e-09
the O 0 2.581638902654504e-09
I113F O 0 1.034979391079105e-06
mutation O 0 3.6145696213907286e-08
originated O 0 3.758214006666094e-08
from O 0 3.978270157745101e-09
a O 0 1.2670189164509793e-07
common O 0 3.0154126307024853e-07
ancestor O 0 3.1865379241935443e-06
. O 0 8.739439181226771e-07

The O 0 2.3524431469468254e-07
other O 0 1.4507068435420933e-08
9 O 0 7.26329432154671e-08
novel O 0 1.3347958827125694e-07
mutations O 0 6.863434691695147e-07
identified O 0 7.846020935176057e-07
in O 0 8.940103768395602e-09
these O 0 1.8803000045863882e-08
23 O 0 3.0908924486539036e-07
patients O 0 1.632810331386736e-08
were O 0 1.357507706245542e-08
each O 0 5.525406798767563e-10
limited O 0 4.665393760205916e-08
to O 0 4.9028670012774e-09
a O 0 1.8425997438953345e-07
single O 0 3.902229309460381e-06
family O 0 9.007507287606131e-06
. O 0 6.171583777359047e-07

These O 0 9.49870440081213e-08
data O 0 1.714351895998334e-07
provide O 0 4.016973864651163e-09
further O 0 1.2478325039921856e-09
evidence O 0 5.0278252672342205e-09
for O 0 1.3038816693011768e-09
extensive O 0 6.767978106836381e-07
allelic O 0 1.3589550690085161e-05
heterogeneity O 0 4.763928518514149e-05
in O 0 1.2865772987424862e-05
MPS B-Disease 1 0.9999772310256958
IVA I-Disease 1 0.9999992847442627
in O 0 4.051536052429583e-06
British O 0 0.00016054074512794614
- O 1 0.6097586154937744
Irish O 0 0.006902919616550207
patients O 0 1.6487385892105522e-06
and O 0 2.3763915280028414e-08
provide O 0 3.218061550569473e-08
evidence O 0 4.4232269402755264e-08
for O 0 3.987781660441669e-09
their O 0 2.5401121206414246e-09
transmission O 0 2.95730865218502e-06
to O 0 8.144342977800534e-09
Australia O 0 6.290820309118317e-09
by O 0 2.4732758063805704e-09
British O 0 1.9269455151516013e-06
- O 0 0.0012082953471690416
Irish O 0 2.032569454968325e-06
migrants O 0 7.442405802748908e-08
. O 0 5.357658761084849e-09
. O 0 5.2169475850405433e-08

Identification O 0 2.4067976482911035e-06
of O 0 2.117152853031712e-08
constitutional O 0 3.020158487743174e-07
WT1 O 0 0.005259589292109013
mutations O 0 2.8316964744590223e-05
, O 0 2.778807939307626e-08
in O 0 4.44106404984268e-08
patients O 0 2.0214470453083777e-07
with O 0 1.0290785468214381e-07
isolated O 1 0.5907711386680603
diffuse B-Disease 1 0.9994667172431946
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 0.9999998807907104
, O 0 5.055445626567234e-07
and O 0 5.249714440935804e-09
analysis O 0 8.551037211645962e-09
of O 0 5.674379188747025e-09
genotype O 0 0.0001993881305679679
/ O 0 0.0001332997198915109
phenotype O 0 4.387819444673369e-06
correlations O 0 2.9896073101554066e-06
by O 0 8.250190752789877e-09
use O 0 8.045468291584257e-09
of O 0 3.0141860118959585e-09
a O 0 2.584518483672582e-07
computerized O 0 0.00011984905722783878
mutation O 0 7.378078407782596e-06
database O 0 3.837176791421371e-06
. O 0 1.0207074865320465e-06

Constitutional O 0 1.2098624210921116e-05
mutations O 0 3.915141860488802e-06
of O 0 2.1311873155127614e-08
the O 0 1.488648759817579e-08
WT1 O 0 5.522555875359103e-05
gene O 0 1.5706231693002337e-07
, O 0 2.4320998548432726e-09
encoding O 0 3.2277245765044427e-08
a O 0 1.0646524515323108e-06
zinc O 0 0.06367270648479462
- O 0 0.001486640889197588
finger O 0 6.16998877376318e-05
transcription O 0 3.6424822269509605e-07
factor O 0 3.546632498796498e-08
involved O 0 1.184628075634464e-07
in O 0 2.113489756538911e-07
renal O 1 0.94481360912323
and O 0 1.4747043906027102e-06
gonadal O 0 0.0016256828093901277
development O 0 4.640553470380837e-07
, O 0 5.09600894815776e-08
are O 0 3.609524901193595e-09
found O 0 1.2833933915601392e-08
in O 0 1.4181930074741445e-09
most O 0 1.1917040687592362e-08
patients O 0 5.8115610102049686e-08
with O 0 2.646252710292174e-07
Denys B-Disease 1 0.9999371767044067
- I-Disease 1 0.9999958276748657
Drash I-Disease 1 0.9999970197677612
syndrome I-Disease 1 0.9999984502792358
( O 0 3.897632723237621e-06
DDS B-Disease 1 0.9999985694885254
) O 0 1.0380561121792198e-07
, O 0 5.752296772243426e-08
or O 0 2.1668407498509623e-05
diffuse B-Disease 1 0.9989068508148193
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.151270953414496e-05
DMS B-Disease 1 0.941224217414856
) O 0 6.270146712950009e-08
associated O 0 4.509688835696579e-07
with O 0 2.0440253933884378e-07
pseudohermaphroditism B-Disease 1 0.9999992847442627
and O 0 3.33786774717737e-05
/ O 0 0.021983370184898376
or O 0 0.000643637147732079
Wilms B-Disease 1 0.9993865489959717
tumor I-Disease 1 0.8927261233329773
( O 0 3.6383298720465973e-06
WT B-Disease 1 0.9999196529388428
) O 0 1.745150939314044e-07
. O 0 2.6561031063465634e-07

Most O 0 7.344903565353889e-07
mutations O 0 8.066619557212107e-06
in O 0 1.8668475831873366e-06
DDS B-Disease 1 0.9999998807907104
patients O 0 0.003970410209149122
lie O 0 0.0005831544985994697
in O 0 3.3165235890919575e-08
exon O 0 1.0754203003671137e-06
8 O 0 1.2667833004798013e-07
or O 0 2.900114992598901e-08
exon O 0 1.938861373673717e-07
9 O 0 1.666969779989813e-07
, O 0 2.8624744796701407e-09
encoding O 0 1.5672969766455935e-07
zinc O 0 0.0061890440993011
finger O 0 0.017891688272356987
2 O 0 9.775970966074965e-07
or O 0 6.686317647108808e-06
zinc O 0 0.05430290475487709
finger O 0 0.010779328644275665
3 O 0 7.27655020682505e-08
, O 0 8.421292108096168e-09
respectively O 0 1.0760770052797852e-08
, O 0 1.6485186549175523e-09
with O 0 1.945143823789408e-09
a O 0 2.22699981122787e-07
hot O 0 0.005967157427221537
spot O 0 2.6560004698694684e-05
( O 0 1.8704979787287357e-09
R394W O 0 5.734724695116711e-08
) O 0 7.179311589666781e-10
in O 0 1.0478983236694717e-09
exon O 0 7.058716278152133e-07
9 O 0 1.022939045469684e-06
. O 0 6.551534852405894e-07

We O 0 9.438165875508275e-07
analyzed O 0 2.319727485655676e-07
a O 0 1.0812080120103928e-08
series O 0 6.171993138792686e-09
of O 0 1.1066786376190407e-09
24 O 0 1.8249332356390369e-07
patients O 0 1.5495780303353968e-07
, O 0 6.47396980468784e-09
10 O 0 8.820388863739481e-09
with O 0 2.2270170063620753e-07
isolated B-Disease 1 0.8563840389251709
DMS I-Disease 1 0.9654203653335571
( O 0 4.034790279661138e-08
IDMS B-Disease 0 0.00011973549408139661
) O 0 4.8373616223784666e-09
, O 0 5.703948424695682e-09
10 O 0 4.562301203492325e-09
with O 0 1.1513400011153863e-07
DDS B-Disease 1 0.9999996423721313
, O 0 4.7018281179589394e-07
and O 0 1.1085704443303257e-07
4 O 0 1.0041628684120951e-07
with O 0 1.458334111248405e-07
urogenital B-Disease 1 0.7919507026672363
abnormalities I-Disease 1 0.994326651096344
and O 0 2.0448067516554147e-05
/ O 0 0.4865187108516693
or O 0 0.0018174188444390893
WT B-Disease 1 0.9999668598175049
. O 0 4.1036669244931545e-06

We O 0 2.6319219159631757e-06
report O 0 5.657522592628084e-07
WT1 O 0 6.877251871628687e-05
heterozygous O 0 2.6879120014200453e-06
mutations O 0 7.62151216804341e-07
in O 0 1.7558544840312607e-08
16 O 0 1.8825826941792911e-07
patients O 0 2.0887793539259292e-07
, O 0 3.15849657539502e-09
4 O 0 1.1400333121969197e-08
of O 0 1.0042315423675063e-08
whom O 0 1.5431614883709699e-06
presented O 0 9.869883115243283e-07
with O 0 1.5185097481662524e-06
IDMS B-Disease 0 0.10048788040876389
. O 0 7.840433227102039e-07

One O 0 2.0602210497600026e-06
male O 0 3.019630867129308e-06
and O 0 9.616081086960548e-08
two O 0 7.653065381418855e-08
female O 0 1.3340466466615908e-05
IDMS B-Disease 1 0.9854955673217773
patients O 0 4.975330284651136e-06
with O 0 2.407111594493472e-07
WT1 O 0 0.14553116261959076
mutations O 0 2.0140734704909846e-05
underwent O 0 2.718512223509606e-05
normal O 0 7.813607226125896e-06
puberty O 0 8.600900764577091e-05
. O 0 1.3021671065871487e-06

Two O 0 1.7664190181676531e-06
mutations O 0 3.332460255478509e-05
associated O 0 1.8291793821845204e-06
with O 0 4.2814676248781325e-07
IDMS B-Disease 0 0.03498362377285957
are O 0 7.627066089810342e-09
different O 0 9.268187883826329e-10
from O 0 1.6693258997335647e-09
those O 0 4.1902459280152016e-09
described O 0 5.30110173713183e-06
in O 0 2.084458401441225e-06
DDS B-Disease 1 0.9999994039535522
patients O 0 3.380578709766269e-05
. O 0 3.6871443853669916e-07

No O 0 3.7185807286732597e-06
WT1 O 0 0.00020288111409172416
mutations O 0 3.990237019024789e-06
were O 0 3.6555806559590565e-07
detected O 0 2.7302482976665488e-06
in O 0 2.683466338027074e-09
the O 0 3.966027506407954e-09
six O 0 3.531054204586326e-08
other O 0 9.214172536076148e-08
IDMS B-Disease 0 0.3372650146484375
patients O 0 5.715309043807792e-07
, O 0 4.0111856058899775e-09
suggesting O 0 3.179171983447304e-07
genetic O 0 3.999888917860517e-07
heterogeneity O 0 8.167631904143491e-07
of O 0 2.430561352184668e-08
this O 0 6.4018222474260256e-06
disease O 0 0.005421869922429323
. O 0 9.329774002253544e-07

We O 0 6.316323606370133e-07
analyzed O 0 4.93343122798251e-07
genotype O 0 1.8640206690179184e-05
/ O 0 1.358646659355145e-05
phenotype O 0 2.9751813599432353e-06
correlations O 0 4.059178536408581e-05
, O 0 8.770351911380203e-08
on O 0 2.0448773341286142e-07
the O 0 1.471501254179941e-09
basis O 0 4.429246303061518e-08
of O 0 3.464803555175422e-09
the O 0 1.6582294648515017e-08
constitution O 0 5.0856461264459085e-09
of O 0 9.643329468289608e-10
a O 0 5.631393378280336e-07
WT1 O 0 0.00015382001583930105
mutation O 0 9.140427437159815e-08
database O 0 1.7891370163169995e-08
of O 0 2.937390108925797e-09
84 O 0 1.547969759485568e-06
germ O 0 0.07899177819490433
- O 0 0.023091549053788185
line O 0 0.002257606713101268
mutations O 0 6.149833780000336e-07
, O 0 1.9552239827191897e-09
to O 0 1.0508003356335394e-09
compare O 0 3.7227774640768985e-08
the O 0 1.0492502422465577e-09
distribution O 0 3.8772211041759874e-07
and O 0 4.807424858199738e-08
type O 0 3.98198835682706e-06
of O 0 1.0184686427550105e-09
mutations O 0 6.635553972955677e-07
, O 0 4.820239762892697e-09
according O 0 3.6133409597738364e-09
to O 0 5.1182942328864556e-09
the O 0 1.351797518367448e-08
different O 0 2.737721160883666e-07
symptoms O 0 2.3352135031018406e-05
. O 0 2.7552650294637715e-07

This O 0 4.897667622572044e-07
demonstrated O 0 6.819615805397916e-07
( O 0 7.242900057491397e-09
1 O 0 1.2576392371954626e-08
) O 0 1.4095633549260356e-09
the O 0 2.043171853927106e-09
association O 0 1.1545325584449984e-08
between O 0 8.782651050864843e-09
mutations O 0 1.5130615338421194e-07
in O 0 3.1319447035826897e-09
exons O 0 2.7556276904761035e-07
8 O 0 8.500612835860011e-08
and O 0 6.587848133676744e-08
9 O 0 4.125544990074559e-07
and O 0 3.208348005045991e-07
DMS B-Disease 0 0.05236703157424927
; O 0 9.139534462576648e-09
( O 0 2.013099908992899e-09
2 O 0 8.56182502673164e-09
) O 0 4.319508306593889e-09
among O 0 2.037215374173229e-08
patients O 0 3.6730391173023236e-08
with O 0 2.3559518780302824e-08
DMS B-Disease 0 0.20009949803352356
, O 0 9.096005726405565e-09
a O 0 4.575320566857499e-09
higher O 0 3.17955528572611e-09
frequency O 0 3.754301758362999e-08
of O 0 6.363429783107222e-10
exon O 0 1.4051462926545355e-07
8 O 0 6.716398814887725e-08
mutations O 0 8.84929320932315e-08
among O 0 9.515129129056277e-09
46 O 0 7.422933663292497e-07
, O 0 3.6632516753343225e-07
XY O 0 0.259375661611557
patients O 0 7.724329407210462e-06
with O 0 9.26487331298631e-08
female O 0 9.577036053087795e-07
phenotype O 0 4.1712704046403815e-07
than O 0 3.9822808162170986e-08
among O 0 2.683232125377799e-08
46 O 0 6.965231591493648e-07
, O 0 2.498373419257405e-07
XY O 0 0.12831346690654755
patients O 0 9.27209157453035e-07
with O 0 3.9823873976274626e-08
sexual O 0 1.6578584336457425e-06
ambiguity O 0 7.657235983060673e-06
or O 0 1.8489012290956452e-05
male O 0 3.4588936159707373e-06
phenotype O 0 3.159635980409803e-06
; O 0 1.461426890614348e-08
and O 0 1.6901634580790414e-07
( O 0 8.347027957711362e-09
3 O 0 7.427215287236777e-09
) O 0 1.3071137505704655e-09
statistically O 0 3.433713402500871e-08
significant O 0 9.536005762811328e-09
evidence O 0 1.9579236720801418e-07
that O 0 1.4075437704264004e-08
mutations O 0 5.996828633669793e-08
in O 0 2.8431523801941694e-09
exons O 0 1.3998683812133095e-07
8 O 0 9.674251799651756e-08
and O 0 3.3849950398234796e-08
9 O 0 6.102998639789803e-08
preferentially O 0 1.0356236401776187e-07
affect O 0 2.4742206505834474e-08
amino O 0 6.157741427870178e-09
acids O 0 1.1564627033777697e-09
with O 0 1.941947158634605e-10
different O 0 1.62315175189498e-10
functions O 0 5.5087410189003094e-09
. O 0 6.5831478046618486e-09
. O 0 7.703768289957225e-08

The O 0 1.9480335140542593e-06
185delAG O 0 0.000169279970577918
BRCA1 O 0 0.0001042415460688062
mutation O 0 8.448434414276562e-07
originated O 0 1.0276583850554744e-07
before O 0 5.120872170749635e-09
the O 0 3.163824757734801e-10
dispersion O 0 1.7993700396345957e-07
of O 0 6.285588161070166e-10
Jews O 0 3.46932864658811e-08
in O 0 4.661975694375542e-09
the O 0 1.2562817452987929e-09
diaspora O 0 3.650062296856049e-08
and O 0 4.1811389905888063e-08
is O 0 4.216842697246648e-08
not O 0 4.010451526426095e-09
limited O 0 1.528708004627788e-08
to O 0 2.7427169868587953e-08
Ashkenazim O 0 3.503518018987961e-05
. O 0 2.9026617198724125e-07

The O 0 1.4258537817113393e-07
185delAG O 0 9.361303455079906e-06
mutation O 0 9.125382689489925e-07
in O 0 1.108536196170462e-08
BRCA1 O 0 8.92729076440446e-06
is O 0 6.257052831415422e-08
detected O 0 2.2089327558205696e-06
in O 0 4.4731454096336165e-09
Ashkenazi O 0 1.0525841389608104e-06
Jews O 0 1.1232243224412741e-07
both O 0 3.566778872254872e-09
in O 0 5.6995684616367726e-08
familial B-Disease 1 0.9822943210601807
breast I-Disease 1 0.9999879598617554
and I-Disease 1 0.999967098236084
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
and O 0 3.2056857435236452e-06
in O 0 1.5183340806856904e-08
the O 0 1.862396459273441e-08
general O 0 7.050469008618165e-08
population O 0 5.914812462037844e-08
. O 0 2.5403008407920424e-07

All O 0 1.035907644109102e-06
tested O 0 2.7508119728736347e-06
Ashkenazi O 0 4.8864703785511665e-06
mutation O 0 9.340902806798113e-07
carriers O 0 1.6344813502655597e-07
share O 0 3.5166838330269456e-08
the O 0 2.165697399192368e-09
same O 0 8.217650560027323e-09
allelic O 0 1.2556806723296177e-06
pattern O 0 1.311349478783086e-05
at O 0 6.520947408716893e-07
the O 0 6.451956124919889e-08
BRCA1 O 0 3.110793841187842e-05
locus O 0 1.0152951290365309e-05
. O 0 1.474064561080013e-06

Our O 0 1.95285861082084e-06
previous O 0 1.3065938730960625e-07
study O 0 1.579612884938797e-08
showed O 0 1.878927520237994e-07
that O 0 1.5998423696927944e-09
this O 0 2.6395259311584596e-09
Ashkenazi O 0 1.2050926670781337e-05
mutation O 0 1.6444754180611199e-07
also O 0 9.47239868764882e-08
occurs O 0 8.359646308520041e-09
in O 0 1.3396381781660693e-09
Iraqi O 0 1.0716266274357622e-07
Jews O 0 4.3466187094054476e-08
with O 0 4.18080192687853e-09
a O 0 5.7547328680129795e-08
similar O 0 4.17944875152898e-07
allelic O 0 2.668623892532196e-05
pattern O 0 0.00015173932479228824
. O 0 1.4677340232083225e-06

We O 0 1.2771366755259805e-06
extended O 0 1.1569821367629629e-07
our O 0 7.808203861259244e-09
analysis O 0 1.3774047458170458e-09
to O 0 4.4679079880260986e-10
other O 0 3.1688374146909837e-10
non O 0 8.600093792665575e-08
- O 0 5.431772933661705e-06
Ashkenazi O 0 3.9757165382070525e-07
subsets O 0 9.79366703290907e-08
354 O 0 4.407604592415737e-08
of O 0 8.673705642614493e-10
Moroccan O 0 9.77080730990565e-07
origin O 0 1.9377239368623123e-08
, O 0 4.4381067709764466e-09
200 O 0 3.666625447706906e-09
Yemenites O 0 1.7430684806640784e-07
and O 0 9.26709642357082e-09
150 O 0 1.9198447276380648e-08
Iranian O 0 1.5368507888524618e-07
Jews O 0 3.2197715427173534e-07
. O 0 1.7344392233553663e-07

Heteroduplex O 0 0.0001990344753721729
analysis O 0 1.1059680673497496e-06
complemented O 0 1.1999329672107706e-06
by O 0 7.201862217698363e-09
direct O 0 1.1961582835340323e-08
DNA O 0 9.490645425103139e-08
sequencing O 0 3.786274049843996e-08
of O 0 3.1105487074967186e-09
abnormally O 0 4.536671895039035e-06
migrating O 0 1.2952317440806382e-08
bands O 0 8.548595076263155e-08
were O 0 4.5578069318708e-08
employed O 0 3.7184986467764247e-07
. O 0 2.596822241685004e-07

Four O 0 3.148745122416585e-07
of O 0 4.782573448380845e-09
Moroccan O 0 2.9785708193230676e-06
origin O 0 3.706821161131302e-08
( O 0 2.5164204053851336e-09
1 O 0 2.2438439994942883e-09
. O 0 7.641564603311224e-10
1 O 0 3.4681226779298413e-09
% O 0 9.085250329832206e-10
) O 0 1.7079742065106984e-09
and O 0 2.7763812582293212e-08
none O 0 5.764199340063669e-09
of O 0 3.296062589530635e-10
the O 0 2.080451810826389e-09
Yemenites O 0 4.474679542454396e-07
or O 0 1.615993028281082e-08
Iranians O 0 1.8173187399384005e-08
was O 0 3.768924727864942e-07
a O 0 1.0768571812036498e-08
carrier O 0 1.7606373603484826e-07
of O 0 6.498014903932869e-10
the O 0 1.4544139226302377e-08
185delAG O 0 9.150698133453261e-06
mutation O 0 9.506160267847008e-07
. O 0 1.757718308681433e-07

BRCA1 O 0 0.0008347234688699245
allelic O 0 6.25982356723398e-05
patterns O 0 2.2120477296994068e-05
were O 0 3.372879575636034e-07
determined O 0 1.5092972205366095e-07
for O 0 2.278731647820109e-09
four O 0 8.617901947616247e-10
of O 0 5.296570404489387e-10
these O 0 2.420479372489126e-09
individuals O 0 2.0113803955723597e-09
and O 0 3.0088154190366367e-09
for O 0 6.712960742838447e-10
12 O 0 6.668232077622349e-10
additional O 0 1.0523889537594755e-09
non O 0 5.794245225843042e-07
- O 0 4.1643535951152444e-05
Ashkenazi O 0 7.0232877078524325e-06
185delAG O 0 6.885318271088181e-07
mutation O 0 9.313525595189276e-08
carriers O 0 1.1622196183225242e-07
who O 0 2.6028521915577585e-07
had O 0 0.0003635214234236628
breast B-Disease 1 0.9999796152114868
/ I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999957084655762
. O 0 1.1464065210020635e-05

Six O 0 6.129298071755329e-06
non O 0 1.4379500498762354e-05
- O 0 0.0005576929543167353
Ashkenazi O 0 9.169742406811565e-05
individuals O 0 5.689673798769945e-08
shared O 0 2.915055397068045e-08
the O 0 1.1223201035193142e-08
common O 0 1.423299664793376e-07
Ashkenazi O 0 4.846760930377059e-06
haplotype O 0 1.7781265341909602e-05
, O 0 1.854992888183915e-07
four O 0 2.9521409317112557e-08
had O 0 8.308558676617395e-07
a O 0 8.625441694221081e-08
closely O 0 5.879263653696398e-07
related O 0 1.0362781495132367e-06
pattern O 0 0.0005556739633902907
, O 0 1.5809531817012612e-07
and O 0 4.604800096785766e-08
the O 0 1.7916906847048608e-09
rest O 0 5.222243970592899e-08
( O 0 3.260436587382287e-09
n O 0 5.0325525080552325e-05
= O 0 8.513449756719638e-06
6 O 0 2.272604149311519e-08
) O 0 2.963569611935668e-09
displayed O 0 2.69829854460113e-07
a O 0 1.0030201735844457e-07
distinct O 0 1.4244187696021982e-06
BRCA1 O 0 7.487663970096037e-05
allelic O 0 4.218955655233003e-05
pattern O 0 0.00025950244162231684
. O 0 2.3218776732392143e-06

We O 0 3.5147704124938173e-07
conclude O 0 1.4350675314744876e-07
that O 0 3.320629993197599e-09
the O 0 2.7353910247995827e-09
185delAG O 0 1.5786910807946697e-05
BRCA1 O 0 1.2399369552440476e-05
mutation O 0 1.5044084022974857e-07
occurs O 0 8.72398242535155e-09
in O 0 1.3585430558293865e-09
some O 0 2.590230918642078e-09
non O 0 5.895192316529574e-07
- O 0 7.875094161136076e-05
Ashkenazi O 0 1.8187831301474944e-05
populations O 0 9.546946699856562e-08
at O 0 4.071355874657456e-08
rates O 0 1.7832864784850244e-07
comparable O 0 1.3263979781186208e-07
with O 0 2.076883554025244e-09
that O 0 5.724296592291012e-09
of O 0 2.9279608071419716e-08
Ashkenazim O 0 0.0001891892170533538
. O 0 6.290595138125354e-07

The O 0 5.201665942422551e-08
majority O 0 1.6518084677841216e-08
of O 0 1.5166775613195682e-09
Jewish O 0 1.9665691297632293e-07
185delAG O 0 4.392223672766704e-06
mutation O 0 4.815059924112575e-07
carriers O 0 8.232369452798594e-08
have O 0 2.1559637630730322e-08
a O 0 4.2289162394126834e-08
common O 0 1.0000038486168705e-07
allelic O 0 1.907402065626229e-06
pattern O 0 0.0025730968918651342
, O 0 1.1735130556189688e-07
supporting O 0 3.254088909443453e-08
the O 0 3.786149616047396e-09
founder O 0 1.827744426918798e-07
effect O 0 8.788717309471394e-09
notion O 0 1.8469025420131402e-08
, O 0 5.114985768273073e-09
but O 0 3.840656237485973e-09
dating O 0 1.7186587797368702e-07
the O 0 1.5557454213777078e-09
mutations O 0 1.5435215772185984e-08
origin O 0 2.7220723453069695e-09
to O 0 6.884725234357347e-09
an O 0 4.480173121379494e-09
earlier O 0 5.4315794528747574e-08
date O 0 2.9348166208365e-07
than O 0 2.0358285723887093e-08
currently O 0 8.078223601160062e-08
estimated O 0 4.507878657022957e-07
. O 0 2.802986216465797e-07

However O 0 2.1839769033249468e-06
, O 0 3.215514965404509e-08
the O 0 1.5420200671911743e-09
different O 0 1.2639775892608895e-09
allelic O 0 2.9159349423935055e-07
pattern O 0 1.534989132778719e-05
at O 0 1.5303818372558453e-06
the O 0 1.3294217282577847e-08
BRCA1 O 0 2.829469849530142e-06
locus O 0 2.172943993627996e-07
even O 0 9.234705089511408e-08
in O 0 2.7233548749450165e-09
some O 0 1.8168186954881094e-09
Jewish O 0 6.167594079897754e-08
mutation O 0 6.997149171183992e-08
carriers O 0 3.980147056381611e-08
, O 0 5.493422605695741e-09
might O 0 1.31114950008282e-08
suggest O 0 4.986674539964042e-08
that O 0 4.5060453146561485e-09
the O 0 1.7712997735230829e-09
mutation O 0 3.7685431664158386e-08
arose O 0 1.7593375645219567e-08
independently O 0 5.468544372888573e-08
. O 0 1.617035216838758e-08
. O 0 1.9591284683428967e-07

Crystal O 0 0.030129792168736458
structure O 0 7.09179130353732e-06
of O 0 4.969194833392976e-08
the O 0 3.2185512282012496e-06
hemochromatosis B-Disease 1 0.9999998807907104
protein O 0 8.104171138256788e-05
HFE O 0 0.006226019933819771
and O 0 9.274120316149492e-08
characterization O 0 9.065591939361184e-07
of O 0 3.1878257811257527e-09
its O 0 1.4010778315309835e-08
interaction O 0 5.445874151632779e-08
with O 0 3.210716315038553e-08
transferrin O 0 3.10601171804592e-05
receptor O 0 1.0960216059174854e-06
. O 0 2.682693036604178e-07

HFE O 0 0.26412174105644226
is O 0 1.1995339264103677e-05
an O 0 6.760108561820743e-08
MHC O 0 5.649620288750157e-05
- O 0 8.45161994220689e-05
related O 0 1.3235464848548872e-06
protein O 0 2.905287033172499e-07
that O 0 3.6131275749085034e-09
is O 0 1.7852986644584234e-08
mutated O 0 1.463200849372015e-08
in O 0 4.067100878302199e-09
the O 0 2.5081706667151593e-07
iron B-Disease 1 0.9992362260818481
- I-Disease 1 0.9999920129776001
overload I-Disease 1 0.9999895095825195
disease I-Disease 1 0.9999511241912842
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
. O 0 0.0014304356882348657

HFE O 0 0.0013434668071568012
binds O 0 9.033918104250915e-06
to O 0 2.7573364036470593e-07
transferrin O 0 3.572697823983617e-05
receptor O 0 2.3412799237121362e-06
( O 0 1.8754752417748932e-08
TfR O 0 9.19453214009991e-06
) O 0 1.5254043583823318e-09
and O 0 1.8912691412964477e-09
reduces O 0 3.075361121318565e-08
its O 0 1.928836201869899e-09
affinity O 0 2.6303702327368228e-08
for O 0 7.33524085916315e-09
iron O 0 0.001071265316568315
- O 0 5.2516326832119375e-05
loaded O 0 5.45125385542633e-06
transferrin O 0 3.25990868077497e-06
, O 0 4.834649569573912e-09
implicating O 0 1.0630661563482136e-05
HFE O 0 0.0007068833219818771
in O 0 4.844778800361382e-07
iron O 0 0.0336843803524971
metabolism O 0 0.00019457866437733173
. O 0 8.227900707424851e-07

The O 0 1.7576523987372639e-06
2 O 0 5.156618954060832e-06
. O 0 1.25987048704701e-06

6 O 0 1.7072094124159776e-05
A O 0 3.4000183859461686e-06
crystal O 0 0.0030906309839338064
structure O 0 7.111872491805116e-06
of O 0 3.981901031124835e-08
HFE O 0 0.003024735953658819
reveals O 0 1.267952370653802e-06
the O 0 6.126158691444061e-09
locations O 0 4.744588295579888e-07
of O 0 5.743799533775018e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0005360919167287648
and O 0 3.6138576433586422e-06
a O 0 2.249857288916246e-06
patch O 1 0.7375357747077942
of O 0 3.6571634609572357e-08
histidines O 0 0.002497889567166567
that O 0 6.371098493218597e-08
could O 0 5.206211994845944e-08
be O 0 3.395617786949856e-09
involved O 0 1.540779948072668e-08
in O 0 3.450652386050024e-08
pH O 0 0.014667023904621601
- O 0 6.019154898240231e-05
dependent O 0 1.1298515119051444e-06
interactions O 0 3.008272244642285e-07
. O 0 1.2419805273111706e-07

We O 0 3.0156077173160156e-06
also O 0 2.94193345240501e-08
demonstrate O 0 2.8529210993610832e-08
that O 0 6.349914372094645e-09
soluble O 0 2.1394964278442785e-05
TfR O 0 0.0008120624115690589
and O 0 7.231859200373947e-08
HFE O 0 9.611488349037245e-05
bind O 0 1.5719014356818661e-07
tightly O 0 5.558101747737965e-06
at O 0 3.642315391516604e-07
the O 0 1.3017446010010758e-09
basic O 0 4.6878188442178725e-08
pH O 0 1.0972809832310304e-05
of O 0 3.061119691061265e-10
the O 0 1.3644249063915481e-09
cell O 0 4.031689513794845e-06
surface O 0 0.0004311727825552225
, O 0 2.7285974368851384e-08
but O 0 5.687370574491979e-09
not O 0 1.0924849469517994e-08
at O 0 7.729819628821133e-08
the O 0 8.578906474099313e-09
acidic O 0 0.00027044309535995126
pH O 0 4.815914508071728e-05
of O 0 1.1473278327400749e-08
intracellular O 0 9.913675057759974e-06
vesicles O 0 0.00010805573401739821
. O 0 1.202280145662371e-06

TfR O 0 0.2789965569972992
HFE O 0 0.003350775223225355
stoichiometry O 0 2.636724639160093e-05
( O 0 2.715128744057438e-07
2 O 0 7.042417848879268e-08
1 O 0 1.4516922774987506e-08
) O 0 1.0961725971370129e-09
differs O 0 2.173279156636454e-08
from O 0 7.121937262155598e-09
TfR O 0 0.00011970971536356956
transferrin O 0 8.139623446368205e-07
stoichiometry O 0 6.06480980991364e-08
( O 0 1.5971166611450371e-09
2 O 0 3.353338273726081e-09
2 O 0 5.2386219806521694e-09
) O 0 9.280217150298142e-10
, O 0 3.609178789165668e-10
implying O 0 1.2866630427765813e-08
a O 0 2.6973625555370973e-09
different O 0 3.3426722501062045e-10
mode O 0 2.9466505679920374e-08
of O 0 3.5506494966419666e-10
binding O 0 6.300597021891008e-08
for O 0 1.317316034032956e-08
HFE O 0 0.0006079808808863163
and O 0 2.7223600795878156e-07
transferrin O 0 1.9033627722819801e-06
to O 0 1.937191740353228e-08
TfR O 0 0.0006563896895386279
, O 0 1.9428531672360805e-08
consistent O 0 1.2972768104191346e-07
with O 0 7.702354309913062e-09
our O 0 1.00665547009271e-08
demonstration O 0 4.4049323832950904e-07
that O 0 1.2729929999011347e-08
HFE O 0 1.752057869452983e-05
, O 0 7.633789600447471e-09
transferrin O 0 1.4180174048306071e-06
, O 0 8.304659182556406e-09
and O 0 1.5648683415747655e-07
TfR O 0 0.00013579256483353674
form O 0 1.570318453048003e-08
a O 0 1.3445979618609272e-07
ternary O 0 3.969775207224302e-05
complex O 0 2.7987045541522093e-05
. O 0 9.424584845874051e-07

Identification O 0 2.2496963083540322e-06
of O 0 5.800376357001369e-08
three O 0 3.4784058300374454e-08
novel O 0 3.1103726882975025e-07
mutations O 0 1.8568862287793308e-06
and O 0 1.0721316812123405e-07
a O 0 6.221494430747043e-08
high O 0 2.297913965776388e-07
frequency O 0 2.3132986370910658e-07
of O 0 7.037724847336335e-10
the O 0 2.72639555376486e-09
Arg778Leu O 0 1.3169942576496396e-05
mutation O 0 1.2273612526314537e-07
in O 0 2.4719330582456678e-08
Korean O 0 5.037916253058938e-06
patients O 0 2.7818339276564075e-07
with O 0 1.3843936130797374e-07
Wilson B-Disease 0 0.00026270427042618394
disease I-Disease 0 0.00021083781030029058
. O 0 7.165732540670433e-07

Four O 0 1.1090056659668335e-06
mutations O 0 4.769859060616e-06
- O 0 9.055560076376423e-05
- O 0 7.202347478596494e-05
R778L O 0 4.52265430794796e-06
, O 0 8.508054705202994e-09
A874V O 0 1.2716891717445833e-07
, O 0 2.5026782868309283e-09
L1083F O 0 5.8908877775820656e-08
, O 0 2.0053854132839888e-09
and O 0 1.1930338938981322e-09
2304delC O 0 7.530169909841788e-07
- O 0 4.109230940230191e-05
- O 0 2.6825606255442835e-05
in O 0 4.586950375085053e-09
the O 0 5.057516183626376e-09
copper O 0 2.6727399017545395e-05
- O 0 6.384967150552256e-07
transporting O 0 1.0034028008476525e-07
enzyme O 0 1.5711842493715267e-08
, O 0 2.6607152037172455e-09
P O 0 1.8616225133882836e-05
- O 0 6.699266918985813e-07
type O 0 6.439307981054299e-06
ATPase O 0 1.6366511772503145e-05
( O 0 3.2652907044905533e-09
ATP7B O 0 4.461731350602349e-06
) O 0 2.3541717464325984e-09
, O 0 1.5557038990365868e-09
were O 0 1.1923543929981406e-08
identified O 0 9.781271614883735e-08
in O 0 1.1135649735649622e-08
Korean O 0 4.479229392018169e-05
Patients O 0 1.68704090697247e-07
with O 0 1.1040568637099568e-07
Wilson B-Disease 0 0.00015428097685799003
disease I-Disease 0 7.517476478824392e-05
. O 0 4.274499190159986e-07

Arg778Leu O 0 0.0006133157876320183
, O 0 3.299812760815257e-07
the O 0 5.180909479207685e-09
most O 0 6.364246019074926e-09
frequently O 0 5.498582922314199e-08
reported O 0 2.522020281503501e-07
mutation O 0 1.4564709438502632e-08
of O 0 1.996632859047054e-10
this O 0 5.115629697627355e-09
enzyme O 0 8.080657920572776e-08
, O 0 1.0424127339092593e-08
was O 0 8.937224151850387e-07
found O 0 1.7610437907933374e-07
in O 0 3.2269167338228044e-09
six O 0 1.7702965759980316e-09
of O 0 9.133831468943754e-10
eight O 0 1.1550171485907867e-08
unrelated O 0 6.936118097655708e-07
patients O 0 4.288864730028763e-08
studied O 0 3.6697127114848627e-08
, O 0 1.502276525400248e-09
an O 0 8.558831976479553e-10
allele O 0 5.122486612663124e-08
frequency O 0 8.029512343910028e-08
of O 0 1.6144188208500054e-08
37 O 0 1.2556507726912969e-06
. O 0 2.4551235355829704e-07

5 O 0 1.1374061159585835e-06
% O 0 3.842584916924352e-08
, O 0 5.97057647766519e-09
which O 0 3.4681226779298413e-09
is O 0 3.3975808833019983e-09
considerably O 0 1.2255127579408054e-08
higher O 0 4.672533915339727e-09
than O 0 1.2995218234834738e-09
those O 0 2.3890642242285764e-10
in O 0 6.614093162049528e-10
other O 0 7.267735857574564e-10
Asian O 0 1.0242999337606307e-08
populations O 0 9.634348430154205e-08
. O 0 7.069347418564575e-08

The O 0 2.1622113877128868e-07
novel O 0 1.3360822492813895e-07
single O 0 5.582254658520469e-08
nucleotide O 0 1.9593488786995295e-07
deletion O 0 3.9929065565047495e-07
, O 0 1.7195661783375726e-08
2304delC O 0 9.647768592913053e-07
, O 0 7.895485154563175e-09
was O 0 7.68597885780764e-07
found O 0 1.2276726124582638e-07
in O 0 6.2490239649548585e-09
one O 0 1.2178401220808155e-07
patient O 0 5.063564913143637e-06
. O 0 2.403615724233532e-07

Since O 0 4.79720313251164e-07
a O 0 5.7117354401725606e-08
mutation O 0 1.8259221690186678e-07
at O 0 1.4085482114012393e-08
cDNA O 0 1.2941112004227762e-07
nucleotide O 0 6.81697599702602e-07
2302 O 0 2.7277648769086227e-05
( O 0 3.6572032069415172e-09
2302insC O 0 2.625599222483288e-07
) O 0 5.615699016914277e-09
had O 0 3.616307608922398e-08
been O 0 2.2405735933261894e-08
previously O 0 2.8209780111865257e-07
described O 0 4.342046850069892e-06
, O 0 9.442270965109856e-09
this O 0 1.4338868981056407e-09
region O 0 2.693148459798067e-08
of O 0 2.2946325395345468e-10
the O 0 2.840593982256223e-09
ATP7B O 0 2.322764521522913e-05
gene O 0 7.805333268606773e-08
may O 0 1.1140370759221696e-07
be O 0 5.3351861595274386e-08
susceptible O 0 4.709246695711045e-06
to O 0 1.9295216091563816e-08
gene O 0 2.5072599783015903e-06
rearrangements O 0 0.004687674809247255
causing O 0 0.007373314816504717
Wilson B-Disease 0 0.0026728063821792603
disease I-Disease 0 0.0014144934248179197
. O 0 1.0645316024238127e-06

Disruption O 0 2.2504973458126187e-05
of O 0 2.487431771669435e-08
splicing O 0 1.0658675364538794e-06
regulated O 0 1.085775124920474e-06
by O 0 7.762054110571626e-09
a O 0 1.2555258877000597e-07
CUG O 0 0.001908349571749568
- O 0 2.0224382751621306e-05
binding O 0 1.3487349406204885e-06
protein O 0 2.555212176957866e-06
in O 0 5.426657480711583e-06
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999974966049194
. O 0 1.7928263332578354e-05

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999997615814209
( O 0 0.013345211744308472
DM B-Disease 1 0.9999998807907104
) O 0 6.277623469941318e-06
is O 0 5.347962428459141e-07
caused O 0 2.7532030344445957e-07
by O 0 2.4286324062927633e-09
a O 0 3.393968484033394e-08
CTG O 0 1.1829029972432181e-05
expansion O 0 2.0785576282378315e-07
in O 0 9.351972529714203e-09
the O 0 3.5140939047551e-09
3 O 0 3.64245380524153e-08
untranslated O 0 3.2321993330697296e-06
region O 0 4.682867782435096e-08
of O 0 5.810516512383401e-09
the O 0 2.7387108048060327e-07
DM B-Disease 1 0.9999991655349731
gene O 0 7.796273166604806e-06
. O 0 9.559050795360235e-07

One O 0 8.522300163349428e-07
model O 0 1.4107927199802361e-06
of O 0 1.9555425012640626e-07
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 0.0013874095166102052
suggests O 0 9.763225534697995e-07
that O 0 1.1508586972297508e-08
RNAs O 0 2.4180135369533673e-06
from O 0 2.12348494343928e-09
the O 0 6.117001349892348e-10
expanded O 0 1.3087809946910056e-08
allele O 0 2.113086239319273e-08
create O 0 4.8333128610522635e-09
a O 0 3.4321683273219605e-08
gain O 0 2.404281076451298e-06
- O 0 1.1807277587649878e-05
of O 0 2.138353671909954e-08
- O 0 0.00024690284044481814
function O 0 1.891844476631377e-07
mutation O 0 9.895792629777134e-09
by O 0 4.100498829373578e-10
the O 0 8.532736184285739e-10
inappropriate O 0 8.63464094891242e-07
binding O 0 1.9588904720535538e-08
of O 0 1.5755760585101086e-10
proteins O 0 2.5865185548923364e-09
to O 0 2.6080482218304724e-09
the O 0 1.9463804790120776e-08
CUG O 0 0.00012993118434678763
repeats O 0 3.8122495880088536e-06
. O 0 3.953575458126579e-07

Data O 0 7.195080343080917e-06
presented O 0 3.6984246776228247e-07
here O 0 3.3164351265213554e-08
indicate O 0 1.01089661086462e-07
that O 0 1.1156691126501528e-09
the O 0 7.792385070537478e-10
conserved O 0 9.625127717072246e-08
heterogeneous O 0 3.4880606563092442e-06
nuclear O 0 6.301712710410357e-05
ribonucleoprotein O 0 3.7006568163633347e-05
, O 0 7.666576706810702e-09
CUG O 0 1.1576852557482198e-05
- O 0 4.1537737160979304e-06
binding O 0 3.941062232115655e-07
protein O 0 6.87049563907749e-08
( O 0 1.7205199487335676e-09
CUG O 0 8.243654519901611e-06
- O 0 1.0174081580771599e-05
BP O 0 8.048138624872081e-06
) O 0 2.495271100855234e-09
, O 0 2.8641018445796362e-09
may O 0 4.0765623765537384e-08
mediate O 0 3.7434022033266956e-06
the O 0 2.4448681301691977e-08
trans O 0 8.895837709133048e-06
- O 0 9.829735063249245e-05
dominant O 0 4.731385615741601e-06
effect O 0 2.0422339375159027e-08
of O 0 1.157433482390502e-09
the O 0 1.2111081026944248e-08
RNA O 0 9.246139711649448e-07
. O 0 6.875148983453983e-08

CUG O 0 0.002636110642924905
- O 0 0.0005126833566464484
BP O 0 0.0002101590362144634
was O 0 1.7686425053398125e-06
found O 0 1.5805591502271454e-08
to O 0 7.093775011846049e-10
bind O 0 1.0821858964504827e-08
to O 0 1.971773411213462e-09
the O 0 2.4422057709472256e-09
human O 0 3.4332688869653794e-07
cardiac O 0 0.0010907052783295512
troponin O 1 0.6817163228988647
T O 0 0.02101770229637623
( O 0 4.66986094238564e-09
cTNT O 0 1.9055734412631864e-07
) O 0 2.4807311760355333e-09
pre O 0 4.839657322008861e-06
- O 0 5.189106741454452e-05
messenger O 0 5.559419946621347e-07
RNA O 0 3.579470231329651e-08
and O 0 1.1932728138930315e-09
regulate O 0 1.649173775319923e-08
its O 0 1.627511458934805e-09
alternative O 0 1.5593586866202713e-08
splicing O 0 6.54561461033154e-07
. O 0 2.2761597051612625e-07

Splicing O 0 8.041794899327215e-06
of O 0 2.480061027654301e-07
cTNT O 0 1.9698027244885452e-05
was O 0 1.3416356523521245e-06
disrupted O 0 1.631620580155868e-05
in O 0 5.486597274284577e-07
DM B-Disease 1 0.9999998807907104
striated O 0 0.29147574305534363
muscle O 0 0.00020171301730442792
and O 0 1.8890932551585138e-07
in O 0 1.3135725396296039e-08
normal O 0 3.641071941729024e-07
cells O 0 6.633290183799545e-08
expressing O 0 2.2264982746378337e-08
transcripts O 0 2.9222488251434697e-07
that O 0 2.513605856790946e-08
contain O 0 1.7190911876241444e-06
CUG O 0 0.0003915086854249239
repeats O 0 1.0958953680528793e-05
. O 0 7.762884024486993e-07

Altered O 0 1.0191871297138277e-05
expression O 0 3.459394406490901e-07
of O 0 3.928578795608928e-09
genes O 0 4.857853497242104e-08
regulated O 0 2.950886823782639e-07
posttranscriptionally O 0 2.4713706352486042e-06
by O 0 1.193496501628033e-08
CUG O 0 0.0001281686854781583
- O 0 5.0317557906964794e-05
BP O 0 2.1451269276440144e-05
therefore O 0 1.56975250575897e-08
may O 0 4.278004173130512e-09
contribute O 0 1.0723807619683612e-08
to O 0 1.823506750042725e-07
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 0.00530986487865448
. O 0 3.4052388286909263e-07
. O 0 4.7446786766158766e-07

Identification O 0 3.669989837362664e-06
of O 0 3.946063387161303e-08
a O 0 2.424036438242183e-07
novel O 0 7.839214504201664e-07
nonsense O 0 0.00047106214333325624
mutation O 0 1.4857519090583082e-06
and O 0 2.3652628300396827e-08
a O 0 1.9317013766340096e-08
missense O 0 2.3597119991336513e-07
substitution O 0 1.2276370142672022e-08
in O 0 2.823632216930605e-09
the O 0 1.5947544396155422e-09
vasopressin O 0 1.7965717802326253e-07
- O 0 1.0292988918081392e-05
neurophysin O 0 1.391664227412548e-05
II O 0 2.5052471755770966e-05
gene O 0 6.705185739974695e-08
in O 0 3.706995821417536e-09
two O 0 6.3919585180372e-09
Spanish O 0 1.3949400567980774e-07
kindreds O 0 3.276607458246872e-05
with O 0 3.804778430094302e-07
familial B-Disease 1 0.9038402438163757
neurohypophyseal I-Disease 1 0.9997001886367798
diabetes I-Disease 1 0.9999673366546631
insipidus I-Disease 1 0.9993529915809631
. O 0 2.656083961483091e-05

Familial B-Disease 1 0.9988541603088379
neurohypophyseal I-Disease 1 0.9998764991760254
diabetes I-Disease 1 0.999997615814209
insipidus I-Disease 1 0.9999858140945435
( O 0 0.0003274606424383819
FNDI B-Disease 1 0.999998927116394
) O 0 6.539124797200202e-07
is O 0 5.309523203322897e-07
an O 0 1.0431226655782666e-06
autosomal B-Disease 1 0.9997417330741882
dominant I-Disease 1 0.999970555305481
disease I-Disease 1 0.999258816242218
caused O 0 0.02220604382455349
by O 0 0.0004752973618451506
deficiency O 1 0.9357131719589233
in O 0 5.23800522955753e-08
the O 0 1.9633122860795993e-07
antidiuretic O 0 0.0020124497823417187
hormone O 0 1.262199930351926e-06
arginine O 0 6.868654054414947e-07
vasopressin O 0 5.288097213451692e-07
( O 0 1.674767524662002e-08
AVP O 0 1.143952658821945e-06
) O 0 1.013614192579837e-09
encoded O 0 3.0219573510237296e-09
by O 0 1.8129002743449973e-09
the O 0 4.876222092775606e-09
AVP O 0 7.143168477341533e-05
- O 0 4.012127101304941e-05
neurophysin O 0 0.0003274428308941424
II O 0 0.00043105316581204534
( O 0 2.0065533234969735e-08
AVP O 0 3.4533102734712884e-05
- O 0 2.8204389309394173e-05
NPII O 0 2.3819857233320363e-05
) O 0 2.218002892462323e-09
gene O 0 1.2778145652703188e-08
on O 0 6.379610084650267e-08
chromosome O 0 4.583972622640431e-05
20p13 O 0 3.0508861527778208e-05
. O 0 6.409272259588761e-07

In O 0 2.0874989559160895e-07
this O 0 5.071329578498762e-09
study O 0 6.601531321592802e-09
, O 0 3.5886562610443207e-09
we O 0 3.1690687851693156e-09
analyzed O 0 1.9072894374971838e-08
two O 0 3.041833007699779e-09
families O 0 1.3717109226263346e-08
with O 0 1.8215040142877115e-08
FNDI B-Disease 1 0.9997172951698303
using O 0 2.3604675547517218e-08
direct O 0 2.229642959150624e-08
automated O 0 1.960208237505867e-06
fluorescent O 0 5.272929115562874e-07
, O 0 4.1314476284526336e-09
solid O 0 5.2252726590040766e-08
phase O 0 8.985202981648399e-08
, O 0 5.071774555887032e-09
single O 0 1.4277206616952753e-07
- O 0 4.490133960644016e-06
stranded O 0 3.747534194076252e-08
DNA O 0 3.801997827679315e-09
sequencing O 0 1.8898629328134575e-09
of O 0 1.1421089629592984e-09
PCR O 0 1.9264696220488986e-06
- O 0 1.5034962643767358e-06
amplified O 0 1.8464448885424645e-06
AVP O 0 6.11014838796109e-05
- O 0 4.3160038330825046e-05
NPII O 0 0.00018634990556165576
DNA O 0 5.018169758841395e-06
. O 0 4.5339891130424803e-07

In O 0 2.747681548953551e-07
one O 0 1.3933175502245376e-08
of O 0 7.877249963428312e-10
the O 0 5.517006407274039e-09
families O 0 3.064399933805362e-08
, O 0 6.910326977305203e-09
affected O 0 7.060049966867155e-08
individuals O 0 3.60468166427097e-09
presented O 0 5.2348095636034486e-08
a O 0 5.118736794429424e-07
novel O 0 5.598034249487682e-07
nonsense O 0 2.5313040168839507e-05
mutation O 0 4.433802303083212e-08
in O 0 1.884424172260424e-09
exon O 0 7.263931678380686e-08
3 O 0 1.4619148558381312e-08
of O 0 4.2595685312285525e-10
the O 0 2.3351476308164365e-09
gene O 0 2.69697810750813e-08
, O 0 2.1349333412246096e-09
consisting O 0 4.880455595213107e-09
in O 0 7.2972423659223296e-09
a O 0 1.5643729511793936e-07
G O 0 0.0002953510847873986
to O 0 1.7377521999151213e-07
T O 0 6.469397339969873e-05
transition O 0 3.2709024821997446e-08
at O 0 3.110805479877854e-08
nucleotide O 0 1.321501628126498e-07
2101 O 0 4.060974788444582e-06
, O 0 6.061789292743924e-09
which O 0 4.142115539451652e-09
produces O 0 9.126487121591254e-09
a O 0 2.4453936653401342e-09
stop O 0 6.211890024587774e-08
signal O 0 2.117123187872494e-07
in O 0 2.333575999102777e-09
codon O 0 1.6158888627160195e-07
82 O 0 1.1674318045606924e-07
( O 0 6.12625239426734e-09
Glu O 0 3.046815618290566e-05
) O 0 6.15198914033499e-09
of O 0 1.388017878412029e-08
NPII O 0 0.0006341275293380022
. O 0 4.6709143930456776e-07

The O 0 7.509637498515076e-07
premature O 0 1.6681175111443736e-05
termination O 0 2.446581220283406e-06
eliminates O 0 1.0365519074184704e-06
part O 0 2.7458888496312284e-08
of O 0 2.203964122315938e-09
the O 0 1.8769460652379166e-08
C O 0 0.0007994346669875085
- O 0 5.582920857705176e-05
terminal O 0 3.370147624082165e-06
domain O 0 6.897922233406462e-09
of O 0 6.257214746341333e-10
NPII O 0 8.402807725360617e-05
, O 0 2.120028819163622e-09
including O 0 4.220877813931878e-10
a O 0 1.949868488893003e-09
cysteine O 0 1.0432998465148557e-08
residue O 0 6.17391435753234e-08
in O 0 5.923488366477159e-10
position O 0 2.8306004651312833e-08
85 O 0 5.613878251153892e-09
, O 0 7.794302425701005e-10
which O 0 6.123495044363381e-09
could O 0 3.960979100270379e-08
be O 0 6.69314692558487e-09
involved O 0 1.0791621818384556e-08
in O 0 1.7444404809552339e-09
the O 0 2.3037818319693315e-09
correct O 0 3.313297611384769e-06
folding O 0 1.6602887171757175e-06
of O 0 5.132968272647531e-09
the O 0 6.376228611770784e-08
prohormone O 0 0.0010380196617916226
. O 0 4.866037670581136e-07

In O 0 2.1738188138442638e-07
the O 0 2.051212710796335e-08
second O 0 5.229280759522226e-07
family O 0 2.5528593141643796e-06
, O 0 7.738136353907521e-09
a O 0 5.317455809006333e-09
G279A O 0 2.616454963799697e-08
substitution O 0 1.1189770887654049e-08
at O 0 8.724652644787056e-08
position O 0 1.532476119336934e-07
- O 0 7.198211733339122e-07
1 O 0 1.4134320380776444e-09
of O 0 1.1403104849261325e-10
the O 0 4.791655960900698e-10
signal O 0 2.8567171739268815e-07
peptide O 0 9.171245984873622e-09
was O 0 2.745925620217804e-08
observed O 0 1.110017233685312e-08
in O 0 1.009647032645944e-09
all O 0 1.6238587141614858e-09
affected O 0 8.062722400836719e-08
individuals O 0 1.8973981497083514e-08
. O 0 8.196990108899627e-08

This O 0 4.772201691594091e-07
missense O 0 0.0001304126635659486
mutation O 0 8.652909855300095e-06
, O 0 1.145530887924906e-07
which O 0 2.0934417932494398e-07
replaces O 0 2.545013921917416e-05
Ala O 0 0.00018791973707266152
with O 0 7.788454325918792e-08
Thr O 0 0.003123387461528182
, O 0 1.2667663895626902e-07
is O 0 7.441809657393605e-08
frequent O 0 3.1897302505967673e-06
among O 0 7.22146580756089e-07
FNDI B-Disease 1 0.9999998807907104
patients O 0 2.646514076332096e-05
and O 0 1.1419804479828599e-07
is O 0 6.928344475909398e-08
thought O 0 1.800763449466558e-08
to O 0 1.4455329155893537e-09
reduce O 0 2.114223285332173e-08
the O 0 9.036135728557326e-10
efficiency O 0 5.617501486199217e-08
of O 0 1.1522880427605742e-09
cleavage O 0 5.92079368288978e-06
by O 0 7.608206509246429e-09
signal O 0 1.270065354219696e-06
peptidases O 0 8.498353054164909e-06
. O 0 3.5815602927868895e-08
. O 0 1.4642553480825882e-07

Genetic O 0 3.3380394597770646e-05
heterogeneity O 0 5.896013135497924e-06
of O 0 2.577375539658533e-07
Saethre B-Disease 1 0.9438243508338928
- I-Disease 1 0.9999806880950928
Chotzen I-Disease 1 0.9999886751174927
syndrome I-Disease 1 0.9999947547912598
, O 0 9.243974830042134e-08
due O 0 1.8407695279165637e-07
to O 0 3.0645519899508145e-08
TWIST O 0 5.6515069445595145e-05
and O 0 1.6895476164791035e-06
FGFR O 0 0.0031920610927045345
mutations O 0 6.360866336763138e-06
. O 0 5.215017608861672e-07

Thirty O 0 1.6022537238313816e-05
- O 0 9.692990715848282e-05
two O 0 5.775912015337781e-08
unrelated O 0 9.836076969804708e-06
patients O 0 1.482854088408203e-07
with O 0 2.1278636630484016e-09
features O 0 6.935318310752336e-07
of O 0 1.0085104662493904e-07
Saethre B-Disease 1 0.8455630540847778
- I-Disease 1 0.999958872795105
Chotzen I-Disease 1 0.9999933242797852
syndrome I-Disease 1 0.9999860525131226
, O 0 1.1917318687437728e-07
a O 0 8.149487484843121e-07
common O 0 3.325577563373372e-05
autosomal B-Disease 1 0.5645273327827454
dominant I-Disease 1 0.6851240396499634
condition I-Disease 0 0.04629436880350113
of O 0 7.783922910675756e-07
craniosynostosis B-Disease 1 0.9996054768562317
and O 0 0.00021791686594951898
limb B-Disease 1 0.5955581665039062
anomalies I-Disease 1 0.7573162317276001
, O 0 4.6661682517878944e-07
were O 0 3.411356033211632e-07
screened O 0 1.450453169127286e-06
for O 0 4.596777181120615e-09
mutations O 0 9.969510728069508e-08
in O 0 1.3451180613799352e-08
TWIST O 0 8.292287930089515e-06
, O 0 3.7293084176326374e-08
FGFR2 O 0 3.4931425034301355e-05
, O 0 7.675398983053583e-09
and O 0 5.7792178154159046e-08
FGFR3 O 0 0.00029732874827459455
. O 0 4.935167794428708e-07

Nine O 0 4.690502919402206e-06
novel O 0 1.529067390038108e-06
and O 0 3.691848746711912e-07
three O 0 4.326956570821494e-08
recurrent O 0 0.00021201770869083703
TWIST O 0 1.8345726857660338e-05
mutations O 0 3.0159615107550053e-06
were O 0 7.268643571478606e-07
found O 0 3.8519786471624684e-07
in O 0 6.172534927628703e-09
12 O 0 6.759231752084816e-08
families O 0 1.1006528666257509e-07
. O 0 1.3720699598707142e-07

Seven O 0 5.575805630542163e-07
families O 0 1.998010787929161e-07
were O 0 1.0578920495163402e-07
found O 0 6.532268770342853e-08
to O 0 1.252501924398075e-08
have O 0 9.993018856846447e-09
the O 0 1.6208757669389229e-09
FGFR3 O 0 3.78683689632453e-05
P250R O 0 1.4527260816521448e-07
mutation O 0 1.4821438298895373e-08
, O 0 2.8721161005051954e-09
and O 0 2.191352521663248e-08
one O 0 8.472007984039465e-09
individual O 0 4.0264240830367726e-09
was O 0 6.6049242377630435e-06
found O 0 2.3919807290440076e-07
to O 0 2.588474146136832e-08
have O 0 1.909513258624429e-08
an O 0 6.716498024417206e-09
FGFR2 O 0 4.8152072849916294e-05
VV269 O 0 3.923596977983834e-06
- O 0 1.3890388800064102e-05
270 O 0 1.4593596233680728e-06
deletion O 0 8.34168622532161e-06
. O 0 7.404635766761203e-07

To O 0 2.865366468540742e-07
date O 0 7.482450428142329e-07
, O 0 1.2323219777954364e-08
our O 0 2.1860913079763122e-09
detection O 0 7.603509288856003e-08
rate O 0 1.3565467327225633e-07
for O 0 1.7468844148993412e-09
TWIST O 0 3.1405479603563435e-06
or O 0 3.9775292748345237e-07
FGFR O 0 3.461804226390086e-05
mutations O 0 1.7033140409239422e-07
is O 0 1.6112380762933753e-08
68 O 0 1.0388880156142477e-07
% O 0 3.1068607686535188e-09
in O 0 3.6372103107140674e-09
our O 0 1.1830419310854268e-07
Saethre B-Disease 0 0.13354133069515228
- I-Disease 1 0.9997864365577698
Chotzen I-Disease 1 0.9999914169311523
syndrome I-Disease 1 0.9999929666519165
patients O 0 1.4969278936405317e-06
, O 0 4.846430368132815e-09
including O 0 8.505961268667761e-09
our O 0 3.8341511299222475e-08
five O 0 3.249387248160929e-08
patients O 0 5.862551333279953e-08
elsewhere O 0 3.325378727936368e-08
reported O 0 4.195874794277188e-07
with O 0 1.241099223392439e-08
TWIST O 0 5.724832590203732e-05
mutations O 0 1.7359003322781064e-05
. O 0 5.080186156192212e-07

More O 0 1.0887078616406143e-07
than O 0 1.9295104181082934e-08
35 O 0 1.4555127769710907e-08
different O 0 1.6377627032326814e-09
TWIST O 0 2.769828881810099e-07
mutations O 0 2.978324857849657e-07
are O 0 1.242352087871268e-08
now O 0 7.15600805278882e-08
known O 0 7.148587144456542e-08
in O 0 2.955125477654974e-09
the O 0 3.5638956230599206e-09
literature O 0 5.103022004959712e-08
. O 0 1.6506126598869741e-07

The O 0 2.1581261933079077e-07
most O 0 1.0941992201196626e-08
common O 0 1.4959068650455265e-08
phenotypic O 0 2.407903707535297e-07
features O 0 4.7244193410733715e-06
, O 0 5.92640994057092e-08
present O 0 1.245441172414985e-08
in O 0 2.9894577924238774e-09
more O 0 1.5240142481331986e-09
than O 0 2.0735360095613942e-08
a O 0 7.722157135958696e-08
third O 0 1.3777554386251722e-07
of O 0 1.1519370346491087e-08
our O 0 5.676470777871145e-07
patients O 0 5.0918604443950244e-08
with O 0 3.2147040585073228e-09
TWIST O 0 7.788016773702111e-06
mutations O 0 7.868545708333841e-07
, O 0 9.02318841866645e-09
are O 0 4.475193549069445e-09
coronal B-Disease 0 3.179582199663855e-05
synostosis I-Disease 0 9.162128117168322e-05
, O 0 2.903358264916278e-08
brachycephaly B-Disease 0 2.9311200705706142e-05
, O 0 1.203336097432839e-07
low B-Disease 0 0.0035502512473613024
frontal I-Disease 1 0.9999594688415527
hairline I-Disease 1 0.9999908208847046
, O 0 1.3738806046603713e-05
facial B-Disease 0 0.09669140726327896
asymmetry I-Disease 0 0.01272488757967949
, O 0 4.129624812776456e-06
ptosis B-Disease 1 0.8685367703437805
, O 0 8.493188943248242e-07
hypertelorism B-Disease 0 0.016148120164871216
, O 0 1.2178393262729514e-06
broad B-Disease 0 3.518202720442787e-05
great I-Disease 0 1.995619822992012e-05
toes I-Disease 0 0.014580447226762772
, O 0 4.336681413974475e-08
and O 0 1.1394315890811413e-07
clinodactyly B-Disease 0 5.539539779420011e-05
. O 0 3.366439500496199e-07

Significant O 0 1.4380858601725777e-06
intra O 0 9.603352373233065e-05
- O 0 0.0007247846806421876
and O 0 1.510561560280621e-07
interfamilial O 0 6.743354788341094e-06
phenotypic O 0 1.1961558357143076e-06
variability O 0 8.544584852643311e-05
is O 0 1.4506730394714396e-07
present O 0 2.7560158599726492e-08
for O 0 7.289438830326844e-09
either O 0 3.041226079858461e-07
TWIST O 0 3.0642611818620935e-05
mutations O 0 8.25690494821174e-06
or O 0 1.0740345715021249e-06
FGFR O 0 0.00450059724971652
mutations O 0 1.7372649381286465e-05
. O 0 1.0549366606937838e-06

The O 0 2.2459012427589187e-07
overlap O 0 8.34591503462434e-07
in O 0 1.5120079410735343e-08
clinical O 0 1.515239205218677e-07
features O 0 5.571761903411243e-06
and O 0 3.3244850783376023e-07
the O 0 6.770545457612798e-09
presence O 0 2.339056379696558e-07
, O 0 9.46639833188101e-09
in O 0 1.6603363128808724e-09
the O 0 2.3877353427792514e-09
same O 0 7.114144384701149e-09
genes O 0 6.933457807889454e-09
, O 0 8.31121560462833e-10
of O 0 5.89700510644775e-11
mutations O 0 6.6201679693733695e-09
for O 0 9.396595723742962e-10
more O 0 2.1160497798433653e-09
than O 0 1.0728308019736232e-08
one O 0 2.1480254019934364e-08
craniosynostotic B-Disease 0 1.2811019587388728e-05
condition I-Disease 0 8.75093428476248e-06
- O 0 1.753276137606008e-06
such O 0 1.3919415842167382e-08
as O 0 1.1836622348937453e-08
Saethre B-Disease 0 5.147023784957128e-06
- I-Disease 0 8.394725227844901e-06
Chotzen I-Disease 0 1.2430567949195392e-05
, I-Disease 0 6.3991798526785715e-09
Crouzon I-Disease 0 1.5887687823123997e-06
, I-Disease 0 7.414971303632001e-09
and I-Disease 0 3.655525233625667e-07
Pfeiffer I-Disease 0 0.014798039570450783
syndromes I-Disease 0 0.0003762673295568675
- O 0 0.00011953586363233626
support O 0 1.3422072697721887e-07
the O 0 3.205972154418646e-09
hypothesis O 0 2.3090075274012634e-07
that O 0 4.880735371415312e-09
TWIST O 0 6.974670441195485e-07
and O 0 6.82185401501556e-08
FGFRs O 0 1.3654978374688653e-06
are O 0 1.953896822115553e-09
components O 0 3.8990716433318084e-08
of O 0 1.986126957342904e-10
the O 0 9.010027723910241e-10
same O 0 4.380322771169176e-09
molecular O 0 4.428621380725417e-08
pathway O 0 7.95847210355305e-09
involved O 0 1.0691865170997517e-08
in O 0 1.0050416054951938e-09
the O 0 6.581700739971552e-10
modulation O 0 7.354464770514824e-08
of O 0 2.06518429024527e-08
craniofacial O 1 0.985798716545105
and O 0 1.5822859495528974e-05
limb O 0 0.006529848091304302
development O 0 1.140254468623425e-07
in O 0 2.02574987895332e-08
humans O 0 2.3655335468220073e-08
. O 0 1.0355698520925216e-08
. O 0 1.9048104604735272e-07

Mutation O 0 2.020901592914015e-05
analysis O 0 1.0753373089755769e-06
of O 0 3.5492553251970094e-07
UBE3A O 1 0.9862989783287048
in O 0 0.19863711297512054
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.018621399998664856
. O 0 5.2073123697482515e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00170573138166219
AS B-Disease 1 0.9998900890350342
) O 0 1.0510036929645139e-07
is O 0 1.209933202517277e-07
caused O 0 5.521029606825323e-07
by O 0 1.4597804742777498e-08
chromosome O 0 2.253461025247816e-05
15q11 O 0 1.887489815999288e-05
- O 0 4.194732537143864e-05
q13 O 0 7.757252546980453e-07
deletions O 0 1.6560522908548592e-07
of O 0 1.7068419566612647e-08
maternal O 0 6.758149083907483e-06
origin O 0 1.0403910977174746e-07
, O 0 5.3602370542193967e-08
by O 0 6.81813361325112e-08
paternal O 0 0.0009749120217747986
uniparental B-Disease 0 0.39599138498306274
disomy I-Disease 1 0.6808023452758789
( O 0 7.661516065127216e-06
UPD B-Disease 1 0.9999940395355225
) O 0 8.431758402593914e-08
15 O 0 3.668844783533132e-08
, O 0 4.3795709281369e-09
by O 0 5.663501667640958e-09
imprinting O 0 0.008721569553017616
defects O 1 0.9887484312057495
, O 0 1.552207749000445e-07
and O 0 1.7963314391522545e-08
by O 0 3.895152644872724e-09
mutations O 0 1.031133649576077e-07
in O 0 6.370427740876039e-09
the O 0 4.035267409108201e-08
UBE3A O 0 0.0007145211566239595
gene O 0 2.2790559341956396e-06
. O 0 4.645769706712599e-07

UBE3A O 0 0.009122481569647789
encodes O 0 3.207410918548703e-05
a O 0 1.6397896160924574e-06
ubiquitin O 0 1.659008012211416e-05
- O 0 6.251614831853658e-05
protein O 0 1.8876490059938078e-07
ligase O 0 6.292779062277987e-07
and O 0 1.7303444010963176e-08
shows O 0 3.547993117081205e-07
brain O 0 4.9983386816165876e-06
- O 0 8.919869287637994e-06
specific O 0 1.3553542999034107e-07
imprinting O 0 9.26205248106271e-05
. O 0 1.2247169252077583e-06

Here O 0 8.330583227689203e-07
we O 0 9.28713035364126e-08
describe O 0 2.7269800284557277e-07
UBE3A O 0 0.0001843823993112892
coding O 0 5.29719254700467e-05
- O 0 0.00023931075702421367
region O 0 3.917880633252935e-07
mutations O 0 3.1961809554559295e-07
detected O 0 1.0727355856943177e-06
by O 0 3.661202674365427e-09
SSCP O 0 4.403757884574588e-06
analysis O 0 2.0598891481427017e-08
in O 0 1.4810501269835186e-08
13 O 0 2.8722553224724834e-07
AS B-Disease 1 0.9677802324295044
individuals O 0 3.827414474244506e-08
or O 0 7.930984793347307e-07
families O 0 1.2718989239601797e-07
. O 0 2.570036485849414e-07

Two O 0 1.2751797839882784e-06
identical O 0 9.969346137950197e-06
de O 0 5.531825536309043e-06
novo O 0 2.6471864202903816e-06
5 O 0 4.9570875404469916e-08
- O 0 2.8934518923051655e-06
bp O 0 4.541189753126673e-07
duplications O 0 1.596661292069257e-07
in O 0 4.530217978526707e-09
exon O 0 8.61884473124519e-07
16 O 0 7.495914644550794e-08
were O 0 1.5595912827848224e-07
found O 0 3.1240833209267294e-07
. O 0 2.2885078010403959e-07

Among O 0 6.346514282995486e-07
the O 0 6.63485621998916e-09
other O 0 2.0425017233094422e-09
11 O 0 3.1894555885259024e-09
unique O 0 7.93640175800192e-09
mutations O 0 1.3721721359161165e-07
, O 0 6.5846674779379555e-09
8 O 0 1.317135112088863e-08
were O 0 8.353226377266765e-08
small O 0 3.696407091524634e-08
deletions O 0 2.7239382305310755e-08
or O 0 1.8357061648544004e-08
insertions O 0 3.8054463402659167e-07
predicted O 0 1.2909476936329156e-05
to O 0 1.3142868127147267e-08
cause O 0 8.386925856029848e-07
frameshifts O 0 0.00013177456276025623
, O 0 8.386576411112401e-08
1 O 0 6.324835055693256e-08
was O 0 3.210170689271763e-06
a O 0 6.777770522603532e-08
mutation O 0 2.66066582099711e-08
to O 0 2.5566868622206584e-09
a O 0 2.015759648088533e-08
stop O 0 1.6505936173416558e-07
codon O 0 4.7883261800052423e-08
, O 0 3.590998165492465e-09
1 O 0 2.0289467883571888e-09
was O 0 1.8733913975665928e-07
a O 0 3.096438305760785e-08
missense O 0 5.8331552281742916e-06
mutation O 0 2.197577089191327e-07
, O 0 1.7966398146995743e-08
and O 0 5.082700837988341e-08
1 O 0 6.848266309589235e-08
was O 0 2.382174352533184e-05
predicted O 0 7.423637725878507e-06
to O 0 5.74582728063433e-08
cause O 0 3.422634335947805e-07
insertion O 0 9.969795655706548e-08
of O 0 5.879928544061386e-09
an O 0 3.0322652833092434e-07
isoleucine O 0 0.011473960243165493
in O 0 4.1632812752823156e-08
the O 0 3.0583549026630408e-09
hect O 0 1.3721867162530543e-06
domain O 0 1.9503827886069303e-08
of O 0 1.3954312150232795e-09
the O 0 4.521697682946524e-09
UBE3A O 0 6.76373892929405e-05
protein O 0 7.827547676697577e-08
, O 0 2.061149695364861e-09
which O 0 8.678967544639704e-10
functions O 0 1.0506441272539746e-09
in O 0 9.640644949016064e-10
E2 O 0 1.4124202607490588e-06
binding O 0 1.4723026708907128e-07
and O 0 1.7349776726405253e-08
ubiquitin O 0 1.172332304122392e-06
transfer O 0 4.389805781102041e-07
. O 0 4.6190066882445535e-07

Eight O 0 6.619778218919237e-07
of O 0 1.5517453988422858e-08
the O 0 1.0096340652410163e-08
cases O 0 4.7550884119118564e-08
were O 0 8.756458669267886e-07
familial O 0 0.00038781092735007405
, O 0 3.614225363435253e-07
and O 0 6.725333179247173e-08
five O 0 1.642361979747875e-08
were O 0 4.408210543260793e-07
sporadic O 0 4.260746936779469e-05
. O 0 5.985875759506598e-07

In O 0 2.74513581643987e-07
two O 0 5.724234242165949e-08
familial O 0 0.00012329814489930868
cases O 0 5.090132617624477e-07
and O 0 1.1395620447274268e-07
one O 0 2.5415671345285773e-08
sporadic O 0 7.547321729362011e-05
case O 0 1.968221567949513e-06
, O 0 1.1955608059111e-08
mosaicism O 0 8.706864718988072e-06
for O 0 1.3911400920108008e-08
UBE3A O 0 0.00025111783179454505
mutations O 0 6.187784720168565e-07
was O 0 1.3046258118265541e-06
detected O 0 1.3139107068127487e-05
in O 0 2.9021402170315014e-08
the O 0 3.938273707149165e-08
mother O 0 5.411442998592975e-06
of O 0 5.302658756534129e-09
three O 0 1.2043927881677519e-06
AS B-Disease 1 0.9999978542327881
sons O 0 0.0004925902467221022
, O 0 4.0443136839485305e-08
in O 0 2.36614727811002e-08
the O 0 8.330394507538585e-08
maternal O 0 2.8818889404647052e-05
grandfather O 0 6.28459611107246e-06
of O 0 9.83550307864789e-09
two O 0 2.179959750492344e-07
AS B-Disease 1 0.9988445043563843
first O 0 3.4526939884926833e-07
cousins O 0 3.436428232816979e-05
, O 0 3.9346250702010366e-08
and O 0 4.110024320880257e-08
in O 0 1.0412839479556624e-08
the O 0 3.621885014126747e-08
mother O 0 2.304883082615561e-06
of O 0 1.3375294205530963e-09
an O 0 1.5605256749040564e-06
AS B-Disease 1 0.9999722242355347
daughter O 0 0.23042821884155273
. O 0 1.1544299240995315e-06

The O 0 2.728160275466962e-08
frequencies O 0 7.281521163804427e-08
with O 0 2.8537903151715227e-09
which O 0 1.2220115586103475e-08
we O 0 6.4974239322168614e-09
detected O 0 4.7053944740582665e-08
mutations O 0 7.297006110462689e-09
were O 0 4.677386655771443e-08
5 O 0 6.192250712189207e-09
( O 0 5.136286396201228e-10
14 O 0 1.2697478624090763e-09
% O 0 1.2151468720134062e-10
) O 0 4.417149979119017e-11
of O 0 1.7719105349645048e-10
35 O 0 5.139473735482625e-09
in O 0 1.6923699108772894e-09
sporadic O 0 1.9207647710572928e-05
cases O 0 1.0236811931463308e-07
and O 0 1.785038961088503e-07
8 O 0 2.605866633587084e-08
( O 0 4.6325454583495684e-10
80 O 0 2.185365888252022e-09
% O 0 2.8522326167568224e-10
) O 0 9.149851015743948e-11
of O 0 1.615948347355456e-10
10 O 0 4.309008705405404e-09
in O 0 1.4327777186906587e-08
familial O 0 5.109206176712178e-05
cases O 0 2.0440465675619635e-07
. O 0 3.38697745405625e-08
. O 0 2.831579024586972e-07

The O 0 6.582022251677699e-06
hemochromatosis B-Disease 1 0.99994957447052
845 O 0 0.000742583186365664
G O 0 0.05471406131982803
- O 0 0.0007124004769138992
- O 0 2.1267638658173382e-05
> O 0 1.9294465403163485e-07
A O 0 2.8953342834370233e-08
and O 0 4.17082191006557e-09
187 O 0 2.9600119688666382e-08
C O 0 3.195368890374084e-06
- O 0 1.8240843928651884e-05
- O 0 0.00024702175869606435
> O 0 3.0335634164657677e-06
G O 0 6.027609924785793e-05
mutations O 0 2.90718560336245e-07
: O 0 5.924508883481394e-09
prevalence O 0 2.724811793086701e-06
in O 0 1.1541934519243569e-08
non O 0 6.6817224251281004e-06
- O 0 0.00576024642214179
Caucasian O 0 9.385869634570554e-05
populations O 0 9.927648534358013e-07
. O 0 2.7351947551323974e-07

Hemochromatosis B-Disease 1 0.9988403916358948
, O 0 2.4134787963703275e-05
the O 0 4.5783941459376365e-05
inherited B-Disease 1 0.9999998807907104
disorder I-Disease 1 1.0
of I-Disease 0 6.030566964909667e-06
iron I-Disease 1 0.9981858134269714
metabolism I-Disease 0 0.00067601737100631
, O 0 1.9104646753476118e-07
leads O 0 2.3147330807660182e-07
, O 0 6.0021498882179e-08
if O 0 2.5914141588145867e-07
untreated O 0 1.590329520695377e-05
, O 0 1.0543061534917797e-08
to O 0 7.157319004136298e-08
progressive O 0 0.000511297897901386
iron B-Disease 1 0.976963460445404
overload I-Disease 0 0.06099372357130051
and O 0 2.6626971703080926e-06
premature B-Disease 0 0.00038800027687102556
death I-Disease 0 5.373234671424143e-06
. O 0 1.0210394520981936e-06

The O 0 6.210353603819385e-06
hemochromatosis B-Disease 1 0.9999922513961792
gene O 0 2.469025093887467e-05
, O 0 1.5333168335018854e-07
HFE O 0 0.00032522709807381034
, O 0 6.426336085496587e-08
recently O 0 8.460996241410612e-07
has O 0 4.545626453023033e-08
been O 0 1.3370892304465087e-07
identified O 0 4.5279998062142113e-07
, O 0 5.39278310895952e-09
and O 0 7.894806586250525e-09
characterization O 0 2.4267822595902544e-07
of O 0 3.960521632873082e-10
this O 0 2.801776144423229e-09
gene O 0 7.570977089699227e-08
has O 0 8.853733390878915e-08
shown O 0 3.757547162308583e-08
that O 0 1.890201772880573e-09
it O 0 2.542623001033917e-09
contains O 0 2.2429282875435774e-09
two O 0 1.1128254984171804e-09
mutations O 0 6.11122246141349e-08
that O 0 2.321947745187458e-09
result O 0 7.47726236483004e-09
in O 0 1.2310316099828356e-09
amino O 0 6.317514511522404e-09
acid O 0 4.8570818478310684e-09
substitutions O 0 1.8919124045169156e-08
- O 0 4.6211482640501345e-08
cDNA O 0 2.7116941581084575e-08
nucleotides O 0 1.687648421011545e-08
845 O 0 9.983649107425663e-08
G O 0 4.534431354841217e-06
- O 0 2.034330645983573e-05
- O 0 0.00010824209311977029
> O 0 1.6134129054989899e-07
A O 0 5.6597677655645384e-08
( O 0 4.712215617708182e-10
C282Y O 0 1.631957324832456e-08
) O 0 1.5146243981245533e-10
and O 0 3.2255489945676175e-10
187 O 0 8.392492922837391e-09
C O 0 2.3862148736952804e-06
- O 0 5.715417501050979e-05
- O 0 0.001565388636663556
> O 0 5.136191703059012e-06
G O 0 0.00013667838356923312
( O 0 3.110621449309292e-08
H63D O 0 2.025727189902682e-05
) O 0 3.5456924507570875e-08
. O 0 1.0533779004617827e-07

Although O 0 0.0006269719451665878
hemochromatosis B-Disease 1 0.999998927116394
is O 0 2.7806001980934525e-06
common O 0 1.55352580577528e-07
in O 0 3.57990570520883e-09
Caucasians O 0 4.873617172052036e-07
, O 0 6.579005784601577e-09
affecting O 0 3.432370832001652e-08
> O 0 3.3764902696020727e-07
= O 0 1.1444426490925252e-06
1 O 0 1.3119599628907963e-08
/ O 0 5.997000585011847e-07
300 O 0 1.2045285657791283e-08
individuals O 0 9.744095530450636e-10
of O 0 5.899765120886968e-10
northern O 0 2.588741665476846e-07
European O 0 1.926744985780715e-08
origin O 0 1.4807253201354342e-08
, O 0 3.864709086087714e-08
it O 0 4.9212701469514286e-08
has O 0 1.3259426623335457e-07
not O 0 1.0926850535497579e-08
been O 0 5.26352330609825e-08
recognized O 0 4.776356199442944e-09
in O 0 1.1755573181559953e-09
other O 0 2.016550926242644e-09
populations O 0 1.0349462797876186e-07
. O 0 1.2151461703524546e-07

The O 0 8.342113488879477e-08
present O 0 1.4782421509096366e-08
study O 0 2.5992532570739968e-09
used O 0 4.6226795724635394e-09
PCR O 0 7.899568004177127e-07
and O 0 2.768162810085073e-09
restriction O 0 1.1767181717914355e-07
- O 0 2.1285727598296944e-06
enzyme O 0 3.2673856509291e-08
digestion O 0 6.773544214411231e-08
to O 0 2.090196682402734e-09
analyze O 0 1.5257890950692854e-08
the O 0 2.116391645268223e-10
frequency O 0 8.624384761901638e-09
of O 0 2.2373002062092695e-10
the O 0 7.847916205783179e-10
845 O 0 3.0261873007475515e-07
G O 0 2.213579682575073e-05
- O 0 1.8403765352559276e-05
- O 0 1.1573562915145885e-05
> O 0 3.376199941840241e-08
A O 0 2.5405979542370005e-08
and O 0 4.9012398584125094e-09
187 O 0 1.767955737363991e-08
C O 0 2.5868264401651686e-06
- O 0 5.000627425033599e-06
- O 0 1.5805017028469592e-05
> O 0 3.240883472699352e-07
G O 0 1.181014567919192e-06
mutations O 0 1.544319516710857e-08
in O 0 6.388180207039795e-09
HLA O 0 3.6832709156442434e-05
- O 0 3.9527940316475e-06
typed O 0 2.6462399205229303e-07
samples O 0 2.646529573269163e-08
from O 0 1.0192129362707192e-09
non O 0 1.9002182227723097e-07
- O 0 3.0797211366007105e-05
Caucasian O 0 5.488907845574431e-06
populations O 0 1.3631409956360585e-07
, O 0 1.001205340855904e-09
comprising O 0 1.5885551762906402e-09
Australian O 0 1.2005330063402653e-08
Aboriginal O 0 9.750611695835687e-08
, O 0 3.4576603802349837e-09
Chinese O 0 6.569547683632493e-10
, O 0 4.3918344516669094e-09
and O 0 1.4036189099897456e-08
Pacific O 0 8.253798711166382e-08
Islanders O 0 4.538821656296932e-07
. O 0 3.285835248334479e-07

Results O 0 3.0498451906169066e-06
showed O 0 8.33702870295383e-07
that O 0 1.6835837168827084e-09
the O 0 1.9511410265238283e-09
845 O 0 8.708896643838671e-07
G O 0 0.00034409129875712097
- O 0 0.00035360187757760286
- O 0 0.001134412596002221
> O 0 4.249113487730938e-07
A O 0 1.2160852236320352e-07
mutation O 0 1.1493609264334737e-07
was O 0 7.585690582345705e-07
present O 0 1.8833077319868607e-08
in O 0 1.2879692867784343e-08
these O 0 3.969371942247335e-09
populations O 0 6.17479578579605e-09
( O 0 1.4311866969318743e-10
allele O 0 2.5407129733423517e-09
frequency O 0 1.643552849373009e-08
0 O 0 4.599750802469771e-09
. O 0 3.6133943059901696e-10
32 O 0 1.2221345047080945e-09
% O 0 3.2203972821776006e-10
) O 0 1.4999401720672267e-09
, O 0 1.1643447095366355e-08
and O 0 2.560485654612421e-07
, O 0 9.9436983092005e-09
furthermore O 0 4.246383156214506e-08
, O 0 2.7148598924497946e-09
it O 0 5.5611355520568395e-09
was O 0 2.6191969482169952e-06
always O 0 2.2875258309795754e-07
seen O 0 2.19576065774163e-07
in O 0 3.9606276591719336e-10
conjunction O 0 8.315040211925862e-09
with O 0 2.2177754743779587e-08
HLA O 0 2.527333708712831e-05
haplotypes O 0 2.9136887746972207e-07
common O 0 1.308596253579708e-08
in O 0 5.136759018142811e-09
Caucasians O 0 2.7586145279201446e-07
, O 0 4.2409573630664e-09
suggesting O 0 3.5007559517907794e-08
that O 0 2.144724620123384e-09
845 O 0 3.2155585927284847e-07
G O 0 0.0005947854369878769
- O 0 0.002425779588520527
- O 0 0.006905646063387394
> O 0 1.1065704939028365e-06
A O 0 2.11974452213326e-06
may O 0 1.3686242255062098e-06
have O 0 1.008533168089798e-08
been O 0 5.5748250460396775e-09
introduced O 0 9.853861060449276e-10
into O 0 2.0182273907654036e-10
these O 0 3.59377111402992e-10
populations O 0 6.850484624010278e-09
by O 0 3.9109870897391374e-09
Caucasian O 0 2.2600481770496117e-06
admixture O 0 1.3438018868328072e-05
. O 0 8.391934329665673e-07

187 O 0 8.372226147912443e-06
C O 0 7.383223419310525e-05
- O 0 4.706211984739639e-05
- O 0 3.368630132172257e-05
> O 0 1.9966411457517097e-07
G O 0 3.6144297155260574e-06
was O 0 4.134588209581125e-07
present O 0 5.5873861093402866e-09
at O 0 1.1112988751449393e-08
an O 0 4.889155191811767e-10
allele O 0 1.8618850461393777e-08
frequency O 0 2.9244446864140627e-08
of O 0 3.625947542218455e-09
2 O 0 1.561731579613479e-07
. O 0 2.344753937677524e-07

68 O 0 9.102843250730075e-06
% O 0 4.5562511985508536e-08
in O 0 7.195285700589693e-09
the O 0 3.999428344059197e-09
two O 0 6.758236192894174e-09
populations O 0 7.571728133370925e-08
analyzed O 0 2.3158482065355201e-07
( O 0 5.1418855839813205e-09
Australian O 0 3.497792633311292e-08
Aboriginal O 0 2.980867748192395e-07
and O 0 3.830226091849909e-08
Chinese O 0 8.494920322732469e-09
) O 0 2.4577772705924872e-08
. O 0 1.7056677847904211e-07

In O 0 2.9874334472879127e-07
the O 0 7.480971397910707e-09
Australian O 0 2.4795022923740362e-08
Aboriginal O 0 2.2338825900192205e-08
samples O 0 8.635083759145346e-09
, O 0 6.381175032821318e-10
187 O 0 9.714797855053803e-09
C O 0 3.2866794299479807e-06
- O 0 6.417887107090792e-06
- O 0 4.665539745474234e-05
> O 0 5.165017569197516e-07
G O 0 5.264378705760464e-05
was O 0 9.396992936672177e-06
found O 0 7.205011343103251e-08
to O 0 4.369600237197346e-09
be O 0 1.6706199090776863e-08
associated O 0 4.510587459094495e-08
with O 0 4.343518966720694e-08
HLA O 0 0.0002498122921679169
haplotypes O 0 4.613279998011421e-06
common O 0 4.969347173755523e-07
in O 0 1.3491726846837082e-08
Caucasians O 0 1.949955645841328e-07
, O 0 4.186355706536915e-09
suggesting O 0 4.364080297136752e-08
that O 0 6.8956329535296845e-09
it O 0 1.241335922941289e-08
was O 0 1.8846917271275743e-07
introduced O 0 8.175860877202012e-09
by O 0 2.691247003028252e-09
recent O 0 2.8817479957865544e-08
admixture O 0 3.0543162665708223e-06
. O 0 3.7065245805933955e-07

In O 0 7.516545252883589e-08
the O 0 1.9526151806559255e-09
Chinese O 0 5.552918680429286e-10
samples O 0 1.0385621251884913e-09
analyzed O 0 5.5990145853002105e-09
, O 0 7.080973585260608e-10
187 O 0 1.368454949357556e-08
C O 0 3.072027539019473e-06
- O 0 2.0140350898145698e-05
- O 0 0.00011505190923344344
> O 0 8.060690674938087e-07
G O 0 4.9333833885611966e-05
was O 0 1.4253373592509888e-05
present O 0 1.992332983036249e-07
in O 0 4.77033132995075e-08
association O 0 5.7897210581359104e-08
with O 0 1.2471978116934679e-08
a O 0 1.526599078260915e-07
wide O 0 5.996291747578653e-07
variety O 0 3.3995789294749557e-08
of O 0 1.036433339152154e-08
HLA O 0 9.057010902324691e-05
haplotypes O 0 2.8684692097158404e-06
, O 0 1.0541050698975596e-08
showing O 0 2.2696850976444694e-07
this O 0 1.111667202735589e-09
mutation O 0 7.612575458892934e-09
to O 0 2.511155949846966e-09
be O 0 1.695381968147558e-08
widespread O 0 2.8829738596414245e-08
and O 0 1.1743124161966989e-07
likely O 0 6.941029084828187e-08
to O 0 2.28456342732386e-09
predate O 0 3.8825749015813926e-07
the O 0 8.719885369323777e-10
more O 0 4.930360009147705e-10
genetically O 0 1.3974616130951745e-08
restricted O 0 2.773644958153909e-08
845 O 0 6.624287038903276e-07
G O 0 0.005938214249908924
- O 0 0.002065386390313506
- O 0 0.0002156950649805367
> O 0 1.113898292715021e-06
A O 0 2.7235284960624995e-07
mutation O 0 9.343824558527558e-07
. O 0 1.400418483399335e-07

Genotype O 0 0.005648551508784294
- O 0 0.002036824356764555
phenotype O 0 0.0001844831567723304
correlations O 0 0.0007523745880462229
in O 0 4.039754276163876e-05
attenuated B-Disease 1 0.9997095465660095
adenomatous I-Disease 1 0.9999939203262329
polyposis I-Disease 1 0.9999207258224487
coli I-Disease 1 0.999900221824646
. O 0 3.4805598261300474e-05

Germ O 0 0.20083467662334442
- O 0 0.0011030645109713078
line O 0 8.915396392694674e-06
mutations O 0 1.3109475105466117e-07
of O 0 9.566186731646553e-10
the O 0 7.32573290918026e-09
tumor B-Disease 0 5.339775452739559e-05
suppressor O 0 1.8661121430341154e-05
APC O 0 1.6505164239788428e-06
are O 0 4.2121961030261446e-08
implicated O 0 2.595698242657818e-05
in O 0 1.1109492334071547e-05
attenuated B-Disease 1 0.9998917579650879
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999963045120239
coli I-Disease 1 0.9999985694885254
( O 0 0.0003918056609109044
AAPC B-Disease 1 0.9999958276748657
) O 0 9.958589544112328e-07
, O 0 6.065631197316179e-08
a O 0 9.972097814170411e-08
variant O 0 0.0011830193689092994
of O 0 7.6213305874262e-05
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.999990701675415
polyposis I-Disease 1 0.9999991655349731
( O 0 4.609885218087584e-05
FAP B-Disease 0 0.00030416843947023153
) O 0 3.4279295846317837e-07
. O 0 6.000822168061859e-07

AAPC B-Disease 1 0.9999487400054932
is O 0 1.0367979484726675e-05
recognized O 0 1.2460237996947399e-07
by O 0 5.572422079325179e-09
the O 0 1.283965600507031e-09
occurrence O 0 3.7593184742945596e-07
of O 0 5.286056925513094e-09
< O 0 4.484726014197804e-05
100 O 0 1.4209113885499391e-07
colonic B-Disease 0 0.0005900335381738842
adenomas I-Disease 0 0.00013069564010947943
and O 0 5.0087898273432074e-08
a O 0 2.8550168451602076e-08
later O 0 2.40349208979751e-07
onset O 0 0.0011575089301913977
of O 0 0.06390780210494995
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 2.142604245136681e-07
age O 0 3.046111203275359e-07
> O 0 8.033906624405063e-07
40 O 0 4.4480493954779377e-08
years O 0 2.6450205581340924e-08
) O 0 4.903935391098457e-08
. O 0 1.325596201695589e-07

The O 0 1.7007315022965486e-07
aim O 0 2.0414363177678752e-07
of O 0 6.014693187950115e-10
this O 0 3.798117931275158e-10
study O 0 1.7015686637478211e-09
was O 0 3.9684429964381707e-08
to O 0 6.578114941646618e-09
assess O 0 1.1003952522514737e-06
genotype O 0 1.425889422534965e-05
- O 0 6.591874989680946e-05
phenotype O 0 1.6266396414721385e-05
correlations O 0 2.7626696464722045e-05
in O 0 4.5294004848983604e-06
AAPC B-Disease 1 0.9999845027923584
families O 0 6.615552592847962e-06
. O 0 4.68570902967258e-07

By O 0 7.131876031962747e-07
protein O 0 8.450174391327891e-07
- O 0 9.31611612031702e-06
truncation O 0 5.216995305090677e-06
test O 0 5.802069154015044e-07
( O 0 1.5194775437876729e-09
PTT O 0 7.172898364160574e-08
) O 0 3.9852857125488583e-10
assay O 0 9.737582473690054e-08
, O 0 9.203081630104748e-10
the O 0 1.8699333748095626e-10
entire O 0 2.206261662252018e-08
coding O 0 5.278211574477609e-07
region O 0 6.114417061553468e-08
of O 0 8.302105114488256e-10
the O 0 6.654678141870818e-09
APC B-Disease 0 1.6505558164681133e-07
gene O 0 4.8661807028338444e-08
was O 0 2.0842824710598506e-07
screened O 0 2.892707584578602e-07
in O 0 4.256305974337238e-09
affected O 0 9.709300741178595e-08
individuals O 0 2.528269815726958e-09
from O 0 1.6201287422745736e-08
11 O 0 1.7376523828716017e-06
AAPC B-Disease 1 0.9999943971633911
kindreds O 0 0.005524332169443369
, O 0 8.527096042598714e-07
and O 0 1.829309859147088e-08
their O 0 2.618175898305708e-09
phenotypic O 0 7.363755685219076e-07
differences O 0 6.127575602477009e-07
were O 0 5.636100013362011e-07
examined O 0 1.0607996046019252e-05
. O 0 7.053803301459993e-07

Five O 0 1.3950800621387316e-06
novel O 0 1.7910837186718709e-06
germ O 0 0.002290642587468028
- O 0 0.0029558727983385324
line O 0 0.00011518155224621296
APC B-Disease 0 3.4075296753144357e-06
mutations O 0 3.1613129181096156e-07
were O 0 1.552453596787018e-07
identified O 0 3.3299332358183165e-07
in O 0 1.749479316970337e-08
seven O 0 2.489573205366469e-07
kindreds O 0 0.00031124602537602186
. O 0 9.718376077216817e-07

Mutations O 0 2.0305609723436646e-05
were O 0 1.9171607164025772e-06
located O 0 1.5341986454586731e-06
in O 0 5.891277687908314e-09
three O 0 1.1003769007089659e-09
different O 0 1.5004832099041465e-10
regions O 0 6.78647360530249e-09
of O 0 5.809006609069911e-10
the O 0 6.739738545036289e-09
APC B-Disease 0 5.392466277953645e-07
gene O 0 3.214301003140463e-08
( O 0 5.303414374324689e-10
1 O 0 1.8944175117496798e-09
) O 0 4.484984050812102e-10
at O 0 1.894982304406767e-08
the O 0 5.793162061173973e-10
5 O 0 6.70235689170795e-09
end O 0 4.505274020516481e-08
spanning O 0 9.362488384567769e-08
exons O 0 4.111279139351609e-08
4 O 0 1.683774186744813e-08
and O 0 3.079182064880115e-08
5 O 0 1.7766703663824046e-08
, O 0 8.410440344164272e-09
( O 0 4.773967332560858e-10
2 O 0 5.226356236676111e-09
) O 0 3.333484877021675e-10
within O 0 4.09165507031517e-10
exon O 0 3.030669049053358e-08
9 O 0 2.2603016702760215e-07
, O 0 9.647252774414028e-09
and O 0 1.9894160985245435e-08
( O 0 5.330664243352601e-10
3 O 0 3.0119045035803538e-09
) O 0 5.147220982770762e-10
at O 0 2.63460808724858e-08
the O 0 6.311753897314532e-10
3 O 0 1.0516951753913872e-08
distal O 0 3.535303903845488e-06
end O 0 7.703075652898406e-07
of O 0 4.455460000940548e-09
the O 0 7.646831612362348e-09
gene O 0 2.1463795008003217e-07
. O 0 3.0256936156547454e-07

Variability O 0 0.0010283607989549637
in O 0 1.2192019482881733e-07
the O 0 5.385978329996988e-09
number O 0 3.3153536804775285e-08
of O 0 1.2320737369009294e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.4458424150943756
most O 0 2.682439799173153e-07
apparent O 0 3.3618944144109264e-06
in O 0 4.670735975764728e-08
individuals O 0 1.152424822237208e-08
with O 0 1.255185377857515e-08
mutations O 0 3.190279187492706e-07
in O 0 8.92417428843828e-09
region O 0 4.298237286093354e-07
1 O 0 2.2880777805767138e-07
, O 0 1.986570765666329e-07
and O 0 1.934206693476881e-06
upper O 0 0.26380521059036255
- O 1 0.9909815192222595
gastrointestinal O 0 0.07343034446239471
manifestations O 0 6.191324700921541e-06
were O 0 1.0780511274788296e-06
more O 0 1.9800694417426712e-08
severe O 0 1.737536308610288e-06
in O 0 2.3050783504174888e-09
them O 0 2.0114965693096565e-08
. O 0 1.951462422766781e-07

In O 0 3.021480949882971e-07
individuals O 0 4.150737709096575e-08
with O 0 6.065189239734536e-09
mutations O 0 1.4366983691616042e-07
in O 0 7.086895514873959e-09
either O 0 8.673300300188203e-08
region O 0 7.271194704117079e-07
2 O 0 2.2969409485540382e-07
or O 0 2.2343009220548993e-07
region O 0 2.0249625265478244e-07
3 O 0 1.039466290819746e-08
, O 0 3.006308535447033e-09
the O 0 5.101820077513253e-10
average O 0 1.3786230113055353e-07
number O 0 9.275810675113405e-10
of O 0 8.507044513272888e-10
adenomas B-Disease 0 8.504344805260189e-06
tended O 0 1.4059842214919627e-06
to O 0 1.1574959657423278e-08
be O 0 3.8727669959826017e-08
lower O 0 1.9865196065893542e-07
than O 0 6.260011176095759e-09
those O 0 5.98994132072761e-10
in O 0 1.4036074524881315e-09
individuals O 0 3.878455057115815e-10
with O 0 2.8918556438384257e-09
mutations O 0 1.9883884760929504e-07
in O 0 1.1503757946229598e-08
region O 0 3.7994411172803666e-07
1 O 0 4.3165620411400596e-08
, O 0 5.540564007588955e-09
although O 0 3.2828448848221115e-09
age O 0 3.441411067228728e-08
at O 0 3.1147897061600816e-07
diagnosis O 0 1.9557232008082792e-05
was O 0 3.330824029035284e-06
similar O 0 3.005295923230733e-07
. O 0 6.005219006510742e-07

In O 0 1.1527873766681296e-06
all O 0 8.545625291844772e-07
AAPC B-Disease 1 0.9999327659606934
kindreds O 0 0.0033013487700372934
, O 0 1.2816693129025225e-07
a O 0 4.2034322689232795e-08
predominance O 0 2.547202711866703e-06
of O 0 5.002831926503859e-08
right O 0 0.04296744987368584
- O 1 0.9999780654907227
sided O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and O 0 0.06466703861951828
rectal B-Disease 1 0.9999321699142456
polyp I-Disease 1 0.5583847761154175
sparing O 0 3.15477655021823e-06
was O 0 3.2086463761515915e-06
observed O 0 2.083790604956448e-06
. O 0 4.7290666316257557e-07

No O 0 9.816321835387498e-05
desmoid B-Disease 1 0.8633849620819092
tumors I-Disease 1 0.9999986886978149
were O 0 2.539881961638457e-06
found O 0 1.8921620892342617e-07
in O 0 9.223752428511034e-09
these O 0 7.425362724688966e-08
kindreds O 0 5.6418899475829676e-05
. O 0 4.1279218976342236e-07

Our O 0 5.377327170208446e-07
data O 0 1.6308581507473718e-07
suggest O 0 6.423995557724993e-08
that O 0 6.610350933300424e-09
, O 0 5.183478979375877e-09
in O 0 2.2350077344412966e-08
AAPC B-Disease 1 0.9999972581863403
families O 0 5.438513994704408e-07
, O 0 3.3856260017728346e-09
the O 0 2.2975142621728395e-10
location O 0 3.5300041645314195e-07
of O 0 2.141217647633198e-09
the O 0 2.5043220830411883e-08
APC B-Disease 0 3.610348721849732e-05
mutation O 0 1.1753201079045539e-06
may O 0 1.49895782897147e-07
partially O 0 1.568775928717514e-06
predict O 0 2.6919320816887193e-07
specific O 0 4.275754861282621e-08
phenotypic O 0 7.823538908269256e-06
expression O 0 4.2227047742926516e-06
. O 0 1.0751352874649456e-06

This O 0 3.26263460692644e-07
should O 0 1.1835993518616306e-07
help O 0 1.2850565056510277e-08
in O 0 1.5882947179690632e-09
the O 0 1.134735083674343e-09
design O 0 1.0959201972582377e-06
of O 0 4.030650480046916e-09
tailored O 0 5.091228103992762e-06
clinical O 0 6.688926532660844e-06
- O 0 0.000670396548230201
management O 0 1.628306108614197e-06
protocols O 0 4.6134510967021924e-07
in O 0 1.2412334493561161e-09
this O 0 3.7442293709943897e-10
subset O 0 2.4749757798758765e-08
of O 0 4.336116798953071e-09
FAP B-Disease 0 1.0537056368775666e-05
patients O 0 1.557153979092618e-07
. O 0 9.02985153317104e-09
. O 0 2.0140711853855464e-07

Wilms B-Disease 1 0.9535161852836609
' I-Disease 0 0.0001148836308857426
tumor I-Disease 0 3.1135867175180465e-05
1 O 0 4.384069640650523e-08
and O 0 2.5842563644573602e-08
Dax O 0 0.4733418822288513
- O 0 0.00012418425467330962
1 O 0 3.082026012179995e-08
modulate O 0 6.067679692023376e-07
the O 0 7.523096812178665e-09
orphan O 0 8.631380410406564e-07
nuclear O 0 3.869809916068334e-06
receptor O 0 1.3741967563873914e-07
SF O 0 0.019191715866327286
- O 0 1.0487251529411878e-05
1 O 0 9.493375863200981e-09
in O 0 8.389640093753314e-10
sex O 0 1.5005568343440245e-07
- O 0 1.7435139909594e-07
specific O 0 1.0407121386890594e-08
gene O 0 1.52394875385653e-07
expression O 0 5.922963168814022e-07
. O 0 1.7287980824676197e-07

Products O 0 8.535234883311205e-06
of O 0 2.4343473015164818e-08
steroidogenic O 0 5.503272404894233e-05
factor O 0 1.1742579317797208e-06
1 O 0 7.773524401955001e-08
( O 0 8.676159346521217e-09
SF O 1 0.8636816143989563
- O 0 7.035477756289765e-05
1 O 0 1.6994741613984843e-08
) O 0 1.6938231928165237e-09
and O 0 3.191879471842185e-08
Wilms B-Disease 0 0.049270059913396835
tumor I-Disease 0 0.00031874136766418815
1 O 0 1.3538313226035825e-07
( O 0 1.4010965720956392e-08
WT1 O 0 3.102019036305137e-05
) O 0 2.476102878290476e-09
genes O 0 3.855195274127254e-09
are O 0 5.337246755665603e-10
essential O 0 2.566977519435909e-09
for O 0 6.670967112043513e-10
mammalian O 0 1.4183160601533018e-07
gonadogenesis O 0 2.8619983822864015e-06
prior O 0 1.8393510714531658e-08
to O 0 6.841657906875298e-09
sexual O 0 1.8525832956584054e-07
differentiation O 0 3.227446768505615e-06
. O 0 8.993542337520921e-07

In O 0 3.3772050755942473e-07
males O 0 4.899316650153196e-07
, O 0 5.956236392989922e-08
SF O 1 0.762978196144104
- O 0 0.0030096147675067186
1 O 0 5.124675794832001e-08
participates O 0 4.554922128363614e-08
in O 0 4.919071372455619e-09
sexual O 0 4.060398239857932e-08
development O 0 2.6348880854953904e-09
by O 0 4.290095501069402e-10
regulating O 0 4.955253629645995e-08
expression O 0 8.680776986125238e-09
of O 0 8.528033834664939e-10
the O 0 1.921313597108565e-08
polypeptide O 0 0.00023317210434470326
hormone O 0 1.9315025383548345e-06
Mullerian O 0 6.028037205396686e-06
inhibiting O 0 8.548404935027065e-07
substance O 0 1.946895054061315e-06
( O 0 4.289821475822464e-08
MIS O 0 7.727334013907239e-05
) O 0 6.105304350967344e-08
. O 0 1.9843157872401207e-07

Here O 0 2.8381693937262753e-06
, O 0 1.5232361150196994e-08
we O 0 1.7350695324935828e-09
show O 0 9.722398885969596e-09
that O 0 3.884305765922136e-09
WT1 O 0 9.704190597403795e-05
- O 0 2.101425707223825e-05
KTS O 0 9.488927753409371e-05
isoforms O 0 3.033456508205745e-08
associate O 0 2.386907560492091e-08
and O 0 8.44566105939748e-09
synergize O 0 2.5147188353003003e-05
with O 0 5.441180519483169e-07
SF O 1 0.9992444515228271
- O 0 0.00168515439145267
1 O 0 4.7450679829807996e-08
to O 0 1.3818315380831336e-08
promote O 0 5.849203716934426e-07
MIS O 0 0.0006959809106774628
expression O 0 1.155955828835431e-06
. O 0 2.801762377657724e-07

In O 0 3.664925429802679e-07
contrast O 0 6.530052019115828e-07
, O 0 5.529608770871164e-08
WT1 O 0 0.0001840426994021982
missense O 0 8.076120138866827e-05
mutations O 0 1.2701726518571377e-05
, O 0 1.1890185902529993e-07
associated O 0 1.0934397778328275e-06
with O 0 4.148657239966269e-07
male B-Disease 0 8.375248580705374e-05
pseudohermaphroditism I-Disease 1 0.9999985694885254
in O 0 8.550127677153796e-05
Denys B-Disease 1 0.999981164932251
- I-Disease 1 0.999992847442627
Drash I-Disease 1 0.9999958276748657
syndrome I-Disease 1 0.9999963045120239
, O 0 1.636243638358792e-07
fail O 0 4.4549526023729413e-07
to O 0 6.87751988692753e-09
synergize O 0 8.20737550384365e-05
with O 0 6.141206085885642e-07
SF O 1 0.9994001388549805
- O 0 0.008115943521261215
1 O 0 5.76983325117908e-07
. O 0 3.3397571996829356e-07

Additionally O 0 4.5888709792052396e-06
, O 0 6.553383968821436e-08
the O 0 4.5590917707727385e-09
X O 0 0.0010864813812077045
- O 0 0.002690941095352173
linked O 0 0.0028175548650324345
, O 0 3.8358482612466105e-08
candidate O 0 5.2616559997886725e-08
dosage O 0 1.1084748621215113e-06
- O 0 2.8696922527160496e-06
sensitive O 0 1.893901571747847e-05
sex O 0 7.837898579055036e-07
- O 0 9.117492822952045e-07
reversal O 0 9.338785389445547e-08
gene O 0 4.7774705080882995e-08
, O 0 1.2346652589201312e-08
Dax O 1 0.6464858651161194
- O 0 0.0004336517595220357
1 O 0 1.0639870851036903e-07
, O 0 8.135183193758166e-09
antagonizes O 0 2.32580237025104e-06
synergy O 0 3.5563672895477794e-07
between O 0 7.719462047361958e-08
SF O 1 0.9197002649307251
- O 0 0.0016642751870676875
1 O 0 1.822241131321789e-07
and O 0 5.354637266918871e-08
WT1 O 0 2.3476597561966628e-05
, O 0 5.14810727381132e-09
most O 0 1.4805918713278743e-09
likely O 0 4.254860908048386e-09
through O 0 3.002461890222463e-10
a O 0 1.5895857963243998e-09
direct O 0 6.30076302243765e-09
interaction O 0 2.891840544805291e-08
with O 0 1.2561582707348862e-07
SF O 1 0.9986769556999207
- O 0 0.006451500114053488
1 O 0 1.441690528736217e-06
. O 0 3.7171372468947084e-07

We O 0 4.798035320163763e-07
propose O 0 3.2705005992283986e-07
that O 0 1.2909599611532485e-08
WT1 O 0 7.70489168644417e-06
and O 0 1.1050976667092982e-07
Dax O 1 0.9836089015007019
- O 0 0.004361120983958244
1 O 0 4.16814387449449e-08
functionally O 0 1.1117445808395132e-07
oppose O 0 2.3603416110518083e-08
each O 0 5.793913127050132e-10
other O 0 6.024257204195749e-10
in O 0 4.093319461162537e-09
testis O 0 1.2132188203395344e-05
development O 0 1.1629109231137136e-08
by O 0 3.118419966696706e-09
modulating O 0 1.7304851098742802e-06
SF O 1 0.9933091402053833
- O 0 0.05994096025824547
1 O 0 1.917681856866693e-06
- O 0 6.87841311446391e-05
mediated O 0 0.00025884859496727586
transactivation O 0 0.00024707382544875145
. O 0 1.5117576879219996e-07
. O 0 5.303612056195561e-07

A O 0 9.36421474762028e-06
mouse O 0 6.036537524778396e-05
model O 0 1.256570340046892e-05
for O 0 8.111718670988921e-06
Prader B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999973773956299
imprinting O 0 0.3868483603000641
- O 1 0.6541099548339844
centre O 0 0.0024375105276703835
mutations O 0 0.00014934244973119348
. O 0 1.695827108960657e-06

Imprinting O 0 9.202521323459223e-05
in O 0 1.8351867936416966e-07
the O 0 3.4838173235129943e-08
15q11 O 0 9.61565092438832e-06
- O 0 6.042124005034566e-05
q13 O 0 8.999506462714635e-06
region O 0 2.044785674115701e-07
involves O 0 3.0493513492046986e-08
an O 0 9.869986605792747e-09
imprinting O 0 1.87016194104217e-05
centre O 0 3.952504266635515e-05
( O 0 8.421420005788605e-09
IC O 0 4.653077667171601e-06
) O 0 1.6762430332661893e-09
, O 0 6.572180022423879e-10
mapping O 0 2.2551557776750997e-07
in O 0 2.067295667984581e-09
part O 0 3.129319026129451e-08
to O 0 1.198409993463656e-08
the O 0 5.333769426130175e-09
promoter O 0 0.00015066808555275202
and O 0 4.77034980406188e-08
first O 0 1.5160884103693206e-08
exon O 0 2.6737205871540937e-07
of O 0 3.5410899101862015e-08
SNRPN O 0 0.0008834543987177312
. O 0 9.657820783104398e-07

Deletion O 0 1.276845250686165e-05
of O 0 5.206251429967779e-08
this O 0 2.6483929715936938e-08
IC O 0 4.299665670259856e-05
abolishes O 0 4.500775048654759e-06
local O 0 3.3957167744347316e-08
paternally O 0 1.2545052641144139e-06
derived O 0 7.713604333048352e-08
gene O 0 7.926389855583693e-08
expression O 0 4.912679330004721e-08
and O 0 1.1349520434578153e-08
results O 0 2.183324028237621e-07
in O 0 6.533235864480957e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0008149212226271629
PWS B-Disease 1 0.9999986886978149
) O 0 2.97408337246452e-06
. O 0 1.1632812402240233e-06

We O 0 2.724871364989667e-06
have O 0 2.3669416648886e-08
created O 0 8.858239475273422e-09
two O 0 2.0878496709286765e-09
deletion O 0 9.736633046486531e-07
mutations O 0 2.2733468085789355e-06
in O 0 1.9192002653767304e-08
mice O 0 9.495418453298043e-06
to O 0 1.7157469756057253e-07
understand O 0 1.1136456123495009e-05
PWS B-Disease 1 0.9999994039535522
and O 0 3.9136608620538027e-07
the O 0 3.0653219962317735e-09
mechanism O 0 7.570399418455054e-08
of O 0 2.233055074185586e-09
this O 0 4.243775819645634e-08
IC O 0 7.141233800211921e-05
. O 0 2.548815700720297e-07

Mice O 0 0.0019714939408004284
harbouring O 0 0.0012695837067440152
an O 0 1.2640222735171847e-07
intragenic O 0 2.9848337362636812e-05
deletion O 0 1.707599494693568e-06
in O 0 3.766179190733965e-08
Snrpn O 0 3.4518878237577155e-05
are O 0 1.0423172547291415e-08
phenotypically O 0 7.100887842170778e-07
normal O 0 6.05481176307876e-08
, O 0 3.2370819358362724e-09
suggesting O 0 2.3090132472702862e-08
that O 0 3.5817975252427914e-09
mutations O 0 1.139602812116891e-08
of O 0 5.966918625865958e-10
SNRPN O 0 8.79264043760486e-05
are O 0 9.953831536790858e-09
not O 0 4.37524638741138e-09
sufficient O 0 1.7253483974855044e-08
to O 0 3.719306818084078e-08
induce O 0 0.00016398831212427467
PWS B-Disease 1 0.9999783039093018
. O 0 5.158763542567613e-06

Mice O 0 0.007085705175995827
with O 0 2.5022265504048846e-07
a O 0 5.21144798426576e-08
larger O 0 6.856265599708422e-08
deletion O 0 2.009250010814867e-07
involving O 0 2.0618827534235606e-07
both O 0 3.835262774032344e-08
Snrpn O 0 0.0005046446458436549
and O 0 3.703662798670848e-07
the O 0 7.152706160695743e-08
putative O 0 0.001297308481298387
PWS O 1 0.9999988079071045
- O 0 0.018259240314364433
IC O 0 0.0007770778611302376
lack O 0 9.442634762990565e-08
expression O 0 1.1043914227570895e-08
of O 0 8.167798104530277e-10
the O 0 4.954400001366821e-09
imprinted O 0 2.0897425201837905e-05
genes O 0 2.940492436209752e-07
Zfp127 O 0 2.1563790141954087e-05
( O 0 2.1812651240793457e-08
mouse O 0 1.3449483731164946e-06
homologue O 0 1.6489148038090207e-06
of O 0 2.441615443160572e-08
ZNF127 O 0 0.0006577251479029655
) O 0 5.0073950319529104e-08
, O 0 1.9647952598234042e-08
Ndn O 0 1.3583175132225733e-05
and O 0 1.0799342753387009e-08
Ipw O 0 2.1261259917082498e-06
, O 0 8.606296830748761e-08
and O 0 5.1042874815721007e-08
manifest O 0 5.496023618434265e-07
several O 0 2.5290958660662e-08
phenotypes O 0 1.2352384146652184e-05
common O 0 1.7738653923515812e-06
to O 0 0.00010790787928272039
PWS B-Disease 1 0.9999997615814209
infants O 0 0.01021257322281599
. O 0 9.228169801644981e-07

These O 0 8.237631021756897e-08
data O 0 1.748362734588227e-07
demonstrate O 0 6.579309541621114e-08
that O 0 4.3227230683839934e-09
both O 0 3.051933150644004e-09
the O 0 3.0221476432501504e-09
position O 0 1.243172675913229e-07
of O 0 7.714318073226423e-10
the O 0 2.3455257736060275e-09
IC O 0 1.3089080312056467e-05
and O 0 1.17508278663081e-08
its O 0 3.3107452335201515e-09
role O 0 6.600473501094939e-09
in O 0 6.341148162114507e-10
the O 0 9.832907821305525e-10
coordinate O 0 3.0998663191894593e-07
expression O 0 1.4096663392137998e-08
of O 0 4.832904632046109e-10
genes O 0 1.655053694094022e-08
is O 0 9.021158042799016e-09
conserved O 0 3.843882723231218e-08
between O 0 6.798369867055953e-08
mouse O 0 0.00021695489704143256
and O 0 5.547831278818194e-07
human O 0 9.474657503005801e-08
, O 0 1.158321971672649e-08
and O 0 1.5493027305524265e-08
indicate O 0 1.854174058735225e-07
that O 0 3.5636233963742825e-09
the O 0 3.6429590455355765e-09
mouse O 0 1.6011264960980043e-05
is O 0 1.042972002096576e-07
a O 0 1.8193858863924106e-08
suitable O 0 3.2665625440131407e-06
model O 0 2.48530136559566e-06
system O 0 4.357176663916107e-08
in O 0 2.5870314779297132e-09
which O 0 1.3851246372098558e-08
to O 0 8.46829184553144e-09
investigate O 0 6.618806480673811e-08
the O 0 6.30614616081715e-10
molecular O 0 6.024687593253475e-08
mechanisms O 0 1.2743097244083401e-08
of O 0 5.384229173621691e-10
imprinting O 0 3.556561068762676e-06
in O 0 1.4299657458138881e-08
this O 0 1.0544106920917784e-08
region O 0 2.1125912041952688e-07
of O 0 1.059243914802721e-09
the O 0 7.95094656780293e-09
genome O 0 8.834199860530134e-08
. O 0 1.4024040595472798e-08
. O 0 1.0110605330737599e-07

Mutations O 0 1.9388684449950233e-05
of O 0 3.4002663795718036e-08
the O 0 1.2758079037666903e-08
ATM O 0 1.4419488252315205e-05
gene O 0 2.6422580390317307e-07
detected O 0 3.195637191311107e-06
in O 0 1.4829814176664513e-07
Japanese O 0 0.059397999197244644
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 1.0
patients O 0 0.047859854996204376
: O 0 2.0262367783629998e-08
possible O 0 6.546712683075384e-08
preponderance O 0 1.9439337393123424e-06
of O 0 6.8633019267849704e-09
the O 0 1.5188437174629144e-08
two O 0 2.9618533403663605e-08
founder O 0 4.962540060660103e-06
mutations O 0 3.0871569833834656e-07
4612del165 O 0 1.4576680769096129e-06
and O 0 1.4664172454104119e-07
7883del5 O 0 1.3557860256696586e-05
. O 0 4.4715184799315466e-07

The O 0 9.933747833201778e-07
ATM O 0 0.000530721212271601
( O 0 6.240867378437542e-07
A O 1 0.9987576007843018
- O 1 0.99997878074646
T O 1 0.9999997615814209
, O 0 1.0511480752484204e-07
mutated O 0 4.997281521923469e-08
) O 0 1.9398231909661945e-09
gene O 0 1.4119534874623696e-08
on O 0 9.061842831670219e-08
human O 0 2.0459617644519312e-07
chromosome O 0 0.00018733848992269486
11q22 O 0 8.430353773292154e-05
. O 0 1.1981514944636729e-06

3 O 0 4.780378731084056e-06
has O 0 1.7024923693043092e-07
recently O 0 1.7416427056105022e-07
been O 0 3.574612605916627e-08
identified O 0 1.6768714772297244e-07
as O 0 1.3073929716611588e-09
the O 0 2.746682326026928e-10
gene O 0 1.5240265938132325e-08
responsible O 0 3.673774529033835e-08
for O 0 2.0257719945959707e-09
the O 0 2.847365365710175e-08
human O 0 3.781514533329755e-05
recessive B-Disease 1 0.9999784231185913
disease I-Disease 1 0.9999687671661377
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.1799958199262619
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999982118606567
T I-Disease 1 0.9999994039535522
) O 0 6.039898607923533e-07
. O 0 4.934490220875887e-07

In O 0 1.414860264503659e-07
order O 0 2.080381378277707e-08
to O 0 2.713637980988892e-09
define O 0 1.0387730497996017e-07
the O 0 2.61442312243787e-09
types O 0 1.2269287026356324e-06
of O 0 6.451931255924137e-08
disease O 0 0.003958718851208687
- O 0 0.013242595829069614
causing O 0 1.495339074608637e-05
ATM O 0 0.00021013578225392848
mutations O 0 1.085797975974856e-06
in O 0 5.16682021611814e-08
Japanese O 0 0.00022368428471963853
A B-Disease 1 0.9999865293502808
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
patients O 0 5.498590326169506e-06
as O 0 3.01084348564018e-08
well O 0 1.553617146043962e-08
as O 0 3.848003249373733e-09
to O 0 1.6564930538365275e-09
look O 0 5.4947140171179853e-08
for O 0 8.650591909464822e-10
possible O 0 2.9232008813551147e-08
mutational O 0 3.8627749745501205e-06
hotspots O 0 1.1385943253117148e-05
, O 0 1.7200024515773293e-08
reverse O 0 1.7420661606593058e-05
- O 0 0.00045013122144155204
transcribed O 0 2.784939397315611e-06
RNA O 0 3.511683743795402e-08
derived O 0 2.9145532653984674e-09
from O 0 1.248718128898929e-09
ten O 0 1.2885688072117318e-08
patients O 0 1.7968556420555615e-08
belonging O 0 1.0814868289799051e-07
to O 0 4.376631945746112e-09
eight O 0 8.613534774326581e-09
unrelated O 0 1.1981891248069587e-06
Japanese O 0 4.17561132053379e-05
A B-Disease 1 0.9999681711196899
- I-Disease 1 0.9999744892120361
T I-Disease 1 0.9999996423721313
families O 0 2.1194684052261437e-07
was O 0 3.825065277851536e-07
analyzed O 0 1.7046620115479527e-08
for O 0 7.351877440164856e-10
mutations O 0 1.1920677778221034e-08
by O 0 4.772110484552172e-10
the O 0 1.5165676492401303e-09
restriction O 0 1.2766992085744278e-07
endonuclease O 0 4.6526961341442075e-06
fingerprinting O 0 3.180242913458642e-07
method O 0 2.588124630165112e-07
. O 0 2.374629417545293e-07

As O 0 1.274991291211336e-06
has O 0 9.594517536015701e-08
been O 0 1.6010275771805027e-08
reported O 0 1.3961245315385895e-07
by O 0 3.6388063673342685e-09
others O 0 1.526039383747957e-08
, O 0 2.25734431147373e-09
mutations O 0 2.7706734684329604e-08
that O 0 2.4681672261550602e-09
lead O 0 1.8482557706533953e-08
to O 0 7.867313023268707e-09
exon O 0 1.0159352541450062e-06
skipping O 0 2.951679107354721e-06
or O 0 1.5636526313755894e-06
premature O 0 2.3526658878836315e-06
protein O 0 2.4997694580974894e-08
truncation O 0 1.1253531511101755e-06
were O 0 7.663991254958091e-07
also O 0 4.1143227491602374e-08
predominant O 0 5.472915631798969e-07
in O 0 2.457138492673039e-09
our O 0 1.3797404108117917e-08
mutants O 0 4.0996354755407083e-07
. O 0 8.857517030946838e-08

Six O 0 6.457311201302218e-07
different O 0 9.503557940604423e-09
mutations O 0 2.3545014471437753e-07
were O 0 1.7335875668322842e-07
identified O 0 3.514431625717407e-07
on O 0 1.1149851530944943e-07
12 O 0 1.190736131917447e-08
of O 0 7.600312046385227e-10
the O 0 5.499209088100088e-09
16 O 0 2.5796470737304844e-08
alleles O 0 1.1770347185802166e-07
examined O 0 5.100880116515327e-06
. O 0 6.129586154202116e-07

Four O 0 3.6132396985522064e-07
were O 0 6.599041313393172e-08
deletions O 0 2.8890903536193946e-07
involving O 0 3.888970923071611e-07
a O 0 1.2278756003070157e-06
loss O 0 5.154018253961112e-06
of O 0 9.673656542474873e-09
a O 0 1.7609346514291246e-07
single O 0 3.1097323471840355e-07
exon O 0 3.052785473300901e-07
exon O 0 3.4952026339851727e-07
7 O 0 4.039972978375772e-08
, O 0 3.746488896894107e-09
exon O 0 9.55997521145946e-08
16 O 0 1.6159376059476926e-08
, O 0 3.6723575291830457e-09
exon O 0 1.9526707717432146e-07
33 O 0 1.7936375229510304e-07
or O 0 5.50618111105905e-08
exon O 0 1.8254378346682643e-06
35 O 0 1.178031311610539e-06
. O 0 3.8760489928790776e-07

The O 0 2.1173312347855244e-07
others O 0 3.4609215049385966e-08
were O 0 9.18425246965171e-09
minute O 0 9.562104885674216e-09
deletions O 0 1.1214090989142278e-07
, O 0 9.749678397952266e-09
4649delA O 0 1.737674324431282e-07
in O 0 1.3468117732173823e-09
exon O 0 1.9070643020313582e-07
33 O 0 2.0876998974017624e-07
and O 0 1.005669147957633e-08
7883del5 O 0 1.6705712369002867e-07
in O 0 7.018171821471242e-09
exon O 0 1.8612939811646356e-06
55 O 0 1.1151971648359904e-06
. O 0 6.859659720248601e-07

The O 0 1.1227488272425035e-07
mutations O 0 1.1038964657927863e-06
4612del165 O 0 2.9222419470897876e-06
and O 0 4.3494715384895244e-08
7883del5 O 0 6.146011060081946e-07
were O 0 7.106321930905324e-08
found O 0 3.759920019774654e-08
in O 0 1.010849404181613e-09
more O 0 3.9995487477462177e-10
than O 0 2.125859710488953e-09
two O 0 6.879865011022446e-10
unrelated O 0 8.593387690325471e-08
families O 0 7.870404772347683e-09
; O 0 5.423944071658582e-10
44 O 0 2.681910915569574e-09
% O 0 5.727985308290329e-10
( O 0 1.008861660878324e-09
7 O 0 1.5246634177401575e-08
of O 0 2.0011707846379068e-09
16 O 0 1.679911854068905e-08
) O 0 4.780309481589029e-10
of O 0 1.5134547781681107e-10
the O 0 1.5016061727379793e-09
mutant O 0 1.6146996983934514e-07
alleles O 0 2.5149102356181174e-08
had O 0 1.2871179251305875e-06
one O 0 6.727268075934489e-09
of O 0 6.968680632546409e-10
the O 0 4.768618833139726e-09
two O 0 3.499467737810846e-08
mutations O 0 3.1100071282708086e-06
. O 0 4.055499402966234e-07

The O 0 3.248966606861359e-07
4612del165 O 0 6.557800134032732e-06
mutations O 0 1.1482011359476019e-06
in O 0 1.980235531107155e-08
three O 0 2.1249029202863312e-09
different O 0 1.3114240804412702e-09
families O 0 6.586300393962574e-09
were O 0 2.6691441945558836e-08
all O 0 3.774704437908838e-10
ascribed O 0 3.5205157900009e-08
to O 0 5.936475755419224e-09
the O 0 1.9095232062227296e-09
same O 0 1.0192955102183987e-07
T O 0 0.008731510490179062
- O 0 1.054494805430295e-05
- O 0 1.1648293366306461e-05
> O 0 2.2642449692966693e-08
A O 0 1.6613310727109365e-09
substitution O 0 5.1136592738032505e-09
at O 0 1.2630383849909776e-08
the O 0 5.342655207130065e-10
splice O 0 1.3785573855784605e-06
donor O 0 2.3170029450625407e-08
site O 0 5.710269874725782e-07
in O 0 1.838887975225134e-08
intron O 0 0.00045228199451230466
33 O 0 2.047423095064005e-06
. O 0 3.2895161439228104e-07

Microsatellite O 0 0.00035134749487042427
genotyping O 0 8.533045911462978e-05
around O 0 1.1365939371899003e-06
the O 0 2.2271096966619552e-08
ATM O 0 1.4378609193954617e-05
locus O 0 7.777808832543087e-07
also O 0 1.6876266784038307e-07
indicated O 0 2.754424031081726e-06
that O 0 1.533807569842338e-08
a O 0 1.468973067630941e-07
common O 0 1.864451206756712e-07
haplotype O 0 2.0623872842406854e-05
was O 0 0.000140422533149831
shared O 0 1.2413529759669473e-07
by O 0 4.19798196205079e-09
the O 0 1.879732591802963e-09
mutant O 0 1.1826155343896971e-07
alleles O 0 1.9466849465743508e-08
in O 0 4.077011173109213e-09
both O 0 5.42404272607655e-08
mutations O 0 2.5590777568140766e-06
. O 0 8.746360435907263e-07

This O 0 1.2874380672656116e-07
suggests O 0 1.1833714097519987e-07
that O 0 2.6115725137998425e-09
these O 0 7.50139950156381e-10
two O 0 2.6243553996607716e-09
founder O 0 2.6723234896053327e-06
mutations O 0 6.68972859330097e-07
may O 0 1.684391577327915e-07
be O 0 1.068658406211398e-08
predominant O 0 2.583360299013293e-07
among O 0 3.83006337756342e-09
Japanese O 0 2.516249821837846e-07
ATM O 0 5.279619017528603e-06
mutant O 0 6.961406597838504e-07
alleles O 0 7.76454328388354e-07
. O 0 6.286732627813763e-07

W474C O 0 0.00011716353765223175
amino O 0 1.1764919918277883e-06
acid O 0 1.6443593153780967e-07
substitution O 0 4.6378371365563e-08
affects O 0 4.685601595610933e-08
early O 0 2.1188646393e-09
processing O 0 8.525728567576607e-09
of O 0 2.001078192037653e-10
the O 0 2.3033323859333876e-10
alpha O 0 1.6261524349303613e-09
- O 0 6.8021281940389144e-09
subunit O 0 1.5651624440948808e-09
of O 0 1.5873823089318506e-10
beta O 0 3.993368746790793e-09
- O 0 5.337354309631337e-07
hexosaminidase O 0 1.5740329217805993e-06
A O 0 1.0734739674944649e-07
and O 0 2.7937092639263028e-08
is O 0 3.925554636907691e-08
associated O 0 2.9320582939362794e-07
with O 0 1.934581774776234e-07
subacute O 1 0.8713555932044983
G B-Disease 0 0.42967841029167175
( I-Disease 0 1.4789506508350314e-07
M2 I-Disease 0 0.007406869437545538
) I-Disease 0 1.2362798429421673e-07
gangliosidosis I-Disease 0 3.841007128357887e-05
. O 0 3.890851871801715e-07

Mutations O 0 4.6177698095561936e-05
in O 0 8.824768116255655e-08
the O 0 1.6433084226719075e-08
HEXA O 0 0.0002900046238210052
gene O 0 2.8712747734971344e-07
, O 0 1.740531940797041e-09
encoding O 0 2.611348248748868e-09
the O 0 3.519283753306013e-10
alpha O 0 1.6969340377315234e-09
- O 0 6.577399513929549e-09
subunit O 0 1.9537402806690807e-09
of O 0 2.1490641211041606e-10
beta O 0 9.758812424820462e-09
- O 0 5.7862930589180905e-06
hexosaminidase O 0 1.6048688848968595e-05
A O 0 2.7895433163394046e-07
( O 0 3.902908662922755e-09
Hex O 0 6.030298322912131e-07
A O 0 1.2938421889430174e-07
) O 0 2.1900141700115228e-09
, O 0 7.68644148330111e-10
that O 0 4.612038528861717e-10
abolish O 0 3.050095997991775e-08
Hex O 0 1.689588060571623e-07
A O 0 6.359477389139556e-09
enzyme O 0 7.894252718188e-08
activity O 0 5.0536605158413295e-06
cause O 0 0.0012228806735947728
Tay B-Disease 1 0.9999998807907104
- I-Disease 1 0.999998927116394
Sachs I-Disease 1 1.0
disease I-Disease 1 0.7698569893836975
( O 0 7.630168141758986e-08
TSD B-Disease 0 0.0007286563632078469
) O 0 7.240581822998138e-08
, O 0 2.1701890062786333e-08
the O 0 4.493208294320539e-08
fatal O 0 0.009144231677055359
infantile B-Disease 0 0.00088006432633847
form I-Disease 0 1.4722998287197697e-07
of I-Disease 0 1.8815841329455907e-08
G I-Disease 0 0.01731123775243759
( I-Disease 0 2.1949080775129914e-08
M2 I-Disease 0 0.000919295649509877
) I-Disease 0 1.3000680532115894e-08
gangliosidosis I-Disease 0 5.392731054598698e-06
, I-Disease 0 7.287103365172243e-09
Type I-Disease 0 2.2107640234025894e-06
1 I-Disease 0 1.459018506011489e-07
. O 0 3.427511217068968e-07

Less O 0 1.6377176507376134e-05
severe O 0 0.000735717243514955
, O 0 9.55328232521424e-07
subacute O 0 0.22732675075531006
( O 0 4.2535489797046466e-07
juvenile O 0 0.034702617675065994
- O 1 0.6983890533447266
onset O 0 0.022315606474876404
) O 0 1.5526683228017646e-06
and O 0 0.00010726401524152607
chronic O 0 0.4550143778324127
( O 0 2.8461164092163926e-08
adult O 0 6.239835784072056e-06
- O 0 0.0401439443230629
onset O 0 0.0001417876483174041
) O 0 1.1173349356852214e-08
variants O 0 5.99363829678623e-08
are O 0 8.184925626153472e-09
characterized O 0 8.227469265875698e-07
by O 0 6.072527813927309e-09
a O 0 6.532792440339108e-08
broad O 0 6.431216661439976e-07
spectrum O 0 4.772329589286528e-07
of O 0 9.002937062518868e-09
clinical O 0 2.5378624286531704e-06
manifestations O 0 2.413014726698748e-06
and O 0 1.4805678461016214e-07
are O 0 2.2404197608238974e-08
associated O 0 7.508994315230666e-08
with O 0 5.945269165863465e-09
residual O 0 7.86490345490165e-05
levels O 0 6.484494861069834e-07
of O 0 6.67590915881533e-09
Hex O 0 4.018756953882985e-06
A O 0 6.0476793350972e-08
enzyme O 0 2.0543259893202048e-07
activity O 0 1.04286402802245e-06
. O 0 1.8826042946784582e-07

We O 0 1.1099092489530449e-06
identified O 0 3.0730396360922896e-07
a O 0 3.66740380286501e-08
1422 O 0 2.743603181443177e-05
G O 0 0.0006560960900969803
- O 0 0.0004156591894570738
- O 0 0.0051650842651724815
> O 0 5.203578893997474e-06
C O 0 8.200623415177688e-05
( O 0 1.8747983165923188e-09
amino O 0 1.7517357564500458e-09
acid O 0 8.761866232553928e-10
W474C O 0 3.553035865522247e-09
) O 0 2.387705484718783e-11
substitution O 0 2.41578756998706e-10
in O 0 2.4793961328484215e-10
the O 0 1.9532027384361328e-10
first O 0 6.592647316949751e-09
position O 0 1.8555885716864395e-08
of O 0 3.930450409583841e-10
exon O 0 1.1228130603058162e-07
13 O 0 9.017098179242566e-09
of O 0 2.847765578906092e-09
HEXA O 0 0.00040231033926829696
of O 0 5.478250741930424e-09
a O 0 4.4454628778112237e-07
non O 0 1.3882345228921622e-06
- O 0 6.711456535413163e-06
Jewish O 0 1.4840582025499316e-06
proband O 0 0.0002558634150773287
who O 0 9.190581806706177e-08
manifested O 0 1.6591141616117966e-07
a O 0 8.73509264920358e-08
subacute O 0 0.0006424962775781751
variant O 0 3.167893009958789e-05
of O 0 1.0863556099138805e-07
G B-Disease 0 0.058083001524209976
( I-Disease 0 1.612431503872358e-07
M2 I-Disease 0 0.006191578693687916
) I-Disease 0 9.557951585748015e-08
gangliosidosis I-Disease 0 8.714526484254748e-05
. O 0 6.046826683814288e-07

On O 0 1.4081499557505595e-06
the O 0 2.0961223867743684e-08
second O 0 9.751875751362604e-08
maternally O 0 5.085678640170954e-05
inherited O 0 8.563265146221966e-05
allele O 0 1.0758901680674171e-06
, O 0 4.4698218459870986e-08
we O 0 2.9591877392931565e-08
identified O 0 2.5992702035182447e-07
the O 0 5.955597348616948e-09
common O 0 2.430788845231291e-05
infantile O 1 0.9951562881469727
disease O 0 0.059762582182884216
- O 0 0.002536207437515259
causing O 0 1.1957808055740315e-05
4 O 0 2.2856700354623172e-07
- O 0 5.4276119044516236e-05
bp O 0 4.878968866250943e-06
insertion O 0 3.861939319449448e-07
, O 0 2.6376097750357985e-08
+ O 0 2.8393259299264173e-07
TATC O 0 4.483347765926737e-06
1278 O 0 1.9712761059054174e-05
, O 0 9.152810065415906e-09
in O 0 2.609829685695786e-09
exon O 0 1.0317518217561883e-06
11 O 0 1.7795471762838133e-07
. O 0 3.0985418675300025e-07

Pulse O 0 0.00010969545837724581
- O 0 2.478560600138735e-05
chase O 0 1.4554955214407528e-06
analysis O 0 1.616067102361285e-08
using O 0 1.0598305344444725e-08
proband O 0 1.2618485243365285e-06
fibroblasts O 0 6.429278869291011e-07
revealed O 0 1.1290252359685837e-06
that O 0 5.088925725260651e-09
the O 0 2.418504285728318e-09
W474C O 0 2.6470047487237025e-07
- O 0 3.954457667987299e-07
containing O 0 1.761113566089989e-08
alpha O 0 3.367104817186828e-09
- O 0 1.3494197759200688e-08
subunit O 0 2.506538310242945e-09
precursor O 0 6.633237070730047e-09
was O 0 3.3113465747192095e-08
normally O 0 1.7324074397251366e-09
synthesized O 0 7.178370786675714e-09
, O 0 5.430620397817165e-10
but O 0 4.099028616533218e-10
not O 0 1.8956057556973605e-10
phosphorylated O 0 7.476121943739145e-09
or O 0 3.140379067900767e-09
secreted O 0 1.2568166951609783e-08
, O 0 3.4350871036537e-09
and O 0 2.6944007025520023e-09
the O 0 1.2431407014901197e-09
mature O 0 1.698881959555365e-07
lysosomal O 0 2.183268634325941e-06
alpha O 0 8.27171486861289e-09
- O 0 3.096934619861713e-08
subunit O 0 1.0389944904432014e-08
was O 0 7.056280537653947e-08
not O 0 7.150411818201974e-09
detected O 0 1.4937135119907907e-06
. O 0 9.727688166094595e-08

When O 0 7.728528998995898e-07
the O 0 3.011957616649852e-08
W474C O 0 9.587124623067211e-07
- O 0 4.381315932278085e-07
containing O 0 2.4195715653263505e-08
alpha O 0 3.807985038406514e-09
- O 0 9.195680661377992e-09
subunit O 0 7.16460979433009e-09
was O 0 9.037609061124385e-08
transiently O 0 6.472113796007761e-07
co O 0 1.6311363424392766e-06
- O 0 3.968370947404765e-06
expressed O 0 1.572776398006681e-08
with O 0 1.1705455493782324e-09
the O 0 5.244988332542277e-10
beta O 0 1.5770471595288882e-09
- O 0 1.2621859113437495e-08
subunit O 0 1.387342241088163e-09
to O 0 7.133951762661184e-10
produce O 0 4.33898144081013e-08
Hex O 0 1.810329081308737e-06
A O 0 9.657235011673038e-08
( O 0 2.009072241904164e-09
alphabeta O 0 4.258821775238175e-07
) O 0 4.6171874656941725e-10
in O 0 1.2261924808854019e-09
COS O 0 0.0010828364174813032
- O 0 0.00012464243627618998
7 O 0 1.215795322195845e-07
cells O 0 6.642392946787368e-08
, O 0 1.1094939411648852e-09
the O 0 4.1284917151607203e-10
mature O 0 7.506499422049728e-09
alpha O 0 1.0354449520022513e-09
- O 0 7.89099807718685e-09
subunit O 0 3.280203664246528e-09
was O 0 7.298680060330298e-08
present O 0 5.769126509846956e-09
, O 0 4.099930173140365e-09
but O 0 2.669519494347128e-09
its O 0 2.7130482305182113e-09
level O 0 4.443868917292093e-08
was O 0 1.4939344339381933e-07
much O 0 2.9440703208649666e-09
lower O 0 4.271703701874685e-08
than O 0 1.3311184376973983e-09
that O 0 1.8210642716010028e-10
from O 0 9.225361446985048e-11
normal O 0 9.423266611463532e-10
alpha O 0 4.908216610921556e-10
- O 0 3.572845574950634e-09
subunit O 0 1.71451519648258e-09
transfections O 0 1.6013687798022147e-07
, O 0 3.5704117440360505e-10
although O 0 3.1885660778385727e-10
higher O 0 3.9309150379196467e-10
than O 0 8.748656799006937e-10
in O 0 4.854939783527357e-10
those O 0 2.5878310605520483e-09
cells O 0 2.5872106235169667e-08
transfected O 0 3.8778716771048494e-07
with O 0 7.0017525111154555e-09
an O 0 2.3516628644415505e-09
alpha O 0 8.499555725904884e-09
- O 0 1.2799836213162052e-07
subunit O 0 5.6893590283380036e-08
associated O 0 7.1498142517612e-08
with O 0 5.638691646936422e-08
infantile O 0 0.3883117139339447
TSD B-Disease 0 0.10690763592720032
. O 0 1.617459929548204e-06

Furthermore O 0 1.2679629435297102e-05
, O 0 1.3352186556403467e-07
the O 0 3.778790613750971e-09
precursor O 0 6.1739612533529e-08
level O 0 9.296275038650492e-08
of O 0 7.275863800337845e-10
the O 0 1.1545936429158132e-09
W474C O 0 3.499080492019857e-08
alpha O 0 2.627701389812387e-09
- O 0 7.385133393711385e-09
subunit O 0 1.6439970496051615e-09
was O 0 4.583105095434803e-08
found O 0 5.80720405096713e-09
to O 0 5.701020211468233e-10
accumulate O 0 1.0785781512367976e-07
in O 0 4.470959436009281e-10
comparison O 0 2.2387792952827112e-08
to O 0 9.214287666203802e-10
the O 0 7.440780769307764e-10
normal O 0 3.742318011035195e-09
alpha O 0 2.821807232322726e-09
- O 0 2.407400145898464e-08
subunit O 0 2.5173914508513917e-08
precursor O 0 1.315592754735917e-07
levels O 0 1.1037600700092298e-07
. O 0 4.114730600690564e-08

We O 0 5.19351715411176e-07
conclude O 0 1.6318460893671727e-07
that O 0 2.7803437330220504e-09
the O 0 1.9219101865530774e-09
1422 O 0 8.128367880999576e-06
G O 0 0.0005656324792653322
- O 0 0.0011217347346246243
- O 0 0.0024849476758390665
> O 0 3.765421524803969e-06
C O 0 5.391392551246099e-05
mutation O 0 7.774992383247081e-08
is O 0 1.0912938108731396e-08
the O 0 3.6023721783351448e-09
cause O 0 1.913334699565894e-07
of O 0 2.093720929963183e-08
Hex B-Disease 0 0.1918303221464157
A I-Disease 0 0.2633129358291626
enzyme I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999982118606567
in O 0 3.7315356138378775e-08
the O 0 6.109964090228459e-08
proband O 0 0.0006110536633059382
. O 0 6.892742590025591e-07

The O 0 2.8649293426497024e-07
resulting O 0 4.169528438069392e-07
W474C O 0 1.0215984502792708e-06
substitution O 0 2.2490775108963135e-07
clearly O 0 2.607816327326873e-07
interferes O 0 1.5048360069158662e-07
with O 0 1.727797571682288e-09
alpha O 0 1.7560110032732723e-09
- O 0 1.5769396455311835e-08
subunit O 0 2.6888766768706773e-09
processing O 0 4.764039474025594e-08
, O 0 2.2090058671153656e-09
but O 0 7.986020733596888e-10
because O 0 2.2511262298685608e-10
the O 0 7.553570963159117e-11
base O 0 1.2193224208090214e-08
substitution O 0 8.981053234435876e-09
falls O 0 2.250896613986697e-05
at O 0 2.956073785753688e-08
the O 0 2.2355511886118506e-10
first O 0 2.4045263558036822e-09
position O 0 1.581928543714639e-08
of O 0 4.482657856019756e-10
exon O 0 1.5731579594557843e-07
13 O 0 1.3877109239501806e-08
, O 0 1.7358308124215682e-09
aberrant O 0 1.392165245306387e-07
splicing O 0 2.5674250991869485e-07
may O 0 5.219569629844045e-07
also O 0 2.6872834624214192e-08
contribute O 0 1.3052011027525623e-08
to O 0 8.307244314664786e-08
Hex B-Disease 0 0.00387914408929646
A I-Disease 0 0.0005447088624350727
deficiency I-Disease 0 0.008113364689052105
in O 0 2.5072841580708882e-09
this O 0 9.583869697848968e-09
proband O 0 2.0207531633786857e-05
. O 0 1.6536274571876675e-08
. O 0 1.5984072376795666e-07

Two O 0 1.8376596244706889e-06
frequent O 0 2.6411160433781333e-05
missense O 0 0.0018782448023557663
mutations O 0 0.0007474507438018918
in O 0 0.00014838529750704765
Pendred B-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999998807907104
. O 0 6.792125350330025e-05

Pendred B-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
is O 0 0.046485453844070435
an O 0 0.43642932176589966
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9972584247589111
by O 0 8.14830491435714e-06
early O 0 0.009420858696103096
childhood O 1 0.9999463558197021
deafness B-Disease 1 1.0
and O 1 0.8000288605690002
goiter B-Disease 1 0.9999998807907104
. O 0 5.336344474926591e-05

A O 0 2.0781146758963587e-06
century O 0 5.443110921987682e-07
after O 0 6.9477572139931e-08
its O 0 8.964315512116627e-09
recognition O 0 7.3783050780207304e-09
as O 0 5.123249025018595e-08
a O 0 1.7465259588789195e-05
syndrome O 0 0.3039356768131256
by O 0 8.872493850731189e-09
Vaughan O 0 5.6417175073875114e-05
Pendred O 0 0.00011314501898596063
, O 0 8.206313850678271e-08
the O 0 8.799640482948234e-08
disease O 0 2.2638170776190236e-05
gene O 0 1.1312693004583707e-06
( O 0 5.831114435750351e-08
PDS O 0 1.870170672191307e-05
) O 0 1.1345148820396389e-08
was O 0 3.2593817422821303e-07
mapped O 0 5.1971710490761325e-06
to O 0 4.934372554998845e-08
chromosome O 0 8.82877575349994e-05
7q22 O 0 6.106519867898896e-05
- O 0 0.00019858957966789603
q31 O 0 4.6323955757543445e-05
. O 0 8.392590302719327e-07

1 O 0 5.984527888358571e-06
and O 0 7.556375862804998e-07
, O 0 1.630538548624827e-08
recently O 0 2.700620598261594e-07
, O 0 3.1714451065312232e-09
found O 0 4.043941626008518e-09
to O 0 1.0099860947576644e-09
encode O 0 1.1425871804249255e-07
a O 0 6.489060524472734e-07
putative O 0 0.00012205127131892368
sulfate O 0 0.0016919979825615883
transporter O 0 0.011376844719052315
. O 0 1.7216473224834772e-06

We O 0 6.8516760620696e-07
performed O 0 1.1061393934141961e-07
mutation O 0 1.6827339521796603e-08
analysis O 0 2.4243931306955346e-09
of O 0 1.6183365758593027e-09
the O 0 6.892109105649524e-09
PDS B-Disease 0 7.558202923974022e-06
gene O 0 1.277041548064517e-07
in O 0 3.912264290306666e-08
patients O 0 3.859663166849714e-08
from O 0 1.3393316455889703e-09
14 O 0 2.020948919323473e-08
Pendred B-Disease 0 4.051072210131679e-06
families O 0 7.686446146237813e-09
originating O 0 1.1281600542645265e-08
from O 0 2.281315136798412e-09
seven O 0 2.1789976489827723e-09
countries O 0 1.0704531705485465e-09
and O 0 9.617711071996382e-09
identified O 0 8.684341423759179e-08
all O 0 4.412464171821284e-09
mutations O 0 3.6339119446893164e-07
. O 0 1.744794815294881e-07

The O 0 2.1277516282225406e-07
mutations O 0 2.0803040570172016e-06
include O 0 2.8203665181081305e-08
three O 0 1.0529556782046257e-08
single O 0 4.145429954860447e-07
base O 0 8.05830836725363e-07
deletions O 0 6.016700808686437e-07
, O 0 3.689434180387252e-08
one O 0 1.6919349477007017e-08
splice O 0 3.074391497648321e-05
site O 0 5.4105523304315284e-05
mutation O 0 3.905950052285334e-07
and O 0 3.131778925080653e-08
10 O 0 1.1078708439526963e-07
missense O 0 8.379387145396322e-05
mutations O 0 8.422213795711286e-06
. O 0 1.1227557479287498e-06

One O 0 3.329864739498589e-06
missense O 0 0.0005938702379353344
mutation O 0 5.308628260536352e-06
( O 0 1.1850989523054523e-08
L236P O 0 9.176286539513967e-07
) O 0 4.948280452055087e-09
was O 0 7.791438747517532e-07
found O 0 1.3371121099226002e-07
in O 0 2.9110809318666497e-09
a O 0 8.748064317387616e-08
homozygous O 0 3.392597136553377e-07
state O 0 4.117790552982115e-09
in O 0 3.807767434693687e-09
two O 0 1.0112085391256187e-08
consanguineous O 0 2.5890729375532828e-05
families O 0 1.5045792167711625e-07
and O 0 5.347441600633829e-08
in O 0 6.791471829359352e-09
a O 0 1.7570370047792494e-08
heterozygous O 0 3.5476741544471224e-08
state O 0 1.5191152780147377e-09
in O 0 8.26836599188141e-10
five O 0 1.154690565385863e-09
additional O 0 5.69832669938819e-09
non O 0 7.317817676266714e-07
- O 0 0.000377769727492705
consanguineous O 0 0.0007498550694435835
families O 0 9.674201919551706e-07
. O 0 2.790964401810925e-07

Another O 0 1.736398735374678e-05
missense O 0 0.0005181607557460666
mutation O 0 5.662257990479702e-06
( O 0 6.598059343332352e-08
T416P O 0 8.723560540602193e-07
) O 0 9.823784452578366e-09
was O 0 1.7623016219658894e-06
found O 0 1.3349156802178186e-07
in O 0 5.238881328750722e-09
a O 0 1.0672410866163773e-07
homozygous O 0 3.393923861949588e-07
state O 0 1.0231596014875777e-08
in O 0 1.0690192731033221e-08
one O 0 1.498311803516117e-07
family O 0 5.939536436017079e-07
and O 0 4.986370427673137e-08
in O 0 6.842988842237219e-09
a O 0 2.4545308008327993e-08
heterozygous O 0 7.514208988368409e-08
state O 0 1.7035236554718836e-09
in O 0 8.96424712237831e-09
four O 0 4.774974371457574e-08
families O 0 1.4575971363228746e-07
. O 0 2.0553606816520187e-07

Pendred B-Disease 0 0.36118659377098083
patients O 0 0.00019569094001781195
in O 0 3.251098590340007e-08
three O 0 9.359717445533988e-09
non O 0 1.0732605915109161e-06
- O 0 0.00019661520491354167
consanguineous O 0 0.0002369646681472659
families O 0 5.4187690778917386e-08
were O 0 8.532533257721298e-08
shown O 0 8.631329428965273e-09
to O 0 1.719637432451293e-09
be O 0 2.6491811411233357e-08
compound O 0 4.2669321942412353e-07
heterozygotes O 0 1.6311551576109196e-07
for O 0 3.169274398473476e-09
L236P O 0 1.5671071196265984e-06
and O 0 4.0631483955166914e-08
T416P O 0 5.902921657252591e-06
. O 0 2.74281205747684e-07

In O 0 2.0890382756988402e-07
total O 0 1.2196346688142512e-07
, O 0 3.280899818491889e-08
one O 0 5.3547166700695925e-09
or O 0 1.8908012933138707e-08
both O 0 4.413295562333275e-10
of O 0 3.3416905353966797e-10
these O 0 3.0334088574335283e-09
mutations O 0 5.105280820316693e-08
were O 0 2.853542184766411e-07
found O 0 1.8400149315311864e-07
in O 0 5.637979416661665e-09
nine O 0 7.94709542617511e-09
of O 0 9.968170733287707e-10
the O 0 7.483169639499465e-09
14 O 0 4.576693157787304e-08
families O 0 2.83505290354924e-08
analyzed O 0 3.4662005532482e-07
. O 0 1.6960150617251202e-07

The O 0 9.025636416026828e-08
identification O 0 7.352584674436002e-08
of O 0 3.4346940847029828e-09
two O 0 2.7017920345429047e-08
frequent O 0 2.303959809069056e-05
PDS B-Disease 0 0.00036556978011503816
mutations O 0 5.428233293969242e-07
will O 0 6.376688510556505e-09
facilitate O 0 3.3114414321744334e-08
the O 0 1.5598644154124486e-08
molecular O 0 2.7978370781056583e-05
diagnosis O 0 0.0020356480963528156
of O 0 0.00018703847308643162
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
. O 0 1.8444774468662217e-05

Insertional O 0 0.0006397273973561823
mutation O 0 7.898100193415303e-06
by O 0 5.2551367701880736e-08
transposable O 0 1.0086688234878238e-05
element O 0 4.886172064288985e-06
, O 0 1.0850116893834638e-07
L1 O 0 0.00010426859080325812
, O 0 2.9414394475679728e-08
in O 0 3.90416721174347e-09
the O 0 3.234324807976918e-08
DMD B-Disease 1 0.9999926090240479
gene O 0 6.004050874253153e-07
results O 0 1.9322806110722013e-07
in O 0 1.921087005030131e-07
X B-Disease 1 0.9991401433944702
- I-Disease 1 0.99989914894104
linked I-Disease 1 0.999931812286377
dilated I-Disease 1 0.9998268485069275
cardiomyopathy I-Disease 1 0.9999978542327881
. O 0 1.6283980585285462e-05

X B-Disease 1 0.9943438768386841
- I-Disease 1 0.9996399879455566
linked I-Disease 1 0.9998737573623657
dilated I-Disease 1 0.9999669790267944
cardiomyopathy I-Disease 1 0.9999998807907104
( O 0 1.8399041437078267e-06
XLDCM B-Disease 0 0.02650093287229538
) O 0 5.025056992735699e-08
is O 0 4.931812824793269e-08
a O 0 7.845140004292261e-08
clinical O 0 2.4650460090924753e-06
phenotype O 0 9.332497370451165e-07
of O 0 3.696785988438478e-09
dystrophinopathy B-Disease 0 0.000482821895275265
which O 0 1.139096184488153e-06
is O 0 1.5347021076195233e-07
characterized O 0 2.0092513750569196e-06
by O 0 3.304576878804255e-08
preferential O 0 2.0958075765520334e-05
myocardial B-Disease 1 0.9319955706596375
involvement I-Disease 0 4.590472144627711e-06
without O 0 1.637226354489485e-08
any O 0 2.1375054615191402e-08
overt O 0 2.6906536731985398e-06
clinical O 0 1.2280266673769802e-05
signs O 0 2.5375056793564e-05
of O 0 2.4643250071676448e-05
skeletal B-Disease 1 0.9999997615814209
myopathy I-Disease 1 1.0
. O 0 0.00031372468220070004

To O 0 1.9441695542354864e-07
date O 0 3.0463931466329086e-07
, O 0 7.0330590240530455e-09
several O 0 1.4981217377751932e-09
mutations O 0 1.2983264241483994e-07
in O 0 2.8808630148091652e-08
the O 0 8.859880836098455e-06
Duchenne B-Disease 1 0.9999943971633911
muscular I-Disease 1 0.9997740387916565
dystrophy I-Disease 1 0.9977967739105225
gene O 0 0.00014754287258256227
, O 0 1.6464398868265562e-05
DMD O 1 0.9999990463256836
, O 0 3.2526420454814797e-06
have O 0 5.9303452815129276e-08
been O 0 1.687156725438399e-07
identified O 0 1.0082967492053285e-06
in O 0 1.64133471258765e-08
patients O 0 5.617930654011616e-08
with O 0 1.009951855479585e-08
XLDCM B-Disease 0 0.0017935186624526978
, O 0 6.673059971262774e-08
but O 0 3.2610336653249306e-09
a O 0 2.0666568456562118e-09
pathogenic O 0 5.917732526228292e-09
correlation O 0 1.8078459618209308e-08
of O 0 4.58203419650971e-10
these O 0 1.925377191014377e-09
cardiospecific O 0 9.254518772650044e-06
mutations O 0 2.7774945010605734e-07
in O 0 2.2395657595097873e-07
DMD O 1 0.999998927116394
with O 0 3.5996234259982884e-07
the O 0 1.4626908750869916e-07
XLDCM B-Disease 0 0.06659132242202759
phenotype O 0 3.1091771234059706e-05
has O 0 1.3647504601976834e-06
remained O 0 5.727188636228675e-06
to O 0 1.3480718763503319e-08
be O 0 1.4173667750583263e-07
elucidated O 0 2.5518062102491967e-05
. O 0 4.4762120410268835e-07

We O 0 1.8926145912701031e-06
report O 0 7.747709673822101e-08
here O 0 2.5664046443552024e-09
the O 0 2.409621113752536e-10
identification O 0 6.8124115237822025e-09
of O 0 9.333399608735249e-10
a O 0 5.756313825600046e-08
unique O 0 2.0562940505897132e-07
de O 0 1.862481985881459e-05
novo O 0 3.19925784424413e-05
L1 O 0 2.725291960814502e-05
insertion O 0 2.377049526103292e-07
in O 0 7.38254213317191e-09
the O 0 2.5252768764971734e-09
muscle O 0 1.7905441040966252e-07
exon O 0 4.771223416355497e-07
1 O 0 2.391105056176457e-07
in O 0 3.734213009920495e-07
DMD O 1 0.9999991655349731
in O 0 3.602271192448825e-07
three O 0 1.7435606025628658e-07
XLDCM B-Disease 0 0.14208754897117615
patients O 0 3.9780076122042374e-07
from O 0 1.4193511921334334e-09
two O 0 2.4993580538534843e-09
unrelated O 0 5.116705779073527e-07
Japanese O 0 7.855925900912553e-07
families O 0 9.726389293973625e-08
. O 0 1.5792549845627946e-07

The O 0 1.5401271014070517e-07
insertion O 0 1.804833459573274e-06
was O 0 1.0564901913312497e-06
a O 0 7.363166787399678e-08
5 O 0 3.6792091151482964e-08
- O 0 1.15806108169636e-06
truncated O 0 4.7136947500803217e-07
form O 0 3.379646784651413e-08
of O 0 2.463623971493689e-09
human O 0 4.32086224577688e-08
L1 O 0 5.332456566975452e-06
inversely O 0 3.455102387306397e-06
integrated O 0 1.9605633951869095e-06
in O 0 3.3440386015826107e-09
the O 0 3.779129453818086e-09
5 O 0 1.4100876910561055e-07
- O 0 0.00040275967330671847
untranslated O 0 8.939544204622507e-05
region O 0 7.16495378583204e-07
in O 0 8.280681029759762e-09
the O 0 3.2965046248278895e-09
muscle O 0 1.0984780374201364e-07
exon O 0 9.167944625687596e-08
1 O 0 4.395926467282152e-08
, O 0 5.012724901831689e-09
which O 0 1.200853727567619e-08
affected O 0 7.761046916243686e-09
the O 0 2.850285840683142e-10
transcription O 0 1.663767932313931e-07
or O 0 1.6312299067067215e-07
the O 0 1.1191607640625989e-08
stability O 0 4.558920068120642e-07
of O 0 1.7452658207517402e-09
the O 0 1.0372283476556277e-08
muscle O 0 6.459516157519829e-07
form O 0 6.349502257307904e-09
of O 0 1.9649817328826202e-09
dystrophin O 0 6.313156291071209e-07
transcripts O 0 6.324491437226243e-07
but O 0 5.031713001812932e-08
not O 0 9.12229314309343e-09
that O 0 5.439017569663918e-10
of O 0 4.26993163049616e-10
the O 0 3.158449857210144e-08
brain O 0 7.909269334049895e-05
or O 0 7.12418113835156e-07
Purkinje O 0 7.9892881331034e-05
cell O 0 3.257832213421352e-05
form O 0 1.5348264525982813e-07
, O 0 3.922261626598811e-08
probably O 0 4.606970662734966e-07
due O 0 1.7108639838170348e-08
to O 0 1.9389798655566892e-09
its O 0 2.9305406989976746e-09
unique O 0 8.71468586183255e-09
site O 0 5.633133923765854e-07
of O 0 2.6516162598966275e-09
integration O 0 7.124127137103642e-07
. O 0 3.850861958198948e-07

We O 0 6.326077368612459e-07
speculate O 0 3.362665950135124e-07
that O 0 4.209399051546825e-09
this O 0 7.377498612015643e-10
insertion O 0 3.510880119961257e-08
of O 0 3.064965392596264e-09
an O 0 2.5066396958095538e-08
L1 O 0 5.225485801929608e-05
sequence O 0 2.151519424842263e-07
in O 0 8.732359901841846e-08
DMD O 1 0.9999970197677612
is O 0 8.579823997934e-07
responsible O 0 3.637552765667351e-07
for O 0 2.6941540109959305e-09
some O 0 4.1082018342741833e-10
of O 0 2.5733293274043945e-10
the O 0 1.1058726157031629e-09
population O 0 6.923542850145736e-10
of O 0 6.010759112662356e-10
Japanese O 0 4.026805527246324e-06
patients O 0 4.4162721479779066e-08
with O 0 1.5782726237034694e-08
XLDCM B-Disease 0 0.00014126177120488137
. O 0 3.358979583367727e-08
. O 0 1.6324359819464007e-07

Severe O 0 0.0003360923728905618
early O 0 8.858663932187483e-06
- O 1 0.8743180632591248
onset O 1 0.9998007416725159
obesity B-Disease 1 1.0
, O 0 0.39536234736442566
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 0.9999998807907104
and O 0 6.126555672381073e-05
red O 0 0.0022340202704072
hair O 1 0.9709051847457886
pigmentation O 0 0.1558695137500763
caused O 0 5.7751796703087166e-05
by O 0 1.348370659570719e-07
POMC O 0 0.009004300460219383
mutations O 0 3.243862920498941e-06
in O 0 6.265436525154655e-08
humans O 0 3.6725808172377583e-07
. O 0 5.951404205006838e-07

Sequential O 0 1.3464214134728536e-05
cleavage O 0 0.00020596457761712372
of O 0 3.679412685642092e-08
the O 0 5.080062148721254e-09
precursor O 0 6.424154719297803e-08
protein O 0 4.281892529434117e-08
pre O 0 5.541018254007213e-06
- O 0 2.7119400328956544e-05
pro O 0 1.9850565877277404e-05
- O 0 4.5536875404650345e-05
opiomelanocortin O 0 4.883141446043737e-05
( O 0 1.768394319867639e-08
POMC O 0 5.150269316800404e-06
) O 0 2.6904873884348035e-09
generates O 0 7.299065796217974e-09
the O 0 2.810232491157194e-09
melanocortin O 0 1.914950553327799e-05
peptides O 0 1.4832843362455606e-06
adrenocorticotrophin O 0 6.87287756591104e-05
( O 0 1.864884602298389e-08
ACTH O 0 1.5130976862565149e-06
) O 0 3.1765483576862152e-09
, O 0 3.798569458979273e-09
melanocyte O 0 1.1782249202951789e-05
- O 0 0.0001371975668007508
stimulating O 0 1.2683451132033952e-05
hormones O 0 2.409132662251068e-07
( O 0 1.2651353298309687e-09
MSH O 0 5.394266509028967e-07
) O 0 4.3475595346009754e-10
alpha O 0 1.2211814892637562e-09
, O 0 1.884311873201483e-10
beta O 0 3.7326924884339974e-10
and O 0 1.5565133903994166e-10
gamma O 0 1.3909590146354844e-09
as O 0 5.21893250837735e-10
well O 0 5.386571189092138e-10
as O 0 3.2912633729509366e-10
the O 0 1.7498748283717447e-10
opioid O 0 8.691699093787975e-08
- O 0 1.7229682214292552e-07
receptor O 0 3.777041612806897e-08
ligand O 0 5.9305939714704436e-08
beta O 0 7.352206665700578e-08
- O 0 2.741279331530677e-06
endorphin O 0 0.0001279588759643957
. O 0 3.5239364137851226e-07

While O 0 1.0891538977375603e-06
a O 0 3.5288454824922155e-08
few O 0 8.047954302980997e-09
cases O 0 6.636299509921173e-09
of O 0 2.9153889968824842e-08
isolated O 1 0.9991826415061951
ACTH B-Disease 1 0.9998051524162292
deficiency I-Disease 1 0.7468735575675964
have O 0 1.6789644519121794e-07
been O 0 2.0788471033483802e-07
reported O 0 1.2399594197631814e-05
( O 0 2.5618136945126935e-08
OMIM O 0 4.2248746467521414e-05
201400 O 0 3.3130258998426143e-06
) O 0 1.627884849142447e-08
, O 0 3.708865037310716e-08
an O 0 1.9049667798753944e-07
inherited O 0 0.03559914603829384
POMC O 1 0.9824287295341492
defect O 0 0.14556582272052765
has O 0 1.5882204706940684e-06
not O 0 3.4480468258379915e-08
been O 0 1.2294019313685567e-07
described O 0 6.749582439624646e-07
so O 0 2.661711384632781e-08
far O 0 1.3711726865039964e-07
. O 0 1.5099854522304668e-07

Recent O 0 1.7432012100471184e-06
studies O 0 7.732901252666124e-08
in O 0 5.462286623014734e-09
animal O 0 5.7100034922541454e-08
models O 0 4.955338681611465e-07
elucidated O 0 2.116282303177286e-06
a O 0 1.16489161428035e-07
central O 0 1.570612084833556e-08
role O 0 3.88684062713196e-09
of O 0 6.642184580130106e-10
alpha O 0 1.924724735147265e-08
- O 0 1.4456928738582064e-06
MSH O 0 6.620840849791421e-06
in O 0 9.818965640562283e-10
the O 0 3.0066341083490045e-10
regulation O 0 2.435223800389963e-09
of O 0 1.2409636651611322e-09
food O 0 7.793908451958487e-08
intake O 0 3.148879912373559e-08
by O 0 3.351853239408342e-10
activation O 0 3.1726976601476053e-09
of O 0 5.815735670822164e-10
the O 0 5.897810240185208e-09
brain O 0 1.432222575203923e-06
melanocortin O 0 2.4544099233025918e-06
- O 0 4.580161203193711e-06
4 O 0 8.131541306966028e-08
- O 0 1.8761656974675134e-05
receptor O 0 4.884528266302368e-07
( O 0 4.417702204051466e-09
MC4 O 0 1.5325214917538688e-05
- O 0 1.0889973964367528e-05
R O 0 3.173293225700036e-05
; O 0 2.018367029066326e-09
refs O 0 1.6059905760812399e-07
3 O 0 3.4381631763835685e-08
- O 0 7.236636974994326e-06
5 O 0 8.293579156770647e-09
) O 0 5.037277817088182e-10
and O 0 1.4178684892840465e-09
the O 0 2.5832730399244497e-10
linkage O 0 3.667701548693003e-06
of O 0 1.024198326149417e-08
human O 0 1.0979772014252376e-05
obesity B-Disease 1 0.9999939203262329
to O 0 2.005987482789351e-07
chromosome O 0 5.6060591305140406e-05
2 O 0 1.4111624579982163e-07
in O 0 8.854708966055114e-09
close O 0 1.1933699397559394e-06
proximity O 0 1.142647533924901e-06
to O 0 1.79051617976711e-08
the O 0 2.784909547415282e-08
POMC O 0 4.52544009021949e-05
locus O 0 4.309084999931656e-07
, O 0 3.760365174798608e-08
led O 0 1.921823056250105e-08
to O 0 3.8527838697177685e-09
the O 0 3.5037204249022125e-09
proposal O 0 2.01951237954745e-07
of O 0 3.8806993174489435e-09
an O 0 2.2990112924503592e-08
association O 0 4.231183581282494e-08
of O 0 1.2996713039115093e-08
POMC O 0 0.0320088155567646
with O 0 4.3054330944869434e-07
human O 0 3.1743253202876076e-05
obesity B-Disease 1 0.9999794960021973
. O 0 7.08191100784461e-06

The O 0 2.474624807291548e-07
dual O 0 6.185383654155885e-07
role O 0 2.7531156021609604e-08
of O 0 1.7380107353304197e-09
alpha O 0 4.342210147001424e-08
- O 0 6.849037617939757e-06
MSH O 0 8.356790203833953e-06
in O 0 7.07120195730937e-10
regulating O 0 2.088500536956417e-07
food O 0 1.0701335639851095e-07
intake O 0 2.8746504199261835e-07
and O 0 1.476354238860722e-08
influencing O 0 1.8907856258465472e-07
hair O 0 0.00040937832091003656
pigmentation O 0 1.6915284504648298e-05
predicts O 0 5.2175681048538536e-05
that O 0 2.848343072514581e-08
the O 0 6.139634134427752e-09
phenotype O 0 3.8141004097269615e-06
associated O 0 4.3306476982252207e-07
with O 0 1.1504026531383715e-07
a O 0 6.170104370539775e-06
defect O 0 0.008357711136341095
in O 0 1.101759750099518e-07
POMC O 0 0.0003662552626337856
function O 0 3.948262587982754e-07
would O 0 1.734950387799472e-07
include O 0 2.7402729756431654e-06
obesity B-Disease 1 0.9999969005584717
, O 0 4.531836239607401e-08
alteration O 0 4.4742068894265685e-06
in O 0 4.2512780851211573e-07
pigmentation O 1 0.5723038911819458
and O 0 0.0055973464623093605
ACTH B-Disease 1 0.9997993111610413
deficiency I-Disease 1 0.9452847242355347
. O 0 8.832866456032207e-07

The O 0 3.1267720146388456e-07
observation O 0 9.499221960140858e-06
of O 0 1.4214218246877408e-08
these O 0 1.0148163198664406e-07
symptoms O 0 1.5688672192482045e-06
in O 0 1.4945713555647444e-09
two O 0 2.413338640039342e-09
probands O 0 1.24231846712064e-05
prompted O 0 2.9166793424906245e-08
us O 0 3.4205336341130987e-09
to O 0 7.119569933600189e-10
search O 0 8.650744121041498e-09
for O 0 4.11955047852075e-09
mutations O 0 1.7184719069973653e-07
within O 0 9.57100976251013e-09
their O 0 2.699252732440982e-08
POMC O 0 0.0004378800222184509
genes O 0 8.232743766711792e-07
. O 0 3.1954311907611554e-07

Patient O 0 0.0007895156741142273
1 O 0 5.689499289474043e-07
was O 0 3.0988751404947834e-06
found O 0 1.2185093112293544e-07
to O 0 2.3088668754667196e-09
be O 0 5.7147184762129655e-09
a O 0 1.2227133083797526e-08
compound O 0 7.247987809932965e-07
heterozygote O 0 1.0881266376827625e-07
for O 0 1.123728998742024e-09
two O 0 1.5117562757183123e-09
mutations O 0 3.921790181493634e-08
in O 0 3.6928957669601914e-09
exon O 0 2.4463730596835376e-07
3 O 0 5.682006332108358e-08
( O 0 2.702718493452494e-09
G7013T O 0 3.0783371585130226e-07
, O 0 1.2497887169615751e-08
C7133delta O 0 3.542566673786496e-06
) O 0 1.2494854040312475e-09
which O 0 2.0344301798758124e-09
interfere O 0 5.268585567819173e-08
with O 0 1.0702918551430685e-09
appropriate O 0 5.830588456490204e-09
synthesis O 0 2.9109937571547562e-08
of O 0 4.71893635278775e-09
ACTH O 0 5.125006282469258e-06
and O 0 2.3928881986989836e-08
alpha O 0 2.1316513709734863e-07
- O 0 3.608190672821365e-05
MSH O 0 0.00026247522328048944
. O 0 5.588187832472613e-07

Patient O 0 0.0002997646515723318
2 O 0 7.067243359415443e-07
was O 0 8.968438578449422e-07
homozygous O 0 8.684968975103402e-07
for O 0 6.055040913111043e-09
a O 0 1.0294082386508308e-07
mutation O 0 2.3828872031117498e-07
in O 0 9.697617819881543e-09
exon O 0 5.148197033122415e-06
2 O 0 1.4221492392607615e-06
( O 0 5.8671489000516885e-08
C3804A O 0 3.502530944388127e-06
) O 0 1.7748957858998438e-08
which O 0 6.99941864468201e-08
abolishes O 0 5.2266623242758214e-05
POMC O 0 0.00026235965196974576
translation O 0 5.157700798008591e-06
. O 0 7.339735930145252e-07

These O 0 2.2079545658471034e-07
findings O 0 7.057155215761668e-08
represent O 0 1.0200185585063082e-08
the O 0 6.344765268728736e-10
first O 0 4.16812584447257e-09
examples O 0 3.304992546304675e-08
of O 0 1.2795609016791332e-08
a O 0 0.000438275485066697
genetic B-Disease 1 0.999998927116394
defect I-Disease 1 0.9999971389770508
within O 0 5.134313028065662e-07
the O 0 5.0580979404912796e-08
POMC O 0 6.0206013586139306e-05
gene O 0 2.973874586587044e-07
and O 0 2.8434088861217788e-08
define O 0 3.163351891544153e-07
a O 0 2.3640681945380493e-07
new O 0 2.8430401926016202e-06
monogenic B-Disease 1 0.9995531439781189
endocrine I-Disease 1 0.9979396462440491
disorder I-Disease 0 0.06030276417732239
resulting O 0 3.132705614916631e-07
in O 0 3.3841750735064124e-08
early O 0 4.876210823567817e-06
- O 1 0.9836049675941467
onset O 1 0.9999356269836426
obesity B-Disease 1 1.0
, O 0 0.4892387092113495
adrenal B-Disease 1 0.9999998807907104
insufficiency I-Disease 1 0.9999998807907104
and O 0 2.8996646506129764e-05
red O 0 0.00012936053099110723
hair O 0 0.15259024500846863
pigmentation O 0 0.00013552079326473176
. O 0 1.3921307129294291e-07
. O 0 3.682386591208342e-07

A O 0 9.898351891024504e-06
European O 0 1.0083966799356858e-06
multicenter O 0 0.0003615593886934221
study O 0 1.2809987310902216e-06
of O 0 1.8600056137074716e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 1.5302197198252543e-07
classification O 0 3.451715997471183e-07
of O 0 2.8464515189341455e-09
105 O 0 3.0140384410515253e-07
mutations O 0 1.5599498510709964e-06
and O 0 7.677100910541412e-08
a O 0 9.767233422053323e-08
general O 0 8.296806797147838e-09
system O 0 1.8881273433635215e-08
for O 0 2.2221948725587026e-09
genotype O 0 5.740611754845304e-07
- O 0 1.1427466688473942e-06
based O 0 3.132986137188709e-08
prediction O 0 2.280473609062028e-06
of O 0 6.441675992618912e-08
metabolic O 0 0.012910595163702965
phenotype O 0 0.00016276138194371015
. O 0 1.9142557903251145e-06

Phenylketonuria B-Disease 1 0.8865100145339966
( O 0 2.355153128519305e-06
PKU B-Disease 0 0.00011097671813331544
) O 0 5.4740752375437296e-08
and O 0 5.521098387362144e-07
mild B-Disease 1 0.8443257212638855
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.002897385274991393
MHP B-Disease 1 0.9999998807907104
) O 0 2.3325097231463587e-07
are O 0 5.042896873419522e-07
allelic B-Disease 0 0.24540495872497559
disorders I-Disease 1 0.9440708756446838
caused O 0 5.970817710476695e-06
by O 0 1.5152673782381498e-08
mutations O 0 7.683926241952577e-07
in O 0 1.1257761833860513e-08
the O 0 7.309124416821078e-09
gene O 0 3.579081919724558e-07
encoding O 0 1.6331442793671158e-06
phenylalanine O 0 0.07950396835803986
hydroxylase O 1 0.7564125657081604
( O 0 9.676462013885612e-07
PAH O 0 0.0004971255548298359
) O 0 7.946690061544359e-08
. O 0 1.5161005251229653e-07

Previous O 0 1.1673287190205883e-06
studies O 0 5.009793113686101e-08
have O 0 1.2741445232222759e-08
suggested O 0 1.4877858056649984e-08
that O 0 8.195621958861921e-10
the O 0 8.574681520379102e-10
highly O 0 2.5365943656652234e-07
variable O 0 4.970718873664737e-05
metabolic O 0 0.0014158705016598105
phenotypes O 0 0.00011012998584192246
of O 0 2.3158485419116914e-05
PAH B-Disease 1 0.9999420642852783
deficiency I-Disease 1 0.9329600930213928
correlate O 0 6.382342689903453e-05
with O 0 1.4138435290078633e-05
PAH O 1 0.7679672837257385
genotypes O 0 0.00011019028897862881
. O 0 8.85852784904273e-07

We O 0 2.6352674922236474e-06
identified O 0 9.257327633349632e-07
both O 0 9.766595532312294e-09
causative O 0 8.532060746802017e-06
mutations O 0 8.846674859341874e-07
in O 0 1.1595690807553183e-07
686 O 0 0.0003190228599123657
patients O 0 1.3997657788422657e-06
from O 0 1.0682161821762293e-08
seven O 0 1.483886258313305e-08
European O 0 4.762231498034453e-08
centers O 0 3.8286489711936156e-07
. O 0 1.666163882418914e-07

On O 0 7.611531600559829e-07
the O 0 5.026626670456835e-09
basis O 0 9.948327495123976e-09
of O 0 6.369246241533233e-10
the O 0 1.508777769387848e-09
phenotypic O 0 1.7894311099553306e-07
characteristics O 0 1.1229715823901643e-07
of O 0 4.620705151836546e-09
297 O 0 1.1018969416909385e-06
functionally O 0 1.7133925211965106e-05
hemizygous O 0 0.0008520038682036102
patients O 0 5.548963599721901e-07
, O 0 2.9562696735041527e-09
105 O 0 1.492828438642846e-08
of O 0 6.097419791295522e-10
the O 0 1.6209840136838238e-09
mutations O 0 4.321026736420208e-08
were O 0 5.227146715469644e-08
assigned O 0 1.4185616237227805e-08
to O 0 2.650589747688059e-09
one O 0 2.0096508901445986e-09
of O 0 8.669404638617095e-10
four O 0 4.634049588503331e-09
arbitrary O 0 1.7200325146404793e-06
phenotype O 0 2.1579629901680164e-05
categories O 0 1.7509435110696359e-06
. O 0 4.893312279818929e-07

We O 0 6.059838142391527e-07
proposed O 0 2.486659411715664e-07
and O 0 1.1346234884967998e-07
tested O 0 7.261957080118009e-07
a O 0 6.793104745383971e-09
simple O 0 2.7066922925200743e-08
model O 0 1.41795638342046e-07
for O 0 1.409649397210444e-09
correlation O 0 8.354533065357828e-08
between O 0 1.979397268314642e-08
genotype O 0 4.524706298525416e-07
and O 0 1.0191649302271344e-08
phenotypic O 0 1.1429549431341002e-06
outcome O 0 1.1310211220916244e-06
. O 0 9.224755785908201e-07

The O 0 6.658705586914948e-08
observed O 0 6.024193908160669e-07
phenotype O 0 2.502121787983924e-06
matched O 0 4.552359769149916e-07
the O 0 7.587540373776847e-09
predicted O 0 4.135552444495261e-06
phenotype O 0 8.484720410706359e-07
in O 0 7.147548330976861e-09
79 O 0 7.92428878071405e-08
% O 0 1.5335170910901752e-09
of O 0 7.318802230926735e-10
the O 0 2.7705834071412028e-08
cases O 0 7.098193464116775e-07
, O 0 3.400765891115043e-08
and O 0 7.512402788734107e-08
in O 0 6.383698014644779e-09
only O 0 3.053680197595554e-09
5 O 0 6.946505592964058e-10
of O 0 5.736425778835041e-10
184 O 0 1.297813838618822e-07
patients O 0 8.8912848639211e-08
was O 0 7.234086751850555e-07
the O 0 1.4744679921463444e-09
observed O 0 1.85028426358258e-07
phenotype O 0 7.004921087627736e-08
more O 0 5.267756231219778e-10
than O 0 3.3810703126135877e-09
one O 0 4.710869916380034e-09
category O 0 1.3917166086230282e-07
away O 0 8.122655437148296e-09
from O 0 7.54997397933721e-10
that O 0 8.168487219961662e-09
expected O 0 2.3078030153556028e-07
. O 0 2.1073633149626403e-07

Among O 0 9.066326356332866e-07
the O 0 1.825963380497342e-08
seven O 0 6.1008669227646806e-09
contributing O 0 5.398312552529205e-08
centers O 0 6.524859941237082e-08
, O 0 2.039208579773799e-09
the O 0 2.8595209533577304e-10
proportion O 0 5.4634750057402925e-09
of O 0 4.549848497958919e-09
patients O 0 7.690320558140229e-08
for O 0 7.39832950458208e-09
whom O 0 4.315936408261223e-08
the O 0 9.712829429631142e-10
observed O 0 1.8153792780140066e-07
phenotype O 0 3.237151986468234e-07
did O 0 9.018666702331757e-08
not O 0 9.138261702901218e-09
match O 0 2.503147378263293e-08
the O 0 1.5622276805515867e-09
predicted O 0 3.104755933236447e-06
phenotype O 0 3.0315541721392947e-07
was O 0 9.30313660774118e-07
4 O 0 8.928992656365153e-09
% O 0 4.922093399528649e-09
- O 0 1.4837420167168602e-05
23 O 0 1.0528998473091633e-07
% O 0 5.109993317375938e-09
( O 0 2.3737221077624326e-09
P O 0 0.003887536935508251
< O 0 4.190187155472813e-06
. O 0 1.889870038240815e-09
0001 O 0 2.932102916020085e-07
) O 0 1.2431479179397797e-09
, O 0 5.837774152972486e-10
suggesting O 0 1.8862518658124827e-08
that O 0 2.785832675655797e-09
differences O 0 3.731158670916557e-08
in O 0 2.730489445657014e-10
methods O 0 9.597791006399348e-09
used O 0 1.834827578761633e-08
for O 0 1.845774644237963e-09
mutation O 0 7.575859228836634e-08
detection O 0 4.137213181820698e-06
or O 0 2.14967485590023e-06
phenotype O 0 5.667097866535187e-06
classification O 0 8.19521210360108e-06
may O 0 1.1243962489970727e-06
account O 0 1.0493131696875935e-07
for O 0 3.2258888893466064e-09
a O 0 1.9032590614642686e-08
considerable O 0 1.1835312285768396e-08
proportion O 0 5.938098368574174e-08
of O 0 1.9423492148007426e-08
genotype O 0 0.00024417947861365974
- O 0 0.009336857125163078
phenotype O 0 0.0002523604198358953
inconsistencies O 0 0.00010368193034082651
. O 0 3.2146247122000204e-06

Our O 0 3.951456903905637e-07
data O 0 7.730763229574222e-08
indicate O 0 9.915218157630079e-08
that O 0 4.303694289831128e-09
the O 0 2.1197712030129878e-08
PAH O 0 0.0011625881306827068
- O 0 4.023038854938932e-05
mutation O 0 4.090863967576297e-07
genotype O 0 4.293644622066495e-07
is O 0 9.74400737874248e-09
the O 0 1.1901134522318557e-09
main O 0 6.977790576456755e-07
determinant O 0 1.220234253196395e-06
of O 0 8.31957791547211e-09
metabolic O 0 0.0020736875012516975
phenotype O 0 1.1758553227991797e-05
in O 0 4.372729023316424e-08
most O 0 7.473742584807042e-07
patients O 0 9.079877600015607e-06
with O 0 8.979863196145743e-05
PAH B-Disease 1 0.9999793767929077
deficiency I-Disease 1 0.9940128922462463
. O 0 2.107509089910309e-06

In O 0 2.3655475445139018e-07
the O 0 8.98317686903738e-09
present O 0 1.2447713970686891e-08
study O 0 1.257317805425373e-08
, O 0 2.609720217705558e-09
the O 0 4.241424711448616e-10
classification O 0 6.397254992407397e-08
of O 0 2.0989379123648177e-09
105 O 0 2.6100658487848705e-06
PAH O 0 0.0007823253399692476
mutations O 0 4.5763704292767216e-07
may O 0 2.218909500584232e-08
allow O 0 3.2238653968619246e-09
the O 0 9.96644100581534e-10
prediction O 0 4.428116426424822e-06
of O 0 8.801562811910912e-10
the O 0 4.436693235021494e-09
biochemical O 0 9.436240020477271e-07
phenotype O 0 2.2364540086527995e-07
in O 0 7.556633541128122e-09
> O 0 2.614971208458883e-07
10 O 0 1.9349574387206303e-08
, O 0 3.453521246754576e-09
000 O 0 8.007561724809875e-09
genotypes O 0 2.0592808880337543e-07
, O 0 9.992256799762345e-09
which O 0 3.4925395908658174e-08
may O 0 5.359521537684486e-08
be O 0 3.3017022449399747e-09
useful O 0 1.3537558629650448e-08
for O 0 9.280960444613129e-10
the O 0 1.0510329273571983e-09
management O 0 9.076771334548539e-08
of O 0 6.081441572547419e-09
hyperphenylalaninemia B-Disease 1 0.9999945163726807
in O 0 1.5716630059614545e-06
newborns O 0 7.470005220966414e-05
. O 0 3.458678463630349e-07

Somatic O 0 0.00011733773135347292
instability O 0 1.3889566616853699e-05
of O 0 1.3305733403967679e-08
the O 0 1.821715933658652e-08
CTG O 0 0.0002683167695067823
repeat O 0 2.0684581159002846e-06
in O 0 1.283941841734304e-08
mice O 0 1.3421525864032446e-06
transgenic O 0 3.2179159461520612e-06
for O 0 1.0598490973734442e-07
the O 0 4.447001629159786e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.00031464279163628817
is O 0 9.85315296020417e-07
age O 0 3.7315000867010895e-08
dependent O 0 7.372469923438985e-08
but O 0 5.786119583461868e-09
not O 0 6.224123993980868e-10
correlated O 0 7.093724718743033e-09
to O 0 7.759681230901094e-10
the O 0 6.654725659416272e-10
relative O 0 4.556746660000499e-07
intertissue O 0 1.8156368923882837e-06
transcription O 0 6.715642371091235e-07
levels O 0 2.3803161752766755e-07
and O 0 1.5715295376139693e-07
proliferative O 0 0.1918080449104309
capacities O 0 2.1870573618798517e-05
. O 0 5.929767894485849e-07

A O 0 7.54584380047163e-06
( O 0 6.73165985176638e-08
CTG O 0 1.779195008566603e-05
) O 0 8.005423879353657e-09
nexpansion O 0 2.3887762381491484e-06
in O 0 5.780052880766107e-09
the O 0 5.043779172098084e-09
3 O 0 2.9116779387550196e-07
- O 0 0.014835668727755547
untranslated O 0 0.002617607591673732
region O 0 2.4291168756462866e-06
( O 0 4.8543036257342465e-09
UTR O 0 4.925303755953792e-07
) O 0 2.1067861344370442e-10
of O 0 2.843183466438859e-10
the O 0 5.599957475510564e-08
DM O 1 0.9999998807907104
protein O 0 6.5582944444031455e-06
kinase O 0 8.509878171025775e-06
gene O 0 2.2211055750176456e-07
( O 0 1.0426433938448554e-08
DMPK O 0 1.6263884390355088e-05
) O 0 3.904546908017892e-09
is O 0 1.010028860548573e-08
responsible O 0 3.113100035534444e-07
for O 0 7.058009714455693e-07
causing O 1 0.960568904876709
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.002322025364264846
DM B-Disease 1 0.9999998807907104
) O 0 8.362459084310103e-06
. O 0 1.7907232177094556e-06

Major O 0 1.7019616279867478e-05
instability O 0 3.9410551835317165e-05
, O 0 9.744866247274331e-08
with O 0 4.571037770517705e-09
very O 0 7.928926848421725e-09
large O 0 4.507583639679069e-09
expansions O 0 1.848682842364724e-07
between O 0 1.7335354485226162e-08
generations O 0 7.470320362301663e-09
and O 0 1.6643987521547388e-08
high O 0 6.597562105525867e-07
levels O 0 4.297484590409795e-09
of O 0 1.388175407956993e-10
somatic O 0 1.4477691934189352e-07
mosaicism O 0 5.166768460185267e-05
, O 0 1.9041088705762377e-08
is O 0 6.4611649364110235e-09
observed O 0 1.0234020209054506e-07
in O 0 4.634450334606299e-08
patients O 0 3.4351293720646936e-07
. O 0 1.2580692043684394e-07

There O 0 1.9849226191581693e-06
is O 0 5.202856812047685e-08
a O 0 2.193627324231784e-08
good O 0 1.0142551332137373e-07
correlation O 0 2.254893445297057e-07
between O 0 2.096082418745482e-08
repeat O 0 9.479670097789494e-07
size O 0 2.2504732442030217e-06
( O 0 2.8562081588745514e-09
at O 0 2.901791518183927e-08
least O 0 1.1796182919354692e-09
in O 0 7.744451746560799e-10
leucocytes O 0 6.783616754546529e-06
) O 0 3.532776959858097e-09
, O 0 2.676437960147382e-09
clinical O 0 9.293456315617732e-08
severity O 0 5.899730695091421e-06
and O 0 4.074315995694633e-08
age O 0 3.494078626431474e-08
of O 0 1.665802429329233e-08
onset O 0 0.0003405757015570998
. O 0 1.0261536544931005e-06

The O 0 1.912540710691246e-06
trinucleotide O 0 0.00028261763509362936
repeat O 0 7.971288141561672e-06
instability O 0 1.336654804617865e-06
mechanisms O 0 1.9665392869683274e-07
involved O 0 9.7158022072108e-08
in O 0 2.874425604204589e-07
DM B-Disease 1 1.0
and O 0 1.1614683899097145e-05
other O 0 1.0603222477811869e-07
human O 0 3.380134148756042e-05
genetic B-Disease 1 0.9999973773956299
diseases I-Disease 1 0.9999977350234985
are O 0 1.491098942096869e-06
unknown O 0 5.6465278248651884e-06
. O 0 6.241986056920723e-07

We O 0 5.576044372901379e-07
studied O 0 6.335882574148854e-08
somatic O 0 7.156963306442776e-07
instability O 0 1.954829940586933e-06
by O 0 2.3726006048718773e-08
measuring O 0 0.009691309183835983
the O 0 3.957897831696755e-08
CTG O 0 0.0001604900899110362
repeat O 0 1.9309741219331045e-06
length O 0 1.2885733440270997e-06
at O 0 6.935297847121547e-07
several O 0 2.99716518270543e-09
ages O 0 1.7685763964436774e-08
in O 0 7.680902025519742e-10
various O 0 2.0054962135418464e-09
tissues O 0 1.2109283886729827e-07
of O 0 1.6929059265535784e-09
transgenic O 0 1.4553716937371064e-05
mice O 0 7.339368949033087e-06
carrying O 0 4.936344453199126e-07
a O 0 1.0343227074827155e-07
( O 0 1.7161388754516338e-08
CTG O 0 1.4513218047795817e-05
) O 0 6.786848860684813e-09
55expansion O 0 4.811562575923745e-06
surrounded O 0 3.4079748729709536e-06
by O 0 5.903122435313435e-09
45 O 0 1.182276854194697e-08
kb O 0 1.6655569652357372e-06
of O 0 3.3824245626590255e-09
the O 0 1.9786497773566225e-08
human O 0 1.3401302567217499e-05
DM B-Disease 1 1.0
region O 0 1.7300533727393486e-05
, O 0 3.411893434446256e-09
using O 0 5.04518382626884e-09
small O 0 1.144126855479044e-07
- O 0 3.8046568079153076e-05
pool O 0 6.671546998404665e-06
PCR O 0 1.9231347323511727e-05
. O 0 2.354779837787646e-07

These O 0 5.561265083997569e-07
mice O 0 8.019875167519785e-06
have O 0 2.055250369892292e-08
been O 0 2.3314102648441803e-08
shown O 0 1.5189945301585794e-08
to O 0 6.146886999403023e-09
reproduce O 0 9.204192679135303e-07
the O 0 2.9676761048591516e-09
intergenerational O 0 9.123049494519364e-06
and O 0 3.52735156639028e-08
somatic O 0 1.9473094425848103e-07
instability O 0 1.9271607243354083e-07
of O 0 1.2590474218754366e-09
the O 0 8.925961303418717e-09
55 O 0 1.1499442109652591e-07
CTG O 0 1.8121245375368744e-05
repeat O 0 2.341107432357603e-07
suggesting O 0 1.563372222790349e-07
that O 0 2.345154515026593e-09
surrounding O 0 3.049560959311748e-08
sequences O 0 4.2383639708987175e-08
and O 0 1.9547325535995697e-08
the O 0 9.828559077718069e-10
chromatin O 0 1.916921661404558e-07
environment O 0 4.5744548060611123e-07
are O 0 3.610006960030887e-09
involved O 0 2.1731921151513234e-08
in O 0 1.6456041862511483e-08
instability O 0 2.675332325452473e-06
mechanisms O 0 2.6154777970077703e-06
. O 0 4.1692101149237715e-07

As O 0 3.1434916536454693e-07
observed O 0 2.4447453483844583e-07
in O 0 8.433857501266573e-10
some O 0 1.8797960410488201e-10
of O 0 2.551930611272013e-10
the O 0 3.199411624521531e-09
tissues O 0 6.68869517994608e-07
of O 0 4.3311186459504825e-07
DM B-Disease 1 1.0
patients O 0 0.00034404671168886125
, O 0 5.166564065461898e-08
there O 0 1.536551792469254e-07
is O 0 6.593077728211938e-08
a O 0 6.448904343869799e-08
tendency O 0 5.095479878036713e-07
for O 0 5.156008064943762e-09
repeat O 0 1.1185246648892644e-06
length O 0 3.679213477880694e-06
and O 0 4.10549567675389e-08
somatic O 0 1.453907003678978e-07
mosaicism O 0 4.344664830568945e-06
to O 0 1.4076888099623375e-08
increase O 0 5.8729597185447346e-08
with O 0 2.5336682085708162e-08
the O 0 7.264607582158078e-09
age O 0 2.6864480417998493e-08
of O 0 6.433443777709158e-10
the O 0 2.69204942782153e-08
mouse O 0 3.704985647345893e-05
. O 0 4.903701551484119e-07

Furthermore O 0 6.270210178627167e-06
, O 0 3.82886007344041e-08
we O 0 5.899531529962587e-09
observed O 0 1.6284685599998738e-08
no O 0 1.904718160972152e-09
correlation O 0 2.0479172135878798e-08
between O 0 3.1297593405810176e-09
the O 0 1.947036754046394e-09
somatic O 0 9.477112143940758e-07
mutation O 0 8.173055334737e-07
rate O 0 1.2921080269734375e-05
and O 0 5.47536956219119e-07
tissue O 0 0.0006347037269733846
proliferation O 0 0.0003710545424837619
capacity O 0 1.0862183899007505e-06
. O 0 2.87302242441001e-07

The O 0 6.542506270079684e-08
somatic O 0 1.792298576219764e-06
mutation O 0 1.521503349977138e-06
rates O 0 3.177900453010807e-06
in O 0 7.706586480082933e-09
different O 0 2.5591948560332867e-09
tissues O 0 2.928380524735985e-07
were O 0 1.9616317104009795e-07
also O 0 1.0863116628456737e-08
not O 0 1.3963203926437018e-09
correlated O 0 2.3262977322247025e-08
to O 0 1.3028524925573493e-09
the O 0 1.656872194999437e-09
relative O 0 1.2626718444153084e-06
inter O 0 3.1958199997461634e-06
- O 0 0.0001334594562649727
tissue O 0 1.0571791790425777e-05
difference O 0 3.3886383477010895e-08
in O 0 8.855987609912574e-10
transcriptional O 0 7.356386788615055e-08
levels O 0 7.590233330745377e-09
of O 0 2.618793792930063e-10
the O 0 4.110414231206505e-09
three O 0 2.918981722999092e-09
genes O 0 5.570955696754254e-09
( O 0 5.434775962598337e-10
DMAHP O 0 6.524289801745908e-06
, O 0 8.889720959359693e-09
DMPK O 0 1.4522383025905583e-05
and O 0 5.129604474518601e-08
59 O 0 6.45904805196551e-08
) O 0 9.946387047321537e-10
surrounding O 0 4.7547981552042984e-08
the O 0 7.017931125119503e-09
repeat O 0 1.4443561440202757e-06
. O 0 2.7379396527749122e-08
. O 0 1.5483179538477998e-07

A O 0 6.716719326504972e-06
novel O 0 2.06277695724566e-06
missense O 0 0.00016252922068815678
mutation O 0 7.66255379858194e-06
in O 0 5.297142138260824e-07
patients O 0 3.8084888842604414e-07
from O 0 6.306726696436726e-09
a O 0 7.134229349503585e-07
retinoblastoma B-Disease 0 0.00634795892983675
pedigree O 0 0.00042212041444145143
showing O 0 3.689197910716757e-05
only O 0 1.5142394715894625e-07
mild O 0 3.4194581530755386e-05
expression O 0 5.385077272990202e-08
of O 0 3.1482596529741613e-09
the O 0 2.4301263579218357e-07
tumor B-Disease 0 0.0026845643296837807
phenotype O 0 2.2865819119033404e-05
. O 0 8.734873517823871e-07

We O 0 1.100444592339045e-06
have O 0 1.490182732766243e-08
used O 0 1.3550269351014776e-08
single O 0 2.2739657268289193e-08
strand O 0 1.6747343352108146e-06
conformation O 0 5.239913889454328e-07
polymorphism O 0 3.06640316694029e-07
analysis O 0 1.589899056853028e-08
to O 0 1.5073021719658186e-09
study O 0 5.329853891566927e-09
the O 0 6.242305339299037e-09
27 O 0 4.3512304870318985e-08
exons O 0 1.4943667636657665e-08
of O 0 1.3052751102193838e-09
the O 0 1.7293645626637044e-08
RB1 O 0 2.4934606699389406e-05
gene O 0 4.62467504291908e-08
in O 0 2.1774686498332585e-09
individuals O 0 2.4114799046515145e-09
from O 0 3.013375549087982e-09
a O 0 6.50435197258048e-07
family O 0 1.9226468793931417e-05
showing O 0 0.00015238266496453434
mild O 0 0.0009809695184230804
expression O 0 1.9918769567084382e-07
of O 0 5.149197512821502e-09
the O 0 9.645012255532492e-08
retinoblastoma B-Disease 0 0.002010749652981758
phenotype O 0 0.00010096901678480208
. O 0 1.7340601061732741e-06

In O 0 3.253003342251759e-07
this O 0 1.8177695793042403e-08
family O 0 3.147619338506047e-07
affected O 0 7.835478754714131e-08
individuals O 0 6.131816387977551e-09
developed O 0 1.2401405911077745e-06
unilateral B-Disease 1 0.9048888087272644
tumors I-Disease 1 1.0
and O 0 1.0508415471122134e-05
, O 0 9.476645601580458e-08
as O 0 1.2882738431585494e-08
a O 0 1.7974487676042372e-08
result O 0 3.5981282398012127e-09
of O 0 4.838697220677091e-10
linkage O 0 3.3046130738512147e-06
analysis O 0 1.4358860767060833e-07
, O 0 2.9321578054464226e-08
unaffected O 0 2.3866402898420347e-06
mutation O 0 8.549719865413863e-08
carriers O 0 5.1679435841833765e-08
were O 0 2.667434557679371e-07
also O 0 9.801235023587651e-08
identified O 0 2.0154219271262264e-07
within O 0 4.542278997377025e-09
the O 0 2.018244948942538e-08
pedigree O 0 9.465828770771623e-05
. O 0 6.859508516754431e-07

A O 0 2.1249707060633227e-06
single O 0 1.3532051923448307e-07
band O 0 2.6753724569061887e-08
shift O 0 3.119509983662283e-08
using O 0 1.2680422933897262e-08
SSCP O 0 2.4271152142318897e-05
was O 0 7.287904963959591e-07
identified O 0 1.0786377657723278e-07
in O 0 1.1767508079074673e-09
exon O 0 1.1851344083879667e-07
21 O 0 8.695645448142386e-08
which O 0 1.2716995456685254e-08
resulted O 0 6.714169842325646e-08
in O 0 8.944794238630038e-09
a O 0 5.865548757810757e-08
missense O 0 3.7846464238100452e-06
mutation O 0 3.262509551404946e-08
converting O 0 1.533049953650334e-08
a O 0 1.5662151042761252e-07
cys O 0 0.00020106090232729912
- O 0 9.31221220525913e-05
- O 0 2.1466023099492304e-05
> O 0 1.249090928467922e-07
arg O 0 1.173604857740429e-07
at O 0 9.524317334808075e-09
nucleotide O 0 2.7314666084521377e-08
position O 0 2.438576274244042e-08
28 O 0 4.617920712490786e-09
in O 0 9.329306216443456e-10
the O 0 9.655647836837034e-09
exon O 0 6.964275598875247e-06
. O 0 1.4693810044263955e-06

The O 0 4.3763003532149014e-07
mutation O 0 3.741902901310823e-06
destroyed O 0 6.992765520408284e-06
an O 0 3.4045882557620644e-08
NdeI O 0 1.0960375220747665e-05
restriction O 0 1.2543879392978852e-06
enzyme O 0 1.0285245934937848e-06
site O 0 7.298864147742279e-06
. O 0 3.0185864829945785e-07

Analysis O 0 7.971128184180998e-07
of O 0 1.4717489449367349e-08
all O 0 2.0810601242260418e-08
family O 0 2.9402932000266446e-07
members O 0 3.2657019310988744e-09
demonstrated O 0 3.975382512066972e-08
that O 0 2.951801914008456e-09
the O 0 7.288979642083859e-09
missense O 0 2.208999649155885e-05
mutation O 0 1.1583395007619401e-06
co O 0 4.0545055526308715e-05
- O 0 9.149347170023248e-05
segregated O 0 3.5325720091350377e-05
with O 0 3.285958882770501e-06
patients O 0 1.2746867469104473e-05
with O 0 3.942485818697605e-06
tumors B-Disease 1 0.9999998807907104
or O 0 0.0003564008802641183
who O 0 7.002769507380435e-06
, O 0 1.489055421188823e-07
as O 0 2.9674399826262743e-08
a O 0 3.9754660008384235e-08
result O 0 7.85699683092389e-09
of O 0 5.20296028483358e-10
linkage O 0 1.4611199503633543e-06
analysis O 0 1.2432272455953353e-07
had O 0 3.22430395272022e-07
been O 0 2.0869229899744823e-08
predicted O 0 3.1985564419301227e-07
to O 0 1.8742476459721047e-09
carry O 0 6.438605026914956e-08
the O 0 2.5374500722818993e-08
predisposing O 0 6.27872723271139e-05
mutation O 0 3.624564214987913e-06
. O 0 8.565075972910563e-07

These O 0 1.2659403125780955e-07
observations O 0 2.6867974156630225e-07
point O 0 2.3624883738193603e-07
to O 0 6.42074704515494e-09
another O 0 2.3406602878139893e-08
region O 0 3.042356766513876e-08
of O 0 6.736175506283359e-10
the O 0 1.7295954890528265e-08
RB1 O 0 4.4118540245108306e-05
gene O 0 7.286855918664514e-08
where O 0 1.676742655831731e-08
mutations O 0 6.591417900381202e-08
only O 0 2.9534350520776798e-09
modify O 0 1.577689516807368e-07
the O 0 4.388668983779098e-09
function O 0 2.4043991686539812e-08
of O 0 4.863281444222878e-10
the O 0 2.45390685549296e-09
gene O 0 7.101890986405124e-08
and O 0 8.496544268155048e-08
raise O 0 1.3802883813696099e-07
important O 0 2.9360137432377087e-08
questions O 0 7.438996973974099e-09
for O 0 2.582417168994766e-09
genetic O 0 4.6318874069584126e-07
counseling O 0 1.270695122457255e-07
in O 0 1.560298912295366e-08
families O 0 2.8181242228697556e-08
with O 0 5.2314628185001766e-09
these O 0 1.785060277370576e-08
distinctive O 0 3.7891747979301726e-06
phenotypes O 0 2.420735881969449e-06
. O 0 5.577273753942791e-08
. O 0 4.2064638705596735e-07

Maternal B-Disease 0 0.006877807434648275
disomy I-Disease 0 0.1850070208311081
and O 0 0.023054489865899086
Prader B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.999998927116394
consistent O 0 0.00012773298658430576
with O 0 1.5558062216314283e-07
gamete O 0 1.4247068065742496e-05
complementation O 0 0.005672260653227568
in O 0 7.256758749463188e-08
a O 0 2.2676425714962534e-07
case O 0 1.3913250995756243e-07
of O 0 3.3942386679086667e-09
familial O 0 0.0001641895214561373
translocation O 0 0.0005591873778030276
( O 0 1.0405756967202251e-07
3 O 0 8.828691022699786e-08
; O 0 1.082276757102818e-08
15 O 0 2.0677855872008877e-08
) O 0 3.3742413307891184e-09
( O 0 7.348288089126243e-10
p25 O 0 5.3972517122247154e-08
; O 0 1.1576897218645854e-09
q11 O 0 8.701668008370689e-08
. O 0 7.595283291195187e-10
2 O 0 1.4905038980828067e-08
) O 0 1.3880496751994542e-08
. O 0 1.23366405091474e-07

Maternal B-Disease 1 0.5758576393127441
uniparental I-Disease 1 0.9855417609214783
disomy I-Disease 1 0.9207475781440735
( I-Disease 0 2.1720295990235172e-05
UPD I-Disease 1 0.999988317489624
) I-Disease 0 4.795382224642708e-08
for I-Disease 0 4.237141304486158e-09
chromosome I-Disease 0 9.194611266138963e-06
15 I-Disease 0 6.056359325157246e-08
is O 0 3.149780880562503e-08
responsible O 0 4.1822556084980533e-08
for O 0 9.836885750402757e-10
an O 0 4.349369309153417e-09
estimated O 0 9.246389964800983e-08
30 O 0 2.867561965658183e-09
% O 0 2.946894950284218e-10
of O 0 3.7564756860675175e-10
cases O 0 1.8338711527121632e-07
of O 0 2.6494990379433148e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.00022533272567670792
PWS B-Disease 1 0.9999978542327881
) O 0 1.7714647810862516e-06
. O 0 7.175565883699164e-07

We O 0 1.7909453617903637e-06
report O 0 5.359725818721017e-08
on O 0 2.244602725909317e-08
an O 0 1.1666293486811696e-09
unusual O 0 5.111945711178123e-08
case O 0 6.996749135623759e-08
of O 0 2.8995217338234625e-09
maternal B-Disease 0 1.5357885786215775e-05
disomy I-Disease 0 0.0002658561570569873
15 I-Disease 0 2.1161683605441794e-07
in O 0 1.527973978454611e-07
PWS B-Disease 1 0.9999992847442627
that O 0 2.8375882266118424e-07
is O 0 9.408853429704322e-08
most O 0 5.9461084944700815e-09
consistent O 0 1.8670668566755921e-07
with O 0 4.921473895080908e-09
adjacent O 0 8.841530870995484e-06
- O 0 3.6702349461847916e-05
1 O 0 2.3778923718964506e-08
segregation O 0 6.97660027526581e-08
of O 0 1.5446104395522298e-09
a O 0 1.459195345887565e-06
paternal O 0 0.0008244911441579461
t O 0 0.003748879302293062
( O 0 3.0262314876239316e-09
3 O 0 2.000912324717774e-08
; O 0 2.7499127419616798e-09
15 O 0 5.6837374806661956e-09
) O 0 1.243000813389017e-09
( O 0 5.591967999762915e-10
p25 O 0 3.416662508470836e-08
; O 0 7.13376135941246e-10
q11 O 0 8.026251663295625e-08
. O 0 1.4188639152479254e-09
2 O 0 6.57233334422358e-09
) O 0 3.7738118185970393e-10
with O 0 1.9193238109949107e-09
simultaneous O 0 9.696333336250973e-07
maternal O 0 3.0474549930659123e-05
meiotic O 0 0.00010448218381498009
nondisjunction O 0 9.709697042126209e-05
for O 0 1.1618627127063519e-07
chromosome O 0 6.048603609087877e-05
15 O 0 9.095450650420389e-07
. O 0 8.115680429909844e-07

The O 0 8.316612820635783e-07
patient O 0 3.03709148283815e-05
( O 0 2.9947553770171e-08
J O 0 0.00915099959820509
. O 0 2.5066828612807512e-08
B O 0 1.4919546629243996e-05
. O 0 8.242416194015334e-10
) O 0 6.265144514294718e-10
, O 0 1.7305218369401132e-09
a O 0 1.6816045445011696e-08
17 O 0 1.8484882957636728e-08
- O 0 2.8177669264550786e-06
year O 0 3.8091863530098635e-07
- O 0 0.0048766182735562325
old O 0 0.014068394899368286
white O 0 6.593962461920455e-05
male O 0 9.480040716880467e-07
with O 0 1.8315186878226086e-07
PWS B-Disease 1 0.9999994039535522
, O 0 1.398571356503453e-07
was O 0 3.499175591059611e-06
found O 0 6.462030199827495e-08
to O 0 1.5655155394256326e-08
have O 0 2.731232129349337e-08
47 O 0 5.0659764383453876e-08
chromosomes O 0 1.5596270941387047e-07
with O 0 4.3369130509063325e-08
a O 0 2.3128429802454775e-06
supernumerary O 0 0.0005641768802888691
, O 0 2.3262791728484444e-06
paternal O 0 0.006336290389299393
der O 1 0.8732700943946838
( O 0 2.971625612246953e-08
15 O 0 7.599388673895646e-09
) O 0 5.881439779642506e-10
consisting O 0 3.2288745011044284e-09
of O 0 1.4133700876328703e-09
the O 0 3.129354908537607e-08
short O 0 2.4353830667678267e-05
arm O 0 0.0055139679461717606
and O 0 5.630309729554028e-08
the O 0 5.503668631945402e-09
proximal O 0 0.0020121396519243717
long O 0 0.00010427873348817229
arm O 0 0.00035484693944454193
of O 0 3.70978270325395e-09
chromosome O 0 1.4689266208733898e-05
15 O 0 2.175556801375933e-07
, O 0 1.90830817814458e-08
and O 0 1.1216722128892798e-07
distal O 0 0.024048717692494392
chromosome O 0 0.1827821582555771
arm O 1 0.7507977485656738
3p O 0 0.012062447145581245
. O 0 2.200539483965258e-06

The O 0 8.359393177670427e-07
t O 0 0.00027646610396914184
( O 0 2.9208195861940567e-09
3 O 0 2.662944087461483e-09
; O 0 2.783696051444906e-10
15 O 0 7.979230054466768e-10
) O 0 3.4502142809422764e-10
was O 0 1.4500989209409454e-07
present O 0 9.3274596935089e-09
in O 0 4.117727492314316e-09
the O 0 1.0194463051504954e-09
balanced O 0 3.651984741281922e-07
state O 0 2.3043531527378036e-09
in O 0 1.967254137369423e-09
the O 0 1.3357555950221922e-08
patients O 0 1.4444923124301567e-07
father O 0 4.0945013779492e-07
and O 0 3.875856080526319e-08
a O 0 2.142571418062289e-07
sister O 0 5.2619801863329485e-05
. O 0 3.037874876099522e-07

Fluorescent O 0 2.148949533875566e-05
in O 0 4.73203485285012e-08
situ O 0 5.119088086757984e-07
hybridization O 0 1.2407303984218743e-07
analysis O 0 7.146760339082903e-08
demonstrated O 0 1.5462713065517164e-07
that O 0 1.0103256009585948e-08
the O 0 2.822847555705721e-08
PWS B-Disease 1 0.9999973773956299
critical O 0 8.254159524767601e-07
region O 0 3.0048889243516896e-07
resided O 0 4.1628018720984983e-07
on O 0 1.5151755405895528e-07
the O 0 5.089488830378741e-09
derivative O 0 5.325240181264235e-06
chromosome O 0 1.8033142623608e-06
3 O 0 2.664383202954923e-08
and O 0 2.1572223118937472e-08
that O 0 2.1023925711460834e-08
there O 0 1.0566337493855826e-07
was O 0 3.952379302063491e-06
no O 0 1.4744687248935406e-08
deletion O 0 6.822554077245968e-09
of O 0 5.376473932727777e-09
the O 0 6.04672777626547e-07
PWS B-Disease 1 0.9999996423721313
region O 0 6.360878160194261e-06
on O 0 3.7166904576224624e-07
the O 0 5.03997110712362e-09
normal O 0 1.6751532427861093e-07
pair O 0 6.547237063614375e-08
of O 0 1.0117560123035219e-09
15s O 0 1.0673286965356965e-07
present O 0 3.4352989786157195e-08
in O 0 9.215191454359228e-08
J O 0 0.036213379353284836
. O 0 1.092978891392704e-06

B O 0 0.0036370425950735807
. O 0 7.750791155558545e-06

Methylation O 0 5.098205292597413e-06
analysis O 0 3.8282729519778513e-07
at O 0 8.368121484636504e-08
exon O 0 8.65672333816292e-08
alpha O 0 1.444893982238682e-08
of O 0 5.114846879372692e-10
the O 0 1.2415412031785422e-09
small O 0 3.169650995005213e-07
nuclear O 0 0.00016361127200070769
ribonucleoprotein O 0 6.215401663212106e-05
- O 0 1.188370879390277e-05
associated O 0 4.967432687408291e-07
polypeptide O 0 9.12403265829198e-06
N O 0 6.925088382558897e-05
( O 0 4.1184189392140524e-09
SNRPN O 0 2.004068846872542e-06
) O 0 6.782303052510485e-10
gene O 0 8.62224691644542e-09
showed O 0 1.656771075886354e-07
a O 0 2.6309121992085238e-08
pattern O 0 2.431382381473668e-05
characteristic O 0 2.0073819086974254e-06
of O 0 9.696434766226503e-09
only O 0 2.0979141979182714e-08
the O 0 1.476064159788848e-08
maternal O 0 1.0113184544024989e-05
chromosome O 0 5.985772077110596e-06
15 O 0 9.638061015948551e-08
in O 0 1.611191038364268e-07
J O 0 0.17094312608242035
. O 0 2.3174620764621068e-06

B O 0 0.00990423932671547
. O 0 2.013785342569463e-05

Maternal B-Disease 0 0.008499279618263245
disomy I-Disease 0 0.0034438527654856443
was O 0 1.5746240023872815e-05
confirmed O 0 3.8206900399018195e-07
by O 0 4.3375645297771825e-09
polymerase O 0 8.320695997099392e-06
chain O 0 1.5715546396677382e-05
reaction O 0 1.5450353885171353e-08
analysis O 0 4.930399644109684e-09
of O 0 1.5555732257865884e-09
microsatellite O 0 5.338761638995493e-06
repeats O 0 2.7833490889861423e-07
at O 0 4.6114362106663975e-08
the O 0 1.4547903992578881e-09
gamma O 0 4.866199176944974e-08
- O 0 2.3868633434176445e-06
aminobutyric O 0 3.2059058412414743e-06
acid O 0 9.030113545804852e-08
receptor O 0 6.902662619268085e-08
beta3 O 0 5.986326527818164e-07
subunit O 0 1.4417837235214392e-07
( O 0 1.5107625372934308e-08
GABRB3 O 0 7.490828011214035e-06
) O 0 1.761190837612503e-08
locus O 0 2.31285184781882e-06
. O 0 6.116902682151704e-07

A O 0 8.693660493008792e-05
niece O 0 0.0018418289255350828
( O 0 1.6987102924304054e-07
B O 0 3.236428528907709e-05
. O 0 7.181547800882981e-09
B O 0 4.850196546613006e-06
. O 0 6.094769133824229e-10
) O 0 1.7354857828610903e-10
with O 0 7.673111590555948e-10
45 O 0 5.735137698081871e-09
chromosomes O 0 4.729445279849642e-08
and O 0 4.654929774972061e-09
the O 0 7.59102558589575e-10
derivative O 0 1.7758627564035123e-06
3 O 0 1.5512837236997257e-08
but O 0 2.0009963463962777e-08
without O 0 5.430726979227529e-09
the O 0 7.012538105755084e-09
der O 0 0.018103307113051414
( O 0 9.09368047530279e-09
15 O 0 8.598318501640279e-09
) O 0 1.3989729374941362e-09
demonstrated O 0 3.664173320316877e-08
a O 0 2.7802656177300378e-08
phenotype O 0 4.3910955582759925e-07
consistent O 0 7.748595294287952e-07
with O 0 5.6879891907613e-09
that O 0 8.354768432639048e-09
reported O 0 4.5577462515211664e-07
for O 0 2.3464790110949707e-09
haploinsufficiency O 0 1.5201342193904566e-06
of O 0 9.005444390197681e-09
distal O 0 0.00015073746908456087
3 O 0 4.742304099636385e-06
p O 0 0.0018447933252900839
. O 0 4.7661799840170715e-07

Uniparental B-Disease 1 0.9999090433120728
disomy I-Disease 1 0.9999299049377441
associated O 0 6.01692809141241e-05
with O 0 9.910869636087227e-08
unbalanced O 0 5.7151013606926426e-05
segregation O 0 3.418929054532782e-06
of O 0 5.092537946893572e-09
non O 0 2.2527276541950414e-06
- O 0 6.175546150188893e-05
Robertsonian O 0 3.034179098904133e-05
translocations O 0 6.301557004917413e-05
has O 0 1.5648729458916932e-06
been O 0 3.681062992200168e-07
reported O 0 5.548069452743221e-07
previously O 0 3.9607681401321315e-07
but O 0 6.322808587810869e-08
has O 0 1.1400859278865028e-07
not O 0 1.5886895354810804e-08
, O 0 3.1863303107115826e-09
to O 0 1.461114007561548e-09
our O 0 1.7813590602600016e-09
knowledge O 0 4.81054751588772e-10
, O 0 1.0705756281481627e-09
been O 0 3.0597202549387248e-09
observed O 0 9.152426372338596e-09
in O 0 1.4363559230901046e-09
a O 0 5.053642837538064e-08
case O 0 7.357803042395972e-07
of O 0 1.0534939747230965e-06
PWS B-Disease 1 0.9999868869781494
. O 0 5.445927854452748e-06

Furthermore O 0 1.695685750746634e-05
, O 0 8.49471391006773e-08
our O 0 9.750719343060155e-09
findings O 0 6.455941559124767e-09
are O 0 1.8961419101515276e-09
best O 0 7.6771851098556e-09
interpreted O 0 4.92876601754233e-08
as O 0 7.821350678227645e-09
true O 0 7.165446191947922e-08
gamete O 0 1.3904101479056408e-06
complementation O 0 0.00017765752272680402
resulting O 0 3.044481786673714e-07
in O 0 6.055146855032945e-07
maternal B-Disease 0 0.07265819609165192
UPD I-Disease 1 0.9999922513961792
15 I-Disease 0 2.691934787435457e-05
and O 0 9.409581252839416e-05
PWS B-Disease 1 0.9999479055404663

Schwartz B-Disease 0 0.1601860672235489
- I-Disease 1 0.9655593633651733
Jampel I-Disease 1 0.996151864528656
syndrome I-Disease 1 0.9997391104698181
type I-Disease 0 0.0001635774242458865
2 I-Disease 0 4.2083979678864125e-07
and O 0 7.56756890041288e-07
Stuve B-Disease 1 0.9631173610687256
- I-Disease 1 0.9999947547912598
Wiedemann I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.999991774559021
: O 0 1.6204809938358267e-08
a O 0 1.0027523700273377e-07
case O 0 9.768685771405217e-08
for O 0 7.596402618048614e-09
" O 0 3.3069605365199095e-07
lumping O 0 3.5525742987374542e-06
" O 0 8.011366503524187e-07
. O 0 2.3373284818717366e-07

Recent O 0 1.947628561538295e-06
studies O 0 1.361776753583399e-07
demonstrated O 0 1.7072854063826526e-07
the O 0 1.7197063773011223e-09
existence O 0 2.253757713788218e-08
of O 0 1.9001786810690646e-09
a O 0 1.4861215902328695e-07
genetically O 0 1.9944213818234857e-06
distinct O 0 1.1871219385284348e-07
, O 0 3.4896697087560824e-08
usually O 0 3.640335322074861e-08
lethal O 0 5.412723158570998e-09
form O 0 1.134328186935818e-09
of O 0 1.0425136309777372e-09
the O 0 4.320911273225647e-08
Schwartz B-Disease 0 0.0009254334145225585
- I-Disease 1 0.9986159801483154
Jampel I-Disease 1 0.9999841451644897
syndrome I-Disease 1 0.9999666213989258
( O 0 1.0459183386046789e-07
SJS B-Disease 0 0.20952561497688293
) O 0 5.0394710626733286e-09
of O 0 1.281060235669429e-08
myotonia B-Disease 1 0.9883506298065186
and O 0 0.00018481750157661736
skeletal B-Disease 1 0.9959772229194641
dysplasia I-Disease 1 0.9999945163726807
, O 0 7.010842182353372e-07
which O 0 1.1401391475374112e-07
we O 0 9.895644836888096e-08
called O 0 1.1731007134585525e-06
SJS B-Disease 0 0.021230969578027725
type I-Disease 0 2.9362961868173443e-05
2 I-Disease 0 5.906695150770247e-07
. O 0 5.058045076111739e-07

This O 0 1.2267249985598028e-05
disorder O 0 0.2726365029811859
is O 0 1.395435162976355e-07
reminiscent O 0 1.4410650237550726e-06
of O 0 4.799652675302468e-09
another O 0 3.4970730666827876e-07
rare O 0 5.191949639993254e-06
condition O 0 8.846685523167253e-05
, O 0 1.2362582069158634e-08
the O 0 2.656578601545334e-08
Stuve B-Disease 1 0.9412806034088135
- I-Disease 1 0.9999948740005493
Wiedemann I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.999996542930603
( O 0 8.472658663549737e-08
SWS B-Disease 0 0.008575732819736004
) O 0 2.7246761291621624e-08
, O 0 1.0487025470240496e-08
which O 0 8.936284601190891e-09
comprises O 0 7.03617502040288e-08
campomelia B-Disease 0 8.668808004586026e-05
at O 0 6.3280485846917145e-06
birth O 0 1.0460262274136767e-05
with O 0 7.412803029183124e-07
skeletal B-Disease 1 0.9881690740585327
dysplasia I-Disease 1 0.9999903440475464
, O 0 1.578139290359104e-06
contractures B-Disease 0 0.010626119561493397
, O 0 2.1949064432646992e-07
and O 0 7.42182280077941e-08
early B-Disease 0 9.006184882309753e-07
death I-Disease 0 1.4443671716435347e-06
. O 0 4.363148491393076e-07

To O 0 8.544883485228638e-07
test O 0 3.033023290299752e-07
for O 0 2.9350604169309236e-09
possible O 0 9.623512653433863e-08
nosologic O 0 4.4810665713157505e-05
identity O 0 5.36330560407805e-07
between O 0 4.564793414374435e-07
these O 0 5.444938437904057e-07
disorders O 0 0.017320796847343445
, O 0 2.48317508777518e-08
we O 0 2.038299662387999e-08
reviewed O 0 4.331357672526792e-08
the O 0 1.257446702318532e-09
literature O 0 4.224343097547489e-09
and O 0 3.3794262943587228e-09
obtained O 0 4.805469355773084e-09
a O 0 1.2283233097321045e-08
follow O 0 3.985715579801763e-08
- O 0 6.452992693084525e-06
up O 0 1.0628816937696683e-07
of O 0 6.975156563449048e-10
the O 0 1.7616030856260068e-09
only O 0 9.00225050060044e-09
two O 0 2.9756113129053574e-09
surviving O 0 1.7317529454885516e-06
patients O 0 8.629571368601319e-08
, O 0 2.268960574980383e-09
one O 0 3.340589804778915e-09
with O 0 1.397368265543264e-08
SJS B-Disease 0 0.007942911237478256
type I-Disease 0 6.658561233052751e-06
2 I-Disease 0 3.052074504239499e-08
at O 0 1.39189964443176e-07
age O 0 1.0759539037508148e-08
10 O 0 1.3878107552045549e-09
years O 0 4.376748741208303e-09
and O 0 1.4419207161608938e-08
another O 0 1.4953762672575976e-08
with O 0 7.8666229086366e-09
SWS B-Disease 0 0.0007012044661678374
at O 0 1.0347050647396827e-06
age O 0 4.755460025762659e-08
7 O 0 3.344301902075131e-08
years O 0 4.778946660621841e-08
. O 0 1.5510387640915724e-07

Patients O 0 0.00021821750851813704
reported O 0 1.2042667549394537e-05
as O 0 2.755894890071886e-08
having O 0 1.6117759571443457e-08
either O 0 2.7186655415789573e-07
neonatal O 1 0.9996912479400635
SJS B-Disease 1 0.9999420642852783
or O 0 1.4530362932418939e-05
SWS B-Disease 0 0.04380885884165764
presented O 0 2.8279598041081044e-07
a O 0 5.054992158193272e-08
combination O 0 2.722084957440529e-07
of O 0 2.8573634569539763e-09
a O 0 1.907225737340923e-06
severe O 0 2.5426752472412772e-05
, O 0 8.886537727903487e-08
prenatal O 0 0.039041925221681595
- O 1 0.9991880059242249
onset O 1 0.9999654293060303
neuromuscular B-Disease 1 0.9999980926513672
disorder I-Disease 1 0.9999487400054932
( O 0 2.8590056899702176e-06
with O 0 0.00018933140381705016
congenital B-Disease 1 0.9999996423721313
joint I-Disease 1 0.9813787937164307
contractures I-Disease 1 0.9999915361404419
, O 0 0.026174316182732582
respiratory O 1 0.9950118064880371
and O 0 4.318606443121098e-06
feeding O 0 0.0006856069667264819
difficulties O 0 6.907640909048496e-06
, O 0 1.2819450390111342e-08
tendency O 0 2.3793128889337822e-07
to O 0 3.585264707339775e-08
hyperthermia B-Disease 0 0.04248105362057686
, O 0 1.6319582130108756e-07
and O 0 8.114358962529877e-08
frequent O 0 3.896803718816955e-06
death O 0 1.281223603655235e-06
in O 0 6.078000325260291e-08
infancy O 0 2.523777084206813e-06
) O 0 1.4380115986867281e-09
with O 0 1.5867110958467379e-09
a O 0 8.846102872439587e-08
distinct O 0 1.3154501630197046e-06
campomelic B-Disease 0 0.02479555271565914
- I-Disease 0 0.292361319065094
metaphyseal I-Disease 1 0.7687389850616455
skeletal I-Disease 1 0.9951674938201904
dysplasia I-Disease 1 0.9997758269309998
. O 0 6.9342936512839515e-06

The O 0 1.349054912225256e-07
similarity O 0 1.2165399709829217e-07
of O 0 3.741411624957891e-09
the O 0 7.553031089457818e-09
clinical O 0 8.009899943317578e-07
and O 0 1.8855367045489402e-07
radiographic O 0 0.0010334915714338422
findings O 0 8.466760164083098e-07
is O 0 3.129528352019406e-07
so O 0 1.0946124895383491e-08
extensive O 0 1.3553324151871493e-07
that O 0 1.156609243935236e-07
these O 0 5.841321808475186e-07
disorders O 0 0.02280195616185665
appear O 0 7.123447289814067e-07
to O 0 5.1549289281638266e-08
be O 0 1.0923312032673493e-07
a O 0 1.087956462697548e-07
single O 0 1.5368080994448974e-06
entity O 0 2.999918069690466e-05
. O 0 5.798528945888393e-07

The O 0 3.6309953088675684e-07
follow O 0 2.1528002491777443e-07
- O 0 1.6144229448400438e-05
up O 0 1.1876405636712661e-07
observation O 0 2.611704076116439e-06
of O 0 2.2539456967507476e-09
an O 0 4.372545703290598e-08
identical O 0 4.700882982433541e-06
and O 0 6.677872477212077e-08
unique O 0 3.4357313438704296e-08
pattern O 0 9.654234418121632e-06
of O 0 3.1631039121293725e-08
progressive O 0 0.042237795889377594
bone B-Disease 1 0.9997194409370422
dysplasia I-Disease 1 0.9999912977218628
in O 0 1.1453051911303191e-06
the O 0 1.7058401624581165e-07
two O 0 3.0304903475553147e-07
patients O 0 6.339956257761514e-07
( O 0 2.602418280872598e-09
one O 0 2.1855671050730052e-08
with O 0 4.976906708975548e-08
SJS B-Disease 0 0.08277299255132675
type I-Disease 0 0.0008815230103209615
2 I-Disease 0 3.815173954535567e-07
, O 0 5.322867124846198e-08
one O 0 4.254619767607437e-08
with O 0 9.348961782507104e-08
SWS B-Disease 0 0.02252054400742054
) O 0 1.6176645800669576e-08
surviving O 0 3.8330330198732554e-07
beyond O 0 3.5340124782123894e-07
infancy O 0 3.1629627983420505e-07
adds O 0 7.179605887586149e-08
to O 0 1.6143533176915525e-09
the O 0 6.033997190790785e-10
evidence O 0 1.1539732724941132e-08
in O 0 7.511793964631863e-10
favor O 0 3.747267829368184e-09
of O 0 3.1461706573310266e-09
identity O 0 9.19926094411494e-07
. O 0 4.1144645024360216e-07

The O 0 4.528147030669061e-07
hypothesis O 0 1.0598283779472695e-06
that O 0 2.64294293117473e-08
SWS B-Disease 0 0.00019161062664352357
and O 0 2.42248574977566e-07
SJS B-Disease 0 0.12550900876522064
type I-Disease 0 0.00010429901885800064
2 I-Disease 0 1.3170728152545053e-07
are O 0 8.833622722193013e-09
the O 0 4.558691646394664e-09
same O 0 2.4282969661726383e-06
disorder O 0 0.004779402632266283
should O 0 1.24551533531303e-07
be O 0 6.486230663682591e-09
testable O 0 7.811484437070249e-08
by O 0 1.1325209658963331e-09
molecular O 0 2.0579138393372887e-08
methods O 0 5.705463834715374e-08
. O 0 1.1255507637031315e-08
. O 0 9.011221635546462e-08

A O 0 7.552164788648952e-06
mouse O 0 1.5192547834885772e-05
model O 0 3.799745172727853e-06
of O 0 4.3833424001604726e-07
severe O 1 0.9994847774505615
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.25049299001693726
defects O 1 0.9999644756317139
in O 0 1.3412105545285158e-05
hemostasis O 1 0.9994869232177734
and O 0 0.0009492189274169505
thrombosis B-Disease 1 0.9321449398994446
. O 0 5.299772055877838e-06

von B-Disease 1 0.9954481720924377
Willebrand I-Disease 1 0.997294008731842
factor I-Disease 0 0.0003810019697993994
( I-Disease 0 6.208127615536796e-06
vWf I-Disease 0 0.022061100229620934
) I-Disease 0 0.0004997167852707207
deficiency I-Disease 1 0.9997976422309875
causes O 0 0.10994138568639755
severe O 1 0.9998451471328735
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.4805629689362831e-05
humans O 0 7.81307062425185e-06
. O 0 1.347778265881061e-06

We O 0 6.564160912603256e-07
generated O 0 7.76744784047878e-08
a O 0 5.533016533831869e-08
mouse O 0 1.7211845033671125e-06
model O 0 4.833937623516249e-07
for O 0 1.0990350851614039e-08
this O 0 1.082419629483411e-07
disease O 0 1.2476710935516167e-06
by O 0 7.700822202139079e-10
using O 0 1.4021526162366627e-08
gene O 0 2.0414167067883682e-07
targeting O 0 2.510875447114813e-06
. O 0 3.8195571505639236e-07

vWf B-Disease 0 0.008182166144251823
- I-Disease 1 0.6673137545585632
deficient I-Disease 0 0.04739287868142128
mice O 0 6.163791113067418e-05
appeared O 0 9.366003723698668e-07
normal O 0 3.681003306610364e-07
at O 0 3.9267794704755943e-07
birth O 0 2.3270128224339715e-07
; O 0 2.7684374792613653e-09
they O 0 7.328025297681506e-09
were O 0 8.957209018944923e-08
viable O 0 7.237584895847249e-07
and O 0 7.986927386127718e-08
fertile O 0 2.4548300643800758e-05
. O 0 4.484146245431475e-07

Neither O 0 1.3543361092160922e-05
vWf O 0 0.0003479903098195791
nor O 0 3.774078140850179e-05
vWf O 0 0.00022934637672733516
propolypeptide O 0 0.0013160231756046414
( O 0 3.58956640411634e-06
von B-Disease 1 0.987903892993927
Willebrand I-Disease 1 0.9974073767662048
antigen O 0 0.010802692733705044
II O 0 0.04125666990876198
) O 0 5.0348713642733856e-08
were O 0 1.2247456027125736e-07
detectable O 0 3.4915746027763817e-07
in O 0 5.296832972234711e-10
plasma O 0 5.632249212794704e-06
, O 0 2.0715278381544522e-08
platelets O 0 1.6783958471933147e-06
, O 0 4.306346390592353e-09
or O 0 1.765159218791723e-08
endothelial O 0 6.201099722602521e-07
cells O 0 1.0672713379733523e-08
of O 0 2.7213611364373946e-09
the O 0 2.0651290455475646e-08
homozygous O 0 3.730899379661423e-06
mutant O 0 1.2352666999504436e-05
mice O 0 4.793925108970143e-05
. O 0 1.0709825346566504e-06

The O 0 8.041480441534077e-07
mutant O 0 6.15228054812178e-05
mice O 0 0.0005559987621381879
exhibited O 0 0.016511473804712296
defects O 1 0.9994083642959595
in O 0 2.8810396202061384e-07
hemostasis O 0 0.2444041520357132
with O 0 6.669655476798653e-07
a O 0 2.7669295832311036e-06
highly O 0 2.68137373495847e-05
prolonged O 0 0.0052943662740290165
bleeding O 0 0.2228209227323532
time O 0 1.3362759432311577e-07
and O 0 3.781164537031145e-08
spontaneous O 0 2.370367383264238e-06
bleeding O 0 6.187228427734226e-05
events O 0 3.53570399624914e-08
in O 0 5.395128788165948e-09
approximately O 0 2.5337214992759982e-08
10 O 0 7.611370200777401e-09
% O 0 5.70561331514341e-09
of O 0 4.090066951789595e-08
neonates O 0 0.001038134447298944
. O 0 9.99239091470372e-07

As O 0 8.605982202425366e-07
in O 0 1.747551792163904e-08
the O 0 6.061962487535766e-09
human O 0 6.474293172686885e-07
disease O 0 1.127040377468802e-05
, O 0 3.5686977817306342e-09
the O 0 1.2345421351867003e-09
factor O 0 4.711932888312731e-08
VIII O 0 8.332129073096439e-05
level O 0 1.5981481737981085e-06
in O 0 7.3075909767794656e-09
these O 0 4.685545729188334e-09
mice O 0 1.4359479791892227e-06
was O 0 1.700351958788815e-06
reduced O 0 1.098274822197709e-07
strongly O 0 1.0080411527724209e-07
as O 0 5.204997766128372e-09
a O 0 1.2882567013150492e-08
result O 0 4.956999699601283e-09
of O 0 1.8264569856540902e-09
the O 0 8.245880422919072e-09
lack O 0 1.651446268624568e-08
of O 0 2.612628557940866e-09
protection O 0 2.572243431586685e-07
provided O 0 2.5499968359099512e-08
by O 0 3.268732129413365e-08
vWf O 0 2.6329553293180652e-05
. O 0 4.327658587044425e-07

Defective O 1 0.9910115003585815
thrombosis B-Disease 1 0.6809444427490234
in O 0 6.067818958399585e-07
mutant O 0 1.8730441297520883e-05
mice O 0 6.283440598053858e-05
was O 0 2.0207262423355132e-05
also O 0 1.1313711922866787e-07
evident O 0 2.0142766743447282e-07
in O 0 3.3443829927648494e-09
an O 0 1.9895782799039807e-09
in O 0 2.3770159174318906e-09
vivo O 0 1.1737804925360251e-05
model O 0 9.399406621923845e-07
of O 0 4.2870325955846056e-07
vascular B-Disease 1 0.9998582601547241
injury I-Disease 0 0.014647073112428188
. O 0 5.58227657165844e-06

In O 0 2.054263461559458e-07
this O 0 1.4193032527032301e-08
model O 0 3.731528863681888e-07
, O 0 1.0040094089447393e-08
the O 0 2.7594384555129636e-09
exteriorized O 0 7.793277291057166e-06
mesentery O 0 4.5543216401711106e-05
was O 0 5.7798683883447666e-06
superfused O 0 4.439764597918838e-05
with O 0 1.4417810234590434e-07
ferric O 0 0.0007255008677020669
chloride O 0 1.4660953638667706e-05
and O 0 3.224359090836515e-08
the O 0 1.8020958059139502e-09
accumulation O 0 2.516628683224553e-07
of O 0 2.9586333383235797e-09
fluorescently O 0 0.0011763876536861062
labeled O 0 0.00027227631653659046
platelets O 0 4.2808173020603135e-05
was O 0 1.0364946092522587e-06
observed O 0 2.0541574485832825e-07
by O 0 5.968481708862328e-09
intravital O 0 2.0525178570096614e-06
microscopy O 0 2.9491129680536687e-06
. O 0 5.966378466837341e-07

We O 0 6.704226507281419e-07
conclude O 0 1.874685295888412e-07
that O 0 6.6290000155788675e-09
these O 0 2.917133867796906e-09
mice O 0 1.9170717280303506e-07
very O 0 3.089064648520434e-08
closely O 0 2.5541889954183716e-06
mimic O 0 0.007186888251453638
severe O 0 0.0015822795685380697
human O 0 0.00383106735534966
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0003523176710586995
will O 0 1.8395901861367747e-05
be O 0 2.9872651907680847e-07
very O 0 3.704432316453676e-08
useful O 0 7.835745385875725e-09
for O 0 7.049480443832579e-10
investigating O 0 3.689849137344936e-08
the O 0 8.517013205810997e-10
role O 0 4.1711163412117e-09
of O 0 5.23280696551609e-10
vWf O 0 7.835372457520862e-07
in O 0 1.1579420089447012e-08
normal O 0 1.8359168052484165e-07
physiology O 0 1.4393383196420473e-07
and O 0 9.737638606566179e-08
in O 0 1.476464746019701e-07
disease O 0 2.911823912654654e-06
models O 0 1.0226561926174327e-06
. O 0 4.264482811322523e-08
. O 0 3.023014301106741e-07

Oral O 0 0.00042485486483201385
contraceptives O 0 0.06695466488599777
and O 0 5.939677976130042e-07
the O 0 2.92373627530651e-08
risk O 0 3.2373111480410444e-06
of O 0 2.7017924821848283e-06
hereditary B-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
. O 0 3.9339887734968215e-05

Hereditary B-Disease 1 0.9999892711639404
Ovarian I-Disease 1 0.9999970197677612
Cancer I-Disease 1 0.8894634246826172
Clinical O 0 9.470740224060137e-06
Study O 0 2.2885078010403959e-07
Group O 0 2.172371068809298e-06
. O 0 1.0413017434984795e-06

BACKGROUND O 0 0.00018504919717088342
Women O 0 1.0969348807066126e-07
with O 0 8.297091014242142e-09
mutations O 0 3.4408242299832636e-07
in O 0 5.635786060054215e-09
either O 0 1.9261540273873834e-07
the O 0 1.3063959158898797e-07
BRCA1 O 0 3.4332144423387945e-05
or O 0 6.917047699062095e-07
the O 0 2.3280687599935845e-08
BRCA2 O 0 1.2123281294407207e-06
gene O 0 9.428416802848005e-08
have O 0 2.8763608383997052e-08
a O 0 6.794402906962205e-08
high O 0 1.14428094093455e-05
lifetime O 0 1.6836894474181463e-06
risk O 0 1.9973349481006153e-05
of O 0 0.00011589900532271713
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999852180480957
. O 0 5.16774480274762e-06

Oral O 0 0.0007161159883253276
contraceptives O 1 0.9153448939323425
protect O 0 0.015706229954957962
against O 0 0.46043723821640015
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999945163726807
in O 0 8.517329774804239e-08
general O 0 1.5961437327405292e-07
, O 0 5.1948045864946835e-08
but O 0 9.56787005179649e-09
it O 0 8.334078316352134e-09
is O 0 3.016562644120313e-08
not O 0 4.4353734018898194e-09
known O 0 1.4140232984516388e-08
whether O 0 3.4780525126620887e-09
they O 0 1.9249817739819264e-08
also O 0 3.186910078056826e-07
protect O 0 1.4201380054146284e-06
against O 0 2.0850299620178703e-07
hereditary B-Disease 0 0.02293536439538002
forms I-Disease 0 0.00011418725625844672
of I-Disease 0 0.1162935197353363
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999905824661255
. O 0 5.093335857964121e-06

METHODS O 0 3.1927918371366104e-06
We O 0 1.3345464822123176e-07
enrolled O 0 2.3255037007174906e-08
207 O 0 4.268906366178271e-07
women O 0 3.003485176122922e-07
with O 0 4.4117066863691434e-05
hereditary B-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
and O 0 7.254548108903691e-06
161 O 0 1.7154964098153869e-06
of O 0 1.5994707780464523e-08
their O 0 7.0363761039971e-08
sisters O 0 1.653746267038514e-06
as O 0 8.904383008712102e-09
controls O 0 1.8912542145699263e-06
in O 0 8.862143019428004e-09
a O 0 2.241813774617185e-07
case O 0 9.165843266600859e-07
- O 0 6.189058331074193e-05
control O 0 2.7134226456837496e-06
study O 0 1.5414774168220902e-07
. O 0 2.467693605012755e-07

All O 0 2.162052652465718e-07
the O 0 3.6385721102760726e-08
patients O 0 8.59625686189247e-08
carried O 0 3.451975416624009e-08
a O 0 3.079804500316641e-08
pathogenic O 0 3.417353582335636e-07
mutation O 0 1.2696933993083803e-07
in O 0 1.1765449947631623e-08
either O 0 4.079588507011067e-07
BRCA1 O 0 1.692017394816503e-05
( O 0 9.618847940373598e-09
179 O 0 2.3883040967120905e-07
women O 0 6.121255324842423e-08
) O 0 1.487763245933138e-08
or O 0 9.553810969009646e-07
BRCA2 O 0 1.528894244984258e-05
( O 0 1.8093777143235457e-08
28 O 0 2.544900610246259e-07
women O 0 4.99169914291997e-08
) O 0 2.940440957388546e-08
. O 0 3.2746922329351946e-07

The O 0 6.344577627714898e-07
control O 0 6.441285677283304e-06
women O 0 4.397435660052906e-08
were O 0 1.8159536097073214e-08
enrolled O 0 2.0146593282532876e-09
regardless O 0 3.830070482990777e-09
of O 0 6.02609628863604e-10
whether O 0 1.5388621932288515e-08
or O 0 9.341956541675245e-08
not O 0 6.41142392510119e-08
they O 0 1.324587373119357e-08
had O 0 1.5485558435557323e-07
either O 0 8.61406448393609e-08
mutation O 0 4.31936229006169e-07
. O 0 1.4532761838381703e-07

Lifetime O 0 6.549881618411746e-06
histories O 0 3.7905699628026923e-06
of O 0 3.785623903240776e-08
oral O 0 2.6359964522271184e-06
- O 0 0.00023007615527603775
contraceptive O 0 9.195617167279124e-05
use O 0 7.253464673340204e-08
were O 0 2.4445837354392097e-08
obtained O 0 2.3225323886322258e-09
by O 0 5.03286257114155e-09
interview O 0 5.996467734803446e-06
or O 0 2.612625848996686e-07
by O 0 1.760948054041478e-09
written O 0 1.2647547897870481e-08
questionnaire O 0 5.272938707889807e-08
and O 0 1.6068034014438126e-08
were O 0 5.4323255227473055e-08
compared O 0 1.7351770509321796e-07
between O 0 6.999952262276565e-08
patients O 0 6.935682250741593e-08
and O 0 5.440351102947716e-08
control O 0 4.2800570554391015e-06
women O 0 1.1691537515901018e-08
, O 0 1.5731714819722242e-09
after O 0 1.800566917786739e-09
adjustment O 0 5.10488177951629e-07
for O 0 1.3332808190824608e-09
year O 0 4.2063170724304655e-09
of O 0 4.102409523198958e-09
birth O 0 2.5395790999027668e-06
and O 0 1.2280415262466704e-07
parity O 0 1.0257143003400415e-05
. O 0 2.1394311033873237e-07

RESULTS O 0 3.284598960817675e-06
The O 0 1.729321574828191e-08
adjusted O 0 2.044280518020969e-05
odds O 0 0.00012821255950257182
ratio O 0 0.000724530837032944
for O 0 0.019935518503189087
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
associated O 0 3.616617323132232e-05
with O 0 1.2043361152791476e-07
any O 0 1.0678866146918153e-07
past O 0 1.4043719431811041e-07
use O 0 1.3149237254594937e-08
of O 0 2.2286128498194557e-09
oral O 0 7.615402068950061e-07
contraceptives O 0 0.00093235750682652
was O 0 2.7130887247039936e-05
0 O 0 1.0217105455012643e-06
. O 0 2.057270762634289e-07

5 O 0 5.66369863008731e-07
( O 0 1.899501889113253e-08
95 O 0 6.541433350548687e-08
percent O 0 5.776076932306751e-07
confidence O 0 8.413605456780715e-08
interval O 0 6.902347138293408e-08
, O 0 9.223747876596633e-10
0 O 0 9.692602276345497e-10
. O 0 1.1054755721939813e-10
3 O 0 3.869861375793704e-10
to O 0 3.3521854736484613e-10
0 O 0 4.390845909085783e-09
. O 0 7.449300620798738e-10
8 O 0 1.357238410548689e-08
) O 0 5.931676927417584e-09
. O 0 5.619763143727141e-08

The O 0 4.2148323586843617e-07
risk O 0 4.04994443670148e-06
decreased O 0 3.574780976123293e-06
with O 0 4.5639638734940036e-09
increasing O 0 5.830388616345772e-09
duration O 0 4.994880242747968e-08
of O 0 3.249842894792465e-10
use O 0 2.1406673766932727e-08
( O 0 1.9680197471672045e-09
P O 0 5.57036992177018e-06
for O 0 4.318542468073616e-10
trend O 0 2.2150113920815784e-07
, O 0 1.6380875544896867e-09
< O 0 1.9415089980157063e-07
0 O 0 6.8547980625055516e-09
. O 0 4.942411480080011e-10
001 O 0 2.1789531956528663e-08
) O 0 2.1536392114107628e-10
; O 0 5.5313933988720976e-11
use O 0 1.1276108935476259e-09
for O 0 5.830719240762505e-10
six O 0 3.6611675913178487e-09
or O 0 1.7383630535050543e-08
more O 0 1.2487230138802374e-09
years O 0 1.1446918080082469e-08
was O 0 1.019913383970561e-06
associated O 0 1.9540394191608357e-08
with O 0 1.9206276569150305e-09
a O 0 7.050118711049436e-08
60 O 0 5.1655685950890984e-08
percent O 0 3.5231229844612244e-07
reduction O 0 1.5120201624085894e-07
in O 0 4.788061502836172e-08
risk O 0 2.42457599597401e-06
. O 0 1.7799172269405972e-07

Oral O 0 6.238251080503687e-05
- O 0 0.0005451872712001204
contraceptive O 0 0.000531989149749279
use O 0 2.2954047835810343e-06
protected O 0 0.16703976690769196
against O 1 0.7399744987487793
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999958276748657
both O 0 1.3400222265147477e-08
for O 0 1.1267149879756744e-08
carriers O 0 2.7549436509843872e-08
of O 0 6.754367620764867e-10
the O 0 4.8923507023346247e-08
BRCA1 O 0 4.025356247439049e-05
mutation O 0 2.3622743583473493e-07
( O 0 1.6323489226977017e-09
odds O 0 8.945733043219661e-07
ratio O 0 7.188785389189434e-07
, O 0 3.076720878070205e-09
0 O 0 2.6840192290933373e-09
. O 0 1.172117819470131e-10
5 O 0 2.9604493856361103e-10
; O 0 7.89767556907961e-11
95 O 0 6.372870675619424e-09
percent O 0 3.701769912822783e-07
confidence O 0 1.1033726821096934e-07
interval O 0 1.5901331096301874e-07
, O 0 9.739282713638886e-10
0 O 0 1.8252696021292536e-09
. O 0 7.664156809195077e-11
3 O 0 2.456640724179948e-10
to O 0 5.95602622777136e-10
0 O 0 3.9271852436684185e-09
. O 0 5.902241473343395e-10
9 O 0 7.588670136726705e-09
) O 0 2.169789625749985e-10
and O 0 6.746744829477791e-10
for O 0 3.842258733399717e-10
carriers O 0 2.0573986958538626e-09
of O 0 5.964052030016376e-10
the O 0 3.013974847476675e-08
BRCA2 O 0 1.7199821741087362e-05
mutation O 0 8.395410588946106e-08
( O 0 3.9333101220506705e-09
odds O 0 1.5958909216351458e-06
ratio O 0 8.992332141133375e-07
, O 0 1.4311465346139585e-09
0 O 0 2.1537185368458722e-09
. O 0 1.661992488077857e-10
4 O 0 5.37755839857823e-10
; O 0 1.8942863944104715e-10
95 O 0 8.34327096299603e-09
percent O 0 1.511527045749972e-07
confidence O 0 1.760216008506177e-07
interval O 0 7.527263079509794e-08
, O 0 8.016665664634104e-10
0 O 0 9.878249329631217e-10
. O 0 2.1929223714689527e-10
2 O 0 1.312735364855655e-09
to O 0 5.399862224031438e-10
1 O 0 2.273756294357554e-09
. O 0 1.0628422586478337e-09
1 O 0 5.372476241660706e-09
) O 0 7.83069520338131e-09
. O 0 3.0416835272717435e-08

CONCLUSIONS O 0 2.2931091734790243e-05
Oral O 0 7.150862984417472e-06
- O 0 5.401551607064903e-05
contraceptive O 0 5.943295036558993e-05
use O 0 1.0871951872104546e-07
may O 0 5.359848387342936e-08
reduce O 0 2.080603600518316e-08
the O 0 1.0518315995966532e-08
risk O 0 1.0108758942806162e-05
of O 0 8.972030627774075e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
in O 0 1.1686029210977722e-06
women O 0 1.2228653645252052e-07
with O 0 1.0392403382297744e-08
pathogenic O 0 3.9181048805403407e-07
mutations O 0 1.0268687589132242e-07
in O 0 7.3583064086335526e-09
the O 0 5.681876302787714e-08
BRCA1 O 0 9.442497685085982e-05
or O 0 2.731110271270154e-06
BRCA2 O 0 0.0001164342465926893
gene O 0 5.058640817878768e-05

A O 0 5.269689154374646e-06
Japanese O 0 7.6377045843401e-06
family O 0 6.900569587742211e-06
with O 0 4.438627001945861e-06
adrenoleukodystrophy B-Disease 1 0.9999994039535522
with O 0 4.1929504845938936e-07
a O 0 3.1514881015937135e-07
codon O 0 2.508795660105534e-06
291 O 0 4.303770708702359e-07
deletion O 0 1.2150898101026542e-06
: O 0 1.403910765418459e-08
a O 0 5.369180300363041e-08
clinical O 0 8.12392727311817e-07
, O 0 2.2746249328520207e-08
biochemical O 0 3.943524006899679e-06
, O 0 4.068825276704047e-08
pathological O 0 3.102477785432711e-05
, O 0 9.477061269080878e-08
and O 0 1.9277104001957923e-07
genetic O 0 1.5576425766994362e-06
report O 0 1.0111701840287424e-06
. O 0 4.517070806286938e-07

We O 0 7.987961225808249e-07
report O 0 4.494922833941928e-08
a O 0 3.8669508484190374e-08
Japanese O 0 9.459937473366153e-07
family O 0 9.488520845479798e-06
with O 0 7.276463293237612e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0006929908995516598
ALD B-Disease 1 1.0
) O 0 5.415689088295039e-07
with O 0 1.3571406043411116e-07
a O 0 4.7219282350852154e-07
three O 0 3.089052924565294e-08
base O 0 3.902504886355018e-06
pair O 0 9.434935464014416e-07
deletion O 0 9.016964241936876e-08
( O 0 2.5720354734914963e-09
delGAG O 0 2.3543037741546868e-07
291 O 0 5.071022712854756e-08
) O 0 3.306378060230486e-09
in O 0 7.584588956888183e-09
the O 0 5.034257810621057e-07
ALD B-Disease 1 0.9999979734420776
gene O 0 1.7559352272655815e-05
. O 0 1.756613414727326e-06

A O 0 3.4768852401612094e-06
variety O 0 2.944528034731775e-07
of O 0 5.448655748807596e-09
phenotypes O 0 1.3730061709793517e-06
were O 0 1.6035801309044473e-07
observed O 0 1.0394469285301966e-07
within O 0 4.650235307934736e-09
this O 0 1.172168140328722e-08
family O 0 3.2441878374811495e-06
. O 0 6.215640837581304e-07

While O 0 7.863833957344468e-07
the O 0 2.9658217215455807e-08
proband O 0 2.262163980049081e-05
( O 0 2.222827788500581e-08
patient O 0 7.133324970709509e-07
1 O 0 1.1151633394490545e-08
) O 0 7.650275080095525e-09
was O 0 1.8782780898618512e-05
classified O 0 7.089803602866596e-06
as O 0 1.3693902189970686e-07
having O 0 5.827200766361784e-08
a O 0 1.0039905617986733e-07
rare O 0 1.4282313998137397e-07
intermediate O 0 1.0141410200503742e-07
type O 0 2.867262992367614e-06
of O 0 5.500163879901265e-09
adult O 0 1.8532175090513192e-05
cerebral O 0 0.00032520940294489264
and O 0 9.389578394802811e-07
cerebello O 0 0.07118046283721924
- O 1 0.8589265942573547
brain O 0 0.0026355492882430553
stem O 0 2.3875420538388425e-06
forms O 0 4.952570407112944e-07
, O 0 2.8026818199577974e-07
his O 0 3.741813543456374e-07
younger O 0 1.6204119219764834e-06
brother O 0 1.012807751976652e-05
( O 0 4.119528895785152e-08
patient O 0 3.945178832509555e-06
2 O 0 1.4974774842357874e-07
) O 0 2.925794717612007e-08
and O 0 2.7943010536546353e-06
nephew O 0 0.014963718131184578
( O 0 1.2100809954063152e-07
patient O 0 2.2816788259660825e-05
3 O 0 1.5502477879181242e-07
) O 0 4.050103186159504e-08
had O 0 1.69180168541061e-06
a O 0 1.2715543562080711e-05
childhood O 0 0.10612750053405762
ALD B-Disease 1 0.9999985694885254
type O 0 0.04809223860502243
. O 0 3.9644824028073344e-06

Another O 0 1.1992182407993823e-05
nephew O 0 0.0006862999289296567
( O 0 9.853343385657354e-08
patient O 0 2.2985370833339402e-06
4 O 0 1.4419949678767807e-08
) O 0 8.358557734844396e-10
of O 0 2.967506462780989e-09
patient O 0 8.53378605825128e-06
1 O 0 1.468919919034306e-07
was O 0 0.00011707084195222706
classified O 0 5.854947175976122e-06
as O 0 8.961789177419632e-08
having O 0 1.352917422536848e-07
an O 0 1.7066595248138583e-08
adolescent O 0 1.305009482166497e-05
form O 0 2.5257992319893674e-07
. O 0 2.816319408793788e-07

The O 0 1.975997179215483e-07
tau O 0 2.786889865546982e-07
level O 0 8.013509500415239e-08
in O 0 1.8624594089189372e-09
the O 0 2.5437204342892983e-08
cerebrospinal O 0 0.0043558687902987
fluid O 0 0.00015470728976652026
( O 0 3.3026807955138793e-07
CSF O 0 0.4828837811946869
) O 0 8.51407744306698e-09
in O 0 1.3447179370018603e-08
patient O 0 2.598638275230769e-06
1 O 0 8.320961342178634e-08
was O 0 0.00018305718549527228
as O 0 7.307455263116935e-08
high O 0 6.066198352527863e-07
as O 0 4.733838210313479e-09
that O 0 5.837428873611827e-10
of O 0 4.507111128759789e-09
patients O 0 7.310465548471257e-07
with O 0 5.456793587654829e-06
Alzheimers B-Disease 1 0.9999946355819702
disease I-Disease 0 0.006947719492018223
( O 0 1.7625012560529285e-08
AD B-Disease 0 1.0655153346306179e-05
) O 0 1.3887229499687237e-07
. O 0 2.998273487264669e-07

His O 0 4.064771928824484e-06
brain O 0 1.7369402485201135e-05
magnetic O 0 8.339904525200836e-06
resonance O 0 1.4201679732650518e-05
image O 0 4.95698259328492e-06
( O 0 8.996003053596269e-09
MRI O 0 8.37749848869862e-06
) O 0 1.9022648345412563e-08
showed O 0 7.352014654316008e-05
abnormalities B-Disease 0 0.44441157579421997
in I-Disease 0 2.093070072817227e-08
the I-Disease 0 4.395943165036442e-08
bilateral I-Disease 0 0.0002597029379103333
cerebellar I-Disease 0 0.13193659484386444
hemispheres I-Disease 0 0.00033292401349171996
and O 0 8.695505130162928e-06
brain O 0 8.058718958636746e-05
stem O 0 1.9690062345034676e-06
, O 0 3.1807211087198084e-08
but O 0 1.906889224301267e-08
not O 0 6.276629882506768e-09
in O 0 4.139351528209545e-09
the O 0 7.005909452573178e-08
cerebral O 0 4.195640576654114e-05
white O 0 2.5392279212610447e-07
matter O 0 1.5307737299963264e-08
, O 0 1.677810446132355e-09
where O 0 5.93278581817458e-09
marked O 0 2.8306113009080036e-08
reductions O 0 3.845063289986683e-08
of O 0 6.857279744032496e-10
the O 0 6.38927915019849e-08
cerebral O 0 0.00011535718658706173
blood O 0 1.0231351552647538e-06
flow O 0 4.1996659660981095e-07
and O 0 1.1865785864983991e-07
oxygen O 0 5.2942127126698324e-08
metabolism O 0 1.1069794680906853e-07
were O 0 2.3607917398749123e-08
clearly O 0 3.135412995902698e-08
demonstrated O 0 3.82964726597379e-09
by O 0 3.5488414984463645e-10
positron O 0 1.854354252373014e-07
emission O 0 1.49827172890582e-07
tomography O 0 1.9380104276933707e-06
( O 0 6.358703785735997e-08
PET O 0 1.1011376045644283e-05
) O 0 6.165159049942304e-08
. O 0 1.0549099727086286e-07

In O 0 4.3740888600041217e-07
patients O 0 2.46827767114155e-07
2 O 0 4.567013789369412e-08
and O 0 3.0296057218492933e-08
3 O 0 2.4970150391823154e-08
, O 0 6.742117086844246e-09
the O 0 1.4662061564862938e-09
autopsy O 0 3.782935527851805e-05
findings O 0 7.69476642403788e-08
showed O 0 9.802793101698626e-07
massive O 0 1.5105691090866458e-05
demyelination B-Disease 1 0.9999722242355347
of I-Disease 0 8.968542886123032e-08
the I-Disease 0 7.402270512102405e-07
cerebral I-Disease 0 0.0035055549815297127
white I-Disease 0 6.526754077640362e-06
matter I-Disease 0 5.842034767056248e-08
with O 0 2.355078798643717e-09
sparing O 0 1.2907875657219847e-08
of O 0 3.2721676479496864e-09
the O 0 7.928340295393355e-08
U O 0 0.10627301782369614
- O 0 0.00035328796366229653
fibers O 0 2.8241291147423908e-05
, O 0 1.0334249900267878e-08
compatible O 0 8.831503350847925e-08
with O 0 7.662073642222822e-09
the O 0 1.6882271136609006e-09
findings O 0 2.688119238314357e-08
of O 0 7.004413049571667e-08
childhood O 0 0.053931672126054764
ALD B-Disease 1 0.9999973773956299
. O 0 1.350799448118778e-05

Oleic O 0 0.005790715105831623
and O 0 2.6322181838622782e-06
erucic O 0 0.0017965440638363361
acids O 0 9.388865152004655e-08
( O 0 2.159674883372986e-09
Lorenzos O 0 4.4368735530042613e-07
Oil O 0 5.9484367653794834e-08
) O 0 3.5641248286033544e-10
were O 0 1.9638313197845036e-09
administered O 0 1.4912396872901468e-09
to O 0 1.701828344913281e-09
patients O 0 6.830157772697021e-09
1 O 0 3.462253594932463e-09
and O 0 4.3743806799056983e-08
4 O 0 6.507571725933303e-08
, O 0 1.637401325638166e-08
but O 0 3.2880398403989375e-09
sufficient O 0 3.6375571443869603e-09
effectiveness O 0 1.7050425071829522e-08
was O 0 1.5736908665076044e-07
not O 0 2.639062746112586e-09
obtained O 0 1.628394130648303e-08
. O 0 1.1534567079252156e-07

The O 0 1.9873306200679508e-07
findings O 0 1.2923980818868586e-07
in O 0 4.195164216014291e-09
this O 0 3.70231800772558e-09
family O 0 2.4146757482412795e-07
suggest O 0 7.880849040020621e-08
that O 0 3.75388520268416e-09
delGAG291 O 0 1.7283609849982895e-06
is O 0 2.3305300800302575e-08
part O 0 1.3389006348063504e-08
of O 0 1.8071624197091296e-09
the O 0 2.0086211804937193e-08
cause O 0 2.675357961834379e-07
of O 0 1.2557240580690632e-08
Japanese O 0 0.001387706259265542
ALD B-Disease 1 0.9999988079071045
with O 0 3.1458370131076663e-07
phenotypic O 0 1.085942130885087e-05
variations O 0 3.6529712815536186e-05
. O 0 1.3944176089353277e-06

Moreover O 0 1.3734888852923177e-05
, O 0 2.7602769847590025e-08
although O 0 5.7425153521251104e-09
the O 0 3.4929889536350345e-10
scale O 0 9.108835911320057e-06
of O 0 1.32966948562796e-09
the O 0 1.250486714177157e-09
study O 0 4.273543297017568e-09
is O 0 9.864886685306828e-09
limited O 0 5.1639037934592125e-08
, O 0 6.4233067753605155e-09
there O 0 3.878000498502843e-08
is O 0 1.5366712347031353e-08
a O 0 6.639958360921128e-09
possibility O 0 3.186903185792289e-08
that O 0 3.13261558915201e-08
PET O 0 1.1954934961977415e-05
can O 0 3.05611145279272e-08
detect O 0 8.569017154513858e-06
an O 0 1.6181768813794406e-08
insidious B-Disease 0 0.00024911516811698675
lesion I-Disease 1 0.9599716663360596
which O 0 1.3082388932161848e-06
is O 0 4.658423051751015e-07
undetectable O 0 8.195456189241668e-07
by O 0 1.2396293991301377e-09
computed O 0 1.673459024686963e-07
tomogram O 0 7.586973879369907e-06
( O 0 4.782901630306924e-09
CT O 0 5.7750970881897956e-05
) O 0 1.3958172395689417e-09
or O 0 6.543639408107538e-09
MRI O 0 3.767950715882762e-07
analysis O 0 1.9031030973337693e-08
, O 0 1.2815661420972901e-08
and O 0 8.645565152676227e-09
that O 0 6.137055308386152e-10
the O 0 1.5780332596193603e-10
higher O 0 8.25648704960713e-09
level O 0 3.224320366257416e-09
of O 0 1.1427055135460051e-10
tau O 0 2.0911377074384063e-09
reflects O 0 6.375493466492799e-10
the O 0 1.0896993724029969e-10
process O 0 1.2179318664706784e-09
of O 0 1.3537242438133035e-09
neuronal B-Disease 0 1.2790170330845285e-05
degeneration I-Disease 0 0.014066106639802456
in O 0 1.7013711840263568e-05
ALD B-Disease 1 0.9999984502792358
. O 0 2.792514169414062e-05

Lorenzos O 0 0.00011893439659615979
Oil O 0 3.4311583476664964e-06
should O 0 4.464309100171704e-08
be O 0 1.366396329416375e-09
given O 0 3.11813880271572e-10
in O 0 1.1117408382776972e-10
the O 0 3.2566310759207795e-10
early O 0 1.2356830225712656e-08
stage O 0 1.1418044323363574e-06
. O 0 1.2646535374472023e-08
. O 0 1.6705791949789273e-07

Nonsense O 0 0.0008080821135081351
mutation O 0 4.304034973756643e-06
in O 0 2.8561222720213664e-08
exon O 0 1.1016984444722766e-06
4 O 0 7.137415281022186e-08
of O 0 2.5682311832753157e-09
human O 0 1.0405934602886191e-07
complement O 0 4.962489583704155e-07
C9 O 0 3.7409936339827254e-05
gene O 0 4.5854574182158103e-07
is O 0 3.6752041410181846e-08
the O 0 2.7015794046292285e-09
major O 0 1.8443577687321522e-07
cause O 0 1.738829809028175e-07
of O 0 1.8901451070973962e-08
Japanese O 0 2.7620531909633428e-05
complement B-Disease 0 0.00016006095393095165
C9 I-Disease 1 0.9872103929519653
deficiency I-Disease 1 0.552180290222168
. O 0 1.3232232731752447e-06

Deficiency B-Disease 1 0.9990768432617188
of I-Disease 0 1.0212376366780518e-07
the I-Disease 0 2.482853034280197e-08
ninth I-Disease 0 2.2996808013431291e-07
component I-Disease 0 8.849594337334565e-07
of I-Disease 0 5.330341945608552e-09
human I-Disease 0 5.280799442175521e-08
complement I-Disease 0 2.1981240649893152e-07
( O 0 7.055510398146225e-09
C9 O 0 3.346431640238734e-06
) O 0 3.4552145589117345e-09
is O 0 7.749213715158021e-09
the O 0 1.5579220136174854e-09
most O 0 3.669180870247146e-08
common O 0 5.461827640829142e-06
complement B-Disease 1 0.9999945163726807
deficiency I-Disease 1 0.9999990463256836
in O 0 2.18661373452278e-08
Japan O 0 3.287772472049255e-07
but O 0 2.1107823044985707e-08
is O 0 2.9424834124824883e-08
rare O 0 4.914066309424925e-08
in O 0 1.9568469067365868e-09
other O 0 2.2595414428394633e-09
countries O 0 1.0730722976859397e-08
. O 0 6.72451250238737e-08

We O 0 3.282496550127689e-07
studied O 0 2.8946770314064452e-08
the O 0 1.2638450286317493e-09
molecular O 0 4.778454609777327e-08
basis O 0 1.4680978210890316e-07
of O 0 1.9250998661846097e-07
C9 B-Disease 1 0.9988195300102234
deficiency I-Disease 1 0.5229336619377136
in O 0 1.003293448320619e-08
four O 0 1.787438463907165e-08
Japanese O 0 1.0001647297031013e-06
C9 B-Disease 0 0.0007311782683245838
- I-Disease 0 0.12211567163467407
deficient I-Disease 0 0.140672504901886
patients O 0 6.904848305566702e-06
who O 0 8.117824563669274e-07
had O 0 5.298410542309284e-05
suffered O 0 0.06282699108123779
from O 0 3.6820700188400224e-05
meningococcal B-Disease 1 0.9999996423721313
meningitis I-Disease 1 0.9999974966049194
. O 0 1.0345904229325242e-05

Direct O 0 4.5435811557581474e-07
sequencing O 0 2.050916094731292e-07
of O 0 1.4196281483691564e-08
amplified O 0 3.407581516512437e-06
C9 O 0 6.9901716415188275e-06
cDNA O 0 4.204378569738765e-07
and O 0 6.785570860756707e-08
DNA O 0 7.091387033142382e-07
revealed O 0 1.6314569961650704e-07
a O 0 1.5453714752311498e-08
nonsense O 0 8.457575972897757e-07
substitution O 0 6.927722751015608e-08
( O 0 5.8654903156707405e-09
CGA O 0 7.165049282775726e-07
- O 0 2.24936429731315e-05
- O 0 4.635488585336134e-05
> O 0 3.468489069291536e-07
TGA O 0 2.1162338725844165e-06
) O 0 1.0522664961598593e-09
at O 0 2.102287233185507e-09
codon O 0 8.427766928775782e-09
95 O 0 2.220745809466962e-09
in O 0 5.002063763193121e-10
exon O 0 1.052795326472733e-07
4 O 0 5.191100171941798e-08
in O 0 4.700350775266315e-09
the O 0 6.312299127841925e-09
four O 0 6.77328628739815e-08
C9 B-Disease 0 0.0015428821789100766
- I-Disease 0 0.031613368541002274
deficient I-Disease 0 0.0008023118134588003
individuals O 0 4.877554715676524e-08
. O 0 1.609810311720139e-07

An O 0 4.324786857523577e-07
allele O 0 6.00599105382571e-06
- O 0 4.671111128118355e-06
specific O 0 7.175334104658759e-08
polymerase O 0 2.4935867259046063e-05
chain O 0 9.52905320446007e-05
reaction O 0 1.486838954178893e-07
system O 0 2.036170165808926e-08
designed O 0 9.451262599213806e-07
to O 0 4.427428645925602e-09
detect O 0 5.993357262923382e-06
exclusively O 0 6.3697136454266e-08
only O 0 7.3370318709464755e-09
one O 0 2.3658617287480865e-09
of O 0 1.8423267078571115e-10
the O 0 9.09461284059887e-10
normal O 0 4.1557761676358496e-08
and O 0 2.5338457998458352e-09
mutant O 0 3.225398259587564e-08
alleles O 0 1.8740699658792437e-08
indicated O 0 4.3961276219306455e-07
that O 0 3.178039387208287e-09
all O 0 3.4199318377226007e-10
the O 0 1.2456257136861382e-09
four O 0 1.8140426050194947e-08
patients O 0 6.308411126809688e-09
were O 0 6.681450059886629e-09
homozygous O 0 3.0344867951725973e-08
for O 0 1.0558027785378954e-09
the O 0 1.1287815127047907e-09
mutation O 0 7.716852934436247e-09
in O 0 1.6508124867087304e-09
exon O 0 1.0166606756456531e-07
4 O 0 1.581051236598796e-07
and O 0 3.7477380487871415e-07
that O 0 2.8395554352300678e-08
the O 0 7.3721859727982064e-09
parents O 0 5.317100537638453e-09
of O 0 8.692171427071571e-10
patient O 0 1.240374785993481e-06
2 O 0 2.983216162988356e-08
were O 0 5.450539219964412e-07
heterozygous O 0 1.8234526351079694e-06
. O 0 3.292095982487808e-07

The O 0 4.07207522812314e-07
common O 0 3.306550695469923e-07
mutation O 0 8.02802730959229e-08
at O 0 6.010040021209306e-09
codon O 0 3.279123106381121e-08
95 O 0 1.7292821397063562e-08
in O 0 1.419307893435473e-09
exon O 0 1.2468844090562925e-07
4 O 0 5.794051816110368e-08
might O 0 5.622239740432633e-08
be O 0 2.961128675593727e-09
responsible O 0 1.6183928863711117e-08
for O 0 2.543108168495678e-09
most O 0 3.812027316030253e-08
Japanese O 0 4.00018434447702e-05
C9 B-Disease 1 0.9794564843177795
deficiency I-Disease 0 0.02698446623980999
. O 0 6.790788376065393e-08
. O 0 3.898038585248287e-07

BRCA1 O 0 7.730870856903493e-05
required O 0 1.4929202052371693e-07
for O 0 1.1151420231669817e-08
transcription O 0 7.676201676076744e-06
- O 0 0.00023822509683668613
coupled O 0 2.0617953850887716e-05
repair O 0 0.0005071362829767168
of O 0 1.543327066144684e-08
oxidative O 0 8.365941903321072e-05
DNA O 0 0.00018775963690131903
damage O 0 0.0035439326893538237
. O 0 2.902087771872175e-06

The O 0 2.531212339818012e-05
breast B-Disease 1 0.9997456669807434
and I-Disease 1 0.9827761650085449
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
susceptibility O 0 0.008914214558899403
gene O 0 6.623879744438455e-05
BRCA1 O 0 0.000201422197278589
encodes O 0 4.5496790335164405e-06
a O 0 6.986803782638162e-05
zinc O 1 0.9825368523597717
finger O 0 0.04453631862998009
protein O 0 3.5941661735705566e-07
of O 0 8.903363379886287e-09
unknown O 0 5.046726414548175e-07
function O 0 2.253710960076205e-07
. O 0 2.299369299407772e-07

Association O 0 1.6620472251815954e-06
of O 0 1.1100193653135193e-08
the O 0 9.36948740815069e-09
BRCA1 O 0 9.942724318534601e-06
protein O 0 1.6690854920398124e-07
with O 0 3.47033268788266e-09
the O 0 5.335692332408826e-09
DNA O 0 7.526963145210175e-06
repair O 0 0.0010993483010679483
protein O 0 1.16448893550114e-06
Rad51 O 0 1.3678745744982734e-05
and O 0 1.4856448515843113e-08
changes O 0 3.5661735786618465e-09
in O 0 6.548430131481098e-10
the O 0 2.0257710786619754e-10
phosphorylation O 0 8.190297329235818e-09
and O 0 1.4649768509400474e-08
cellular O 0 2.4169021344278008e-06
localization O 0 3.466891485004453e-07
of O 0 1.1552149237203935e-09
the O 0 4.646245610473443e-09
protein O 0 2.70209614683381e-08
after O 0 6.035485000666085e-09
exposure O 0 1.0245094728134063e-07
to O 0 5.993018969974173e-09
DNA O 0 4.661214461521013e-06
- O 0 0.00030809329473413527
damaging O 0 8.296198211610317e-05
agents O 0 1.8927811140656559e-07
are O 0 1.3161356449131745e-08
consistent O 0 4.081464339833474e-07
with O 0 3.493930478271068e-09
a O 0 4.1897127545098556e-08
role O 0 2.3126936810058396e-08
for O 0 7.4795734050781e-09
BRCA1 O 0 1.584137635290972e-06
in O 0 1.299606910976081e-08
DNA O 0 2.5099103368120268e-05
repair O 0 0.0035375631414353848
. O 0 2.23344113692292e-06

Here O 0 2.4451396711810958e-06
, O 0 3.2690810058966235e-08
it O 0 3.946784232766731e-09
is O 0 6.3437282094014336e-09
shown O 0 6.338624292112627e-09
that O 0 2.779601437907786e-09
mouse O 0 3.788343974520103e-06
embryonic O 0 1.7758492276698234e-06
stem O 0 2.406721932857181e-06
cells O 0 2.889745701395441e-06
deficient B-Disease 0 4.505885954131372e-05
in I-Disease 0 1.9579118770707282e-08
BRCA1 I-Disease 0 5.613909252133453e-06
are O 0 3.8124348122892115e-08
defective O 0 0.00012171690468676388
in O 0 2.6126599550480023e-08
the O 0 9.14764441972693e-09
ability O 0 1.9847959720209474e-08
to O 0 1.977034314037951e-09
carry O 0 7.90142351547729e-08
out O 0 5.1200421680164254e-09
transcription O 0 2.3747745103719353e-07
- O 0 7.820070095476694e-06
coupled O 0 3.1590877824783092e-06
repair O 0 0.00010371387907071039
of O 0 2.651004304965454e-09
oxidative O 0 5.984322797303321e-06
DNA O 0 5.548877015826292e-05
damage O 0 0.009226982481777668
, O 0 1.510973675067362e-07
and O 0 9.218145180511783e-08
are O 0 2.854123870577041e-08
hypersensitive O 0 0.000125430291518569
to O 0 7.722495354300918e-08
ionizing O 0 2.4501054213033058e-05
radiation O 0 6.824756837886525e-06
and O 0 2.6766382887899454e-08
hydrogen O 0 5.84359497679543e-07
peroxide O 0 0.00012248160783201456
. O 0 9.887604619507329e-07

These O 0 1.5744937797990133e-07
results O 0 4.970417677441219e-08
suggest O 0 6.562640209040183e-08
that O 0 9.066040362881722e-09
BRCA1 O 0 2.5290535177191487e-06
participates O 0 1.9112302140911197e-07
, O 0 9.644714360490525e-09
directly O 0 9.434206305058979e-09
or O 0 5.7229019745363985e-08
indirectly O 0 2.0154909918801422e-07
, O 0 6.06766548116866e-09
in O 0 1.1663312537990578e-09
transcription O 0 3.7290353702701395e-06
- O 0 0.0005678810412064195
coupled O 0 2.0689571101684123e-05
repair O 0 0.002595684491097927
of O 0 1.0509692671689663e-08
oxidative O 0 1.0572224709903821e-05
DNA O 0 0.00012268325372133404
damage O 0 0.00016678233805578202
. O 0 9.728226757488301e-08
. O 0 6.121430828898156e-07

Truncation O 0 0.00017241858586203307
mutations O 0 8.767773397266865e-05
in O 0 1.60107560986944e-07
the O 0 2.193736214906039e-08
transactivation O 0 3.41857157764025e-05
region O 0 3.123743681499036e-07
of O 0 1.0120846383188109e-08
PAX6 O 0 0.00014990240742918104
result O 0 8.235604553874509e-08
in O 0 1.2920487790779589e-08
dominant O 0 3.1786339604877867e-06
- O 0 9.42036604101304e-06
negative O 0 4.936381969855574e-07
mutants O 0 1.4387169358087704e-06
. O 0 3.12497746790541e-07

PAX6 O 0 0.005604489706456661
is O 0 9.239212204192881e-07
a O 0 5.0313676780433525e-08
transcription O 0 5.876903514945298e-07
factor O 0 2.781586943001457e-07
with O 0 1.1062359916991227e-08
two O 0 1.0679880979580503e-08
DNA O 0 1.7887887224787846e-05
- O 0 0.00015377486124634743
binding O 0 3.523489795043133e-06
domains O 0 7.510511181862967e-07
( O 0 6.54733511851191e-09
paired O 0 2.594648833564861e-07
box O 0 0.00011334261944284663
and O 0 4.667036535010993e-07
homeobox O 0 1.6432256870757556e-06
) O 0 2.346801197816717e-09
and O 0 6.21809892464853e-09
a O 0 1.0112664483585831e-08
proline O 0 6.504656994366087e-06
- O 0 1.0224192010355182e-05
serine O 0 7.310755336220609e-06
- O 0 6.826852768426761e-06
threonine O 0 8.444442755717319e-06
( O 0 4.246721196921044e-09
PST O 0 2.8535280307551147e-06
) O 0 1.3615140126432834e-08
- O 0 3.0096261980361305e-06
rich O 0 3.9821864561417897e-07
transactivation O 0 1.3842255611962173e-05
domain O 0 1.7750060123944422e-06
. O 0 4.948755076839007e-07

PAX6 O 0 0.0064020222052931786
regulates O 0 0.0003655159380286932
eye O 0 0.00020916150242555887
development O 0 2.274100694421577e-07
in O 0 1.1793849452601535e-08
animals O 0 3.0300910225378175e-08
ranging O 0 6.1518164784502e-07
from O 0 8.78499673007127e-09
jellyfish O 0 6.754656567409256e-08
to O 0 4.033988254548149e-09
Drosophila O 0 3.7742186265177224e-08
to O 0 9.804410616709447e-09
humans O 0 1.0729499422268418e-07
. O 0 1.5245419149323425e-07

Heterozygous O 0 4.6158900659065694e-05
mutations O 0 1.1748969882319216e-05
in O 0 9.755224539276242e-08
the O 0 2.4961579470073048e-08
human O 0 1.2937162807702407e-07
PAX6 O 0 0.00018535948765929788
gene O 0 8.911461009120103e-07
result O 0 2.7913761968534345e-08
in O 0 1.8231436360593989e-09
various O 0 4.91406382252535e-09
phenotypes O 0 3.2510322398593416e-06
, O 0 5.799557811769773e-08
including O 0 1.4455356449616374e-06
aniridia B-Disease 1 0.999998927116394
, O 0 0.00045857945224270225
Peters B-Disease 1 0.9999977350234985
anomaly I-Disease 1 0.9999983310699463
, O 0 5.624573532259092e-06
autosomal B-Disease 0 0.29473695158958435
dominant I-Disease 0 0.010961324907839298
keratitis I-Disease 1 0.9931402802467346
, O 0 3.947399818571284e-06
and O 0 5.565245828620391e-06
familial B-Disease 1 0.876560628414154
foveal I-Disease 1 0.9983487129211426
dysplasia I-Disease 1 0.9999806880950928
. O 0 3.6373803595779464e-05

It O 0 2.4708282353458344e-07
is O 0 8.99674432730535e-08
believed O 0 4.077230997268089e-08
that O 0 1.1661309695654154e-09
the O 0 7.972505988718126e-10
mutated O 0 4.182614432579612e-08
allele O 0 6.35987973396368e-08
of O 0 4.948526033388134e-09
PAX6 O 0 0.0003355987719260156
produces O 0 1.018593479784613e-06
an O 0 8.07889843912335e-09
inactive O 0 1.2745825017645984e-07
protein O 0 1.9911134074845904e-07
and O 0 1.337710841653461e-06
aniridia B-Disease 1 0.9999985694885254
is O 0 5.8761365835380275e-06
caused O 0 1.943385086633498e-06
due O 0 9.369329490027667e-08
to O 0 6.733740320896686e-08
genetic O 0 2.3812159270164557e-05
haploinsufficiency O 0 0.0014984308509156108
. O 0 1.8528777445681044e-06

However O 0 1.0194680726272054e-06
, O 0 9.157105296253576e-09
several O 0 6.754186654411853e-10
truncation O 0 1.0293076684320113e-06
mutations O 0 1.6654045111863525e-06
have O 0 7.621368069976597e-08
been O 0 2.305528710166982e-07
found O 0 8.190348665948477e-08
to O 0 3.672063542126125e-09
occur O 0 6.9263856872225915e-09
in O 0 1.0096239400070317e-09
the O 0 4.969789912934175e-09
C O 0 0.0022135209292173386
- O 0 0.00015637012256775051
terminal O 0 1.0399668099125847e-05
half O 0 6.560835874580562e-09
of O 0 6.778527184003735e-10
PAX6 O 0 2.1342244508559816e-05
in O 0 4.1340037171266886e-08
patients O 0 8.576292742645819e-08
with O 0 5.9281060060811797e-08
Aniridia B-Disease 1 0.9999964237213135
resulting O 0 1.1949244935749448e-06
in O 0 6.994518297886998e-09
mutant O 0 1.0894099489178188e-07
proteins O 0 5.2435500386138756e-09
that O 0 6.056473100812809e-09
retain O 0 2.0362364239190356e-08
the O 0 1.2834171503328662e-09
DNA O 0 1.4479529681921122e-06
- O 0 2.1558955722866813e-06
binding O 0 1.3759040484728757e-07
domains O 0 9.603305528571582e-08
but O 0 3.9879054725133756e-08
have O 0 2.2510810993026098e-08
lost O 0 9.161720981865074e-08
most O 0 7.147258895834341e-10
of O 0 3.9892711356515065e-10
the O 0 1.2414709260610834e-08
transactivation O 0 1.7573776858625934e-05
domain O 0 6.78694789257861e-07
. O 0 1.7826249631980318e-07

It O 0 4.348061679593229e-07
is O 0 4.5678415716565723e-08
not O 0 3.0858713362391654e-09
clear O 0 9.61727053550021e-09
whether O 0 1.5911812978330886e-09
such O 0 2.3870885268451048e-09
mutants O 0 3.723594375060202e-07
really O 0 6.456596679527138e-07
behave O 0 6.090625959132012e-08
as O 0 2.6135855701880928e-09
loss O 0 9.32164780920175e-08
- O 0 2.1330351955839433e-06
of O 0 6.1086447011859946e-09
- O 0 7.540839578723535e-05
function O 0 1.1854904613528561e-07
mutants O 0 4.143808496337442e-08
as O 0 2.9775191201508733e-09
predicted O 0 1.28856683545564e-07
by O 0 2.5049621044104242e-08
haploinsufficiency O 0 9.210492135025561e-05
. O 0 5.18599449605972e-07

Contrary O 0 6.501742518594256e-06
to O 0 5.086036480861367e-08
this O 0 3.6419169902046633e-09
theory O 0 4.802686603966322e-08
, O 0 2.486709504978535e-09
our O 0 1.0799049432463903e-09
data O 0 1.567451590744895e-08
showed O 0 7.823621928082503e-08
that O 0 6.448087064292451e-10
these O 0 2.614661265276652e-10
mutants O 0 5.593101537471057e-09
are O 0 2.5832744832143817e-09
dominant O 0 5.248981551631005e-07
- O 0 2.1706359802919906e-06
negative O 0 1.0396194483064392e-07
in O 0 2.4526856101658723e-09
transient O 0 1.5986175583293516e-07
transfection O 0 1.4014153748576064e-06
assays O 0 1.3266551377455471e-06
when O 0 1.2449707931239118e-08
they O 0 3.350787203260097e-09
are O 0 1.2956016259835224e-09
coexpressed O 0 1.3790347566100536e-06
with O 0 6.96673030375905e-09
wild O 0 2.889398501793039e-06
- O 0 0.00048403613618575037
type O 0 0.0008532802457921207
PAX6 O 0 0.0005755097372457385
. O 0 1.1672885875668726e-06

We O 0 1.6439311139038182e-06
found O 0 5.152137561026393e-08
that O 0 2.9350717412057747e-09
the O 0 2.605134774569251e-09
dominant O 0 1.5664960528738447e-06
- O 0 9.207878065353725e-06
negative O 0 9.525053883407963e-07
effects O 0 6.600085953323287e-07
result O 0 3.9973770959989e-09
from O 0 6.182923617537028e-10
the O 0 4.1753012158807223e-10
enhanced O 0 5.4489291301251797e-08
DNA O 0 4.7173460870908457e-07
binding O 0 6.934227059218756e-08
ability O 0 4.590924529424001e-09
of O 0 4.4698256207453824e-10
these O 0 2.107377827798018e-09
mutants O 0 6.5858444031619e-07
. O 0 1.681106596151949e-07

Kinetic O 0 1.5791956684552133e-05
studies O 0 2.854598335488845e-07
of O 0 6.710019206934703e-09
binding O 0 1.201100758407847e-06
and O 0 4.499554862036348e-08
dissociation O 0 6.815103574808745e-07
revealed O 0 1.943142677873766e-07
that O 0 5.019515358917204e-10
various O 0 1.4977695472762065e-10
truncation O 0 1.5025472066554357e-07
mutants O 0 2.109289596319286e-07
have O 0 6.515244788118935e-09
3 O 0 8.092531977865747e-09
- O 0 5.465334652399179e-06
5 O 0 2.2626217344168253e-08
- O 0 1.0587111773929792e-06
fold O 0 1.2800323645478784e-07
higher O 0 4.280305887505165e-09
affinity O 0 1.6273097314112306e-09
to O 0 2.370987850497386e-10
various O 0 3.671053183662565e-10
DNA O 0 7.830070813952261e-08
- O 0 1.1348875972316819e-07
binding O 0 2.4417877497739937e-08
sites O 0 6.449655387541497e-08
when O 0 2.7134829938546545e-09
compared O 0 2.1578973274927193e-08
with O 0 1.632510793214692e-09
the O 0 2.9396658440816736e-09
wild O 0 1.0863893749046838e-06
- O 0 0.000779425201471895
type O 0 0.0018346355063840747
PAX6 O 0 0.0007298745913431048
. O 0 6.612837637476332e-07

These O 0 1.8429545889375731e-07
results O 0 7.429045467688411e-08
provide O 0 1.2679381988789373e-08
a O 0 5.30940891252385e-09
new O 0 5.809419612035072e-09
insight O 0 2.0592214156067712e-08
into O 0 1.899087997969673e-09
the O 0 6.546931885509366e-10
role O 0 3.967979278485245e-09
of O 0 9.516649690510803e-10
mutant O 0 6.937004854989937e-07
PAX6 O 0 4.4753825932275504e-05
in O 0 4.739306191936521e-08
causing O 0 2.330403913219925e-05
aniridia B-Disease 1 0.9999603033065796
. O 0 3.694398742482008e-07
. O 0 7.979129463819845e-07

Reversal O 0 0.000298394268611446
of O 0 8.230575986090116e-06
severe O 1 0.9849759936332703
hypertrophic B-Disease 1 0.999976634979248
cardiomyopathy I-Disease 1 0.9999998807907104
and O 0 4.7216220991685987e-05
excellent O 0 3.606037353165448e-05
neuropsychologic O 0 0.0001965068804565817
outcome O 0 3.2597376957710367e-06
in O 0 1.1983486558619916e-07
very B-Disease 0 9.004415346680616e-07
- I-Disease 0 0.0016379785956814885
long I-Disease 0 6.948976079002023e-05
- I-Disease 0 0.0005160051514394581
chain I-Disease 0 0.0009121051989495754
acyl I-Disease 0 2.3842014797992306e-06
- I-Disease 0 2.4615135771455243e-05
coenzyme I-Disease 0 4.358026671980042e-06
A I-Disease 0 1.0266645404044539e-05
dehydrogenase I-Disease 1 0.9184813499450684
deficiency I-Disease 1 0.6032395362854004
. O 0 6.840981541245128e-07

Very B-Disease 0 3.0291315852082334e-05
- I-Disease 0 0.00036015614750795066
long I-Disease 0 1.9817673091893084e-05
- I-Disease 0 0.00017535287770442665
chain I-Disease 0 0.00017122211284004152
acyl I-Disease 0 7.388799190266582e-07
- I-Disease 0 5.493830940395128e-06
coenzyme I-Disease 0 2.7645560862765706e-07
A I-Disease 0 5.7974453682163585e-08
dehydrogenase I-Disease 0 1.8676737454370596e-05
( I-Disease 0 3.011883009662597e-08
VLCAD I-Disease 0 0.15910546481609344
) I-Disease 0 4.4488574530987535e-06
deficiency I-Disease 0 0.1722329705953598
is O 0 7.791587677274947e-07
a O 0 8.597905434726272e-06
disorder O 0 0.06552861630916595
of O 0 7.882965391559082e-09
fatty O 0 8.571976650273427e-06
acid O 0 3.327904494199174e-07
beta O 0 1.473453026257232e-09
oxidation O 0 4.6971604383827525e-09
that O 0 2.8529740792038183e-09
reportedly O 0 1.240765186594217e-06
has O 0 4.993718150103632e-08
high O 0 4.894329777016537e-07
rates O 0 3.8515227629432047e-07
of O 0 7.911464372512e-09
morbidity O 0 0.00316141196526587
and O 0 1.43186196055467e-06
mortality O 0 7.220316183520481e-05
. O 0 2.8924787898176874e-07

We O 0 7.250898761412827e-07
describe O 0 1.6102464428513485e-07
the O 0 1.3878213023232888e-09
outcome O 0 1.0983937315245385e-08
of O 0 1.0006478978752398e-09
a O 0 5.380785239594843e-08
5 O 0 2.476520144512051e-08
- O 0 1.1588937923079357e-05
year O 0 1.3655612463026046e-07
- O 0 0.0002354247699258849
old O 0 0.006335570476949215
girl O 0 0.03395478054881096
with O 0 2.0757081074407324e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
who O 0 4.25882353738416e-06
was O 0 1.7455316765335738e-06
first O 0 2.1717253773090306e-08
seen O 0 5.501401574292686e-06
at O 0 9.351101937227213e-08
5 O 0 1.1077261330427746e-09
months O 0 8.560970821136493e-10
of O 0 4.435277978220853e-10
age O 0 3.0288896368801943e-07
with O 0 2.676404392332188e-06
severe O 1 0.9428791403770447
hypertrophic B-Disease 1 0.9999849796295166
cardiomyopathy I-Disease 1 1.0
, O 0 0.0827915146946907
hepatomegaly B-Disease 1 1.0
, O 0 0.13847984373569489
encephalopathy B-Disease 1 0.9549883604049683
, O 0 2.798162768158363e-07
and O 0 3.2795062452350976e-06
hypotonia B-Disease 1 0.767714262008667
. O 0 3.077021119679557e-06

Biochemical O 0 0.00012075357517460361
studies O 0 5.593900368694449e-06
indicated O 0 0.31399399042129517
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
caused O 0 0.0001451205025659874
by O 0 1.5953371246268944e-07
a O 0 1.7119008361987653e-06
stable O 0 0.0007963462267071009
yet O 0 4.5635138690158783e-07
inactive O 0 6.503161102955346e-07
enzyme O 0 7.15427461273066e-07
. O 0 1.3459013814554055e-07

Molecular O 0 4.272269507055171e-05
genetic O 0 3.567016392480582e-06
analysis O 0 1.9279660534721188e-07
of O 0 2.7337547336969692e-08
her O 0 1.1790090184149449e-06
VLCAD O 0 0.00405969237908721
gene O 0 1.2314665127632907e-06
revealed O 0 2.6093737233168213e-06
a O 0 3.9994080225369544e-07
T1372C O 0 1.1365677892172243e-05
( O 0 7.686738356937894e-09
F458L O 0 5.315897055879759e-07
) O 0 6.762182369612901e-09
missense O 0 4.577593244903255e-06
mutation O 0 9.188143508254143e-07
and O 0 2.4735936676734127e-07
a O 0 6.879621651023626e-06
1668 O 0 0.2533169388771057
ACAG O 0 0.0986887514591217
1669 O 0 0.0008312722784467041
splice O 0 0.0016147667774930596
site O 0 0.00020679144654422998
mutation O 0 1.1381981494196225e-05
. O 0 1.138774791797914e-06

After O 0 8.02481736172922e-07
initial O 0 4.959210855304264e-07
treatment O 0 1.529652195131348e-06
with O 0 1.0296891161942767e-07
intravenous O 0 2.9371171876846347e-06
glucose O 0 0.010976113379001617
and O 0 2.3590953901475586e-07
carnitine O 0 1.4692838703922462e-05
, O 0 8.707258913887017e-09
the O 0 3.3025651102747133e-09
patient O 0 9.061002401722362e-07
has O 0 4.403571196576195e-08
thrived O 0 8.687611625646241e-07
on O 0 1.2063223664426914e-07
a O 0 1.7333429980226356e-07
low O 0 0.0016665300354361534
- O 0 7.201371772680432e-05
fat O 0 1.6395972579630325e-06
diet O 0 4.4680483313186414e-08
supplemented O 0 9.841281567446458e-09
with O 0 1.4680978654979526e-09
medium O 0 1.6227351807174273e-05
- O 0 5.116735337651335e-05
chain O 0 6.694435433018953e-05
triglyceride O 0 1.9706949387909845e-06
oil O 0 3.54481386466432e-07
and O 0 9.20424447770074e-09
carnitine O 0 1.6011182424335857e-06
and O 0 6.663620322200359e-09
avoidance O 0 4.578133996346878e-07
of O 0 2.94193345240501e-08
fasting O 0 1.9410441382206045e-05
. O 0 6.065782258701802e-07

Her O 0 3.744106288650073e-05
ventricular O 1 0.5178143978118896
hypertrophy O 0 0.03801923990249634
resolved O 0 1.783819607226178e-05
significantly O 0 6.795905846956884e-07
over O 0 3.8706108540509376e-08
1 O 0 4.086589200369417e-08
year O 0 1.3177783309004099e-08
, O 0 1.7645328753701506e-08
and O 0 1.0695499952362297e-07
cognitively O 0 1.1220226042496506e-05
, O 0 7.540310065223821e-08
she O 0 1.0608502520881302e-07
is O 0 1.695242879407033e-08
in O 0 2.4012172250564845e-09
the O 0 4.8354427129027044e-09
superior O 0 1.9208488311051042e-07
range O 0 1.4431914223678177e-06
for O 0 5.761209287413749e-09
age O 0 2.3236286494920932e-07
. O 0 1.3450198821374215e-07

Clinical O 0 4.168222949374467e-05
recognition O 0 1.697147354207118e-06
of O 0 2.6747491574496962e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 4.549809091258794e-06
important O 0 3.537354018590122e-07
because O 0 6.921647610624859e-08
it O 0 2.28758185727429e-08
is O 0 2.6639311201392957e-08
one O 0 9.836866876611339e-10
of O 0 2.7177390893307063e-10
the O 0 5.2065067812634425e-09
few O 0 9.497037467554037e-08
directly O 0 2.5789393021113938e-06
treatable O 0 0.17975804209709167
causes O 0 1.9541684537216497e-07
of O 0 3.2545239037062856e-07
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 6.421086595764791e-07
children O 0 2.869194588583923e-07
. O 0 1.896443002635806e-08
. O 0 1.6868382601842313e-07

Cloning O 0 1.8694183381740004e-05
of O 0 3.9867952494887504e-08
a O 0 1.5992016244581464e-07
novel O 0 7.232065968310053e-08
member O 0 3.8654519585179514e-09
of O 0 5.089583199335834e-10
the O 0 1.8123402778513764e-09
low O 0 5.972014696453698e-05
- O 0 2.9033890314167365e-05
density O 0 4.8527541366638616e-05
lipoprotein O 0 0.3595241606235504
receptor O 0 1.694515231065452e-05
family O 0 2.5022175123012858e-06
. O 0 5.169343921807013e-07

A O 0 3.198533477188903e-06
gene O 0 1.7029726677719736e-06
encoding O 0 7.492283202736871e-07
a O 0 7.850541123843868e-07
novel O 0 7.478163297491847e-07
transmembrane O 0 4.372201146907173e-06
protein O 0 5.245208853921213e-07
was O 0 5.056278041593032e-06
identified O 0 2.5364587941112404e-07
by O 0 1.8093905262972498e-09
DNA O 0 5.8908877775820656e-08
sequence O 0 4.373494011389312e-09
analysis O 0 2.5443744888775655e-09
within O 0 1.2791989689731054e-09
the O 0 1.5820543763922501e-09
insulin B-Disease 0 0.00016661957488395274
- I-Disease 1 0.9901055693626404
dependent I-Disease 1 0.99978107213974
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.1924328646273352e-05
IDDM B-Disease 0 0.03172856941819191
) O 0 4.822974020157744e-08
locus O 0 3.184396064170869e-06
IDDM4 O 0 0.0004150915483478457
on O 0 5.844458996762114e-07
chromosome O 0 0.00014629453653469682
11q13 O 0 0.00010574148473097011
. O 0 1.0231468650090392e-06

Based O 0 1.3958518820800236e-06
on O 0 1.3814499766340305e-07
its O 0 2.695008660680287e-08
chromosomal O 0 0.00784794706851244
position O 0 9.842851795838214e-06
, O 0 9.545559898072042e-09
this O 0 7.922679179372949e-10
gene O 0 9.245860610462842e-08
is O 0 3.271351900480113e-08
a O 0 3.544563043078597e-08
candidate O 0 4.6592671054668244e-08
for O 0 4.9378625632812145e-09
conferring O 0 6.064879585210292e-07
susceptibility O 0 0.00010530539293540642
to O 0 8.426118256465998e-06
diabetes B-Disease 1 0.9895411133766174
. O 0 4.0449572225043084e-06

The O 0 1.6206824682285514e-07
gene O 0 4.604546006703458e-07
, O 0 9.982274562503335e-09
termed O 0 9.212131431013404e-07
low O 0 1.5694757166784257e-05
- O 0 1.2327460353844799e-05
density O 0 7.773497054586187e-05
lipoprotein O 0 0.08313148468732834
receptor O 0 9.8962084393861e-07
related O 0 4.969735414306342e-07
protein O 0 1.6170884009625297e-07
5 O 0 1.1205106176248592e-08
( O 0 2.9068365492435078e-09
LRP5 O 0 3.328001912450418e-05
) O 0 2.797002629506551e-09
, O 0 4.76919836955858e-10
encodes O 0 1.1598556559633266e-09
a O 0 3.1770392983077045e-09
protein O 0 5.724023477426954e-09
of O 0 1.2000013205337723e-09
1615 O 0 7.004733106441563e-06
amino O 0 1.2772103374913968e-08
acids O 0 1.7522837625350007e-09
that O 0 8.860008837707767e-10
contains O 0 2.351909778042227e-09
conserved O 0 7.603854434989898e-09
modules O 0 2.476378213600583e-08
which O 0 2.072994220725377e-08
are O 0 8.343648549846705e-10
characteristic O 0 5.5962923184438296e-09
of O 0 2.2778355590613586e-10
the O 0 3.636447365451545e-09
low O 0 2.431929715385195e-05
- O 0 5.157557097845711e-05
density O 0 0.0008460116805508733
lipoprotein O 1 0.9414951801300049
( O 0 2.6258845764459693e-07
LDL O 0 0.001201098202727735
) O 0 4.397922381826902e-08
receptor O 0 7.732782592029253e-07
family O 0 7.023248826953932e-07
. O 0 3.745826688827947e-07

These O 0 1.6746403730394377e-07
modules O 0 6.512066761388269e-07
include O 0 3.6944477699307754e-08
a O 0 3.1228200469968215e-08
putative O 0 1.3154425460015773e-06
signal O 0 2.700591949178488e-06
peptide O 0 2.0640579023734063e-08
for O 0 3.810307902529786e-10
protein O 0 3.7252261275710907e-09
export O 0 3.023123440470954e-08
, O 0 5.702237571014734e-10
four O 0 5.362051913593291e-10
epidermal O 0 4.5800030079590215e-07
growth O 0 4.253029715073353e-07
factor O 0 1.9217870317334018e-07
( O 0 6.231681837221004e-09
EGF O 0 2.161227030228474e-06
) O 0 3.346712240670513e-09
repeats O 0 2.184184069164985e-07
with O 0 1.7208130032031477e-08
associated O 0 2.787665778214432e-07
spacer O 0 3.613652370404452e-05
domains O 0 1.8925748008769006e-06
, O 0 2.54797427601261e-08
three O 0 1.767126356355675e-08
LDL O 0 0.00015626908862031996
- O 0 3.387411197763868e-05
receptor O 0 4.0878140339373203e-07
( O 0 2.495642359434669e-09
LDLR O 0 4.1560447243682574e-06
) O 0 1.7032572019459735e-09
repeats O 0 6.562590471048679e-08
, O 0 3.921631464010034e-09
a O 0 1.0799898753077741e-08
single O 0 3.11569891664476e-07
transmembrane O 0 3.8124787238302815e-07
spanning O 0 1.534393305746562e-07
domain O 0 4.147818515320978e-07
, O 0 3.0943837714403344e-08
and O 0 1.6066653785173912e-08
a O 0 1.363840738122235e-07
cytoplasmic O 0 5.4455690587928984e-06
domain O 0 1.2271849527678569e-06
. O 0 3.7010110531809914e-07

The O 0 2.5786587798393157e-07
encoded O 0 4.992351705368492e-07
protein O 0 4.511452402766736e-07
has O 0 4.7271814906935106e-08
a O 0 7.378094135646052e-09
unique O 0 1.0115674520250195e-08
organization O 0 5.6000186710036814e-09
of O 0 1.1114000830758641e-09
EGF O 0 7.458003892679699e-06
and O 0 1.507800959643646e-07
LDLR O 0 7.507568807341158e-05
repeats O 0 2.8603619739442365e-07
; O 0 4.673781361930196e-09
therefore O 0 2.30306671511471e-08
, O 0 3.905991974306744e-09
LRP5 O 0 1.085135772882495e-05
likely O 0 9.301383130377872e-08
represents O 0 6.854745659978789e-09
a O 0 2.8629496551246802e-09
new O 0 7.874669805119083e-09
category O 0 9.606457496147414e-08
of O 0 1.0861971322384534e-09
the O 0 4.260791541810249e-08
LDLR O 0 0.0024844547733664513
family O 0 2.953661351057235e-06
. O 0 4.0041786064648477e-07

Both O 0 6.96169820457726e-07
human O 0 1.3165252710223285e-07
and O 0 3.420979410861946e-08
mouse O 0 9.926352504407987e-06
LRP5 O 0 0.00012163972860435024
cDNAs O 0 5.563181730394717e-06
have O 0 3.766545475514249e-08
been O 0 9.210710771867525e-08
isolated O 0 2.064109139610082e-05
and O 0 1.7119543116450586e-08
the O 0 6.625191506515193e-10
encoded O 0 1.3343550264721671e-08
mature O 0 8.64925997490218e-09
proteins O 0 4.595442637533864e-10
are O 0 4.09374700804932e-10
95 O 0 3.315649088619921e-09
% O 0 8.023733344408868e-10
identical O 0 3.753185637833667e-07
, O 0 1.3151117528309442e-08
indicating O 0 5.91785919823451e-07
a O 0 5.121939850027957e-08
high O 0 5.194735308577947e-07
degree O 0 2.157007239489417e-09
of O 0 1.9903513559516028e-10
evolutionary O 0 1.6714038153509136e-08
conservation O 0 1.028415255177606e-07
. O 0 8.773124449135139e-09
. O 0 1.4739435982846771e-07

The O 0 5.221636456553824e-07
APC B-Disease 0 4.008483301731758e-06
variants O 0 5.761783086200012e-07
I1307K O 0 1.731356633172254e-06
and O 0 3.7474698899586656e-08
E1317Q O 0 1.0305266187060624e-06
are O 0 2.1883451495341433e-08
associated O 0 5.953980689810123e-06
with O 1 0.8324829936027527
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.00011221944441786036
but O 0 3.7629735061273095e-07
not O 0 1.9028495046313765e-07
always O 0 1.4247827095914545e-07
with O 0 4.890239768684523e-09
a O 0 2.86409317595826e-07
family O 0 1.2624911960301688e-06
history O 0 4.525552128598065e-07
. O 0 7.651298119526473e-07

Classical O 0 0.20249365270137787
familial B-Disease 1 0.9999971389770508
adenomatous I-Disease 1 0.999983549118042
polyposis I-Disease 1 0.999998927116394
( O 0 2.8541395295178518e-05
FAP B-Disease 0 4.572861143969931e-05
) O 0 4.989776059005635e-08
is O 0 8.854814126380006e-08
a O 0 2.822541489422292e-07
high O 0 0.004731888882815838
- O 1 0.999393105506897
penetrance O 1 0.9980545043945312
autosomal B-Disease 1 0.9996392726898193
dominant I-Disease 1 0.968982458114624
disease I-Disease 0 0.07812825590372086
that O 0 3.66333487988868e-08
predisposes O 0 3.759751962206792e-06
to O 0 2.2447355974009042e-08
hundreds O 0 2.1697999841308047e-08
or O 0 2.768248741347179e-08
thousands O 0 2.5023261684964382e-08
of O 0 7.960272341733798e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9963894486427307
carcinoma I-Disease 1 1.0
and O 0 0.0004093660681974143
that O 0 1.7241286798252986e-07
results O 0 1.0617895185305315e-07
from O 0 5.35102095966522e-09
truncating O 0 3.4595996112329885e-06
mutations O 0 1.048794501912198e-06
in O 0 1.0232786173958175e-08
the O 0 2.2603527938258594e-08
APC B-Disease 0 2.308215471202857e-06
gene O 0 7.380164674941625e-07
. O 0 5.418830255621288e-07

A O 0 3.7496545246540336e-06
variant O 0 1.7007838323479518e-05
of O 0 1.378816136821115e-07
FAP B-Disease 0 0.0006360504776239395
is O 0 5.832218084833585e-05
attenuated B-Disease 1 0.9971585273742676
adenomatous I-Disease 1 0.999997615814209
polyposis I-Disease 1 0.999987006187439
coli I-Disease 1 0.9999957084655762
, O 0 2.5474359972577076e-06
which O 0 5.374953389036818e-07
results O 0 1.350478555650625e-07
from O 0 1.7841413679775542e-08
germ O 0 0.01756053790450096
- O 0 0.007100789807736874
line O 0 0.0006864438764750957
mutations O 0 2.1060193944322236e-07
in O 0 4.9511790223277785e-09
the O 0 1.4039555074063514e-09
5 O 0 7.482398700631165e-09
and O 0 1.563736873322341e-08
3 O 0 4.4245833663580925e-09
regions O 0 2.439468183013105e-09
of O 0 5.47381917570533e-10
the O 0 1.0626988178330521e-08
APC B-Disease 0 2.082209448417416e-06
gene O 0 4.6388188934542995e-07
. O 0 2.898534319228929e-07

Attenuated B-Disease 1 0.999018669128418
adenomatous I-Disease 1 0.9999918937683105
polyposis I-Disease 1 0.9999874830245972
coli I-Disease 1 0.9999959468841553
patients O 0 0.020631011575460434
have O 0 1.7056431715900544e-06
" O 0 4.7720427573949564e-06
multiple O 0 6.789159670006484e-05
" O 1 0.9953848719596863
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999996423721313
( O 0 2.362734079497386e-07
typically O 0 7.98010475477895e-08
fewer O 0 4.071851300579965e-09
than O 0 4.486714555440585e-09
100 O 0 9.071558615403319e-09
) O 0 8.284483654641406e-10
without O 0 1.1649461395535354e-09
the O 0 3.3990845693665506e-09
florid O 0 4.1073111788136885e-05
phenotype O 0 4.2833298152800126e-07
of O 0 5.6708300277819035e-09
classical O 0 1.4514121176034678e-06
FAP B-Disease 0 2.261279587401077e-05
. O 0 3.452522605584818e-07

Another O 0 9.410914572072215e-07
group O 0 8.051716804402531e-07
of O 0 2.4895486561149482e-08
patients O 0 3.648712265658105e-07
with O 0 2.250265573877641e-08
multiple O 0 4.496514520724304e-06
adenomas B-Disease 1 0.5864442586898804
has O 0 3.0684168450534344e-05
no O 0 4.155990893650596e-07
mutations O 0 1.8019014191850147e-07
in O 0 6.5969114615427316e-09
the O 0 4.879124659851186e-09
APC B-Disease 0 2.853792580026493e-07
gene O 0 4.11223588514531e-08
, O 0 5.560859772657523e-09
and O 0 4.973888678705407e-08
their O 0 3.3175913127792e-09
phenotype O 0 3.700202739764791e-07
probably O 0 5.117516366226482e-07
results O 0 5.938831648677478e-09
from O 0 7.410231317450666e-10
variation O 0 8.539848863620136e-07
at O 0 9.772755902304198e-07
a O 0 1.4060015018912964e-07
locus O 0 2.634438260429306e-06
, O 0 4.662600616711643e-08
or O 0 2.344851779412238e-08
loci O 0 1.3536939569291917e-08
, O 0 3.2954858841804935e-09
elsewhere O 0 1.5348376791735063e-08
in O 0 2.5032560468929432e-09
the O 0 7.298342374895128e-09
genome O 0 6.888930670356785e-07
. O 0 4.95886524731759e-07

Recently O 0 2.3558681277791038e-05
, O 0 4.8777966554780505e-08
however O 0 1.5749016313293396e-08
, O 0 4.56050930353058e-09
a O 0 1.8828876235943426e-08
missense O 0 1.8734552213572897e-05
variant O 0 2.086701715597883e-05
of O 0 5.548350756612308e-08
APC B-Disease 0 1.5186667042144109e-05
( O 0 1.2895350565145236e-08
I1307K O 0 5.778043146165146e-07
) O 0 7.591579809229643e-09
was O 0 6.925443472027837e-07
described O 0 5.368493702917476e-07
that O 0 1.177748387704014e-08
confers O 0 7.970734827722481e-08
an O 0 7.739862972755418e-09
increased O 0 8.185177193809068e-07
risk O 0 0.00012530585809145123
of O 0 0.061799678951501846
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.796585588133894e-05
including O 0 8.870752594702935e-07
multiple O 0 5.337091351975687e-06
adenomas B-Disease 0 0.013961460441350937
, O 0 1.4940653159101203e-07
in O 0 7.933044798846822e-08
Ashkenazim O 0 0.0011104752775281668
. O 0 6.511185119961738e-07

We O 0 1.0869707693927921e-06
have O 0 7.146307989813749e-09
studied O 0 7.470106311302516e-09
a O 0 5.949693182571991e-09
set O 0 2.3357635825504985e-08
of O 0 2.290339917720985e-09
164 O 0 7.70011047279695e-06
patients O 0 4.075855599694478e-07
with O 0 1.6225319541263161e-06
multiple O 1 0.9964008331298828
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 0 0.1477603167295456
/ I-Disease 1 0.9962906837463379
or I-Disease 0 0.4396634101867676
carcinoma I-Disease 1 1.0
and O 0 5.20701905770693e-06
analyzed O 0 1.3175003914511763e-06
codons O 0 6.25970301371126e-07
1263 O 0 3.841175930574536e-05
- O 0 0.00013265505549497902
1377 O 0 7.869712135288864e-05
( O 0 2.4669404297128494e-08
exon O 0 3.7581713741019485e-07
15G O 0 1.97542749447166e-06
) O 0 1.881985456364532e-09
of O 0 6.051065759571372e-10
the O 0 2.4480351079603224e-09
APC B-Disease 0 3.15460340516438e-07
gene O 0 4.217984539423014e-08
for O 0 2.3321620190586145e-08
germ O 0 0.005649183876812458
- O 0 0.0010189779568463564
line O 0 0.0001473804732086137
variants O 0 3.939810085284989e-06
. O 0 4.7468512320847367e-07

Three O 0 2.490542556188302e-06
patients O 0 1.299778773500293e-06
with O 0 6.7139751536160475e-09
the O 0 2.252819486514568e-09
I1307K O 0 6.355926984724647e-07
allele O 0 1.5612759796113096e-07
were O 0 1.0954441620469879e-07
detected O 0 4.007687948615057e-06
, O 0 4.820773114033727e-09
each O 0 8.870492673729302e-10
of O 0 9.087335328672452e-09
Ashkenazi O 0 6.17282566963695e-05
descent O 0 7.787965296301991e-05
. O 0 8.46092348183447e-07

Four O 0 4.972057013219455e-06
patients O 0 9.629159649193753e-06
had O 0 5.96798372498597e-07
a O 0 6.814668154220271e-07
germ O 0 0.1707713007926941
- O 0 0.012678640894591808
line O 0 0.0004331996897235513
E1317Q O 0 6.3138700170384254e-06
missense O 0 4.286102921469137e-06
variant O 0 2.057595793303335e-06
of O 0 6.6352110472678305e-09
APC O 0 9.222838457390026e-07
that O 0 2.6404084252362736e-08
was O 0 2.1744085643149447e-06
not O 0 3.930184888645272e-08
present O 0 1.3035442059106117e-08
in O 0 5.929980506635957e-09
controls O 0 8.997069016913883e-06
; O 0 1.7405120678049002e-09
one O 0 1.3023705447423595e-09
of O 0 5.148271808863569e-10
these O 0 5.148539372612504e-09
individuals O 0 5.994527985109244e-09
had O 0 2.665024396719673e-07
an O 0 5.817768933269463e-09
unusually O 0 1.2575644632306648e-06
large O 0 6.527598372940702e-08
number O 0 6.578842803861562e-09
of O 0 5.7467004488387374e-09
metaplastic B-Disease 0 0.0005936464876867831
polyps I-Disease 0 1.4860444935038686e-05
of I-Disease 0 1.0282089846214149e-08
the I-Disease 0 1.1012051004399837e-07
colorectum I-Disease 0 0.0003518451994750649
. O 0 1.0580732805465232e-06

There O 0 9.21395042041695e-07
is O 0 1.5642918071989698e-08
increasing O 0 8.434327902762107e-09
evidence O 0 1.0280304607590551e-08
that O 0 2.038839097551204e-09
there O 0 1.5427149335778267e-08
exist O 0 6.245034711582775e-08
germ O 0 0.0003022596356458962
- O 0 0.0004547466232907027
line O 0 2.286154449393507e-05
variants O 0 6.323435997046545e-08
of O 0 2.0447663562350726e-09
the O 0 7.742447571956745e-09
APC B-Disease 0 1.3695782286049507e-07
gene O 0 1.0638182779132421e-08
that O 0 1.1059443361105536e-09
predispose O 0 4.309816148406753e-08
to O 0 2.825657929861336e-09
the O 0 8.075982105282264e-10
development O 0 3.370653445244898e-08
of O 0 2.3530780879355007e-07
multiple O 1 0.9985195994377136
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9978792667388916
carcinoma I-Disease 1 1.0
, O 0 4.2922303691739216e-05
but O 0 4.06831389909712e-07
without O 0 2.318130221112824e-08
the O 0 1.6124216628554677e-08
florid O 0 8.16230894997716e-05
phenotype O 0 1.0210287655354477e-06
of O 0 5.8102287425754184e-09
classical O 0 2.3511512381446664e-07
FAP B-Disease 0 2.5519855171296513e-06
, O 0 2.9811232593601744e-08
and O 0 3.815822768871158e-09
possibly O 0 4.093368133339936e-08
with O 0 6.763859250469295e-09
importance O 0 1.2763136965077138e-06
for O 1 0.6095470190048218
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0004348356742411852
in O 0 1.0358997215575982e-08
the O 0 3.8664915713582104e-09
general O 0 2.067686999396301e-08
population O 0 2.8230196846834588e-08
. O 0 1.5959969346113212e-08
. O 0 2.0031200165249174e-07

Genomic O 0 9.487327588431071e-06
structure O 0 1.8062247590933111e-06
of O 0 1.2402969318259238e-08
the O 0 2.824970692927309e-07
human O 0 0.042032625526189804
congenital B-Disease 1 1.0
chloride I-Disease 1 0.999998927116394
diarrhea I-Disease 1 1.0
( O 0 6.0220827435841784e-05
CLD B-Disease 0 0.1264629364013672
) O 0 2.3144330896229803e-07
gene O 0 2.220583382950281e-06
. O 0 1.1017551742042997e-06

Congenital B-Disease 1 0.9999998807907104
chloride I-Disease 1 0.999997615814209
diarrhea I-Disease 1 1.0
( O 0 0.00023743642668705434
CLD B-Disease 1 0.8810868859291077
) O 0 7.619150323989743e-07
is O 0 2.821370799210854e-07
caused O 0 3.668425563319033e-07
by O 0 7.144249636326094e-09
mutations O 0 3.4583683827804634e-07
in O 0 3.467421461067488e-09
a O 0 4.0801719336514e-08
gene O 0 3.919338098512526e-07
which O 0 1.3179787572425994e-07
encodes O 0 8.670915576658444e-07
an O 0 2.9427133085846435e-06
intestinal O 1 0.8282034993171692
anion O 0 0.0014967430615797639
transporter O 0 0.010371606796979904
. O 0 1.4626618849433726e-06

We O 0 2.8045958515576785e-06
report O 0 4.0705174342292594e-08
here O 0 4.193484226533428e-09
the O 0 1.7696542842227103e-10
complete O 0 4.888868865293716e-09
genomic O 0 3.84462310876188e-08
organization O 0 4.876919756924281e-09
of O 0 4.687519261636908e-10
the O 0 6.0183800165702905e-09
human O 0 4.178547641231489e-08
CLD B-Disease 0 1.8774580894387327e-05
gene O 0 9.989630456175291e-08
which O 0 2.1706899389073442e-08
spans O 0 3.8009667946425907e-07
approximately O 0 8.631892711719047e-08
39kb O 0 1.8937191271106713e-05
, O 0 1.541150496109367e-08
and O 0 1.4410051818458669e-08
comprises O 0 7.065141716111611e-08
21 O 0 1.0086393587016573e-07
exons O 0 1.6686826711520553e-06
. O 0 3.0867212785778975e-07

All O 0 2.326440409206043e-07
exon O 0 6.438601758418372e-06
/ O 0 6.345184374367818e-05
intron O 0 0.00010542896779952571
boundaries O 0 2.7033806304643804e-07
conform O 0 1.693025382110136e-07
to O 0 9.407145284967555e-09
the O 0 1.1260983256988766e-08
GT O 0 3.133400605292991e-05
/ O 0 0.0017520188121125102
AG O 1 0.8518056273460388
rule O 0 3.0473217975668376e-06
. O 0 1.1055547020077938e-06

An O 0 1.0537195294091362e-07
analysis O 0 4.887696647415396e-08
of O 0 3.492324873732855e-09
the O 0 1.567385865541837e-08
putative O 0 3.6368694509292254e-06
promoter O 0 0.0004193439963273704
region O 0 3.6072628972760867e-07
sequence O 0 1.0170815301080438e-07
shows O 0 4.527836097167892e-07
a O 0 1.7852347866664786e-07
putative O 0 1.7173558717331616e-06
TATA O 0 0.0006453942623920739
box O 0 1.4919290151738096e-05
and O 0 9.9450112145405e-08
predicts O 0 1.9688748125190614e-06
multiple O 0 2.3847917418606812e-08
transcription O 0 2.7917923262066324e-07
factor O 0 1.0702600405920748e-07
binding O 0 5.723894673792529e-07
sites O 0 3.605306574172573e-06
. O 0 7.733903544249188e-07

The O 0 4.418640031644827e-08
genomic O 0 1.8119304456831742e-07
structure O 0 2.6721451718003664e-07
was O 0 2.0627362573577557e-07
determined O 0 5.625307508694277e-08
using O 0 2.157954881454316e-08
DNA O 0 3.227263505323208e-07
from O 0 8.027774556218503e-10
several O 0 2.84827494922979e-10
sources O 0 9.894806085597452e-10
including O 0 8.140410012735799e-10
multiple O 0 2.090229500595342e-08
large O 0 2.4546835675209877e-07
- O 0 0.0019715866073966026
insert O 0 2.9759628887404688e-05
libaries O 0 2.5577779524610378e-05
and O 0 8.068365531244126e-09
genomic O 0 5.8491711030228544e-08
DNA O 0 1.1735605767171364e-06
from O 0 3.887850752448685e-08
Finnish O 0 0.0006368166650645435
CLD B-Disease 0 0.05559016764163971
patients O 0 1.935118234541733e-06
and O 0 2.9483258501272758e-08
controls O 0 8.109513146337122e-06
. O 0 9.548235766487778e-07

Exon O 0 5.9525864344323054e-05
- O 0 0.00012524194607976824
specific O 0 1.2379433655951289e-07
primers O 0 2.852355464710854e-06
developed O 0 2.3350513345121726e-07
in O 0 8.629513770230801e-10
this O 0 4.2459899485258745e-10
study O 0 5.720233176020884e-10
will O 0 5.042083972561784e-10
facilitate O 0 4.254487873112112e-09
mutation O 0 3.913337209837664e-09
screening O 0 3.8718197536979915e-09
studies O 0 1.0391130178533103e-09
of O 0 3.148733940250281e-09
patients O 0 1.110178544649898e-07
with O 0 2.0198699601792214e-08
the O 0 2.7519611194293248e-06
disease O 0 0.002224641852080822
. O 0 4.924340828438289e-07

Genomic O 0 3.301350034234929e-06
sequencing O 0 3.835651227745984e-07
of O 0 2.034656176874705e-08
a O 0 2.431095253996318e-07
BAC O 0 0.00013655306247528642
clone O 0 0.005080095026642084
H O 1 0.9999992847442627
_ O 0 1.8921367939128686e-07
RG364P16 O 0 4.23514791236812e-07
revealed O 0 1.0356610857797932e-07
the O 0 1.102137159314509e-09
presence O 0 1.0499233482619275e-08
of O 0 7.474563745724083e-10
another O 0 1.482933384977514e-07
, O 0 1.0569316089004133e-08
highly O 0 8.232208692504628e-09
homologous O 0 3.943009119211638e-08
gene O 0 5.406215564107697e-08
3 O 0 9.352793206574006e-09
of O 0 1.2220505718474328e-09
the O 0 3.068359433200385e-08
CLD B-Disease 0 7.408583769574761e-05
gene O 0 3.3913872243829246e-07
, O 0 4.2956429524565465e-08
with O 0 1.2014494288337119e-08
a O 0 6.076771086327426e-08
similar O 0 1.9815731278072235e-08
genomic O 0 2.6925015106371575e-08
structure O 0 1.6653315242365352e-06
, O 0 7.049981487483592e-09
recently O 0 7.938690771425172e-08
identified O 0 1.9890561020474706e-07
as O 0 6.583728406894807e-08
the O 0 2.4337881768587977e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.255105755466502e-05
( O 0 1.4940226833459747e-07
PDS B-Disease 0 6.645232497248799e-05
) O 0 8.960589603645985e-09
. O 0 1.7372691729633516e-08
. O 0 1.9018008856619417e-07

The O 0 7.242915671668015e-07
APCI1307K O 0 0.0003601324278861284
allele O 0 1.3021376616961788e-05
and O 0 5.036821221438004e-06
cancer B-Disease 0 0.00032571551855653524
risk O 0 8.971141483016254e-07
in O 0 5.357045917975256e-09
a O 0 1.6094357135898463e-07
community O 0 4.3531233728799634e-08
- O 0 3.373874505996355e-06
based O 0 3.841486062583499e-08
study O 0 6.635008098498929e-09
of O 0 1.1127624155449212e-08
Ashkenazi O 0 1.534064176667016e-05
Jews O 0 4.867044367529161e-07
. O 0 2.895683053338871e-07

Mutations O 0 0.0002403076650807634
in O 0 3.364827989571495e-07
APC O 0 7.691281098232139e-06
are O 0 8.639766235774005e-08
classically O 0 0.0007255790987983346
associated O 0 4.1208582842955366e-05
with O 0 0.005652029532939196
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.999997615814209
polyposis I-Disease 1 0.9999998807907104
( O 0 1.0107120033353567e-05
FAP B-Disease 0 2.7244344892096706e-05
) O 0 1.583800290916315e-08
, O 0 7.431650850264759e-09
a O 0 3.128889716208505e-07
highly O 0 0.0009624358499422669
penetrant O 1 0.9998027682304382
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999990463256836
disorder I-Disease 1 1.0
characterized O 1 0.6790140867233276
by O 0 1.0929853488050867e-05
multiple O 0 0.008300197310745716
intestinal O 1 0.9799304008483887
polyps B-Disease 0 0.21689477562904358
and O 0 4.363116659078514e-06
, O 0 6.776981820166839e-08
without O 0 1.511537917053829e-08
surgical O 0 8.264546522696037e-06
intervention O 0 1.3019395339597395e-07
, O 0 2.996330739080122e-09
the O 0 8.099182435827856e-10
development O 0 5.988302405057766e-07
of O 0 0.003453208366408944
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.2407164831529371e-05
CRC B-Disease 0 0.0010410507675260305
) O 0 2.2670306520922168e-07
. O 0 2.468195248184202e-07

APC B-Disease 0 0.0001696226536296308
is O 0 1.0908410104093491e-06
a O 0 1.6102200106615783e-06
tumour O 1 0.9999964237213135
- O 0 0.0008458512020297348
suppressor O 0 2.4491737349308096e-05
gene O 0 2.0984009552194038e-07
, O 0 6.9349126441409226e-09
and O 0 6.716728950806328e-09
somatic O 0 2.7413630050432403e-06
loss O 0 9.463192327530123e-06
occurs O 0 5.197193218009488e-07
in O 0 1.0838591606443515e-06
tumours B-Disease 1 0.9999929666519165
. O 0 4.0037302824202925e-06

The O 0 4.708379606199742e-07
germline O 0 0.00015834288205951452
T O 0 0.042080752551555634
- O 0 1.873394285212271e-05
to O 0 4.586288326891008e-08
- O 0 3.4437600788805867e-06
A O 0 1.4529284442232893e-07
transversion O 0 2.0263682927179616e-06
responsible O 0 6.28398737489988e-08
for O 0 8.402740170332379e-10
the O 0 2.1641075598211046e-09
APC O 0 1.0624661683777958e-07
I1307K O 0 4.310720314038008e-08
allele O 0 1.3315635705168916e-08
converts O 0 3.2682316852827853e-09
the O 0 7.873013352366343e-10
wild O 0 1.0980004105931584e-07
- O 0 1.4175835531204939e-05
type O 0 6.194726665853523e-06
sequence O 0 2.5707025841370523e-08
to O 0 8.343365998086938e-09
a O 0 8.317961146531161e-07
homopolymer O 1 0.9194128513336182
tract O 1 0.9949252605438232
( O 0 3.7024301491328515e-07
A8 O 0 0.4837941825389862
) O 0 2.975953528050468e-08
that O 0 1.1397593091544422e-08
is O 0 1.9653543859021738e-07
genetically O 0 6.625666173931677e-06
unstable O 0 0.41021981835365295
and O 0 3.2735104014136596e-06
prone O 0 0.0003001910517923534
to O 0 2.654795672185628e-08
somatic O 0 1.1172965059813578e-05
mutation O 0 8.948463801061735e-06
. O 0 1.2572802461363608e-06

The O 0 4.2319746285102156e-07
I1307K O 0 1.1163900126121007e-05
allele O 0 2.1905809717281954e-06
was O 0 6.3730493593539e-07
found O 0 4.734996394972768e-08
in O 0 8.489574376824294e-09
6 O 0 1.9825394304007204e-07
. O 0 1.6013810011372698e-07

1 O 0 1.981472678380669e-06
% O 0 3.128591075096665e-08
of O 0 6.309963218598114e-09
unselected O 0 6.504317570943385e-05
Ashkenazi O 0 3.566757732187398e-05
Jews O 0 1.1126476238132454e-06
and O 0 1.16706218022955e-07
higher O 0 1.0609777234549256e-07
proportions O 0 4.338534722592158e-07
of O 0 4.0281449287249416e-09
Ashkenazim O 0 9.514734119875357e-05
with O 0 7.677421649532334e-07
family O 0 2.9582695788121782e-05
or O 0 3.0694006909470772e-06
personal O 0 1.0103785825776868e-05
histories O 0 9.304191735282075e-06
of O 0 2.9148785074539774e-07
CRC B-Disease 0 0.016081606969237328
( O 0 8.814102869791896e-08
ref O 0 0.0001702489098533988
. O 0 1.1196304328109363e-08
2 O 0 4.295946354204716e-08
) O 0 4.016041188492636e-08
. O 0 7.41982688623466e-08

To O 0 3.2598791221971624e-07
evaluate O 0 5.318645435181679e-07
the O 0 2.929808395890632e-09
role O 0 3.755474597966213e-09
of O 0 4.167138578647922e-10
I1307K O 0 1.2790516166205634e-06
in O 0 3.970918882600927e-08
cancer B-Disease 0 2.430233735140064e-06
, O 0 5.364540811569896e-09
we O 0 2.5625272570550806e-08
genotyped O 0 1.8387079308013199e-06
5 O 0 1.2788703429578163e-08
, O 0 5.901996669166465e-09
081 O 0 1.2004595646430971e-06
Ashkenazi O 0 4.976479317519988e-07
volunteers O 0 5.3441460146075315e-09
in O 0 6.415039055518434e-10
a O 0 1.1031891844481834e-08
community O 0 2.976032931201189e-08
survey O 0 1.8171666624766658e-06
. O 0 4.899185910289816e-07

Risk O 0 4.646588786272332e-05
of O 0 7.230121212842278e-08
developing O 0 0.00014917904627509415
colorectal B-Disease 1 1.0
, I-Disease 0 0.0003932123654522002
breast I-Disease 0 0.15198664367198944
and I-Disease 0 1.2095426882297033e-06
other I-Disease 0 1.1965238400080125e-07
cancers I-Disease 0 0.0003068898804485798
were O 0 5.154860218681279e-07
compared O 0 3.5940016118729545e-07
between O 0 4.9629814924401217e-08
genotyped O 0 4.048616756335832e-05
I1307K O 0 1.8807359083439223e-06
carriers O 0 6.421263520905995e-08
and O 0 7.2633885572770396e-09
non O 0 1.77362394992997e-07
- O 0 3.495161945465952e-05
carriers O 0 1.9662242323192913e-07
and O 0 7.194297602097777e-09
their O 0 7.780844857308011e-10
first O 0 1.4938596137881177e-08
- O 0 9.594748007657472e-06
degree O 0 2.163610020033957e-07
relatives O 0 3.1377169307234e-07
. O 0 1.2603987897819025e-07

Sperm O 0 5.204285844229162e-05
DNA O 0 3.162481561957975e-06
analysis O 0 1.7199539570356137e-07
in O 0 2.581738911544562e-08
a O 0 2.444207211738103e-06
Friedreich B-Disease 1 0.9991673231124878
ataxia I-Disease 1 0.9999380111694336
premutation O 1 0.730086088180542
carrier O 0 0.0013233399949967861
suggests O 0 6.266560035328439e-07
both O 0 4.724583391180204e-09
meiotic O 0 4.585965598380426e-06
and O 0 3.401096648758539e-08
mitotic O 0 2.808605131576769e-06
expansion O 0 4.53136948408428e-07
in O 0 1.260347914922022e-08
the O 0 2.1497509550272298e-08
FRDA B-Disease 0 0.00015070041990838945
gene O 0 9.332408126283553e-07
. O 0 3.0385297122847987e-07

Friedreich B-Disease 1 0.9996294975280762
ataxia I-Disease 1 0.9999738931655884
is O 0 5.623550896416418e-05
usually O 0 2.8628555810428225e-06
caused O 0 1.339376694886596e-06
by O 0 4.396251362948078e-09
an O 0 2.182753977564289e-09
expansion O 0 1.31856452867396e-07
of O 0 2.750344307855812e-08
a O 0 2.0651389149861643e-06
GAA O 0 2.5002827896969393e-05
trinucleotide O 0 7.115841071936302e-06
repeat O 0 7.67415656355297e-07
in O 0 1.1667923516256451e-08
intron O 0 6.321370165096596e-05
1 O 0 3.671000570193428e-08
of O 0 2.5472732811948617e-09
the O 0 1.4895690014782303e-08
FRDA B-Disease 0 4.356379577075131e-05
gene O 0 5.772683948634949e-07
. O 0 3.297972170912544e-07

Occasionally O 0 7.273785013239831e-05
, O 0 5.111106915478558e-08
a O 0 1.629593349150582e-08
fully O 0 2.5329532249429576e-08
expanded O 0 4.2356809615284874e-08
allele O 0 2.2879926575569698e-07
has O 0 6.366166616089686e-08
been O 0 5.036629602273024e-08
found O 0 4.527723618252821e-08
to O 0 3.098374445897889e-09
arise O 0 1.2356500711518947e-08
from O 0 8.216329283605717e-10
a O 0 1.6550727011122035e-08
premutation O 0 1.2847033303842181e-06
of O 0 1.0844541931120943e-09
100 O 0 6.720088663314527e-08
or O 0 7.302940474573916e-08
less O 0 2.0569686398630438e-07
triplet O 0 0.0007641874835826457
repeats O 0 2.7305522962706164e-05
. O 0 1.023780328068824e-06

We O 0 2.747461394392303e-06
have O 0 1.863107002009201e-08
examined O 0 1.0460141197654593e-07
the O 0 1.0145909667969022e-09
sperm O 0 9.944119483407121e-08
DNA O 0 1.3155212741366995e-07
of O 0 3.3663087872781716e-09
a O 0 6.754231094419083e-07
premutation O 0 0.0015397591050714254
carrier O 0 0.00012028067430946976
. O 0 5.727411576117447e-07

This O 0 2.497844491244905e-07
mans O 0 1.320141655014595e-05
leucocyte O 0 6.75613118801266e-05
DNA O 0 1.4150441529636737e-05
showed O 0 1.0556864253885578e-06
one O 0 1.0207114264915162e-08
normal O 0 5.573275529968669e-08
allele O 0 9.768145758926039e-08
and O 0 2.7379972067365088e-08
one O 0 2.2096169338681193e-09
allele O 0 1.1654400999816517e-08
of O 0 7.408831881328126e-10
approximately O 0 4.276684961723731e-08
100 O 0 6.073896940961276e-08
repeats O 0 2.4670873699506046e-06
. O 0 3.487554351977451e-07

His O 0 5.280444383970462e-06
sperm O 0 7.477331564587075e-06
showed O 0 2.2458034436567686e-06
an O 0 3.610791887709297e-09
expanded O 0 4.388554231127273e-08
allele O 0 1.36112504378616e-07
in O 0 8.542820673085316e-09
a O 0 3.0675934681312356e-07
tight O 0 1.0946941074507777e-05
range O 0 1.6312825437125866e-06
centering O 0 1.7612150315926556e-07
on O 0 5.714437989468024e-08
a O 0 7.570959859037885e-09
size O 0 7.321155237605126e-08
of O 0 1.6333330243867294e-09
approximately O 0 1.688086967988056e-07
320 O 0 7.948938787194493e-07
trinucleotide O 0 4.4351345422910526e-05
repeats O 0 9.51684978645062e-06
. O 0 9.361984893985209e-07

His O 0 3.2983980418066494e-06
affected O 0 1.5265368347172625e-05
son O 0 0.0003230272268410772
has O 0 1.685140347262859e-07
repeat O 0 2.0344782569736708e-07
sizes O 0 7.585590822145605e-08
of O 0 1.813031724751113e-09
1040 O 0 8.079416033979214e-07
and O 0 3.985608998391399e-08
540 O 0 1.577328248458798e-06
. O 0 2.13197253629005e-07

These O 0 1.568131153817376e-07
data O 0 1.3303657908636524e-07
suggest O 0 7.211322383682273e-08
that O 0 2.11947104311605e-09
expansion O 0 5.8361770527426415e-08
occurs O 0 1.0151276264025455e-08
in O 0 1.226789003716533e-09
two O 0 1.0879077638747958e-09
stages O 0 1.1281653087280574e-06
, O 0 1.5895016858280542e-08
the O 0 3.098467593609655e-10
first O 0 4.043748447202233e-09
during O 0 1.2612136224277037e-08
meiosis O 0 3.515074453730449e-08
followed O 0 4.267279862801843e-09
by O 0 5.261610591666965e-10
a O 0 4.290785060589997e-09
second O 0 2.4243249185929017e-08
mitotic O 0 2.6335681468481198e-05
expansion O 0 6.053592642274452e-06
. O 0 7.053043873384013e-07

We O 0 2.9068546609778423e-06
also O 0 6.603195856769162e-08
show O 0 9.240007869948386e-08
that O 0 1.8475496688097337e-09
in O 0 9.976520720655913e-10
all O 0 7.559498582665469e-10
informative O 0 1.3186304386181291e-06
carrier O 0 5.98578935750993e-06
father O 0 5.900862376506666e-08
to O 0 3.2212528200403767e-09
affected O 0 1.3087027639357984e-07
child O 0 1.032670411404979e-06
transmissions O 0 1.1501121662149671e-05
, O 0 5.8643408351599646e-08
with O 0 1.3785329322502093e-08
the O 0 3.3366351903652003e-09
notable O 0 5.511266465418885e-08
exception O 0 2.0612135998021586e-08
of O 0 5.715151685237174e-10
the O 0 9.11698805339256e-09
premutation O 0 3.5764951462624595e-05
carrier O 0 2.3434042759618023e-06
, O 0 1.258411153060024e-09
the O 0 1.2570217089447056e-10
expansion O 0 1.8245986055376306e-08
size O 0 4.294840323382232e-07
decreases O 0 6.459233077293902e-07
. O 0 1.574805530424328e-08
. O 0 9.851182625197907e-08

The O 0 2.359698640930219e-07
R496H O 0 7.823672603990417e-06
mutation O 0 4.4617132743951515e-07
of O 0 7.752480435385678e-09
arylsulfatase O 0 0.0002078634570352733
A O 0 1.7073064100259217e-06
does O 0 4.48554914100896e-07
not O 0 4.123578207781975e-07
cause O 0 0.0001428513351129368
metachromatic B-Disease 1 0.9999885559082031
leukodystrophy I-Disease 1 0.999972939491272
. O 0 1.6203985069296323e-05

Deficiency B-Disease 1 0.9986893534660339
of I-Disease 0 2.2184191550422838e-07
arylsulfatase I-Disease 0 0.006170240230858326
A I-Disease 0 1.6873280401341617e-05
( O 0 7.147782810079661e-08
ARSA O 0 0.0234968438744545
) O 0 2.741393778649126e-08
enzyme O 0 1.4850833167656674e-06
activity O 0 4.3558975448831916e-05
causes O 0 0.0011477936059236526
metachromatic B-Disease 1 0.9999958276748657
leukodystrophy I-Disease 1 0.9999980926513672
( O 0 0.00020169760682620108
MLD B-Disease 1 0.9999711513519287
) O 0 2.0752711407112656e-06
. O 0 1.0992299621648272e-06

A O 0 3.60417902811605e-06
number O 0 7.051840356098182e-08
of O 0 2.6297081845427783e-08
ARSA O 0 0.07969412952661514
gene O 0 1.5324029618568602e-06
mutations O 0 7.108354793672333e-07
responsible O 0 1.4079593029237003e-06
for O 0 4.900354610981594e-07
MLD B-Disease 1 0.9999973773956299
have O 0 2.386180767643964e-06
been O 0 2.5345466383441817e-06
identified O 0 4.3565387386479415e-06
. O 0 4.6697431344000506e-07

Recently O 0 8.7512016762048e-05
, O 0 6.830642718114177e-08
the O 0 3.4203120335973836e-09
R496H O 0 4.1165918673868873e-07
mutation O 0 4.7421362836530534e-08
of O 0 5.4042743613536e-09
ARSA O 0 0.022374898195266724
was O 0 3.5571717944549164e-06
proposed O 0 5.046610951353614e-08
to O 0 8.926165584455248e-09
be O 0 5.13667330892531e-08
a O 0 1.2720687436740263e-07
cause O 0 8.217103300012241e-07
of O 0 2.2034235769297084e-07
MLD B-Disease 1 0.9999990463256836
( O 0 2.293793244234621e-07
Draghia O 0 3.265944906161167e-05
et O 0 5.308228992362274e-06
al O 0 1.5027929293864872e-05
. O 0 9.205894713204543e-09
, O 0 3.3012235167717563e-09
1997 O 0 1.3750377725330054e-08
) O 0 2.1623716150998007e-08
. O 0 9.920325538814723e-08

We O 0 1.4752951074115117e-06
have O 0 2.7966576610083393e-08
investigated O 0 6.928198814648567e-08
the O 0 1.3636599627275814e-09
R496H O 0 1.0952369393635308e-06
mutation O 0 1.1907525276910746e-07
and O 0 2.1973459496393843e-08
found O 0 5.65066429203398e-08
this O 0 1.4358902955535768e-09
mutation O 0 3.897346445569383e-08
at O 0 6.835816890315982e-08
a O 0 1.0426930430185166e-08
relatively O 0 3.471618725825465e-08
high O 0 3.2994751819614976e-08
frequency O 0 1.239176583567314e-07
in O 0 6.447696598854691e-09
an O 0 1.126858384381535e-09
African O 0 9.367892017664303e-10
American O 0 6.121039786144422e-10
population O 0 1.3405482279793546e-09
( O 0 4.038620826651851e-10
f O 0 2.73784621640516e-06
= O 0 2.805575434194907e-07
0 O 0 5.972774719253948e-09
. O 0 2.9639807275216867e-10
09 O 0 8.296773934546309e-09
, O 0 2.9696693992775636e-09
n O 0 1.6227037349381135e-06
= O 0 7.508878638873284e-07
61 O 0 3.809774185015158e-08
subjects O 0 8.472658663549737e-08
) O 0 3.7481488135426844e-08
. O 0 1.0843062625554012e-07

The O 0 1.1447745009718346e-06
ARSA O 0 0.0005180177395232022
enzyme O 0 4.1114364535133063e-07
activity O 0 5.248631396170822e-07
in O 0 1.5811855158531785e-09
subjects O 0 5.036860173390778e-08
with O 0 1.0053085475192347e-08
and O 0 1.5739159664462932e-07
without O 0 2.1406949546332044e-09
the O 0 1.9492736313964087e-09
R496H O 0 4.010438487966894e-07
mutation O 0 2.559415612779503e-08
was O 0 4.3467017007969844e-07
determined O 0 8.222810379265866e-07
and O 0 2.8142137509235e-08
found O 0 5.63028770272922e-08
to O 0 5.848052264667558e-09
be O 0 4.4293308576470736e-08
normal O 0 4.326205953475437e-07
. O 0 1.8549840774539916e-07

It O 0 1.2616005733434577e-06
is O 0 5.84401860237449e-08
therefore O 0 1.4602427711452037e-08
concluded O 0 2.9079471275395008e-08
that O 0 1.5813061970959552e-09
the O 0 9.320413330016208e-10
R496H O 0 4.5419173488880915e-07
mutation O 0 2.7606297692273074e-08
of O 0 4.4350265682169265e-09
ARSA O 0 0.04515884816646576
does O 0 1.273462260087399e-07
not O 0 2.6706958866640207e-09
negatively O 0 1.5655365004363375e-08
influence O 0 5.331216357262747e-09
the O 0 5.008326531275031e-10
activity O 0 1.517492052016678e-07
of O 0 2.840333968023856e-09
ARSA O 0 0.30465278029441833
and O 0 1.2806454208202922e-07
is O 0 1.2115809511215048e-07
not O 0 1.880543720744754e-08
a O 0 1.8778848698275397e-07
cause O 0 2.530081246732152e-06
of O 0 2.2872995941725094e-06
MLD B-Disease 1 0.9999878406524658

Down O 0 0.00019786585471592844
- O 0 1.0900145753112156e-05
regulation O 0 1.5543527354111575e-07
of O 0 2.1706528130494007e-08
transmembrane O 0 9.521270840195939e-06
carbonic O 0 8.371946933038998e-06
anhydrases O 0 0.0002153428504243493
in O 0 1.2271040759515017e-05
renal B-Disease 1 0.9999940395355225
cell I-Disease 1 0.999988317489624
carcinoma I-Disease 1 1.0
cell O 1 0.9783172011375427
lines O 0 0.0014223156031221151
by O 0 1.0633683444893904e-07
wild O 0 1.0286158612871077e-05
- O 0 0.031520262360572815
type O 0 0.43473514914512634
von B-Disease 1 0.999264657497406
Hippel I-Disease 1 0.9987691044807434
- I-Disease 1 0.6065776348114014
Lindau I-Disease 1 0.7141574621200562
transgenes O 0 0.0011597179109230638
. O 0 4.1700714064063504e-06

To O 0 4.5967797746016004e-07
discover O 0 9.422786888535484e-07
genes O 0 9.40072766297817e-08
involved O 0 1.000833975695059e-07
in O 0 9.162804559537108e-08
von B-Disease 1 0.9990183115005493
Hippel I-Disease 1 0.999886155128479
- I-Disease 1 0.9999091625213623
Lindau I-Disease 1 0.9998685121536255
( O 0 3.6457840906223282e-06
VHL B-Disease 0 0.00023461089585907757
) O 0 5.719890339150879e-08
- O 0 8.216529386118054e-05
mediated O 0 0.0002725919184740633
carcinogenesis O 0 0.00412326492369175
, O 0 5.046457118851322e-08
we O 0 9.880481144364239e-08
used O 0 0.00020946863514836878
renal B-Disease 1 0.9999932050704956
cell I-Disease 1 0.9999884366989136
carcinoma I-Disease 1 1.0
cell O 1 0.9859522581100464
lines O 0 0.08794013410806656
stably O 0 0.021832475438714027
transfected O 0 0.00027103934553451836
with O 0 2.5582940565982426e-07
wild O 0 1.581881588208489e-05
- O 0 0.007411365397274494
type O 0 0.12535451352596283
VHL O 0 0.0014132497599348426
- O 0 0.00010634862701408565
expressing O 0 1.7227690705112764e-06
transgenes O 0 8.27769108582288e-05
. O 0 1.2246806591065251e-06

Large O 0 9.04331318452023e-06
- O 0 5.9406665968708694e-05
scale O 0 2.579358078946825e-05
RNA O 0 3.286261573975935e-07
differential O 0 4.046420940539974e-07
display O 0 3.0487589697258954e-07
technology O 0 1.6173931527418972e-08
applied O 0 2.4996631431406513e-09
to O 0 9.411448287366397e-10
these O 0 2.7293820537011015e-09
cell O 0 4.332496246206574e-06
lines O 0 2.5519636892568087e-06
identified O 0 3.1880679784990207e-07
several O 0 1.4681230675606116e-09
differentially O 0 7.654801379430864e-07
expressed O 0 7.135874557917532e-09
genes O 0 3.562075789886876e-08
, O 0 4.7630286381661335e-09
including O 0 2.8962552356404103e-09
an O 0 3.975782369991521e-09
alpha O 0 3.3413115829716844e-08
carbonic O 0 3.360422056175594e-07
anhydrase O 0 7.462945177394431e-07
gene O 0 1.1395076882081412e-07
, O 0 1.0027654262501073e-08
termed O 0 4.589736818161327e-06
CA12 O 0 0.0007303052116185427
. O 0 7.886056891948101e-07

The O 0 3.072488539146434e-07
deduced O 0 1.0514534096728312e-06
protein O 0 1.0664739846788507e-07
sequence O 0 3.826159300501786e-08
was O 0 5.589861302723875e-07
classified O 0 5.987166105114738e-07
as O 0 1.5863943048088913e-08
a O 0 4.413291776472761e-07
one O 0 1.797838308448263e-06
- O 1 0.6557871103286743
pass O 0 1.226905169460224e-05
transmembrane O 0 1.1947868188144639e-05
CA O 0 9.045168553711846e-06
possessing O 0 3.147061136132834e-07
an O 0 1.0988756571350677e-08
apparently O 0 3.5784194096777355e-07
intact O 0 7.612738528450791e-08
catalytic O 0 1.8012794100741303e-07
domain O 0 1.238481956988835e-07
in O 0 6.905083171915294e-09
the O 0 1.015751216471017e-08
extracellular O 0 6.169692824187223e-06
CA O 0 6.805636803619564e-05
module O 0 1.79130001924932e-05
. O 0 5.226364123700478e-07

Reintroduced O 0 1.1173784514539875e-05
wild O 0 1.8929553334601223e-05
- O 0 0.00025468619423918426
type O 0 0.00016219761164393276
VHL B-Disease 0 3.9417467633029446e-05
strongly O 0 1.148504011894147e-07
inhibited O 0 1.1080081918635187e-07
the O 0 1.1905130214984183e-09
overexpression O 0 2.7925903367531646e-08
of O 0 8.663421091625878e-10
the O 0 5.515911727371758e-09
CA12 O 0 3.490957897156477e-05
gene O 0 6.219050163736028e-08
in O 0 4.583767143628847e-09
the O 0 1.1153169765520943e-07
parental O 0 0.11445131152868271
renal B-Disease 1 0.9999977350234985
cell I-Disease 1 0.9999921321868896
carcinoma I-Disease 1 1.0
cell O 1 0.9925873875617981
lines O 0 0.04199784994125366
. O 0 4.823171821044525e-06

Similar O 0 1.405958755640313e-06
results O 0 1.2208960242787725e-07
were O 0 4.2473470074355646e-08
obtained O 0 1.4387532054627172e-08
with O 0 2.1403041117196153e-08
CA9 O 0 0.001175818033516407
, O 0 1.3120251551868023e-08
encoding O 0 6.21007743006885e-08
another O 0 1.0528973461987334e-06
transmembrane O 0 3.3751512091839686e-05
CA O 0 5.9599416999844834e-05
with O 0 1.4025940409112536e-08
an O 0 1.4062424114058558e-08
intact O 0 4.359747435955796e-06
catalytic O 0 6.856487289041979e-06
domain O 0 1.8662992715690052e-06
. O 0 3.763206564144639e-07

Although O 0 1.659859663050156e-06
both O 0 1.7291501563931888e-08
domains O 0 5.443381567715733e-08
of O 0 2.8965976284212047e-09
the O 0 2.07976249555486e-08
VHL B-Disease 0 6.459667019953486e-06
protein O 0 5.036608019537425e-09
contribute O 0 1.9656714034255174e-09
to O 0 7.742960161927215e-10
regulation O 0 3.5157834421539746e-09
of O 0 2.111143482252942e-09
CA12 O 0 9.369450708618388e-05
expression O 0 1.255075687822682e-07
, O 0 4.803471842507179e-09
the O 0 7.628109255364279e-10
elongin O 0 2.1091016151331132e-06
binding O 0 4.308205348024785e-08
domain O 0 2.292833158890062e-07
alone O 0 1.763305732538356e-07
could O 0 1.4943953630108808e-08
effectively O 0 6.913862904411872e-08
regulate O 0 1.0410476534161717e-06
CA9 O 0 0.0008753517176955938
expression O 0 1.272645477001788e-06
. O 0 9.126557642957778e-07

We O 0 2.433445615679375e-06
mapped O 0 7.310055661946535e-05
CA12 O 0 0.001352444407530129
and O 0 3.497673617403052e-07
CA9 O 0 0.00015908654313534498
loci O 0 3.6693353422379005e-07
to O 0 1.4548688476168081e-08
chromosome O 0 3.5597033729573013e-06
bands O 0 6.107832177804084e-07
15q22 O 0 6.813818345108302e-06
and O 0 2.530293272684503e-07
17q21 O 0 1.540030280011706e-05
. O 0 5.04797810663149e-07

2 O 0 4.849724518862786e-06
respectively O 0 7.878095971136645e-07
, O 0 6.769178639842721e-08
regions O 0 1.5971851041740592e-07
prone O 0 0.00015782404807396233
to O 0 1.171120000975634e-08
amplification O 0 3.109405042778235e-06
in O 0 9.856159444154855e-09
some O 0 1.2505254609607164e-08
human O 0 9.120041113419575e-07
cancers B-Disease 0 0.0015128777595236897
. O 0 4.2205559225294564e-07

Additional O 0 3.0271166906459257e-07
experiments O 0 6.911950549692847e-07
are O 0 4.454848046009374e-09
needed O 0 1.6682819570235097e-09
to O 0 7.029032911276545e-10
define O 0 4.7158884797227074e-08
the O 0 1.1815458611508234e-09
role O 0 1.6660440138593913e-08
of O 0 3.4984983798835856e-09
CA O 0 0.0003968223463743925
IX O 0 8.907065057428554e-05
and O 0 3.3740225262590684e-06
CA O 0 0.00022703167633153498
XII O 0 4.017429819214158e-05
enzymes O 0 6.543130126601682e-08
in O 0 7.922755229650136e-10
the O 0 2.828525469400489e-10
regulation O 0 9.59334300887349e-09
of O 0 3.4032103801706626e-09
pH O 0 0.002980921883136034
in O 0 3.967041362074042e-09
the O 0 1.031351004598946e-09
extracellular O 0 5.916606582445638e-08
microenvironment O 0 3.711013278007158e-06
and O 0 1.0531926442070016e-08
its O 0 1.2674684635172184e-09
potential O 0 3.576179574693583e-09
impact O 0 1.957269546437601e-08
on O 0 1.491464445280144e-06
cancer B-Disease 0 1.8327225916436873e-05
cell O 0 7.944718163344078e-06
growth O 0 2.8431650207494386e-06
. O 0 4.099432260318281e-07

A O 0 3.2915354495344218e-06
gene O 0 2.728030722209951e-06
encoding O 0 8.746009712012892e-07
a O 0 4.145003060784802e-07
transmembrane O 0 4.450626875041053e-06
protein O 0 3.0162988196025253e-07
is O 0 1.7385520578727665e-08
mutated O 0 7.797744672188855e-08
in O 0 5.565478744529173e-08
patients O 0 7.1024846874934155e-06
with O 0 0.006738948170095682
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9984322190284729
optic B-Disease 1 0.9999998807907104
atrophy I-Disease 1 0.9999697208404541
( O 1 0.5051932334899902
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 1.9679587239807006e-06
. O 0 1.3212336398282787e-06

Wolfram B-Disease 1 0.999997615814209
syndrome I-Disease 1 1.0
( O 0 9.823589061852545e-05
WFS B-Disease 0 0.31461790204048157
; O 0 3.2759589885245077e-06
OMIM O 0 0.027050232514739037
222300 O 0 6.86419298290275e-05
) O 0 5.1003755885403734e-08
is O 0 6.143948212411487e-07
an O 0 1.8071034446620615e-06
autosomal B-Disease 1 0.999972939491272
recessive I-Disease 1 0.999997615814209
neurodegenerative I-Disease 1 0.9999990463256836
disorder I-Disease 1 0.9996825456619263
defined O 0 9.384187433170155e-05
by O 0 2.2621046014137391e-07
young O 0 3.276888378422882e-07
- O 0 0.00032323115738108754
onset O 0 0.0004914969904348254
non O 0 5.397792119765654e-05
- O 0 0.2185128629207611
immune O 0 0.00015113860717974603
insulin B-Disease 0 0.0009016486583277583
- I-Disease 1 0.9836785197257996
dependent I-Disease 1 0.999762237071991
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.032241933047771454
progressive O 1 0.9909182786941528
optic B-Disease 1 0.9999929666519165
atrophy I-Disease 1 0.8183962106704712
. O 0 9.387462341692299e-06

Linkage O 0 0.0003159018815495074
to O 0 4.0379399024459417e-07
markers O 0 3.4745840821415186e-05
on O 0 3.89329812833239e-07
chromosome O 0 0.00013044562365394086
4p O 0 0.22454631328582764
was O 0 3.67737484339159e-05
confirmed O 0 1.0036284265879658e-06
in O 0 1.0604088274135393e-08
five O 0 2.98886639882312e-08
families O 0 1.8700606574384437e-07
. O 0 2.828440130997478e-07

On O 0 9.34190040879912e-07
the O 0 5.486448628744256e-09
basis O 0 1.141495520329272e-08
of O 0 6.608695812815313e-10
meiotic O 0 0.00016711313219275326
recombinants O 1 0.5096295475959778
and O 0 4.326726411818527e-05
disease O 0 0.007017036434262991
- O 0 0.003308783285319805
associated O 0 1.2020350368402433e-05
haplotypes O 0 4.2924555600620806e-05
, O 0 3.758314193191836e-08
the O 0 8.376548343846935e-09
WFS B-Disease 0 1.1583877494558692e-05
gene O 0 8.184585453818727e-08
was O 0 4.2760242990880215e-07
localized O 0 3.565179895304027e-06
to O 0 4.377710993708206e-08
a O 0 7.516709956689738e-07
BAC O 0 0.00011358021583873779
/ O 0 6.694107923976844e-06
P1 O 0 2.9749384339083917e-05
contig O 0 2.672797563718632e-06
of O 0 2.6595075031110582e-09
less O 0 1.5724404889283505e-08
than O 0 1.859461029596332e-08
250 O 0 1.55614145569416e-07
kb O 0 7.253206422319636e-05
. O 0 8.209145221371728e-07

Mutations O 0 0.00016000847972463816
in O 0 1.5076975046213192e-07
a O 0 1.4223388689060812e-07
novel O 0 2.0535797773391096e-07
gene O 0 7.641307888661686e-07
( O 0 1.3720720559717847e-08
WFS1 O 0 2.3131511625251733e-05
) O 0 4.269200992723654e-09
encoding O 0 2.8605164459349908e-08
a O 0 1.6013656534141774e-07
putative O 0 2.4215626126533607e-06
transmembrane O 0 4.460079594537092e-07
protein O 0 9.688156410447846e-08
were O 0 2.32623847296054e-07
found O 0 1.4844700046978687e-07
in O 0 3.6386815782663007e-09
all O 0 2.0362547203944814e-09
affected O 0 8.772943971280256e-08
individuals O 0 1.502998836500069e-09
in O 0 4.105376039120756e-09
six O 0 4.356196114940758e-08
WFS B-Disease 0 2.3299728127312846e-05
families O 0 1.8255768452490884e-08
, O 0 2.5129911485066714e-09
and O 0 4.393979402550485e-09
these O 0 2.0910340126079063e-09
mutations O 0 5.3512067665906216e-08
were O 0 1.3985099656110833e-07
associated O 0 4.6525801167263126e-07
with O 0 6.676153674334273e-08
the O 0 2.1569462660409044e-06
disease O 0 0.00908135436475277
phenotype O 0 3.68461332982406e-05
. O 0 9.893320793707971e-07

WFS1 O 0 0.0043098763562738895
appears O 0 4.253948645782657e-06
to O 0 1.0587839049946979e-08
function O 0 2.0279610879470056e-08
in O 0 2.8312578947975453e-09
survival O 0 2.3356260214768554e-07
of O 0 7.626483444767018e-09
islet O 1 0.6353930830955505
beta O 0 3.813249520590034e-07
- O 0 1.9028300812351517e-05
cells O 0 1.46898159414377e-07
and O 0 7.829918935442493e-09
neurons O 0 4.539709053119623e-08
. O 0 7.0260068874006265e-09
. O 0 7.906217547315464e-08

Stable O 0 0.0007705781026743352
interaction O 0 1.007314381240576e-06
between O 0 7.13544210384498e-08
the O 0 1.377875036290277e-09
products O 0 2.7954848746958305e-07
of O 0 1.2999928911128222e-09
the O 0 1.3701525247711288e-08
BRCA1 O 0 2.3689983208896592e-05
and O 0 5.162387424206827e-07
BRCA2 O 0 1.8588547391118482e-05
tumor B-Disease 0 1.2370715012366418e-05
suppressor O 0 1.0408597518107854e-05
genes O 0 1.0725038634973316e-07
in O 0 1.5549511900303514e-08
mitotic O 0 4.542021270026453e-05
and O 0 1.4447363128056168e-06
meiotic O 0 0.005636889487504959
cells O 0 4.5049662730889395e-05
. O 0 9.556325721860048e-07

BRCA1 O 0 0.0031379174906760454
and O 0 3.283709474999341e-06
BRCA2 O 0 2.7707226763595827e-05
account O 0 1.2787610614850564e-07
for O 0 2.843304480748543e-09
most O 0 5.6314877205920766e-09
cases O 0 5.113835133130351e-09
of O 0 1.1206811034725206e-09
familial O 0 0.0004648258618544787
, O 0 6.664868124062195e-08
early O 0 1.3098493809593492e-06
onset O 0 0.00512284180149436
breast B-Disease 0 0.21992337703704834
and I-Disease 0 3.886267222696915e-05
/ I-Disease 1 0.999767005443573
or I-Disease 1 0.9999873638153076
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
and O 0 3.9645925653530867e-07
encode O 0 1.2123334158786747e-07
products O 0 2.385309198871255e-05
that O 0 4.6975365819434955e-09
each O 0 1.7970125387734015e-09
interact O 0 1.42737164310347e-08
with O 0 1.2075788369259044e-08
hRAD51 O 0 1.2224157217133325e-05
. O 0 4.906564754492138e-07

Results O 0 3.7711354252678575e-06
presented O 0 1.9966925890457787e-07
here O 0 3.9121154316035245e-08
show O 0 1.1009383626969793e-07
that O 0 2.6542791076167305e-08
BRCA1 O 0 4.239079498802312e-05
and O 0 8.062097549554892e-07
BRCA2 O 0 1.679296838119626e-05
coexist O 0 3.177485496053123e-06
in O 0 1.0405970307658663e-08
a O 0 5.851357798292156e-08
biochemical O 0 1.4006778883413062e-06
complex O 0 9.770475116965827e-06
and O 0 1.4626544952989207e-07
colocalize O 0 1.7291196854785085e-05
in O 0 1.5067481484720702e-08
subnuclear O 0 1.6168727597687393e-05
foci O 0 6.560057954629883e-06
in O 0 5.471254560518446e-09
somatic O 0 4.4346947447593266e-07
cells O 0 1.2422530915046082e-07
and O 0 3.329535758211932e-08
on O 0 6.776607364145093e-08
the O 0 2.34417063538217e-09
axial O 0 3.488957389663483e-08
elements O 0 1.746352218390257e-08
of O 0 3.920883617780646e-09
developing O 0 3.035650877336593e-07
synaptonemal O 0 5.5081076425267383e-05
complexes O 0 2.614809272927232e-05
. O 0 1.0478706826688722e-06

Like O 0 1.3865957043890376e-05
BRCA1 O 0 6.734814087394625e-05
and O 0 1.252967649634229e-06
RAD51 O 0 0.0033388216979801655
, O 0 1.7054888701295567e-07
BRCA2 O 0 2.1292223664204357e-06
relocates O 0 8.218372613555402e-07
to O 0 2.3472860988249522e-08
PCNA O 0 7.550654845545068e-05
+ O 0 3.075608105973515e-07
replication O 0 1.625484031819724e-07
sites O 0 7.13545560415696e-08
following O 0 3.4970772944120654e-09
exposure O 0 9.11010715753946e-08
of O 0 2.0129768962817707e-09
S O 0 0.00021744031982962042
phase O 0 1.722913793855696e-06
cells O 0 1.1303250602168191e-07
to O 0 2.035743129624734e-08
hydroxyurea O 0 6.110055892349919e-06
or O 0 1.777511897671502e-07
UV O 0 5.84503541176673e-05
irradiation O 0 3.962316441175062e-06
. O 0 2.229728579550283e-07

Thus O 0 6.596450930373976e-06
, O 0 1.6671540947754693e-07
BRCA1 O 0 1.1455584171926603e-05
and O 0 8.583820942931197e-08
BRCA2 O 0 1.587988663231954e-06
participate O 0 1.2607350718951693e-08
, O 0 5.010526216153721e-09
together O 0 1.6053636642254787e-08
, O 0 1.4152266913924905e-08
in O 0 5.058229834986605e-09
a O 0 3.620959887484787e-07
pathway O 0 1.2251853149791714e-06
( O 0 1.274552818841812e-08
s O 0 0.00011832367454189807
) O 0 5.119104695694432e-09
associated O 0 6.672347296898806e-08
with O 0 3.0503211068122482e-09
the O 0 1.6960085558181959e-09
activation O 0 1.1839873970131976e-08
of O 0 1.7976673483133254e-09
double O 0 1.609295213711448e-05
- O 0 0.001582058146595955
strand O 0 5.297091411193833e-05
break O 0 3.3041815186152235e-06
repair O 0 0.0029828401748090982
and O 0 3.7073095882078633e-07
/ O 0 4.173381512373453e-06
or O 0 2.2469629712418282e-08
homologous O 0 3.463339055542747e-07
recombination O 0 3.371063939994201e-06
. O 0 7.413107141474029e-07

Dysfunction O 0 0.02676447294652462
of O 0 9.635781594852233e-08
this O 0 2.916879715542109e-08
pathway O 0 7.092908731465286e-07
may O 0 1.743159856459897e-07
be O 0 9.908257325719205e-09
a O 0 4.956422827717688e-09
general O 0 3.6729319585759868e-09
phenomenon O 0 1.6945469383244927e-07
in O 0 1.0632558167245065e-09
the O 0 9.276694967752519e-10
majority O 0 4.396703889852915e-09
of O 0 6.470163849137123e-10
cases O 0 2.1530130567271044e-08
of O 0 6.679631070483083e-08
hereditary B-Disease 1 0.9993621706962585
breast I-Disease 1 0.9955512285232544
and I-Disease 0 0.01881624571979046
/ I-Disease 1 0.9999872446060181
or I-Disease 1 0.9999958276748657
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999993085861206
. O 0 2.1553844931077037e-07
. O 0 7.297022648344864e-07

A O 0 5.155566668690881e-06
novel O 0 1.0349517651775386e-06
Arg362Ser O 0 7.848233508411795e-05
mutation O 0 8.500173862557858e-07
in O 0 6.867518109743287e-09
the O 0 8.250568228618249e-09
sterol O 0 4.986880594515242e-05
27 O 0 1.325719154010585e-06
- O 0 0.0002763928787317127
hydroxylase O 0 0.0002675687719602138
gene O 0 3.830011223726615e-07
( O 0 4.453718283059516e-09
CYP27 O 0 9.564518222759943e-06
) O 0 2.7479414299591554e-09
: O 0 3.666938419577548e-10
its O 0 7.94895649303129e-10
effects O 0 4.961722410712355e-08
on O 0 8.550225771841724e-08
pre O 0 1.2208011867187452e-05
- O 0 2.05643641493225e-06
mRNA O 0 7.71388020126551e-09
splicing O 0 1.0967315944299116e-08
and O 0 3.9073855262472534e-09
enzyme O 0 1.1138713063019168e-07
activity O 0 6.602049893444928e-07
. O 0 1.0295261176906934e-07

A O 0 6.1513501350418665e-06
novel O 0 8.269697104879015e-07
C O 0 3.303105404484086e-05
to O 0 4.422583632646138e-09
A O 0 3.554983152298519e-08
mutation O 0 3.360363720616988e-08
in O 0 2.7771953625688184e-09
the O 0 4.213752902160195e-09
sterol O 0 1.786766733857803e-05
27 O 0 1.0556905181147158e-06
- O 0 4.9589296395424753e-05
hydroxylase O 0 0.0001340720773441717
gene O 0 1.479198914466906e-07
( O 0 3.690248551180275e-09
CYP27 O 0 1.6417425285908394e-05
) O 0 1.2766988355394915e-08
was O 0 6.067529056963394e-07
identified O 0 3.2761096946387624e-08
by O 0 9.677066925561917e-10
sequencing O 0 1.9957514751922645e-08
amplified O 0 4.1937141759262886e-07
CYP27 O 0 1.0418320925964508e-05
gene O 0 1.363195707426712e-07
products O 0 7.212559580693778e-07
from O 0 4.8619477333033956e-09
a O 0 6.383347681548912e-07
patient O 0 2.6319889002479613e-05
with O 0 4.259729394107126e-06
cerebrotendinous B-Disease 1 0.9999938011169434
xanthomatosis I-Disease 1 0.9999905824661255
( O 0 1.2583522220666055e-05
CTX B-Disease 0 0.03611043468117714
) O 0 4.143924172694824e-07
. O 0 3.629596392329404e-07

The O 0 1.8488307773623092e-07
mutation O 0 7.438417242155992e-07
changed O 0 1.4114330326719937e-07
the O 0 2.18753437586372e-09
adrenodoxin O 0 9.055499390342447e-07
cofactor O 0 1.3301323065206816e-07
binding O 0 9.609168927227074e-08
residue O 0 8.217824074563396e-07
362Arg O 0 1.9019981891688076e-06
to O 0 1.8452615435649022e-08
362Ser O 0 4.982291102351155e-06
( O 0 1.4720633600973088e-08
CGT O 0 9.124920325120911e-06
362Arg O 0 8.268442570624757e-07
to O 0 1.2428166051847711e-08
AGT O 0 9.625395250623114e-06
362Ser O 0 2.518838073228835e-06
) O 0 3.5381104712683964e-09
, O 0 1.8933410395050032e-09
and O 0 7.469209251098619e-09
was O 0 6.956933589208347e-07
responsible O 0 4.203077878628392e-06
for O 0 6.234363354451489e-06
deficiency O 0 0.029841933399438858
in O 0 1.8897332587641813e-09
the O 0 4.121845087468046e-09
sterol O 0 2.44003240368329e-05
27 O 0 1.6630016830276872e-07
- O 0 1.6263600173260784e-06
hydroxylase O 0 1.9532590158632956e-06
activity O 0 1.1664718613246805e-06
, O 0 2.8575051214119185e-09
as O 0 1.6088019805238218e-09
confirmed O 0 4.939888054167341e-09
by O 0 3.248653013265823e-10
expression O 0 1.597762588900764e-09
of O 0 7.992660699951415e-11
mutant O 0 8.96670915295772e-09
cDNA O 0 1.5376153683632765e-08
into O 0 6.706104116460665e-09
COS O 0 4.8935835366137326e-05
- O 0 4.746172635350376e-06
1 O 0 7.753105535357463e-08
cells O 0 3.4699843354246696e-07
. O 0 1.145517813938568e-07

Quantitative O 0 1.6251552779067424e-06
analysis O 0 3.915049546776572e-07
showed O 0 2.769363845800399e-06
that O 0 5.64199176267266e-09
the O 0 8.979507137851783e-10
expression O 0 1.3562265976929666e-08
of O 0 7.45124795198393e-10
CYP27 O 0 3.111475507466821e-06
gene O 0 1.1881407857572412e-08
mRNA O 0 2.554522593456454e-09
in O 0 1.8138894830599384e-09
the O 0 4.5376631341298435e-09
patient O 0 3.0756521596231323e-07
represented O 0 9.439519743636993e-08
52 O 0 1.0337206504118512e-06
. O 0 3.5630483807835844e-07

5 O 0 1.6490123471157858e-06
% O 0 2.0877511275330107e-08
of O 0 3.7019651788483543e-09
the O 0 7.674930913026401e-09
normal O 0 3.5285029298393056e-07
level O 0 7.9980230793808e-07
. O 0 2.0308416992520506e-07

As O 0 3.637746885942761e-07
the O 0 1.3312180691116282e-08
mutation O 0 1.3018302524869796e-07
occurred O 0 1.746033291283311e-07
at O 0 2.9603846485315444e-08
the O 0 7.508127453093039e-10
penultimate O 0 1.2264953852536564e-07
nucleotide O 0 4.3487663248242825e-08
of O 0 3.1923406140776933e-09
exon O 0 2.5365122269249696e-07
6 O 0 1.2996817133625882e-07
( O 0 7.46855377542488e-09
- O 0 3.2818434192449786e-06
2 O 0 2.4764917228026206e-08
position O 0 1.813748617962574e-08
of O 0 1.3602777793053633e-09
exon O 0 3.9326221212832024e-07
6 O 0 3.2254544635179627e-07
- O 0 1.744578366924543e-05
intron O 0 7.253047806443647e-05
6 O 0 6.204927416320061e-08
splice O 0 6.614013273065211e-06
site O 0 6.240341463126242e-06
) O 0 9.32941279785382e-10
of O 0 2.2547358424773734e-10
the O 0 1.203669053317924e-09
gene O 0 4.459738534023927e-08
, O 0 3.383844093818311e-09
we O 0 4.30845803478519e-09
hypothesized O 0 1.104701041754197e-08
that O 0 2.6277615639003216e-09
the O 0 1.3274978893917933e-09
mutation O 0 4.839504867959477e-07
may O 0 1.6312516493144358e-07
partially O 0 5.907202194066485e-07
affect O 0 7.659136436188874e-09
the O 0 3.1111288545382365e-10
normal O 0 3.5180642843357646e-09
splicing O 0 9.868330153040006e-09
efficiency O 0 8.909262305678567e-08
in O 0 3.8501837273940964e-09
exon O 0 3.137319026791374e-07
6 O 0 5.174725288270565e-07
and O 0 8.657713834736569e-08
cause O 0 2.1420683893325076e-08
alternative O 0 6.963143839300301e-09
splicing O 0 4.6752283822115714e-08
elsewhere O 0 1.265158289243118e-07
, O 0 2.882092786649082e-09
which O 0 4.12100398250459e-09
resulted O 0 1.70077782968292e-08
in O 0 5.341536990499662e-09
decreased O 0 1.3022987559452304e-06
transcript O 0 5.948754164819547e-07
in O 0 2.424570055836739e-08
the O 0 4.369627504274831e-08
patient O 0 1.0784341611724813e-05
. O 0 1.8029567172561656e-07

Transfection O 0 0.00017142159049399197
of O 0 8.310937715805267e-08
constructed O 0 3.425117756705731e-05
minigenes O 0 0.0005273596034385264
, O 0 1.1603191296671866e-07
with O 0 1.463636234433352e-08
or O 0 9.413143686742842e-08
without O 0 7.108338806460779e-09
the O 0 3.0763158687108216e-09
mutation O 0 2.2137101041153073e-08
, O 0 1.3190551984010312e-09
into O 0 2.776634255852173e-09
COS O 0 0.0006582308560609818
- O 0 8.630651791463606e-06
1 O 0 3.174757168267206e-08
cells O 0 3.62657175401182e-08
confirmed O 0 4.363647576610674e-08
that O 0 8.343394308774066e-10
the O 0 3.4519651026521103e-10
mutant O 0 7.609355634485837e-08
minigene O 0 3.718268544616876e-06
was O 0 2.1343578282539966e-06
responsible O 0 3.813216835624189e-07
for O 0 5.480466302998366e-09
a O 0 3.0922890914553136e-08
mRNA O 0 1.3559653844197328e-08
species O 0 2.1764889890363293e-09
alternatively O 0 2.5394303548864627e-08
spliced O 0 2.9079417345201364e-06
at O 0 1.157010274255299e-06
an O 0 1.617917533280888e-08
activated O 0 4.404925675771665e-06
cryptic O 0 3.007004636401689e-07
5 O 0 4.987946500278895e-09
splice O 0 1.3487091337083257e-06
site O 0 1.3996857433085097e-06
88 O 0 4.073764259260315e-08
bp O 0 2.3780789604188612e-07
upstream O 0 4.576605761030805e-08
from O 0 5.406395331419844e-10
the O 0 5.388256507643518e-10
3 O 0 2.538165233545442e-09
end O 0 2.2559769163876808e-08
of O 0 3.3600862092697525e-09
exon O 0 2.325331934116548e-06
6 O 0 4.185499733466713e-07
. O 0 5.030974534747656e-07

Our O 0 4.228029126807087e-07
data O 0 1.3238251028724335e-07
suggest O 0 4.175560164298986e-08
that O 0 1.709626773482853e-09
the O 0 1.142167915801906e-09
C O 0 4.996680218027905e-06
to O 0 5.633572275343113e-09
A O 0 1.199850316879747e-07
mutation O 0 4.127747743609689e-08
at O 0 3.998736275434567e-08
the O 0 4.0234435227937126e-10
penultimate O 0 1.1579446379528235e-07
nucleotide O 0 2.358775397226509e-08
of O 0 6.242099614972574e-10
exon O 0 6.028193411111715e-08
6 O 0 9.177038684526906e-09
of O 0 2.7213181708063416e-10
the O 0 1.0984435583338836e-09
CYP27 O 0 8.014019840629771e-06
gene O 0 2.9209214602587963e-08
not O 0 1.7215976200191108e-08
only O 0 8.510196991551311e-09
causes O 0 3.787387186093838e-07
the O 0 3.9033432130963774e-07
deficiency B-Disease 0 0.010806472972035408
in I-Disease 0 2.3532826798344786e-09
the I-Disease 0 3.319774899424033e-09
sterol I-Disease 0 5.901553777221125e-06
27 I-Disease 0 1.8750448305127065e-07
- I-Disease 0 2.2764795630791923e-06
hydroxylase I-Disease 0 1.6564059706070111e-06
activity I-Disease 0 3.1475411788051133e-07
, O 0 2.8237077120962795e-09
but O 0 7.446293359691936e-09
also O 0 4.562573607813647e-08
partially O 0 2.090986754410551e-06
leads O 0 1.3536242349232452e-08
to O 0 1.186491571658621e-09
alternative O 0 1.903687518733932e-08
pre O 0 2.083462732116459e-06
- O 0 4.198476517558447e-07
mRNA O 0 5.6557718508543076e-09
splicing O 0 7.65322294427051e-09
of O 0 4.077522486323204e-10
the O 0 4.6047543555971515e-09
gene O 0 2.6753630777420767e-07
. O 0 2.2505581398490904e-07

To O 0 6.183614118526748e-07
our O 0 3.587166119700669e-08
knowledge O 0 1.2587238806816003e-08
, O 0 1.4408697568413231e-09
this O 0 5.690655724421845e-10
is O 0 1.6169828143119958e-08
the O 0 4.3947986916315074e-10
first O 0 1.130113425062973e-08
report O 0 2.2323193960005483e-08
regarding O 0 2.565049062042135e-09
effects O 0 9.537809830817423e-08
on O 0 1.0774719072514927e-07
pre O 0 4.1219755075871944e-06
- O 0 2.0931425126491376e-07
mRNA O 0 1.6200659702647613e-09
splicing O 0 1.6510108835632309e-09
of O 0 4.2422659829455256e-10
a O 0 1.0072470857380722e-08
mutation O 0 2.411766253374026e-08
at O 0 4.1504211623077936e-08
the O 0 2.6174069578388526e-09
- O 0 2.896450496336911e-05
2 O 0 3.830584205388732e-08
position O 0 4.349960747163095e-08
of O 0 1.0062577437963682e-09
a O 0 1.0063622113420934e-07
5 O 0 7.136598867418797e-08
splice O 0 2.591093652881682e-05
site O 0 4.667621760745533e-05
. O 0 8.114852221297042e-07

ATM O 0 0.0019269398180767894
germline O 0 0.0005635477718897164
mutations O 0 4.827266820939258e-05
in O 0 3.982273710789741e-07
classical O 0 0.0072151171043515205
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
patients O 0 0.07408257573843002
in O 0 9.16572346909561e-08
the O 0 2.9552282398981333e-08
Dutch O 0 7.94426814536564e-05
population O 0 3.6029720718033786e-07
. O 0 3.5596212910604663e-07

Germline O 0 0.00102700584102422
mutations O 0 4.874980731983669e-05
in O 0 6.748050651594895e-08
the O 0 9.114397236942295e-09
ATM O 0 2.666311411303468e-05
gene O 0 1.0317199183873527e-07
are O 0 3.739007325975763e-09
responsible O 0 1.842448682509712e-07
for O 0 1.6719117468255718e-07
the O 0 0.012723750434815884
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.2210243046283722
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999982118606567
T I-Disease 1 0.9999995231628418
) O 0 2.9935907264189154e-07
. O 0 3.1228680086314853e-07

In O 0 5.052813776273979e-07
our O 0 3.4848739005610696e-08
study O 0 6.221587245391902e-09
, O 0 1.479883215971256e-09
we O 0 3.3263158893959144e-09
have O 0 7.86297416066617e-10
determined O 0 6.837639787704575e-09
the O 0 6.357679382951176e-10
ATM O 0 2.841871946657193e-06
mutation O 0 7.820441183525872e-09
spectrum O 0 5.01806525221582e-08
in O 0 2.2378816577628413e-09
19 O 0 1.5610311265845667e-08
classical O 0 1.4134700450085802e-06
A B-Disease 1 0.9999948740005493
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 3.7731426800746704e-06
, O 0 5.594893881522012e-09
including O 0 2.155493783462248e-09
some O 0 2.017874312087997e-09
immigrant O 0 3.3463476256656577e-07
populations O 0 3.410919191537687e-08
, O 0 4.070655368337839e-09
as O 0 5.732184948925578e-09
well O 0 2.4897907735521585e-08
as O 0 1.157072127000447e-08
12 O 0 2.9443569804499248e-09
of O 0 5.592714624746975e-10
Dutch O 0 2.881550244637765e-06
ethnic O 0 1.300512479929239e-07
origin O 0 3.8656904166600725e-07
. O 0 3.239115926589875e-07

Both O 0 4.4238854002287553e-07
the O 0 1.5561676391939727e-08
protein O 0 5.1594930994269816e-08
truncation O 0 5.073440206615487e-06
test O 0 1.483121650380781e-06
( O 0 5.319169993356354e-09
PTT O 0 3.397155410311825e-07
) O 0 7.60637386409968e-10
and O 0 1.140741834326775e-09
the O 0 5.425082050258823e-10
restriction O 0 3.771901191385041e-08
endonuclease O 0 6.721468253090279e-06
fingerprinting O 0 8.87781243363861e-06
( O 0 1.73681193871289e-08
REF O 0 2.116426912834868e-05
) O 0 3.2301786245803044e-10
method O 0 5.1541593215631565e-09
were O 0 2.265584164717893e-08
used O 0 7.101809984533247e-08
and O 0 1.880794897601845e-08
compared O 0 3.6165420880251986e-08
for O 0 9.113801380244979e-10
their O 0 3.517948155007389e-10
detection O 0 1.627034329487742e-08
efficiency O 0 1.1214407180659691e-08
, O 0 2.1832399776933187e-10
identifying O 0 2.257831033247726e-09
76 O 0 7.31859683966718e-09
% O 0 7.387426226301841e-10
and O 0 6.937307173160434e-09
60 O 0 6.060540957975036e-09
% O 0 7.623876530082896e-10
of O 0 1.0189835641938316e-09
the O 0 2.4679522425685718e-08
mutations O 0 1.6200317531911423e-06
, O 0 3.876950316339389e-08
respectively O 0 4.80746166431345e-07
. O 0 4.6622318450317835e-07

Most O 0 3.4827755825972417e-06
patients O 0 2.01333500626788e-06
were O 0 1.3091384687413665e-07
found O 0 2.4064544135171673e-08
to O 0 3.589854413732496e-09
be O 0 1.3352313033010432e-07
compound O 0 6.559044777532108e-06
heterozygote O 0 2.0873028915957548e-05
. O 0 2.767827140814916e-07

Seventeen O 0 4.1365346987731755e-06
mutations O 0 3.6609778817364713e-06
were O 0 4.2219934925924463e-07
distinct O 0 1.6815628001154437e-08
, O 0 2.7444424510747467e-09
of O 0 5.339150788152836e-10
which O 0 6.190458634591778e-08
10 O 0 1.4550908922217332e-08
were O 0 4.755886351404115e-08
not O 0 4.940342535064701e-08
reported O 0 8.534638027413166e-07
previously O 0 4.248246341376216e-07
. O 0 2.2734849380867672e-07

Mutations O 0 3.926219142158516e-05
are O 0 8.419078767474275e-08
small O 0 1.5294348543193337e-07
deletions O 0 5.960894668533001e-06
or O 0 2.004650013986975e-06
point O 0 2.4589739950897638e-06
mutations O 0 6.056503025320126e-06
frequently O 0 5.357569534680806e-07
affecting O 0 5.450445428323292e-07
splice O 0 0.00010663314606063068
sites O 0 2.1652582290698774e-05
. O 0 1.2926509498356609e-06

Moreover O 0 2.696945557545405e-05
, O 0 1.6366432475933834e-07
a O 0 1.1503818342362138e-07
16 O 0 3.1524950827588327e-07
. O 0 2.2145677291973698e-07

7 O 0 1.5028359484858811e-05
- O 0 7.97135871835053e-05
kb O 0 1.2617976608453318e-05
genomic O 0 2.314357914201537e-07
deletion O 0 1.29961975403603e-07
of O 0 3.076151555703177e-09
the O 0 3.4521052683089692e-09
3 O 0 1.1227269780533788e-08
end O 0 1.5254983054546756e-08
of O 0 3.73168856926398e-10
the O 0 1.954541639648255e-09
gene O 0 5.0373596849340174e-08
, O 0 2.6429114452497515e-09
most O 0 2.8277500341289397e-09
likely O 0 5.825433646577949e-08
a O 0 4.909697981503314e-09
result O 0 1.6271515246302215e-09
of O 0 1.21101906280785e-10
recombination O 0 1.5761465022023913e-07
between O 0 1.0152828622267407e-07
two O 0 5.083650833626052e-08
LINE O 0 9.902460442390293e-05
elements O 0 1.3163361245460692e-06
, O 0 5.636971422973147e-08
was O 0 1.6982662600639742e-06
identified O 0 1.4849445051368093e-06
. O 0 2.2138581812214397e-07

The O 0 1.9131157102947327e-07
most O 0 1.6741031672040663e-08
frequently O 0 7.460242557044694e-08
found O 0 6.615348269178867e-08
mutation O 0 9.249900756458374e-08
, O 0 8.072398749447984e-09
identified O 0 4.0734539652476087e-07
in O 0 1.0464087374373321e-08
three O 0 3.1868424343883817e-08
unrelated O 0 6.381560979207279e-06
Turkish O 0 7.04694539308548e-05
A B-Disease 1 0.9999781847000122
- I-Disease 1 0.9999126195907593
T I-Disease 1 0.9999995231628418
individuals O 0 1.693937861091399e-07
, O 0 3.629104483593437e-08
was O 0 6.72288433634094e-06
previously O 0 6.809230512772046e-07
described O 0 4.51833011538838e-06
to O 0 5.427333604757223e-08
be O 0 1.5230857286496757e-07
a O 0 3.053402792829729e-07
Turkish O 0 8.440601959591731e-06
A B-Disease 1 0.9998251795768738
- I-Disease 1 0.9999849796295166
T I-Disease 1 0.999997615814209
founder O 0 8.203134348150343e-05
mutation O 0 2.6331572371418588e-06
. O 0 3.613260730617185e-07

The O 0 9.577112081160521e-08
presence O 0 9.448525872812752e-08
of O 0 1.6676138248072903e-09
a O 0 1.851057334079087e-07
founder O 0 2.770869514279184e-06
mutation O 0 5.769976496594609e-07
among O 0 6.015201226006184e-09
relatively O 0 6.942617858385347e-08
small O 0 1.2849197617015307e-07
ethnic O 0 1.4061538600174117e-08
population O 0 3.1875218020616103e-09
groups O 0 1.8990482519853913e-09
in O 0 8.777338300625104e-10
Western O 0 8.471830348355525e-09
Europe O 0 6.150607134713937e-08
could O 0 4.5614076071842646e-08
indicate O 0 3.541508419857564e-08
a O 0 2.0182294946380352e-08
high O 0 1.1033406508431653e-06
carrier O 0 2.137298196203119e-07
frequency O 0 4.4207894234205014e-08
in O 0 1.2471995658458468e-09
such O 0 7.2279950913411994e-09
communities O 0 8.757814384807716e-08
. O 0 1.7018365383592027e-07

In O 0 9.799998679227429e-07
patients O 0 7.197175477813289e-07
of O 0 3.6436957895347177e-09
Dutch O 0 1.6811460227472708e-05
ethnic O 0 8.653669425484622e-08
origin O 0 2.0213737172980473e-07
, O 0 2.4899097894603983e-08
however O 0 1.9093022274319082e-08
, O 0 7.259648437951682e-09
no O 0 4.899108674294439e-09
significant O 0 3.752696819958601e-09
founder O 0 2.7072425723417837e-07
effect O 0 5.439541439500317e-08
could O 0 6.71511770633515e-08
be O 0 2.8821382613841706e-08
identified O 0 7.032672897366865e-07
. O 0 1.38394739224168e-07

The O 0 1.7116546757733886e-07
observed O 0 5.754929475187964e-07
genetic O 0 1.8774478860450472e-07
heterogeneity O 0 2.402139784862811e-07
including O 0 6.982350697626316e-08
the O 0 1.1350559603329202e-08
relative O 0 3.2575342174823163e-06
high O 0 1.5385562619485427e-06
percentage O 0 2.0051115257047059e-07
of O 0 2.0946824275114295e-09
splice O 0 0.002278913976624608
- O 0 0.001268541906028986
site O 0 0.0006468237261287868
mutations O 0 2.9559216727648163e-06
had O 0 8.202477488339355e-07
no O 0 1.6105037303759673e-08
reflection O 0 5.434978689322634e-08
on O 0 1.3743461124704481e-07
the O 0 4.71329890672223e-08
phenotype O 0 1.2894736755697522e-05
. O 0 2.4512704044354905e-07

All O 0 1.0477087926119566e-06
patients O 0 1.3824162579112453e-06
manifested O 0 4.3206478039792273e-07
classical O 0 3.543313596310327e-06
A B-Disease 1 0.9998519420623779
- I-Disease 1 0.9999312162399292
T I-Disease 1 0.9999990463256836
and O 0 1.387094812344003e-07
increased O 0 9.050010874034342e-08
cellular O 0 4.037988674099324e-06
radioresistant O 0 9.786972441361286e-06
DNA O 0 8.463014182780171e-07
synthesis O 0 1.7700294847600162e-06
. O 0 3.7780435491185926e-07

Determination O 0 4.344871740613598e-06
of O 0 1.4140880466584349e-08
the O 0 2.903677964738449e-09
genomic O 0 4.726027924562004e-08
structure O 0 2.259931051185049e-07
of O 0 1.6349381848357325e-09
the O 0 4.570348988153228e-09
COL4A4 O 0 4.205812365398742e-05
gene O 0 8.61281606034936e-08
and O 0 4.60695037673986e-09
of O 0 8.65746230260811e-09
novel O 0 5.167871495359577e-05
mutations O 0 0.020819589495658875
causing O 1 0.6052907705307007
autosomal B-Disease 1 0.9999821186065674
recessive I-Disease 1 0.9999979734420776
Alport I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999973773956299
. O 0 0.0001519020297564566

Autosomal B-Disease 1 0.9999796152114868
recessive I-Disease 1 0.9999988079071045
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999997615814209
is O 0 0.0001670691417530179
a O 0 1.1493270903883968e-05
progressive O 0 0.08863205462694168
hematuric B-Disease 1 0.9995986819267273
glomerulonephritis I-Disease 1 0.9999995231628418
characterized O 0 0.2567313611507416
by O 0 7.048100997053552e-06
glomerular B-Disease 1 0.9949949979782104
basement I-Disease 1 0.9875806570053101
membrane I-Disease 0 0.17145642638206482
abnormalities I-Disease 1 0.9996551275253296
and O 0 2.073280938930111e-06
associated O 0 6.597782089556858e-07
with O 0 5.219355969643402e-08
mutations O 0 1.4398233361134771e-06
in O 0 2.8197479906566514e-08
either O 0 1.1140539868392807e-07
the O 0 2.6838208100343763e-08
COL4A3 O 0 0.0008345612441189587
or O 0 6.008059472151217e-08
the O 0 2.1709580799722517e-09
COL4A4 O 0 7.956614354043268e-06
gene O 0 2.8392035389401826e-08
, O 0 3.10533199154861e-09
which O 0 1.4081741328553221e-09
encode O 0 2.924710917895368e-09
the O 0 4.553216914615632e-09
alpha3 O 0 1.6778289136709645e-05
and O 0 9.836819003794517e-08
alpha4 O 0 0.0004116541240364313
type O 0 0.016987362876534462
IV O 0 0.06582395732402802
collagen O 0 0.006607287563383579
chains O 0 0.0020093845669180155
, O 0 1.0281485174346017e-07
respectively O 0 3.9651484939895454e-07
. O 0 3.252916371820902e-07

To O 0 1.180668220968073e-07
date O 0 4.138288431931869e-07
, O 0 7.3217942819781e-09
mutation O 0 9.043174209466542e-09
screening O 0 2.8210605407252842e-08
in O 0 4.467858971679561e-09
the O 0 1.1689771373113444e-09
two O 0 2.8626763182160175e-09
genes O 0 6.885936443268292e-08
has O 0 1.788987447071122e-07
been O 0 4.2147760836996895e-07
hampered O 0 1.558855001349002e-05
by O 0 5.366167954434786e-09
the O 0 1.3991597880291806e-09
lack O 0 4.345662940608008e-09
of O 0 2.1863987009762553e-10
genomic O 0 1.3807202492444048e-07
structure O 0 9.396278528583935e-07
information O 0 1.5456285495929478e-07
. O 0 2.0615445350813388e-07

We O 0 2.257097548863385e-06
report O 0 5.20116998359299e-08
here O 0 7.492852560631036e-09
the O 0 2.7217958442626866e-10
complete O 0 8.728459732765259e-09
characterization O 0 1.2817661172448425e-06
of O 0 1.997692899990966e-09
the O 0 4.11188061377743e-09
48 O 0 1.5651036022745757e-08
exons O 0 1.0031862451853613e-08
of O 0 8.666230510989692e-10
the O 0 3.42286998744612e-09
COL4A4 O 0 2.0918920199619606e-05
gene O 0 9.144995516408017e-08
, O 0 1.8915506938554927e-09
a O 0 2.1586783471860826e-09
comprehensive O 0 1.3730543457768363e-07
gene O 0 2.859001142496709e-07
screen O 0 2.300486266904045e-05
, O 0 1.2965273299414548e-07
and O 0 2.451798053471066e-08
the O 0 6.93457846701051e-10
subsequent O 0 4.802079622834299e-09
detection O 0 8.185444499986261e-08
of O 0 1.2072282062902673e-09
10 O 0 5.650381051935938e-09
novel O 0 1.401227578412545e-08
mutations O 0 9.63787698537999e-08
in O 0 7.412312985621838e-09
eight O 0 2.181166792070144e-06
patients O 0 0.00011531001655384898
diagnosed O 0 0.2781728506088257
with O 0 0.0002482793352100998
autosomal B-Disease 1 0.9999967813491821
recessive I-Disease 1 0.9999990463256836
Alport I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999974966049194
. O 0 4.727831037598662e-05

Furthermore O 0 3.3892188184836414e-06
, O 0 3.19435216056263e-08
we O 0 9.68035784865151e-09
identified O 0 1.4081749100114394e-08
a O 0 2.6909083850057414e-09
glycine O 0 9.844840178629966e-07
to O 0 1.6532860636075952e-09
alanine O 0 2.1701504238080815e-07
substitution O 0 1.4172364615205879e-08
in O 0 3.806010173690311e-09
the O 0 1.2365358736943222e-09
collagenous O 0 8.462872756354045e-06
domain O 0 6.16855828639018e-08
that O 0 2.1460433430320336e-08
is O 0 7.628436549111939e-08
apparently O 0 4.990271236238186e-07
silent O 0 1.3991211744723842e-06
in O 0 9.491090136037883e-10
the O 0 1.2379447467125715e-09
heterozygous O 0 8.962779673993282e-08
carriers O 0 3.1762716901084787e-08
, O 0 2.2189337034461687e-09
in O 0 6.201612112732846e-09
11 O 0 2.1501286084912863e-07
. O 0 2.3753315758767712e-07

5 O 0 3.6802202885155566e-07
% O 0 8.370687254455333e-09
of O 0 1.1025114154961102e-09
all O 0 2.0257255872735414e-09
control O 0 9.807159813135513e-07
individuals O 0 2.145085709059913e-08
, O 0 4.013966048432849e-08
and O 0 1.1973686753208312e-07
in O 0 1.4537871351194553e-08
one O 0 6.026353815968832e-08
control O 0 7.165527335928346e-07
individual O 0 2.6344058046134933e-09
homozygous O 0 3.459614816847534e-08
for O 0 1.027681051368745e-09
this O 0 1.868814658578799e-09
glycine O 0 1.2223924841237022e-06
substitution O 0 1.9904261705505633e-07
. O 0 8.205030610497488e-08

There O 0 2.6185875867668074e-06
has O 0 3.0132682127259613e-07
been O 0 5.569619787593183e-08
no O 0 1.917326919453899e-08
previous O 0 1.0822684970435148e-08
finding O 0 5.560615967681315e-09
of O 0 5.167130057159852e-10
a O 0 9.339387929685472e-09
glycine O 0 7.841369864536318e-08
substitution O 0 4.152224342135469e-09
that O 0 3.7188507828744832e-09
is O 0 1.1886281292561307e-08
not O 0 2.476887139835071e-09
associated O 0 1.9620015834220794e-08
with O 0 5.069027864124109e-09
any O 0 5.378528200594701e-08
obvious O 0 3.485492925392464e-07
phenotype O 0 9.523373591946438e-07
in O 0 1.98319511923728e-08
homozygous O 0 2.4052765184023883e-06
individuals O 0 7.254904232922854e-08
. O 0 2.434568671105808e-07

Founder O 0 0.0009940600721165538
BRCA1 O 0 0.0026821396313607693
and O 0 5.894444257137366e-06
BRCA2 O 0 0.000268643896561116
mutations O 0 4.937299763696501e-06
in O 0 5.339767383816252e-08
French O 0 7.487135735573247e-05
Canadian O 0 0.0078805610537529
breast B-Disease 1 0.9999802112579346
and I-Disease 1 0.9999338388442993
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
families O 0 7.38644257580745e-06
. O 0 2.239511331936228e-06

We O 0 3.947124696423998e-06
have O 0 3.614831811660224e-08
identified O 0 1.0515712034475655e-07
four O 0 1.8212320540555993e-09
mutations O 0 4.114024321211218e-08
in O 0 1.133378835227461e-09
each O 0 1.2057140841292835e-09
of O 0 8.346836999351126e-09
the O 0 3.4004137887677643e-06
breast B-Disease 1 0.998188316822052
cancer I-Disease 0 0.021888451650738716
- O 0 0.03220946714282036
susceptibility O 0 0.0006877825944684446
genes O 0 8.611926318735641e-07
, O 0 1.6875461028575955e-07
BRCA1 O 0 1.2414277989591938e-05
and O 0 2.7120415779791074e-07
BRCA2 O 0 1.98019574781938e-06
, O 0 1.6295187421633273e-08
in O 0 9.97399585145331e-09
French O 0 2.7750747904065065e-05
Canadian O 0 0.0011295053409412503
breast B-Disease 1 0.9998161196708679
cancer I-Disease 1 0.9632567167282104
and O 0 0.11672845482826233
breast B-Disease 1 0.9999980926513672
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 2.719853227972635e-06
from O 0 1.131537388232573e-07
Quebec O 0 3.1278657843358815e-05
. O 0 1.7299290675509837e-06

To O 0 2.530534572997567e-07
identify O 0 4.077787991718651e-07
founder O 0 4.820628305424179e-07
effects O 0 1.9991668978036614e-06
, O 0 1.3840788071206589e-08
we O 0 7.189743467250764e-09
examined O 0 2.556991489655047e-07
independently O 0 9.94821718336425e-08
ascertained O 0 9.344306022285309e-07
French O 0 2.198883976234356e-06
Canadian O 0 2.0366114767966792e-05
cancer B-Disease 0 0.0006989060784690082
families O 0 3.43398838253961e-08
for O 0 2.9917850419280967e-09
the O 0 1.182461017990022e-09
distribution O 0 5.760135834975699e-08
of O 0 1.2318795983290443e-09
these O 0 5.996608987146601e-09
eight O 0 4.5478728338821384e-08
mutations O 0 1.3038186352787307e-06
. O 0 2.4886401206458686e-07

Mutations O 0 3.522788392729126e-05
were O 0 8.13802444099565e-07
found O 0 2.496643425331513e-08
in O 0 1.941029781349357e-09
41 O 0 1.492256274104875e-08
of O 0 2.1910628866805837e-09
97 O 0 5.673872465195018e-07
families O 0 2.0060411998201744e-07
. O 0 2.8532267037917336e-07

Six O 0 4.613578710177535e-07
of O 0 7.09882730376421e-09
eight O 0 1.4275512327799333e-08
mutations O 0 5.5389929087823475e-08
were O 0 2.4749663651846276e-08
observed O 0 9.538700851408066e-08
at O 0 7.712015559491192e-08
least O 0 1.7249863759616346e-08
twice O 0 6.615764647222022e-08
. O 0 1.2189008202767582e-07

The O 0 5.561626039707335e-07
BRCA1 O 0 6.84705883031711e-05
C4446T O 0 1.2879227142548189e-05
mutation O 0 2.087402435790864e-06
was O 0 3.2004681997932494e-06
the O 0 6.726369683462963e-09
most O 0 7.339691077135058e-09
common O 0 9.789464883169785e-08
mutation O 0 1.651314676109905e-07
found O 0 4.0191184780269396e-07
, O 0 6.985225731170885e-09
followed O 0 2.2959483203521813e-08
by O 0 6.36470742776396e-09
the O 0 3.218073629795981e-08
BRCA2 O 0 3.744788045878522e-05
8765delAG O 0 1.492839783168165e-05
mutation O 0 5.246951786830323e-06
. O 0 7.698610602346889e-07

Together O 0 2.880962256313069e-06
, O 0 2.590894609966199e-08
these O 0 1.4483865218295477e-09
mutations O 0 3.46226833869423e-08
were O 0 1.3795488484902307e-07
found O 0 2.0219599150550494e-07
in O 0 4.161056388340967e-09
28 O 0 1.1152675227776854e-08
of O 0 1.2487705314256914e-09
41 O 0 1.8051795791507175e-07
families O 0 1.410989813876995e-08
identified O 0 1.4708992068790394e-07
to O 0 7.661270728931413e-09
have O 0 2.99067970388478e-08
a O 0 1.0621216972594993e-07
mutation O 0 1.0111798474099487e-06
. O 0 1.8687609326661914e-07

The O 0 2.5046691121133335e-07
odds O 0 1.4998057622506167e-06
of O 0 1.636083046818726e-09
detection O 0 7.5653474596038e-08
of O 0 3.084328070723785e-10
any O 0 4.042222112587979e-09
of O 0 1.242735359063829e-09
the O 0 7.756105091516474e-09
four O 0 6.78491005601245e-08
BRCA1 O 0 7.66948505770415e-06
mutations O 0 5.467803703140817e-07
was O 0 3.971013484260766e-06
18 O 0 3.3582625746930717e-07
. O 0 5.426116445050866e-07

7x O 0 0.0010035209124907851
greater O 0 1.992278839679784e-06
if O 0 1.7419915820937604e-07
one O 0 1.023676876599211e-08
or O 0 1.8875439877774625e-08
more O 0 1.4642219658966837e-09
cases O 0 1.2983090869056468e-07
of O 0 0.00012982889893464744
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
were O 0 4.411933696246706e-05
also O 0 5.909940909987199e-07
present O 0 5.999494590014365e-08
in O 0 1.800334281654159e-08
the O 0 3.668264270118016e-08
family O 0 4.018197159894044e-06
. O 0 3.362916345395206e-07

The O 0 1.4863285002775228e-07
odds O 0 8.39587244172435e-07
of O 0 1.233770086095376e-09
detection O 0 9.425432523357813e-08
of O 0 6.825023324275037e-10
any O 0 1.287303774688553e-08
of O 0 3.023842731764148e-09
the O 0 1.9783779947601943e-08
four O 0 2.8804984708585835e-07
BRCA2 O 0 2.1990577806718647e-05
mutations O 0 8.253104510913545e-07
was O 0 6.01574811298633e-06
5 O 0 8.61485091263603e-07
. O 0 1.059115106727404e-06

3x O 0 0.00011755724699469283
greater O 0 5.959099667052214e-07
if O 0 3.434604423091514e-08
there O 0 7.180561478747904e-09
were O 0 8.190688127740486e-09
at O 0 8.414258623190563e-09
least O 0 7.250138822634256e-10
five O 0 3.7270578290282685e-10
cases O 0 6.926795581563283e-09
of O 0 1.2158730555711372e-07
breast B-Disease 1 0.9947913885116577
cancer I-Disease 0 0.00038946743006817997
in O 0 5.043127870862918e-08
the O 0 1.327243239757081e-07
family O 0 5.582697667705361e-06
. O 0 3.823540737357689e-07

Interestingly O 0 1.4683551853522658e-05
, O 0 3.403212289754265e-08
the O 0 9.923875055051212e-10
presence O 0 6.052639278664174e-09
of O 0 1.2014120809311635e-09
a O 0 1.5583644199068658e-05
breast B-Disease 1 0.9895300269126892
cancer I-Disease 0 0.00019827831420116127
case O 0 1.1293144552837475e-07
< O 0 4.84502788822283e-06
36 O 0 5.321679452663375e-08
years O 0 5.975805628111175e-09
of O 0 1.7882116898348954e-09
age O 0 1.7359087678414653e-07
was O 0 5.412802579485287e-07
strongly O 0 2.245716324011937e-08
predictive O 0 7.186016404148177e-08
of O 0 6.165448152017916e-10
the O 0 2.1605648381495257e-09
presence O 0 9.08678021716014e-09
of O 0 2.0004943535045783e-10
any O 0 7.511268940163518e-09
of O 0 6.704553578984473e-10
the O 0 4.680918763710906e-09
eight O 0 2.4506855211825496e-08
mutations O 0 5.624169148177316e-07
screened O 0 2.775143229882815e-06
. O 0 5.56820680230885e-07

Carriers O 0 4.96471329824999e-06
of O 0 7.095064535889151e-09
the O 0 2.221610229113935e-09
same O 0 1.1107479380711993e-08
mutation O 0 4.9064052376479594e-08
, O 0 1.292360995996944e-09
from O 0 2.286602296397433e-10
different O 0 9.482657992165855e-10
families O 0 1.7905742666357582e-08
, O 0 1.306905073050757e-08
shared O 0 4.618185389659857e-09
similar O 0 1.038047781065643e-08
haplotypes O 0 1.3851584981239284e-06
, O 0 1.3108369500969275e-08
indicating O 0 4.355440808012645e-07
that O 0 3.61051655239919e-09
the O 0 6.313595757312385e-10
mutant O 0 1.6779905465114098e-08
alleles O 0 2.646386887406038e-09
were O 0 6.113589279266307e-08
likely O 0 2.3552553685135535e-08
to O 0 9.570205961040301e-09
be O 0 6.069264912866856e-08
identical O 0 8.330806053891138e-07
by O 0 1.590429654640957e-08
descent O 0 7.384653599729063e-06
for O 0 2.74579470271874e-08
a O 0 2.574344080130686e-07
mutation O 0 3.2235661251434067e-07
in O 0 5.7197890868110335e-09
the O 0 2.0506140785414573e-08
founder O 0 7.941362127894536e-06
population O 0 1.5087907456745597e-07
. O 0 3.3520487363603024e-07

The O 0 1.1273947109202709e-07
identification O 0 1.372899731677535e-07
of O 0 1.689526030190791e-08
common O 0 2.5550564259901876e-06
BRCA1 O 0 0.0003975587897002697
and O 0 2.0289419353503035e-06
BRCA2 O 0 2.4400138499913737e-05
mutations O 0 7.250870908137586e-07
will O 0 2.3469681309506996e-08
facilitate O 0 1.1797520471645839e-07
carrier O 0 4.116487616556697e-06
detection O 0 4.328352076754527e-07
in O 0 2.4291153977173963e-08
French O 0 6.830929578427458e-06
Canadian O 0 0.00048221845645457506
breast B-Disease 1 0.9998040795326233
cancer I-Disease 1 0.7167271971702576
and O 0 0.032667167484760284
breast B-Disease 1 0.9999977350234985
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
families O 0 2.4922792363213375e-05
. O 0 1.5554323908872902e-06

Are O 0 1.5852726846787846e-06
Dp71 O 0 0.0001200029655592516
and O 0 3.2896164725571e-07
Dp140 O 0 5.050591062172316e-05
brain O 0 1.615803012100514e-05
dystrophin O 0 3.6684712085843785e-06
isoforms O 0 8.277652341348585e-08
related O 0 1.6405356291215867e-06
to O 0 1.417907640188787e-07
cognitive B-Disease 0 0.0016370478551834822
impairment I-Disease 1 0.8076768517494202
in O 0 0.0004250630736351013
Duchenne B-Disease 1 0.9999971389770508
muscular I-Disease 1 0.9999898672103882
dystrophy I-Disease 1 0.9999665021896362
? O 0 0.0022813451942056417

Molecular O 0 1.3603736078948714e-05
study O 0 1.6575343408931076e-07
and O 0 1.516637837539747e-08
neuropsychological O 0 7.478648171854729e-07
analysis O 0 3.303467366322366e-08
were O 0 5.316454476655963e-08
performed O 0 1.4360067268626153e-07
concurrently O 0 1.2391430104230494e-08
on O 0 6.973692165956891e-07
49 O 0 4.9038433644454926e-05
patients O 0 3.5647856293508084e-06
with O 0 2.9538268790929578e-05
Duchenne B-Disease 1 0.9999972581863403
muscular I-Disease 1 0.999996542930603
dystrophy I-Disease 1 0.9999947547912598
( O 0 6.884829781483859e-05
DMD B-Disease 1 0.9999996423721313
) O 0 4.1225635527553095e-07
in O 0 1.692538731390414e-08
order O 0 3.0811559526000565e-08
to O 0 3.3270030286303154e-08
find O 0 1.6426791660251183e-07
a O 0 7.3343451312268826e-09
molecular O 0 7.200188889555648e-08
explanation O 0 4.455332103248111e-09
for O 0 2.25639751327833e-09
the O 0 1.0211359757761329e-08
cognitive B-Disease 0 2.6562599941826193e-06
impairment I-Disease 0 3.859152002405608e-06
observed O 0 4.540505358363589e-07
in O 0 3.621788380314683e-08
most O 0 5.479002538777422e-06
DMD B-Disease 1 0.9999990463256836
patients O 0 3.127078525722027e-05
. O 0 6.863918997623841e-07

Complete O 0 6.677859687442833e-07
analysis O 0 1.322936640235639e-07
of O 0 6.161312793295792e-09
the O 0 7.353535558252133e-09
dystrophin O 0 2.9913810521975392e-06
gene O 0 3.018200800397608e-07
was O 0 1.2856201010436052e-06
performed O 0 4.982824179933232e-07
to O 0 4.3702752527963185e-09
define O 0 7.86043230505129e-08
the O 0 2.5520487945129844e-09
localization O 0 3.552625003067078e-07
of O 0 6.087995663150991e-10
deletions O 0 3.536116253144428e-07
and O 0 1.9783824711794296e-07
duplications O 0 3.298582385014015e-07
in O 0 5.995533847169554e-09
relation O 0 4.246658704687434e-07
to O 0 5.33227417776061e-09
the O 0 1.3942241139375255e-08
different O 0 2.513913557322667e-07
DMD B-Disease 1 0.9999665021896362
promoters O 0 8.147610788000748e-05
. O 0 6.637762908212608e-07

Qualitative O 0 4.374099262349773e-06
analysis O 0 1.700533687198913e-07
of O 0 8.96756535695431e-09
the O 0 6.707869371069819e-09
Dp71 O 0 1.3960029718873557e-05
transcript O 0 4.7738408284203615e-06
and O 0 1.0355643098591827e-07
testing O 0 2.187590411040219e-07
for O 0 9.645776399835881e-10
the O 0 3.239655765874261e-10
specific O 0 1.6708167072110314e-09
first O 0 2.2663524390509338e-09
exon O 0 2.488921957422008e-08
of O 0 2.880422123041626e-09
Dp140 O 0 1.2699140370386885e-06
were O 0 6.231661018318846e-07
also O 0 6.69834747668574e-08
carried O 0 5.370198437049112e-07
out O 0 5.1537295320258636e-08
. O 0 1.4704615125538112e-07

Neuropsychological O 0 0.00039275852032005787
analysis O 0 2.537533418944804e-06
assessed O 0 2.4204027795349248e-05
verbal O 0 2.2030184481991455e-05
and O 0 2.551676061557373e-07
visuospatial O 0 0.00010078393097501248
intelligence O 0 8.044901846915309e-07
, O 0 2.7718627393369388e-08
verbal O 0 9.782032748262282e-07
memory O 0 7.36512229195796e-05
, O 0 2.3066318632913863e-08
and O 0 1.8133265555775324e-08
reading O 0 1.8724140318227e-06
skills O 0 7.311176659641205e-07
. O 0 1.8293836490101967e-07

Comparison O 0 2.6291572794434614e-06
of O 0 9.493049901720951e-09
molecular O 0 8.447644290754397e-07
and O 0 4.0273633317156055e-08
psychometric O 0 2.4377510271733627e-05
findings O 0 6.67443487145647e-08
demonstrated O 0 6.327067580969015e-08
that O 0 1.050860509721474e-09
deletions O 0 7.667793511245691e-08
and O 0 1.2722794373587476e-08
duplications O 0 7.249453659596838e-08
that O 0 5.698337357529226e-09
were O 0 4.539959874705346e-08
localized O 0 2.6917421109828865e-06
in O 0 1.1508389796688334e-08
the O 0 2.824472655760246e-09
distal O 0 2.726051206991542e-05
part O 0 7.887418291829817e-07
of O 0 4.159516731050417e-09
the O 0 1.5941888920067981e-09
gene O 0 3.5433732392675665e-08
seemed O 0 4.7160597205220256e-08
to O 0 1.6354526621853438e-09
be O 0 3.4979976692994796e-09
preferentially O 0 1.0248925264022546e-07
associated O 0 5.8913144584948895e-08
with O 0 6.61259775824874e-08
cognitive B-Disease 0 6.901269807713106e-05
impairment I-Disease 0 0.0003011128574144095
. O 0 6.866368380542553e-07

Two O 0 2.6343903414272063e-07
altered O 0 6.221933972483384e-07
Dp71 O 0 8.800210707704537e-06
transcripts O 0 2.0311683783802437e-06
and O 0 7.390321599132221e-08
two O 0 2.2177997216488166e-09
deleted O 0 9.653422949895685e-08
Dp140 O 0 2.53563399610357e-07
DNA O 0 3.077174426380225e-08
sequences O 0 6.0130100898447836e-09
were O 0 3.570537643327043e-08
found O 0 2.2968592361394258e-08
in O 0 6.409929476092202e-09
four O 0 3.820114002905939e-08
patients O 0 2.0065539274582989e-07
with O 0 2.943887693618308e-07
severe O 0 0.3111875057220459
cerebral B-Disease 1 0.992073655128479
dysfunction I-Disease 0 0.4228278398513794
. O 0 3.622711801654077e-06

These O 0 1.4637764422786859e-07
findings O 0 3.1958084178995705e-08
suggest O 0 3.365193279591949e-08
that O 0 1.1488819895433267e-09
some O 0 2.5160401539991994e-10
sequences O 0 9.81005943145874e-09
located O 0 1.305591695199837e-06
in O 0 9.000430623018474e-09
the O 0 2.832565071386739e-09
distal O 0 7.915277819847688e-06
part O 0 1.423750290996395e-07
of O 0 2.3990198716461464e-09
the O 0 2.3125779069488317e-09
gene O 0 3.627955535989713e-08
and O 0 5.73697889194591e-08
, O 0 6.246891004479949e-09
in O 0 8.870796874838049e-10
particular O 0 1.2050065834046109e-08
, O 0 6.299969879108858e-09
some O 0 6.2454135196787774e-09
DMD B-Disease 1 0.9995529055595398
isoforms O 0 4.139558384963493e-08
expressed O 0 2.3576959051752056e-08
in O 0 1.1121427334614964e-08
the O 0 3.275747317843525e-08
brain O 0 0.00032030741567723453
may O 0 6.704661359435704e-07
be O 0 1.870734323006218e-08
related O 0 2.1395658222900238e-07
to O 0 1.0646119541490862e-08
the O 0 3.295110673207091e-08
cognitive B-Disease 0 2.343999767617788e-05
impairment I-Disease 0 0.00010720174759626389
associated O 0 4.2565620788082015e-06
with O 0 7.060197276587132e-06
DMD B-Disease 1 0.999997615814209
. O 0 4.993842139811022e-07
. O 0 7.141881042116438e-07

I1307K O 0 0.00022138742497190833
APC O 0 6.0999947891104966e-05
and O 0 3.198236129264842e-07
hMLH1 O 0 6.617406597797526e-06
mutations O 0 7.646848416698049e-07
in O 0 8.030197840014353e-09
a O 0 5.384501733374236e-08
non O 0 7.232313805616286e-07
- O 0 0.0003342986456118524
Jewish O 0 1.1797979823313653e-05
family O 0 3.49148535860877e-06
with O 0 3.735922859959828e-07
hereditary B-Disease 1 0.9480260014533997
non I-Disease 1 0.94893479347229
- I-Disease 1 0.9999992847442627
polyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 5.721459092455916e-05

We O 0 1.6090351664388436e-06
describe O 0 1.337754156338633e-06
a O 0 3.084346644754987e-07
French O 0 4.606039510690607e-06
Canadian O 0 4.790893399331253e-06
hereditary B-Disease 1 0.9453749656677246
non I-Disease 1 0.9936860203742981
- I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.000638048630207777
HNPCC B-Disease 1 0.9831923842430115
) O 0 9.796149242902175e-07
kindred O 0 3.567849489627406e-05
which O 0 7.873048843975994e-07
carries O 0 3.6075550724490313e-07
a O 0 9.726816330157817e-08
novel O 0 2.695011858122598e-07
truncating O 0 5.4825100050948095e-06
mutation O 0 8.242847115980112e-07
in O 0 5.4565834517461553e-08
hMLH1 O 0 2.946618951682467e-05
. O 0 5.591626290879503e-07

Interestingly O 0 3.0006616725586355e-05
, O 0 7.024294035318235e-08
the O 0 4.820028376428809e-09
I1307K O 0 1.1245764426348615e-06
APC O 0 6.323411412267887e-07
polymorphism O 0 1.7615085425859434e-06
, O 0 4.131780784177863e-08
associated O 0 4.3189999132664525e-08
with O 0 9.434206305058979e-09
an O 0 2.9792362354896795e-08
increased O 0 1.5543484551017173e-05
risk O 0 0.000813595368526876
of O 0 0.0424274317920208
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.979323537350865e-06
is O 0 1.8389481510894257e-06
also O 0 1.9037189247228525e-07
present O 0 1.553083883720774e-08
in O 0 7.61273533100848e-09
this O 0 2.7057525997520315e-08
family O 0 2.802929884637706e-06
. O 0 3.20638406492435e-07

The O 0 2.977421900141053e-07
I1307K O 0 4.402749709697673e-06
polymorphism O 0 9.50301910052076e-06
has O 0 1.1769370900083231e-07
previously O 0 4.433616140886443e-08
only O 0 1.7715869882195534e-09
been O 0 5.6887841992647736e-08
identified O 0 9.87488306236628e-07
in O 0 4.845321033286609e-09
individuals O 0 1.2127833182162817e-09
of O 0 1.435950580663814e-09
self O 0 4.5739772758679464e-05
- O 0 0.0513070784509182
reported O 0 0.00015559110033791512
Ashkenazi O 0 1.6853580746101215e-05
Jewish O 0 5.127120061843016e-07
origins O 0 1.2209408168928348e-06
. O 0 4.3110580350003147e-07

In O 0 2.906002123381768e-07
addition O 0 6.11570030173425e-08
, O 0 7.440529525837292e-09
in O 0 1.2483372113791802e-09
this O 0 3.5582714552617745e-09
family O 0 3.8248171563282085e-07
, O 0 1.1297987434488732e-08
there O 0 1.3863854064766201e-08
appears O 0 9.604973172372411e-08
to O 0 1.033397456495777e-08
be O 0 2.549284943142993e-07
no O 0 6.116166417768909e-08
relationship O 0 3.742762189062887e-08
between O 0 2.572202228989795e-09
the O 0 1.336356247882975e-09
I1307K O 0 2.032321901879186e-07
polymorphism O 0 9.736428410178632e-07
and O 0 1.9029979370088768e-08
the O 0 1.4445928897544036e-09
presence O 0 1.3203300852637767e-07
or O 0 2.5029658345943062e-08
absence O 0 1.1704746505358798e-08
of O 0 1.9211634949556355e-08
cancer B-Disease 0 2.6628889827406965e-05
. O 0 1.8093327724955088e-08
. O 0 2.878485645396722e-07

Identification O 0 1.7273491721425671e-06
of O 0 3.1876691508614385e-08
a O 0 1.7002435015456285e-07
novel O 0 1.9675184148582048e-07
mutation O 0 2.7080304221271945e-07
of O 0 3.250129720910877e-09
the O 0 1.3119100472636092e-08
CPO O 0 9.63602724368684e-05
gene O 0 9.771351017207053e-08
in O 0 3.1134095301865727e-09
a O 0 3.109655040134385e-07
Japanese O 0 1.757655991241336e-05
hereditary B-Disease 0 0.03239449858665466
coproporphyria I-Disease 0 0.036708664149045944
family O 0 9.119652531808242e-05
. O 0 1.5472642189706676e-06

Hereditary B-Disease 1 0.9977098703384399
coproporphyria I-Disease 1 0.941466748714447
( O 0 5.46670526091475e-06
HCP B-Disease 0 0.2727692723274231
) O 0 1.4323548214179027e-07
is O 0 3.1057547289492504e-07
an O 0 2.2719092385159456e-07
autosomal B-Disease 1 0.9987614154815674
dominant I-Disease 1 0.9998856782913208
disease I-Disease 1 0.7386373281478882
characterized O 0 0.004648375790566206
by O 0 5.378787136578467e-06
a O 0 0.010894190520048141
deficiency B-Disease 0 0.4164654016494751
of I-Disease 0 2.224418160778896e-08
coproporphyrinogen I-Disease 0 0.015397608280181885
oxidase I-Disease 0 0.00045394207700155675
( O 0 2.7851646322574197e-08
CPO O 0 0.00030866279848851264
) O 0 1.5049559820567993e-08
caused O 0 1.2130064419579867e-07
by O 0 2.7560300708273644e-09
a O 0 6.040369981974436e-08
mutation O 0 7.921099864915959e-08
in O 0 2.8104734095535377e-09
the O 0 1.814506234154578e-08
CPO O 0 0.00022181573149282485
gene O 0 4.459475633211696e-07
. O 0 2.766929867448198e-07

Only O 0 4.552854875328194e-07
11 O 0 1.8344319840934986e-08
mutations O 0 2.1288716567369192e-08
of O 0 5.497014510247311e-10
the O 0 2.9037334758896804e-09
gene O 0 1.449081423743337e-07
have O 0 5.1726377847671756e-08
been O 0 1.6535715019472264e-07
reported O 0 6.462649253080599e-06
in O 0 2.1462116706061352e-07
HCP B-Disease 1 0.9638928174972534
patients O 0 4.822412847715896e-06
. O 0 2.749343366303947e-07

We O 0 9.471257271798095e-07
report O 0 3.852242613788803e-08
another O 0 1.3174014767969311e-08
mutation O 0 5.052881135725329e-08
in O 0 2.208171867579267e-09
a O 0 1.246235257212902e-07
Japanese O 0 3.191668611179921e-06
family O 0 2.913396201620344e-06
. O 0 2.340567135661331e-07

Polymerase O 0 0.0004591131000779569
chain O 0 0.0006192118744365871
reaction O 0 1.906731199596834e-06
- O 0 4.43599492427893e-06
single O 0 9.303352044298663e-08
strand O 0 6.571940502908546e-07
conformational O 0 2.4170807577661435e-08
polymorphism O 0 7.427429977724387e-07
and O 0 4.340849901751653e-09
direct O 0 2.0482677776101355e-09
sequence O 0 1.0912230230530895e-08
analyses O 0 5.849327067153354e-08
demonstrated O 0 3.587132013649352e-08
a O 0 1.4530052716565933e-08
C O 0 4.295735379855614e-06
to O 0 2.020377642963922e-09
T O 0 9.225547046298743e-07
substitution O 0 3.6850786866438057e-09
in O 0 9.554990132443208e-10
exon O 0 2.714348923404941e-08
1 O 0 3.0935030093104388e-09
of O 0 8.255507388810202e-10
the O 0 2.8682678454572397e-09
CPO O 0 6.233566637092736e-06
gene O 0 1.0738708589030921e-08
at O 0 6.53702780795129e-09
nucleotide O 0 1.6270002234364256e-08
position O 0 6.069624447491151e-08
85 O 0 9.991760308025732e-09
, O 0 2.059660220155024e-09
which O 0 1.2992301456904443e-08
lies O 0 5.7714137255970854e-06
in O 0 4.0179237714710325e-09
the O 0 1.5865385671887111e-09
putative O 0 1.9277416640761658e-07
presequence O 0 9.932952025337727e-07
for O 0 1.6786874112995065e-09
targeting O 0 1.0218631274483414e-07
to O 0 2.0619488338979863e-08
mitochondria O 0 1.5544610505457968e-06
. O 0 2.728712615862605e-07

This O 0 2.0147838597495138e-07
mutation O 0 2.7216955800213327e-07
changes O 0 7.196562012978802e-09
the O 0 1.0408267581141217e-09
codon O 0 4.0980477677976523e-08
for O 0 7.859060624504366e-10
glutamine O 0 1.1103285402214169e-08
to O 0 1.4437721018722982e-09
a O 0 1.1282138778767603e-08
termination O 0 2.612765399589989e-07
codon O 0 2.2581686209832696e-07
at O 0 4.9862180162563163e-08
amino O 0 1.9407197626719608e-08
acid O 0 3.738560039323602e-08
position O 0 1.3741652082899236e-07
29 O 0 3.2762477530923206e-07
. O 0 1.2813197258765285e-07

MaeI O 0 0.00012607745884452015
restriction O 0 2.9934017220512033e-06
analysis O 0 2.276035928616693e-07
showed O 0 1.0132321222044993e-06
two O 0 3.10628012201164e-09
other O 0 1.5992077662119186e-09
carriers O 0 2.7058145946057266e-08
in O 0 4.077617798969868e-09
the O 0 2.2984719905139173e-08
family O 0 2.760527650025324e-06
. O 0 3.4949994187627453e-07

The O 0 1.3068223552181735e-06
C O 0 0.0039817229844629765
- O 0 0.07025471329689026
T O 0 0.018673868849873543
mutation O 0 2.919978214777075e-07
is O 0 2.536917875772815e-08
located O 0 2.123972677736674e-07
within O 0 3.51296813860813e-09
a O 0 4.173044487743027e-08
recently O 0 2.507013334707153e-07
proposed O 0 5.1642388143591234e-08
putative O 0 9.329278327641077e-08
alternative O 0 9.084111241008941e-09
translation O 0 2.3821366212928297e-08
initiation O 0 1.878923328035853e-08
codon O 0 2.2285742318217672e-07
( O 0 2.467098969560766e-09
TIC O 0 1.0848890497072716e-06
- O 0 9.813072665565414e-07
1 O 0 4.242203477389239e-09
) O 0 3.814452920192224e-10
, O 0 2.336714710615695e-10
supporting O 0 2.098061058219969e-09
that O 0 4.169971035139497e-09
TIC O 0 4.180663381703198e-06
- O 0 4.072073807037668e-06
1 O 0 2.2752411510396087e-08
is O 0 1.5154697052821575e-08
the O 0 1.1856974291291067e-09
real O 0 7.572875233563536e-07
TIC O 0 6.872342510177987e-06
rather O 0 1.3597388104358288e-08
than O 0 6.753881010013174e-09
TIC O 0 2.131627979906625e-06
- O 0 6.316468557088228e-07
2 O 0 1.038645880413469e-08
. O 0 3.7178014000716075e-09
. O 0 4.777069406713963e-08

Human B-Disease 0 5.714279723179061e-06
complement I-Disease 0 1.7051379472832195e-05
factor I-Disease 0 0.007606045808643103
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999125003814697
associated O 0 0.0017503299750387669
with O 1 0.5540459156036377
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999964237213135
. O 0 4.655583688872866e-05

This O 0 6.149785747311398e-08
study O 0 1.682290928783914e-08
reports O 0 3.311687990503742e-08
on O 0 4.5010484228669156e-08
six O 0 4.5512134505543145e-08
cases O 0 1.1724525705858468e-07
of O 0 6.024952767802461e-07
deficiency B-Disease 1 0.6656655669212341
in I-Disease 0 1.0619207735373948e-08
the I-Disease 0 1.4976246909270685e-09
human I-Disease 0 3.6393479341256807e-09
complement I-Disease 0 1.1819634160303849e-08
regulatory I-Disease 0 3.1263240884982224e-08
protein I-Disease 0 2.8329779411251366e-07
Factor I-Disease 0 1.4059172599445446e-06
H I-Disease 1 0.9999960660934448
( O 0 4.169161726963466e-08
FH O 0 1.9705486920429394e-05
) O 0 2.738497206777879e-09
in O 0 3.829031536284333e-10
the O 0 2.1728915888807876e-10
context O 0 4.876184789281979e-09
of O 0 6.535906038607209e-09
an O 0 0.00017225723422598094
acute B-Disease 1 0.9999971389770508
renal I-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
. O 0 2.6027926651295274e-05

Five O 0 3.344404433391901e-07
of O 0 1.58428967722557e-08
the O 0 9.033417569526137e-09
cases O 0 2.2637181018581032e-08
were O 0 2.6432907418438845e-08
observed O 0 1.666386424403754e-07
in O 0 9.94787274777309e-09
children O 0 3.488984035016074e-08
presenting O 0 1.5775915471749613e-06
with O 0 0.010669007897377014
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.002709401771426201
HUS B-Disease 1 0.9999854564666748
) O 0 5.275109288049862e-06
. O 0 2.8082436074328143e-06

Two O 0 3.3904427709785523e-07
of O 0 9.321911242921033e-09
the O 0 2.1285710971596927e-08
children O 0 2.73261889560672e-07
exhibited O 0 1.9057284589507617e-05
a O 0 8.171560330083594e-05
homozygous O 1 0.9740240573883057
deficiency O 1 0.8822713494300842
characterized O 0 1.0291319995303638e-05
by O 0 2.7429260640587927e-08
the O 0 9.589574467838702e-09
absence O 0 4.4596365711413455e-08
of O 0 9.243190102203869e-10
the O 0 1.6571820582456098e-09
150 O 0 7.168546645175411e-09
- O 0 1.5017020871255227e-07
kD O 0 5.01660622376221e-07
form O 0 1.5468539782403923e-09
of O 0 1.1024524626535026e-09
Factor O 0 7.655875151613145e-07
H O 1 0.9999986886978149
and O 0 2.3934231307976006e-07
the O 0 2.1268331540369445e-09
presence O 0 7.490169195989438e-08
, O 0 9.290063718303543e-10
upon O 0 2.2067096761002603e-10
immunoblotting O 0 7.419557732646354e-07
, O 0 1.3045509117404208e-09
of O 0 1.1515096515202217e-10
the O 0 7.598891516025219e-10
42 O 0 1.2966728135666017e-08
- O 0 3.7417490261759667e-07
kD O 0 1.0433004717924632e-05
Factor O 0 6.86088924339856e-07
H O 1 0.9999289512634277
- O 0 2.070461050607264e-05
like O 0 8.24953403366635e-08
protein O 0 4.980381973496151e-08
1 O 0 5.8088098775499475e-09
( O 0 6.082946368834996e-10
FHL O 0 2.588889742582978e-07
- O 0 8.267236921710719e-07
1 O 0 2.9237290366523894e-09
) O 0 2.420215139409265e-10
and O 0 1.3596914705260588e-09
other O 0 1.1635782337648948e-09
FH O 0 0.00014291261322796345
- O 0 2.4131659301929176e-05
related O 0 2.77097001344373e-06
protein O 0 3.1570678515890904e-07
( O 0 4.324833824398411e-09
FHR O 0 5.601448719971813e-06
) O 0 6.74121691801588e-09
bands O 0 2.314309313078411e-07
. O 0 1.8506831622744357e-07

Southern O 0 5.9150761444470845e-06
blot O 0 8.80900479387492e-05
and O 0 3.103385637359679e-08
PCR O 0 4.171731973201531e-07
analysis O 0 6.092436333204887e-09
of O 0 4.1195324929077515e-10
DNA O 0 1.845073711592704e-07
of O 0 2.4114292784815916e-09
one O 0 2.0388368682233704e-07
patient O 0 1.5051193258841522e-05
with O 0 1.2278792382858228e-06
homozygous O 0 0.22221283614635468
deficiency O 0 0.2097609043121338
ruled O 0 1.2206672863612766e-06
out O 0 3.97269133145528e-08
the O 0 8.167595488828283e-10
presence O 0 1.829365636751845e-08
of O 0 2.6990285006966985e-10
a O 0 2.1894306811987008e-08
large O 0 2.9219579644745863e-08
deletion O 0 9.222063113156764e-09
of O 0 1.2995368114943062e-09
the O 0 9.27346199830481e-09
FH O 0 7.580905366921797e-05
gene O 0 6.663825757868835e-08
as O 0 1.2129759419110542e-08
the O 0 8.68630856132313e-09
underlying O 0 8.24421804281883e-05
defect O 0 5.8434750826563686e-05
for O 0 1.07575729657583e-07
the O 0 1.4101246051723137e-05
deficiency O 1 0.6795913577079773
. O 0 5.881372544536134e-07

The O 0 2.3657146641653526e-07
other O 0 1.0483825363394317e-08
four O 0 8.349065439006154e-09
children O 0 5.00856991436649e-08
presented O 0 2.2004647348694562e-07
with O 0 1.817022848626948e-06
heterozygous O 0 0.04409635066986084
deficiency O 0 0.4436350166797638
and O 0 2.938020031706401e-07
exhibited O 0 9.419135494681541e-06
a O 0 6.169217670048965e-08
normal O 0 3.448435563768726e-07
immunoblotting O 0 1.3852238225808833e-05
pattern O 0 2.8862093586212723e-06
of O 0 1.6882915065963289e-09
proteins O 0 9.896830022171343e-09
of O 0 2.980007351993663e-09
the O 0 1.566424288057533e-07
FH O 0 0.23982030153274536
family O 0 5.60371427127393e-06
. O 0 5.484452572090959e-07

Factor B-Disease 0 0.4716631770133972
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9998635053634644
is O 0 4.802512876267429e-07
the O 0 1.8733766538048258e-08
only O 0 2.559450877015479e-06
complement B-Disease 1 0.9999960660934448
deficiency I-Disease 1 0.9999996423721313
associated O 0 4.5452452468452975e-05
with O 0 8.398865247727372e-06
HUS B-Disease 1 0.99992835521698
. O 0 8.37792958918726e-06

These O 0 2.0866887950887758e-07
observations O 0 4.239245754433796e-07
suggest O 0 1.14115088933886e-07
a O 0 3.2066097332972276e-08
role O 0 2.207840310575193e-08
for O 0 1.0812822637262798e-08
FH O 0 0.0007139596855267882
and O 0 8.878862445271807e-08
/ O 0 1.766205059539061e-05
or O 0 3.809135193932889e-07
FH O 0 0.00024870887864381075
receptors O 0 6.925080953124052e-08
in O 0 3.2343663303180392e-09
the O 0 4.981196344289174e-09
pathogenesis O 0 9.908288120641373e-06
of O 0 3.611920362800447e-07
idiopathic O 1 0.9999421834945679
HUS B-Disease 1 0.9999693632125854
. O 0 5.514305030374089e-07
. O 0 1.3389321793511044e-06

Further O 0 3.6189439356348885e-07
evidence O 0 1.040543864405663e-07
for O 0 5.434166894247028e-09
a O 0 1.8452967154303224e-08
major O 0 5.376076828156329e-08
ancient O 0 7.257567631313577e-07
mutation O 0 0.0011421693488955498
underlying O 1 0.9916025996208191
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999997615814209
from O 0 8.088597951427801e-07
linkage O 0 0.00033876943052746356
disequilibrium O 0 0.006288769654929638
studies O 0 1.1650205067326169e-07
in O 0 9.476442741629398e-09
the O 0 5.83376991158957e-09
Japanese O 0 3.988164962720475e-07
population O 0 5.629643595739253e-08
. O 0 1.242553935298929e-07

The O 0 0.0017669632798060775
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.002099389210343361
DM B-Disease 1 1.0
) O 0 1.3874032447347417e-06
mutation O 0 2.711880824790569e-06
is O 0 5.639035407511983e-07
an O 0 1.0201824096611745e-07
unstable O 0 0.18680356442928314
( O 0 2.0645462228685574e-08
CTG O 0 7.338656723732129e-05
) O 0 5.2631992097929015e-09
n O 0 3.635912435129285e-06
repeat O 0 4.6416113264058367e-07
, O 0 3.210316679158609e-09
present O 0 1.0834829922146128e-08
at O 0 1.7264041218822967e-07
a O 0 5.3130051469452155e-09
copy O 0 8.650814464772338e-08
number O 0 6.14605144555469e-10
of O 0 4.2363310082116357e-10
5 O 0 1.4185616237227805e-08
- O 0 3.109511681032018e-06
37 O 0 2.9561190828530926e-08
repeats O 0 2.0713935455773935e-08
on O 0 1.0661339366890843e-08
normal O 0 2.2161348312010887e-08
chromosomes O 0 1.5435155376053444e-08
but O 0 1.874641109012032e-09
amplified O 0 2.9481572738632167e-08
to O 0 1.5117448404211586e-09
50 O 0 8.485268487845588e-09
- O 0 2.29632561854487e-07
3000 O 0 5.590885621131747e-08
copies O 0 5.326584329168327e-08
on O 0 8.312018508149777e-06
DM B-Disease 1 0.9999971389770508
chromosomes O 0 9.498996223555878e-05
. O 0 2.4653022592247e-06

Previous O 0 2.4816445147735067e-06
findings O 0 4.857191129303828e-07
in O 0 4.14711358587283e-08
Caucasian O 0 8.543175681552384e-06
populations O 0 2.2063422022711165e-07
of O 0 7.478631935953217e-09
a O 0 6.748771556885913e-05
DM B-Disease 1 1.0
founder O 0 0.00046673795441165566
chromosome O 0 0.0002212216058978811
raise O 0 2.0582886008924106e-06
a O 0 1.286513793274935e-07
question O 0 8.85120030602593e-08
about O 0 6.976011768244916e-09
the O 0 3.661110026254022e-10
molecular O 0 2.3917385405525238e-08
events O 0 3.7851890510864905e-09
involved O 0 1.0645226034000643e-08
in O 0 2.0016366342190395e-09
the O 0 1.721888964745233e-09
expansion O 0 1.175566694655572e-06
mutation O 0 1.6663959740981227e-06
. O 0 1.8415035185626039e-07

To O 0 2.9657206823685556e-07
investigate O 0 4.0078501228890673e-07
whether O 0 7.042054761541294e-08
a O 0 1.1543238542799372e-07
founder O 0 4.840612746193074e-06
chromosome O 0 1.3637144547828939e-05
for O 0 2.3833955253849126e-08
the O 0 5.347442311176565e-07
DM B-Disease 1 1.0
mutation O 0 1.0434218893351499e-05
exists O 0 1.978733479290895e-07
in O 0 3.532197201394638e-09
the O 0 1.8790944356084083e-09
Japanese O 0 5.898510835322668e-08
population O 0 2.3379107538801236e-09
, O 0 2.299198831323679e-09
we O 0 4.9164636806153794e-09
genotyped O 0 5.328204792931501e-07
families O 0 1.1261235277615356e-09
using O 0 3.4601805865008828e-09
polymorphic O 0 7.770320848976553e-07
markers O 0 0.00013591512106359005
near O 0 0.0004130923480261117
the O 0 1.8066049989329258e-08
( O 0 1.5128097885508396e-08
CTG O 0 8.365570465684868e-06
) O 0 1.0911522352330394e-08
n O 0 6.9753482421219815e-06
repeat O 0 1.9002450244443025e-06
region O 0 5.818592967443692e-07
and O 0 2.0194045191601617e-07
constructed O 0 0.0003621455980464816
haplotypes O 0 9.833148214966059e-05
. O 0 1.8393358232060564e-06

Six O 0 4.231865489146003e-07
different O 0 1.121139181492481e-08
haplotypes O 0 9.388101034346619e-07
were O 0 1.655834438452075e-07
found O 0 1.1904872962986701e-06
and O 0 3.083495585087803e-06
DM B-Disease 1 0.9999997615814209
alleles O 0 1.8927933069790015e-06
were O 0 3.162186203553574e-06
always O 0 3.380909220140893e-06
haplotype O 0 1.62105388881173e-05
A O 0 7.303789857360243e-07
. O 0 6.059971155991661e-07

To O 0 3.0297621833597077e-07
find O 0 1.0499037728095573e-07
an O 0 8.314893773508913e-10
origin O 0 2.759333206370229e-09
of O 0 1.2871164134509172e-09
the O 0 1.3054351377661533e-08
( O 0 4.368625017292516e-09
CTG O 0 6.402298367902404e-06
) O 0 2.1325932131333047e-09
n O 0 7.834116786398226e-07
repeat O 0 2.9356002073654963e-07
mutation O 0 9.161057334949874e-08
and O 0 9.050180160841137e-09
to O 0 6.451855050215727e-09
investigate O 0 6.044957245876503e-08
the O 0 1.432353569086331e-09
mechanism O 0 1.3898087125596703e-08
of O 0 1.746756905784963e-10
the O 0 3.4396618886489705e-10
expansion O 0 6.00059308908385e-08
mutation O 0 4.867926151064239e-08
in O 0 1.3118092168085127e-09
the O 0 1.0234968428335378e-09
Japanese O 0 1.5389245788810513e-07
population O 0 2.6783528728202555e-09
we O 0 3.0495590497281455e-09
have O 0 2.519343900164728e-10
studied O 0 8.495612546788323e-10
90 O 0 3.604922138578104e-09
Japanese O 0 5.167569838704367e-07
DM B-Disease 1 0.9999994039535522
families O 0 6.703932342588814e-08
comprising O 0 1.670218452431982e-08
190 O 0 9.007011669837084e-08
affected O 0 7.894268350128186e-08
and O 0 2.7515930867139105e-08
130 O 0 4.0294040104527085e-07
unaffected O 0 1.3581517123384401e-05
members O 0 5.967630301029203e-08
. O 0 2.2802250043696404e-07

The O 0 3.152221381697018e-07
results O 0 2.0437757086710917e-07
suggest O 0 1.2631497270376713e-07
that O 0 9.981246940071742e-09
a O 0 2.3250867897672833e-08
few O 0 2.5871909059560494e-08
common O 0 4.1994571375880696e-08
ancestral O 0 9.77080730990565e-07
mutations O 0 4.274393461400905e-07
in O 0 1.9082863289554552e-08
both O 0 2.860423897743658e-08
Caucasian O 0 5.597917152044829e-07
and O 0 8.746011559424005e-08
Japanese O 0 3.5321122027198726e-07
populations O 0 1.2016510453349838e-08
have O 0 8.998126133086259e-10
originated O 0 9.646070608937407e-10
by O 0 6.946926367490391e-11
expansion O 0 5.098913735679389e-09
of O 0 4.74606798306354e-10
an O 0 4.097521877355348e-09
ancestral O 0 2.6216359856334748e-06
n O 0 5.1284150686115026e-05
= O 0 7.58450426019408e-07
5 O 0 4.578908807673088e-09
repeat O 0 1.8316979932819777e-08
to O 0 2.717844171939987e-09
n O 0 5.964340743958019e-06
= O 0 1.737389254685695e-07
19 O 0 7.367574550443123e-09
- O 0 2.785558592677262e-07
37 O 0 1.565043739049088e-08
copies O 0 4.3391636950218526e-08
. O 0 1.1605914096435299e-07

These O 0 6.679911024320973e-08
data O 0 5.7440082912307844e-08
support O 0 3.574760931712717e-09
multistep O 0 1.9314515498081164e-07
models O 0 3.0423919383792963e-07
of O 0 3.33753913395185e-09
triplet O 0 2.336594661755953e-05
repeat O 0 2.3769428025843808e-07
expansion O 0 1.2530436777069554e-07
that O 0 3.068640452852378e-08
have O 0 2.3480459798719266e-09
been O 0 1.7263810381251687e-09
proposed O 0 4.0682954782766956e-09
for O 0 2.9260722733681632e-09
both O 0 2.1578627240614878e-07
DM B-Disease 1 0.9999998807907104
and O 0 7.12951659807004e-05
Friedreichs B-Disease 0 0.4340786039829254
ataxia I-Disease 1 0.9960301518440247
. O 0 2.516652841677569e-07
. O 0 8.100888067019696e-07

The O 0 1.520054411230376e-07
molecular O 0 1.727780841065396e-06
basis O 0 1.527692802483216e-06
of O 0 1.5630976122338325e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
in O 0 2.4865667569429206e-07
the O 0 9.560153557686135e-09
western O 0 6.372337679749762e-08
Cape O 0 1.4628069493483054e-06
, O 0 2.0929103783373648e-08
South O 0 3.922246349929992e-08
Africa O 0 6.095902449487767e-08
. O 0 1.203683979156267e-07

Deficiency B-Disease 1 0.9976404905319214
of I-Disease 0 8.882742008609057e-08
the I-Disease 0 1.6837484295706417e-08
sixth I-Disease 0 2.421797375973256e-07
component I-Disease 0 1.2139987575210398e-06
of I-Disease 0 5.3305244662738005e-09
human I-Disease 0 1.0902768110554462e-07
complement I-Disease 0 5.122531092638383e-07
( O 0 1.9077040391835e-08
C6 O 0 0.00010630542237777263
) O 0 3.2455145237975103e-09
has O 0 1.505199875850849e-08
been O 0 3.7761196836072486e-08
reported O 0 3.0727116495654627e-07
in O 0 2.1242627656903323e-09
a O 0 1.3632445394762271e-08
number O 0 3.0175395515641412e-09
of O 0 7.059478002169328e-10
families O 0 9.894281838285224e-09
from O 0 6.096769200603092e-10
the O 0 1.1963515733626195e-09
western O 0 3.140806015267117e-08
Cape O 0 5.134861567057669e-07
, O 0 1.145574124450377e-08
South O 0 3.2682958561736086e-08
Africa O 0 6.403797669918276e-08
. O 0 1.2631713275368384e-07

Meningococcal B-Disease 1 0.9996669292449951
disease I-Disease 1 0.9563860297203064
is O 0 5.28587588632945e-06
endemic O 0 1.037120364344446e-05
in O 0 3.190984898537863e-08
the O 0 1.9591071875879607e-08
Cape O 0 1.1469051969470456e-05
and O 0 1.5359364624600857e-07
almost O 0 7.103242882777749e-09
all O 0 4.13650780295427e-10
pedigrees O 0 2.3987701069927425e-07
of O 0 1.8967142523251823e-08
total O 0 0.44677475094795227
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
( O 0 7.302828919364401e-08
C6Q0 O 0 0.00031796921393834054
) O 0 6.3472498368355446e-09
have O 0 4.1771990311190166e-09
been O 0 2.9960922631744324e-08
ascertained O 0 2.7724979645427084e-07
because O 0 7.896267639750931e-09
of O 0 2.158387069073342e-08
recurrent O 1 0.9641231298446655
disease O 0 0.009650039486587048
. O 0 1.0324507684345008e-06

We O 0 2.327874881302705e-06
have O 0 1.2311285324528853e-08
sequenced O 0 2.8615207980919877e-08
the O 0 3.5105771623022974e-09
expressed O 0 3.0679190299309766e-09
exons O 0 2.3724195941099424e-08
of O 0 9.227055230986991e-10
the O 0 8.221726410795327e-09
C6 O 0 3.09301249217242e-05
gene O 0 3.985913110682304e-08
from O 0 2.345047267482414e-09
selected O 0 6.650706652067129e-09
cases O 0 1.9606959611451202e-08
and O 0 2.128003444568094e-07
have O 0 3.4609354315762175e-07
found O 0 3.6146047932561487e-07
three O 0 3.192823427866642e-08
molecular O 0 0.0005414020852185786
defects O 0 0.4201405644416809
leading O 0 1.01991543033364e-06
to O 0 1.9401652195938368e-07
total O 0 8.791348955128342e-05
deficiency O 0 0.25731876492500305
879delG O 0 1.4097910934651736e-05
, O 0 3.673928716807495e-08
which O 0 6.643672634254472e-08
is O 0 3.695194905617427e-08
the O 0 3.905820555871742e-09
common O 0 5.354494874154625e-07
defect O 0 2.0706744180643e-05
in O 0 5.8151510273773965e-09
the O 0 1.2148653638632823e-08
Cape O 0 3.4569413855933817e-06
and O 0 4.3973518160100866e-08
hitherto O 0 4.3687276729542646e-07
unreported O 0 1.3250578945189773e-07
, O 0 6.2419838187111054e-09
and O 0 6.0001439372570076e-09
1195delC O 0 7.520725375798065e-07
and O 0 2.137562482573685e-08
1936delG O 0 2.0177540136501193e-06
, O 0 6.570553434670501e-09
which O 0 1.835040919218045e-08
have O 0 1.2965021944921773e-08
been O 0 1.8705630822068997e-08
previously O 0 1.1876473138272559e-07
reported O 0 5.799004725304258e-07
in O 0 6.554556897242492e-09
African O 0 2.875570892513224e-08
- O 0 2.6660114599508233e-05
Americans O 0 7.03016524994382e-08
. O 0 1.474944752999363e-07

We O 0 1.2757539025187725e-06
also O 0 2.282952848986497e-08
show O 0 4.698399180824708e-08
that O 0 9.157992142405647e-10
the O 0 1.4878531739981327e-09
879delG O 0 2.328962864339701e-06
and O 0 1.043437549697046e-07
1195delC O 0 0.00042159337317571044
defects O 1 0.6704872250556946
are O 0 2.5066732689538185e-08
associated O 0 5.876646014257858e-07
with O 0 1.4493771516299603e-07
characteristic O 0 0.005832919385284185
C6 O 1 0.9941790103912354
/ O 0 0.028772026300430298
C7 O 0 0.004223115276545286
region O 0 1.0897866786763188e-06
DNA O 0 1.417983730789274e-05
marker O 0 9.257213241653517e-05
haplotypes O 0 4.91093669552356e-06
, O 0 1.7682356912018804e-08
although O 0 9.513115628578817e-09
small O 0 5.280074333313678e-08
variations O 0 7.152514740482729e-07
were O 0 5.472759312397102e-07
observed O 0 2.248962573503377e-06
. O 0 2.339391045325101e-07

The O 0 2.1652611792433163e-07
1936delG O 0 7.725314935669303e-05
defect O 0 0.0001145919450209476
was O 0 3.203083167591103e-07
observed O 0 2.2840313818051072e-07
only O 0 5.011157266920918e-09
once O 0 6.411106312498305e-08
in O 0 1.376123215379721e-09
the O 0 2.03377048535458e-09
Cape O 0 1.5981039496182348e-06
, O 0 2.1228949265150732e-08
but O 0 1.8081554031823543e-09
its O 0 1.4893750677202888e-09
associated O 0 5.989546991713723e-08
haplotype O 0 3.607686721807113e-06
could O 0 8.717380524103646e-07
be O 0 6.675096386743462e-08
deduced O 0 7.85655572599353e-07
. O 0 2.197430291062119e-07

The O 0 1.0628249214050811e-07
data O 0 1.6035174610351532e-07
from O 0 1.9267401007994067e-09
the O 0 5.203654729335483e-10
haplotypes O 0 5.4393177606471e-07
indicate O 0 3.464065798652882e-07
that O 0 5.761638277590464e-09
these O 0 1.3409905408323652e-09
three O 0 1.1273577626980114e-08
molecular O 0 0.00010478230979060754
defects O 0 0.13068453967571259
account O 0 7.875602250351221e-07
for O 0 1.546541170682758e-07
the O 0 6.891638122397126e-07
defects O 1 0.815273642539978
in O 0 1.0703352870677918e-08
all O 0 1.968459173440351e-09
the O 0 2.3121722314556337e-09
38 O 0 3.1709024739257075e-08
unrelated O 0 1.3037050905495562e-07
C6Q0 O 0 1.2186724234197754e-05
individuals O 0 6.0834368653672755e-09
we O 0 1.813786631998937e-08
have O 0 7.354766795586443e-10
studied O 0 3.0604205836226583e-09
from O 0 7.133434953843221e-10
the O 0 1.0458381716205167e-08
Cape O 0 7.96100175648462e-06
. O 0 3.249134010729904e-07

We O 0 1.9049463162446045e-06
have O 0 7.943580015989937e-09
also O 0 2.370048601818553e-09
observed O 0 1.8752498220919733e-08
the O 0 2.621803885105578e-09
879delG O 0 1.7281650798395276e-05
defect O 0 1.7695365386316553e-05
in O 0 1.0390064808518673e-08
two O 0 1.121584531915687e-07
Dutch O 1 0.8898576498031616
C6 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999783039093018
deficient I-Disease 1 0.9999953508377075
kindreds O 0 0.0019212114857509732
, O 0 1.2834672702410899e-07
but O 0 9.023050751011397e-09
the O 0 2.9899824838253153e-09
879delG O 0 1.2256748959771357e-05
defect O 0 8.541504939785227e-06
in O 0 5.88663917611143e-09
the O 0 5.335692332408826e-09
Cape O 0 1.89084835255926e-06
probably O 0 1.581052742949396e-06
did O 0 1.1839827784854151e-08
not O 0 3.0482683044397163e-09
come O 0 8.761548153657372e-10
from O 0 2.401105980709417e-10
The O 0 7.568602411467396e-10
Netherlands O 0 1.565829848004796e-07
. O 0 8.181491928382911e-09
. O 0 6.712581779311222e-08

Complement B-Disease 1 0.9979597330093384
C7 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999998807907104
: O 0 3.8872059349159827e-07
seven O 0 2.0994633587179123e-08
further O 0 4.984525503459736e-08
molecular O 0 0.0005376897752285004
defects O 1 0.9834463000297546
and O 0 4.611471524640365e-07
their O 0 3.0375730375453713e-08
associated O 0 4.3222653403063305e-06
marker O 0 0.0021831796038895845
haplotypes O 0 7.906524842837825e-05
. O 0 1.009085508485441e-06

Seven O 0 8.309303325404471e-07
further O 0 7.435396298660635e-08
molecular O 0 8.162789413290739e-07
bases O 0 1.457951839256566e-06
of O 0 3.0338578653754666e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 8.867859833117109e-07
described O 0 3.8495254557346925e-05
. O 0 9.362466926177149e-07

All O 0 5.783584455798518e-08
these O 0 3.884031762879658e-09
new O 0 6.744844238681935e-09
molecular O 0 1.554214941279497e-05
defects O 0 0.0718071386218071
involve O 0 4.09374393939288e-07
single O 0 1.8685288978304015e-06
- O 0 1.101640646083979e-05
nucleotide O 0 3.240481589728006e-07
events O 0 8.337070767083787e-08
, O 0 2.5319373264665046e-09
deletions O 0 1.586430542488415e-08
and O 0 2.2814118594283173e-08
substitutions O 0 1.7863708023924119e-07
, O 0 3.9465883894251874e-09
some O 0 1.2870199350700773e-10
of O 0 8.087816527613256e-11
which O 0 9.338426032456937e-09
alter O 0 6.046906833034882e-07
splice O 0 7.404752068396192e-06
sites O 0 3.3779988370952196e-06
, O 0 2.3939017879115454e-08
and O 0 5.97236677890578e-08
others O 0 7.929187972877116e-08
codons O 0 1.968148126252345e-06
. O 0 2.374901271195995e-07

They O 0 4.910164079774404e-07
are O 0 6.209329050932411e-09
distributed O 0 1.2421482509239468e-08
along O 0 3.992166952571097e-08
the O 0 4.858684565789417e-09
C7 O 0 2.444292294967454e-05
gene O 0 1.271843217409696e-07
, O 0 3.1171887293623968e-09
but O 0 4.467379799422133e-10
predominantly O 0 1.3589163128102655e-09
towards O 0 3.424019290321212e-09
the O 0 1.2971297369546164e-09
3 O 0 1.6474759334528244e-08
end O 0 3.3923640785360476e-07
. O 0 1.1648027253841065e-07

All O 0 6.589959866687423e-08
were O 0 7.454368500248165e-08
found O 0 2.3495390522043635e-08
in O 0 5.1301891623722895e-09
compound O 0 2.5392425868631108e-06
heterozygous O 0 7.421468808388454e-07
individuals O 0 4.169233491779778e-08
. O 0 1.713876116582469e-07

The O 0 1.9491206330712885e-05
C6 O 1 0.8842570781707764
/ O 0 0.20824843645095825
C7 O 0 0.1303817629814148
marker O 0 0.0013946014223620296
haplotypes O 0 0.00032220385037362576
associated O 0 9.745507668412756e-06
with O 0 3.928206808723189e-07
most O 0 1.5378200259874575e-05
C7 B-Disease 1 0.9996724128723145
defects I-Disease 1 0.9982314705848694
are O 0 2.069719613473353e-07
tabulated O 0 1.894681918201968e-05
. O 0 8.368264303726392e-08
. O 0 6.827847869317338e-07

A O 0 1.4605523574573454e-05
genome O 0 4.02236082663876e-06
- O 0 3.929676313418895e-05
wide O 0 4.1320890886709094e-07
search O 0 3.346452359664909e-08
for O 0 4.737369607710207e-09
chromosomal O 0 0.003600944997742772
loci O 0 1.2117546930312528e-06
linked O 0 0.00032729055965319276
to O 0 1.769003347362741e-06
mental O 0 0.038010288029909134
health O 0 1.2833330629291595e-06
wellness O 0 9.064779987966176e-06
in O 0 3.5533897602135767e-08
relatives O 0 1.8006456059538323e-07
at O 0 4.3908607949560974e-07
high O 0 1.417015755578177e-05
risk O 0 2.732702114371932e-06
for O 0 1.5137586615310283e-06
bipolar B-Disease 1 0.9999953508377075
affective I-Disease 1 0.9999288320541382
disorder I-Disease 1 0.9701815843582153
among O 0 5.389002311062541e-08
the O 0 8.537689666354709e-09
Old O 0 1.1374168025213294e-05
Order O 0 1.4624119160089322e-07
Amish O 0 7.968759746290743e-05
. O 0 7.697964292674442e-07

Bipolar B-Disease 1 0.99998939037323
affective I-Disease 1 0.9999709129333496
disorder I-Disease 1 0.9999717473983765
( O 0 0.0001597974478499964
BPAD B-Disease 1 0.9999985694885254
; O 0 0.00011890367022715509
manic B-Disease 1 0.9999871253967285
- I-Disease 1 0.9999969005584717
depressive I-Disease 1 0.9999996423721313
illness I-Disease 1 0.9385153651237488
) O 0 1.9717468546787131e-07
is O 0 2.520264956729079e-07
characterized O 0 3.531287120495108e-06
by O 0 2.4860169478557737e-09
episodes O 0 8.288885311458216e-08
of O 0 5.363121147183847e-08
mania B-Disease 0 0.11783519387245178
and O 0 1.7792531252780464e-06
/ O 0 0.0033433930948376656
or O 0 4.583114787237719e-06
hypomania B-Disease 0 0.015412152744829655
interspersed O 0 2.270030563522596e-05
with O 0 6.349553416384879e-08
periods O 0 5.272546559353941e-07
of O 0 2.612117384614976e-07
depression B-Disease 0 0.00075343536445871
. O 0 1.240845676875324e-06

Compelling O 0 6.9030443228257354e-06
evidence O 0 7.648263249393494e-07
supports O 0 4.1674059048091294e-07
a O 0 3.0278840768005466e-08
significant O 0 1.612876765477722e-08
genetic O 0 3.123624878753617e-07
component O 0 2.2230667582334718e-06
in O 0 8.491340075522658e-09
the O 0 7.387217948462421e-09
susceptibility O 0 2.4758626750553958e-05
to O 0 3.2042200359683193e-07
develop O 0 5.3875995945418254e-05
BPAD B-Disease 1 0.9999849796295166
. O 0 7.960546099639032e-06

To O 0 1.4356177757690602e-07
date O 0 8.736947734178102e-07
, O 0 1.5478937243074142e-08
however O 0 1.7340109348396027e-09
, O 0 8.726308564632745e-10
linkage O 0 2.6979924427905644e-07
studies O 0 2.9939086765295997e-09
have O 0 2.5065571840343637e-09
attempted O 0 3.4312853358642315e-07
only O 0 5.135563529989895e-09
to O 0 5.356371346465494e-09
identify O 0 5.506695401891193e-07
chromosomal O 0 0.0003360926639288664
loci O 0 4.106115341073746e-07
that O 0 4.112126816835371e-07
cause O 0 7.535292070315336e-07
or O 0 7.07744263195309e-08
increase O 0 6.427818988186118e-08
the O 0 1.293434515048375e-08
risk O 0 3.6504457057162654e-07
of O 0 9.200628703354141e-09
developing O 0 3.0900348065188155e-05
BPAD B-Disease 1 0.9999886751174927
. O 0 5.9110507208970375e-06

To O 0 1.6619473797163664e-07
determine O 0 8.071170043422171e-08
whether O 0 8.636352077928677e-09
there O 0 3.609058651932173e-08
could O 0 7.703150828319849e-08
be O 0 1.007185534973587e-08
protective O 0 2.396670879534213e-07
alleles O 0 1.4625590516459397e-08
that O 0 6.082288450670603e-09
prevent O 0 4.924664835925796e-07
or O 0 1.3334319248770043e-07
reduce O 0 4.3781119529739954e-07
the O 0 8.711877441669458e-09
risk O 0 2.1344098399822542e-07
of O 0 8.938393913915377e-10
developing O 0 3.3864400847960496e-06
BPAD B-Disease 1 0.9999996423721313
, O 0 1.2972719787285314e-07
similar O 0 6.4535532473541934e-09
to O 0 6.641148964092736e-09
what O 0 7.523441425405508e-09
is O 0 7.665334145201541e-09
observed O 0 5.713544126706438e-08
in O 0 9.230175734842305e-09
other O 0 2.698162006709026e-06
genetic B-Disease 1 0.9999995231628418
disorders I-Disease 1 0.9999997615814209
, O 0 1.0084986570291221e-06
we O 0 2.5559386358509073e-06
used O 0 0.0005255277501419187
mental O 0 0.02061002515256405
health O 0 2.725482318055583e-06
wellness O 0 8.227090438595042e-05
( O 0 8.239465998371998e-09
absence O 0 1.9528394901158208e-08
of O 0 3.90683396744862e-09
any O 0 1.3382414181251079e-05
psychiatric B-Disease 1 0.991855263710022
disorder I-Disease 0 0.471597284078598
) O 0 3.926857772285075e-08
as O 0 7.206880781041036e-08
the O 0 5.1072648332706194e-09
phenotype O 0 7.060655207169475e-07
in O 0 9.984521653905176e-09
our O 0 1.7447840505724344e-08
genome O 0 5.279107639921676e-08
- O 0 7.683211151743308e-06
wide O 0 1.8294340407010168e-06
linkage O 0 7.728588570898864e-06
scan O 0 7.952259693411179e-06
of O 0 1.0824042773194265e-09
several O 0 2.7976643224292275e-09
large O 0 9.038453185894468e-08
multigeneration O 0 1.0956392543448601e-05
Old O 0 3.2545594876864925e-06
Order O 0 1.4477989473959951e-08
Amish O 0 7.647266102139838e-06
pedigrees O 0 5.149232947587734e-06
exhibiting O 0 8.677517371324939e-07
an O 0 1.4891401001193572e-08
extremely O 0 1.3367376595851965e-05
high O 0 9.962893273041118e-06
incidence O 0 0.0025115518365055323
of O 0 1.1648443205558578e-06
BPAD B-Disease 1 0.999995231628418
. O 0 8.957258614827879e-06

We O 0 3.0712162697454914e-06
have O 0 2.90420008042247e-08
found O 0 5.299382710433065e-09
strong O 0 2.7070108377102997e-09
evidence O 0 3.7821292764306236e-09
for O 0 2.2158632706492654e-09
a O 0 7.015457725856322e-08
locus O 0 1.3099693205731455e-06
on O 0 1.670693677624513e-06
chromosome O 0 9.498035797150806e-05
4p O 0 0.011832647025585175
at O 0 5.906813385081477e-07
D4S2949 O 0 3.655308944416902e-07
( O 0 2.5835651396022286e-09
maximum O 0 8.39076790271065e-08
GENEHUNTER O 0 1.9295588572276756e-05
- O 0 1.6708005432519712e-06
PLUS O 0 1.0670518690858444e-07
nonparametric O 0 1.2535126643342664e-06
linkage O 0 2.319788109161891e-06
score O 0 3.435495443682157e-08
= O 0 5.4563752627245776e-08
4 O 0 1.4415652005439483e-09
. O 0 2.9915209198705384e-10
05 O 0 2.2683169120796265e-08
, O 0 1.7368707583287346e-09
P O 0 1.6266598322545178e-05
= O 0 3.0344867951725973e-08
5 O 0 6.647722927688449e-10
. O 0 1.549912836962264e-10
22 O 0 9.96343785253373e-10
x O 0 9.299074008595198e-07
10 O 0 2.238667251575066e-09
( O 0 1.1805951771748369e-09
- O 0 1.931640781549504e-06
4 O 0 8.743039181524637e-09
) O 0 5.721652041046354e-10
; O 0 5.892589749478816e-10
SIBPAL O 0 1.1027810842278996e-06
Pempirical O 0 2.3237485891058896e-07
value O 0 9.377782994590689e-09
< O 0 3.4955661476487876e-07
3 O 0 3.691374761416455e-09
x O 0 2.0224356376274955e-06
10 O 0 8.920106431276054e-09
( O 0 2.3088315703745366e-09
- O 0 4.325036115915282e-06
5 O 0 1.2388263748164263e-08
) O 0 3.896398759195563e-10
) O 0 1.9830682929100618e-10
and O 0 2.5468263054051477e-09
suggestive O 0 4.057022579218028e-06
evidence O 0 4.2685357470872987e-08
for O 0 1.211837630243906e-09
a O 0 4.299471001445454e-08
locus O 0 7.817131972842617e-07
on O 0 2.879792191379238e-06
chromosome O 0 0.0026958021335303783
4q O 0 0.0566636361181736
at O 0 1.5012225276223035e-06
D4S397 O 0 1.7326318584309774e-06
( O 0 7.580394978390359e-09
maximum O 0 1.0743568168436468e-07
GENEHUNTER O 0 1.8347722289036028e-05
- O 0 3.451881411820068e-06
PLUS O 0 1.6009182957077428e-07
nonparametric O 0 1.045363319462922e-06
linkage O 0 4.404395895107882e-06
score O 0 9.136034861967346e-08
= O 0 3.043349394715733e-08
3 O 0 1.32778898986885e-09
. O 0 3.992985664336146e-10
29 O 0 4.410621645689616e-09
, O 0 9.50841294589111e-10
P O 0 1.4566367099178024e-05
= O 0 3.54448204120672e-08
2 O 0 1.0325615917849973e-09
. O 0 3.658666702932578e-10
57 O 0 2.8705606780476955e-09
x O 0 9.236499067810655e-07
10 O 0 6.373332528397668e-09
( O 0 2.142067412336246e-09
- O 0 4.060123046656372e-06
3 O 0 8.594531308858677e-09
) O 0 4.4973366697398376e-10
; O 0 2.83658624367078e-10
SIBPAL O 0 3.6197860708853113e-07
Pempirical O 0 1.0581462817071952e-07
value O 0 4.5414036975444105e-09
< O 0 1.589293248116519e-07
1 O 0 2.6617252846250494e-09
x O 0 3.658709374576574e-06
10 O 0 1.3984400304423161e-08
( O 0 1.4590336716580055e-09
- O 0 9.982698247767985e-05
3 O 0 4.9111054778450125e-08
) O 0 9.480958240715154e-10
) O 0 2.3562457540649007e-10
that O 0 5.007962933234467e-10
are O 0 7.413868186034733e-09
linked O 0 3.048283360840287e-05
to O 0 1.0832804946403485e-06
mental O 0 0.001723448745906353
health O 0 5.687324573955266e-06
wellness O 0 9.820684499572963e-05
. O 0 8.0074488550963e-07

These O 0 1.359281611712504e-07
findings O 0 1.265694038465881e-07
are O 0 5.840829153669347e-09
consistent O 0 2.2383785847068793e-07
with O 0 1.0739404920911966e-08
the O 0 1.9835459941219824e-09
hypothesis O 0 8.345279667310024e-08
that O 0 1.5520464913265641e-09
certain O 0 1.662950999126167e-09
alleles O 0 1.2620462896961726e-08
could O 0 5.619645193633005e-08
prevent O 0 2.310915192538232e-07
or O 0 2.2456868009612663e-07
modify O 0 1.761676571732096e-06
the O 0 2.17978879391012e-08
clinical O 0 7.755647857266013e-07
manifestations O 0 6.419194846785103e-07
of O 0 1.3464584469602414e-07
BPAD B-Disease 1 0.9999997615814209
and O 0 1.4028863688508864e-06
perhaps O 0 6.158119703059128e-08
other O 0 1.61981343893558e-08
related O 0 8.295216684928164e-05
affective B-Disease 1 0.9982391595840454
disorders I-Disease 1 0.9693601131439209
. O 0 1.8209779000244453e-06

Segregation O 0 0.0006834502564743161
distortion O 0 0.13816067576408386
in O 0 0.0006509824306704104
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999988079071045
. O 0 0.00014911805919837207

Myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999997615814209
( O 0 0.023737041279673576
DM B-Disease 1 0.9999998807907104
) O 0 1.5819494365132414e-05
is O 0 3.099602281508851e-06
an O 0 4.3716451614272955e-07
autosomal B-Disease 1 0.9905800223350525
dominant I-Disease 1 0.9990984201431274
disease I-Disease 1 0.9082550406455994
which O 0 8.626685485069174e-06
, O 0 1.9456589939181868e-07
in O 0 1.377520941758803e-08
the O 0 5.015900139682117e-09
typical O 0 5.342173608369194e-06
pedigree O 0 4.3360534618841484e-05
, O 0 7.090572573531517e-09
shows O 0 3.629229183843563e-08
a O 0 1.1245057329745123e-08
three O 0 4.16963663596448e-09
generation O 0 8.968885367721668e-08
anticipation O 0 4.617474189672066e-07
cascade O 0 6.420531281037256e-05
. O 0 8.197707757062744e-07

This O 0 1.0886227386208702e-07
results O 0 4.484064959342504e-07
in O 0 4.573333569624083e-07
infertility B-Disease 1 0.998781144618988
and O 1 0.9913327097892761
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.385058905929327e-05
CDM B-Disease 0 0.0016252432251349092
) O 0 5.41463620606919e-08
with O 0 1.171975849700857e-08
the O 0 7.150029901481503e-09
disappearance O 0 1.40708959861513e-06
of O 0 1.962185507409231e-07
DM B-Disease 1 0.9999998807907104
in O 0 1.1277178373347851e-06
that O 0 5.050443405707483e-07
pedigree O 0 0.00010443208157084882
. O 0 4.7651255385972036e-07

The O 0 1.4227460098936717e-07
concept O 0 1.4579558182958863e-07
of O 0 4.8284940490361805e-09
segregation O 0 2.5906481937454373e-07
distortion O 0 4.8944053560262546e-05
, O 0 4.4032606894006676e-08
where O 0 1.0033661901331925e-08
there O 0 2.7683899617159113e-09
is O 0 1.5996135527274191e-09
preferential O 0 4.076756709991969e-08
transmission O 0 9.662354614192736e-07
of O 0 7.934232715278711e-10
the O 0 2.1417936313383734e-09
larger O 0 2.2113129105605367e-08
allele O 0 5.899084598581794e-08
at O 0 1.568692056252985e-07
the O 0 2.739412607866143e-08
DM B-Disease 1 0.9999998807907104
locus O 0 6.668900823569857e-06
, O 0 1.2754482270338485e-07
has O 0 3.5983296697850164e-07
been O 0 2.2400463706162554e-07
put O 0 4.6173067147492475e-08
forward O 0 1.6089193977109062e-08
to O 0 5.819400072937242e-09
explain O 0 8.223926073469556e-08
partially O 0 6.10756444530125e-07
the O 0 8.737600087904696e-10
maintenance O 0 2.122754722222453e-06
of O 0 2.3070104049338624e-08
DM B-Disease 1 1.0
in O 0 1.9629304404134018e-07
the O 0 1.950531647310072e-08
population O 0 1.2858514253366593e-07
. O 0 2.2436961444327608e-07

In O 0 3.204727363481652e-07
a O 0 9.268284628660695e-08
survey O 0 7.11056543423183e-07
of O 0 3.8676883917787563e-08
DM B-Disease 1 0.9999998807907104
in O 0 6.431805559259374e-07
Northern O 0 1.1275758424744708e-06
Ireland O 0 2.2068597615998442e-07
, O 0 1.2385569903017313e-08
59 O 0 5.095416355516136e-08
pedigrees O 0 5.619386911348556e-07
were O 0 3.082061823533877e-07
ascertained O 0 5.72401086174068e-06
. O 0 2.0487031804350408e-07

Sibships O 0 0.000624620879534632
where O 0 3.980785265866871e-07
the O 0 2.6206441461340546e-09
status O 0 5.605981900913548e-09
of O 0 5.51887702204823e-10
all O 0 1.3318269820317141e-09
the O 0 5.037815720143612e-10
members O 0 6.023361254214876e-10
had O 0 6.124665219431336e-08
been O 0 5.617941312152652e-08
identified O 0 1.5916381812530744e-07
were O 0 1.527836523962378e-08
examined O 0 6.374988714696883e-08
to O 0 9.589734561998853e-10
determine O 0 3.3494472972961375e-08
the O 0 2.0229651287451134e-09
transmission O 0 1.0349922376917675e-06
of O 0 6.142629738192795e-10
the O 0 4.006309595183666e-08
DM B-Disease 1 0.9999996423721313
expansion O 0 2.1881924112676643e-06
from O 0 1.9342380142006732e-08
affected O 0 7.749128627665414e-08
parents O 0 1.0146282036771481e-08
to O 0 3.2665490312666634e-09
their O 0 1.308406449851418e-08
offspring O 0 1.4615212649005116e-06
. O 0 2.3419023875703715e-07

Where O 0 1.6920146208576625e-06
the O 0 1.9534803996634764e-08
transmitting O 0 2.1537256543524563e-05
parent O 0 4.2758633753692266e-06
was O 0 5.762624823546503e-06
male O 0 9.838279311225051e-07
, O 0 4.343800696915423e-08
58 O 0 3.098270440204942e-07
. O 0 2.0926475485794072e-07

3 O 0 6.965164516259392e-07
% O 0 9.056016381236986e-09
of O 0 1.0613431244976823e-09
the O 0 2.9562527981141784e-09
offspring O 0 1.4435778439292335e-07
were O 0 4.573752505621087e-07
affected O 0 4.1212192058992514e-07
, O 0 2.4582883284551826e-08
and O 0 5.479026654597874e-08
in O 0 5.443897777013262e-09
the O 0 5.852180962051534e-09
case O 0 1.4222412403341878e-07
of O 0 1.2262860726863778e-09
a O 0 5.218858518674097e-07
female O 0 9.07933156213403e-07
transmitting O 0 0.00010552794265095145
parent O 0 9.098071132029872e-07
, O 0 1.7253746875667275e-08
68 O 0 3.4233949008921627e-07
. O 0 3.7235659533507715e-07

7 O 0 4.0886352508096024e-06
% O 0 2.576117310582049e-07
were O 0 3.088399580519763e-07
affected O 0 1.0572744031378534e-06
. O 0 4.2403047473271727e-07

Studies O 0 4.033010156945238e-07
on O 0 8.818206964633646e-08
meiotic O 0 1.2824439181713387e-05
drive O 0 1.4364862181537319e-05
in O 0 4.489233447202423e-07
DM B-Disease 1 0.9999998807907104
have O 0 3.2804280181153445e-07
shown O 0 2.1296797214631624e-08
increased O 0 3.428373673841634e-08
transmission O 0 1.7731939578879974e-06
of O 0 1.1635205021676143e-09
the O 0 1.8602156481861698e-09
larger O 0 2.6915977002772706e-08
allele O 0 9.16311932996905e-08
at O 0 7.059107787199537e-08
the O 0 8.386304273244605e-08
DM B-Disease 1 0.9999995231628418
locus O 0 9.211057658831123e-06
in O 0 2.568350794263097e-07
non O 0 2.3410200810758397e-05
- O 0 0.2853385806083679
DM O 1 0.9999974966049194
heterozygotes O 0 4.0335144149139524e-05
for O 0 2.1474852474057116e-07
CTGn O 0 7.724423630861565e-05
. O 0 5.362916795093042e-07

This O 0 6.000536245664989e-08
study O 0 1.0774900083276862e-08
provides O 0 7.0901129411993224e-09
further O 0 3.5559648559058132e-09
evidence O 0 1.871862309599237e-08
that O 0 4.974379574917975e-09
the O 0 2.1333997679562344e-08
DM B-Disease 1 0.9999992847442627
expansion O 0 2.7967166715825442e-06
tends O 0 1.5678845102229388e-06
to O 0 4.308080114867607e-09
be O 0 1.794673742949726e-08
transmitted O 0 1.9477565729175694e-06
preferentially O 0 2.3042236989567755e-06
. O 0 2.437079729133984e-07

Diagnosis O 0 0.21390654146671295
of O 0 4.966179403709248e-05
hemochromatosis B-Disease 1 0.9999933242797852
. O 0 0.0001255655224667862

If O 0 3.324578938190825e-05
untreated O 0 0.014104154892265797
, O 0 9.327673069492448e-06
hemochromatosis B-Disease 1 1.0
can O 0 0.0021946222987025976
cause O 0 0.0005017739604227245
serious O 0 0.006072327960282564
illness O 0 0.0009688465506769717
and O 0 1.4030479178472888e-07
early B-Disease 0 1.0274717396896449e-06
death I-Disease 0 5.381270057114307e-06
, O 0 7.418284297955324e-08
but O 0 4.5483584898420304e-08
the O 0 3.9520138273019256e-08
disease O 0 3.7602610518661095e-06
is O 0 3.577927643050316e-08
still O 0 8.607659651715949e-08
substantially O 0 3.2348498280043714e-07
under O 0 3.55316728928301e-07
- O 1 0.919723629951477
diagnosed O 0 0.16535687446594238
. O 0 5.381410801419406e-07

The O 0 8.321057265447962e-08
cornerstone O 0 1.5916790516712354e-06
of O 0 1.9653489946591662e-09
screening O 0 1.1773378361112918e-07
and O 0 1.3198310000461788e-08
case O 0 4.430809852351558e-08
detection O 0 3.61254393510535e-07
is O 0 9.709982151662189e-09
the O 0 7.55132789631574e-10
measurement O 0 2.42431701735768e-06
of O 0 5.554976478805429e-09
serum O 0 4.937210633215727e-06
transferrin O 0 2.1059761365904706e-06
saturation O 0 2.5556314540153835e-06
and O 0 3.944001747413495e-08
the O 0 2.105868190938054e-08
serum O 0 1.3341968042368535e-05
ferritin O 0 0.00011279425962129608
level O 0 6.319456815617741e-07
. O 0 1.3650664243414212e-07

Once O 0 5.843054623255739e-06
the O 0 2.8827868092662357e-08
diagnosis O 0 1.2660343600146007e-05
is O 0 2.6403412789477443e-07
suspected O 0 5.007314757676795e-05
, O 0 2.4419927413532605e-08
physicians O 0 1.1600111093912346e-08
must O 0 9.140144641150982e-09
use O 0 1.0029953045886941e-07
serum O 0 3.107852171524428e-05
ferritin O 0 0.0013764138566330075
levels O 0 1.4241728649722063e-06
and O 0 4.481012751966773e-07
hepatic O 0 0.002043465618044138
iron O 0 0.0010667538736015558
stores O 0 1.0127382665814366e-05
on O 0 2.4644018594699446e-06
liver O 0 3.900338560924865e-05
biopsy O 0 0.00010377253056503832
specimens O 0 2.1313769593689358e-07
to O 0 6.521660100844429e-09
assess O 0 3.9581054807058536e-06
patients O 0 8.853463384639326e-08
for O 0 1.756620626736094e-09
the O 0 4.6512997897707464e-09
presence O 0 1.4180427854171285e-07
of O 0 2.0884885998384561e-07
iron B-Disease 1 0.8963590860366821
overload I-Disease 0 0.0051044803112745285
. O 0 6.744756433363364e-07

Liver O 1 0.7493097186088562
biopsy O 1 0.834953248500824
is O 0 2.7186083570995834e-06
also O 0 2.8760371861835665e-08
used O 0 1.5176681245065993e-08
to O 0 2.4356185956975196e-09
establish O 0 3.231938450198868e-08
the O 0 8.218116187563851e-10
presence O 0 1.3686955924185895e-07
or O 0 7.217747821641751e-08
absence O 0 1.9423492148007426e-08
of O 0 3.772966294945945e-08
cirrhosis B-Disease 0 0.04480705037713051
, O 0 2.6868274716207452e-08
which O 0 6.790127571321136e-08
can O 0 1.4383202540102502e-07
affect O 0 9.919111789713497e-07
prognosis O 0 0.00024114197003655136
and O 0 8.816457608418204e-08
management O 0 8.547459060537221e-07
. O 0 2.2188361015196278e-07

A O 0 6.430722805816913e-06
DNA O 0 5.647174020850798e-06
- O 0 1.0282294169883244e-05
based O 0 8.831487008365002e-08
test O 0 5.1091188169039015e-08
for O 0 5.95670790470848e-10
the O 0 8.483419522420377e-10
HFE O 0 5.040300038672285e-06
gene O 0 1.3510526031268455e-08
is O 0 7.4268613481365264e-09
commercially O 0 1.2345691402515513e-07
available O 0 1.626333023807547e-08
, O 0 2.915303776163114e-09
but O 0 1.004434091456119e-09
its O 0 8.824255215422738e-10
place O 0 8.92983109679335e-08
in O 0 2.8741271584920014e-09
the O 0 6.002822683370823e-09
diagnosis O 0 4.2509571358095855e-05
of O 0 2.0016820201362862e-07
hemochromatosis B-Disease 1 1.0
is O 0 1.5339910532929935e-05
still O 0 6.429965537790849e-07
being O 0 9.510270615464833e-08
evaluated O 0 6.175187081680633e-07
. O 0 2.1963910512567963e-07

Currently O 0 5.6391177167824935e-06
, O 0 3.562164252457478e-08
the O 0 6.852154399439314e-10
most O 0 4.053538338322227e-10
useful O 0 1.2252299619319729e-08
role O 0 7.616758779249722e-09
for O 0 1.0051796062171547e-09
this O 0 1.1983087855327312e-09
test O 0 1.2486287914725835e-07
is O 0 1.1829444090949437e-08
in O 0 4.4306278090822104e-10
the O 0 5.007944059443048e-10
detection O 0 2.754271690719179e-07
of O 0 1.1913500230775753e-07
hemochromatosis B-Disease 1 1.0
in O 0 3.3090395845647436e-07
the O 0 5.867831731620754e-08
family O 0 6.489716497526388e-07
members O 0 1.1684041512083354e-09
of O 0 5.277916770296542e-09
patients O 0 1.1626053009194948e-07
with O 0 9.539662393365234e-09
a O 0 1.7530687728140038e-06
proven O 0 0.00014038584777154028
case O 0 7.10656564706369e-08
of O 0 3.3072864447092343e-09
the O 0 3.542813260537514e-07
disease O 0 8.486305887345225e-05
. O 0 2.8032056320626e-07

It O 0 2.6039245426545676e-07
is O 0 3.756622746209359e-08
crucial O 0 9.064695660754296e-08
to O 0 6.357230404319125e-07
diagnose O 1 0.9999598264694214
hemochromatosis B-Disease 1 1.0
before O 0 0.14273972809314728
hepatic B-Disease 1 0.9999954700469971
cirrhosis I-Disease 1 0.9999624490737915
develops O 0 0.022454798221588135
because O 0 1.1874235497089103e-06
phlebotomy O 0 0.010229556821286678
therapy O 0 0.0002913964563049376
can O 0 4.383226951176766e-06
avert O 0 0.013253230601549149
serious O 1 0.9851411581039429
chronic O 1 0.9999939203262329
disease O 1 0.6520479917526245
and O 0 8.749780704420118e-07
can O 0 1.6389641359637608e-06
even O 0 1.7892945436415175e-07
lead O 0 1.220295331449961e-07
to O 0 1.4591653219042655e-08
normal O 0 8.829177886582329e-07
life O 0 3.3135648891402525e-07
expectancy O 0 3.2912275855778717e-06
. O 0 1.745812738818131e-08
. O 0 1.5144965459512605e-07

Prevalence O 0 0.0009376058005727828
of O 0 3.5893084060489855e-08
the O 0 1.6442644579228727e-08
I1307K O 0 2.3911420612421352e-06
APC B-Disease 0 5.989102191961138e-07
gene O 0 5.855265428067469e-08
variant O 0 6.562389671671554e-07
in O 0 4.195116254379627e-09
Israeli O 0 5.26382245880086e-06
Jews O 0 5.761366139722668e-08
of O 0 5.835124605724218e-10
differing O 0 8.210099267103033e-09
ethnic O 0 2.3408968985449974e-08
origin O 0 9.613092544213941e-08
and O 0 4.28736768753879e-07
risk O 0 8.055814396357164e-05
for O 0 0.0075548491440713406
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 2.44828643189976e-05

BACKGROUND O 0 0.00026604783488437533
& O 0 1.590061219758354e-05
AIMS O 0 1.8227292457595468e-06
Israeli O 0 2.186039864682243e-06
Jews O 0 2.7512887967873212e-08
of O 0 6.319294532097786e-10
European O 0 5.7685465293388916e-08
birth O 0 1.2406693485900178e-06
, O 0 4.0280546897975e-08
i O 0 2.542395122873131e-06
. O 0 9.488809737945303e-10
e O 0 4.7026489369272895e-08
. O 0 6.375323047258519e-10
, O 0 1.9732557809959417e-09
Ashkenazim O 0 7.238834314193809e-07
, O 0 8.869583290049832e-09
have O 0 1.1752351092297886e-08
the O 0 2.1371226921473863e-07
highest O 1 0.9998486042022705
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.5120994448661804
of O 0 1.3766778828028237e-08
any O 0 1.2308706232033728e-07
Israeli O 0 3.2649168133502826e-05
ethnic O 0 5.531707074624137e-07
group O 0 1.4377293382494827e-06
. O 0 2.7928868462367973e-07

The O 0 3.066107581162214e-07
I1307K O 0 1.7028678485075943e-05
APC B-Disease 0 5.278500793792773e-06
gene O 0 8.198458090191707e-07
variant O 0 2.0694877093774267e-05
was O 0 8.119697668007575e-06
found O 0 4.457604347862798e-07
in O 0 4.1466389433253426e-08
6 O 0 4.941077804687666e-07
. O 0 4.271557259016845e-07

1 O 0 6.084785582061158e-07
% O 0 5.629555044350809e-09
of O 0 9.893975638775032e-10
American O 0 4.0588710170652575e-09
Jews O 0 7.203362173413552e-08
, O 0 8.619188918146392e-09
28 O 0 3.3722595826901625e-09
% O 0 4.996171254489923e-10
of O 0 3.9443461830046544e-09
their O 0 3.832924267044291e-05
familial O 1 0.9999996423721313
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 5.635845081997104e-05
, O 0 2.0181799698093528e-07
but O 0 6.489512571761225e-08
not O 0 1.0446160381150094e-08
in O 0 3.001421333692633e-09
non O 0 6.724358172505163e-07
- O 0 7.547435961896554e-05
Jews O 0 2.494212367309956e-06
. O 0 3.43121655532741e-07

We O 0 1.1991596693405882e-06
assessed O 0 8.054758495745773e-07
the O 0 1.1526996246402632e-08
I1307K O 0 1.232898966918583e-06
prevalence O 0 8.603835340181831e-06
in O 0 2.611567628818534e-09
Israeli O 0 3.87994941775105e-06
Jews O 0 3.516603541697805e-08
of O 0 4.204750991831929e-10
differing O 0 6.606267088926643e-09
ethnic O 0 3.3865706683400276e-08
origin O 0 7.66811538710499e-08
and O 0 6.23648247710662e-07
risk O 0 6.465186015702784e-05
for O 0 0.00757983373478055
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
. O 0 1.2681902262556832e-05

METHODS O 0 5.583570782619063e-06
DNA O 0 1.6536233715669368e-06
samples O 0 1.0198107958103719e-07
from O 0 3.089204447803695e-09
500 O 0 6.56866117054733e-09
unrelated O 0 3.206279686196467e-08
Jews O 0 2.213237060288975e-08
of O 0 1.4270360448875863e-09
European O 0 1.5952548437780933e-07
or O 0 1.086811153072631e-06
non O 0 2.563319867476821e-06
- O 0 0.0002230077370768413
European O 0 9.933503974934865e-08
origin O 0 1.1307692915352163e-07
, O 0 4.7612779496830626e-08
with O 0 9.245839649452137e-09
or O 0 1.6851707584919495e-07
without O 0 6.5886127664782634e-09
a O 0 1.433633940450818e-07
personal O 0 3.3980797979893396e-06
and O 0 1.2595568250617362e-06
/ O 0 0.0012462770100682974
or O 0 4.3859699871973135e-06
family O 0 9.444324859941844e-07
history O 0 3.2121313608968194e-08
of O 0 6.3877414469004634e-09
neoplasia B-Disease 0 0.00030266534304246306
, O 0 3.244928237222666e-08
were O 0 7.32118294877182e-08
examined O 0 5.932392355134652e-07
for O 0 2.1013171203065895e-09
the O 0 4.17935108742995e-09
I1307K O 0 1.00045770068391e-06
variant O 0 5.713761765946401e-07
by O 0 2.0274186773860947e-09
the O 0 3.923142699591153e-09
allele O 0 4.3887678202736424e-07
- O 0 3.2431019008072326e-06
specific O 0 6.525805673618379e-08
oligonucleotide O 0 1.1758776963688433e-05
( O 0 8.394609807282905e-08
ASO O 0 0.00014848024875391275
) O 0 3.4278417881949963e-09
method O 0 1.5948593556913693e-07
. O 0 1.8840700022337842e-07

RESULTS O 0 4.190003437543055e-06
In O 0 1.3650528707387366e-08
persons O 0 4.1765002123383965e-08
at O 0 7.304013394104913e-08
average O 0 9.969117854780052e-06
risk O 0 3.601470234571025e-05
for O 0 0.0032176158856600523
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
, O 0 7.370641128545685e-07
I1307K O 0 1.1069335414504167e-05
was O 0 7.808183909219224e-06
found O 0 6.327284296503422e-08
in O 0 7.480743136056844e-09
5 O 0 1.0216078294433828e-07
. O 0 2.1996842747284973e-07

0 O 0 1.1678098417178262e-06
% O 0 1.4526644775969544e-08
of O 0 5.79433279135344e-10
120 O 0 1.7747399994050284e-08
European O 0 6.1562266395753795e-09
and O 0 2.349324113026796e-08
1 O 0 9.717544457998883e-08
. O 0 2.4151134425665077e-07

6 O 0 2.4562646103731822e-06
% O 0 1.50819445821071e-08
of O 0 1.972405350159079e-09
188 O 0 8.732011025358588e-08
non O 0 3.781035218253237e-07
- O 0 1.4633825230703223e-05
European O 0 1.8095676068696775e-08
Jews O 0 6.712556199772735e-08
( O 0 3.439716067532572e-09
P O 0 0.0006376216188073158
= O 0 2.841452442226e-07
0 O 0 1.812465555417475e-08
. O 0 5.979291506363893e-10
08 O 0 2.520394204452714e-08
) O 0 6.16596862457186e-09
. O 0 2.3972187790377575e-08

It O 0 2.1573093533788779e-07
occurred O 0 3.4797005810105475e-07
in O 0 9.759817842791563e-09
15 O 0 3.2085857526453765e-08
. O 0 1.1097065311105325e-07

4 O 0 1.777258717083896e-06
% O 0 6.616055259200948e-08
of O 0 4.954948451540986e-09
52 O 0 9.522867827627124e-08
Ashkenazi O 0 3.698082764458377e-06
Israelis O 0 9.53509152168408e-06
with O 0 3.735894438250398e-07
familial O 1 0.9701671004295349
cancer B-Disease 0 0.014912687242031097
( O 0 1.7896375936743425e-07
P O 1 0.6232009530067444
= O 0 5.499597136804368e-06
0 O 0 8.319660338429458e-08
. O 0 2.3000408244655546e-09
02 O 0 8.962933861766942e-08
) O 0 6.795822238281346e-10
and O 0 7.377263688823632e-09
was O 0 1.2118806580474484e-06
not O 0 1.7853837519510307e-08
detected O 0 2.222722201850047e-07
in O 0 2.0740333894764262e-09
51 O 0 9.498958064568797e-08
non O 0 1.4740841436378105e-07
- O 0 2.0334766759333434e-06
European O 0 8.752282454338456e-09
Jews O 0 3.9650910110822224e-08
at O 0 1.2835162976898573e-07
increased O 0 2.28662793233525e-06
cancer B-Disease 0 4.5601147576235235e-05
risk O 0 1.4669629990748945e-06
. O 0 2.373963781110433e-07

Colorectal B-Disease 1 0.9972293972969055
neoplasia I-Disease 1 0.7016634941101074
occurred O 0 0.0003359488327987492
personally O 0 4.282066583982669e-05
or O 0 4.177368850832863e-07
in O 0 4.0802938805484246e-09
the O 0 1.9253698635424144e-09
families O 0 5.714609230267342e-09
of O 0 3.7640926486837145e-10
13 O 0 5.81434145274784e-09
of O 0 1.4435297401860225e-09
20 O 0 2.015901934271369e-08
Ashkenazi O 0 6.630620532632747e-07
I1307K O 0 2.1275000960940815e-07
carriers O 0 2.4547226473714545e-08
, O 0 1.2153884565435646e-09
8 O 0 3.2942293337612227e-09
of O 0 1.3953087574236633e-09
whom O 0 4.034714038425591e-07
also O 0 8.189432492144988e-07
had O 0 6.042668246664107e-06
a O 0 1.2829353863708093e-06
personal O 0 2.6772266210173257e-05
or O 0 5.6919802773336414e-06
family O 0 1.7178803091155714e-07
history O 0 5.3897935003988096e-08
of O 0 4.693293931268272e-08
noncolonic O 0 0.023779572919011116
neoplasia B-Disease 0 0.015071275644004345
. O 0 1.1853722980958992e-06

CONCLUSIONS O 0 1.4433108844968956e-05
The O 0 1.91074718713935e-07
I1307K O 0 1.6571706510148942e-05
APC O 0 1.0419443242426496e-05
variant O 0 0.00010585023846942931
may O 0 2.49356048698246e-07
represent O 0 8.910363114011943e-09
a O 0 6.489376147555959e-08
susceptibility O 0 3.377695247763768e-05
gene O 0 1.084895666281227e-05
for O 0 1.0004243449657224e-05
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 2.7086291538580554e-06
or I-Disease 0 1.0749240573204588e-06
other I-Disease 0 8.987927913040039e-08
, I-Disease 0 4.791578476215363e-07
cancers I-Disease 0 0.00029807977261953056
in O 0 8.267424078667318e-09
Ashkenazi O 0 3.5482844396028668e-06
Jews O 0 3.054485944176122e-07
, O 0 3.739943466030127e-08
and O 0 7.939190282968411e-08
partially O 0 6.691950602544239e-06
explains O 0 1.0548012596700573e-07
the O 0 1.3269054743858533e-09
higher O 0 3.5394700148572156e-07
incidence O 0 0.06849512457847595
of O 0 0.013347592204809189
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
in O 0 4.666924837692932e-07
European O 0 3.9050820532793296e-07
Israelis O 0 2.6378313123132102e-05
. O 0 1.2011237231490668e-06

Systematic O 0 5.615258942270884e-06
analysis O 0 2.9980478188917914e-07
of O 0 4.265629982569408e-08
coproporphyrinogen O 0 0.0009763695416040719
oxidase O 0 0.013184848241508007
gene O 0 0.000569010095205158
defects O 1 0.9886510372161865
in O 0 7.130121275622514e-07
hereditary B-Disease 1 0.8541566133499146
coproporphyria I-Disease 0 0.16077104210853577
and O 0 1.859267854342761e-06
mutation O 0 6.092420335335191e-06
update O 0 5.378525202104356e-06
. O 0 1.5827407651158865e-06

Hereditary B-Disease 1 0.9934514760971069
coproporphyria I-Disease 0 0.46036002039909363
( O 0 1.8693202719077817e-06
HC B-Disease 1 0.955287754535675
) O 0 7.00713883361459e-07
is O 0 1.9547085230442462e-06
an O 0 1.8980781533173285e-05
acute O 1 0.9999395608901978
hepatic B-Disease 1 0.9999939203262329
porphyria I-Disease 1 0.9999978542327881
with O 0 0.024803470820188522
autosomal O 1 0.9997710585594177
dominant O 1 0.6132133603096008
inheritance O 0 0.01628158614039421
caused O 0 0.00013294974633026868
by O 0 1.2382905367758212e-07
deficient B-Disease 0 1.4889766134729143e-05
activity I-Disease 0 3.9326747014456487e-07
of I-Disease 0 1.506650448845903e-08
coproporphyrinogen I-Disease 0 0.0011022567050531507
III I-Disease 0 0.03761719539761543
oxidase I-Disease 0 0.0022335960529744625
( O 0 1.8833979709143023e-07
CPO O 0 0.0002336541365366429
) O 0 1.0465767985579078e-07
. O 0 2.7328849228069885e-07

Clinical O 0 9.319052333012223e-05
manifestations O 0 2.8688533348031342e-05
of O 0 9.320669391854608e-08
the O 0 1.1274436246822006e-06
disease O 0 0.0016162991523742676
are O 0 5.965501514992866e-08
characterized O 0 1.1478156011435203e-05
by O 0 6.47609624593315e-07
acute O 0 0.0019569024443626404
attacks O 0 5.0143768021371216e-05
of O 0 1.0965894944092724e-05
neurological B-Disease 1 0.9999597072601318
dysfunction I-Disease 0 0.40342751145362854
often O 0 4.108867415197892e-06
precipitated O 0 3.0372368655662285e-06
by O 0 1.2334648857859065e-08
drugs O 0 7.02914633166074e-08
, O 0 1.5117102014627903e-09
fasting O 0 7.310731575671525e-08
, O 0 3.5689702304608772e-09
cyclical O 0 3.935241693397984e-05
hormonal O 0 5.064236120233545e-06
changes O 0 3.03763698639159e-08
, O 0 9.012768487082212e-08
or O 0 5.8374293985252734e-06
infectious B-Disease 0 0.006261390633881092
diseases I-Disease 0 0.0004292139783501625
. O 0 6.031276029716537e-07

Skin O 1 0.9987741112709045
photosensitivity O 1 0.9974884986877441
may O 0 5.294056609272957e-05
also O 0 2.2192020310285443e-07
be O 0 4.231272043853096e-08
present O 0 1.664866289274869e-07
. O 0 2.4108700813485484e-07

The O 0 3.627963280905533e-07
seven O 0 8.286767183562915e-08
exons O 0 4.209248913866759e-07
, O 0 1.2694481910102695e-08
the O 0 1.8544483726401495e-09
exon O 0 5.479109859152231e-07
/ O 0 1.698011146800127e-05
intron O 0 9.185941598843783e-05
boundaries O 0 1.6487135781062534e-06
and O 0 4.4082099748266046e-08
part O 0 2.7576563255138353e-08
of O 0 2.4463735481816684e-09
3 O 0 9.526424982198023e-09
noncoding O 0 1.7109479699684016e-07
sequence O 0 6.16905060368822e-09
of O 0 3.889641386756182e-10
the O 0 1.1069996030954599e-09
CPO O 0 2.6100658487848705e-06
gene O 0 1.2209025790355099e-08
were O 0 1.1826331913766808e-08
systematically O 0 3.5728751868191466e-07
analyzed O 0 4.332134295736978e-08
by O 0 1.729630771940549e-09
an O 0 3.4883700372745352e-09
exon O 0 3.4567000284368987e-07
- O 0 4.062109383085044e-06
by O 0 4.081027782376623e-08
- O 0 3.167802424286492e-05
exon O 0 5.341200449038297e-06
denaturing O 0 0.0007317131385207176
gradient O 0 0.0036708484403789043
gel O 0 0.008152461610734463
electrophoresis O 0 7.602043478982523e-05
( O 0 3.7266278951619825e-08
DGGE O 0 1.2015490028716158e-05
) O 0 1.2362858514691766e-09
strategy O 0 2.7210200315153088e-08
followed O 0 2.390852182898584e-09
by O 0 1.8532805845516975e-10
direct O 0 1.3561224365687963e-09
sequencing O 0 2.2066361182737637e-08
in O 0 6.739095947949636e-09
seven O 0 1.2592042075709742e-08
unrelated O 0 9.488506975685596e-07
heterozygous O 0 9.197443432640284e-06
HC B-Disease 1 0.9964123368263245
patients O 0 2.2273947251960635e-05
from O 0 4.453873359011595e-08
France O 0 1.0774985639727674e-05
, O 0 8.30813178254175e-08
Holland O 0 2.1791127437609248e-05
, O 0 2.2891188677931495e-07
and O 0 5.116062311572023e-07
Czech O 0 2.481114825059194e-05
Republic O 0 6.145682505120931e-07
. O 0 3.49642277797102e-07

Seven O 0 1.5688806342950556e-06
novel O 0 8.620077665000281e-07
mutations O 0 2.9462626116583124e-06
and O 0 2.7455957507527273e-08
two O 0 2.679722221898828e-09
new O 0 3.057691699837051e-08
polymorphisms O 0 4.728011117549613e-05
were O 0 1.1194744047315908e-06
detected O 0 1.9758344933507033e-05
. O 0 3.252066562708933e-07

Among O 0 1.0312984386473545e-06
these O 0 1.7080337144648183e-08
mutations O 0 1.6425757110027916e-07
two O 0 1.0202948708126769e-08
are O 0 3.0469966105783897e-08
missense O 0 1.0592428225209005e-05
( O 0 2.3747556809894377e-08
G197W O 0 3.9130140976340044e-06
, O 0 1.3686480393459988e-08
W427R O 0 3.110278044005099e-07
) O 0 3.795382674809389e-09
, O 0 2.9443512072901967e-09
two O 0 1.325921261674523e-09
are O 0 2.534770437989664e-08
nonsense O 0 2.3992966816877015e-05
( O 0 4.853377699731709e-09
Q306X O 0 3.9083604974621267e-07
, O 0 2.171546276130698e-09
Q385X O 0 5.179291662216201e-08
) O 0 5.811710557246386e-10
, O 0 1.0316461018788914e-09
two O 0 5.910938405406796e-10
are O 0 3.445743912422472e-09
small O 0 5.705833672209337e-08
deletions O 0 1.9663254136048636e-07
( O 0 4.204808945473815e-09
662de14bp O 0 2.1194826160808589e-07
; O 0 2.5962010319346973e-09
1168del3bp O 0 9.600886414773413e-07
removing O 0 1.362745933874976e-07
a O 0 1.6518118428621165e-08
glycine O 0 3.5885293527826434e-06
at O 0 3.364847600551002e-07
position O 0 3.534652393000215e-08
390 O 0 1.4774951040408268e-08
) O 0 6.664989671278931e-10
, O 0 1.7701615728782372e-09
and O 0 1.0304117559201131e-08
one O 0 9.481884610806901e-09
is O 0 1.9578894949745518e-08
a O 0 7.233787790994484e-09
splicing O 0 2.0580833393069042e-07
mutation O 0 2.1014670892327558e-07
( O 0 7.955073044740857e-09
IVS1 O 0 5.140131634107092e-06
- O 0 1.154133406089386e-05
15c O 0 1.3752386621490587e-05
- O 0 2.2933694708626717e-05
- O 0 8.158021228155121e-05
> O 0 5.701612053599092e-07
g O 0 7.4091599344683345e-06
) O 0 3.1672799938320395e-09
which O 0 8.346629165600916e-09
creates O 0 2.4582085700330936e-08
a O 0 8.453799438257192e-09
new O 0 1.4288369598602912e-08
acceptor O 0 2.2339044392083451e-07
splice O 0 3.231210575904697e-05
site O 0 2.8723736249958165e-05
. O 0 4.15181972357459e-07

The O 0 1.454322955396492e-07
pathological O 0 1.2056937066518003e-06
significance O 0 1.1551696132983125e-07
of O 0 2.55872611987229e-09
the O 0 5.370857536490803e-09
point O 0 1.133675368691911e-06
mutations O 0 1.7227561954769044e-07
G197W O 0 3.225048317290202e-07
, O 0 4.6363659578219085e-09
W427R O 0 3.599421063427144e-07
, O 0 8.505978144057735e-09
and O 0 7.223116327281787e-09
the O 0 2.227125595055668e-09
in O 0 4.244544626885727e-08
- O 0 8.53093879413791e-05
frame O 0 0.003698812099173665
deletion O 0 6.091067916713655e-07
390delGly O 0 1.5121339629331487e-06
were O 0 2.561736209827359e-07
assessed O 0 1.0753362857940374e-06
by O 0 8.988970456869083e-09
their O 0 4.426482291819411e-09
respective O 0 6.218952908199071e-09
expression O 0 1.1521215981247224e-08
in O 0 9.893749153278009e-10
a O 0 4.2892303042663116e-09
prokaryotic O 0 4.88481681770736e-08
system O 0 1.3542930332732794e-08
using O 0 7.982157157471192e-09
site O 0 2.8867680157418363e-06
- O 0 4.809699930774514e-06
directed O 0 5.215335932007292e-07
mutagenesis O 0 2.9576322049251758e-05
. O 0 4.972561100657913e-07

These O 0 1.4936395587028528e-07
mutations O 0 4.921636218568892e-07
resulted O 0 6.69039224021617e-08
in O 0 1.2578310837341178e-08
the O 0 1.7196351009829414e-08
absence O 0 8.62561989833921e-07
or O 0 6.574554731741955e-07
a O 0 5.194606700342774e-08
dramatic O 0 5.053377662989078e-07
decrease O 0 5.39957795808732e-07
of O 0 1.0500155411818923e-08
CPO O 0 0.0006230268627405167
activity O 0 4.097722467122367e-06
. O 0 2.540884622703743e-07

The O 0 3.4201153198409884e-07
two O 0 3.1987173798597723e-08
polymorphisms O 0 5.004825652576983e-06
were O 0 1.4521414470891614e-07
localized O 0 2.2869985514262225e-06
in O 0 4.069498515946179e-09
noncoding O 0 1.338632159786357e-06
part O 0 2.778002183845274e-08
of O 0 2.807809262872496e-10
the O 0 3.156188088659917e-10
gene O 0 7.893497411259887e-09
1 O 0 3.6292551186534183e-09
) O 0 6.777893801768187e-10
a O 0 3.667879155955234e-08
C O 0 0.001378640765324235
/ O 0 1.7822738300310448e-05
G O 0 1.5724121112725697e-05
polymorphism O 0 6.363905868056463e-06
in O 0 2.5270466608162678e-08
the O 0 8.382734506540146e-09
promotor O 0 5.4180702136363834e-05
region O 0 1.7710750910282513e-07
, O 0 2.4013866450900423e-09
142 O 0 1.5710524436940432e-08
bp O 0 3.798470231686224e-07
upstream O 0 5.3878924433092834e-08
from O 0 7.208606489506053e-10
the O 0 2.4039839563450016e-10
transcriptional O 0 3.119605196388875e-08
initiation O 0 2.459259107467915e-08
site O 0 1.824409196160559e-06
( O 0 2.2364394780538532e-09
- O 0 1.1531062682479387e-06
142C O 0 8.878962489689002e-07
/ O 0 2.166324065910885e-06
G O 0 1.9161388991051354e-06
) O 0 9.769851594398915e-10
, O 0 8.783769267495245e-10
and O 0 8.865896461429656e-09
2 O 0 7.600315932165813e-09
) O 0 4.970137634785488e-10
a O 0 6.004689190319823e-09
6 O 0 1.8902280629617962e-08
bp O 0 2.3382624192436197e-07
deletion O 0 2.8936337770346654e-08
polymorphism O 0 1.3861099432688206e-06
in O 0 2.127824316744409e-08
the O 0 1.5376388162735566e-08
3 O 0 3.166768536289055e-08
noncoding O 0 4.859883233621076e-07
part O 0 2.5041167361905536e-08
of O 0 4.87494544731959e-10
the O 0 1.4401773107408644e-09
CPO O 0 1.1776609426306095e-05
gene O 0 3.735651787906136e-08
, O 0 1.8368681020675126e-09
574 O 0 1.4284391447461076e-08
bp O 0 1.3502389606401266e-07
downstream O 0 3.0076694912395396e-08
of O 0 5.432589378351338e-10
the O 0 3.300090423152824e-09
last O 0 4.4023284573313504e-08
base O 0 2.6424086030374383e-08
of O 0 2.2206940453184387e-10
the O 0 1.8983092875402008e-09
normal O 0 5.411704151470076e-08
termination O 0 1.4332074727008148e-07
codon O 0 1.2402453819504444e-07
( O 0 7.490280395927584e-09
+ O 0 1.461589249629469e-07
574 O 0 2.7432724891696125e-07
delATTCTT O 0 1.0475189355929615e-06
) O 0 3.536850812224657e-08
. O 0 7.533381563007424e-08

Five O 0 1.1364010106262867e-06
intragenic O 0 4.887166869593784e-05
dimorphisms O 0 7.590533641632646e-05
are O 0 4.5386698843685735e-08
now O 0 4.395272412693885e-08
well O 0 1.540759519969015e-08
characterized O 0 2.027224581979681e-06
and O 0 4.787157337204917e-08
the O 0 2.885437000443858e-09
high O 0 1.065048536474933e-06
degree O 0 2.2617621109333186e-09
of O 0 1.2599098431209654e-09
allelic O 0 2.094029923682683e-06
heterogeneity O 0 7.495737463614205e-06
in O 0 3.736778069196589e-07
HC B-Disease 1 0.9942907094955444
is O 0 2.323533408343792e-05
demonstrated O 0 1.6032496432671905e-06
with O 0 4.630807293182215e-09
seven O 0 1.6058649965344785e-09
new O 0 2.361340012413393e-09
different O 0 9.34155641729717e-10
mutations O 0 9.189175642632108e-09
making O 0 6.554994325114194e-09
a O 0 8.250898630990378e-09
total O 0 6.710172417712101e-09
of O 0 1.6012832171341529e-09
nineteen O 0 9.103975884272586e-08
CPO O 0 0.0018155308207497
gene B-Disease 0 1.9425106074777432e-05
defects I-Disease 0 0.19538559019565582
reported O 0 5.9984349718433805e-06
so O 0 9.756173824371217e-08
far O 0 4.2660122545612467e-08
. O 0 1.019269824098501e-08
. O 0 8.821840680184323e-08

Coincidence O 0 5.6081407819874585e-06
of O 0 7.011283997826467e-08
two O 0 2.017359790329465e-08
novel O 0 1.9737503009764623e-07
arylsulfatase O 0 3.7294241337804124e-05
A O 0 4.144947638451413e-07
alleles O 0 1.3095392148443352e-07
and O 0 4.3063977273050114e-08
mutation O 0 3.8646732036795584e-07
459 O 0 1.2368404895823915e-06
+ O 0 5.692023478331976e-06
1G O 0 0.00021566011128015816
> O 0 1.9202789189876057e-06
A O 0 2.378609593733927e-07
within O 0 1.112371883493779e-08
a O 0 8.326263127855782e-07
family O 0 0.00012074113328708336
with O 0 0.00012214359594509006
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.999997615814209
: O 0 5.523747859115247e-08
molecular O 0 1.0368331970767031e-07
basis O 0 4.2691052470900104e-08
of O 0 1.5644110007428935e-08
phenotypic O 0 3.665802796604112e-05
heterogeneity O 0 0.000491587386932224
. O 0 4.533778792392695e-06

In O 0 6.410556352420826e-07
a O 0 8.506783046868804e-07
family O 0 4.421895937412046e-06
with O 0 1.418903252670134e-07
three O 0 1.1516914355524932e-07
siblings O 0 1.7857599232229404e-05
, O 0 1.9958580566026285e-08
one O 0 3.529813108471558e-09
developed O 0 3.6620214416416275e-08
classical O 0 2.835010377566505e-07
late O 0 0.0001036405228660442
infantile O 1 0.9996734857559204
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999994039535522
( O 0 8.735582923691254e-06
MLD B-Disease 1 0.9999858140945435
) O 0 4.317978437029524e-07
, O 0 3.4909611201783264e-08
fatal O 0 6.319376097962959e-06
at O 0 1.1016952612408204e-06
age O 0 5.459539664798285e-08
5 O 0 2.1944726924516544e-08
years O 0 2.8146594388545054e-08
, O 0 1.9927236749595068e-08
with O 0 7.041142424668578e-08
deficient O 0 0.00045093288645148277
arylsulfatase O 0 7.485779497073963e-05
A O 0 1.6248499150606222e-06
( O 0 2.1483860024318346e-08
ARSA O 0 6.546220538439229e-05
) O 0 7.435985160952896e-10
activity O 0 3.492526445825206e-08
and O 0 4.884963100693085e-09
increased O 0 2.003750552148631e-07
galactosylsulfatide O 0 0.00018841242126654834
( O 0 3.739943963410042e-07
GS O 1 0.9999637603759766
) O 0 2.6238544137413555e-07
excretion O 0 4.477237325772876e-06
. O 0 3.336335225867515e-07

The O 0 5.590484875028778e-07
two O 0 3.107383861333801e-08
other O 0 9.672679546213203e-09
siblings O 0 8.382672262996493e-07
, O 0 1.7353020353993998e-08
apparently O 0 9.069716497833724e-07
healthy O 0 3.980413225690427e-07
at O 0 1.45442285770514e-07
12 O 0 2.494976003575289e-09
( O 0 2.2877889860328793e-10
1 O 0 4.942715126077246e-09
/ O 0 3.157631169870001e-07
2 O 0 5.011252746101036e-09
) O 0 6.744712011119702e-10
and O 0 4.182700408250639e-09
15 O 0 2.259838982610063e-09
years O 0 5.33188737605883e-09
, O 0 1.7816920161450867e-09
respectively O 0 1.78281478468989e-08
, O 0 1.0818846263305204e-08
and O 0 4.7194877339507e-08
their O 0 1.647802783111274e-08
father O 0 1.3629763770950376e-06
, O 0 1.276596606203384e-08
apparently O 0 3.496446367989847e-07
healthy O 0 9.27236953884858e-08
as O 0 5.474751318956805e-09
well O 0 1.8748135488522166e-08
, O 0 5.968174399129111e-09
presented O 0 3.253921221357814e-08
ARSA O 0 0.011615206487476826
and O 0 2.3617253646079917e-06
GS O 1 0.9999388456344604
values O 0 1.8839963900063594e-07
within O 0 5.666483726685101e-09
the O 0 4.327606717424715e-09
range O 0 2.1327280137484195e-06
of O 0 2.850501346074452e-07
MLD B-Disease 1 0.9999961853027344
patients O 0 4.132987669436261e-05
. O 0 7.848280461075774e-07

Mutation O 0 1.3755075997323729e-05
screening O 0 2.811461854435038e-06
and O 0 1.0612343892546505e-08
sequence O 0 4.805469355773084e-09
analysis O 0 6.360386883841329e-09
disclosed O 0 3.065347584652045e-07
the O 0 7.227495268935513e-10
involvement O 0 9.997235395076132e-08
of O 0 1.203363741986152e-09
three O 0 5.6499280809418906e-09
different O 0 9.083072072257892e-09
ARSA O 0 0.014713923446834087
mutations O 0 4.3578378949860053e-07
being O 0 5.9240370831048494e-08
the O 0 9.23253029583293e-10
molecular O 0 3.2683644235476095e-08
basis O 0 2.0862623628659094e-08
of O 0 2.598610393533818e-08
intrafamilial O 0 0.0002838284126482904
phenotypic O 0 3.6784796975553036e-05
heterogeneity O 0 0.000308006361592561
. O 0 4.572680609271629e-06

The O 0 5.557204190154152e-07
late O 0 6.6356451497995295e-06
infantile O 1 0.9629035592079163
patient O 0 0.01800363138318062
inherited O 0 0.0133617352694273
from O 0 4.276375307199487e-07
his O 0 2.0018951545353048e-06
mother O 0 6.577655312867137e-06
the O 0 2.243450314409756e-09
frequent O 0 6.533913960993232e-07
0 O 0 2.013212707652201e-07
- O 0 6.0237602156121284e-05
type O 0 4.73945947305765e-05
mutation O 0 2.7338234076523804e-07
459 O 0 4.5447555407918117e-07
+ O 0 6.505300689241267e-07
1G O 0 4.754687688546255e-05
> O 0 4.511930171702261e-07
A O 0 7.523156568822742e-07
, O 0 3.043488661091942e-08
and O 0 2.2511885688913935e-08
from O 0 1.4666599490453791e-08
his O 0 4.3797405169243575e-07
father O 0 5.3113226385903545e-06
a O 0 2.647726944360329e-07
novel O 0 1.9764966907587223e-07
, O 0 6.245640005175801e-09
single O 0 4.370744477455446e-08
basepair O 0 1.3778332004221738e-06
microdeletion O 0 2.846288111868489e-07
of O 0 6.263244922699585e-10
guanine O 0 5.247344958547728e-08
at O 0 5.45000666818396e-09
nucleotide O 0 1.4826867733575e-08
7 O 0 4.1370782355443225e-09
in O 0 1.036743246807248e-09
exon O 0 1.500533954867933e-07
1 O 0 8.729712419608404e-08
( O 0 1.1965690660531436e-08
7delG O 0 2.034297267528018e-06
) O 0 4.3611347422256586e-08
. O 0 1.095989645705231e-07

The O 0 2.749686700553866e-07
two O 0 3.2477521472173976e-07
clinically O 0 0.003053132211789489
unaffected O 0 0.004886486101895571
siblings O 0 1.121010700444458e-05
carried O 0 1.735794171509042e-06
the O 0 1.6700273164360624e-08
maternal O 0 8.358879313163925e-06
mutation O 0 5.284476856104448e-07
459 O 0 9.485775080975145e-07
+ O 0 3.064218390136375e-06
1G O 0 0.00031990918796509504
> O 0 1.1373356301191961e-06
A O 0 2.4227961148426402e-06
and O 0 3.531054630911967e-07
, O 0 1.9123380212704433e-08
on O 0 7.677672186900963e-08
their O 0 9.488235086507757e-09
paternal O 0 3.169864612573292e-06
allele O 0 1.3712589463921177e-07
, O 0 1.1962496770934195e-08
a O 0 7.3723547266979494e-09
novel O 0 1.7446009081822922e-08
cytosine O 0 6.786217454646248e-08
to O 0 6.858587586755505e-10
thymidine O 0 1.0316176002334032e-07
transition O 0 8.728130751478602e-08
at O 0 3.4534700432686805e-08
nucleotide O 0 8.814506458065807e-08
2435 O 0 1.569093228681595e-06
in O 0 2.1195640798055138e-09
exon O 0 1.3511767349427828e-07
8 O 0 5.8906067579300725e-08
, O 0 1.6663738167110864e-09
resulting O 0 2.786502140139646e-09
in O 0 2.899005757672768e-10
substitution O 0 4.5189469943807126e-09
of O 0 1.3707373014426594e-09
alanine O 0 4.193361291982001e-06
464 O 0 6.227502353794989e-07
by O 0 4.484817495153948e-08
valine O 0 0.000311680807499215
( O 0 5.444669781695666e-08
A464V O 0 1.5014630889709224e-06
) O 0 2.9417988045565835e-08
. O 0 9.632125141934011e-08

The O 0 2.441783522044716e-07
fathers O 0 1.5002034388089669e-06
genotype O 0 3.720850827448885e-06
thus O 0 2.0050045179687004e-07
was O 0 2.1946627839497523e-06
7delG O 0 4.435261871549301e-05
/ O 0 0.0001595596258994192
A464V O 0 5.4376465413952246e-05
. O 0 2.334317514396389e-06

Mutation O 0 2.2945947421249002e-05
A464V O 0 3.230054790037684e-05
was O 0 6.631988526351051e-06
not O 0 1.869001131638015e-08
found O 0 8.831567477329827e-09
in O 0 1.3355052619345997e-09
18 O 0 1.0410283124429043e-07
unrelated O 0 4.053186785313301e-05
MLD B-Disease 1 0.9999982118606567
patients O 0 1.452429478376871e-05
and O 0 2.7103290278773784e-08
50 O 0 8.612224888793207e-08
controls O 0 7.1390336415788624e-06
. O 0 8.132190600917966e-07

A464V O 0 0.00012442820298019797
, O 0 1.2172084495887248e-07
although O 0 1.8469588525249492e-08
clearly O 0 4.9822251213527124e-08
modifying O 0 3.9790697314856516e-07
ARSA O 0 0.3232022821903229
and O 0 9.018285709316842e-06
GS O 1 0.9999954700469971
levels O 0 9.813011274673045e-06
, O 0 2.0519404841934374e-08
apparently O 0 1.8571576276826818e-07
bears O 0 6.701554866594961e-08
little O 0 1.1315649750542889e-08
significance O 0 1.021357931563216e-08
for O 0 5.993750384902796e-09
clinical O 0 3.449152643497655e-07
manifestation O 0 1.4477735703621875e-06
of O 0 2.2800118415489123e-07
MLD B-Disease 1 0.9999977350234985
, O 0 3.9421672681783093e-07
mimicking O 0 3.6069297948415624e-06
the O 0 1.0703050179472484e-07
frequent O 0 3.565972292562947e-05
ARSA O 0 0.40043601393699646
pseudodeficiency O 0 0.001135516562499106
allele O 0 5.5402317229891196e-05
. O 0 1.0990412420142093e-06

Our O 0 5.379312142395065e-07
results O 0 9.092297403867633e-08
demonstrate O 0 8.941965745634661e-08
that O 0 1.960743789553021e-09
in O 0 6.361087767636775e-10
certain O 0 4.816609777691383e-09
genetic O 0 1.708290028545889e-06
conditions O 0 0.0013005243381485343
MLD B-Disease 1 0.9999942779541016
- O 0 0.04959695413708687
like O 0 6.118551937106531e-06
ARSA O 1 0.7461791634559631
and O 0 1.1156758773722686e-05
GS O 1 0.9998999834060669
values O 0 5.155883400220773e-07
need O 0 6.041105837795158e-09
not O 0 8.355274250249067e-10
be O 0 8.03094479806532e-10
paralleled O 0 2.0798744060357421e-07
by O 0 6.1685348384799e-08
clinical O 0 0.0009772637858986855
disease O 0 0.004193984903395176
, O 0 4.6767979711148655e-08
a O 0 1.0168390929266025e-07
finding O 0 3.1454408144782064e-07
with O 0 2.7498441568241105e-07
serious O 0 1.4063104572414886e-05
diagnostic O 0 2.5791367079364136e-05
and O 0 9.927024393618922e-07
prognostic O 0 0.0014719708124175668
implications O 0 8.056778824538924e-06
. O 0 1.2871265653302544e-06

Moreover O 0 2.0755656805704348e-05
, O 0 1.4039956397482456e-07
further O 0 1.4132662329302548e-07
ARSA O 0 0.022811997681856155
alleles O 0 7.475660481759405e-07
functionally O 0 1.960062490979908e-06
similar O 0 4.512532569833638e-08
to O 0 3.810609783272412e-08
A464V O 0 6.300654604274314e-06
might O 0 5.656044663737703e-07
exist O 0 4.5792081238005267e-08
which O 0 1.942964189538543e-08
, O 0 2.53180232334671e-09
together O 0 3.217538013799981e-09
with O 0 5.784155820975911e-09
0 O 0 3.419700931317493e-07
- O 0 0.0013350669760257006
type O 0 0.02060539461672306
mutations O 0 4.2833976294787135e-06
, O 0 1.7194669510445237e-07
may O 0 1.5945871609801543e-06
cause O 0 4.888149192083802e-07
pathological O 0 9.640411008149385e-05
ARSA O 1 0.9741023182868958
and O 0 0.00011088299652328715
GS O 1 0.9999969005584717
levels O 0 1.0139539881492965e-05
, O 0 8.619944757981557e-09
but O 0 6.868186464004111e-09
not O 0 7.921882705375083e-09
clinical O 0 5.556155713293265e-08
outbreak O 0 4.0419200786345755e-07
of O 0 3.4459413100762504e-09
the O 0 1.801131475076545e-06
disease O 0 4.2441970435902476e-05
. O 0 2.977741964116376e-08
. O 0 4.5183332986198366e-07

Human O 0 0.008841088972985744
MLH1 O 1 0.9995492100715637
deficiency O 1 0.9996635913848877
predisposes O 0 0.0010263742879033089
to O 0 1.5991771533663268e-06
hematological B-Disease 1 0.9926532506942749
malignancy I-Disease 1 0.9961504936218262
and O 0 3.671032754937187e-05
neurofibromatosis B-Disease 1 0.9993569254875183
type I-Disease 0 0.003761659376323223
1 I-Disease 0 3.0734108804608695e-06
. O 0 1.6319205542458803e-06

Heterozygous O 0 0.00018488449859432876
germ O 0 0.04211557283997536
- O 0 0.004086802247911692
line O 0 4.369993257569149e-05
mutations O 0 4.261190440502105e-07
in O 0 4.253773777662673e-09
the O 0 7.446123273524563e-09
DNA O 0 2.135309659934137e-05
mismatch O 0 0.011935226619243622
repair O 0 0.008742883801460266
genes O 0 1.3802794001094298e-06
lead O 0 1.7362709741064464e-06
to O 0 2.9932140023447573e-05
hereditary B-Disease 1 0.9999810457229614
nonpolyposis I-Disease 1 0.999998927116394
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 6.609284901060164e-05

The O 0 3.951950020564254e-06
disease O 0 0.001361871836706996
susceptibility O 0 3.451282100286335e-05
of O 0 3.684778349111184e-08
individuals O 0 1.0939362482531578e-06
who O 0 3.140434273518622e-06
constitutionally O 0 2.319212035217788e-05
lack O 0 3.1313823001255514e-07
both O 0 1.5747515291764103e-08
wild O 0 1.978821501325001e-06
- O 0 0.0002462910779286176
type O 0 0.0005381224909797311
alleles O 0 2.1174805908685812e-07
is O 0 2.240886232129924e-07
unknown O 0 8.097381396510173e-07
. O 0 2.2529459897668858e-07

We O 0 1.3631245110445889e-06
have O 0 2.4634184470073706e-08
identified O 0 4.4827565659488755e-08
three O 0 2.8240954019764786e-09
offspring O 0 1.8864521678096935e-07
in O 0 1.8079632013723312e-08
a O 0 1.7306754671153612e-05
hereditary B-Disease 1 0.9999861717224121
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.2299301028251648
who O 0 4.064105814904906e-05
developed O 0 0.00010059229680337012
hematological B-Disease 1 0.9577481746673584
malignancy I-Disease 0 0.3729669153690338
at O 0 4.1310272536065895e-06
a O 0 6.383407935572905e-08
very O 0 3.067879816853747e-08
early O 0 1.914184544205e-08
age O 0 2.3052157516190164e-08
, O 0 5.318338214266305e-09
and O 0 2.1335422317747543e-08
at O 0 1.1142410016873328e-07
least O 0 1.1296710233921203e-09
two O 0 8.763265113564955e-11
of O 0 1.1155281559593888e-10
them O 0 1.16477727463149e-09
displayed O 0 8.513105171914503e-07
signs O 0 1.3547421531256987e-06
of O 0 1.5593496272003904e-08
neurofibromatosis B-Disease 1 0.965280294418335
type I-Disease 0 0.0006061479216441512
1 I-Disease 0 7.393648502329597e-07
( O 0 1.0919771398221201e-07
NF1 B-Disease 0 0.0001393534184899181
) O 0 1.1262599031169884e-07
. O 0 3.0689395202898595e-07

DNA O 0 2.7291628157399828e-06
sequence O 0 1.589866229778636e-07
analysis O 0 4.869374947702454e-08
and O 0 9.41112876517991e-09
allele O 0 1.459383014434934e-07
- O 0 1.9383135168027366e-06
specific O 0 1.2991310249788057e-08
amplification O 0 1.0099953442477272e-06
in O 0 1.3053356617831469e-08
two O 0 3.752827026914929e-08
siblings O 0 1.284071231566486e-06
revealed O 0 1.2739958492602454e-06
a O 0 2.574633697349782e-07
homozygous O 0 3.5715052945306525e-05
MLH1 O 0 0.03615884855389595
mutation O 0 3.784837645071093e-06
( O 0 4.355731064720203e-08
C676T O 0 6.370348273776472e-06
- O 0 0.00038892123848199844
- O 0 0.0012549113016575575
> O 0 6.544555617438164e-06
Arg226Stop O 0 3.806239692494273e-05
) O 0 7.917807209878447e-08
. O 0 1.835003047290229e-07

Thus O 0 3.2412899599876255e-06
, O 0 6.575633904049027e-08
a O 0 3.7219678006295e-08
homozygous O 0 3.2151951927517075e-06
germ O 0 0.0451967790722847
- O 0 0.06698962301015854
line O 0 0.0052779135294258595
MLH1 O 0 0.171246737241745
mutation O 0 7.088911388564156e-06
and O 0 1.8893527453656134e-07
consequent O 0 0.00017381871293764561
mismatch O 1 0.999876856803894
repair O 1 0.9999918937683105
deficiency O 1 0.9994599223136902
results O 0 2.0750335352204274e-06
in O 0 4.6214299942448633e-08
a O 0 1.4278175513027236e-06
mutator O 1 0.5756862163543701
phenotype O 0 7.86668824730441e-05
characterized O 0 2.8995487809879705e-05
by O 0 1.843884547270136e-06
leukemia B-Disease 1 0.9700470566749573
and O 0 1.3346727428142913e-05
/ O 1 0.9602662920951843
or O 1 0.886818528175354
lymphoma B-Disease 1 1.0
associated O 0 0.007339737843722105
with O 0 4.928747330268379e-06
neurofibromatosis B-Disease 1 0.9976767897605896
type I-Disease 0 0.003601011587306857
1 I-Disease 0 2.7198015573048906e-07
. O 0 4.647666429491437e-08
. O 0 2.1115599224685866e-07

Missense O 0 0.001685247290879488
mutations O 0 5.974002488073893e-05
in O 0 5.265611946470017e-08
the O 0 5.522017065828777e-09
most O 0 1.0071082856555336e-09
ancient O 0 4.4512042940425545e-09
residues O 0 1.1444367942203826e-07
of O 0 1.571312302495187e-09
the O 0 1.234834812180452e-08
PAX6 O 0 0.00020312384003773332
paired O 0 3.563170594134135e-07
domain O 0 1.27230407542811e-07
underlie O 0 9.893830110740964e-07
a O 0 3.292792172260306e-08
spectrum O 0 1.7649339270064957e-06
of O 0 1.2063270560247474e-07
human O 0 0.014892729930579662
congenital B-Disease 1 0.9999990463256836
eye I-Disease 1 0.9997519850730896
malformations I-Disease 1 0.9998718500137329
. O 0 4.871406781603582e-05

Mutations O 0 5.717902968171984e-05
of O 0 6.391570650521317e-08
the O 0 8.195004852495913e-08
human O 0 4.017980188564252e-07
PAX6 O 0 0.0022881655022501945
gene O 0 9.379069524584338e-05
underlie O 1 0.7789197564125061
aniridia B-Disease 1 0.9999998807907104
( O 0 0.05382474884390831
congenital B-Disease 1 0.9999994039535522
absence I-Disease 0 8.779471500020009e-06
of I-Disease 0 1.1731303573014884e-07
the I-Disease 0 2.9212205276962777e-07
iris I-Disease 0 0.16337786614894867
) O 0 5.15423117519731e-08
, O 0 2.5065872932827915e-08
a O 0 1.5592017632570787e-07
rare O 0 2.250033685413655e-05
dominant O 0 0.09967471659183502
malformation B-Disease 1 0.9973127245903015
of I-Disease 0 9.286581814649253e-08
the I-Disease 0 5.386838211052236e-07
eye I-Disease 0 0.002143793972209096
. O 0 2.4033458885242e-06

The O 0 1.0696356156358888e-07
spectrum O 0 1.0754203003671137e-06
of O 0 2.2006469535540418e-08
PAX6 O 0 0.0006061603198759258
mutations O 0 1.1257567166467197e-05
in O 0 1.221729348799272e-06
aniridia B-Disease 1 0.9999992847442627
patients O 0 3.3533095120219514e-05
is O 0 7.538239543691816e-08
highly O 0 1.5236901163007133e-07
biased O 0 3.0687863272760296e-06
, O 0 9.187266059029753e-09
with O 0 3.0564071273886384e-09
92 O 0 4.530919994749638e-08
% O 0 7.491276488025278e-10
of O 0 3.427428341140626e-10
all O 0 6.0962142001130815e-09
reported O 0 3.196368652425008e-06
mutations O 0 5.110629786031495e-07
leading O 0 2.1715375453368324e-07
to O 0 6.514550676683939e-08
premature O 0 1.042438498188858e-06
truncation O 0 3.6745639135915553e-06
of O 0 2.0219900420670456e-08
the O 0 3.708581886030515e-08
protein O 0 4.4745388549927156e-07
( O 0 6.29554985920322e-09
nonsense O 0 1.899891572065826e-06
, O 0 8.675095086729812e-10
splicing O 0 1.0772557956784112e-08
, O 0 2.85975132463534e-09
insertions O 0 6.219359249826084e-08
and O 0 1.304434693594203e-08
deletions O 0 4.0975944415322374e-08
) O 0 6.0026970061244356e-09
and O 0 2.7521284806653057e-08
just O 0 7.29058200477084e-08
2 O 0 1.1892358209308895e-08
% O 0 1.078957923006385e-09
leading O 0 4.947922072062738e-09
to O 0 3.378722024383052e-10
substitution O 0 3.2500926394618546e-09
of O 0 7.683920166812186e-10
one O 0 6.171946065336442e-09
amino O 0 6.882361791582525e-09
acid O 0 8.444629884252208e-09
by O 0 1.3932982545483696e-09
another O 0 3.393592962197545e-08
( O 0 1.4103224366124323e-08
missense O 0 2.6219786377623677e-06
) O 0 3.767328493609057e-08
. O 0 7.971267024231565e-08

The O 0 2.0558429980610526e-07
extraordinary O 0 7.0507915950202e-08
conservation O 0 3.017380123537805e-08
of O 0 8.145488727961947e-10
the O 0 2.384694886004013e-09
PAX6 O 0 3.287135768914595e-05
protein O 0 1.0784403059460601e-07
at O 0 8.145325836039774e-08
the O 0 9.520770838378212e-10
amino O 0 8.817966801188959e-09
acid O 0 2.1689270823799234e-08
level O 0 7.546652192047532e-09
amongst O 0 1.8359432862879999e-09
vertebrates O 0 2.2841113889171538e-08
predicts O 0 3.608753331718617e-06
that O 0 1.4720324514883032e-08
pathological O 0 6.703601684421301e-06
missense O 0 5.248779052635655e-05
mutations O 0 2.4181219941965537e-06
should O 0 3.3616979067119246e-07
in O 0 8.436885856610843e-09
fact O 0 5.84075401377504e-08
be O 0 6.199721980237882e-08
common O 0 3.0718553034603246e-08
even O 0 2.930586617821973e-08
though O 0 1.1620262974076923e-08
they O 0 6.5074701183220895e-09
are O 0 1.0725643706521737e-09
hardly O 0 4.1694956820492735e-08
ever O 0 2.2254621256934115e-08
seen O 0 3.9164163467830804e-07
in O 0 9.329740890962057e-08
aniridia B-Disease 1 0.9999914169311523
patients O 0 3.102219579886878e-06
. O 0 1.9915918869628513e-07

This O 0 2.0892375118819473e-07
indicates O 0 4.709430641014478e-07
that O 0 1.2610356314723958e-08
there O 0 1.1233352914530315e-08
is O 0 2.988066905018627e-09
a O 0 5.076274511850443e-09
heavy O 0 7.552131137344986e-05
ascertainment O 0 4.157774310442619e-05
bias O 0 4.667844405048527e-05
in O 0 8.63391491634502e-09
the O 0 1.2582576092157183e-09
selection O 0 8.770263626445285e-09
of O 0 8.615605118222902e-09
patients O 0 7.239726329544283e-08
for O 0 3.419464045251175e-09
PAX6 O 0 4.20748874603305e-05
mutation O 0 3.8358773934987767e-08
analysis O 0 1.3707693646836105e-08
and O 0 5.6402406301003793e-08
that O 0 1.0219718404869127e-08
the O 0 8.094353631804552e-09
missing O 0 1.1775235861932742e-06
PAX6 O 0 0.000568096584174782
missense O 0 0.0002170266816392541
mutations O 0 1.5134602108446416e-05
frequently O 0 5.211455118114827e-06
may O 0 2.213736706835334e-06
underlie O 0 5.710731784347445e-05
phenotypes O 0 1.7920518075698055e-05
distinct O 0 2.650693033956486e-07
from O 0 1.5109030471194274e-07
textbook O 0 0.004253520164638758
aniridia B-Disease 1 0.9999672174453735
. O 0 5.691415935871191e-06

Here O 0 3.385962145330268e-06
we O 0 6.187955392533695e-08
present O 0 1.2617308975393371e-08
four O 0 4.340436010608073e-09
novel O 0 1.6500034405453334e-07
PAX6 O 0 0.0003546274674590677
missense O 0 9.13397889235057e-05
mutations O 0 6.4168102653638925e-06
, O 0 6.61151347003397e-08
two O 0 1.002730964927423e-08
in O 0 5.42494262845139e-08
association O 0 3.7169805011672e-08
with O 0 2.0209451889741104e-08
atypical O 0 4.728227577288635e-05
phenotypes O 0 1.911910658236593e-05
ectopia B-Disease 0 0.0011496548540890217
pupillae I-Disease 0 0.0026459023356437683
( O 0 6.012163566992967e-08
displaced B-Disease 0 4.0709335280553205e-07
pupils I-Disease 0 2.110309651470743e-07
) O 0 9.761496500004796e-08
and O 0 0.0002888911112677306
congenital B-Disease 1 0.9999992847442627
nystagmus I-Disease 1 0.7323551774024963
( O 0 6.268257379815623e-08
searching B-Disease 0 4.1523558138578665e-06
gaze I-Disease 0 1.2151861483289395e-05
) O 0 8.679982066439607e-09
, O 0 2.0690322344307788e-08
and O 0 8.063907586119967e-08
two O 0 1.114954883973951e-08
in O 0 3.0450330257281166e-08
association O 0 2.2400136856504105e-08
with O 0 3.3778213559543246e-09
more O 0 1.708731112159967e-08
recognizable O 0 8.032916230149567e-05
aniridia B-Disease 1 0.9999415874481201
phenotypes O 0 0.0002659289166331291
. O 0 1.4090219337958843e-06

Strikingly O 0 0.000159657618496567
, O 0 1.3845757962371863e-07
all O 0 2.6822690735173182e-09
four O 0 9.715535043142154e-10
mutations O 0 5.599594032901223e-08
are O 0 3.1508367026589212e-09
located O 0 2.9783620902890107e-07
within O 0 6.838031030298453e-09
the O 0 9.504682374483764e-09
PAX6 O 0 5.2407012844923884e-05
paired O 0 2.5230932010344986e-07
domain O 0 8.926748762405623e-08
and O 0 1.8914651178647546e-08
affect O 0 4.1665543903945945e-08
amino O 0 4.090860983296807e-09
acids O 0 1.2945788885332377e-09
which O 0 2.008275101772483e-09
are O 0 5.398461122574361e-10
highly O 0 1.284396700107493e-09
conserved O 0 6.4104557218058744e-09
in O 0 1.226655776953578e-09
all O 0 9.472643780483736e-10
known O 0 4.869504977023098e-08
paired O 0 8.629243097857398e-08
domain O 0 4.4098332097064485e-08
proteins O 0 1.0241284087442182e-07
. O 0 1.4334344200506166e-07

Our O 0 1.6879724853424705e-06
results O 0 1.266282083633996e-07
support O 0 1.9831912112522332e-08
the O 0 1.7341629243716739e-09
hypothesis O 0 5.260432089926326e-08
that O 0 2.1589665610832753e-09
the O 0 6.489790926877959e-10
under O 0 4.0729073447209885e-09
- O 0 7.397146646326291e-07
representation O 0 1.275287253577062e-08
of O 0 3.921765578951408e-09
missense O 0 0.0001265846221940592
mutations O 0 2.6810128019860713e-06
is O 0 6.051049012967269e-07
caused O 0 6.993026318014017e-07
by O 0 7.487323649968403e-09
ascertainment O 0 4.3195203033974394e-05
bias O 0 0.00033252884168177843
and O 0 4.734061747058149e-07
suggest O 0 2.83513486465381e-07
that O 0 4.744540316181656e-09
a O 0 1.385055892200171e-08
substantial O 0 4.2420275292442966e-08
burden O 0 1.725316138845301e-07
of O 0 1.3117649189098302e-08
PAX6 B-Disease 0 0.19272609055042267
- I-Disease 1 0.509170651435852
related I-Disease 0 0.1812974363565445
disease I-Disease 0 0.1199256181716919
remains O 0 8.059045285335742e-06
to O 0 1.4682050242242894e-08
be O 0 2.6200638103546225e-07
uncovered O 0 8.43802627059631e-05
. O 0 2.7968441784764764e-08
. O 0 1.2241301305948582e-07

The O 0 2.061489539073591e-07
chromosomal O 0 0.00025509862462058663
order O 0 8.868505574355368e-08
of O 0 8.194110279191591e-09
genes O 0 4.355012777068623e-07
controlling O 0 2.389026849414222e-05
the O 0 3.987175389852382e-08
major O 0 1.457937969462364e-06
histocompatibility O 0 8.305807568831369e-05
complex O 0 7.247238499985542e-06
, O 0 5.3016675494177434e-09
properdin O 0 1.5023854302853579e-06
factor O 0 1.8129536272226687e-07
B O 0 0.0001859126059571281
, O 0 2.0488573682087008e-07
and O 0 6.784276592952665e-06
deficiency B-Disease 0 0.0003571452689357102
of I-Disease 0 3.3834812729338637e-10
the I-Disease 0 4.016790011718285e-09
second I-Disease 0 6.2639074371873e-08
component I-Disease 0 8.798471640147909e-07
of I-Disease 0 1.2674667537737605e-08
complement I-Disease 0 2.028330754910712e-06
. O 0 5.241063263383694e-07

The O 0 1.5979256318132684e-07
relationship O 0 6.536269552270824e-07
of O 0 2.4015560651236e-09
the O 0 2.945839794321614e-09
genes O 0 1.9935068706899983e-08
coding O 0 2.3148434991071554e-07
for O 0 1.2326604625911841e-08
HLA O 0 2.845675771823153e-05
to O 0 6.333645163891788e-09
those O 0 1.3904815077125932e-09
coding O 0 5.2390042526440084e-08
for O 0 1.939416405249972e-09
properdin O 0 1.5711865444245632e-06
Factor O 0 8.535576512258558e-08
B O 0 9.880905054160394e-06
allotypes O 0 2.38560933212284e-05
and O 0 4.4878382254864846e-07
for O 0 3.7918178463769436e-07
deficiency B-Disease 0 0.00017993942310567945
of I-Disease 0 7.886014063984703e-10
the I-Disease 0 8.023461894879347e-09
second I-Disease 0 1.0251133630845288e-07
component I-Disease 0 1.3824108009430347e-06
of I-Disease 0 3.2280802475526116e-09
complement I-Disease 0 4.3002094685107295e-07
( O 0 1.8685412328522943e-08
C2 O 0 4.2745018618006725e-06
) O 0 1.2285851225257716e-09
was O 0 9.828998770444741e-08
studied O 0 1.083799183732026e-08
in O 0 1.6528951540806247e-09
families O 0 4.4417736155821785e-09
of O 0 8.194328771082837e-09
patients O 0 8.685216812409635e-07
with O 0 1.5422552905874909e-06
connective O 1 0.9999351501464844
tissue O 1 0.9999741315841675
disorders O 1 0.9614948630332947
. O 0 2.5343942979816347e-06

Patients O 0 2.6081745090777986e-05
were O 0 1.4285241434208729e-07
selected O 0 8.894249781121744e-09
because O 0 5.0449626698423344e-09
they O 0 2.1832327057325074e-09
were O 0 3.0324038391427166e-08
heterozygous O 0 1.1504575070375722e-07
or O 0 3.5884602311853087e-07
homozygous O 0 4.084916508872993e-05
for O 0 0.003304458223283291
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999984502792358
. O 0 7.956932677188888e-06

12 O 0 5.057556336396374e-06
families O 0 5.695557661056228e-07
with O 0 3.1676382405976256e-08
15 O 0 3.755805977334603e-08
matings O 0 0.00010215714428341016
informative O 0 0.032515231519937515
for O 0 0.26766204833984375
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
were O 0 1.518649332865607e-05
found O 0 3.103124981862493e-06
. O 0 4.774099693349854e-07

Of O 0 3.938484667287412e-07
57 O 0 1.5920677469694056e-06
informative O 0 3.070466618737555e-06
meioses O 0 7.258057303261012e-05
, O 0 1.0006924178185272e-08
two O 0 3.9366476745072987e-10
crossovers O 0 2.1505019276446546e-07
were O 0 2.2368571706010698e-07
noted O 0 1.4549374327543774e-07
between O 0 3.83901806344511e-07
the O 0 0.0012534961570054293
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999990701675415
gene O 0 3.805736525919201e-07
and O 0 2.228911633039843e-08
the O 0 7.876892915703593e-09
HLA O 0 7.97652974142693e-05
- O 0 0.00010824136552400887
B O 0 3.127537274849601e-05
gene O 0 2.9071154372672936e-08
, O 0 1.992707554521189e-09
with O 0 7.99475374790859e-10
a O 0 1.6511714218125917e-09
recombinant O 0 5.045366791023298e-09
fraction O 0 1.5867906100197615e-08
of O 0 2.6874513725516636e-09
0 O 0 3.269917385750887e-07
. O 0 2.09269131801193e-07

035 O 0 0.0480167418718338
. O 0 8.869474550010636e-05

A O 0 9.589204637450166e-06
lod O 0 0.0007142965332604945
score O 0 3.858265529288474e-07
of O 0 2.4983142221657317e-09
13 O 0 1.495390478112313e-08
was O 0 2.6569333400061623e-08
calculated O 0 1.081055813756393e-07
for O 0 6.59330146035586e-09
linkage O 0 0.003920018672943115
between O 0 0.014798249118030071
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999983310699463
and O 0 8.701882165951247e-07
HLA O 0 0.0004418106109369546
- O 0 0.00031776376999914646
B O 0 4.329223884269595e-05
at O 0 1.7847778366331113e-08
a O 0 1.6865761010009805e-09
maximum O 0 3.976646567593889e-09
likelihood O 0 3.839564666208162e-09
value O 0 1.0325693633461697e-09
of O 0 3.962975780869016e-11
the O 0 1.7544833641469637e-10
recombinant O 0 6.011267039696122e-09
fraction O 0 9.053841232287141e-09
of O 0 1.7118783057767928e-09
0 O 0 2.2599050453209202e-07
. O 0 3.074024448324053e-07

04 O 0 0.0019192674662917852
. O 0 1.8186477973358706e-05

18 O 0 7.647252459719311e-06
families O 0 4.0108213283929217e-07
with O 0 1.070651833856573e-08
21 O 0 1.1237467845148785e-08
informative O 0 2.2194413418219483e-07
matings O 0 7.933148481242824e-06
for O 0 6.339845093350505e-09
both O 0 2.763826278950887e-09
properdin O 0 2.154993126168847e-06
Factor O 0 6.014824549538389e-08
B O 0 2.3871639314165805e-06
allotype O 0 2.015305881286622e-06
and O 0 4.316249402336325e-08
HLA O 0 0.0001367506047245115
- O 0 0.0010439585894346237
B O 0 9.23790066735819e-05
were O 0 1.0445666731584424e-07
found O 0 2.67433250655813e-07
. O 0 1.9249803528964549e-07

Of O 0 4.0149464552996506e-07
72 O 0 1.617305542822578e-06
informative O 0 5.372394298319705e-06
meioses O 0 0.00017814876628108323
, O 0 2.9337632767578725e-08
three O 0 2.262430687238748e-09
recombinants O 0 4.708609139925102e-06
were O 0 4.71050384476257e-07
found O 0 2.7563794446905376e-07
, O 0 1.670619087512648e-09
giving O 0 3.1099656183641855e-10
a O 0 1.8209402874447278e-09
recombinant O 0 4.473162285023591e-09
fraction O 0 1.951618244788733e-08
of O 0 2.7461128926375977e-09
0 O 0 2.939951286862197e-07
. O 0 2.0193274963276053e-07

042 O 0 0.004497365560382605
. O 0 2.4161454348359257e-05

A O 0 7.3629307735245675e-06
lod O 0 0.0005985107272863388
score O 0 2.7139302005707577e-07
of O 0 1.3837507806258031e-09
16 O 0 3.919193414247957e-09
between O 0 5.326418861528737e-09
HLA O 0 2.639612830535043e-05
- O 0 3.580058182706125e-05
B O 0 6.3930306168913376e-06
and O 0 6.53474652168029e-09
Factor O 0 2.1258447446825812e-08
B O 0 3.196607849531574e-07
allotypes O 0 1.2090981726942118e-07
was O 0 3.540590043371594e-08
calculated O 0 4.562451749734464e-08
at O 0 1.1807128608154471e-08
a O 0 2.1055295285066222e-09
maximum O 0 1.1429900581561014e-08
likelihood O 0 9.328491756832591e-09
value O 0 1.7533201557284883e-09
of O 0 8.820413843757535e-11
the O 0 1.461021303938992e-10
recombinant O 0 3.2266704863559426e-09
fraction O 0 1.6150563553196662e-08
of O 0 4.161437416883018e-09
0 O 0 4.469830514608475e-07
. O 0 2.1174481901198305e-07

04 O 0 0.00287575158290565
. O 0 3.554350769263692e-05

A O 0 8.337609642694588e-07
crossover O 0 5.789113401988288e-07
was O 0 1.16924172743893e-06
shown O 0 4.0229796383073335e-08
to O 0 4.661353525392542e-09
have O 0 1.7363473991949263e-09
occurred O 0 4.066433856309004e-09
between O 0 2.8166061150081134e-10
genes O 0 8.887970914805976e-10
for O 0 2.3241089608383447e-10
Factor O 0 2.185487879557968e-08
B O 0 3.990061941294698e-06
and O 0 4.095391048508645e-08
HLA O 0 4.7639241529395804e-05
- O 0 0.001028319587931037
D O 0 0.0006321387481875718
, O 0 5.863622032364901e-09
in O 0 1.2744160171607177e-09
which O 0 1.0548898643492066e-07
HLA O 0 0.00011932108463952318
- O 0 0.00045007074368186295
D O 0 9.995804430218413e-05
segregared O 0 6.624478828598512e-06
with O 0 2.616040717384749e-08
HLA O 0 5.494776996783912e-05
- O 0 2.1215577362454496e-05
A O 0 6.326439461190603e-07
and O 0 1.0857917231987813e-06
B O 0 6.420782301574945e-05
. O 0 1.4087798660966655e-07

These O 0 1.796462072434224e-07
studies O 0 1.4499765832454159e-08
suggest O 0 1.775295110917341e-08
that O 0 8.994419653518548e-10
the O 0 1.795658205461237e-10
genes O 0 4.530744668329589e-09
for O 0 3.674824000654553e-09
Factor O 0 1.8994188621945796e-06
B O 1 0.7078139185905457
and O 1 0.5576012134552002
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
are O 0 8.369381987449742e-08
located O 0 2.2391309357772116e-06
outside O 0 1.5068665959461214e-07
those O 0 4.4803161181050655e-10
for O 0 1.2996210774218753e-09
HLA O 0 4.509591235546395e-05
, O 0 1.8872055917995567e-08
that O 0 2.3070576560257905e-09
the O 0 4.3284381634478564e-10
order O 0 2.515998076546566e-09
of O 0 3.9435166243606545e-10
genese O 0 5.202313332119957e-06
is O 0 1.8270594637215254e-07
HLA O 0 1.3970257896289695e-05
- O 0 2.3779573893989436e-05
A O 0 1.9715803318831604e-06
, O 0 5.9199706470280944e-08
- O 0 2.6402674848213792e-05
B O 0 3.571757406461984e-05
, O 0 2.7681855030436964e-08
- O 0 0.000365452520782128
D O 0 0.00010623895650496706
, O 0 2.0134685030370747e-09
Factor O 0 4.438439304976782e-08
B O 0 3.8001136999810115e-05
allotype O 0 0.012588177807629108
, O 0 0.00590885803103447
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
, O 0 3.7416061360318054e-08
that O 0 2.809942944992372e-09
the O 0 1.329413357176179e-09
genes O 0 3.6778551759653055e-08
coding O 0 6.686439064651495e-06
for O 0 0.0005404881667345762
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999990463256836
and O 0 1.144466210689643e-07
Factor O 0 2.0194045191601617e-07
B O 0 6.735115675837733e-06
allotypes O 0 1.2739059229716077e-06
are O 0 8.565234077551054e-10
approximately O 0 3.8447827144239e-09
3 O 0 8.674157392363213e-09
- O 0 5.153551228431752e-06
- O 0 5.43205760550336e-06
5 O 0 4.59581306344603e-09
centimorgans O 0 5.606208333119866e-07
from O 0 5.868542318765435e-10
the O 0 1.010101668974528e-09
HLA O 0 5.471519671118585e-06
- O 0 3.100539515799028e-06
A O 0 2.803296297315683e-07
and O 0 1.5766485716994794e-07
HLA O 0 1.9263394278823398e-05
- O 0 1.3568791473517194e-05
B O 0 4.839273969992064e-06
loci O 0 7.286533154626795e-09
, O 0 3.2014686457415564e-09
and O 0 3.2567324392829278e-09
that O 0 1.8011542257667656e-09
the O 0 2.388400144326397e-09
apparent O 0 5.135664764566172e-07
lack O 0 2.7509148292637065e-09
of O 0 3.642575130413661e-10
recombinants O 0 1.1435960232120124e-06
between O 0 2.506127083634624e-09
the O 0 1.8817269964443994e-09
Factor O 0 1.6293144255996594e-07
B O 0 0.00010133497562492266
gene O 0 6.245080840017181e-06
and O 0 0.07815861701965332
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
gene O 0 1.0216833743470488e-06
suggests O 0 1.0337842581975565e-07
that O 0 6.401487340212952e-09
these O 0 2.6570992073260413e-09
two O 0 4.041520451636416e-09
genes O 0 6.649605666098068e-08
lie O 0 1.5039341633382719e-05
in O 0 1.0617567269832762e-08
close O 0 1.6384390164603246e-06
proximity O 0 7.802622690178396e-07
to O 0 6.584757983318923e-08
one O 0 8.555315389457974e-08
another O 0 8.297171802951198e-07
. O 0 6.808932084823027e-07

Distribution O 0 2.7762787340179784e-06
of O 0 5.822678872391407e-08
emerin O 0 0.00022263552818913013
and O 0 3.2978968533825537e-07
lamins O 0 0.0002004747511819005
in O 0 2.973264123795616e-08
the O 0 2.4698969980363472e-08
heart O 0 6.074574230297003e-06
and O 0 1.857571518826262e-08
implications O 0 1.0147176254804435e-07
for O 0 3.869754294782979e-08
Emery B-Disease 0 0.37912848591804504
- I-Disease 1 0.999910831451416
Dreifuss I-Disease 1 0.9999828338623047
muscular I-Disease 1 0.9999282360076904
dystrophy I-Disease 1 0.9995825886726379
. O 0 1.4137235666566994e-05

Emerin O 0 0.000920137797947973
is O 0 1.4324383528219187e-06
a O 0 1.2507479141277145e-07
nuclear O 0 7.804062079230789e-06
membrane O 0 4.7227567279151117e-07
protein O 0 1.7516255468308373e-07
which O 0 5.74312082335382e-08
is O 0 4.869096059678668e-08
missing O 0 2.0540433354199195e-08
or O 0 1.2929214143753143e-08
defective O 0 4.904645720671397e-06
in O 0 5.082487675167613e-08
Emery B-Disease 0 0.4035068452358246
- I-Disease 1 0.9999723434448242
Dreifuss I-Disease 1 0.9999953508377075
muscular I-Disease 1 0.9999922513961792
dystrophy I-Disease 1 0.9999856948852539
( O 0 5.773560769739561e-05
EDMD B-Disease 1 0.9999964237213135
) O 0 1.373213081024005e-06
. O 0 9.044244961842196e-07

It O 0 9.356067494081799e-07
is O 0 8.806625118040756e-08
one O 0 3.415506988346806e-09
member O 0 7.334761686905722e-10
of O 0 5.440490280506083e-10
a O 0 2.625529020860995e-07
family O 0 1.3466925565808197e-06
of O 0 3.180915442158039e-08
lamina O 0 0.398908793926239
- O 0 0.04274246469140053
associated O 0 3.774273125145555e-07
proteins O 0 4.485225968409168e-09
which O 0 9.507038711831228e-09
includes O 0 2.2552455902768997e-08
LAP1 O 0 1.1231230928387959e-05
, O 0 6.813229980195956e-09
LAP2 O 0 5.126873929839348e-06
and O 0 9.003971257470766e-08
lamin O 0 0.001077241380698979
B O 0 0.0005211102543398738
receptor O 0 1.916568635351723e-06
( O 0 1.1268636512795638e-07
LBR O 0 8.344645175384358e-05
) O 0 4.8567230237495096e-08
. O 0 2.0070285700057866e-07

A O 0 1.5594262094964506e-06
panel O 0 4.100425314845779e-07
of O 0 1.5765726502081634e-08
16 O 0 1.099354065559055e-07
monoclonal O 0 1.9644599888124503e-05
antibodies O 0 2.655644664173451e-07
( O 0 1.6512691214387587e-09
mAbs O 0 1.2403069149513613e-07
) O 0 2.1499835245464283e-09
has O 0 5.651857648558689e-09
been O 0 7.65831931204275e-09
mapped O 0 2.5295237264799653e-06
to O 0 4.1486858393113835e-09
six O 0 1.1618838113847119e-09
specific O 0 1.8741264096178156e-09
sites O 0 3.113340341087678e-08
throughout O 0 1.207267286140734e-09
the O 0 9.742238127330438e-10
emerin O 0 3.853962766697805e-07
molecule O 0 3.4867287723727713e-08
using O 0 1.5729023417065946e-08
phage O 0 3.10280029225396e-07
- O 0 1.0431446071379469e-06
displayed O 0 1.3831412104536867e-07
peptide O 0 1.5763502503318705e-08
libraries O 0 3.073489018845521e-09
and O 0 3.5518907814946488e-09
has O 0 4.5638071100029265e-09
been O 0 2.159147749480894e-09
used O 0 2.5535387138120313e-09
to O 0 1.214290112905303e-09
localize O 0 7.7733393482049e-06
emerin O 0 5.339154085959308e-05
in O 0 2.5872797237980194e-08
human O 0 2.2125624354885076e-07
and O 0 5.842503014719114e-07
rabbit O 0 0.024308454245328903
heart O 0 0.0001739787112455815
. O 0 8.40947961933125e-07

Several O 0 8.889731475392182e-07
mAbs O 0 1.1851612725877203e-05
against O 0 7.183440686731046e-08
different O 0 6.425500131967965e-09
emerin O 0 7.770345291646663e-06
epitopes O 0 1.6131763914017938e-05
did O 0 1.607637898359826e-07
not O 0 8.078590241211714e-09
recognize O 0 3.0313382914926024e-09
intercalated O 0 2.4590526948031766e-08
discs O 0 3.348943937453441e-05
in O 0 2.709326274441537e-08
the O 0 3.8115910427904964e-08
heart O 0 3.628992271842435e-05
, O 0 1.2762849443959112e-08
though O 0 9.535042089225954e-09
they O 0 3.679509141818471e-09
recognized O 0 1.0049706622439203e-09
cardiomyocyte O 0 3.315075787213573e-07
nuclei O 0 5.135468583716829e-08
strongly O 0 7.517218847397089e-08
, O 0 3.6697598293500278e-09
both O 0 8.163997811116985e-10
at O 0 1.2571791785376263e-07
the O 0 1.225010315408781e-08
rim O 0 4.279086169844959e-06
and O 0 1.3682774024914579e-08
in O 0 8.061320500019065e-09
intranuclear O 0 5.284243343339767e-06
spots O 0 3.0110621196399734e-07
or O 0 7.26168707387842e-08
channels O 0 8.747327910896274e-07
. O 0 4.145086052176339e-07

A O 0 1.40688061947003e-05
polyclonal O 0 0.0002036944351857528
rabbit O 0 6.299730739556253e-05
antiserum O 0 1.5761926988488995e-05
against O 0 1.6423689430666855e-07
emerin O 0 3.017728158738464e-05
did O 0 2.0576750614509365e-07
recognize O 0 3.073877508086298e-08
both O 0 5.92952753564191e-09
nuclear O 0 1.3553155440604314e-05
membrane O 0 3.9784171690371295e-07
and O 0 1.0125866367616254e-08
intercalated O 0 2.3295433138059707e-08
discs O 0 2.954818592115771e-05
but O 0 9.616099561071678e-08
, O 0 1.8217739539139188e-09
after O 0 8.007985385916072e-10
affinity O 0 2.1029129548821857e-09
purification O 0 2.2974552038590446e-08
against O 0 4.735698500013541e-09
a O 0 7.668288226625464e-09
pure O 0 1.4965867478622386e-07
- O 0 8.160584911820479e-06
emerin O 0 9.175339982903097e-06
band O 0 9.54246743845033e-08
on O 0 2.820054589847132e-08
a O 0 1.3237462681559009e-08
western O 0 2.4229334982805995e-08
blot O 0 0.00025328455376438797
, O 0 4.1939660633261155e-08
it O 0 2.5447540963341453e-08
stained O 0 0.0009408735204488039
only O 0 1.8377974697614263e-08
the O 0 4.620291260692966e-09
nuclear O 0 1.235061699844664e-05
membrane O 0 2.70999862550525e-06
. O 0 2.2588687897950877e-07

These O 0 1.1417724010698294e-07
results O 0 3.259598813087905e-08
would O 0 1.321080134175645e-08
not O 0 2.5003021875136255e-09
be O 0 1.759309808946341e-09
expected O 0 1.9182634147796307e-08
if O 0 5.922248913492467e-09
immunostaining O 0 3.265783561801072e-06
at O 0 4.209866943938323e-08
intercalated O 0 2.2676333699678253e-08
discs O 0 1.7608450434636325e-05
were O 0 7.927627621029387e-07
due O 0 3.3768440488302076e-08
to O 0 3.4090963385580153e-09
a O 0 2.8076193814285944e-08
product O 0 1.6140745628945297e-07
of O 0 5.936337532652658e-10
the O 0 1.2622887179958298e-09
emerin O 0 1.634523300708679e-06
gene O 0 2.4249031227441264e-08
and O 0 7.992215245167245e-08
, O 0 5.7835376487958e-09
therefore O 0 1.5238638795267434e-08
, O 0 1.5675645226309598e-09
cast O 0 4.998975899894731e-09
some O 0 8.116735616958692e-10
doubt O 0 5.763803212488483e-09
upon O 0 1.834577351145228e-10
the O 0 7.540361113278493e-10
hypothesis O 0 3.196467446286988e-07
that O 0 2.876833491427533e-07
cardiac B-Disease 0 0.07067902386188507
defects I-Disease 1 0.9076145887374878
in O 0 8.436019243163173e-07
EDMD B-Disease 1 0.9999998807907104
are O 0 3.4805145787686342e-06
caused O 0 1.428798327651748e-06
by O 0 3.5460219205418753e-09
absence O 0 7.164803861314795e-08
of O 0 1.4822088445498594e-08
emerin O 0 7.362355972873047e-05
from O 0 4.0390176536675426e-08
intercalated O 0 2.1221069346211152e-06
discs O 0 0.00018646742682904005
. O 0 1.6395910051869578e-06

Although O 0 1.708956574475451e-06
emerin O 0 2.1268977434374392e-05
was O 0 7.333396752073895e-07
abundant O 0 4.2235878794372184e-08
in O 0 5.95659699342832e-09
the O 0 2.569000345786776e-09
membranes O 0 7.995935646931684e-08
of O 0 7.827465342558071e-10
cardiomyocyte O 0 5.6314438552362844e-06
nuclei O 0 1.2380142777601577e-07
, O 0 6.8600822800135575e-09
it O 0 5.418673065804569e-09
was O 0 3.1815653755984385e-07
absent O 0 8.868264345096577e-09
from O 0 6.019226783671172e-10
many O 0 6.816306963308705e-10
non O 0 7.955713243745777e-08
- O 0 1.1993131010967772e-05
myocyte O 0 8.752469148021191e-05
cells O 0 1.3129067610861966e-07
in O 0 6.9867982510629645e-09
the O 0 5.1332158079731016e-08
heart O 0 2.874308302125428e-05
. O 0 4.823644985663122e-07

This O 0 3.7527126295344715e-08
distribution O 0 1.8656464817468077e-07
of O 0 7.434457494071012e-09
emerin O 0 3.796462624450214e-05
was O 0 6.493932573903294e-07
similar O 0 7.26664461936366e-09
to O 0 4.145039422809305e-09
that O 0 2.3212038957609593e-09
of O 0 1.3629111172974717e-09
lamin O 0 0.00014896399807184935
A O 0 1.8235813286082703e-06
, O 0 3.1114641529939036e-08
a O 0 6.884491909886492e-08
candidate O 0 2.0200054962060676e-07
gene O 0 2.7548338721317123e-07
for O 0 3.1734135319538836e-08
an O 0 3.482605279714335e-07
autosomal O 0 0.0013760592555627227
form O 0 5.845423061145993e-07
of O 0 2.796353783196537e-06
EDMD B-Disease 1 0.9999992847442627
. O 0 3.386765092727728e-05

In O 0 2.0732611574203474e-06
contrast O 0 3.093728537351126e-06
, O 0 2.367737010899873e-07
lamin O 0 0.00369076244533062
B1 O 1 0.9632108211517334
was O 0 1.4596112123399507e-05
absent O 0 1.7135459984274348e-07
from O 0 3.857166586129779e-09
cardiomyocyte O 0 5.441063422040315e-06
nuclei O 0 3.076429493376054e-07
, O 0 5.179733530980002e-09
showing O 0 6.582893092854647e-07
that O 0 2.412217838809738e-07
lamin O 0 0.11133541166782379
B1 O 1 0.7431243658065796
is O 0 1.7289364961925457e-07
not O 0 2.1074502143392237e-09
essential O 0 1.3795711240049968e-09
for O 0 8.833483389203423e-10
localization O 0 7.530752554885112e-08
of O 0 9.532127309697103e-10
emerin O 0 1.211316975968657e-05
to O 0 2.8148367192670776e-08
the O 0 4.0443136839485305e-08
nuclear O 0 0.00021143128105904907
lamina O 0 0.00042349196155555546
. O 0 4.1514434201417316e-07

Lamin O 1 0.9522572159767151
B1 O 1 0.9981447458267212
is O 0 2.737911472650012e-06
also O 0 1.4374069223777042e-07
almost O 0 2.637785989634267e-08
completely O 0 1.0174303497478832e-06
absent O 0 3.629907894264761e-07
from O 0 4.490895122444272e-08
skeletal O 0 0.0008115283562801778
muscle O 0 1.9851740944432095e-05
nuclei O 0 1.0122284038516227e-05
. O 0 5.994084517624287e-07

In O 0 6.065138222766109e-06
EDMD B-Disease 1 0.9999717473983765
, O 0 7.289914094599226e-08
the O 0 8.798423656308785e-10
additional O 0 2.179517233358297e-09
absence O 0 1.7840461552509623e-08
of O 0 2.0029819580713593e-08
lamin O 1 0.8434472680091858
B1 O 1 0.9937940835952759
from O 0 1.5587927464366658e-06
heart O 0 0.0028276355005800724
and O 0 2.115862798746093e-06
skeletal O 0 0.06003416329622269
muscle O 0 1.661981877987273e-05
nuclei O 0 1.6907920326048043e-06
which O 0 4.821713446290232e-07
already O 0 3.667404371299199e-07
lack O 0 4.263840480689396e-08
emerin O 0 6.505961937364191e-05
may O 0 5.934236924076686e-07
offer O 0 1.3481591842889884e-08
an O 0 6.619659265183486e-10
alternative O 0 4.713970547243207e-09
explanation O 0 4.390058983005929e-09
of O 0 8.674747586923104e-10
why O 0 2.8822810804740584e-08
these O 0 1.0883705048314596e-09
tissues O 0 3.717661201108058e-08
are O 0 1.7983874389670973e-09
particularly O 0 2.9339592089172584e-08
affected O 0 2.6481755455165512e-08
. O 0 4.720115853729112e-09
. O 0 1.0015290285991796e-07

Genetic O 0 7.844682841096073e-06
mapping O 0 2.407851525276783e-06
of O 0 3.5497659922612e-08
the O 0 1.0695010388417359e-07
copper B-Disease 0 0.008891128934919834
toxicosis I-Disease 0 0.0008884929702617228
locus O 0 1.0891498050114023e-06
in O 0 1.1884154815788861e-07
Bedlington O 0 0.00011957201058976352
terriers O 0 0.00015806275769136846
to O 0 4.2966919977516227e-07
dog O 0 0.010719839483499527
chromosome O 0 2.2325668396661058e-05
10 O 0 7.634957910340745e-08
, O 0 1.0065480893217682e-08
in O 0 3.3939020482876003e-09
a O 0 8.944882523564957e-08
region O 0 9.120188906308613e-07
syntenic O 0 0.0001137863946496509
to O 0 7.190377004917536e-08
human O 0 1.1405121824736852e-07
chromosome O 0 1.8857786926673725e-05
region O 0 1.8625760276336223e-06
2p13 O 0 2.6579313271213323e-05
- O 0 8.91995950951241e-05
p16 O 0 3.95989918615669e-05
. O 0 9.754588745636283e-07

Abnormal O 1 0.9977995753288269
hepatic B-Disease 1 0.9995414018630981
copper I-Disease 0 0.43412259221076965
accumulation I-Disease 0 0.0008803516393527389
is O 0 2.674707502592355e-06
recognized O 0 2.549861335410242e-07
as O 0 3.908230041815841e-07
an O 0 0.00013288141053635627
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 4.759906914841849e-06
man O 0 0.009400991722941399
, O 0 4.1248679849559267e-07
mouse O 0 0.0001226179738296196
, O 0 3.981787699558481e-07
rat O 0 0.00031692086486145854
and O 0 7.816401534910256e-07
dog O 0 0.0017270564567297697
. O 0 1.5222667570924386e-06

The O 0 7.748026291665155e-07
major O 0 1.9352473827893846e-06
cause O 0 1.7460145045333775e-06
of O 0 2.1736819633133564e-07
hepatic B-Disease 1 0.9939256310462952
copper I-Disease 1 0.8726527690887451
accumulation I-Disease 0 0.0010146275162696838
in O 0 1.3457591876431252e-06
man O 0 0.00040571452700532973
is O 0 2.84891967794465e-07
a O 0 1.403346345796308e-07
dysfunctional O 0 1.3119361028657295e-05
ATP7B O 0 0.0001690146600594744
gene O 0 1.5312300547520863e-06
, O 0 1.246553864575617e-07
causing O 0 4.465210440685041e-05
Wilson B-Disease 0 0.0010118569480255246
disease I-Disease 0 0.008684935048222542
( O 0 3.932412084850512e-07
WD B-Disease 0 0.021057335659861565
) O 0 2.407469708032295e-07
. O 0 2.8529163387247536e-07

Mutations O 0 8.39293425087817e-05
in O 0 9.480948648388221e-08
the O 0 1.6789636347880332e-08
ATP7B O 0 2.8370537620503455e-05
genes O 0 8.790548378101448e-08
have O 0 2.179152680525931e-08
also O 0 2.681881383637119e-08
been O 0 1.0668809125036205e-07
demonstrated O 0 4.122924579519349e-08
in O 0 5.7424056620902775e-09
mouse O 0 5.746381248172838e-06
and O 0 2.9233135023787327e-07
rat O 0 0.0007614452042616904
. O 0 4.871019427810097e-07

The O 0 1.2173337893273128e-07
ATP7B O 0 2.168175888073165e-05
gene O 0 8.456930231659499e-07
has O 0 8.415916141757407e-08
been O 0 2.480968852580645e-08
excluded O 0 2.0391557598031795e-07
in O 0 2.586794778380863e-09
the O 0 1.027536056241729e-09
much O 0 5.974167294198196e-08
rarer O 0 9.153909559245221e-06
human O 0 2.123779268004e-06
copper B-Disease 1 0.6514397859573364
overload I-Disease 0 0.3469081223011017
disease O 0 6.644649693043903e-05
non B-Disease 0 2.0592135570041137e-06
- I-Disease 0 0.0013370928354561329
Indian I-Disease 0 3.0321577924041776e-06
childhood I-Disease 0 0.00039028527680784464
cirrhosis I-Disease 0 0.05516829714179039
, O 0 2.048784430996875e-08
indicating O 0 1.2067728221154539e-06
genetic O 0 2.949298732346506e-06
heterogeneity O 0 3.2326963264495134e-05
. O 0 4.5998458517715335e-06

By O 0 1.239277480635792e-06
investigating O 0 2.4175708404072793e-06
the O 0 4.9402295587697154e-08
common O 0 1.612839514564257e-05
autosomal O 1 0.9809445142745972
recessive O 1 0.9992642998695374
copper B-Disease 1 0.9996702671051025
toxicosis I-Disease 1 0.9738845229148865
( O 0 6.922928719177435e-08
CT B-Disease 0 0.001987085910513997
) O 0 7.101319088320679e-09
in O 0 6.003177510649493e-09
Bedlington O 0 3.923677286366001e-05
terriers O 0 0.00011414609616622329
, O 0 8.284886376941358e-08
we O 0 6.745644043348875e-08
have O 0 1.321720333180565e-08
identified O 0 5.905523536853252e-08
a O 0 1.959236994864e-09
new O 0 4.356035976371686e-09
locus O 0 1.4692028571516857e-07
involved O 0 5.110790652906871e-07
in O 0 3.194607188561349e-06
progressive O 1 0.9996616840362549
liver B-Disease 1 0.9999998807907104
disease I-Disease 1 0.999994158744812
. O 0 6.350016974465689e-06

We O 0 1.344871407127357e-06
examined O 0 6.653360173913825e-07
whether O 0 2.579366586985543e-08
the O 0 1.0957070806227875e-08
WD B-Disease 0 0.0002594098914414644
gene O 0 7.14970497028844e-07
ATP7B O 0 9.038668940775096e-05
was O 0 4.058829745190451e-06
also O 0 3.020673489118053e-08
causative O 0 1.8834359138963919e-07
for O 0 1.840764540794737e-09
CT B-Disease 0 6.171259883558378e-05
by O 0 5.714435147297081e-09
investigating O 0 9.40723836606594e-08
the O 0 1.156926554557458e-08
chromosomal O 0 0.18333293497562408
co O 0 0.0012263731332495809
- O 0 2.916498669947032e-05
localization O 0 5.205710635891592e-07
of O 0 3.5886975613408367e-09
ATP7B O 0 0.00017581111751496792
and O 0 2.6566041810838215e-08
C04107 O 0 9.063450789881244e-08
, O 0 1.830089829679693e-10
using O 0 3.9809097684972983e-10
fluorescence O 0 7.621597575280248e-09
in O 0 8.044942489959794e-10
situ O 0 1.815926538029089e-07
hybridization O 0 8.597633893714374e-08
( O 0 9.770247721974101e-09
FISH O 0 3.448106724590616e-07
) O 0 2.279593758203191e-08
. O 0 1.303489938209168e-07

C04107 O 0 0.0003213761665392667
is O 0 6.776263603569532e-07
an O 0 1.166810204011881e-08
anonymous O 0 8.526155426125115e-08
microsatellite O 0 3.2225201721303165e-05
marker O 0 0.00012789631728082895
closely O 0 2.148510475308285e-06
linked O 0 9.234982826455962e-06
to O 0 2.014514848269755e-07
CT B-Disease 0 0.13716083765029907
. O 0 1.8300046349395416e-06

However O 0 3.1219797165249474e-06
, O 0 1.904051316614641e-07
BAC O 0 5.6720778047747444e-06
clones O 0 2.968628677990637e-06
containing O 0 5.106658704789879e-07
ATP7B O 0 0.00017683817713987082
and O 0 3.7189096246947884e-08
C04107 O 0 9.150253958978283e-07
mapped O 0 1.6210045941988938e-05
to O 0 3.868403908313667e-08
the O 0 1.6825797644060003e-08
canine O 0 1.4821947843302041e-05
chromosome O 0 4.839976099901833e-06
regions O 0 1.6828309412630915e-07
CFA22q11 O 0 2.6842391889658757e-05
and O 0 1.8463464357409975e-07
CFA10q26 O 0 3.0544291803380474e-05
, O 0 1.9700713949077908e-08
respectively O 0 2.8640871008178692e-08
, O 0 2.0102528530685504e-09
demonstrating O 0 2.0388284838190884e-08
that O 0 1.0355995172517396e-08
WD B-Disease 0 0.0001275111426366493
cannot O 0 4.084243698798673e-08
be O 0 5.342634668004109e-10
homologous O 0 1.6275246039754165e-08
to O 0 2.7291179094390827e-08
CT B-Disease 0 0.005102073773741722
. O 0 8.365661301468208e-07

The O 0 7.431156632264901e-07
copper O 0 2.3199330826173536e-05
transport O 0 5.298182941260166e-07
genes O 0 6.30218366381996e-08
CTR1 O 0 2.4611381377326325e-05
and O 0 3.3455204828669594e-08
CTR2 O 0 1.5864125089137815e-05
were O 0 7.602218232705127e-08
also O 0 1.52558552457549e-08
excluded O 0 1.017364894551065e-07
as O 0 4.324306246417109e-09
candidate O 0 9.355005659017479e-09
genes O 0 2.2826904810813176e-09
for O 0 2.37906139233246e-09
CT B-Disease 0 0.0002403642429271713
since O 0 7.039074034764781e-08
they O 0 7.84500198136584e-09
both O 0 1.0028222696689681e-09
mapped O 0 9.639303243602626e-06
to O 0 3.7650877970918373e-07
canine O 0 0.000396992196328938
chromosome O 0 0.0001724715402815491
region O 0 1.2322452676016837e-05
CFA11q22 O 0 0.000335313641699031
. O 0 1.9375040665181587e-06

2 O 0 1.6900030459510162e-05
- O 0 6.485563790192828e-05
22 O 0 8.97593338322622e-07
. O 0 3.5004831033802475e-07

5 O 0 6.520874740090221e-05
. O 0 9.496631719230209e-06

A O 0 6.064305580366636e-06
transcribed O 0 2.029150891758036e-06
sequence O 0 1.493085477477507e-07
identified O 0 1.5826699950594048e-07
from O 0 1.375650815482743e-09
the O 0 2.833678180991228e-09
C04107 O 0 4.666765107685933e-06
- O 0 1.2198235708638094e-05
containing O 0 2.750040835053369e-07
BAC O 0 4.550251560431207e-06
was O 0 2.5306796942459187e-06
found O 0 5.285131976506818e-08
to O 0 1.4065877351754352e-09
be O 0 2.2446702274692143e-09
homologous O 0 8.89423290573177e-09
to O 0 1.0137422457034972e-08
a O 0 1.931104520735971e-08
gene O 0 6.544664898910924e-08
expressed O 0 8.020738739844546e-09
from O 0 1.781651270960083e-09
human O 0 2.272855681439978e-08
chromosome O 0 4.611560143530369e-06
2p13 O 0 3.5336590826773318e-06
- O 0 1.1317007192701567e-05
p16 O 0 1.1021650152542861e-06
, O 0 1.1271556132896876e-08
a O 0 2.1463545607502965e-08
region O 0 4.511930029593714e-08
devoid O 0 1.7388462936196447e-07
of O 0 1.6845924655228828e-09
any O 0 1.8007359159355474e-08
positional O 0 4.338271992310183e-06
candidate O 0 1.3386116961555672e-06
genes O 0 1.8998445057150093e-06
. O 0 7.856577894926886e-07

Molecular O 0 2.523112698327168e-06
analysis O 0 1.0853283782807921e-07
of O 0 5.328227636880456e-09
the O 0 1.2417999961655823e-08
APC B-Disease 0 2.9157234848753433e-07
gene O 0 4.132631659103936e-08
in O 0 4.7769939115482885e-09
205 O 0 1.5963962596288184e-07
families O 0 3.706375295564612e-08
: O 0 2.926312303586087e-09
extended O 0 9.409733081611193e-08
genotype O 0 1.0981624654959887e-05
- O 0 0.00013369762746151537
phenotype O 0 2.3941861400089692e-06
correlations O 0 2.9545321922341827e-06
in O 0 3.208059595749546e-08
FAP B-Disease 0 5.095455435366603e-07
and O 0 1.0254572302415e-08
evidence O 0 1.0309404885333606e-08
for O 0 1.3057184222731166e-09
the O 0 1.0470670996909348e-09
role O 0 1.2225220835659911e-08
of O 0 2.2861237347626684e-09
APC B-Disease 0 5.693347588930919e-07
amino O 0 3.1627660490585185e-08
acid O 0 6.773493055334256e-08
changes O 0 5.096991273489948e-08
in O 0 0.0006835825042799115
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
predisposition O 1 0.6034870147705078
. O 0 6.417018084903248e-06

BACKGROUND O 0 2.7099911676486954e-05
/ O 0 1.620069451746531e-05
AIMS O 0 5.092992410027364e-07
The O 0 1.4141466886385956e-09
development O 0 5.179706619173885e-08
of O 0 4.993342736270279e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 1.9619960767158773e-06
a O 0 1.9519538341228326e-07
variable O 0 4.978562174073886e-06
range O 0 3.039317334696534e-06
of O 0 2.266301635245327e-08
extracolonic O 0 0.00042641692562028766
manifestations O 0 0.00011171783989993855
in O 0 4.605847425409593e-05
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 0.9999889135360718
polyposis I-Disease 1 0.9999994039535522
( O 0 5.0829512474592775e-06
FAP B-Disease 0 1.1112417269032449e-05
) O 0 2.2413258804476754e-08
is O 0 1.68672169564843e-08
the O 0 1.0687760676475477e-09
result O 0 2.9930919964726854e-09
of O 0 3.483993094022253e-10
the O 0 2.123469933223987e-08
dominant O 0 7.08174702594988e-05
inheritance O 0 6.856264371890575e-05
of O 0 0.00020101833797525615
adenomatous B-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999958276748657
coli I-Disease 1 0.9999974966049194
( O 0 4.9459854380984325e-06
APC B-Disease 0 2.7628384486888535e-05
) O 0 8.983249699667795e-08
gene O 0 1.2682364740612684e-06
mutations O 0 7.047301551210694e-06
. O 0 1.041911673382856e-06

In O 0 4.513617213319776e-08
this O 0 8.392488926034503e-10
study O 0 1.2989321840350954e-09
, O 0 2.371982887883206e-10
direct O 0 1.491660794883387e-09
mutation O 0 1.714660058382833e-08
analysis O 0 1.0282207085765549e-08
of O 0 1.2397806115060916e-09
the O 0 7.492795717212175e-09
APC B-Disease 0 3.914511808034149e-07
gene O 0 7.001180790666695e-08
was O 0 7.75484863879683e-07
performed O 0 1.2808652627427364e-07
to O 0 2.598846693402379e-09
determine O 0 1.3210832605636824e-07
genotype O 0 9.519718332740013e-06
- O 0 0.00023346794478129596
phenotype O 0 3.8056673474784475e-06
correlations O 0 4.971952876076102e-06
for O 0 3.1923789833854244e-08
nine O 0 4.3400905980206517e-08
extracolonic O 0 6.037691491656005e-06
manifestations O 0 1.2694889619524474e-06
and O 0 2.3253617698060225e-08
to O 0 6.5806746718521936e-09
investigate O 0 1.7470459567903163e-07
the O 0 7.857506645336798e-09
incidence O 0 0.00026156785315833986
of O 0 8.776304127877665e-09
APC B-Disease 0 4.070971044711769e-06
mutations O 0 1.3795646225389646e-07
in O 0 3.445207141794526e-08
non O 0 0.000216359127080068
- O 1 0.9998086094856262
FAP O 1 0.9998934268951416
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
. O 0 1.2204985068819951e-05

METHODS O 0 4.20609330831212e-06
The O 0 4.048666824019165e-08
APC B-Disease 0 8.794520454102894e-07
gene O 0 1.6459031826343562e-07
was O 0 1.4828188454885094e-07
analysed O 0 2.3113602765079122e-07
in O 0 4.051924573644783e-09
190 O 0 3.449691376999908e-08
unrelated O 0 1.188553753195265e-07
FAP B-Disease 0 6.833535053374362e-07
and O 0 4.752893900672461e-08
15 O 0 8.01040727083091e-08
non O 0 4.504494063439779e-05
- O 1 0.9998546838760376
FAP O 1 0.9999747276306152
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
patients O 0 1.0148285582545213e-05
using O 0 5.647792136187491e-07
denaturing O 0 0.001011007116176188
gradient O 0 0.004754051566123962
gel O 0 0.018872197717428207
electrophoresis O 0 0.00013803172623738647
, O 0 2.8345768399162807e-08
the O 0 6.953876363624545e-10
protein O 0 4.647255913425852e-09
truncation O 0 1.9022689912162605e-07
test O 0 4.3951553152510314e-07
, O 0 1.7628736248553878e-09
and O 0 8.622900171673109e-10
direct O 0 1.0491347346430757e-08
sequencing O 0 5.803142926197324e-07
. O 0 4.049362303248927e-07

RESULTS O 0 4.243399598635733e-05
Chain O 0 1.862870885815937e-05
terminating O 0 1.030118824019155e-06
signals O 0 2.434742896184616e-07
were O 0 2.7641016586699152e-08
only O 0 2.992275760504981e-09
identified O 0 1.649366367928451e-07
in O 0 2.6107372264050355e-08
patients O 0 3.385292046687027e-08
belonging O 0 6.943848802620778e-07
to O 0 7.88231879766954e-09
the O 0 8.558346920040094e-09
FAP B-Disease 0 9.479489335717517e-07
group O 0 3.398062276005476e-08
( O 0 2.0067132400214405e-09
105 O 0 8.32456521493441e-08
patients O 0 6.053911505432552e-08
) O 0 2.6115937856729943e-08
. O 0 1.4820058424902527e-07

Amino O 0 2.744488938333234e-06
acid O 0 4.841130021304707e-07
changes O 0 1.437516061741917e-08
were O 0 2.272855681439978e-08
identified O 0 7.486113418053719e-08
in O 0 3.0293383357360426e-09
four O 0 2.564101464486157e-08
patients O 0 2.6634589289642463e-07
, O 0 1.0070857037192127e-08
three O 0 2.4339605886325444e-09
of O 0 5.054970220186306e-09
whom O 0 1.6979684858142718e-07
belonged O 0 1.9731567135750083e-06
to O 0 1.1200683047718485e-08
the O 0 2.895459871865569e-09
non O 0 1.0467020956639317e-06
- O 0 0.00024387445591855794
FAP O 0 5.347429123503389e-06
group O 0 1.8639370864548255e-06
of O 0 0.000348608911735937
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 0.000152208682266064
. O 0 1.1962197277171072e-06

Genotype O 0 0.0019840337336063385
- O 0 0.0005717820022255182
phenotype O 0 1.9428145606070757e-05
correlations O 0 5.024304482503794e-05
identified O 0 8.547975994588342e-06
significant O 0 4.073656043601659e-07
differences O 0 2.778887619570014e-06
in O 0 3.2406358485559394e-08
the O 0 8.127180706196668e-09
nature O 0 1.5665855812585505e-07
of O 0 7.308242344628013e-10
certain O 0 1.8024472581146256e-08
extracolonic O 0 1.8294609617441893e-05
manifestations O 0 9.790395552045084e-07
in O 0 8.452981603568333e-08
FAP B-Disease 0 2.7653506549540907e-05
patients O 0 1.3545596289077366e-07
belonging O 0 2.941064565220586e-07
to O 0 1.7375542782360753e-08
three O 0 4.1338143574876085e-08
mutation O 0 4.28756629844429e-06
subgroups O 0 1.734764919092413e-05
. O 0 8.890519325177593e-07

CONCLUSIONS O 0 7.65643926570192e-06
Extended O 0 2.0020288502564654e-06
genotype O 0 6.385342567227781e-05
- O 0 0.00012780659017153084
phenotype O 0 7.062372333166422e-06
correlations O 0 1.3372974535741378e-05
made O 0 3.93674980614378e-07
in O 0 1.272580352207342e-08
this O 0 1.7109511585289283e-09
study O 0 4.088239968780272e-09
may O 0 1.1703166080678784e-07
have O 0 4.194684155578443e-09
the O 0 5.655035884011284e-10
potential O 0 5.549173121011108e-09
to O 0 9.614825602355381e-10
determine O 0 1.1652933729067172e-08
the O 0 6.099851179719451e-10
most O 0 6.165871146990298e-10
appropriate O 0 3.1876432604605043e-09
surveillance O 0 7.75876912939566e-07
and O 0 1.378924796568981e-08
prophylactic O 0 1.1812209777417593e-05
treatment O 0 2.9198696438470506e-07
regimens O 0 4.935360564672919e-08
for O 0 6.3994729515570725e-09
those O 0 2.06728074658713e-08
patients O 0 5.0093440506771e-08
with O 0 5.720912632511954e-09
mutations O 0 6.640397600676806e-07
associated O 0 8.203228958336695e-07
with O 0 3.6478357401392714e-07
life O 0 1.077296201401623e-05
threatening O 0 0.00031613506143912673
conditions O 0 0.00010030178964370862
. O 0 1.0417705880172434e-06

This O 0 1.0418208518103711e-07
study O 0 4.129732289470667e-08
also O 0 1.50953258781783e-08
provided O 0 2.228561779560323e-09
evidence O 0 7.580206684565383e-09
for O 0 1.5945689213481273e-09
the O 0 6.656075246525006e-09
pathological O 0 5.64675929126679e-06
nature O 0 1.3903925832892128e-07
of O 0 2.004777233111099e-09
amino O 0 2.0449585136361748e-08
acid O 0 1.9371841020188185e-08
changes O 0 1.6456472851089643e-09
in O 0 1.7056596135489599e-09
APC O 0 2.6916444539892836e-07
associated O 0 1.5490838833898124e-08
with O 0 7.500745802246911e-09
both O 0 9.80594361266185e-09
FAP B-Disease 0 8.33039280223602e-07
and O 0 9.423634139693604e-08
non O 0 0.00021073612151667476
- O 1 0.999893069267273
FAP O 1 0.9999567270278931
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 6.345009023789316e-05
. O 0 7.998406204023922e-08
. O 0 3.7667686569875514e-07

Inherited B-Disease 1 0.9999321699142456
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999803304672241
and O 0 0.07360360771417618
cancer B-Disease 1 0.8149714469909668
risk O 0 5.645230430673109e-06
of O 0 5.082969600778142e-09
the O 0 1.116755896646282e-07
APC O 0 2.571366167103406e-05
I1307K O 0 1.4104824003879912e-05
polymorphism O 0 6.817861867602915e-05
. O 0 8.040720445023908e-07

Germ O 0 0.01500463206321001
- O 0 0.0007813337142579257
line O 0 1.672046710154973e-05
and O 0 1.7085453052345656e-08
somatic O 0 1.840994201529611e-07
truncating O 0 1.130371970248234e-06
mutations O 0 1.199860548695142e-07
of O 0 2.353349959349771e-09
the O 0 9.097081310471822e-09
APC B-Disease 0 2.332265012228163e-07
gene O 0 2.6041028888812434e-08
are O 0 2.7104207767081334e-09
thought O 0 1.2566609086661629e-08
to O 0 2.0999721073167166e-08
initiate O 0 0.0038416802417486906
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 0 0.4771272540092468
formation O 0 0.00012027058255625889
in O 0 0.0008036684594117105
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999990463256836
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
and O 0 0.0004543366958387196
sporadic O 1 0.9997672438621521
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.998083233833313
, O 0 6.739599939464824e-06
respectively O 0 7.545894277427578e-06
. O 0 1.0080159427161561e-06

Recently O 0 5.426167990663089e-05
, O 0 8.331363687830162e-08
an O 0 1.293671392232909e-08
isoleucine O 0 0.00801083818078041
- O 0 0.008445782586932182
- O 0 0.0005829363944940269
> O 0 1.953847686309018e-06
lysine O 0 5.022181994718267e-06
polymorphism O 0 3.163498377034557e-06
at O 0 1.7691000664399326e-07
codon O 0 1.7824703490987304e-07
1307 O 0 1.6366290083169588e-06
( O 0 4.70578687128409e-09
I1307K O 0 7.42981143275756e-08
) O 0 3.506847590095674e-10
of O 0 7.699291204588121e-11
the O 0 3.778161949963277e-10
APC B-Disease 0 5.324593388422727e-08
gene O 0 2.307529634038019e-08
has O 0 3.654401936614704e-08
been O 0 6.530250828973294e-08
identified O 0 1.629348673759523e-07
in O 0 2.3019017802994313e-09
6 O 0 1.2007758343202113e-08
% O 0 2.662217779558773e-09
- O 0 6.844466952315997e-06
7 O 0 6.302953181602788e-08
% O 0 1.3420141664610696e-09
of O 0 5.097394173425585e-10
the O 0 2.0259275146372602e-08
Ashkenazi O 0 7.809881935827434e-06
Jewish O 0 3.491184941140091e-07
population O 0 5.691356363968225e-08
. O 0 1.8667925871795887e-07

To O 0 1.8845246074761235e-07
assess O 0 1.4433069281949429e-06
the O 0 1.0038140096924053e-08
risk O 0 1.6476967346079618e-07
of O 0 1.0955434337489578e-09
this O 0 9.457645333554865e-09
common O 0 1.579911668159184e-07
APC B-Disease 0 2.3225086351885693e-06
allelic O 0 7.5321190706745256e-06
variant O 0 0.0007612415938638151
in O 0 9.743295777298044e-06
colorectal O 1 0.9999994039535522
carcinogenesis O 1 0.770278811454773
, O 0 2.9745629035460297e-06
we O 0 2.1692669349704374e-07
have O 0 2.7755751030866804e-09
analyzed O 0 1.1394289956001558e-08
a O 0 4.076093684801663e-09
large O 0 1.3133921505925628e-08
cohort O 0 1.9577326426656327e-08
of O 0 1.345851319278779e-09
unselected O 0 1.447959766665008e-05
Ashkenazi O 0 1.088038243324263e-05
Jewish O 0 1.5998269873307436e-06
subjects O 0 1.2301483138799085e-06
with O 0 4.418905632519454e-07
adenomatous B-Disease 0 0.07775168865919113
polyps I-Disease 0 0.00833927933126688
and O 0 5.406367563409731e-06
. O 0 1.979278067665291e-06
or O 1 0.9991706609725952
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
, I-Disease 0 4.818734851141926e-07
for O 0 1.3875784077299613e-08
the O 0 5.424249494012656e-08
APC O 0 7.525319688284071e-06
I1307K O 0 4.664394054998411e-06
polymorphism O 0 3.496695717331022e-05
. O 0 1.2013827017653966e-06

The O 0 5.959474833616696e-07
APC O 0 6.953537194931414e-06
I1307K O 0 3.438489329710137e-06
allele O 0 1.1749324357879232e-06
was O 0 1.4653144262410933e-06
identified O 0 1.899649220149513e-07
in O 0 4.670413389362693e-09
48 O 0 3.205998311273106e-08
( O 0 5.417915560634867e-10
10 O 0 4.789654783898811e-10
. O 0 2.061258663754728e-10
1 O 0 1.4220501443062972e-09
% O 0 7.673667812291285e-10
) O 0 3.5932709585573264e-10
of O 0 3.6476801579254925e-09
476 O 0 9.612882422516122e-06
patients O 0 1.3723778238272644e-06
. O 0 3.2380319225921994e-07

Compared O 0 8.034741767914966e-06
with O 0 1.1192973659035488e-08
the O 0 6.978350119979382e-10
frequency O 0 2.1295583962910314e-07
in O 0 3.763505951326351e-09
two O 0 8.335186985064524e-10
separate O 0 8.751414704022409e-09
population O 0 2.522152930950483e-09
control O 0 3.367666181475215e-07
groups O 0 8.561253039829353e-09
, O 0 2.5679276483003832e-09
the O 0 1.5221839344548016e-09
APC O 0 2.479453371506679e-07
I1307K O 0 2.566901287082146e-07
allele O 0 7.340898378060956e-08
is O 0 1.388118509026981e-08
associated O 0 3.329326148104883e-08
with O 0 5.041326467392082e-09
an O 0 6.65153132572982e-09
estimated O 0 2.4851277657944593e-07
relative O 0 5.776638545285095e-07
risk O 0 8.910451754218229e-08
of O 0 1.5651684392992138e-09
1 O 0 3.9932720596880245e-07
. O 0 3.785144713219779e-07

5 O 0 1.5201140740828123e-05
- O 0 0.0001746766793075949
1 O 0 1.7850794620244415e-06
. O 0 5.62824709504639e-07

7 O 0 3.633514643297531e-05
for O 0 1.1670944331854116e-05
colorectal B-Disease 1 0.9999996423721313
neoplasia I-Disease 1 0.9323124289512634
( O 0 1.3254293662612326e-07
both O 0 6.659200835201773e-08
P O 0 0.4631156921386719
= O 0 9.550089998811018e-06
. O 0 1.750296974023513e-08
01 O 0 2.73667160399782e-06
) O 0 5.516525192206245e-08
. O 0 1.5563493604986434e-07

Furthermore O 0 5.696063908544602e-06
, O 0 4.147105769902737e-08
compared O 0 1.0794589400120458e-07
with O 0 1.3883091121158486e-08
noncarriers O 0 6.55351541354321e-05
, O 0 2.917614061459517e-08
APC O 0 1.6575658889905753e-07
I1307K O 0 2.0761842733918456e-07
carriers O 0 2.759718853440063e-08
had O 0 7.261130363644952e-09
increased O 0 5.912587752732179e-09
numbers O 0 4.11149647661091e-09
of O 0 1.737122667933022e-09
adenomas B-Disease 0 0.4429403245449066
and O 0 0.007566770538687706
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.8661988973617554
per O 0 2.0867297280346975e-05
patient O 0 0.000714767025783658
( O 0 1.3159177569832536e-07
P O 1 0.7231137752532959
= O 0 7.334226211241912e-06
. O 0 7.182259675886371e-09
03 O 0 6.436959409938936e-08
) O 0 7.239028820826832e-10
, O 0 1.2473351240771535e-09
as O 0 3.6501230926688777e-09
well O 0 1.949222472319434e-08
as O 0 6.80267353558861e-09
a O 0 2.5219232924200696e-08
younger O 0 1.2828712669943343e-07
age O 0 5.720043105839068e-08
at O 0 3.0281213980742905e-07
diagnosis O 0 2.831593701557722e-05
. O 0 4.1311514564768004e-07

We O 0 2.1265103100631677e-07
conclude O 0 9.670654321780603e-08
that O 0 3.537564241540281e-09
the O 0 1.8188646144778886e-09
APC O 0 6.903939038238605e-07
I1307K O 0 7.563384087916347e-07
variant O 0 2.8473598376876907e-06
leads O 0 1.2972869001259824e-07
to O 0 5.016514847966391e-08
increased O 0 3.0379402232938446e-05
adenoma B-Disease 1 0.9999990463256836
formation O 0 1.37009919853881e-05
and O 0 9.278826951231167e-08
directly O 0 1.2002536742272696e-08
contributes O 0 1.3194508596825472e-08
to O 0 1.7787378236988616e-09
3 O 0 6.616103220835612e-09
% O 0 3.009016147359489e-09
- O 0 5.808928563055815e-06
4 O 0 7.758963249671069e-08
% O 0 1.2492256118434852e-09
of O 0 7.964299220120097e-10
all O 0 4.942303277744031e-08
Ashkenazi O 0 0.12931497395038605
Jewish O 1 0.9801936745643616
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999994158744812
. O 0 3.6974161048419774e-06

The O 0 2.5974611617129995e-07
estimated O 0 3.749293284727173e-07
relative O 0 1.5197674656519666e-06
risk O 0 5.348748004507797e-07
for O 0 1.065296473257149e-08
carriers O 0 4.488869649321714e-07
may O 0 2.90800254987289e-08
justify O 0 1.0388801285898808e-07
specific O 0 7.646438149322421e-09
clinical O 0 1.6268016267417806e-08
screening O 0 1.3819896338418403e-08
for O 0 5.377763234726274e-10
the O 0 7.570450377691884e-10
360 O 0 4.22658565923939e-08
, O 0 1.8397432466343844e-09
000 O 0 1.6093359977986665e-09
Americans O 0 5.175494477427378e-10
expected O 0 9.742149309488468e-09
to O 0 2.363579554298667e-09
harbor O 0 9.619086540624266e-07
this O 0 1.1346268369294421e-09
allele O 0 1.3790089070653266e-08
, O 0 2.144753263877419e-09
and O 0 5.7045030921187845e-09
genetic O 0 5.0161705900109155e-08
testing O 0 1.805053813086488e-07
in O 0 1.682328720775672e-09
the O 0 1.0407393835620837e-09
setting O 0 3.718959646903386e-07
of O 0 1.1390617338236098e-08
long O 0 5.280091954773525e-06
- O 0 9.912058885674924e-05
term O 0 9.334775654679106e-07
- O 0 1.2863166602983256e-06
outcome O 0 2.9567505777094993e-08
studies O 0 2.173062618737731e-09
may O 0 3.650735713733866e-09
impact O 0 3.6169833350641056e-08
significantly O 0 4.943452950101346e-06
on O 1 0.9478545188903809
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
prevention O 0 7.271982030943036e-05
in O 0 1.2897466206140962e-08
this O 0 1.4167255812935764e-08
population O 0 4.3923055415007184e-08
. O 0 2.236539415889638e-07

Localization O 0 3.301795004517771e-05
of O 0 1.024880731392841e-07
human O 0 2.5204670350831293e-07
BRCA1 O 0 3.677242057165131e-05
and O 0 1.8528994871758186e-07
its O 0 7.154875447668019e-08
loss O 0 4.0290678953169845e-06
in O 0 7.309239435926429e-08
high O 0 5.687823795597069e-05
- O 0 0.008679430931806564
grade O 0 0.00013556680642068386
, O 0 8.093476111525888e-08
non B-Disease 0 1.2215790775371715e-05
- I-Disease 1 0.9802170991897583
inherited I-Disease 1 0.9989984631538391
breast I-Disease 1 0.9998252987861633
carcinomas I-Disease 1 0.9999979734420776
. O 0 1.546933526697103e-05

Although O 0 8.272915579254914e-07
the O 0 1.1467546912058424e-08
link O 0 8.535623123862024e-07
between O 0 1.7995480661170404e-08
the O 0 5.826433735478531e-08
BRCA1 O 0 0.040915679186582565
tumour B-Disease 1 0.9999985694885254
- O 0 0.0003963919298257679
suppressor O 0 9.084310295293108e-05
gene O 0 8.803735909168608e-06
and O 0 2.8048365493305027e-05
hereditary B-Disease 1 0.999942421913147
breast I-Disease 1 0.9999972581863403
and I-Disease 1 0.9999926090240479
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
is O 0 1.7015561752486974e-05
established O 0 2.1108431269567518e-07
, O 0 2.273193722146516e-08
the O 0 1.887924483412462e-09
role O 0 1.3792305253446102e-07
, O 0 1.114706105198593e-08
if O 0 3.407978121927613e-09
any O 0 1.7282029141085786e-09
, O 0 7.532368617724217e-10
of O 0 5.988079476715313e-10
BRCA1 O 0 1.2346708899713121e-06
in O 0 8.263577377931597e-09
non B-Disease 0 1.3252237295091618e-05
- I-Disease 1 0.5747942328453064
familial I-Disease 1 0.8598719239234924
cancers I-Disease 0 0.2968272566795349
is O 0 8.523486485501053e-07
unclear O 0 1.1597720686040702e-06
. O 0 2.6902279159912723e-07

BRCA1 O 0 0.0036192121915519238
mutations O 0 6.710337765980512e-05
are O 0 1.1884563377861923e-07
rare O 0 2.4211462346102053e-07
in O 0 1.724742837438953e-08
sporadic B-Disease 0 0.14639906585216522
cancers I-Disease 1 0.6969104409217834
, O 0 1.0968177832637593e-07
but O 0 5.251990486954128e-08
loss O 0 5.255618589217192e-07
of O 0 8.17041989620293e-09
BRCA1 O 0 1.0645921065588482e-05
resulting O 0 5.925347323909591e-08
from O 0 6.062390589534061e-09
reduced O 0 1.2064063525940583e-07
expression O 0 1.9718595467566047e-07
or O 0 6.617165126954205e-08
incorrect O 0 8.05519675850519e-07
subcellular O 0 1.243795395566849e-05
localization O 0 2.8689205464615952e-06
is O 0 1.137144867158213e-08
postulated O 0 2.5180973750593694e-08
to O 0 6.8600822800135575e-09
be O 0 6.267776964108407e-09
important O 0 1.7324570666943373e-09
in O 0 2.129065368450256e-09
non B-Disease 0 4.082206942257471e-06
- I-Disease 1 0.6911990642547607
familial I-Disease 1 0.9996132254600525
breast I-Disease 1 0.999980092048645
and I-Disease 1 0.9995850920677185
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999983310699463
. O 0 1.3669121472048573e-05

Epigenetic O 0 0.0007508976268582046
loss O 0 0.0003101639449596405
, O 0 5.728580276809225e-07
however O 0 1.2131083337862947e-07
, O 0 5.162407035186334e-08
has O 0 1.0634474278958805e-07
not O 0 5.47574385834082e-09
received O 0 5.408375969295776e-10
general O 0 1.472284516523814e-09
acceptance O 0 6.895478321666815e-08
due O 0 2.6526597807219332e-08
to O 0 7.549632030645625e-09
controversy O 0 6.635593052806144e-08
regarding O 0 1.6283475900991107e-08
the O 0 2.248432329210459e-09
subcellular O 0 1.0427146662550513e-05
localization O 0 1.7233476228284417e-06
of O 0 1.0513301340608905e-08
BRCA1 O 0 1.635396415622381e-06
proteins O 0 8.21780687942919e-09
, O 0 3.990658026253868e-09
reports O 0 2.5762590283306963e-08
of O 0 4.843396794740329e-10
which O 0 4.0778070342639694e-07
have O 0 3.1890376561705125e-08
ranged O 0 7.410435500787571e-07
from O 0 5.436890937460248e-10
exclusively O 0 1.215138745180866e-08
nuclear O 0 1.3316544027475175e-05
, O 0 7.809480839782168e-10
to O 0 2.2520023346128681e-10
conditionally O 0 3.273209188137116e-07
nuclear O 0 5.8500017985352315e-06
, O 0 6.016311338008506e-10
to O 0 2.6398067065613873e-10
the O 0 1.9763481962087326e-09
ER O 0 1.6282923752442002e-05
/ O 0 3.1307035897043534e-06
golgi O 0 3.8027576465538004e-06
, O 0 4.652470853017121e-09
to O 0 4.065348058190921e-09
cytoplasmic O 0 4.150493282395473e-07
invaginations O 0 3.101474248978775e-06
into O 0 3.2691669371587295e-09
the O 0 5.856446438912144e-09
nucleus O 0 3.1099577313398186e-07
. O 0 8.856604694074122e-08

In O 0 2.9246854182929383e-07
an O 0 6.786654793700109e-09
attempt O 0 1.2818844652429107e-07
to O 0 2.3015603645148985e-08
resolve O 0 6.291494969445921e-07
this O 0 1.472276078828827e-09
issue O 0 1.6164253224815184e-07
, O 0 7.177685557024915e-09
we O 0 3.780477264569981e-09
have O 0 2.3492017220405614e-09
comprehensively O 0 8.076626727415714e-06
characterized O 0 1.1766928764700424e-06
19 O 0 1.1125463572625449e-07
anti O 0 2.2283125872490928e-05
- O 0 0.002994421636685729
BRCA1 O 0 0.00020574789959937334
antibodies O 0 2.9337886644498212e-06
. O 0 2.403853898158559e-07

These O 0 1.342017839078835e-07
reagents O 0 7.075464054651093e-07
detect O 0 2.3119143861549674e-06
a O 0 3.851823748846073e-08
220 O 0 1.1776028685517304e-07
- O 0 2.748976157818106e-06
kD O 0 3.1720931019663112e-06
protein O 0 2.6017149323820377e-08
localized O 0 7.485713382493486e-08
in O 0 2.970859114270752e-09
discrete O 0 3.6811820791626815e-07
nuclear O 0 8.006241841940209e-05
foci O 0 9.631951797928195e-06
in O 0 6.939623098389802e-09
all O 0 2.2620079143109706e-09
epithelial O 0 8.179076394299045e-05
cell O 0 0.002152480883523822
lines O 0 5.785730536445044e-05
, O 0 3.690707828241102e-08
including O 0 3.5608309634227453e-09
those O 0 1.1294362112224121e-09
derived O 0 1.9881907675767252e-08
from O 0 1.1737100180653215e-07
breast B-Disease 0 0.011092719621956348
malignancies I-Disease 0 0.0007735227118246257
. O 0 1.4418417322303867e-06

Immunohistochemical O 0 0.0009026547195389867
staining O 0 6.106631190050393e-05
of O 0 1.1830260859824193e-07
human O 0 2.151500211766688e-06
breast O 0 0.003562931902706623
specimens O 0 1.0725038009695709e-05
also O 0 1.2796630244338303e-06
revealed O 0 8.017444088181946e-06
BRCA1 O 0 4.2434803617652506e-05
nuclear O 0 0.00012845362653024495
foci O 0 9.649065032135695e-05
in O 0 4.1163721675729903e-07
benign O 1 0.976382315158844
breast O 1 0.7802636027336121
, O 0 7.490618827432627e-07
invasive B-Disease 0 0.006649809889495373
lobular I-Disease 1 0.9998416900634766
cancers I-Disease 1 0.9657911658287048
and O 0 4.6100035433482844e-06
low B-Disease 0 0.23628470301628113
- I-Disease 1 0.9939706325531006
grade I-Disease 1 0.92061448097229
ductal I-Disease 1 0.9998119473457336
carcinomas I-Disease 1 0.9999958276748657
. O 0 5.179268555366434e-05

Conversely O 0 6.532165571115911e-05
, O 0 3.2534347838009126e-07
BRCA1 O 0 3.908404778485419e-06
expression O 0 2.690530607196706e-07
was O 0 1.1088840210504713e-06
reduced O 0 2.0953073942564515e-07
or O 0 4.807058076039539e-07
undetectable O 0 6.460018539655721e-06
in O 0 2.2428383594785828e-09
the O 0 9.20578502316971e-10
majority O 0 2.854808611729709e-09
of O 0 1.770887658736342e-09
high O 0 1.9175968191120774e-05
- O 0 0.004193214699625969
grade O 0 0.00016276635869871825
, O 0 4.906569301965646e-07
ductal B-Disease 1 0.9907354712486267
carcinomas I-Disease 1 0.9999997615814209
, O 0 3.313978709229559e-07
suggesting O 0 5.449722948469571e-07
that O 0 2.61520760602707e-08
absence O 0 4.8785132378270646e-08
of O 0 8.925144179272593e-09
BRCA1 O 0 3.576774906832725e-05
may O 0 9.318056726215218e-08
contribute O 0 8.016424857260063e-09
to O 0 4.230196637422523e-09
the O 0 4.422094690426093e-09
pathogenesis O 0 4.90182230805658e-07
of O 0 6.282004361146676e-10
a O 0 1.3061475456765947e-08
significant O 0 2.421667488761159e-08
percentage O 0 1.6312081640990073e-07
of O 0 1.882086841931141e-08
sporadic B-Disease 1 0.8314411044120789
breast I-Disease 1 0.9989652633666992
cancers I-Disease 0 0.3914463222026825
. O 0 1.7463480617152527e-07
. O 0 6.22652180481964e-07

